Phase  O
I  O
study  O
of  O
escalating  O
doses  O
of  O
edatrexate  B-DRUG
in  O
combination  O
with  O
paclitaxel  B-DRUG
in  O
patients  O
with  O
metastatic  O
breast  B-CANCER
cancer  I-CANCER
.  O


Motivated  O
by  O
the  O
observation  O
of  O
preclinical  O
synergy  O
,  O
a  O
Phase  O
I  O
dose  O
escalation  O
study  O
of  O
edatrexate  B-DRUG
in  O
combination  O
with  O
a  O
3-h  O
paclitaxel  B-DRUG
infusion  O
was  O
performed  O
in  O
patients  O
with  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
edatrexate  B-DRUG
and  O
the  O
toxicities  O
associated  O
with  O
this  O
combination  O
and  O
to  O
report  O
preliminary  O
observations  O
of  O
efficacy  O
with  O
this  O
novel  O
combination  O
.  O

Thirty-six  O
patients  O
were  O
enrolled  O
in  O
this  O
Phase  O
I  O
trial  O
.  O

Thirty-five  O
eligible  O
patients  O
were  O
treated  O
every  O
21  O
days  O
in  O
cohorts  O
of  O
at  O
least  O
three  O
patients  O
and  O
were  O
assessable  O
for  O
toxicity  O
.  O

One  O
patient  O
was  O
ineligible  O
due  O
to  O
hyperbilirubinemia  B-TOXI
.  O

Stepwise  O
dose  O
escalations  O
of  O
edatrexate  B-DRUG
were  O
administered  O
until  O
grade  O
&  O
gt  O
;  O
3  O
nonhematological  B-TOXI
dose-limiting  I-TOXI
toxicities  I-TOXI
were  O
reported  O
.  O

The  O
initial  O
dose  O
level  O
of  O
edatrexate  B-DRUG
was  O
180  O
mg  O
/  O
m2  O
;  O
subsequent  O
cohorts  O
were  O
treated  O
with  O
escalating  O
doses  O
of  O
edatrexate  B-DRUG
(  O
210  O
,  O
240  O
,  O
270  O
,  O
300  O
,  O
350  O
,  O
and  O
400  O
mg  O
/  O
m2  O
)  O
.  O

Edatrexate  B-DRUG
was  O
administered  O
by  O
i.v.  O
infusion  O
over  O
1  O
h.  O
Paclitaxel  B-DRUG
was  O
administered  O
24  O
h  O
later  O
at  O
a  O
fixed  O
dose  O
of  O
175  O
mg  O
/  O
m2  O
as  O
a  O
3-h  O
infusion  O
with  O
standard  O
dexamethasone  B-DRUG
,  O
diphenhydramine  B-DRUG
,  O
and  O
cimetidine  B-DRUG
premedication  O
.  O

The  O
MTD  O
of  O
edatrexate  B-DRUG
was  O
reached  O
at  O
the  O
350  O
mg  O
/  O
m2  O
level  O
in  O
this  O
study  O
.  O

Grade  O
3  O
diarrhea  B-TOXI
was  O
seen  O
in  O
one  O
patient  O
at  O
the  O
300  O
and  O
400  O
mg  O
/  O
m2  O
dose  O
levels  O
,  O
requiring  O
dose  O
reductions  O
.  O

Two  O
patients  O
experienced  O
grade  O
4  O
stomatitis  B-TOXI
at  O
the  O
400  O
mg  O
/  O
m2  O
dose  O
level  O
and  O
also  O
required  O
dose  O
reduction  O
,  O
establishing  O
the  O
MTD  O
as  O
350  O
mg  O
/  O
m2  O
.  O

Grade  O
3  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
were  O
noted  O
in  O
two  O
of  O
three  O
patients  O
at  O
the  O
highest  O
dose  O
level  O
.  O

Of  O
35  O
patients  O
,  O
4  O
patients  O
reported  O
grade  O
3  O
myalgias  B-TOXI
and  O
1  O
patient  O
reported  O
grade  O
3  O
neurosensory  B-TOXI
complaints  I-TOXI
,  O
which  O
were  O
seen  O
mostly  O
at  O
the  O
350  O
and  O
400  O
mg  O
/  O
m2  O
dose  O
levels  O
;  O
however  O
,  O
1  O
patient  O
reported  O
grade  O
3  O
myalgias  B-TOXI
at  O
180  O
mg  O
/  O
m2  O
.  O

No  O
cumulative  O
neurotoxicity  B-TOXI
was  O
observed  O
,  O
and  O
no  O
patient  O
experienced  O
an  O
allergic  B-TOXI
reaction  I-TOXI
to  O
paclitaxel  B-DRUG
.  O

In  O
23  O
patients  O
with  O
bidimensionally  O
measurable  O
disease  O
,  O
there  O
were  O
four  O
complete  O
(  O
17  O
%  O
)  O
and  O
seven  O
partial  O
responses  O
,  O
with  O
an  O
overall  O
response  O
rate  O
of  O
48  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
27-69  O
%  O
)  O
.  O

All  O
of  O
the  O
responses  O
were  O
seen  O
in  O
patients  O
who  O
had  O
not  O
received  O
prior  O
chemotherapy  O
for  O
stage  O
IV  O
disease  O
.  O

The  O
median  O
duration  O
of  O
response  O
was  O
not  O
assessable  O
because  O
many  O
responding  O
patients  O
went  O
on  O
to  O
receive  O
high-dose  O
chemotherapy  O
treatment  O
with  O
stem  O
cell  O
support  O
.  O

The  O
combination  O
of  O
edatrexate  B-DRUG
and  O
paclitaxel  B-DRUG
for  O
treatment  O
of  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
is  O
a  O
feasible  O
and  O
safe  O
regimen  O
.  O

The  O
MTD  O
of  O
edatrexate  B-DRUG
was  O
350  O
mg  O
/  O
m2  O
when  O
combined  O
with  O
a  O
3-h  O
infusion  O
of  O
paclitaxel  B-DRUG
(  O
175  O
mg  O
/  O
m2  O
)  O
given  O
24  O
h  O
later  O
.  O

Activity  O
was  O
noted  O
even  O
among  O
patients  O
who  O
had  O
relapsed  O
shortly  O
after  O
receiving  O
methotrexate-  B-DRUG
and  O
/  O
or  O
doxorubicin-containing  B-DRUG
adjuvant  O
regimens  O
.  O

Additional  O
studies  O
evaluating  O
the  O
sequences  O
and  O
dosing  O
schema  O
for  O
this  O
combination  O
are  O
warranted  O
to  O
improve  O
the  O
response  O
proportion  O
and  O
define  O
the  O
duration  O
of  O
the  O
response  O
.  O

Phase  O
I  O
study  O
of  O
a  O
weekly  O
schedule  O
of  O
irinotecan  B-DRUG
,  O
high-dose  O
leucovorin  B-DRUG
,  O
and  O
infusional  B-DRUG
fluorouracil  I-DRUG
as  O
first-line  O
chemotherapy  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
a  O
weekly  O
schedule  O
of  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
,  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
,  O
and  O
a  O
24-hour  O
infusion  O
of  O
fluorouracil  B-DRUG
(  O
5-FU24h  B-DRUG
)  O
as  O
first-line  O
chemotherapy  O
in  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
and  O
to  O
assess  O
preliminary  O
data  O
on  O
the  O
antitumor  O
activity  O
.  O

Twenty-six  O
patients  O
with  O
measurable  B-CANCER
metastatic  I-CANCER
colorectal  I-CANCER
cancer  I-CANCER
were  O
entered  O
onto  O
this  O
phase  O
I  O
study  O
.  O

In  O
the  O
first  O
six  O
dose  O
levels  O
,  O
fixed  O
doses  O
of  O
CPT-11  B-DRUG
(  O
80  O
mg  O
/  O
m2  O
)  O
and  O
LV  B-DRUG
(  O
500  O
mg  O
/  O
m2  O
)  O
in  O
combination  O
with  O
escalated  O
doses  O
of  O
5-FU24h  B-DRUG
ranging  O
from  O
1.8  O
to  O
2.6  O
g  O
/  O
m2  O
were  O
administered  O
on  O
a  O
weekly-times-four  O
(  O
dose  O
levels  O
1  O
to  O
4  O
)  O
or  O
weekly-times-six  O
(  O
dose  O
levels  O
5  O
to  O
6  O
)  O
schedule  O
.  O

The  O
dose  O
of  O
CPT-11  B-DRUG
was  O
then  O
increased  O
to  O
100  O
mg  O
/  O
m2  O
(  O
dose  O
level  O
7  O
)  O
.  O

Seventy-nine  O
cycles  O
of  O
5-FU24h  B-DRUG
/  I-DRUG
LV  I-DRUG
with  O
CPT-11  B-DRUG
were  O
administered  O
in  O
an  O
outpatient  O
setting  O
.  O

No  O
dose-limiting  O
toxicities  O
were  O
observed  O
during  O
the  O
first  O
cycle  O
at  O
dose  O
levels  O
1  O
to  O
6  O
,  O
but  O
diarrhea  B-TOXI
of  O
grade  O
4  O
(  O
National  O
Cancer  O
Institute  O
common  O
toxicity  O
criteria  O
)  O
was  O
observed  O
in  O
three  O
patients  O
after  O
multiple  O
treatment  O
cycles  O
.  O

Other  O
nonhematologic  B-TOXI
and  I-TOXI
hematologic  I-TOXI
side  I-TOXI
effects  I-TOXI
,  O
specifically  O
alopecia  B-TOXI
and  O
neutropenia  B-TOXI
,  O
did  O
not  O
exceed  O
grade  O
2.  O
With  O
the  O
escalation  O
of  O
CPT-11  B-DRUG
to  O
100  O
mg  O
/  O
m2  O
(  O
dose  O
level  O
7  O
)  O
,  O
diarrhea  B-TOXI
of  O
grade  O
3  O
or  O
higher  O
was  O
observed  O
in  O
four  O
of  O
six  O
patients  O
during  O
the  O
first  O
cycle  O
;  O
thus  O
,  O
the  O
MTD  O
was  O
achieved  O
.  O

Sixteen  O
of  O
25  O
response-assessable  O
patients  O
(  O
64  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
,  O
45  O
%  O
to  O
83  O
%  O
)  O
achieved  O
an  O
objective  O
response  O
.  O

The  O
recommended  O
doses  O
for  O
further  O
studies  O
are  O
CPT-11  B-DRUG
80  O
mg  O
/  O
m2  O
,  O
LV  B-DRUG
500  O
mg  O
/  O
m2  O
,  O
and  O
5-FU24h  B-DRUG
2.6  O
g  O
/  O
m2  O
given  O
on  O
a  O
weekly-times-six  O
schedule  O
followed  O
by  O
a  O
1-week  O
rest  O
period  O
.  O

The  O
addition  O
of  O
CPT-11  B-DRUG
to  O
5-FU24h  B-DRUG
/  I-DRUG
LV  I-DRUG
seems  O
to  O
improve  O
the  O
therapeutic  O
efficacy  O
in  O
terms  O
of  O
tumor  B-CANCER
response  O
with  O
manageable  O
toxicity  O
.  O

Phase  O
I-II  O
study  O
of  O
gemcitabine  B-DRUG
and  O
carboplatin  B-DRUG
in  O
stage  O
IIIB-IV  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Platinum-based  B-DRUG
chemotherapy  I-DRUG
currently  O
represents  O
standard  O
treatment  O
for  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

Gemcitabine  B-DRUG
is  O
one  O
of  O
the  O
most  O
interesting  O
agents  O
currently  O
in  O
use  O
in  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
,  O
and  O
high  O
response  O
rates  O
have  O
been  O
reported  O
when  O
it  O
is  O
administered  O
in  O
combination  O
with  O
cisplatin  B-DRUG
.  O

The  O
aim  O
of  O
the  O
present  O
study  O
was  O
to  O
evaluate  O
the  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
carboplatin  B-DRUG
in  O
a  O
phase  O
I-II  O
study  O
.  O

Chemotherapy-naive  O
patients  O
with  O
stage  O
IIIB-IV  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
received  O
carboplatin  B-DRUG
at  O
area  O
under  O
the  O
concentration-time  O
curve  O
(  O
AUC  O
)  O
5  O
mg  O
/  O
mL  O
/  O
min  O
and  O
gemcitabine  B-DRUG
at  O
an  O
initial  O
dose  O
of  O
800  O
mg  O
/  O
m2  O
,  O
subsequently  O
escalated  O
by  O
100  O
mg  O
/  O
m2  O
per  O
step  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
on  O
days  O
1  O
and  O
8  O
and  O
carboplatin  B-DRUG
on  O
day  O
8  O
of  O
the  O
28-day  O
cycle  O
.  O

Dose  O
escalation  O
proceeded  O
up  O
to  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
,  O
which  O
was  O
defined  O
as  O
grade  O
4  O
neutropenia  B-TOXI
or  O
thrombocytopenia  B-TOXI
or  O
grade  O
3  O
nonhematologic  B-TOXI
toxicity  I-TOXI
.  O

Neutropenia  B-TOXI
was  O
DLT  O
,  O
inasmuch  O
as  O
it  O
occurred  O
in  O
three  O
of  O
five  O
patients  O
receiving  O
gemcitabine  B-DRUG
1,200  O
mg  O
/  O
m2  O
.  O

Nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
mild  O
.  O

Gemcitabine  B-DRUG
1,100  O
mg  O
/  O
m2  O
plus  O
carboplatin  B-DRUG
AUC  I-DRUG
5  I-DRUG
was  O
recommended  O
for  O
phase  O
II  O
studies  O
.  O

An  O
objective  O
response  O
was  O
observed  O
in  O
13  O
(  O
50  O
%  O
)  O
of  O
26  O
patients  O
,  O
including  O
four  O
complete  O
responses  O
(  O
15  O
%  O
)  O
and  O
nine  O
partial  O
responses  O
(  O
35  O
%  O
)  O
.  O

Median  O
duration  O
of  O
response  O
was  O
13  O
months  O
(  O
range  O
,  O
3  O
to  O
23  O
months  O
)  O
.  O

Median  O
overall  O
survival  O
was  O
16  O
months  O
(  O
range  O
,  O
3  O
to  O
26  O
months  O
)  O
.  O

The  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
carboplatin  B-DRUG
is  O
well  O
tolerated  O
and  O
active  O
.  O

Neutropenia  B-TOXI
was  O
DLT  O
.  O

The  O
observed  O
activity  O
matches  O
that  O
observable  O
in  O
cisplatin-gemcitabine  B-DRUG
studies  O
,  O
whereas  O
duration  O
of  O
response  O
and  O
survival  O
are  O
even  O
higher  O
.  O

A  O
phase  O
II  O
trial  O
is  O
under  O
way  O
.  O

Paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
in  O
the  O
treatment  O
of  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
patients  O
resistant  O
to  O
cyclophosphamide  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
etoposide  B-DRUG
:  O
a  O
non-cross-resistant  O
schedule  O
.  O


To  O
evaluate  O
the  O
efficacy  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
(  O
PC  B-DRUG
)  O
in  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
SCLC  B-CANCER
)  O
patients  O
resistant  O
to  O
cyclophosphamide  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
etoposide  B-DRUG
(  O
CDE  B-DRUG
)  O
.  O

We  O
performed  O
a  O
phase  O
II  O
study  O
with  O
PC  B-DRUG
in  O
SCLC  B-CANCER
patients  O
who  O
relapsed  O
within  O
3  O
months  O
after  O
first-line  O
treatment  O
with  O
CDE  B-DRUG
.  O

Paclitaxel  B-DRUG
administration  O
(  O
175  O
mg  O
/  O
m2  O
by  O
a  O
3-hour  O
intravenous  O
infusion  O
)  O
was  O
followed  O
by  O
a  O
30-minute  O
infusion  O
of  O
carboplatin  B-DRUG
(  O
area  O
under  O
the  O
curve  O
7  O
;  O
Chatelut  O
formula  O
)  O
once  O
every  O
3  O
weeks  O
for  O
five  O
cycles  O
.  O

Dexamethasone  B-DRUG
,  O
clemastine  B-DRUG
,  O
and  O
ranitidine  B-DRUG
were  O
standard  O
premedication  O
before  O
every  O
cycle  O
.  O

Included  O
were  O
35  O
patients  O
(  O
median  O
age  O
,  O
59  O
years  O
;  O
16  O
with  O
limited  B-TOXI
disease  I-TOXI
and  O
19  O
with  O
extensive  B-TOXI
disease  I-TOXI
;  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
status  O
of  O
&  O
lt  O
;  O
or  O
=  O
1  O
;  O
median  O
time  O
off  O
treatment  O
6  O
weeks  O
)  O
who  O
were  O
previously  O
treated  O
with  O
CDE  B-DRUG
(  O
n  O
=  O
33  O
)  O
,  O
oral  B-DRUG
etoposide  I-DRUG
(  O
n  O
=  O
2  O
)  O
,  O
and  O
reinduction  B-DRUG
CDE  I-DRUG
(  O
n  O
=  O
15  O
)  O
;  O
only  O
one  O
patient  O
had  O
received  O
three  O
CDE  B-DRUG
treatments  O
of  O
five  O
cycles  O
.  O

The  O
CDE  B-DRUG
regimen  O
was  O
followed  O
by  O
local  O
thoracic  O
radiotherapy  O
in  O
seven  O
patients  O
.  O

Hematologic  B-TOXI
toxicity  I-TOXI
of  O
grade  O
3  O
or  O
4  O
,  O
for  O
leukopenia  B-TOXI
was  O
27  O
%  O
and  O
6  O
%  O
,  O
for  O
thrombocytopenia  B-TOXI
21  O
%  O
and  O
13  O
%  O
,  O
and  O
for  O
anemia  B-TOXI
17  O
%  O
and  O
0  O
%  O
,  O
respectively  O
,  O
for  O
a  O
total  O
of  O
132  O
cycles  O
.  O

Two  O
patients  O
had  O
neutropenic  B-TOXI
fever  I-TOXI
;  O
no  O
toxic  B-TOXI
death  I-TOXI
occurred  O
.  O

Nonhematologic  B-TOXI
toxicity  I-TOXI
was  O
paresthesia  B-TOXI
CTC  O
grade  O
3  O
,  O
diarrhea  B-TOXI
grade  O
4  O
,  O
and  O
myalgia  B-TOXI
grade  O
3  O
in  O
one  O
patient  O
each  O
.  O

Reversible  B-TOXI
paresthesia  I-TOXI
(  O
CTC  O
grade  O
1  O
and  O
2  O
)  O
in  O
toes  O
and  O
fingers  O
was  O
reported  O
in  O
69  O
%  O
of  O
patients  O
.  O

Thirty-four  O
patients  O
were  O
assessable  O
for  O
response  O
:  O
complete  O
response  O
in  O
two  O
patients  O
,  O
partial  O
response  O
in  O
23  O
patients  O
,  O
stable  O
disease  O
in  O
eight  O
patients  O
,  O
and  O
progressive  B-TOXI
disease  I-TOXI
in  O
one  O
patient  O
(  O
response  O
rate  O
,  O
73.5  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
,  O
59  O
%  O
to  O
88  O
%  O
)  O
.  O

One  O
patient  O
was  O
found  O
to  O
have  O
atypical  B-TOXI
carcinoid  I-TOXI
at  O
pathologic  O
review  O
and  O
was  O
excluded  O
.  O

Median  O
time  O
to  O
progression  O
was  O
21  O
weeks  O
(  O
range  O
,  O
3  O
to  O
40  O
weeks  O
)  O
.  O

Median  O
survival  O
was  O
31  O
weeks  O
(  O
range  O
,  O
6  O
to  O
112  O
weeks  O
)  O
.  O

One-year  O
survival  O
was  O
9  O
%  O
.  O

Second-line  O
PC  B-DRUG
in  O
CDE-resistant  B-DRUG
SCLC  B-CANCER
patients  O
yields  O
a  O
high  O
response  O
rate  O
and  O
seems  O
non-cross-resistant  O
to  O
CDE  B-DRUG
.  O

Toxicity  B-TOXI
was  O
mild  O
in  O
these  O
poor-prognosis  B-TOXI
patients  O
.  O

Phase  O
I-II  O
study  O
of  O
gemcitabine  B-DRUG
and  O
fluorouracil  B-DRUG
as  O
a  O
continuous  O
infusion  O
in  O
patients  O
with  O
pancreatic  B-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
dose-limiting  B-TOXI
toxicities  I-TOXI
,  O
and  O
efficacy  O
of  O
gemcitabine  B-DRUG
combined  O
with  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
in  O
patients  O
with  O
pancreatic  B-CANCER
cancer  I-CANCER
.  O

Patients  O
with  O
measurable  B-CANCER
,  I-CANCER
locally  I-CANCER
advanced  I-CANCER
,  I-CANCER
nonresectable  I-CANCER
or  I-CANCER
metastatic  I-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
were  O
candidates  O
for  O
the  O
study  O
.  O

5-FU  B-DRUG
was  O
given  O
via  O
protracted  O
venous  O
infusion  O
(  O
PVI  O
)  O
at  O
a  O
fixed  O
dosage  O
of  O
200  O
mg  O
/  O
m2  O
/  O
d  O
,  O
and  O
gemcitabine  B-DRUG
was  O
administered  O
weekly  O
for  O
3  O
consecutive  O
weeks  O
every  O
4  O
weeks  O
.  O

The  O
initial  O
dose  O
of  O
gemcitabine  B-DRUG
was  O
700  O
mg  O
/  O
m2  O
and  O
was  O
escalated  O
in  O
increments  O
of  O
100  O
mg  O
/  O
m2  O
/  O
wk  O
until  O
the  O
appearance  O
of  O
severe  B-TOXI
toxicity  I-TOXI
.  O

Measurements  O
of  O
efficacy  O
included  O
the  O
following  O
:  O
response  O
rate  O
;  O
clinical  O
benefit  O
response  O
,  O
which  O
is  O
a  O
composite  O
measurement  O
of  O
pain  B-TOXI
,  O
performance  O
status  O
,  O
and  O
weight  B-TOXI
loss  I-TOXI
;  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
;  O
and  O
survival  O
.  O

Twenty-six  O
patients  O
received  O
a  O
total  O
of  O
109  O
courses  O
.  O

Dose-limiting  B-TOXI
toxicity  I-TOXI
,  O
which  O
consisted  O
of  O
grade  O
4  O
neutropenia  B-TOXI
with  O
fever  B-TOXI
(  O
one  O
patient  O
)  O
and  O
grade  O
4  O
thrombocytopenia  B-TOXI
(  O
one  O
patient  O
)  O
,  O
was  O
observed  O
in  O
two  O
of  O
three  O
patients  O
treated  O
with  O
1,100  O
mg  O
/  O
m2  O
/  O
wk  O
of  O
gemcitabine  B-DRUG
.  O

On  O
the  O
basis  O
of  O
these  O
results  O
,  O
the  O
MTD  O
of  O
gemcitabine  B-DRUG
with  O
5-FU  B-DRUG
via  O
PVI  O
on  O
this  O
schedule  O
was  O
1,000  O
mg  O
/  O
m2  O
.  O

Sixteen  O
patients  O
developed  O
grade  O
3-4  O
neutropenia  B-TOXI
,  O
and  O
three  O
patients  O
developed  O
grade  O
3-4  O
thrombocytopenia  B-TOXI
.  O

Grade  O
3-4  O
nonhematologic  B-TOXI
toxicity  I-TOXI
consisted  O
of  O
diarrhea  B-TOXI
(  O
two  O
patients  O
)  O
and  O
cutaneous  B-TOXI
toxicity  I-TOXI
,  O
asthenia  B-TOXI
,  O
edema  B-TOXI
,  O
mucositis  B-TOXI
,  O
and  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
(  O
one  O
patient  O
each  O
)  O
.  O

The  O
delivered  O
dose-intensity  O
of  O
gemcitabine  B-DRUG
was  O
similar  O
at  O
the  O
1,000  O
mg  O
/  O
m2  O
dose  O
level  O
(  O
599  O
mg  O
/  O
m2  O
/  O
wk  O
)  O
as  O
at  O
the  O
900  O
mg  O
/  O
m2  O
(  O
601  O
mg  O
/  O
m2  O
/  O
wk  O
)  O
dose  O
level  O
.  O

For  O
this  O
reason  O
,  O
the  O
recommended  O
dose  O
of  O
gemcitabine  B-DRUG
for  O
phase  O
II  O
evaluation  O
on  O
this  O
schedule  O
was  O
900  O
mg  O
/  O
m2  O
.  O

Five  O
patients  O
had  O
objective  O
responses  O
(  O
one  O
complete  O
response  O
and  O
four  O
partial  O
responses  O
;  O
response  O
rate  O
,  O
19.2  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
[  O
CI  O
]  O
,  O
6.5  O
to  O
39.3  O
)  O
,  O
and  O
10  O
patients  O
had  O
improvement  O
of  O
disease-related  B-TOXI
symptoms  I-TOXI
(  O
45  O
%  O
;  O
95  O
%  O
CI  O
,  O
24  O
to  O
67  O
)  O
.  O

After  O
a  O
median  O
follow-up  O
of  O
17.7  O
months  O
(  O
range  O
,  O
7.8  O
to  O
24.8  O
months  O
)  O
,  O
the  O
median  O
progression-free  O
survival  O
and  O
overall  O
survival  O
times  O
were  O
7.4  O
months  O
(  O
95  O
%  O
CI  O
,  O
3.3  O
to  O
11.4  O
)  O
and  O
10.3  O
months  O
(  O
95  O
%  O
CI  O
,  O
8.1  O
to  O
12.5  O
)  O
,  O
respectively  O
.  O

The  O
MTD  O
of  O
gemcitabine  O
when  O
combined  O
with  O
5-FU  B-DRUG
via  O
PVI  O
on  O
this  O
schedule  O
was  O
1,000  O
mg  O
/  O
m2  O
/  O
wk  O
;  O
however  O
,  O
on  O
the  O
basis  O
of  O
administered  O
dose-intensity  O
,  O
the  O
recommended  O
dose  O
for  O
additional  O
investigation  O
is  O
900  O
mg  O
/  O
m2  O
.  O

This  O
combination  O
chemotherapy  O
regimen  O
was  O
well  O
tolerated  O
and  O
showed  O
promising  O
antitumor  O
activity  O
in  O
the  O
treatment  O
of  O
pancreatic  B-CANCER
cancer  I-CANCER
.  O

First-line  O
chemotherapy  O
with  O
epirubicin  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
carboplatin  B-DRUG
for  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
I  O
/  O
II  O
study  O
of  O
the  O
Arbeitsgemeinschaft  O
Gyn√§kologische  O
Onkologie  O
Ovarian  O
Cancer  O
Study  O
Group  O
.  O


Despite  O
the  O
progress  O
that  O
has  O
been  O
achieved  O
over  O
the  O
years  O
,  O
survival  O
rates  O
in  O
patients  O
with  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
are  O
still  O
disappointing  O
.  O

New  O
methods  O
to  O
improve  O
the  O
efficiency  O
of  O
first-line  O
chemotherapy  O
are  O
warranted  O
.  O

One  O
method  O
to  O
improve  O
results  O
is  O
to  O
add  O
more  O
non-cross-resistant  O
drugs  O
to  O
platinum-paclitaxel  B-DRUG
combination  O
regimens  O
.  O

Anthracyclines  B-DRUG
are  O
among  O
the  O
candidates  O
for  O
incorporation  O
as  O
the  O
"  O
third  O
drug  O
"  O
into  O
first-line  O
regimens  O
for  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

We  O
performed  O
a  O
phase  O
I  O
/  O
II  O
trial  O
with  O
escalating  O
doses  O
of  O
epirubicin  B-DRUG
(  O
60  O
,  O
75  O
,  O
and  O
90  O
mg  O
/  O
m2  O
)  O
combined  O
with  O
fixed  O
doses  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
in  O
27  O
previously  O
untreated  O
patients  O
with  O
advanced  B-CANCER
gynecologic  I-CANCER
malignancies  I-CANCER
.  O

Dose-limiting  B-TOXI
toxicity  I-TOXI
occurred  O
at  O
dose  O
level  O
2  O
(  O
75  O
mg  O
/  O
m2  O
epirubicin  O
)  O
and  O
consisted  O
of  O
myelosuppression  B-TOXI
(  O
neutropenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
)  O
.  O

No  O
dose-limiting  O
,  O
nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
observed  O
.  O

The  O
maximum  O
tolerable  O
dose  O
was  O
epirubicin  B-DRUG
60  O
mg  O
/  O
m2  O
(  O
E  O
)  O
combined  O
with  O
a  O
3-hour  O
infusion  O
of  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m2  O
(  O
T  O
)  O
and  O
carboplatin  B-DRUG
AUC  O
5  O
(  O
Carbo  B-DRUG
)  O
.  O

Preliminary  O
analysis  O
indicated  O
promising  O
activity  O
against  O
ovarian  B-CANCER
cancer  I-CANCER
.  O

The  O
three-drug  O
combination  O
ET-Carbo  B-DRUG
,  O
given  O
according  O
to  O
the  O
outlined  O
dose  O
and  O
schedule  O
,  O
should  O
be  O
considered  O
for  O
further  O
phase  O
III  O
evaluation  O
.  O

A  O
randomized  O
German-French  O
intergroup  O
trial  O
comparing  O
ET-Carbo  B-DRUG
with  O
carboplatin-paclitaxel  B-DRUG
has  O
already  O
been  O
initiated  O
.  O

Sequential  O
dose-dense  O
doxorubicin  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
cyclophosphamide  B-DRUG
for  O
resectable  B-CANCER
high-risk  I-CANCER
breast  I-CANCER
cancer  I-CANCER
:  O
feasibility  O
and  O
efficacy  O
.  O


Dose-dense  O
chemotherapy  O
is  O
predicted  O
to  O
be  O
a  O
superior  O
treatment  O
plan  O
.  O

Therefore  O
,  O
we  O
studied  O
dose-dense  O
doxorubicin  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
cyclophosphamide  B-DRUG
(  O
A  O
--  O
&  O
gt  O
;  O
T  O
--  O
&  O
gt  O
;  O
C  O
)  O
as  O
adjuvant  O
therapy  O
.  O

Patients  O
with  O
resected  B-CANCER
breast  I-CANCER
cancer  I-CANCER
involving  O
four  O
or  O
more  O
ipsilateral  O
axillary  O
lymph  O
nodes  O
were  O
treated  O
with  O
nine  O
cycles  O
of  O
chemotherapy  O
,  O
using  O
14-day  O
intertreatment  O
intervals  O
.  O

Doses  O
were  O
as  O
follows  O
:  O
doxorubicin  B-DRUG
90  O
mg  O
/  O
m2  O
x  O
3  O
,  O
then  O
paclitaxel  B-DRUG
250  O
mg  O
/  O
m2  O
/  O
24  O
hours  O
x  O
3  O
,  O
and  O
then  O
cyclophosphamide  B-DRUG
3.0  O
g  O
/  O
m2  O
x  O
3  O
;  O
all  O
doses  O
were  O
given  O
with  O
subcutaneous  O
injections  O
of  O
5  O
microg  O
/  O
kg  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
on  O
days  O
3  O
through  O
10  O
.  O

Amenorrheic  B-TOXI
patients  O
with  O
hormone  B-CANCER
receptor-positive  I-CANCER
tumors  I-CANCER
received  O
tamoxifen  B-DRUG
20  O
mg  O
/  O
day  O
for  O
5  O
years  O
.  O

Patients  O
treated  O
with  O
breast  O
conservation  O
,  O
those  O
with  O
10  O
or  O
more  O
positive  B-TOXI
nodes  I-TOXI
,  O
and  O
those  O
with  O
tumors  B-CANCER
larger  O
than  O
5  O
cm  O
received  O
radiotherapy  O
.  O

Between  O
March  O
1993  O
and  O
June  O
1994  O
,  O
we  O
enrolled  O
42  O
patients  O
.  O

The  O
median  O
age  O
was  O
46  O
years  O
(  O
range  O
,  O
29  O
to  O
63  O
years  O
)  O
,  O
the  O
median  O
number  O
of  O
positive  B-TOXI
lymph  I-TOXI
nodes  I-TOXI
was  O
eight  O
(  O
range  O
,  O
four  O
to  O
25  O
)  O
,  O
and  O
the  O
median  O
tumor  B-CANCER
size  O
was  O
3.0  O
cm  O
(  O
range  O
,  O
0  O
to  O
11.0  O
cm  O
)  O
.  O

The  O
median  O
intertreatment  O
interval  O
was  O
14  O
days  O
(  O
range  O
,  O
13  O
to  O
36  O
days  O
)  O
,  O
and  O
the  O
median  O
delivered  O
dose-intensity  O
exceeded  O
92  O
%  O
of  O
the  O
planned  O
dose-intensity  O
for  O
all  O
three  O
drugs  O
.  O

Hospital  O
admission  O
was  O
required  O
for  O
29  O
patients  O
(  O
69  O
%  O
)  O
,  O
and  O
28  O
patients  O
(  O
67  O
%  O
)  O
required  O
blood  O
product  O
transfusion  O
.  O

No  O
treatment-related  B-TOXI
deaths  I-TOXI
or  O
cardiac  B-TOXI
toxicities  I-TOXI
occurred  O
.  O

Doxorubicin  B-DRUG
was  O
dose-reduced  O
in  O
four  O
patients  O
(  O
10  O
%  O
)  O
and  O
paclitaxel  B-DRUG
was  O
reduced  O
in  O
eight  O
(  O
20  O
%  O
)  O
.  O

At  O
a  O
median  O
follow-up  O
from  O
surgery  O
of  O
48  O
months  O
(  O
range  O
,  O
3  O
to  O
57  O
months  O
)  O
,  O
nine  O
patients  O
(  O
19  O
%  O
)  O
had  O
relapsed  B-TOXI
,  O
the  O
actuarial  O
disease-free  O
survival  O
rate  O
was  O
78  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
66  O
%  O
to  O
92  O
%  O
)  O
,  O
and  O
four  O
patients  O
(  O
10  O
%  O
)  O
had  O
died  B-TOXI
of  I-TOXI
metastatic  I-TOXI
disease  I-TOXI
.  O

Dose-dense  O
sequential  O
adjuvant  O
chemotherapy  O
with  O
doxorubicin  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
cyclophosphamide  B-DRUG
(  O
A  O
--  O
&  O
gt  O
;  O
T  O
--  O
&  O
gt  O
;  O
C  O
)  O
is  O
feasible  O
and  O
promising  O
.  O

Several  O
ongoing  O
phase  O
III  O
trials  O
are  O
evaluating  O
this  O
approach  O
.  O

Induction  O
with  O
mitomycin  B-DRUG
C  I-DRUG
,  O
doxorubicin  B-DRUG
,  O
cisplatin  B-DRUG
and  O
maintenance  O
with  O
weekly  O
5-fluorouracil  B-DRUG
,  O
leucovorin  B-DRUG
for  O
treatment  O
of  O
metastatic  B-CANCER
nasopharyngeal  I-CANCER
carcinoma  I-CANCER
:  O
a  O
phase  O
II  O
study  O
.  O


The  O
combination  O
of  O
cisplatin  B-DRUG
and  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
(  O
PF  B-DRUG
)  O
is  O
the  O
most  O
popular  O
regimen  O
for  O
treating  O
metastatic  B-CANCER
nasopharyngeal  I-CANCER
carcinoma  I-CANCER
(  O
NPC  B-CANCER
)  O
but  O
it  O
is  O
limited  O
by  O
severe  B-TOXI
stomatitis  I-TOXI
and  O
chronic  B-TOXI
cisplatin-related  I-TOXI
toxicity  I-TOXI
.  O

A  O
novel  O
approach  O
including  O
induction  O
with  O
mitomycin  B-DRUG
C  I-DRUG
,  O
doxorubicin  B-DRUG
and  O
cisplatin  B-DRUG
(  O
MAP  B-DRUG
)  O
and  O
subsequent  O
maintenance  O
with  O
weekly  O
5-FU  B-DRUG
and  O
leucovorin  B-DRUG
(  O
FL  B-DRUG
)  O
were  O
designed  O
with  O
an  O
aim  O
to  O
reduce  O
acute  B-TOXI
and  I-TOXI
chronic  I-TOXI
toxicity  I-TOXI
of  O
PF  B-DRUG
.  O

Thirty-two  O
patients  O
of  O
NPC  B-CANCER
with  O
measurable  O
metastatic  B-TOXI
lesions  I-TOXI
in  I-TOXI
the  I-TOXI
liver  I-TOXI
or  I-TOXI
lung  I-TOXI
were  O
entered  O
into  O
this  O
phase  O
II  O
trial  O
.  O

Mitomycin  B-DRUG
C  I-DRUG
8  O
mg  O
m  O
(  O
-2  O
)  O
,  O
doxorubicin  B-DRUG
40  O
mg  O
m  O
(  O
-2  O
)  O
and  O
cisplatin  B-DRUG
60  O
mg  O
m  O
(  O
-2  O
)  O
were  O
given  O
on  O
day  O
1  O
every  O
3  O
weeks  O
as  O
initial  O
induction  O
.  O

After  O
either  O
four  O
courses  O
or  O
remission  O
was  O
achieved  O
,  O
patients  O
received  O
weekly  O
dose  O
of  O
5-FU  B-DRUG
450  O
mg  O
m  O
(  O
-2  O
)  O
and  O
leucovorin  B-DRUG
30  O
mg  O
m  O
(  O
-2  O
)  O
for  O
maintenance  O
until  O
disease  B-TOXI
progression  I-TOXI
.  O

With  O
105  O
courses  O
of  O
MAP  B-DRUG
given  O
,  O
5  O
%  O
were  O
accompanied  O
by  O
grade  O
3  O
and  O
0  O
%  O
were  O
accompanied  O
by  O
grade  O
4  O
stomatitis  B-TOXI
.  O

The  O
dose-limiting  B-TOXI
toxicity  I-TOXI
of  O
MAP  B-DRUG
was  O
myelosuppression  B-TOXI
.  O

Forty  O
per  O
cent  O
of  O
courses  O
had  O
grade  O
3  O
and  O
13  O
%  O
of  O
courses  O
had  O
grade  O
4  O
leukopenia  B-TOXI
.  O

No  O
grade  O
3  O
or  O
4  O
cisplatin-related  B-TOXI
toxicity  I-TOXI
was  O
observed  O
.  O

The  O
overall  O
response  O
rate  O
was  O
94  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
84.9-100  O
%  O
)  O
with  O
a  O
complete  O
response  O
rate  O
(  O
CR  O
)  O
of  O
6  O
%  O
(  O
95  O
%  O
CI  O
:  O
0-15.2  O
%  O
)  O
and  O
a  O
good  O
partial  O
response  O
(  O
PR  O
)  O
rate  O
of  O
28  O
%  O
(  O
95  O
%  O
CI  O
11.7-44.6  O
%  O
)  O
,  O
which  O
was  O
optionally  O
defined  O
as  O
observance  O
of  O
only  O
equivocal  B-TOXI
lesion  I-TOXI
identifiable  O
under  O
imaging  O
study  O
.  O

Twenty-seven  O
cases  O
entered  O
weekly  O
FL  B-DRUG
maintenance  O
phase  O
.  O

The  O
median  O
duration  O
of  O
maintenance  O
with  O
weekly  O
FL  B-DRUG
was  O
38  O
weeks  O
(  O
8-91  O
weeks  O
)  O
.  O

There  O
was  O
no  O
grade  O
3  O
or  O
4  O
toxicity  B-TOXI
noted  O
during  O
weekly  O
FL  B-DRUG
.  O

The  O
median  O
progression-free  O
survival  O
and  O
overall  O
survival  O
were  O
11.6+  O
/  O
-0.4  O
and  O
18.1+  O
/  O
-3.6  O
months  O
respectively  O
.  O

Six  O
patients  O
with  O
a  O
median  O
follow-up  O
of  O
19.8  O
months  O
(  O
9.6-41.0  O
months  O
)  O
were  O
still  O
alive  O
and  O
five  O
of  O
them  O
had  O
disease  O
under  O
control  O
with  O
FL  B-DRUG
.  O

Good  O
responders  O
(  O
CR  O
and  O
good  O
PR  O
)  O
had  O
better  O
survival  O
than  O
less  O
satisfactory  O
responders  O
(  O
PR  O
and  O
stable  O
disease  O
)  O
(  O
P  O
=  O
0.05  O
)  O
.  O

From  O
Cox  O
's  O
multivariate  O
regression  O
analysis  O
,  O
the  O
only  O
significant  O
prognostic  O
factor  O
for  O
survival  O
was  O
good  O
response  O
to  O
MAP  B-DRUG
(  O
P  O
=  O
0.042  O
)  O
.  O

Liver  B-TOXI
metastasis  I-TOXI
was  O
the  O
only  O
significant  O
variable  O
in  O
the  O
best  O
subset  O
regression  O
model  O
that  O
predicted  O
good  O
response  O
to  O
MAP  B-DRUG
(  O
CR  O
and  O
good  O
PR  O
)  O
(  O
P  O
=  O
0.027  O
)  O
.  O

MAP  B-DRUG
was  O
an  O
effective  O
combination  O
for  O
metastatic  O
NPC  O
with  O
minimal  B-TOXI
stomatitis  I-TOXI
and  O
cisplatin-related  B-TOXI
toxicity  I-TOXI
but  O
had  O
significant  O
myelosuppression  B-TOXI
.  O

Weekly  O
FL  B-DRUG
was  O
a  O
maintenance  O
therapy  O
with  O
minimal  B-TOXI
side-effects  I-TOXI
.  O

The  O
response  O
rate  O
and  O
overall  O
survival  O
of  O
MAP-FL  B-DRUG
were  O
better  O
than  O
series  O
previously  O
reported  O
even  O
when  O
a  O
subset  O
of  O
patients  O
with  O
poor  B-TOXI
prognosis  I-TOXI
was  O
selected  O
.  O

MAP-FL  B-DRUG
's  I-DRUG
role  O
as  O
neoadjuvant  O
or  O
adjuvant  O
therapy  O
is  O
worthy  O
of  O
further  O
study  O
.  O

Phase  O
II  O
study  O
of  O
area  O
under  O
the  O
plasma-concentration-versus-time  O
curve-based  O
carboplatin  B-DRUG
plus  O
standard-dose  O
intravenous  O
etoposide  B-DRUG
in  O
elderly  O
patients  O
with  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


The  O
target  O
area  O
under  O
the  O
plasma-concentration-versus-time  O
curve  O
(  O
AUC  O
)  O
-based  O
dosing  O
of  O
carboplatin  B-DRUG
using  O
Calvert  O
's  O
formula  O
is  O
expected  O
to  O
result  O
in  O
more  O
acceptable  B-TOXI
toxicity  I-TOXI
and  O
greater  O
efficacy  O
in  O
elderly  O
patients  O
with  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
SCLC  B-CANCER
)  O
than  O
the  O
body  O
surface  O
area-based  O
dosing  O
strategy  O
.  O

This  O
phase  O
II  O
study  O
was  O
designed  O
to  O
determine  O
the  O
toxicity  O
and  O
efficacy  O
of  O
carboplatin  B-DRUG
based  O
on  O
Calvert  O
's  O
formula  O
plus  O
the  O
standard  O
dose  O
of  O
intravenous  O
etoposide  B-DRUG
for  O
elderly  O
patients  O
with  O
SCLC  B-CANCER
.  O

Carboplatin  B-DRUG
,  O
dosed  O
to  O
a  O
target  O
AUC  O
of  O
5  O
x  O
(  O
24-hour  O
creatinine  O
clearance  O
+  O
25  O
)  O
,  O
was  O
given  O
intravenously  O
on  O
day  O
1  O
and  O
etoposide  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
was  O
given  O
intravenously  O
on  O
days  O
1  O
,  O
2  O
,  O
and  O
3.  O
Patients  O
aged  O
&  O
gt  O
;  O
/  O
=  O
70  O
years  O
old  O
with  O
a  O
performance  O
status  O
of  O
0  O
to  O
2  O
were  O
eligible  O
.  O

Thirty-six  O
patients  O
were  O
enrolled  O
onto  O
the  O
study  O
.  O

The  O
patient  O
characteristics  O
were  O
as  O
follows  O
:  O
median  O
age  O
,  O
73  O
years  O
;  O
limited  B-TOXI
disease  I-TOXI
(  O
LD  O
)  O
,  O
16  O
patients  O
;  O
and  O
extensive  B-TOXI
disease  I-TOXI
(  O
ED  O
)  O
,  O
20  O
patients  O
.  O

Grades  O
3  O
and  O
4  O
leukopenia  B-TOXI
occurred  O
in  O
57  O
%  O
and  O
3  O
%  O
of  O
patients  O
,  O
and  O
grades  O
3  O
and  O
4  O
thrombocytopenia  B-TOXI
occurred  O
in  O
40  O
%  O
and  O
11  O
%  O
of  O
patients  O
,  O
respectively  O
.  O

There  O
was  O
one  O
treatment-related  B-TOXI
death  I-TOXI
due  O
to  O
hemoptysis  B-TOXI
.  O

Other  O
toxicities  B-TOXI
were  O
relatively  O
mild  O
.  O

There  O
were  O
two  O
complete  O
responses  O
and  O
25  O
partial  O
responses  O
,  O
for  O
a  O
response  O
rate  O
of  O
75  O
%  O
.  O

The  O
median  O
survival  O
time  O
was  O
10.8  O
months  O
(  O
LD  O
,  O
11.6  O
months  O
;  O
ED  O
,  O
10.1  O
months  O
)  O
,  O
and  O
the  O
1-year  O
survival  O
rate  O
was  O
47  O
%  O
.  O

This  O
carboplatin  B-DRUG
/  I-DRUG
etoposide  I-DRUG
combination  O
chemotherapy  O
is  O
an  O
active  O
and  O
relatively  O
nontoxic  O
regimen  O
in  O
elderly  O
patients  O
with  O
SCLC  B-CANCER
,  O
which  O
suggests  O
that  O
the  O
combination  O
may  O
be  O
suitable  O
for  O
randomized  O
controlled  O
trials  O
.  O

Multicenter  O
phase  O
II  O
study  O
of  O
bimonthly  O
high-dose  O
leucovorin  B-DRUG
,  O
fluorouracil  B-DRUG
infusion  I-DRUG
,  O
and  O
oxaliplatin  B-DRUG
for  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
resistant  O
to  O
the  O
same  O
leucovorin  B-DRUG
and  O
fluorouracil  B-DRUG
regimen  O
.  O


To  O
evaluate  O
the  O
objective  O
tumor  B-CANCER
response  O
rates  O
and  O
toxicities  B-TOXI
of  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
plus  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
cancer  O
regimen  O
combined  O
with  O
oxaliplatin  B-DRUG
(  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
every  O
2  O
weeks  O
on  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
patients  O
with  O
documented  O
proof  O
of  O
progression  O
while  O
on  O
bimonthly  O
LV  B-DRUG
and  O
5-FU  B-DRUG
alone  O
.  O

One  O
hundred  O
patients  O
were  O
enrolled  O
onto  O
this  O
study  O
and  O
97  O
received  O
the  O
study  O
drugs  O
between  O
October  O
1995  O
and  O
December  O
1996  O
.  O

Eighty-nine  O
patients  O
were  O
eligible  O
for  O
per-protocol  O
efficacy  O
analysis  O
with  O
documented  O
proof  O
of  O
progression  O
on  O
one  O
of  O
the  O
following  O
two  O
treatments  O
:  O
LV  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
continuous  O
5-FU  B-DRUG
infusion  O
1.5  O
to  O
2  O
g  O
/  O
m  O
(  O
2  O
)  O
/  O
22  O
hours  O
,  O
days  O
1  O
through  O
2  O
every  O
2  O
weeks  O
(  O
FOLFUHD  O
)  O
;  O
or  O
LV  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
bolus  O
5-FU  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
continuous  O
5-FU  B-DRUG
infusion  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
22  O
hours  O
,  O
days  O
1  O
through  O
2  O
every  O
2  O
weeks  O
(  O
LV5FU2  B-DRUG
)  O
.  O

In  O
our  O
study  O
,  O
40  O
patients  O
received  O
FOLFUHD  B-DRUG
+  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
of  O
oxaliplatin  B-DRUG
day  O
1  O
(  O
FOLFOX3  B-DRUG
)  O
and  O
57  O
patients  O
received  O
LV5FU2  B-DRUG
+  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
of  O
oxaliplatin  B-DRUG
day  O
1  O
(  O
FOLFOX4  B-DRUG
)  O
.  O

Of  O
the  O
97  O
patients  O
treated  O
,  O
20  O
partial  O
responses  O
were  O
observed  O
(  O
FOLFOX3  B-DRUG
/  I-DRUG
4  I-DRUG
:  O
response  O
rate  O
,  O
20.6  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
,  O
13  O
%  O
to  O
31.1  O
%  O
;  O
FOLFOX3  B-DRUG
:  O
response  O
rate,18.4  O
%  O
;  O
FOLFOX4  B-DRUG
:  O
response  O
rate  O
,  O
23.5  O
%  O
)  O
.  O

For  O
patients  O
treated  O
with  O
FOLFOX3  B-DRUG
/  I-DRUG
4  I-DRUG
,  O
the  O
median  O
response  O
duration  O
for  O
was  O
7.5  O
months  O
,  O
and  O
the  O
major  O
toxicities  O
were  O
peripheral  B-TOXI
neuropathy  I-TOXI
and  O
neutropenia  B-TOXI
.  O

The  O
incidence  O
of  O
grade  O
3  O
(  O
National  O
Cancer  O
Institute  O
common  O
toxicity  O
criteria  O
)  O
peripheral  B-TOXI
neuropathy  I-TOXI
was  O
20.6  O
%  O
;  O
whereas  O
the  O
overall  O
incidence  O
of  O
grade  O
3  O
to  O
4  O
neutropenia  B-TOXI
was  O
27.8  O
%  O
,  O
15  O
%  O
,  O
and  O
36.9  O
%  O
for  O
FOLFOX3  B-DRUG
/  I-DRUG
4  I-DRUG
,  O
FOLFOX3  B-DRUG
,  O
and  O
FOLFOX4  B-DRUG
,  O
respectively  O
(  O
P  O
=.02  O
)  O
.  O

From  O
the  O
start  O
of  O
treatment  O
,  O
median  O
progression-free  O
survival  O
was  O
4.  O
7  O
,  O
4.6  O
,  O
and  O
5.1  O
months  O
for  O
FOLFOX3  B-DRUG
/  I-DRUG
4  I-DRUG
,  O
FOLFOX3  B-DRUG
,  O
FOLFOX4  B-DRUG
,  O
respectively  O
,  O
and  O
median  O
overall  O
survival  O
was  O
10.8  O
,  O
10.6  O
,  O
and  O
11.1  O
months  O
,  O
respectively  O
.  O

This  O
phase  O
II  O
study  O
of  O
oxaliplatin  B-DRUG
at  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
combination  O
with  O
bimonthly  O
LV  B-DRUG
plus  O
5-FU  B-DRUG
in  O
patients  O
with  O
colorectal  B-CANCER
cancer  I-CANCER
resistant  O
to  O
LV  B-DRUG
plus  O
5-FU  B-DRUG
alone  O
confirms  O
the  O
enhanced  O
antitumor  O
activity  O
of  O
oxaliplatin  B-DRUG
in  O
combination  O
with  O
5-FU  B-DRUG
.  O

Paclitaxel  B-DRUG
and  O
cisplatin  B-DRUG
as  O
first-line  O
therapy  O
in  O
recurrent  O
or  O
advanced  B-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
cervix  I-CANCER
:  O
a  O
gynecologic  O
oncology  O
group  O
study  O
.  O


On  O
the  O
basis  O
of  O
the  O
activity  O
of  O
paclitaxel  B-DRUG
as  O
a  O
single  O
agent  O
in  O
chemotherapy-naive  B-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
cervix  I-CANCER
in  O
a  O
prior  O
Gynecologic  O
Oncology  O
Group  O
(  O
GOG  O
)  O
trial  O
,  O
a  O
phase  O
II  O
study  O
of  O
paclitaxel  B-DRUG
and  O
cisplatin  B-DRUG
as  O
first-line  O
therapy  O
was  O
conducted  O
by  O
the  O
GOG  O
.  O

Eligibility  O
included  O
squamous  B-CANCER
cell  I-CANCER
cancer  I-CANCER
of  I-CANCER
the  I-CANCER
cervix  I-CANCER
not  O
curable  O
by  O
surgery  O
or  O
radiation  O
,  O
measurable  O
disease  O
,  O
WBC  O
count  O
&  O
gt  O
;  O
or  O
=  O
3,000  O
/  O
microL  O
,  O
platelet  O
count  O
&  O
gt  O
;  O
or  O
=  O
100  O
,  O
000  O
/  O
microL  O
,  O
serum  O
creatinine  O
&  O
gt  O
;  O
or  O
=  O
2  O
mg  O
/  O
100  O
mL  O
,  O
and  O
adequate  O
hepatic  O
function  O
.  O

The  O
starting  O
dose  O
was  O
paclitaxel  B-DRUG
135  O
mg  O
/  O
m  O
(  O
2  O
)  O
infused  O
over  O
24  O
hours  O
followed  O
by  O
cisplatin  B-DRUG
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
21  O
days  O
.  O

On  O
the  O
basis  O
of  O
toxicity  O
,  O
a  O
dose  O
escalation  O
of  O
paclitaxel  B-DRUG
to  O
a  O
maximum  O
dose  O
of  O
170  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
was  O
prescribed  O
.  O

Forty-seven  O
patients  O
were  O
enrolled  O
onto  O
this  O
study  O
;  O
44  O
patients  O
were  O
assessable  O
for  O
toxicity  O
and  O
41  O
for  O
response  O
.  O

Forty  O
(  O
90.9  O
%  O
)  O
had  O
received  O
prior  O
radiation  O
therapy  O
.  O

A  O
median  O
of  O
six  O
courses  O
of  O
chemotherapy  O
was  O
given  O
(  O
range  O
,  O
one  O
to  O
10  O
courses  O
)  O
.  O

Neutropenia  B-TOXI
grade  O
3  O
(  O
15.9  O
%  O
)  O
and  O
4  O
(  O
61.4  O
%  O
)  O
was  O
the  O
most  O
frequent  O
severe  B-TOXI
adverse  I-TOXI
effect  I-TOXI
and  O
was  O
associated  O
with  O
fever  B-TOXI
in  O
13  O
patients  O
(  O
27.7  O
%  O
)  O
.  O

Two  O
patients  O
(  O
4.5  O
%  O
)  O
died  O
from  O
neutropenic  B-TOXI
sepsis  I-TOXI
.  O

Grade  O
4  O
thrombocytopenia  B-TOXI
occurred  O
in  O
6.8  O
%  O
of  O
patients  O
.  O

Of  O
41  O
assessable  O
patients  O
,  O
five  O
(  O
12.2  O
%  O
)  O
had  O
complete  O
responses  O
and  O
14  O
(  O
34.1  O
%  O
)  O
had  O
partial  O
responses  O
for  O
an  O
overall  O
response  O
rate  O
of  O
46.3  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
30.7  O
%  O
to  O
62.6  O
%  O
)  O
.  O

The  O
median  O
progression-free  O
interval  O
,  O
was  O
5.4+  O
months  O
(  O
range  O
,  O
0.3  O
to  O
22+  O
months  O
)  O
with  O
a  O
median  O
survival  O
of  O
10.0+  O
months  O
(  O
range  O
,  O
0.9  O
to  O
22  O
.  O

2  O
months  O
)  O
.  O

Response  O
was  O
more  O
frequent  O
in  O
patients  O
with  O
disease  B-TOXI
in  I-TOXI
nonirradiated  I-TOXI
sites  I-TOXI
(  O
70  O
%  O
v  O
23  O
%  O
,  O
P  O
=.008  O
)  O
.  O

This  O
regimen  O
seems  O
highly  O
active  O
in  O
advanced  B-CANCER
and  I-CANCER
recurrent  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
cervix  I-CANCER
and  O
is  O
currently  O
being  O
evaluated  O
by  O
the  O
GOG  O
in  O
a  O
phase  O
III  O
randomized  O
study  O
comparing  O
the  O
combination  O
of  O
paclitaxel  B-DRUG
and  O
cisplatin  B-DRUG
with  O
cisplatin  B-DRUG
alone  O
.  O

Irinotecan  B-DRUG
combined  O
with  O
bolus  B-DRUG
fluorouracil  I-DRUG
,  O
continuous  O
infusion  O
fluorouracil  B-DRUG
,  O
and  O
high-dose  O
leucovorin  B-DRUG
every  O
two  O
weeks  O
(  O
LV5FU2  B-DRUG
regimen  O
)  O
:  O
a  O
clinical  O
dose-finding  O
and  O
pharmacokinetic  O
study  O
in  O
patients  O
with  O
pretreated  B-CANCER
metastatic  I-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
recommended  O
dose  O
of  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
in  O
combination  O
with  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
and  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
,  O
using  O
a  O
biweekly  O
LV5FU2  B-DRUG
regimen  O
and  O
increasing  O
doses  O
of  O
CPT-11  B-DRUG
,  O
and  O
to  O
assess  O
the  O
efficacy  O
of  O
this  O
combination  O
in  O
pretreated  O
patients  O
with  O
colorectal  B-CANCER
cancer  I-CANCER
(  O
CRC  B-CANCER
)  O
.  O

All  O
patients  O
had  O
metastatic  B-CANCER
CRC  I-CANCER
and  O
a  O
World  O
Health  O
Organization  O
performance  O
status  O
of  O
0  O
or  O
1.  O
CPT-11  B-DRUG
was  O
administered  O
over  O
a  O
90-minute  O
infusion  O
every  O
2  O
weeks  O
at  O
a  O
range  O
of  O
dose  O
levels  O
(  O
100  O
,  O
120  O
,  O
150  O
,  O
180  O
,  O
200  O
,  O
220  O
,  O
and  O
260  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
.  O

LV5FU2  B-DRUG
was  O
started  O
1  O
hour  O
after  O
the  O
end  O
of  O
the  O
biweekly  O
CPT-11  B-DRUG
infusion  O
and  O
was  O
also  O
administered  O
on  O
day  O
2.  O
Fifty-five  O
patients  O
were  O
entered  O
onto  O
this  O
trial  O
;  O
549  O
cycles  O
were  O
administered  O
.  O

The  O
MTD  O
was  O
not  O
reached  O
at  O
260  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
a  O
dose  O
level  O
of  O
300  O
mg  O
/  O
m  O
(  O
2  O
)  O
was  O
added  O
.  O

The  O
MTD  O
as  O
defined  O
in  O
the  O
protocol  O
was  O
not  O
reached  O
at  O
this  O
dose  O
level  O
either  O
,  O
but  O
all  O
patients  O
had  O
cycles  O
delayed  O
and  O
/  O
or  O
required  O
a  O
dose  O
reduction  O
.  O

This  O
dose  O
was  O
deemed  O
to  O
be  O
the  O
MTD  O
.  O

To  O
take  O
into  O
account  O
both  O
the  O
toxicity  O
of  O
and  O
compliance  O
with  O
the  O
biweekly  O
schedule  O
,  O
the  O
recommended  O
CPT-11  B-DRUG
dose  O
was  O
established  O
at  O
180  O
to  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Antitumor  O
activity  O
was  O
observed  O
at  O
almost  O
all  O
dose  O
levels  O
,  O
with  O
an  O
objective  O
response  O
rate  O
of  O
22  O
%  O
.  O

Median  O
time  O
to  O
progression  O
was  O
6.3  O
months  O
and  O
overall  O
survival  O
was  O
15  O
months  O
.  O

The  O
biweekly  O
CPT-11  B-DRUG
/  O
LV5FU2  B-DRUG
combination  O
is  O
feasible  O
and  O
safe  O
,  O
without  O
overlapping  O
toxicity  O
.  O

CPT-11  B-DRUG
at  O
180  O
to  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
combination  O
with  O
LV5FU2  B-DRUG
has  O
been  O
selected  O
as  O
the  O
recommended  O
dose  O
for  O
further  O
studies  O
.  O

Ifosfamide  B-DRUG
,  O
carboplatin  B-DRUG
,  O
and  O
etoposide  B-DRUG
:  O
a  O
highly  O
effective  O
cytoreduction  B-TOXI
and  O
peripheral-blood  B-TOXI
progenitor-cell  I-TOXI
mobilization  I-TOXI
regimen  O
for  O
transplant-eligible  O
patients  O
with  O
non-Hodgkin  B-CANCER
's  I-CANCER
lymphoma  I-CANCER
.  O


To  O
evaluate  O
a  O
chemotherapy  O
regimen  O
that  O
consisted  O
of  O
ifosfamide  B-DRUG
administered  O
as  O
an  O
infusion  O
with  O
bolus  B-DRUG
carboplatin  I-DRUG
,  O
and  O
etoposide  B-DRUG
(  O
ICE  B-DRUG
)  O
supported  O
by  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
(  O
G-CSF  B-DRUG
)  O
for  O
cytoreduction  B-TOXI
and  O
stem-cell  B-TOXI
mobilization  I-TOXI
in  O
transplant-eligible  O
patients  O
with  O
primary  O
refractory  O
or  O
relapsed  O
non-Hodgkin  B-CANCER
's  I-CANCER
lymphoma  I-CANCER
(  O
NHL  B-CANCER
)  O
.  O

One  O
hundred  O
sixty-three  O
transplant-eligible  O
patients  O
with  O
relapsed  O
or  O
primary  O
refractory  O
NHL  B-CANCER
were  O
treated  O
from  O
October  O
1993  O
to  O
December  O
1997  O
with  O
ICE  B-DRUG
chemotherapy  O
at  O
Memorial  O
Sloan-Kettering  O
Cancer  O
Center  O
.  O

Administration  O
of  O
three  O
cycles  O
of  O
ICE  B-DRUG
chemotherapy  O
was  O
planned  O
at  O
2-week  O
intervals  O
.  O

Peripheral-blood  O
progenitor  O
cells  O
were  O
collected  O
after  O
cycle  O
3  O
,  O
and  O
all  O
patients  O
who  O
achieved  O
a  O
partial  O
response  O
(  O
PR  O
)  O
or  O
complete  O
response  O
(  O
CR  O
)  O
to  O
ICE  B-DRUG
chemotherapy  O
were  O
eligible  O
to  O
proceed  O
to  O
transplantation  O
.  O

Event-free  O
and  O
overall  O
survival  O
,  O
ICE-related  B-TOXI
toxicity  I-TOXI
,  O
and  O
the  O
number  O
of  O
CD34  O
(  O
+  O
)  O
cells  O
collected  O
after  O
treatment  O
with  O
ICE  B-DRUG
and  O
G-CSF  B-DRUG
were  O
evaluated  O
.  O

All  O
163  O
patients  O
were  O
assessable  O
for  O
response  O
,  O
and  O
there  O
was  O
no  O
treatment-related  O
mortality  O
.  O

A  O
major  O
response  O
(  O
CR  O
/  O
PR  O
)  O
was  O
evident  O
in  O
108  O
patients  O
(  O
66.3  O
%  O
)  O
;  O
89  O
%  O
of  O
the  O
responding  O
patients  O
underwent  O
successful  O
transplantation  O
.  O

Patient  O
who  O
underwent  O
transplantation  O
and  O
achieved  O
a  O
CR  O
to  O
ICE  B-DRUG
had  O
a  O
superior  O
overall  O
survival  O
to  O
that  O
of  O
patients  O
who  O
achieved  O
a  O
PR  O
(  O
65  O
%  O
v  O
30  O
%  O
;  O
P  O
=.003  O
)  O
.  O

The  O
median  O
number  O
of  O
CD34  O
(  O
+  O
)  O
cells  O
/  O
kg  O
collected  O
was  O
8.4  O
x  O
10  O
(  O
6  O
)  O
.  O

The  O
dose-limiting  B-TOXI
toxicity  I-TOXI
of  O
ICE  B-DRUG
was  O
hematologic  B-TOXI
,  O
with  O
29.4  O
%  O
of  O
patients  O
developing  O
grade  O
3  O
/  O
4  O
thrombocytopenia  B-TOXI
.  O

There  O
were  O
minimal  B-TOXI
nonhematologic  I-TOXI
side  I-TOXI
effects  I-TOXI
.  O

ICE  B-DRUG
chemotherapy  O
,  O
with  O
ifosfamide  B-DRUG
administered  O
as  O
a  O
24-hour  O
infusion  O
to  O
decrease  O
CNS  B-TOXI
side  I-TOXI
effects  I-TOXI
,  O
and  O
the  O
substitution  O
of  O
carboplatin  B-DRUG
for  O
cisplatin  B-DRUG
to  O
minimize  O
nephrotoxicity  B-TOXI
,  O
is  O
a  O
very  O
effective  O
cytoreduction  B-TOXI
and  O
mobilization  B-TOXI
regimen  O
in  O
patients  O
with  O
NHL  B-CANCER
.  O

Furthermore  O
,  O
the  O
quality  O
of  O
the  O
clinical  O
response  O
to  O
ICE  B-DRUG
predicts  O
for  O
posttransplant  O
outcome  O
.  O

A  O
phase  O
I  O
study  O
of  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
in  O
patients  O
with  O
metastatic  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


A  O
Phase  O
I  O
study  O
was  O
initiated  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
of  O
weekly  O
gemcitabine  B-DRUG
combined  O
with  O
monthly  O
,  O
fixed-dose  O
docetaxel  B-DRUG
.  O

Patients  O
with  O
metastatic  B-CANCER
solid  I-CANCER
tumors  I-CANCER
were  O
treated  O
with  O
docetaxel  B-DRUG
,  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
on  O
Day  O
1  O
every  O
28  O
days  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
on  O
Days  O
1  O
,  O
8  O
,  O
and  O
15  O
and  O
underwent  O
dose  O
adjustment  O
in  O
cohorts  O
of  O
3-6  O
patients  O
.  O

At  O
the  O
maximum  O
tolerated  O
dose  O
,  O
11  O
additional  O
patients  O
were  O
enrolled  O
.  O

Twenty-six  O
patients  O
received  O
85  O
cycles  O
of  O
therapy  O
.  O

At  O
the  O
first  O
dose  O
level  O
,  O
the  O
planned  O
gemcitabine  B-DRUG
dose  O
on  O
Days  O
1  O
,  O
8  O
,  O
and  O
15  O
was  O
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Two  O
of  O
the  O
6  O
patients  O
treated  O
at  O
this  O
dose  O
level  O
experienced  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
requiring  O
the  O
reduction  O
of  O
gemcitabine  B-DRUG
to  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
dose  O
and  O
the  O
administration  O
of  O
ciprofloxacin  B-DRUG
,  O
500  O
mg  O
orally  O
twice  O
daily  O
,  O
on  O
Days  O
8-18  O
.  O

At  O
the  O
second  O
dose  O
level  O
the  O
first  O
3  O
patients  O
experienced  O
no  O
DLTs  O
and  O
the  O
dose  O
of  O
gemcitabine  B-DRUG
was  O
increased  O
to  O
700  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Two  O
of  O
the  O
6  O
patients  O
treated  O
at  O
the  O
700  O
mg  O
/  O
m  O
(  O
2  O
)  O
dose  O
level  O
experienced  O
DLTs  O
.  O

Eleven  O
additional  O
patients  O
were  O
enrolled  O
at  O
the  O
recommended  O
Phase  O
II  O
dose  O
of  O
gemcitabine  B-DRUG
(  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
.  O

At  O
this  O
dose  O
level  O
,  O
Grade  O
3  O
/  O
4  O
(  O
according  O
the  O
National  O
Cancer  O
Institute  O
's  O
common  O
toxicity  O
criteria  O
)  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
occurred  O
in  O
12.5  O
%  O
and  O
2.1  O
%  O
of  O
cycles  O
,  O
respectively  O
.  O

Grade  O
3  O
and  O
4  O
nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
uncommon  O
.  O

Three  O
of  O
seven  O
evaluable  O
patients  O
with  O
pancreatic  B-CANCER
carcinoma  I-CANCER
had  O
evidence  O
of  O
significant  O
antineoplastic  O
activity  O
(  O
three  O
partial  O
responses  O
)  O
.  O

In  O
addition  O
,  O
two  O
complete  O
responses  O
(  O
one  O
patient  O
with  O
gastric  B-CANCER
carcinoma  I-CANCER
and  O
one  O
patient  O
with  O
ovarian  B-CANCER
carcinoma  I-CANCER
)  O
and  O
one  O
partial  O
response  O
(  O
patient  O
with  O
hepatocellular  B-CANCER
carcinoma  I-CANCER
)  O
were  O
noted  O
in  O
patients  O
with  O
other  O
solid  B-CANCER
tumors  I-CANCER
.  O

The  O
regimen  O
comprised  O
of  O
docetaxel  B-DRUG
,  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
on  O
Day  O
1  O
and  O
gemcitabine  B-DRUG
,  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
on  O
Days  O
1  O
,  O
8  O
,  O
and  O
15  O
with  O
ciprofloxacin  B-DRUG
on  O
Days  O
8-18  O
every  O
28  O
days  O
is  O
safe  O
,  O
well  O
tolerated  O
,  O
and  O
active  O
.  O

Phase  O
I  O
study  O
of  O
3-week  O
schedule  O
of  O
irinotecan  B-DRUG
combined  O
with  O
cisplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


To  O
assess  O
the  O
feasibility  O
,  O
pharmacokinetic  O
interaction  O
,  O
and  O
possible  O
sequence-dependent  O
effects  O
of  O
the  O
irinotecan  B-DRUG
/  I-DRUG
cisplatin  I-DRUG
combination  O
given  O
every  O
3  O
weeks  O
,  O
and  O
to  O
assess  O
the  O
influence  O
of  O
additional  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
(  O
G-CSF  B-DRUG
)  O
on  O
the  O
hematologic  B-TOXI
toxicity  I-TOXI
.  O

Patients  O
who  O
had  O
received  O
no  O
more  O
than  O
one  O
prior  O
combination  O
chemotherapy  O
regimen  O
or  O
two  O
single-agent  O
regimens  O
were  O
entered  O
.  O

Treatment  O
consisted  O
of  O
a  O
90-minute  O
irinotecan  B-DRUG
infusion  O
followed  O
by  O
a  O
3-hour  O
cisplatin  B-DRUG
infusion  O
on  O
day  O
1  O
,  O
with  O
cycles  O
repeated  O
once  O
every  O
3  O
weeks  O
.  O

After  O
the  O
maximum-tolerated  O
dose  O
was  O
determined  O
,  O
the  O
sequence  O
of  O
administration  O
was  O
reversed  O
.  O

In  O
a  O
separate  O
cohort  O
of  O
six  O
patients  O
,  O
we  O
assessed  O
the  O
effect  O
of  O
G-CSF  B-DRUG
on  O
the  O
experienced  O
hematologic  B-TOXI
toxicity  I-TOXI
and  O
dose-intensity  O
.  O

Irinotecan  B-DRUG
doses  O
ranged  O
from  O
175  O
to  O
300  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
cisplatin  B-DRUG
doses  O
ranged  O
from  O
60  O
to  O
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Fifty-two  O
patients  O
entered  O
the  O
study  O
;  O
one  O
was  O
not  O
eligible  O
,  O
and  O
two  O
were  O
not  O
assessable  O
for  O
response  O
.  O

Twenty-five  O
patients  O
were  O
pretreated  O
,  O
and  O
26  O
were  O
not  O
.  O

Fifty-one  O
patients  O
received  O
a  O
total  O
of  O
223  O
courses  O
.  O

The  O
dose-limiting  O
toxicity  O
was  O
a  O
combination  O
of  O
neutropenic  B-TOXI
fever  I-TOXI
,  O
diarrhea  B-TOXI
,  O
and  O
fatigue  B-TOXI
at  O
a  O
dose  O
level  O
combining  O
irinotecan  B-DRUG
300  O
mg  O
/  O
m  O
(  O
2  O
)  O
with  O
cisplatin  B-DRUG
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Neutropenia  B-TOXI
was  O
common  O
(  O
grades  O
3  O
to  O
4  O
,  O
68  O
%  O
)  O
.  O

Irinotecan  B-DRUG
pharmacokinetics  O
were  O
linear  O
over  O
the  O
dose  O
range  O
studied  O
.  O

No  O
sequence-dependent  O
side  O
effects  O
were  O
observed  O
.  O

Tumor  O
responses  O
included  O
three  O
complete  O
responses  O
and  O
eight  O
partial  O
responses  O
.  O

For  O
phase  O
II  O
studies  O
,  O
we  O
recommend  O
irinotecan  B-DRUG
260  O
mg  O
/  O
m  O
(  O
2  O
)  O
combined  O
with  O
cisplatin  B-DRUG
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
once  O
every  O
3  O
weeks  O
for  O
chemotherapy-naive  O
patients  O
in  O
good  O
physical  O
condition  O
,  O
and  O
irinotecan  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
combined  O
with  O
cisplatin  B-DRUG
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
for  O
other  O
patients  O
.  O

Phase  O
I  O
and  O
pharmacokinetic  O
study  O
of  O
tomudex  B-DRUG
combined  O
with  O
5-fluorouracil  B-DRUG
plus  O
levofolinic  B-DRUG
acid  I-DRUG
in  O
advanced  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
and  O
colorectal  B-CANCER
cancer  I-CANCER
.  O


In  O
vitro  O
studies  O
have  O
shown  O
a  O
schedule-dependent  O
synergism  O
between  O
Tomudex  B-DRUG
and  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
.  O

Incubation  O
of  O
different  O
types  O
of  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
and  I-CANCER
colorectal  I-CANCER
cancer  I-CANCER
cells  O
with  O
levofolinic  B-DRUG
acid  I-DRUG
(  O
LFA  B-DRUG
)  O
plus  O
5-FU  B-DRUG
for  O
4  O
or  O
24  O
h  O
,  O
after  O
24-h  O
incubation  O
with  O
Tomudex  B-DRUG
,  O
produces  O
a  O
clear  O
synergism  O
.  O

The  O
purpose  O
of  O
this  O
study  O
was  O
to  O
evaluate  O
the  O
tolerability  O
and  O
activity  O
of  O
a  O
combination  O
of  O
Tomudex  B-DRUG
,  O
LFA  B-DRUG
,  O
and  O
5-FU  B-DRUG
in  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
and  I-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Furthermore  O
,  O
the  O
potential  O
for  O
5-FU  B-DRUG
pharmacomodulation  O
by  O
Tomudex  B-DRUG
was  O
also  O
evaluated  O
through  O
an  O
intrapatient  O
assessment  O
of  O
dihydropyrimidine  B-DRUG
dehydrogenase  I-DRUG
(  O
DPD  B-DRUG
)  O
activity  O
and  O
5-FU  B-DRUG
AUC  O
with  O
and  O
without  O
pretreatment  O
with  O
Tomudex  B-DRUG
.  O

Eligible  O
patients  O
were  O
treated  O
with  O
Tomudex  B-DRUG
at  O
the  O
starting  O
dose  O
of  O
1.5  O
mg  O
/  O
m2  O
on  O
day  O
1  O
,  O
LFA  B-DRUG
at  O
a  O
fixed  O
dose  O
of  O
250  O
mg  O
/  O
m2  O
on  O
day  O
2  O
,  O
immediately  O
followed  O
by  O
bolus  O
5-FU  B-DRUG
at  O
the  O
starting  O
dose  O
of  O
600  O
mg  O
/  O
m2  O
.  O

Tomudex  B-DRUG
and  O
5-FU  B-DRUG
doses  O
were  O
alternately  O
escalated  O
.  O

Courses  O
were  O
repeated  O
every  O
2  O
weeks  O
.  O

In  O
the  O
second  O
course  O
,  O
LFA  B-DRUG
and  O
5-FU  B-DRUG
were  O
administered  O
on  O
day  O
1  O
and  O
Tomudex  B-DRUG
on  O
day  O
2  O
;  O
further  O
treatment  O
was  O
given  O
according  O
to  O
the  O
sequence  O
used  O
in  O
the  O
first  O
course  O
.  O

Plasma  O
5-FU  B-DRUG
concentrations  O
were  O
analyzed  O
on  O
courses  O
1  O
and  O
2  O
using  O
a  O
high-performance  O
liquid  O
chromatography  O
assay  O
with  O
UV  O
detection  O
.  O

DPD  B-DRUG
activity  O
was  O
measured  O
in  O
peripheral  O
blood  O
mononuclear  O
cells  O
on  O
courses  O
1  O
and  O
2  O
using  O
incubation  O
of  O
cytosol  O
with  O
[  O
14C  O
]  O
FU  B-DRUG
and  O
quantitation  O
of  O
metabolite  O
formation  O
.  O

Fifty-eight  O
patients  O
were  O
enrolled  O
in  O
the  O
study  O
.  O

Dose  O
escalation  O
was  O
stopped  O
at  O
step  O
8  O
,  O
because  O
of  O
the  O
occurrence  O
of  O
dose-limiting  O
toxicity  O
in  O
two  O
of  O
three  O
patients  O
.  O

The  O
dose  O
level  O
immediately  O
before  O
(  O
3  O
mg  O
/  O
m2  O
Tomudex  B-DRUG
,  O
1050  O
mg  O
/  O
m2  O
5-FU  B-DRUG
)  O
was  O
selected  O
for  O
further  O
evaluation  O
.  O

Tomudex  B-DRUG
and  O
5-FU  B-DRUG
mean  O
dose  O
intensities  O
actually  O
delivered  O
at  O
the  O
seventh  O
step  O
were  O
1.32  O
and  O
462  O
mg  O
/  O
m2  O
/  O
week  O
,  O
respectively  O
.  O

Six  O
of  O
40  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
obtained  O
an  O
objective  O
response  O
(  O
15  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
,  O
6-30  O
%  O
)  O
.  O

In  O
particular  O
,  O
three  O
complete  O
responses  O
and  O
three  O
partial  O
responses  O
were  O
observed  O
.  O

Six  O
of  O
17  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
or  I-CANCER
metastatic  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
obtained  O
an  O
objective  O
response  O
(  O
1  O
complete  O
response  O
+  O
5  O
partial  O
responses  O
;  O
35  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
,  O
14-62  O
%  O
)  O
.  O

Median  O
duration  O
of  O
response  O
in  O
colorectal  B-CANCER
cancer  I-CANCER
patients  O
was  O
12  O
months  O
.  O

5-FU  B-DRUG
AUC  O
was  O
not  O
significantly  O
different  O
between  O
the  O
two  O
courses  O
(  O
median  O
intrapatient  O
difference  O
,  O
9.3  O
%  O
;  O
P  O
=  O
0.28  O
)  O
.  O

DPD  B-DRUG
activity  O
in  O
course  O
1  O
was  O
significantly  O
higher  O
than  O
course  O
2  O
(  O
P  O
=  O
0.041  O
)  O
in  O
the  O
16  O
patients  O
in  O
which  O
values  O
were  O
evaluable  O
.  O

The  O
combination  O
of  O
Tomudex  B-DRUG
,  O
LFA  B-DRUG
,  O
and  O
5-FU  B-DRUG
is  O
well  O
tolerated  O
and  O
active  O
in  O
colorectal  B-CANCER
and  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
.  O

The  O
Tomudex  B-DRUG
mean  O
dose  O
intensity  O
actually  O
delivered  O
is  O
higher  O
than  O
usually  O
achieved  O
in  O
monotherapy  O
.  O

The  O
absence  O
of  O
a  O
clear  O
pharmacokinetic  O
interaction  O
suggests  O
that  O
the  O
synergism  O
of  O
Tomudex  B-DRUG
and  O
5-FU  B-DRUG
might  O
occur  O
at  O
the  O
cellular  O
level  O
.  O

Phase  O
I  O
study  O
of  O
dose-escalated  O
paclitaxel  B-DRUG
,  O
ifosfamide  B-DRUG
,  O
and  O
cisplatin  B-DRUG
(  O
PIC  B-DRUG
)  O
combination  O
chemotherapy  O
in  O
advanced  B-CANCER
solid  I-CANCER
tumours  I-CANCER
.  O


Based  O
on  O
the  O
already  O
known  O
in  O
vitro  O
synergy  O
between  O
paclitaxel  B-DRUG
(  O
taxol  B-DRUG
)  O
,  O
cisplatin  B-DRUG
and  O
oxazophosphorine  O
cytostatics  O
and  O
the  O
broad  O
spectrum  O
of  O
activity  O
of  O
the  O
above  O
drugs  O
we  O
sought  O
to  O
evaluate  O
the  O
paclitaxel  B-DRUG
(  O
taxol  B-DRUG
)  O
-ifosfamide-cisplatin  B-DRUG
(  O
PIC  B-DRUG
)  O
combination  O
in  O
the  O
outpatient  O
setting  O
in  O
individuals  O
with  O
a  O
variety  O
of  O
advanced  B-CANCER
solid  I-CANCER
tumours  I-CANCER
.  O

Cohorts  O
of  O
patients  O
were  O
entered  O
into  O
six  O
successive  O
dose  O
levels  O
(  O
DLs  O
)  O
with  O
drug  O
doses  O
ranging  O
as  O
follows  O
:  O
paclitaxel  B-DRUG
135-215  O
mg  O
m  O
(  O
-2  O
)  O
day  O
1  O
-  O
(  O
1  O
h  O
infusion  O
)  O
,  O
ifosfamide  B-DRUG
4.5-6.0  O
g  O
m  O
(  O
-2  O
)  O
(  O
total  O
dose  O
)  O
-  O
divided  O
over  O
days  O
1  O
and  O
2  O
,  O
and  O
cisplatin  B-DRUG
80-100  O
mg  O
m  O
(  O
-2  O
)  O
(  O
total  O
)  O
-  O
divided  O
over  O
days  O
1  O
and  O
2.  O
Granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
was  O
given  O
from  O
day  O
5  O
to  O
14  O
.  O

Forty-two  O
patients  O
were  O
entered  O
.  O

Eighteen  O
patients  O
had  O
2-8  O
cycles  O
of  O
prior  O
chemotherapy  O
with  O
no  O
taxanes  B-DRUG
or  O
ifosfamide  B-DRUG
(  O
cisplatin  B-DRUG
was  O
allowed  O
)  O
.  O

The  O
regimen  O
was  O
tolerated  O
with  O
outpatient  O
administration  O
in  O
36  O
/  O
42  O
patients  O
.  O

Toxicities  O
included  O
:  O
grade  O
4  O
neutropenia  B-TOXI
for  O
&  O
lt  O
;  O
or  O
=  O
5  O
days  O
in  O
27  O
%  O
of  O
cycles  O
;  O
5  O
episodes  O
of  O
febrile  B-TOXI
neutropenia  I-TOXI
in  O
three  O
patients  O
at  O
DL-III  O
,  O
-V  O
and  O
-VI  O
.  O

Grade  O
3  O
/  O
4  O
thrombocytopenia  B-TOXI
and  O
cumulative  O
grade  O
3  O
anaemia  B-TOXI
were  O
seen  O
in  O
7  O
%  O
and  O
13  O
%  O
of  O
cycles  O
respectively  O
.  O

Three  O
cases  O
of  O
severe  O
grade  O
3  O
neuromotor  B-TOXI
/  O
sensory  B-TOXI
neuropathy  I-TOXI
were  O
recorded  O
at  O
DL-II  O
,  O
-III  O
,  O
and  O
-V  O
,  O
all  O
after  O
cycle  O
3.  O
The  O
maximum  O
tolerated  O
dose  O
was  O
not  O
formally  O
reached  O
at  O
DL-V  O
,  O
but  O
because  O
of  O
progressive  O
anaemia  B-TOXI
and  O
asthenia  B-TOXI
/  O
fatigue  B-TOXI
,  O
it  O
was  O
decided  O
to  O
test  O
a  O
new  O
DL-VI  O
with  O
doses  O
of  O
paclitaxel  B-DRUG
200  O
mg  O
m  O
(  O
-2  O
)  O
,  O
ifosfamide  B-DRUG
5.0  O
g  O
m  O
(  O
-2  O
)  O
and  O
cisplatin  B-DRUG
100  O
mg  O
m  O
(  O
-2  O
)  O
;  O
this  O
appeared  O
to  O
be  O
tolerable  O
and  O
is  O
recommended  O
for  O
further  O
phase  O
II  O
testing  O
.  O

The  O
response  O
rate  O
was  O
47.5  O
%  O
(  O
complete  O
response  O
+  O
partial  O
response  O
:  O
20  O
/  O
42  O
)  O
.  O

The  O
PIC  B-DRUG
regimen  O
appears  O
to  O
be  O
feasible  O
and  O
safe  O
in  O
the  O
outpatient  O
setting  O
.  O

Care  O
should  O
be  O
paid  O
to  O
neurotoxicity  B-TOXI
.  O

Phase  O
II  O
studies  O
are  O
starting  O
in  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
,  O
ovarian  B-CANCER
cancer  I-CANCER
and  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
at  O
DL-VI  O
.  O

Multi-institutional  O
phase  O
I  O
/  O
II  O
trial  O
of  O
paclitaxel  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
etoposide  B-DRUG
with  O
concurrent  O
radiation  O
for  O
limited-stage  O
small-cell  B-CANCER
lung  I-CANCER
carcinoma  I-CANCER
.  O


To  O
determine  O
the  O
feasibility  O
of  O
adding  O
paclitaxel  B-DRUG
to  O
standard  O
cisplatin  B-DRUG
/  I-DRUG
etoposide  I-DRUG
(  O
EP  B-DRUG
)  O
and  O
thoracic  O
radiotherapy  O
.  O

Thirty-one  O
patients  O
were  O
enrolled  O
onto  O
this  O
study  O
.  O

During  O
the  O
phase  O
I  O
section  O
of  O
this  O
study  O
,  O
the  O
dose  O
of  O
paclitaxel  B-DRUG
was  O
escalated  O
in  O
groups  O
of  O
three  O
or  O
more  O
patients  O
.  O

Cycles  O
were  O
repeated  O
every  O
21  O
days  O
.  O

For  O
cycles  O
1  O
and  O
2  O
,  O
paclitaxel  B-DRUG
was  O
administered  O
according  O
to  O
the  O
dose-escalation  O
schema  O
at  O
doses  O
of  O
100  O
,  O
135  O
,  O
or  O
170  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenously  O
over  O
3  O
hours  O
on  O
day  O
1.  O
Once  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
paclitaxel  B-DRUG
(  O
for  O
cycles  O
1  O
and  O
2  O
,  O
concurrent  O
with  O
radiation  O
)  O
was  O
determined  O
,  O
that  O
dose  O
was  O
used  O
in  O
all  O
subsequent  O
patients  O
entered  O
onto  O
the  O
phase  O
II  O
section  O
of  O
this  O
study  O
.  O

For  O
cycles  O
3  O
and  O
4  O
,  O
the  O
paclitaxel  B-DRUG
dose  O
was  O
fixed  O
at  O
170  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
all  O
patients  O
.  O

On  O
day  O
2  O
,  O
cisplatin  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
was  O
administered  O
for  O
all  O
cycles  O
.  O

On  O
days  O
1  O
,  O
2  O
,  O
and  O
3  O
,  O
etoposide  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
(  O
cycles  O
1  O
and  O
2  O
)  O
or  O
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
(  O
cycles  O
3  O
and  O
4  O
)  O
was  O
administered  O
.  O

Chest  O
radiation  O
was  O
given  O
at  O
9  O
Gy  O
/  O
wk  O
in  O
five  O
fractions  O
for  O
5  O
weeks  O
beginning  O
on  O
day  O
1  O
of  O
cycle  O
1.  O
Granulocyte  B-DRUG
colony-stimulating  I-DRUG
factors  I-DRUG
were  O
used  O
during  O
cycles  O
3  O
and  O
4  O
only  O
.  O

Twenty-eight  O
patients  O
were  O
assessable  O
.  O

The  O
MTD  O
of  O
paclitaxel  B-DRUG
was  O
135  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
with  O
the  O
dose-limiting  O
toxicity  O
being  O
grade  O
4  O
neutropenia  B-TOXI
.  O

Cycles  O
1  O
and  O
2  O
were  O
associated  O
with  O
grade  O
4  O
neutropenia  B-TOXI
in  O
32  O
%  O
of  O
courses  O
,  O
with  O
fever  B-TOXI
occurring  O
in  O
7  O
%  O
of  O
courses  O
and  O
grade  O
2  O
/  O
3  O
esophagitis  B-TOXI
in  O
13  O
%  O
.  O

Cycles  O
3  O
and  O
4  O
were  O
complicated  O
by  O
grade  O
4  O
neutropenia  B-TOXI
in  O
20  O
%  O
of  O
courses  O
,  O
with  O
fever  B-TOXI
occurring  O
in  O
6  O
%  O
of  O
courses  O
and  O
grade  O
2  O
/  O
3  O
esophagitis  B-TOXI
in  O
16  O
%  O
.  O

The  O
overall  O
response  O
rate  O
was  O
96  O
%  O
(  O
complete  O
responses  O
,  O
39  O
%  O
;  O
partial  O
responses  O
,  O
57  O
%  O
)  O
.  O

After  O
a  O
median  O
follow-up  O
period  O
of  O
23  O
months  O
(  O
range  O
,  O
9  O
to  O
40  O
months  O
)  O
,  O
the  O
median  O
survival  O
time  O
was  O
22.3  O
months  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
15.1  O
to  O
34.3  O
months  O
)  O
The  O
MTD  O
of  O
paclitaxel  B-DRUG
with  O
radiation  O
and  O
EP  B-DRUG
treatment  O
is  O
135  O
mg  O
/  O
m  O
(  O
2  O
)  O
given  O
over  O
3  O
hours  O
.  O

In  O
this  O
schedule  O
of  O
administration  O
,  O
a  O
high  O
response  O
rate  O
and  O
acceptable  O
toxicity  O
can  O
be  O
anticipated  O
.  O

Sequential  O
dose-intensive  O
paclitaxel  B-DRUG
,  O
ifosfamide  B-DRUG
,  O
carboplatin  B-DRUG
,  O
and  O
etoposide  B-DRUG
salvage  O
therapy  O
for  O
germ  B-CANCER
cell  I-CANCER
tumor  I-CANCER
patients  O
.  O


To  O
evaluate  O
the  O
efficacy  O
and  O
toxicity  O
of  O
sequential  O
,  O
dose-intensified  O
chemotherapy  O
with  O
paclitaxel  B-DRUG
/  I-DRUG
ifosfamide  I-DRUG
and  O
carboplatin  B-DRUG
/  I-DRUG
etoposide  I-DRUG
administered  O
plus  O
peripheral  B-DRUG
blood-derived  I-DRUG
stem-cell  I-DRUG
(  O
PBSC  B-DRUG
)  O
support  O
for  O
patients  O
with  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
(  O
GCT  B-CANCER
)  O
who  O
have  O
unfavorable  O
prognostic  O
features  O
in  O
response  O
to  O
conventional-dose  O
salvage  O
programs  O
.  O

Carboplatin  B-DRUG
was  O
dose  O
escalated  O
by  O
target  O
area  O
under  O
the  O
curve  O
(  O
AUC  O
;  O
in  O
[  O
milligrams  O
per  O
milliliter  O
]  O
x  O
minutes  O
)  O
among  O
patient  O
cohorts  O
,  O
and  O
pharmacokinetic  O
studies  O
were  O
performed  O
for  O
comparison  O
.  O

Thirty-seven  O
previously  O
treated  O
patients  O
who  O
had  O
cisplatin-resistant  B-DRUG
GCT  I-DRUG
and  O
unfavorable  O
prognostic  O
features  O
for  O
response  O
to  O
conventional-dose  O
salvage  O
therapy  O
were  O
treated  O
.  O

Two  O
cycles  O
of  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
ifosfamide  B-DRUG
6  O
g  O
/  O
m  O
(  O
2  O
)  O
were  O
given  O
2  O
weeks  O
apart  O
with  O
leukapheresis  B-DRUG
,  O
followed  O
by  O
three  O
cycles  O
of  O
carboplatin  B-DRUG
plus  O
etoposide  B-DRUG
given  O
14  O
to  O
21  O
days  O
apart  O
with  O
reinfusion  O
of  O
PBSCs  B-DRUG
.  O

The  O
dose  O
of  O
etoposide  B-DRUG
was  O
1  O
,  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
the  O
carboplatin  B-DRUG
target  O
AUC  O
ranged  O
among  O
cohorts  O
from  O
12  O
to  O
32  O
(  O
mg  O
/  O
mL  O
)  O
x  O
min  O
.  O

Pharmacokinetic  O
studies  O
of  O
carboplatin  B-DRUG
were  O
performed  O
for  O
comparison  O
of  O
target  O
to  O
measured  O
AUC  O
.  O

Twenty-one  O
patients  O
(  O
57  O
%  O
)  O
achieved  O
a  O
complete  O
response  O
and  O
an  O
additional  O
two  O
patients  O
(  O
5  O
%  O
)  O
achieved  O
a  O
partial  O
response  O
with  O
normal  O
tumor  O
markers  O
;  O
therefore  O
,  O
23  O
(  O
62  O
%  O
)  O
achieved  O
a  O
favorable  O
response  O
.  O

Eight  O
patients  O
relapsed  O
,  O
and  O
15  O
(  O
41  O
%  O
)  O
of  O
the  O
favorable  O
responses  O
remained  O
durable  O
at  O
a  O
median  O
follow-up  O
of  O
30  O
months  O
.  O

Myelosuppression  B-TOXI
was  O
the  O
major  O
toxicity  O
;  O
58  O
%  O
of  O
carboplatin  B-DRUG
/  I-DRUG
etoposide  I-DRUG
cycles  O
were  O
associated  O
with  O
hospitalization  O
for  O
nadir  B-TOXI
fever  I-TOXI
.  O

The  O
AUC  O
of  O
carboplatin  B-DRUG
measured  O
in  O
serum  O
was  O
lower  O
than  O
the  O
target  O
AUC  O
;  O
this  O
may  O
be  O
related  O
to  O
underestimation  O
of  O
the  O
glomerular  O
filtration  O
rate  O
used  O
in  O
the  O
dosing  O
formula  O
.  O

Dose-intense  O
therapy  O
with  O
sequential  O
,  O
accelerated  O
chemotherapy  O
of  O
paclitaxel  B-DRUG
/  I-DRUG
ifosfamide  I-DRUG
and  O
carboplatin  B-DRUG
/  I-DRUG
etoposide  I-DRUG
administered  O
with  O
PBSC  B-DRUG
support  O
was  O
relatively  O
well  O
tolerated  O
.  O

The  O
durable  O
complete  O
response  O
proportion  O
was  O
substantial  O
in  O
patients  O
with  O
unfavorable  O
prognostic  O
features  O
for  O
achieving  O
durable  O
complete  O
response  O
to  O
conventional-dose  O
salvage  O
programs  O
.  O

Optimal  O
dosing  O
of  O
carboplatin  B-DRUG
in  O
the  O
high-dose  O
setting  O
warrants  O
further  O
investigation  O
.  O

Phase  O
II  O
trial  O
of  O
up-front  O
accelerated  O
thoracic  O
radiotherapy  O
combined  O
with  O
chemotherapy  O
and  O
optional  O
up-front  O
prophylactic  O
cranial  O
irradiation  O
in  O
limited  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer.  I-CANCER
Groupe  O
d'Oncologie  O
Thoracique  O
des  O
R√©gions  O
Alpines  O
.  O


To  O
investigate  O
the  O
feasibility  O
and  O
outcome  O
of  O
bifractionated  O
,  O
up-front  O
thoracic  O
radiotherapy  O
(  O
TR  O
)  O
(  O
45  O
Gy  O
in  O
30  O
fractions  O
of  O
1.5  O
Gy  O
twice  O
daily  O
over  O
3  O
weeks  O
)  O
combined  O
with  O
chemotherapy  O
(  O
CT  O
)  O
(  O
six  O
cycles  O
of  O
cisplatin  O
and  O
etoposide  O
)  O
and  O
optional  O
low-dose  O
,  O
up-front  O
prophylactic  O
cranial  O
irradiation  O
(  O
18  O
Gy  O
in  O
10  O
fractions  O
of  O
1.8  O
Gy  O
twice  O
daily  O
over  O
5  O
days  O
)  O
in  O
limited  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

CT  B-DRUG
(  O
etoposide  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
for  O
3  O
days  O
and  O
cisplatin  B-DRUG
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
for  O
3  O
days  O
)  O
was  O
started  O
on  O
day  O
8  O
or  O
15  O
after  O
the  O
first  O
TR  O
treatment  O
.  O

In  O
the  O
five  O
subsequent  O
cycles  O
,  O
cisplatin  B-DRUG
was  O
given  O
as  O
a  O
single  O
100-mg  O
/  O
m  O
(  O
2  O
)  O
dose  O
on  O
day  O
1  O
every  O
4  O
weeks  O
.  O

A  O
total  O
of  O
52  O
patients  O
were  O
entered  O
(  O
41  O
men  O
and  O
11  O
women  O
)  O
;  O
the  O
median  O
age  O
was  O
55  O
years  O
(  O
range  O
,  O
33  O
to  O
67  O
years  O
)  O
.  O

World  O
Health  O
Organization  O
performance  O
status  O
was  O
0  O
in  O
34  O
patients  O
,  O
1  O
in  O
16  O
patients  O
,  O
and  O
2  O
in  O
two  O
patients  O
.  O

Thirty-six  O
patients  O
(  O
69  O
%  O
)  O
received  O
the  O
full  O
planned  O
six  O
cycles  O
of  O
CT.  B-DRUG
All  O
treated  O
patients  O
were  O
assessable  O
for  O
response  O
.  O

Thirty-one  O
patients  O
(  O
60  O
%  O
)  O
achieved  O
a  O
complete  O
response  O
,  O
and  O
16  O
(  O
30  O
%  O
)  O
had  O
a  O
partial  O
response  O
.  O

One-  O
,  O
3-  O
,  O
and  O
4-year  O
survival  O
rates  O
were  O
74  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
[  O
CI  O
]  O
,  O
60  O
%  O
to  O
84  O
%  O
)  O
,  O
34  O
%  O
(  O
95  O
%  O
CI  O
,  O
21  O
%  O
to  O
49  O
%  O
)  O
,  O
and  O
32  O
%  O
(  O
95  O
CI  O
,  O
16  O
%  O
to  O
46  O
%  O
)  O
,  O
respectively  O
.  O

The  O
median  O
survival  O
time  O
was  O
18  O
months  O
.  O

Event-free  O
survival  O
at  O
1  O
year  O
was  O
45  O
%  O
(  O
95  O
%  O
CI  O
,  O
32  O
%  O
to  O
58  O
%  O
)  O
and  O
at  O
3  O
years  O
,  O
30  O
%  O
(  O
95  O
%  O
CI  O
,  O
18  O
%  O
to  O
44  O
%  O
)  O
.  O

The  O
main  O
radiation-related  O
acute  B-TOXI
toxicity  I-TOXI
was  O
esophageal  O
:  O
38  O
%  O
of  O
the  O
patients  O
experienced  O
grade  O
3  O
or  O
4  O
acute  B-TOXI
toxicity  I-TOXI
.  O

CT  B-DRUG
was  O
well  O
tolerated  O
.  O

Although  O
grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
was  O
observed  O
in  O
86  O
%  O
of  O
the  O
patients  O
,  O
only  O
4  O
%  O
presented  O
with  O
associated  B-TOXI
fever  I-TOXI
.  O

Grade  O
3  O
/  O
4  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
was  O
seen  O
in  O
35  O
%  O
of  O
patients  O
.  O

This  O
trial  O
demonstrates  O
that  O
up-front  O
accelerated  O
TR  O
associated  O
with  O
CT  B-DRUG
is  O
feasible  O
,  O
has  O
acceptable  O
toxicity  O
,  O
and  O
shows  O
considerable  O
long-term  O
survival  O
potential  O
.  O

Phase  O
II  O
trial  O
of  O
gemcitabine  B-DRUG
plus  O
cisplatin  B-DRUG
in  O
patients  O
with  O
metastatic  B-CANCER
urothelial  I-CANCER
cancer  I-CANCER
.  O


To  O
assess  O
the  O
activity  O
and  O
toxicity  O
of  O
the  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
the  O
treatment  O
of  O
chemotherapy-naive  O
patients  O
with  O
metastatic  B-CANCER
urothelial  I-CANCER
cancer  I-CANCER
.  O

Forty-six  O
patients  O
with  O
measurable  O
stage  O
IV  O
carcinoma  B-CANCER
of  I-CANCER
the  I-CANCER
urothelium  I-CANCER
were  O
enrolled  O
onto  O
this  O
trial  O
.  O

Gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
was  O
administered  O
intravenously  O
for  O
30  O
to  O
60  O
minutes  O
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
of  O
each  O
28-day  O
cycle  O
.  O

Cisplatin  B-DRUG
was  O
administered  O
after  O
gemcitabine  B-DRUG
on  O
day  O
1  O
of  O
each  O
cycle  O
.  O

The  O
first  O
11  O
patients  O
received  O
an  O
initial  O
cisplatin  B-DRUG
dose  O
of  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Due  O
to  O
the  O
hematologic  B-TOXI
toxicity  I-TOXI
observed  O
in  O
several  O
of  O
these  O
patients  O
,  O
the  O
dose  O
was  O
reduced  O
to  O
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
the  O
remaining  O
35  O
patients  O
.  O

Patients  O
were  O
treated  O
with  O
six  O
cycles  O
,  O
unless  O
disease  B-TOXI
progression  I-TOXI
or  O
severe  B-TOXI
toxicity  I-TOXI
necessitated  O
earlier  O
discontinuation  O
.  O

Ten  O
of  O
the  O
46  O
patients  O
achieved  O
a  O
complete  O
response  O
and  O
nine  O
showed  O
a  O
partial  O
response  O
.  O

The  O
overall  O
response  O
rate  O
was  O
41  O
%  O
.  O

The  O
median  O
time  O
to  O
treatment  O
failure  O
was  O
5.5  O
months  O
.  O

The  O
median  O
survival  O
was  O
14.3  O
months  O
,  O
and  O
the  O
1-year  O
survival  O
probability  O
was  O
54  O
%  O
.  O

Most  O
of  O
the  O
toxicities  O
were  O
hematologic  O
and  O
,  O
in  O
general  O
,  O
easily  O
manageable  O
.  O

Gemcitabine  B-DRUG
plus  O
cisplatin  B-DRUG
is  O
active  O
in  O
the  O
treatment  O
of  O
metastatic  B-CANCER
urothelial  I-CANCER
cancer  I-CANCER
in  O
chemotherapy-naive  O
patients  O
and  O
has  O
an  O
acceptable  O
clinical  O
safety  O
profile  O
.  O

Studies  O
are  O
under  O
way  O
to  O
further  O
define  O
the  O
place  O
of  O
gemcitabine  B-DRUG
in  O
combination  O
with  O
other  O
chemotherapeutic  O
agents  O
in  O
the  O
treatment  O
of  O
metastatic  B-CANCER
urothelial  I-CANCER
cancer  I-CANCER
.  O

Chemo-biotherapy  O
with  O
5-fluorouracil  B-DRUG
,  O
leucovorin  B-DRUG
,  O
and  O
alpha  B-DRUG
interferon  I-DRUG
in  O
metastatic  B-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
colon  I-CANCER
--  O
a  O
Cancer  O
Biotherapy  O
Research  O
Group  O
[  O
CBRG  O
]  O
phase  O
II  O
study  O
.  O


Biochemical  O
modulation  O
of  O
5-Fluorouracil  B-DRUG
activity  O
with  O
Leucovorin  B-DRUG
has  O
been  O
well  O
documented  O
in  O
colorectal  B-CANCER
cancer  I-CANCER
.  O

Several  O
studies  O
have  O
shown  O
increased  O
efficacy  O
of  O
5-fluorouracil  B-DRUG
in  O
combination  O
with  O
alpha  B-DRUG
interferon  I-DRUG
.  O

We  O
therefore  O
initiated  O
a  O
phase  O
II  O
trial  O
of  O
dual  O
modulation  O
of  O
5-fluorouracil  B-DRUG
with  O
leucovorin  B-DRUG
and  O
alpha  B-DRUG
interferon  I-DRUG
to  O
evaluate  O
outcomes  O
in  O
patients  O
with  O
metastatic  B-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
colon  I-CANCER
.  O

Patients  O
with  O
metastatic  B-CANCER
colon  I-CANCER
carcinoma  I-CANCER
with  O
expected  O
survival  O
&  O
gt  O
;  O
4  O
months  O
and  O
performance  O
status  O
of  O
ECOG  O
&  O
lt  O
;  O
or  O
=  O
2  O
were  O
treated  O
weekly  O
with  O
Leucovorin  B-DRUG
400  O
mg  O
i.v.  O
followed  O
by  O
5-FU  B-DRUG
600  O
mg  O
/  O
m2  O
i.v.  O
bolus  O
.  O

Alpha  B-DRUG
interferon  I-DRUG
3-9  O
million  O
units  O
was  O
administered  O
subcutaneously  O
every  O
Monday  O
,  O
Wednesday  O
and  O
Friday  O
.  O

Patients  O
were  O
analyzed  O
for  O
toxicity  O
,  O
tumor  O
response  O
and  O
survival  O
.  O

Sixteen  O
patients  O
with  O
a  O
median  O
age  O
of  O
66  O
years  O
were  O
treated  O
.  O

Three  O
patients  O
were  O
not  O
evaluable  O
for  O
response  O
but  O
were  O
evaluable  O
for  O
toxicity  O
.  O

Grades  O
3  O
and  O
4  O
toxicities  O
were  O
neutropenia  B-TOXI
,  O
diarrhea  B-TOXI
,  O
mucositis  B-TOXI
,  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
,  O
fatigue  B-TOXI
,  O
fever  B-TOXI
,  O
asthenia  B-TOXI
and  O
elevated  B-TOXI
hepatic  I-TOXI
enzymes  I-TOXI
.  O

One  O
patient  O
died  O
from  O
complications  O
associated  O
with  O
diverticulitis  B-TOXI
and  O
neutropenia  B-TOXI
.  O

Objective  O
response  O
rate  O
was  O
23  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
4-46  O
%  O
)  O
and  O
median  O
survival  O
was  O
11.5  O
months  O
(  O
95  O
%  O
confidence  O
interval  O
6.3-19  O
months  O
)  O
.  O

Thirty-eight  O
percent  O
of  O
the  O
patients  O
were  O
alive  O
at  O
one  O
year  O
and  O
19  O
%  O
at  O
two  O
years  O
.  O

The  O
combination  O
of  O
5-fluorouracil  B-DRUG
,  O
leucovorin  B-DRUG
and  O
alpha  B-DRUG
interferon  I-DRUG
as  O
administered  O
in  O
this  O
phase  O
II  O
study  O
did  O
not  O
result  O
in  O
enhanced  O
response  O
rate  O
or  O
survival  O
.  O

However  O
this  O
regimen  O
was  O
associated  O
with  O
considerable  O
toxicity  O
.  O

Weekly  O
docetaxel  B-DRUG
plus  O
gemcitabine  B-DRUG
or  O
vinorelbine  B-DRUG
in  O
refractory  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
:  O
a  O
parallel  O
dose-finding  O
study.  O
Southern  O
Italy  O
Cooperative  O
Oncology  O
Group  O
(  O
SICOG  O
)  O
.  O


The  O
objective  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
docetaxel  B-DRUG
MTD  O
when  O
combined  O
with  O
gemcitabine  B-DRUG
or  O
vinorelbine  B-DRUG
in  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
who  O
had  O
received  O
previous  O
anthracycline-based  B-DRUG
chemotherapy  O
for  O
advanced  O
disease  O
.  O

Advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
aged  O
between  O
18  O
and  O
70  O
with  O
ECOG  O
PS  O
0-2  O
who  O
had  O
not  O
responded  O
to  O
,  O
or  O
had  O
relapsed  O
after  O
,  O
first-line  O
anthracycline-based  B-DRUG
chemotherapy  O
,  O
were  O
randomized  O
to  O
receive  O
either  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m2  O
or  O
vinorelbine  B-DRUG
25  O
mg  O
/  O
m2  O
in  O
combination  O
with  O
escalating  O
doses  O
of  O
docetaxel  B-DRUG
(  O
starting  O
from  O
30  O
mg  O
/  O
m2  O
)  O
,  O
all  O
on  O
days  O
1  O
and  O
8  O
every  O
three  O
weeks  O
.  O

Escalation  O
was  O
stopped  O
if  O
&  O
gt  O
;  O
33  O
%  O
of  O
patients  O
treated  O
at  O
a  O
given  O
dose  O
level  O
showed  O
DLT  O
at  O
the  O
first  O
cycle  O
.  O

A  O
total  O
of  O
34  O
patients  O
with  O
locally  O
advanced  O
(  O
8  O
)  O
or  O
metastatic  B-CANCER
disease  I-CANCER
(  O
26  O
)  O
were  O
treated  O
,  O
for  O
a  O
total  O
of  O
94  O
cycles  O
delivered  O
.  O

Nineteen  O
patients  O
received  O
docetaxel  B-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
and  O
15  O
with  O
vinorelbine  B-DRUG
.  O

All  O
patients  O
had  O
been  O
pretreated  O
with  O
anthracyclines  B-DRUG
,  O
and  O
24  O
of  O
34  O
had  O
also  O
received  O
weekly  O
dose-dense  O
paclitaxel  B-DRUG
.  O

A  O
docetaxel  B-DRUG
dose  O
of  O
40  O
/  O
m2  O
proved  O
to  O
be  O
safe  O
when  O
combined  O
on  O
days  O
1  O
and  O
8  O
with  O
gemcitabine  B-DRUG
,  O
while  O
a  O
dose  O
of  O
35  O
mg  O
/  O
m2  O
was  O
tolerated  O
in  O
combination  O
with  O
vinorelbine  B-DRUG
.  O

Overall  O
,  O
nine  O
episodes  O
of  O
DLT  O
,  O
all  O
of  O
them  O
neutropenia  B-TOXI
,  O
occurred  O
at  O
the  O
first  O
cycle  O
.  O

Considering  O
all  O
94  O
cycles  O
,  O
grades  O
3  O
or  O
4  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
occurred  O
in  O
15  O
(  O
44  O
%  O
)  O
,  O
and  O
7  O
(  O
20  O
%  O
)  O
patients  O
.  O

Non-hematologic  B-TOXI
toxicity  I-TOXI
was  O
mild  O
,  O
except  O
for  O
three  O
cases  O
of  O
grade  O
2  O
peripheral  B-TOXI
neuropathy  I-TOXI
.  O

All  O
patients  O
were  O
assessed  O
for  O
response  O
on  O
an  O
'intent-to-treat  O
'  O
basis  O
.  O

Overall  O
,  O
five  O
partial  O
responses  O
were  O
recorded  O
(  O
docetaxel  B-DRUG
+  O
gemcitabine  B-DRUG
=  O
3  O
and  O
docetaxel  B-DRUG
+  O
vinorelbine  B-DRUG
=  O
2  O
)  O
,  O
for  O
a  O
15  O
%  O
(  O
95  O
%  O
CI  O
:  O
5  O
%  O
-31  O
%  O
)  O
overall  O
response  O
rate  O
.  O

Only  O
1  O
of  O
24  O
(  O
4  O
%  O
)  O
patients  O
who  O
had  O
received  O
weekly  O
dose-dense  O
paclitaxel  B-DRUG
responded  O
to  O
treatment  O
.  O

The  O
weekly  O
docetaxel  B-DRUG
administration  O
in  O
combination  O
with  O
either  O
gemcitabine  B-DRUG
or  O
vinorelbine  B-DRUG
is  O
a  O
well-tolerated  O
treatment  O
for  O
heavily  O
pretreated  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
.  O

This  O
approach  O
,  O
although  O
sometimes  O
capable  O
of  O
achieving  O
a  O
major  O
response  O
,  O
does  O
not  O
seem  O
advisable  O
in  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
refractory  O
to  O
both  O
anthracyclines  B-DRUG
and  O
paclitaxel  B-DRUG
.  O

Gemcitabine  B-DRUG
combined  O
with  O
continuous  O
infusion  O
5-fluorouracil  B-DRUG
in  O
advanced  B-CANCER
and  I-CANCER
symptomatic  I-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
:  O
a  O
clinical  O
benefit-oriented  O
phase  O
II  O
study  O
.  O


Gemcitabine  B-DRUG
and  O
5-fluorouracil  B-DRUG
are  O
the  O
only  O
two  O
compounds  O
with  O
reproducible  O
activity  O
against  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
(  O
APC  B-CANCER
)  O
.  O

We  O
have  O
evaluated  O
a  O
novel  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
5-fluorouracil  B-DRUG
on  O
the  O
clinical  O
benefit  O
response  O
(  O
CBR  O
)  O
end  O
point  O
.  O

Eleven  O
consecutive  O
patients  O
with  O
symptomatic  B-CANCER
APC  I-CANCER
were  O
entered  O
in  O
a  O
two-stage  O
phase  O
II  O
trial  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
by  O
intravenous  O
(  O
i.v.  O
)  O
bolus  O
injection  O
at  O
the  O
dose  O
of  O
1,000  O
mg  O
m  O
(  O
-2  O
)  O
on  O
days  O
1  O
,  O
8  O
,  O
15  O
and  O
5-fluorouracil  B-DRUG
500  O
mg  O
m  O
(  O
-2  O
)  O
was  O
given  O
by  O
continuous  O
i.v.  O
infusion  O
on  O
days  O
1-5  O
.  O

Treatment  O
was  O
repeated  O
every  O
28  O
days  O
.  O

A  O
CBR  O
was  O
achieved  O
in  O
7  O
/  O
11  O
patients  O
.  O

The  O
mean  O
time  O
to  O
loss  O
of  O
CBR  O
was  O
26.5  O
weeks  O
(  O
range  O
14-18  O
,  O
median  O
22  O
)  O
.  O

Toxicity  O
was  O
mild  O
and  O
no  O
APC  B-CANCER
patient  O
experienced  O
WHO  O
grade  O
3  O
toxicity  O
.  O

The  O
gemcitabine  B-DRUG
/  O
5-fluorouracil  B-DRUG
combination  O
is  O
well  O
tolerated  O
and  O
produces  O
a  O
symptomatic  O
relief  O
in  O
the  O
majority  O
of  O
APC  B-CANCER
patients  O
.  O

Phase  O
II  O
trial  O
of  O
weekly  O
intravenous  O
gemcitabine  B-DRUG
with  O
continuous  O
infusion  O
fluorouracil  B-DRUG
in  O
patients  O
with  O
metastatic  B-CANCER
renal  I-CANCER
cell  I-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
clinical  O
response  O
rate  O
of  O
the  O
combination  O
of  O
weekly  O
intravenous  O
(  O
IV  O
)  O
gemcitabine  B-DRUG
with  O
continuous  O
infusion  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
in  O
patients  O
with  O
metastatic  B-CANCER
renal  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
(  O
RCC  B-CANCER
)  O
.  O

Between  O
June  O
1998  O
and  O
February  O
1999  O
,  O
41  O
patients  O
with  O
metastatic  B-CANCER
RCC  I-CANCER
were  O
enrolled  O
onto  O
this  O
multi-institutional  O
phase  O
II  O
study  O
of  O
gemcitabine  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
over  O
30  O
minutes  O
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
and  O
5-FU  B-DRUG
150  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
via  O
continuous  O
IV  O
infusion  O
through  O
a  O
permanent  O
catheter  O
on  O
days  O
1  O
to  O
21  O
of  O
a  O
28-day  O
cycle  O
.  O

Patients  O
had  O
a  O
Cancer  O
and  O
Leukemia  O
Group  O
B  O
performance  O
status  O
of  O
0  O
or  O
1  O
,  O
with  O
a  O
median  O
time  O
since  O
diagnosis  O
of  O
metastatic  B-TOXI
disease  I-TOXI
of  O
10  O
months  O
(  O
range  O
,  O
0  O
to  O
129  O
months  O
)  O
.  O

Thirty-three  O
patients  O
(  O
80  O
%  O
)  O
had  O
multiple  O
metastatic  O
sites  O
,  O
and  O
34  O
patients  O
(  O
83  O
%  O
)  O
had  O
prior  O
chemotherapy  O
or  O
immunotherapy  O
.  O

Of  O
the  O
39  O
assessable  O
patients  O
,  O
there  O
were  O
no  O
complete  O
responses  O
but  O
seven  O
partial  O
responses  O
(  O
objective  O
response  O
rate  O
=  O
17  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
,  O
8  O
%  O
to  O
34  O
%  O
)  O
.  O

Five  O
minor  O
responses  O
(  O
25  O
%  O
to  O
50  O
%  O
decreased  O
tumor  O
size  O
)  O
were  O
also  O
observed  O
.  O

The  O
duration  O
of  O
response  O
for  O
the  O
seven  O
partial  O
responders  O
was  O
2  O
,  O
3  O
,  O
7  O
,  O
8  O
,  O
10  O
,  O
11  O
,  O
and  O
14  O
months  O
.  O

Median  O
progression-free  O
survival  O
for  O
the  O
gemcitabine  B-DRUG
/  I-DRUG
5-FU  I-DRUG
group  O
was  O
28.7  O
weeks  O
versus  O
8  O
weeks  O
for  O
a  O
similar  O
cohort  O
of  O
patients  O
treated  O
on  O
previous  O
phase  O
II  O
studies  O
at  O
the  O
University  O
of  O
Chicago  O
(  O
P  O
=.008  O
)  O
.  O

The  O
regimen  O
was  O
well  O
tolerated  O
,  O
with  O
fatigue  B-TOXI
,  O
mucositis  B-TOXI
,  O
nausea  B-TOXI
/  O
vomiting  B-TOXI
,  O
and  O
grade  O
2  O
hematologic  B-TOXI
toxicities  I-TOXI
being  O
most  O
common  O
.  O

Weekly  O
gemcitabine  B-DRUG
with  O
continuous  O
infusion  O
5-FU  B-DRUG
is  O
an  O
active  O
combination  O
in  O
patients  O
with  O
metastatic  B-CANCER
RCC  I-CANCER
.  O

Therapy  O
was  O
well  O
tolerated  O
and  O
produced  O
an  O
improvement  O
in  O
progression-free  O
survival  O
over  O
historical  O
controls  O
.  O

A  O
dose-finding  O
study  O
of  O
raltitrexed  B-DRUG
(  O
tomudex  B-DRUG
)  O
with  O
cisplatin  B-DRUG
and  O
epirubicin  B-DRUG
in  O
advanced  B-CANCER
gastro-oesophageal  I-CANCER
adenocarcinoma  I-CANCER
.  O


The  O
standard  O
treatment  O
for  O
advanced  B-CANCER
gastro-oesophageal  I-CANCER
cancer  I-CANCER
in  O
the  O
UK  O
is  O
epirubicin  B-DRUG
,  O
cisplatin  B-DRUG
and  O
continuous  O
infusion  O
5-fluoruracil  B-DRUG
by  O
an  O
indwelling  O
central  O
venous  O
catheter  O
(  O
ECF  O
)  O
,  O
which  O
has  O
significant  O
morbidity  O
.  O

Raltitrexed  B-DRUG
(  O
tomudex  B-DRUG
)  O
,  O
a  O
specific  O
inhibitor  O
of  O
thymidylate  B-DRUG
synthase  I-DRUG
with  O
a  O
long  O
plasma  O
terminal  O
half-life  O
(  O
50-100  O
h  O
)  O
has  O
activity  O
in  O
gastro-intestinal  B-CANCER
tract  I-CANCER
malignancy  I-CANCER
.  O

To  O
reduce  O
the  O
Hickman  O
line-associated  O
morbidity  O
of  O
ECF  O
;  O
we  O
have  O
conducted  O
a  O
dose-finding  O
study  O
of  O
tomudex  B-DRUG
combined  O
with  O
epirubicin  B-DRUG
and  O
cisplatin  B-DRUG
.  O

Twenty-four  O
patients  O
(  O
22  O
males  O
,  O
two  O
female  O
)  O
,  O
median  O
age  O
63  O
years  O
(  O
range  O
21-75  O
)  O
,  O
ECOG  O
performance  O
status  O
&  O
lt  O
;  O
or  O
=2  O
with  O
histologically  O
proven  O
,  O
unresectable  O
or  O
metastatic  O
gastric  O
(  O
14  O
patients  O
)  O
,  O
gastro-oesophageal  O
junction  O
(  O
nine  O
patients  O
)  O
or  O
oesophageal  O
(  O
one  O
patient  O
)  O
adenocarcinoma  B-CANCER
received  O
treatment  O
with  O
3-weekly  O
cisplatin  B-DRUG
60  O
mg  O
m  O
(  O
-2  O
)  O
,  O
epirubicin  B-DRUG
50  O
mg  O
m  O
(  O
-2  O
)  O
and  O
tomudex  B-DRUG
at  O
doses  O
of  O
2  O
mg  O
m  O
(  O
-2  O
)  O
,  O
2.5  O
mg  O
m  O
(  O
-2  O
)  O
or  O
3  O
mg  O
m  O
(  O
-2  O
)  O
in  O
successive  O
cohorts  O
.  O

Six  O
patients  O
were  O
treated  O
per  O
dose  O
level  O
with  O
no  O
intra-patient  O
dose  O
escalation  O
.  O

Dose  O
escalation  O
occurred  O
after  O
six  O
patients  O
had  O
completed  O
at  O
least  O
one  O
cycle  O
of  O
chemotherapy  O
at  O
the  O
previous  O
dose  O
level  O
.  O

After  O
defining  O
the  O
maximum  O
tolerated  O
dose  O
a  O
further  O
six  O
patients  O
were  O
treated  O
at  O
the  O
preceding  O
dose  O
level  O
to  O
assess  O
toxicity  O
at  O
the  O
proposed  O
phase  O
II  O
dose  O
.  O

A  O
total  O
of  O
102  O
cycles  O
(  O
50  O
%  O
completed  O
6  O
cycles  O
)  O
were  O
administered  O
.  O

The  O
dose-limiting  O
toxicities  O
are  O
neutropenia  B-TOXI
and  O
diarrhoea  B-TOXI
occurring  O
in  O
2  O
/  O
6  O
patients  O
at  O
the  O
3  O
mg  O
m  O
(  O
-2  O
)  O
dose  O
level  O
.  O

Of  O
those  O
patients  O
evaluable  O
for  O
response  O
,  O
there  O
were  O
eight  O
partial  O
and  O
one  O
complete  O
response  O
(  O
overall  O
response  O
rate  O
38  O
%  O
)  O
.  O

The  O
median  O
survival  O
was  O
9.9  O
months  O
.  O

ECT  O
is  O
an  O
active  O
regimen  O
in  O
oesophagogastric  B-CANCER
adenocarcinoma  I-CANCER
.  O

The  O
recommended  O
dose  O
of  O
tomudex  B-DRUG
for  O
further  O
study  O
in  O
combination  O
with  O
epirubicin  B-DRUG
and  O
cisplatin  B-DRUG
is  O
2.5  O
mg  O
m  O
(  O
-2  O
)  O
.  O

The  O
effect  O
of  O
tamoxifen  B-DRUG
and  O
cisplatin  B-DRUG
on  O
the  O
disease-free  O
and  O
overall  O
survival  O
of  O
patients  O
with  O
high  O
risk  O
malignant  B-CANCER
melanoma  I-CANCER
.  O


The  O
adjuvant  O
treatment  O
of  O
high-risk  O
malignant  B-CANCER
melanoma  I-CANCER
remains  O
problematic  O
.  O

Previously  O
we  O
reported  O
moderate  O
success  O
in  O
the  O
treatment  O
of  O
metastatic  B-CANCER
disease  I-CANCER
using  O
tamoxifen  B-DRUG
,  O
cisplatin  B-DRUG
,  O
dacarbazine  B-DRUG
and  O
carmustine  B-DRUG
.  O

Based  O
upon  O
data  O
that  O
suggested  O
tamoxifen  B-DRUG
and  O
cisplatin  B-DRUG
were  O
the  O
active  O
agents  O
in  O
this  O
regimen  O
,  O
we  O
initiated  O
a  O
phase  O
II  O
trial  O
of  O
this  O
combination  O
in  O
the  O
adjuvant  O
setting  O
.  O

We  O
treated  O
153  O
patients  O
with  O
4  O
cycles  O
of  O
tamoxifen  B-DRUG
(  O
160  O
mg  O
day  O
(  O
-1  O
)  O
,  O
days  O
1-7  O
)  O
and  O
cisplatin  B-DRUG
(  O
100  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
2  O
)  O
for  O
28-day  O
intervals  O
.  O

Patients  O
received  O
an  O
anti-nausea  O
regimen  O
of  O
dexamethasone  B-DRUG
with  O
ondansetron  B-DRUG
or  O
granisetron  B-DRUG
.  O

During  O
the  O
first  O
2  O
years  O
of  O
follow-up  O
,  O
patients  O
were  O
evaluated  O
every  O
2  O
months  O
with  O
a  O
history  O
,  O
physical  O
exam  O
,  O
laboratory  O
work  O
and  O
computed  O
tomography  O
scans  O
of  O
the  O
chest  O
,  O
abdomen  O
and  O
pelvis  O
every  O
4  O
months  O
.  O

Thereafter  O
,  O
patients  O
were  O
evaluated  O
every  O
3  O
months  O
and  O
radiographic  O
studies  O
were  O
performed  O
if  O
necessary  O
.  O

Currently  O
,  O
with  O
a  O
median  O
follow-up  O
of  O
36  O
months  O
,  O
the  O
disease-free  O
survival  O
(  O
DFS  O
)  O
is  O
68.4  O
%  O
and  O
overall  O
survival  O
(  O
OS  O
)  O
is  O
84.5  O
%  O
.  O

Kaplan-Meier  O
analysis  O
predicts  O
a  O
5-year  O
DFS  O
of  O
62  O
%  O
with  O
an  O
OS  O
of  O
79  O
%  O
.  O

Relapses  O
after  O
20  O
months  O
have  O
been  O
rare  O
.  O

No  O
effect  O
of  O
gender  O
or  O
number  O
of  O
positive  B-TOXI
lymph  I-TOXI
nodes  I-TOXI
was  O
noted  O
,  O
however  O
,  O
stage  O
of  O
disease  O
prior  O
treatment  O
was  O
a  O
factor  O
.  O

The  O
major  O
toxicity  O
proved  O
to  O
be  O
gastrointestinal  O
in  O
nature  O
with  O
nausea  B-DRUG
the  O
most  O
prevalent  O
symptom  O
.  O

Minimal  B-TOXI
renal  I-TOXI
,  O
haematologic  B-TOXI
and  I-TOXI
neurologic  I-TOXI
toxicity  I-TOXI
occurred  O
.  O

These  O
preliminary  O
results  O
suggest  O
that  O
there  O
is  O
a  O
positive  O
impact  O
of  O
tamoxifen  B-DRUG
and  O
cisplatin  B-DRUG
on  O
both  O
the  O
DFS  O
and  O
OS  O
of  O
high-risk  O
malignant  B-CANCER
melanoma  I-CANCER
patients  O
.  O

The  O
5-year  O
projected  O
DFS  O
and  O
OS  O
compare  O
favourably  O
with  O
those  O
reported  O
for  O
the  O
ECOG  O
1684  O
trial  O
and  O
warrant  O
confirmation  O
in  O
a  O
prospective  O
randomized  O
trial  O
.  O

Southwest  O
Oncology  O
Group  O
Study  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
for  O
advanced  B-CANCER
transitional-cell  I-CANCER
carcinoma  I-CANCER
:  O
the  O
importance  O
of  O
survival  O
as  O
a  O
clinical  O
trial  O
end  O
point  O
.  O


The  O
combination  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
for  O
the  O
treatment  O
of  O
advanced  B-CANCER
transitional-cell  I-CANCER
carcinoma  I-CANCER
(  O
TCC  B-CANCER
)  O
of  O
the  O
urothelium  O
has  O
promising  O
activity  O
and  O
acceptable  O
toxicity  O
.  O

The  O
purpose  O
of  O
this  O
trial  O
was  O
to  O
evaluate  O
the  O
efficacy  O
of  O
this  O
regimen  O
in  O
a  O
cooperative  O
group  O
setting  O
.  O

Twenty-nine  O
patients  O
with  O
advanced  B-CANCER
TCC  I-CANCER
were  O
treated  O
every  O
21  O
days  O
with  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
administered  O
as  O
a  O
3-hour  O
infusion  O
,  O
followed  O
by  O
carboplatin  B-DRUG
dosed  O
to  O
an  O
area  O
under  O
the  O
curve  O
of  O
5.  O
Prior  O
systemic  O
adjuvant  O
or  O
neoadjuvant  O
platinum-based  B-DRUG
therapy  O
was  O
not  O
permitted  O
unless  O
completed  O
at  O
least  O
1  O
year  O
before  O
enrollment  O
.  O

Patients  O
were  O
evaluated  O
for  O
response  O
every  O
three  O
cycles  O
,  O
and  O
follow-up  O
was  O
conducted  O
to  O
determine  O
survival  O
.  O

Twenty-nine  O
patients  O
were  O
enrolled  O
and  O
were  O
assessable  O
.  O

Four  O
(  O
14  O
%  O
)  O
had  O
received  O
prior  O
adjuvant  O
or  O
neoadjuvant  O
therapy  O
.  O

Node-only  O
disease  O
was  O
present  O
in  O
24  O
%  O
,  O
and  O
76  O
%  O
of  O
patients  O
had  O
extranodal  B-TOXI
disease  I-TOXI
.  O

The  O
median  O
number  O
of  O
cycles  O
received  O
was  O
five  O
.  O

Grade  O
4  O
toxicity  O
consisted  O
primarily  O
of  O
neutropenia  B-TOXI
(  O
38  O
%  O
of  O
patients  O
)  O
.  O

Neurologic  B-TOXI
toxicity  I-TOXI
was  O
noted  O
in  O
16  O
patients  O
(  O
grade  O
1  O
in  O
four  O
patients  O
,  O
grade  O
2  O
in  O
five  O
patients  O
,  O
grade  O
3  O
in  O
six  O
patients  O
,  O
and  O
grade  O
4  O
in  O
one  O
patient  O
)  O
.  O

Six  O
partial  O
responses  O
and  O
no  O
complete  O
responses  O
were  O
noted  O
,  O
for  O
a  O
response  O
proportion  O
of  O
20.7  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
8  O
%  O
to  O
40  O
%  O
)  O
.  O

Median  O
progression-free  O
survival  O
time  O
was  O
4  O
months  O
,  O
and  O
overall  O
survival  O
time  O
was  O
9  O
months  O
.  O

The  O
combination  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
for  O
the  O
treatment  O
of  O
advanced  B-CANCER
TCC  I-CANCER
is  O
reasonably  O
well  O
tolerated  O
.  O

However  O
,  O
a  O
response  O
proportion  O
considerably  O
lower  O
than  O
that  O
previously  O
reported  O
was  O
noted  O
.  O

In  O
addition  O
,  O
the  O
median  O
survival  O
time  O
of  O
9  O
months  O
was  O
less  O
than  O
the  O
survival  O
time  O
previously  O
reported  O
for  O
patients  O
treated  O
with  O
the  O
combination  O
of  O
methotrexate  B-DRUG
,  O
vinblastine  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
cisplatin  B-DRUG
.  O

Although  O
our  O
results  O
may  O
reflect  O
enrollment  O
of  O
patients  O
with  O
poor  B-TOXI
prognostic  I-TOXI
features  I-TOXI
,  O
they  O
also  O
call  O
into  O
question  O
the  O
utility  O
of  O
this  O
regimen  O
.  O

Cyclophosphamide  B-DRUG
,  O
methotrexate  B-DRUG
,  O
and  O
fluorouracil  B-DRUG
versus  O
tamoxifen  B-DRUG
plus  O
ovarian  B-DRUG
suppression  I-DRUG
as  O
adjuvant  O
treatment  O
of  O
estrogen  O
receptor-positive  O
pre-  O
/  O
perimenopausal  O
breast  B-CANCER
cancer  I-CANCER
patients  O
:  O
results  O
of  O
the  O
Italian  O
Breast  O
Cancer  O
Adjuvant  O
Study  O
Group  O
02  O
randomized  O
trial.  O
boccardo  O
@  O
hp380.ist.unige.it  O
.  O


To  O
compare  O
the  O
efficacy  O
of  O
chemotherapy  O
versus  O
that  O
of  O
tamoxifen  B-DRUG
plus  O
ovarian  B-DRUG
suppression  I-DRUG
in  O
pre-  O
/  O
perimenopausal  O
estrogen  O
receptor-positive  O
patients  O
with  O
early  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O

Patients  O
were  O
randomly  O
assigned  O
to  O
receive  O
either  O
six  O
cycles  O
of  O
a  O
standard  O
regimen  O
of  O
cyclophosphamide  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
orally  O
days  O
1  O
to  O
14  O
,  O
methotrexate  B-DRUG
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenously  O
(  O
IV  O
)  O
days  O
1  O
and  O
8  O
,  O
and  O
fluorouracil  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
IV  O
days  O
1  O
and  O
8  O
(  O
CMF  B-DRUG
)  O
,  O
with  O
all  O
drugs  O
restarted  O
on  O
day  O
29  O
,  O
or  O
5  O
years  O
of  O
tamoxifen  B-DRUG
,  O
30  O
mg  O
/  O
d  O
,  O
plus  O
ovarian  B-DRUG
suppression  I-DRUG
with  O
surgical  O
oophorectomy  O
,  O
ovarian  O
irradiation  O
,  O
or  O
monthly  O
goserelin  B-DRUG
3.6-mg  O
injections  O
.  O

Disease-free  O
survival  O
was  O
the  O
main  O
study  O
end  O
point  O
.  O

Overall  O
survival  O
and  O
toxicity  O
were  O
additional  O
end  O
points  O
.  O

Between  O
1989  O
and  O
1997  O
,  O
120  O
patients  O
were  O
assigned  O
to  O
CMF  B-DRUG
and  O
124  O
to  O
tamoxifen  B-DRUG
and  O
ovarian  B-DRUG
suppression  I-DRUG
(  O
oophorectomy  O
,  O
n  O
=  O
6  O
;  O
ovarian  O
irradiation  O
,  O
n  O
=  O
31  O
;  O
and  O
goserelin  B-DRUG
injections  O
,  O
n  O
=  O
87  O
)  O
.  O

At  O
the  O
time  O
of  O
analysis  O
(  O
median  O
follow-up  O
time  O
,  O
76  O
months  O
;  O
range  O
,  O
9  O
to  O
121  O
months  O
)  O
,  O
82  O
patients  O
had  O
relapsed  O
and  O
39  O
had  O
died  O
.  O

No  O
difference  O
between  O
groups  O
had  O
emerged  O
with  O
respect  O
to  O
either  O
disease-free  O
or  O
overall  O
survival  O
.  O

Treatments  O
were  O
comparable  O
even  O
in  O
respect  O
to  O
age  O
,  O
tumor  O
size  O
,  O
and  O
nodal  O
status  O
,  O
although  O
a  O
nonsignificant  O
trend  O
favored  O
patients  O
with  O
poorly  B-CANCER
differentiated  I-CANCER
tumors  I-CANCER
treated  O
with  O
CMF  B-DRUG
.  O

Leukopenia  B-TOXI
,  O
nausea  B-TOXI
,  O
vomiting  B-TOXI
,  O
stomatitis  B-TOXI
,  O
and  O
alopecia  B-TOXI
were  O
significantly  O
more  O
common  O
in  O
patients  O
treated  O
with  O
CMF  B-DRUG
.  O

There  O
were  O
few  O
patients  O
who  O
developed  O
benign  B-CANCER
gynecologic  I-CANCER
changes  O
in  O
either  O
group  O
,  O
and  O
numbers  O
were  O
comparable  O
.  O

The  O
combination  O
of  O
tamoxifen  B-DRUG
with  O
ovarian  B-DRUG
suppression  I-DRUG
seems  O
to  O
be  O
safe  O
and  O
to  O
yield  O
comparable  O
results  O
relative  O
to  O
standard  O
CMF  B-DRUG
.  O

Cisplatin  B-DRUG
,  O
raltitrexed  B-DRUG
,  O
levofolinic  B-DRUG
acid  I-DRUG
and  O
5-fluorouracil  B-DRUG
in  O
locally  O
advanced  B-CANCER
or  I-CANCER
metastatic  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
:  O
a  O
phase  O
I-II  O
trial  O
of  O
the  O
Southern  O
Italy  O
Cooperative  O
Oncology  O
Group  O
(  O
SICOG  O
)  O
.  O


The  O
combination  O
of  O
cisplatin  B-DRUG
(  O
CDDP  B-DRUG
)  O
and  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
can  O
be  O
regarded  O
as  O
a  O
reference  O
regimen  O
in  O
squamous  B-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
(  O
SCCHN  B-CANCER
)  O
.  O

Raltitrexed  B-DRUG
(  O
Tomudex  B-DRUG
)  O
is  O
a  O
direct  O
and  O
specific  O
thymidilate  O
synthase  O
(  O
TS  O
)  O
inhibitor  O
,  O
which  O
has  O
shown  O
clinical  O
activity  O
against  O
SCCHN  B-CANCER
in  O
a  O
previous  O
phase  O
I  O
study  O
,  O
when  O
combined  O
with  O
5-FU  B-DRUG
and  O
levo-folinic  B-DRUG
acid  I-DRUG
(  O
LFA  B-DRUG
)  O
.  O

Preclinical  O
data  O
support  O
the  O
combination  O
of  O
CDDP  B-DRUG
and  O
raltitrexed  B-DRUG
.  O

The  O
aim  O
of  O
the  O
present  O
study  O
was  O
to  O
evaluate  O
the  O
combination  O
of  O
cisplatin  B-DRUG
,  O
raltitrexed  B-DRUG
.  O

LFA  B-DRUG
and  O
5-FU  B-DRUG
in  O
a  O
phase  O
I-II  O
study  O
.  O

Patients  O
with  O
locally  O
advanced  B-CANCER
or  I-CANCER
metastatic  I-CANCER
SCCHN  I-CANCER
were  O
treated  O
with  O
a  O
combination  O
of  O
cisplatin  B-DRUG
at  O
the  O
starting  O
dose  O
of  O
40  O
mg  O
/  O
m2  O
.  O

followed  O
by  O
raltitrexed  B-DRUG
at  O
the  O
starting  O
dose  O
of  O
2.5  O
mg  O
/  O
m2  O
on  O
day  O
1  O
;  O
levo-folinic  B-DRUG
acid  I-DRUG
at  O
fixed  O
dose  O
of  O
250  O
mg  O
/  O
m2  O
,  O
followed  O
by  O
5-fluorouracil  B-DRUG
at  O
the  O
starting  O
dose  O
of  O
750  O
mg  O
/  O
m2  O
on  O
day  O
2.  O
Doses  O
of  O
the  O
three  O
cytotoxic  B-DRUG
agents  I-DRUG
were  O
alternately  O
escalated  O
up  O
to  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
.  O

Treatment  O
was  O
recycled  O
every  O
two  O
weeks  O
and  O
given  O
up  O
to  O
a  O
maximum  O
of  O
eight  O
courses  O
;  O
after  O
chemotherapy  O
,  O
patients  O
with  O
locally  O
advanced  B-CANCER
disease  I-CANCER
received  O
a  O
locoregional  O
treatment  O
.  O

Forty-five  O
patients  O
were  O
entered  O
into  O
the  O
study  O
.  O

Six  O
dose  O
levels  O
were  O
tested  O
.  O

At  O
CDDP  B-DRUG
50  O
mg  O
/  O
m2  O
,  O
raltitrexed  B-DRUG
3  O
mg  O
/  O
m2  O
,  O
5-FU  B-DRUG
900  O
mg  O
/  O
m2  O
,  O
four  O
out  O
of  O
six  O
patients  O
showed  O
DLT  O
,  O
which  O
was  O
in  O
all  O
cases  O
grade  O
4  O
neutropenia  B-TOXI
.  O

Therefore  O
,  O
this  O
dose  O
level  O
was  O
defined  O
as  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
.  O

CDDP  B-DRUG
60  O
mg  O
/  O
m2  O
,  O
raltitrexed  B-DRUG
2.5  O
mg  O
/  O
m2  O
,  O
LFA  B-DRUG
250  O
mg  O
/  O
m2  O
,  O
5-FU  B-DRUG
900  O
mg  O
/  O
m2  O
was  O
the  O
dose  O
level  O
recommended  O
for  O
phase  O
II  O
.  O

CDDP  B-DRUG
,  O
Raltitrexed  B-DRUG
and  O
5-FU  B-DRUG
mean  O
actually  O
delivered  O
dose  O
intensities  O
at  O
the  O
selected  O
dose  O
level  O
were  O
26  O
,  O
1.05  O
,  O
and  O
378  O
mg  O
/  O
m2  O
/  O
week  O
,  O
respectively  O
.  O

Neutropenia  B-TOXI
was  O
the  O
main  O
side  O
effect  O
and  O
was  O
observed  O
even  O
at  O
the  O
lowest  O
dose  O
levels  O
.  O

Nonhematologic  B-TOXI
side  I-TOXI
effects  I-TOXI
were  O
mild  O
.  O

Nine  O
complete  O
responses  O
(  O
20  O
%  O
)  O
and  O
twenty-one  O
partial  O
responses  O
(  O
47  O
%  O
)  O
were  O
observed  O
,  O
for  O
an  O
overall  O
response  O
rate  O
of  O
67  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
(  O
95  O
%  O
CI  O
)  O
:  O
51  O
%  O
-80  O
%  O
)  O
,  O
according  O
to  O
intention  O
to  O
treat  O
analysis  O
.  O

Fifteen  O
of  O
fifteen  O
patients  O
(  O
100  O
%  O
)  O
treated  O
at  O
the  O
dose  O
level  O
selected  O
for  O
phase  O
II  O
had  O
an  O
objective  O
response  O
(  O
5  O
complete  O
responses  O
,  O
10  O
partial  O
responses  O
)  O
.  O

The  O
results  O
of  O
our  O
dose  O
escalation  O
clearly  O
demonstrate  O
that  O
it  O
is  O
possible  O
to  O
combine  O
CDDP  B-DRUG
,  O
raltitrexed  B-DRUG
,  O
and  O
modulated  O
5-FU  B-DRUG
at  O
effective  O
doses  O
,  O
without  O
unexpected  O
toxicities  O
.  O

The  O
response  O
data  O
point  O
to  O
an  O
impressive  O
clinical  O
activity  O
,  O
which  O
will  O
be  O
better  O
defined  O
by  O
an  O
ongoing  O
large  O
phase  O
II  O
study  O
.  O

A  O
phase  O
I  O
study  O
of  O
gemcitabine  B-DRUG
and  O
epirubicin  B-DRUG
for  O
the  O
treatment  O
of  O
platinum-resistant  O
or  O
refractory  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O


Gemcitabine  B-DRUG
is  O
active  O
in  O
patients  O
with  O
otherwise  O
resistant  O
or  O
refractory  O
ovarian  B-CANCER
cancer  I-CANCER
.  O

As  O
the  O
drug  O
is  O
well  O
tolerated  O
,  O
studies  O
using  O
gemcitabine  B-DRUG
combined  O
with  O
other  O
antineoplastic  B-DRUG
agents  I-DRUG
are  O
needed  O
.  O

The  O
aim  O
of  O
the  O
study  O
was  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
epirubicin  B-DRUG
combined  O
with  O
gemcitabine  B-DRUG
,  O
with  O
and  O
without  O
support  O
of  O
G-CSF  B-DRUG
.  O

Patients  O
with  O
platinum-resistant  O
or  O
refractory  O
ovarian  B-CANCER
cancer  I-CANCER
were  O
eligible  O
.  O

Gemcitabine  B-DRUG
(  O
G  O
)  O
(  O
starting  O
dose  O
800  O
mg  O
/  O
m2  O
day  O
1  O
and  O
8  O
;  O
200  O
mg  O
/  O
m2  O
escalation  O
per  O
level  O
)  O
and  O
epirubicin  B-DRUG
(  O
E  O
)  O
(  O
starting  O
dose  O
60  O
mg  O
/  O
m2  O
day  O
1  O
;  O
15  O
mg  O
/  O
m2  O
escalation  O
per  O
level  O
)  O
were  O
given  O
every  O
21  O
days  O
for  O
four  O
to  O
six  O
cycles  O
.  O

G-CSF  B-DRUG
(  O
filgrastim  B-DRUG
5  O
microg  O
/  O
kg  O
/  O
die  O
)  O
was  O
given  O
in  O
case  O
of  O
grade  O
4  O
neutropenia  B-TOXI
(  O
levels  O
without  O
support  O
)  O
or  O
from  O
day  O
9  O
up  O
to  O
leukocyte  O
count  O
&  O
gt  O
;  O
10.000  O
/  O
mm3  O
after  O
nadir  O
(  O
levels  O
with  O
support  O
)  O
.  O

Cohorts  O
of  O
three  O
patients  O
were  O
enrolled  O
at  O
each  O
level  O
,  O
and  O
another  O
three  O
patients  O
were  O
planned  O
,  O
if  O
one  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
was  O
registered  O
.  O

MTD  O
was  O
determined  O
first  O
without  O
and  O
then  O
with  O
G-CSF  B-DRUG
.  O

Four  O
levels  O
were  O
studied  O
(  O
G  O
800  O
+  O
E  O
60  O
;  O
G  O
1000  O
+  O
E  O
60  O
;  O
G  O
1000  O
+  O
E  O
75  O
;  O
G  O
1000  O
+  O
E  O
75  O
+  O
G-CSF  O
)  O
with  O
four  O
,  O
four  O
,  O
three  O
and  O
three  O
patients  O
enrolled  O
,  O
respectively  O
.  O

DLT  O
(  O
grade  O
4  O
febrile  B-TOXI
neutropenia  I-TOXI
)  O
was  O
observed  O
in  O
two  O
patients  O
at  O
level  O
3.  O
Thus  O
,  O
G1000  O
+  O
E  O
60  O
mg  O
/  O
m2  O
was  O
the  O
MTD  O
without  O
G-CSF  B-DRUG
.  O

The  O
addition  O
of  O
prophylactic  O
G-CSF  B-DRUG
did  O
not  O
allow  O
a  O
further  O
increase  O
of  O
the  O
dose  O
and  O
grade  O
4  O
thrombocytopenia  B-TOXI
was  O
the  O
DLT  O
at  O
level  O
4.  O
Non-hematological  B-TOXI
toxicity  I-TOXI
was  O
mild  O
.  O

Grade  O
2  O
mucositis  B-TOXI
was  O
reported  O
in  O
four  O
patients  O
.  O

Among  O
the  O
13  O
patients  O
with  O
measurable  O
or  O
evaluable  O
disease  O
,  O
3  O
partial  O
responses  O
were  O
observed  O
for  O
an  O
overall  O
response  O
rate  O
of  O
23.1  O
%  O
.  O

The  O
combination  O
of  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m2  O
(  O
day  O
1  O
,  O
8  O
)  O
and  O
epirubicin  B-DRUG
at  O
60  O
mg  O
/  O
m2  O
(  O
day  O
1  O
)  O
is  O
a  O
feasible  O
therapy  O
.  O

Grade  O
4  O
neutropenia  B-TOXI
is  O
frequent  O
and  O
G-CSF  B-DRUG
support  O
is  O
often  O
required  O
.  O

With  O
prophylactic  O
support  O
of  O
G-CSF  B-DRUG
,  O
the  O
DLT  O
is  O
thrombocytopenia  B-TOXI
.  O

Cisplatin  B-DRUG
,  O
ifosfamide  B-DRUG
,  O
oral  B-DRUG
etoposide  I-DRUG
,  O
and  O
concurrent  O
accelerated  O
hyperfractionated  O
thoracic  O
radiation  O
for  O
patients  O
with  O
limited  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
carcinoma  I-CANCER
:  O
results  O
of  O
radiation  O
therapy  O
oncology  O
group  O
trial  O
93-12  O
.  O


The  O
combination  O
of  O
cisplatin  B-DRUG
,  O
ifosfamide  B-DRUG
,  O
and  O
oral  B-DRUG
etoposide  I-DRUG
(  O
PIEo  B-DRUG
)  O
given  O
concurrently  O
with  O
accelerated  O
hyperfractionated  O
thoracic  O
radiation  O
was  O
studied  O
in  O
patients  O
with  O
limited  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
in  O
a  O
phase  O
II  O
trial  O
to  O
assess  O
response  O
,  O
survival  O
,  O
and  O
toxicity  O
.  O

Sixty-seven  O
patients  O
were  O
accrued  O
between  O
March  O
1994  O
and  O
April  O
1996  O
.  O

Chemotherapy  O
doses  O
were  O
cisplatin  B-DRUG
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
ifosfamide  B-DRUG
1,200  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
to  O
3  O
and  O
etoposide  B-DRUG
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
orally  O
days  O
1  O
through  O
14  O
.  O

Radiation  O
consisted  O
of  O
accelerated  O
hyperfractionated  O
thoracic  O
radiation  O
(  O
AHTRT  O
)  O
1.5  O
Gy  O
bid  O
x  O
30  O
fractions  O
(  O
total  O
45  O
Gy  O
)  O
days  O
1  O
through  O
19  O
,  O
concurrent  O
with  O
cycle  O
1  O
of  O
chemotherapy  O
.  O

Three  O
additional  O
cycles  O
of  O
chemotherapy  O
were  O
given  O
every  O
4  O
weeks  O
after  O
completion  O
of  O
chemoradiation  O
.  O

Prophylactic  O
cranial  O
radiation  O
(  O
25  O
Gy  O
in  O
10  O
fractions  O
)  O
was  O
offered  O
to  O
patients  O
for  O
whom  O
complete  O
response  O
(  O
CR  O
)  O
after  O
completion  O
of  O
chemotherapy  O
was  O
achieved  O
.  O

An  O
overall  O
objective  O
response  O
rate  O
of  O
78  O
%  O
(  O
41  O
CRs  O
[  O
67  O
%  O
]  O
and  O
seven  O
partial  O
responses  O
[  O
11  O
%  O
]  O
)  O
was  O
seen  O
in  O
61  O
patients  O
whose  O
disease  O
response  O
could  O
be  O
evaluated  O
.  O

Median  O
progression-free  O
and  O
overall  O
survival  O
estimates  O
were  O
12.7  O
and  O
23.7  O
months  O
,  O
respectively  O
.  O

Two-  O
and  O
3-year  O
survival  O
rates  O
were  O
estimated  O
at  O
50  O
%  O
and  O
39  O
%  O
,  O
respectively  O
.  O

Major  O
toxic  O
effects  O
included  O
grade  O
4  O
granulocytopenia  B-TOXI
in  O
34  O
(  O
55  O
%  O
)  O
,  O
grade  O
4  O
thrombocytopenia  B-TOXI
in  O
16  O
(  O
26  O
%  O
)  O
,  O
grade  O
3  O
to  O
5  O
fever  B-TOXI
/  O
infection  B-TOXI
in  O
six  O
(  O
10  O
%  O
;  O
with  O
one  O
death  B-TOXI
resulting  O
from  O
sepsis  O
)  O
,  O
and  O
grade  O
3  O
/  O
4  O
esophagitis  B-TOXI
in  O
27  O
patients  O
(  O
43  O
%  O
)  O
.  O

Other  O
nonhematologic  B-TOXI
toxic  I-TOXI
greater  O
than  O
grade  O
2  O
occurred  O
in  O
11  O
patients  O
(  O
18  O
%  O
)  O
.  O

Relative  O
to  O
conventional  O
etoposide  B-DRUG
/  O
cisplatin  B-DRUG
and  O
concurrent  O
AHTRT  O
,  O
chemoradiation  O
with  O
PIEo  B-DRUG
produced  O
similar  O
median  O
and  O
2-year  O
survival  O
rates  O
and  O
a  O
higher  O
rate  O
of  O
acute  B-TOXI
esophageal  I-TOXI
toxicity  I-TOXI
.  O

However  O
,  O
the  O
locoregional  O
control  O
rate  O
with  O
a  O
minimum  O
follow-up  O
of  O
2  O
years  O
is  O
excellent  O
at  O
80  O
%  O
.  O

It  O
is  O
conceivable  O
that  O
longer  O
follow-up  O
will  O
prove  O
this  O
regimen  O
more  O
promising  O
.  O

Research  O
efforts  O
should  O
focus  O
on  O
other  O
methods  O
to  O
improve  O
disease  O
control  O
in  O
all  O
potential  O
sites  O
of  O
recurrence  O
.  O

Gemcitabine  B-DRUG
plus  O
vinorelbine  B-DRUG
in  O
elderly  O
or  O
unfit  O
patients  O
with  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Cisplatin-based  B-DRUG
combinations  O
are  O
efficacious  O
in  O
increasing  O
the  O
overall  O
survival  O
of  O
patients  O
with  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
,  O
but  O
their  O
toxicity  O
makes  O
them  O
unsuitable  O
for  O
elderly  O
and  O
unfit  O
patients  O
.  O

The  O
primary  O
objective  O
of  O
this  O
non-randomized  O
phase  O
II  O
study  O
was  O
to  O
evaluate  O
the  O
feasibility  O
and  O
activity  O
of  O
the  O
gemcitabine  B-DRUG
plus  O
vinorelbine  B-DRUG
combination  O
in  O
previously  O
untreated  O
elderly  O
and  O
/  O
or  O
unfit  O
patients  O
with  O
measurable  O
stage  O
III  O
or  O
IV  O
NSCLC  B-CANCER
.  O

Forty-three  O
patients  O
aged  O
&  O
gt  O
;  O
/  O
=  O
65  O
years  O
or  O
with  O
contraindications  O
against  O
cisplatin  B-DRUG
treatment  O
(  O
36  O
males  O
and  O
seven  O
females  O
:  O
median  O
age  O
66  O
years  O
;  O
range  O
48-75  O
:  O
PS  O
0  O
=  O
11  O
,  O
PS  O
1  O
=  O
19  O
,  O
PS  O
2  O
=  O
13  O
)  O
received  O
intravenous  O
(  O
i.v.  O
)  O
gemcitabine  B-DRUG
1000  O
mg  O
m  O
(  O
-2  O
)  O
,  O
followed  O
by  O
vinorelbine  B-DRUG
25  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
on  O
day  O
1  O
and  O
8  O
every  O
21  O
days  O
.  O

Fifteen  O
patients  O
(  O
34.9  O
%  O
)  O
achieved  O
partial  O
remission  O
(  O
confidence  O
interval  O
:  O
27  O
.  O

6-42.2  O
%  O
)  O
for  O
a  O
median  O
duration  O
of  O
6  O
months  O
;  O
the  O
median  O
survival  O
of  O
these  O
patients  O
has  O
not  O
yet  O
been  O
reached  O
.  O

A  O
further  O
15  O
had  O
stable  O
disease  O
for  O
a  O
median  O
of  O
4  O
months  O
and  O
a  O
median  O
survival  O
of  O
7  O
months  O
.  O

The  O
10  O
patients  O
(  O
23.2  O
%  O
)  O
who  O
experienced  O
disease  B-TOXI
progression  I-TOXI
had  O
a  O
median  O
survival  O
of  O
4  O
months  O
.  O

Three  O
patients  O
are  O
not  O
evaluable  O
.  O

The  O
1-year  O
actuarial  O
survival  O
rate  O
is  O
31.1  O
%  O
.  O

The  O
treatment  O
was  O
well  O
tolerated  O
:  O
only  O
35  O
%  O
of  O
the  O
patients  O
had  O
grade  O
3  O
or  O
4  O
granulocytopenia  B-TOXI
on  O
day  O
14  O
,  O
none  O
experienced  O
episodes  O
of  O
neutropenic  B-TOXI
fever  I-TOXI
,  O
and  O
there  O
was  O
no  O
evidence  O
of  O
severe  B-TOXI
haematological  I-TOXI
toxicity  I-TOXI
upon  O
recycling  O
.  O

Only  O
9  O
%  O
of  O
the  O
patients  O
suffered  O
from  O
gastrointestinal  B-TOXI
toxicity  I-TOXI
(  O
grade  O
3  O
)  O
;  O
increased  O
but  O
reversible  O
transaminase  O
levels  O
were  O
observed  O
in  O
11.6  O
%  O
.  O

In  O
conclusion  O
,  O
the  O
results  O
of  O
this  O
phase  O
II  O
study  O
show  O
that  O
the  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
vinorelbine  B-DRUG
is  O
active  O
and  O
well  O
tolerated  O
in  O
NSCLC  B-CANCER
,  O
and  O
thus  O
encourage  O
its  O
use  O
in  O
elderly  O
or  O
unfit  O
patients  O
.  O

A  O
phase  O
II  O
trial  O
of  O
paclitaxel  B-DRUG
and  O
epirubicin  B-DRUG
in  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O


Initial  O
trials  O
of  O
paclitaxel  B-DRUG
and  O
doxorubicin  B-DRUG
in  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
yielded  O
high  O
response  O
rates  O
but  O
significant  O
cardiac  B-TOXI
toxicity  I-TOXI
was  O
observed  O
.  O

In  O
this  O
phase  O
II  O
trial  O
we  O
investigated  O
the  O
efficacy  O
and  O
safety  O
of  O
paclitaxel  B-DRUG
combined  O
with  O
epirubicin  B-DRUG
.  O

Patients  O
with  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
,  O
performance  O
status  O
0-2  O
,  O
measurable  O
disease  O
,  O
and  O
a  O
normal  O
left  O
ventricular  O
ejection  O
fraction  O
,  O
who  O
may  O
have  O
received  O
adjuvant  O
chemotherapy  O
were  O
treated  O
with  O
epirubicin  B-DRUG
75  O
mg  O
m  O
(  O
-2  O
)  O
followed  O
by  O
a  O
3-h  O
infusion  O
of  O
paclitaxel  B-DRUG
175  O
mg  O
m  O
(  O
-2  O
)  O
repeated  O
every  O
3  O
weeks  O
.  O

Forty-three  O
eligible  O
patients  O
were  O
treated  O
at  O
six  O
centres  O
.  O

67  O
%  O
patients  O
received  O
the  O
maximum  O
of  O
six  O
cycles  O
.  O

The  O
response  O
rate  O
was  O
54  O
%  O
(  O
95  O
%  O
CI  O
38-69  O
%  O
)  O
,  O
12  O
%  O
CR  O
and  O
42  O
%  O
PR  O
.  O

Estimated  O
median  O
progression-free  O
survival  O
was  O
6.9  O
months  O
(  O
95  O
%  O
CI  O
5.4-10.0  O
)  O
and  O
estimated  O
median  O
overall  O
survival  O
was  O
17.9  O
months  O
(  O
95  O
%  O
CI  O
14.2-25.7  O
)  O
.  O

Four  O
patients  O
had  O
a  O
decrease  O
in  O
the  O
left  O
ventricular  O
ejection  O
fraction  O
(  O
LVEF  O
)  O
of  O
&  O
gt  O
;  O
or  O
=20  O
%  O
of  O
baseline  O
value  O
,  O
and  O
in  O
two  O
patients  O
the  O
LVEF  O
decreased  O
to  O
below  O
the  O
lower  O
limit  O
of  O
normal  O
,  O
but  O
no  O
patient  O
developed  O
clinical  O
evidence  O
of  O
cardiac  O
failure  O
.  O

Grade  O
4  O
neutropenia  B-TOXI
occurred  O
in  O
56  O
%  O
cycles  O
,  O
but  O
only  O
4  O
%  O
of  O
cycles  O
were  O
complicated  O
by  O
febrile  B-TOXI
neutropenia  I-TOXI
.  O

Grade  O
3  O
or  O
4  O
non-haematologic  B-TOXI
toxicity  I-TOXI
was  O
uncommon  O
.  O

In  O
conclusion  O
,  O
paclitaxel  B-DRUG
175  O
mg  O
m  O
(  O
-2  O
)  O
and  O
epirubicin  B-DRUG
75  O
mg  O
m  O
(  O
-2  O
)  O
is  O
a  O
well  O
tolerated  O
,  O
promising  O
regimen  O
for  O
the  O
treatment  O
of  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O

Gemcitabine  B-DRUG
plus  O
vinorelbine  B-DRUG
in  O
advanced  B-CANCER
non-small  I-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
II  O
study  O
of  O
three  O
different  O
doses.  O
Gem  B-DRUG
Vin  I-DRUG
Investigators  O
.  O


Our  O
aim  O
was  O
to  O
study  O
the  O
activity  O
and  O
toxicity  O
of  O
the  O
gemcitabine  B-DRUG
plus  O
vinorelbine  B-DRUG
(  O
Gem  B-DRUG
Vin  I-DRUG
)  O
combination  O
and  O
to  O
identify  O
the  O
optimal  O
dose  O
.  O

Previously  O
untreated  O
patients  O
aged  O
&  O
lt  O
;  O
70  O
years  O
,  O
with  O
stage  O
IV  O
or  O
IIIb  O
(  O
not  O
candidates  O
for  O
radiotherapy  O
)  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
were  O
eligible  O
.  O

Studied  O
dose-levels  O
of  O
Gem  B-DRUG
Vin  I-DRUG
,  O
administered  O
on  O
days  O
1  O
and  O
8  O
every  O
3  O
weeks  O
,  O
were  O
(  O
mg  O
m  O
(  O
-2  O
)  O
)  O
:  O
level  O
I  O
=  O
1000  O
/  O
25  O
;  O
level  O
II  O
=  O
1200  O
/  O
25  O
;  O
level  O
III  O
=  O
1000  O
/  O
30  O
;  O
level  O
IV  O
=  O
1200  O
/  O
30  O
.  O

A  O
feasibility  O
study  O
was  O
performed  O
at  O
each  O
dose-level  O
,  O
followed  O
by  O
a  O
single-stage  O
phase  O
II  O
study  O
.  O

Dose-level  O
IV  O
was  O
unfeasible  O
because  O
of  O
grade  O
4  O
neutropenia  B-TOXI
.  O

Overall  O
,  O
out  O
of  O
126  O
patients  O
enrolled  O
in  O
phase  O
II  O
studies  O
,  O
there  O
were  O
one  O
complete  O
and  O
32  O
partial  O
responses  O
(  O
response  O
rate  O
26  O
%  O
:  O
95  O
%  O
CI  O
18-34  O
%  O
)  O
.  O

Response  O
rates  O
were  O
27.9  O
%  O
,  O
21.4  O
%  O
and  O
29.3  O
%  O
at  O
levels  O
I  O
,  O
II  O
and  O
III  O
,  O
respectively  O
.  O

The  O
treatment  O
was  O
well  O
tolerated  O
.  O

Toxicity  O
was  O
less  O
frequent  O
and  O
severe  O
at  O
level  O
I.  O
Overall  O
median  O
survival  O
was  O
33  O
weeks  O
(  O
95  O
%  O
CI  O
28-40  O
)  O
.  O

Descriptive  O
quality  O
of  O
life  O
analysis  O
showed  O
that  O
patients  O
with  O
a  O
worse  O
baseline  O
global  O
health  O
status  O
score  O
tended  O
to  O
drop  O
out  O
of  O
the  O
study  O
earlier  O
than  O
those  O
with  O
a  O
better  O
score  O
.  O

Gem  B-DRUG
Vin  I-DRUG
is  O
feasible  O
at  O
different  O
doses  O
.  O

It  O
is  O
sufficiently  O
active  O
and  O
well  O
tolerated  O
.  O

A  O
phase  O
III  O
study  O
to  O
compare  O
the  O
effect  O
on  O
quality  O
of  O
life  O
of  O
Gem  B-DRUG
Vin  I-DRUG
(  O
level  O
I  O
)  O
vs  O
cisplatin-based  B-DRUG
chemotherapy  O
is  O
ongoing  O
.  O

Phase  O
I  O
dose  O
escalation  O
study  O
of  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
plus  O
colony-stimulating  B-DRUG
factors  I-DRUG
in  O
previously  O
treated  O
patients  O
with  O
advanced  B-CANCER
breast  I-CANCER
and  I-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O


Gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
(  O
PTX  B-DRUG
)  O
are  O
among  O
the  O
most  O
active  O
new  O
drugs  O
in  O
advanced  B-CANCER
breast  I-CANCER
and  I-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

In  O
this  O
Phase  O
I  O
study  O
,  O
we  O
used  O
fixed  O
doses  O
of  O
gemcitabine  B-DRUG
administered  O
on  O
days  O
1  O
and  O
8  O
and  O
escalating  O
doses  O
of  O
paclitaxel  B-DRUG
on  O
day  O
1  O
of  O
a  O
21-day  O
cycle  O
in  O
patients  O
with  O
pretreated  B-CANCER
metastatic  I-CANCER
breast  I-CANCER
or  I-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

The  O
dose  O
of  O
gemcitabine  B-DRUG
was  O
fixed  O
at  O
1,000  O
mg  O
/  O
m2  O
;  O
PTX  B-DRUG
was  O
commenced  O
in  O
the  O
first  O
small  O
patient  O
group  O
at  O
a  O
dose  O
of  O
90  O
mg  O
/  O
m2  O
,  O
which  O
was  O
then  O
escalated  O
in  O
subsequent  O
groups  O
by  O
30  O
mg  O
/  O
m2  O
per  O
step  O
.  O

From  O
the  O
third  O
dose  O
level  O
onwards  O
,  O
all  O
patients  O
received  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
300  O
microg  O
by  O
subcutaneous  O
injection  O
on  O
days  O
5  O
and  O
6  O
,  O
and  O
granulocyte  B-DRUG
macrophage  I-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
on  O
days  O
15-18  O
.  O

Cohorts  O
of  O
at  O
least  O
3  O
patients  O
were  O
treated  O
at  O
each  O
dose  O
level  O
.  O

Dose  O
escalation  O
was  O
stopped  O
if  O
at  O
least  O
a  O
third  O
of  O
the  O
patients  O
in  O
a  O
given  O
cohort  O
had  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
,  O
which  O
was  O
defined  O
as  O
grade  O
4  O
neutropenia  B-TOXI
or  O
thrombocytopenia  B-TOXI
,  O
or  O
grade  O
3-4  O
non-haematological  B-TOXI
toxicity  I-TOXI
.  O

The  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
was  O
defined  O
as  O
the  O
dose  O
level  O
immediately  O
below  O
that  O
causing  O
DLT  O
in  O
one-third  O
of  O
the  O
patients  O
or  O
more  O
.  O

Evaluation  O
of  O
the  O
tumour  O
response  O
was  O
performed  O
every  O
three  O
cycles  O
.  O

Forty-five  O
patients  O
(  O
31  O
with  O
breast  B-CANCER
cancer  I-CANCER
,  O
14  O
with  O
ovarian  B-CANCER
cancer  I-CANCER
)  O
were  O
treated  O
at  O
seven  O
different  O
dose  O
levels  O
.  O

Only  O
at  O
the  O
seventh  O
PTX  B-DRUG
dose  O
level  O
was  O
DLT  O
observed  O
after  O
the  O
first  O
course  O
of  O
therapy  O
:  O
three  O
grade  O
4  O
neutropenia  B-TOXI
,  O
one  O
grade  O
4  O
thrombocytopenia  B-TOXI
,  O
and  O
one  O
grade  O
4  O
anaemia  B-TOXI
.  O

DLT  O
occurred  O
in  O
5  O
/  O
6  O
patients  O
at  O
at  O
PTX  B-DRUG
dose  O
of  O
270  O
mg  O
/  O
m2  O
;  O
therefore  O
dose  O
escalation  O
was  O
stopped  O
at  O
that  O
level  O
and  O
the  O
dose  O
immediately  O
before  O
it  O
(  O
PTX  B-DRUG
240  O
mg  O
/  O
m2  O
)  O
was  O
considered  O
as  O
the  O
MTD  O
and  O
recommended  O
for  O
further  O
studies  O
.  O

No  O
toxic  B-TOXI
deaths  I-TOXI
occurred  O
.  O

Grade  O
3-4  O
uncomplicated  B-TOXI
neutropenia  I-TOXI
was  O
observed  O
in  O
four  O
patients  O
.  O

Three  O
had  O
uncomplicated  O
grade  O
3-4  O
thrombocytopenia  B-TOXI
.  O

One  O
patient  O
had  O
grade  O
3  O
and  O
one  O
grade  O
4  O
anaemia  B-TOXI
.  O

Nonhaematological  B-TOXI
side  I-TOXI
effects  I-TOXI
were  O
generally  O
mild  O
.  O

Among  O
30  O
evaluable  O
patients  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
,  O
four  O
complete  O
responses  O
(  O
CR  O
)  O
(  O
13  O
%  O
)  O
and  O
12  O
partial  O
responses  O
(  O
PR  O
)  O
(  O
40  O
%  O
)  O
were  O
observed  O
,  O
for  O
an  O
overall  O
response  O
rate  O
of  O
53  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
34-72  O
)  O
.  O

The  O
median  O
duration  O
of  O
response  O
was  O
31  O
weeks  O
.  O

Among  O
13  O
evaluable  O
patients  O
with  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
,  O
one  O
CR  O
(  O
8  O
%  O
)  O
and  O
five  O
PRs  O
(  O
38  O
%  O
)  O
were  O
observed  O
,  O
for  O
an  O
overall  O
response  O
rate  O
of  O
46  O
%  O
(  O
95  O
%  O
CI  O
19-78  O
)  O
.  O

The  O
median  O
duration  O
of  O
response  O
was  O
32  O
weeks  O
.  O

Our  O
study  O
shows  O
that  O
gemcitabine  B-DRUG
and  O
PTX  B-DRUG
can  O
be  O
administered  O
in  O
combination  O
in  O
patients  O
with  O
breast  B-CANCER
and  I-CANCER
ovarian  I-CANCER
cancer  I-CANCER
without  O
unexpected  O
toxicities  O
and  O
with  O
encouraging  O
therapeutic  O
results  O
.  O

Eastern  O
Cooperative  O
Oncology  O
Group  O
Phase  O
I  O
trial  O
of  O
protracted  O
venous  O
infusion  O
fluorouracil  B-DRUG
plus  O
weekly  O
gemcitabine  B-DRUG
with  O
concurrent  O
radiation  O
therapy  O
in  O
patients  O
with  O
locally  O
advanced  B-DRUG
pancreas  I-DRUG
cancer  I-DRUG
:  O
a  O
regimen  O
with  O
unexpected  O
early  O
toxicity  O
.  O


We  O
performed  O
a  O
phase  O
I  O
trial  O
of  O
protracted  O
venous  O
infusion  O
(  O
PVI  O
)  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
plus  O
weekly  O
gemcitabine  B-DRUG
with  O
concurrent  O
radiation  O
therapy  O
in  O
patients  O
with  O
locally  O
advanced  B-CANCER
pancreas  I-CANCER
cancer  I-CANCER
to  O
determine  O
the  O
maximum-tolerated  O
dose  O
of  O
gemcitabine  B-DRUG
that  O
could  O
be  O
safely  O
administered  O
.  O

We  O
also  O
sought  O
to  O
identify  O
the  O
toxicities  O
associated  O
with  O
this  O
treatment  O
protocol  O
.  O

Seven  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
pancreas  I-CANCER
cancer  I-CANCER
were  O
treated  O
with  O
planned  O
doses  O
of  O
radiation  O
(  O
59.4  O
Gy  O
)  O
and  O
PVI  O
of  O
5-FU  B-DRUG
(  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
)  O
with  O
gemcitabine  B-DRUG
doses  O
of  O
50  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
wk  O
.  O

Two  O
of  O
three  O
patients  O
at  O
the  O
100-mg  O
/  O
m  O
(  O
2  O
)  O
/  O
wk  O
dose  O
level  O
experienced  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
,  O
as  O
did  O
three  O
of  O
four  O
at  O
the  O
50-mg  O
/  O
m  O
(  O
2  O
)  O
/  O
wk  O
dose  O
level  O
.  O

One  O
patient  O
experienced  O
a  O
mucocutaneous  O
reaction  O
described  O
as  O
a  O
Stevens-Johnson  O
syndrome  O
that  O
was  O
attributed  O
to  O
chemotherapy  O
.  O

Three  O
patients  O
developed  O
gastric  B-TOXI
or  O
duodenal  B-TOXI
ulcers  I-TOXI
with  O
severe  B-TOXI
bleeding  I-TOXI
requiring  O
transfusion  O
.  O

One  O
patient  O
developed  O
severe  O
thrombocytopenia  B-TOXI
lasting  O
longer  O
than  O
4  O
weeks  O
.  O

Three  O
of  O
the  O
five  O
episodes  O
of  O
DLT  O
developed  O
at  O
radiation  O
doses  O
&  O
lt  O
;  O
or  O
=  O
36  O
Gy  O
.  O

Based  O
on  O
this  O
experience  O
,  O
we  O
can  O
not  O
recommend  O
further  O
investigation  O
of  O
regimens  O
incorporating  O
gemcitabine  B-DRUG
into  O
regimens  O
of  O
radiation  O
with  O
PVI  O
5-FU  B-DRUG
.  O

The  O
mechanism  O
of  O
this  O
synergistic  O
toxicity  O
remains  O
to  O
be  O
determined  O
.  O

Phase  O
I  O
chemotherapy  O
study  O
of  O
biochemical  O
modulation  O
of  O
folinic  B-DRUG
acid  I-DRUG
and  O
fluorouracil  B-DRUG
by  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
solid  B-CANCER
tumor  I-CANCER
malignancies  I-CANCER
.  O


This  O
phase  O
I  O
biochemical  O
modulation  O
study  O
evaluated  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
toxicity  O
,  O
and  O
effectiveness  O
of  O
the  O
combination  O
of  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
/  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
followed  O
by  O
escalated  O
dose  O
levels  O
of  O
gemcitabine  B-DRUG
(  O
FFG  B-DRUG
)  O
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

Patients  O
were  O
refractory  O
to  O
primary  O
treatment  O
and  O
/  O
or  O
without  O
effective  O
treatment  O
options  O
.  O

Twenty-eight  O
patients  O
received  O
an  O
intravenous  O
(  O
IV  O
)  O
infusion  O
of  O
FA  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
over  O
1  O
hour  O
and  O
a  O
5-FU  B-DRUG
450  O
mg  O
/  O
m  O
(  O
2  O
)  O
IV  O
bolus  O
in  O
the  O
middle  O
of  O
the  O
FA  B-DRUG
infusion  O
.  O

After  O
the  O
FA  B-DRUG
infusion  O
,  O
gemcitabine  B-DRUG
was  O
administered  O
at  O
a  O
steady  O
rate  O
of  O
infusion  O
of  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
min  O
over  O
initially  O
30  O
minutes  O
and  O
with  O
increases  O
of  O
an  O
additional  O
15  O
minutes  O
at  O
each  O
given  O
level  O
.  O

One  O
cycle  O
consisted  O
of  O
six  O
weekly  O
treatments  O
followed  O
by  O
a  O
2-week  O
rest  O
.  O

The  O
MTD  O
of  O
gemcitabine  B-DRUG
was  O
established  O
at  O
900  O
mg  O
/  O
m  O
(  O
2  O
)  O
given  O
over  O
90  O
minutes  O
.  O

Eight  O
patients  O
of  O
21  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
achieved  O
responses  O
(  O
one  O
complete  O
response  O
;  O
seven  O
partial  O
responses  O
)  O
,  O
for  O
a  O
response  O
rate  O
of  O
38  O
%  O
.  O

Responses  O
were  O
seen  O
across  O
the  O
gemcitabine  B-DRUG
doses  O
of  O
300  O
to  O
900  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

One  O
patient  O
had  O
prior  O
treatment  O
with  O
FA  B-DRUG
/  I-DRUG
5-FU  I-DRUG
for  O
advanced  O
disease  O
.  O

Patients  O
with  O
colorectal  B-CANCER
carcinoma  I-CANCER
had  O
a  O
median  O
survival  O
of  O
18  O
months  O
,  O
and  O
the  O
patient  O
with  O
lung  B-CANCER
carcinoma  I-CANCER
has  O
been  O
alive  O
for  O
24+  O
months  O
.  O

The  O
combination  O
chemotherapy  O
of  O
FFG  B-DRUG
was  O
well  O
tolerated  O
and  O
may  O
benefit  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
.  O

A  O
phase  O
II  O
evaluation  O
in  O
this  O
patient  O
population  O
is  O
in  O
progress  O
.  O

Phase  O
I  O
dose-finding  O
and  O
pharmacokinetic  O
study  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
with  O
oral  O
valspodar  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


To  O
evaluate  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
,  O
and  O
pharmacokinetic  O
(  O
PK  O
)  O
profile  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
when  O
administered  O
every  O
3  O
weeks  O
with  O
the  O
oral  O
semisynthetic  B-DRUG
cyclosporine  I-DRUG
analog  I-DRUG
valspodar  I-DRUG
(  O
PSC  B-DRUG
833  I-DRUG
)  O
,  O
an  O
inhibitor  O
of  O
P-glycoprotein  B-DRUG
function  O
.  O

Fifty-eight  O
patients  O
were  O
treated  O
with  O
escalating  O
doses  O
of  O
paclitaxel  B-DRUG
ranging  O
from  O
54  O
to  O
94.5  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
carboplatin  B-DRUG
area  O
under  O
the  O
plasma  O
concentration  O
versus  O
time  O
curve  O
(  O
AUC  O
)  O
ranging  O
from  O
6  O
to  O
9  O
mg.min  O
/  O
mL  O
,  O
every  O
21  O
days  O
.  O

The  O
dose  O
of  O
valspodar  B-DRUG
was  O
fixed  O
at  O
5  O
mg  O
/  O
kg  O
every  O
6  O
hours  O
for  O
a  O
total  O
of  O
12  O
doses  O
from  O
day  O
0  O
to  O
day  O
3.  O
The  O
MTD  O
was  O
determined  O
for  O
the  O
following  O
two  O
groups  O
:  O
(  O
1  O
)  O
previously  O
treated  O
patients  O
,  O
where  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
doses  O
were  O
escalated  O
;  O
and  O
(  O
2  O
)  O
chemotherapy-na√Øve  O
patients  O
,  O
where  O
paclitaxel  B-DRUG
dose  O
was  O
escalated  O
and  O
carboplatin  B-DRUG
AUC  O
was  O
fixed  O
at  O
6  O
mg.min  O
/  O
mL  O
.  O

PK  O
studies  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
were  O
performed  O
on  O
day  O
1  O
of  O
course  O
1.  O
Fifty-eight  O
patients  O
were  O
treated  O
with  O
186  O
courses  O
of  O
paclitaxel  B-DRUG
,  O
carboplatin  B-DRUG
,  O
and  O
valspodar  B-DRUG
.  O

Neutropenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
,  O
and  O
hepatic  B-TOXI
transaminase  I-TOXI
elevations  I-TOXI
were  O
DLTs  O
.  O

In  O
previously  O
treated  O
patients  O
,  O
no  O
DLTs  O
occurred  O
at  O
the  O
first  O
dose  O
level  O
(  O
paclitaxel  B-DRUG
54  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
carboplatin  B-DRUG
AUC  O
6  O
mg.min  O
/  O
mL  O
)  O
.  O

However  O
,  O
one  O
of  O
12  O
,  O
two  O
of  O
six  O
,  O
two  O
of  O
four  O
,  O
four  O
of  O
11  O
,  O
and  O
two  O
of  O
five  O
patients  O
experienced  O
DLTs  O
at  O
doses  O
of  O
paclitaxel  B-DRUG
(  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
/  O
carboplatin  B-DRUG
AUC  O
(  O
mg.min  O
/  O
mL  O
)  O
of  O
67.5  O
/  O
6  O
,  O
81  O
/  O
6  O
,  O
94.5  O
/  O
6  O
,  O
67  O
.  O

5  O
/  O
7.5  O
,  O
and  O
67.5  O
/  O
9  O
,  O
respectively  O
.  O

In  O
chemotherapy-na√Øve  O
patients  O
,  O
one  O
of  O
17  O
developed  O
DLT  O
at  O
paclitaxel  B-DRUG
81  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
carboplatin  B-DRUG
AUC  O
6  O
mg  O
/  O
mL.min  O
.  O

There  O
was  O
prolongation  O
of  O
the  O
terminal  O
phase  O
of  O
paclitaxel  B-DRUG
elimination  O
as  O
evidenced  O
by  O
an  O
increased  O
time  O
that  O
plasma  O
paclitaxel  B-DRUG
concentration  O
was  O
&  O
gt  O
;  O
/  O
=  O
0.05  O
micromol  O
/  O
L  O
,  O
ranging  O
from  O
16.6  O
+  O
/  O
-  O
6.7  O
hours  O
to  O
41.5  O
+  O
/  O
-  O
9.8  O
hours  O
for  O
paclitaxel  B-DRUG
doses  O
of  O
54.5  O
mg  O
/  O
m  O
(  O
2  O
)  O
to  O
94.5  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
respectively  O
.  O

The  O
recommended  O
phase  O
II  O
dose  O
in  O
chemotherapy-na√Øve  O
patients  O
is  O
paclitaxel  B-DRUG
81  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
carboplatin  B-DRUG
AUC  O
6  O
mg.min  O
/  O
mL  O
,  O
and  O
valspodar  B-DRUG
5  O
mg  O
/  O
kg  O
every  O
6  O
hours  O
.  O

In  O
previously  O
treated  O
patients  O
,  O
the  O
recommended  O
phase  O
II  O
dose  O
is  O
paclitaxel  B-DRUG
67.5  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
carboplatin  B-DRUG
AUC  O
6  O
mg.min  O
/  O
mL  O
,  O
and  O
valspodar  B-DRUG
5  O
mg  O
/  O
kg  O
every  O
6  O
hours  O
.  O

The  O
acceptable  O
toxicity  O
profile  O
supports  O
the  O
rationale  O
for  O
performing  O
disease-directed  O
evaluations  O
of  O
paclitaxel  B-DRUG
,  O
carboplatin  B-DRUG
and  O
valspodar  B-DRUG
on  O
the  O
schedule  O
evaluated  O
in  O
this  O
study  O
.  O

Phase  O
I  O
and  O
pharmacokinetic  O
trial  O
of  O
weekly  O
oral  O
fluorouracil  B-DRUG
given  O
with  O
eniluracil  B-DRUG
and  O
low-dose  O
leucovorin  B-DRUG
to  O
patients  O
with  O
solid  B-CANCER
tumors  I-CANCER
.  O


Fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
given  O
as  O
a  O
weekly  O
,  O
high-dose  O
24-hour  O
infusion  O
is  O
active  O
and  O
tolerable  O
.  O

We  O
evaluated  O
an  O
oral  O
regimen  O
of  O
eniluracil  B-DRUG
(  O
which  O
inactivates  B-DRUG
dihydropyrimidine  I-DRUG
dehydrogenase  I-DRUG
[  O
DPD  B-DRUG
]  O
)  O
,  O
5-FU  B-DRUG
,  O
and  O
leucovorin  B-DRUG
to  O
simulate  O
this  O
schedule  O
.  O

Patients  O
received  O
a  O
single  O
24-hour  O
infusion  O
of  O
5-FU  B-DRUG
(  O
2,300  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
2  O
)  O
with  O
leucovorin  B-DRUG
(  O
15  O
mg  O
orally  O
[  O
PO  O
]  O
bid  O
on  O
days  O
1  O
through  O
3  O
)  O
to  O
provide  O
reference  O
pharmacokinetic  O
data  O
.  O

Two  O
weeks  O
later  O
,  O
patients  O
began  O
treatment  O
with  O
eniluracil  B-DRUG
(  O
20  O
mg  O
)  O
and  O
leucovorin  B-DRUG
(  O
15  O
mg  O
)  O
(  O
PO  O
bid  O
on  O
days  O
1  O
through  O
3  O
)  O
and  O
5-FU  B-DRUG
(  O
10  O
to  O
15  O
mg  O
/  O
m  O
(  O
2  O
)  O
PO  O
bid  O
on  O
day  O
2  O
)  O
.  O

Dose-limiting  O
toxicity  O
(  O
diarrhea  B-TOXI
,  O
neutropenia  B-TOXI
,  O
and  O
fatigue  B-TOXI
)  O
was  O
seen  O
with  O
5-FU  B-DRUG
15  O
mg  O
/  O
m  O
(  O
2  O
)  O
PO  O
bid  O
on  O
day  O
2  O
given  O
weekly  O
for  O
either  O
6  O
of  O
8  O
weeks  O
or  O
3  O
of  O
4  O
weeks  O
,  O
whereas  O
five  O
of  O
seven  O
patients  O
tolerated  O
5-FU  B-DRUG
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
PO  O
bid  O
given  O
weekly  O
for  O
3  O
of  O
4  O
weeks  O
.  O

Eniluracil  B-DRUG
led  O
to  O
a  O
35-fold  O
reduction  O
in  O
5-FU  B-DRUG
clearance  O
.  O

Fluoro-beta-alanine  B-DRUG
,  O
a  O
5-FU  B-DRUG
catabolite  I-DRUG
,  O
was  O
not  O
detected  O
in  O
plasma  O
during  O
oral  O
5-FU-eniluracil  B-DRUG
therapy  O
.  O

DPD  B-DRUG
activity  O
was  O
markedly  O
suppressed  O
in  O
all  O
patients  O
during  O
eniluracil  B-DRUG
therapy  O
;  O
the  O
inactivation  O
persisted  O
after  O
the  O
last  O
eniluracil  B-DRUG
dose  O
;  O
percentages  O
of  O
baseline  O
values  O
were  O
1.8  O
%  O
on  O
day  O
5  O
,  O
4.5  O
%  O
on  O
day  O
12  O
,  O
and  O
23.6  O
%  O
on  O
day  O
19  O
.  O

The  O
recommended  O
oral  O
dosage  O
of  O
5-FU  B-DRUG
(  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
PO  O
bid  O
)  O
given  O
with  O
eniluracil  B-DRUG
and  O
leucovorin  B-DRUG
is  O
approximately  O
115-fold  O
lower  O
than  O
the  O
reference  O
dosage  O
for  O
24-hour  O
infusional  O
5-FU  O
.  O

This  O
difference  O
is  O
greater  O
than  O
expected  O
given  O
the  O
reduction  O
in  O
5-FU  B-DRUG
clearance  O
.  O

DPD  B-DRUG
inactivation  O
persisted  O
for  O
several  O
weeks  O
after  O
completion  O
of  O
eniluracil  B-DRUG
therapy  O
.  O

A  O
medical  O
research  O
council  O
randomized  O
trial  O
of  O
single  O
agent  O
carboplatin  B-DRUG
versus  O
etoposide  B-DRUG
and  O
cisplatin  B-DRUG
for  O
advanced  B-CANCER
metastatic  I-CANCER
seminoma.  I-CANCER
MRC  O
Testicular  O
Tumour  O
Working  O
Party  O
.  O


The  O
UK  O
Medical  O
Research  O
Council  O
conducted  O
this  O
trial  O
of  O
carboplatin  B-DRUG
chemotherapy  O
in  O
advanced  B-CANCER
seminoma  I-CANCER
to  O
compare  O
single  O
agent  O
carboplatin  B-DRUG
with  O
a  O
standard  O
combination  O
of  O
etoposide  B-DRUG
with  O
cisplatin  B-DRUG
.  O

The  O
use  O
of  O
single  O
agent  O
carboplatin  B-DRUG
was  O
expected  O
to  O
be  O
associated  O
with  O
reduced  O
toxicity  O
.  O

A  O
total  O
of  O
130  O
patients  O
with  O
advanced  B-CANCER
seminoma  I-CANCER
were  O
randomly  O
assigned  O
to  O
treatment  O
with  O
either  O
single  O
agent  O
carboplatin  B-CANCER
(  O
C  O
)  O
at  O
a  O
dose  O
of  O
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
to  O
be  O
corrected  O
for  O
glomerular  O
filtration  O
rate  O
outside  O
the  O
range  O
81-120  O
ml  O
min  O
(  O
-1  O
)  O
and  O
to  O
be  O
administered  O
on  O
day  O
1  O
of  O
a  O
21  O
day  O
cycle  O
to  O
a  O
total  O
of  O
4  O
cycles  O
or  O
to  O
etoposide  B-DRUG
+  O
platinum  B-DRUG
(  O
EP  B-DRUG
)  O
.  O

The  O
trial  O
was  O
designed  O
as  O
an  O
equivalence  O
study  O
aiming  O
to  O
exclude  O
a  O
reduction  O
in  O
the  O
3-year  O
progression-free  O
survival  O
in  O
patients  O
allocated  O
to  O
carboplatin  B-DRUG
of  O
between  O
10  O
and  O
15  O
%  O
,  O
requiring  O
initially  O
a  O
target  O
accrual  O
of  O
250  O
patients  O
(  O
90  O
%  O
power  O
significance  O
level  O
5  O
%  O
(  O
one-sided  O
)  O
)  O
.  O

The  O
trial  O
closed  O
after  O
130  O
patients  O
had  O
been  O
randomized  O
following  O
recommendation  O
by  O
an  O
independent  O
data  O
monitoring  O
committee  O
.  O

At  O
a  O
median  O
follow-up  O
time  O
of  O
4.5  O
years  O
,  O
81  O
%  O
of  O
patients  O
had  O
been  O
followed  O
up  O
for  O
at  O
least  O
3  O
years  O
and  O
19  O
patients  O
have  O
died  O
.  O

The  O
estimated  O
PFS  O
rate  O
(  O
95  O
%  O
Confidence  O
Intervals  O
(  O
CI  O
)  O
)  O
at  O
3  O
years  O
was  O
71  O
%  O
(  O
60-82  O
%  O
)  O
in  O
patients  O
allocated  O
C  O
and  O
81  O
%  O
(  O
71-90  O
%  O
)  O
in  O
those  O
allocated  O
EP  B-DRUG
;  O
the  O
95  O
%  O
CI  O
for  O
the  O
difference  O
in  O
3  O
year  O
PFS  O
was  O
-  O
6  O
%  O
to  O
+19  O
%  O
.  O

The  O
hazard  O
ratio  O
of  O
0.64  O
(  O
95  O
%  O
CI  O
0.32-1.28  O
)  O
favoured  O
EP  B-DRUG
but  O
the  O
difference  O
was  O
not  O
statistically  O
significant  O
(  O
log  O
rank  O
chi-squared  O
=  O
1.59  O
P  O
=  O
0.21  O
)  O
.  O

The  O
3-year  O
survival  O
rate  O
was  O
84  O
%  O
(  O
75-92  O
%  O
)  O
in  O
those  O
allocated  O
C  O
,  O
and  O
89  O
%  O
(  O
81-96  O
%  O
)  O
in  O
those  O
allocated  O
EP  B-DRUG
.  O

The  O
hazard  O
ratio  O
for  O
survival  O
was  O
0.85  O
with  O
95  O
%  O
CI  O
,  O
0.35-2.10  O
,  O
log  O
rank  O
chi-squared  O
=  O
0.12  O
,  O
P  O
=  O
0.73  O
.  O

The  O
trial  O
has  O
not  O
demonstrated  O
statistically  O
significant  O
differences  O
in  O
the  O
major  O
survival  O
endpoints  O
comparing  O
single  O
agent  O
carboplatin  B-DRUG
with  O
a  O
combination  O
of  O
etoposide  B-DRUG
+  O
cisplatin  B-DRUG
.  O

This  O
can  O
not  O
be  O
taken  O
as  O
an  O
indication  O
of  O
equivalence  O
since  O
the  O
limited  O
size  O
of  O
this  O
trial  O
rendered  O
it  O
unable  O
to  O
exclude  O
a  O
19  O
%  O
lower  O
progression-free  O
survival  O
and  O
survival  O
in  O
those  O
treated  O
with  O
single  O
agent  O
carboplatin  B-DRUG
which  O
would  O
be  O
important  O
clinically  O
.  O

Standard  O
initial  O
chemotherapy  O
for  O
advanced  B-CANCER
seminoma  I-CANCER
should  O
be  O
based  O
on  O
cisplatin  B-DRUG
combinations  O
and  O
the  O
role  O
of  O
carboplatin  B-DRUG
awaits  O
the  O
outcome  O
of  O
further  O
studies  O
.  O

Neoadjuvant  O
therapy  O
for  O
organ  O
preservation  O
in  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
.  O


We  O
designed  O
two  O
sequential  O
trials  O
of  O
induction  O
chemotherapy  O
followed  O
by  O
definitive  O
radiation  O
in  O
patients  O
with  O
potentially  O
resectable  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
to  O
determine  O
whether  O
organ  O
preservation  O
is  O
feasible  O
without  O
apparent  O
compromise  O
of  O
survival  O
Study  O
Design  O
Both  O
trials  O
were  O
Phase  O
II  O
studies  O
.  O

Two  O
clinical  O
trials  O
were  O
conducted  O
sequentially  O
at  O
the  O
University  O
of  O
Michigan  O
.  O

Fifty-two  O
patients  O
enrolled  O
in  O
the  O
first  O
study  O
and  O
were  O
treated  O
with  O
a  O
planned  O
three  O
cycles  O
of  O
carboplatin  B-DRUG
and  O
5-fluorouracil  B-DRUG
.  O

Patients  O
who  O
achieved  O
at  O
least  O
50  O
%  O
reduction  O
in  O
the  O
size  O
of  O
the  O
primary  O
tumor  O
received  O
definitive  O
radiation  O
therapy  O
,  O
to  O
a  O
dose  O
of  O
6600  O
to  O
7380  O
cGy  O
.  O

Patients  O
with  O
minimal  O
response  O
or  O
progression  O
had  O
immediate  O
salvage  O
surgery  O
.  O

Thirty-seven  O
patients  O
enrolled  O
in  O
the  O
second  O
trial  O
,  O
in  O
which  O
the  O
chemotherapy  O
consisted  O
of  O
carboplatin  B-DRUG
,  O
5-fluororuracil  B-DRUG
,  O
and  O
leukovorin  B-DRUG
.  O

Responders  O
were  O
treated  O
with  O
accelerated  O
radiation  O
therapy  O
,  O
to  O
a  O
total  O
dose  O
of  O
7120  O
cGy  O
delivered  O
in  O
41  O
fractions  O
over  O
5.5  O
weeks  O
.  O

Toxicity  O
and  O
response  O
were  O
similar  O
in  O
both  O
trials  O
;  O
therefore  O
,  O
the  O
results  O
are  O
reported  O
first  O
separately  O
and  O
then  O
combined  O
for  O
all  O
89  O
patients  O
.  O

Tumor  O
sites  O
included  O
:  O
oropharynx  O
,  O
55  O
patients  O
;  O
hypopharynx  O
,  O
34  O
patients  O
.  O

Eighty-three  O
percent  O
of  O
patients  O
tolerated  O
all  O
three  O
cycles  O
of  O
chemotherapy  O
and  O
toxicity  O
was  O
mild  O
.  O

Response  O
to  O
chemotherapy  O
was  O
:  O
48  O
%  O
complete  O
response  O
at  O
the  O
primary  O
tumor  O
site  O
,  O
and  O
34  O
%  O
partial  O
response  O
at  O
the  O
primary  O
tumor  O
site  O
.  O

Initial  O
organ  O
preservation  O
at  O
individual  O
tumor  O
sites  O
was  O
:  O
oropharynx  O
,  O
58  O
%  O
;  O
hypopharynx  O
,  O
59  O
%  O
.  O

Median  O
survival  O
was  O
28  O
months  O
,  O
and  O
survival  O
at  O
3  O
and  O
5  O
years  O
was  O
40  O
%  O
and  O
24  O
%  O
,  O
respectively  O
.  O

These  O
two  O
regimens  O
were  O
well  O
tolerated  O
,  O
and  O
survival  O
did  O
not  O
appear  O
to  O
be  O
compromised  O
by  O
organ  O
preservation  O
treatment  O
compared  O
with  O
historical  O
controls  O
.  O

This  O
approach  O
warrants  O
further  O
investigation  O
,  O
particularly  O
in  O
those  O
patients  O
for  O
whom  O
surgery  O
could  O
be  O
functionally  O
debilitating  O
.  O

Paclitaxel  B-DRUG
,  O
estramustine  B-DRUG
phosphate  I-DRUG
,  O
and  O
carboplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
prostate  I-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
safety  O
and  O
activity  O
of  O
weekly  O
paclitaxel  B-DRUG
in  O
combination  O
with  O
estramustine  B-DRUG
and  O
carboplatin  B-DRUG
(  O
TEC  B-DRUG
)  O
in  O
patients  O
with  O
advanced  B-CANCER
prostate  I-CANCER
cancer  I-CANCER
.  O

In  O
a  O
dose-escalation  O
study  O
,  O
patients  O
with  O
advanced  B-CANCER
prostate  I-CANCER
cancer  I-CANCER
were  O
administered  O
paclitaxel  B-DRUG
(  O
weekly  O
1-hour  O
infusions  O
of  O
60  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
,  O
oral  O
estramustine  B-DRUG
(  O
10  O
mg  O
/  O
kg  O
)  O
,  O
and  O
carboplatin  B-DRUG
(  O
area  O
under  O
the  O
curve  O
,  O
6  O
mg  O
/  O
mL-min  O
every  O
4  O
weeks  O
)  O
.  O

Paclitaxel  B-DRUG
levels  O
were  O
determined  O
0  O
,  O
30  O
,  O
60  O
,  O
90  O
,  O
and  O
120  O
minutes  O
and  O
18  O
hours  O
after  O
infusion  O
,  O
and  O
a  O
concentration-time  O
curve  O
was  O
estimated  O
.  O

Once  O
a  O
safe  O
dose  O
was  O
established  O
,  O
a  O
multi-institutional  O
phase  O
II  O
trial  O
was  O
conducted  O
in  O
patients  O
with  O
progressive  B-TOXI
androgen-independent  I-TOXI
disease  I-TOXI
.  O

Fifty-six  O
patients  O
with  O
progressive  B-TOXI
androgen-independent  I-TOXI
disease  I-TOXI
were  O
treated  O
for  O
a  O
median  O
of  O
four  O
cycles  O
.  O

The  O
dose  O
of  O
paclitaxel  B-DRUG
was  O
escalated  O
from  O
60  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
without  O
the  O
occurrence  O
of  O
DLT  O
.  O

Posttherapy  O
decreases  O
in  O
serum  O
prostate-specific  O
antigen  O
levels  O
of  O
50  O
%  O
,  O
80  O
%  O
,  O
and  O
90  O
%  O
were  O
seen  O
in  O
67  O
%  O
,  O
48  O
%  O
,  O
and  O
39  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
55  O
%  O
to  O
79  O
%  O
,  O
35  O
%  O
to  O
61  O
%  O
,  O
26  O
%  O
to  O
52  O
%  O
)  O
of  O
the  O
patients  O
,  O
respectively  O
.  O

Of  O
the  O
33  O
patients  O
with  O
measurable  O
disease  O
,  O
two  O
(  O
6  O
%  O
)  O
had  O
a  O
complete  O
response  O
and  O
13  O
(  O
39  O
%  O
)  O
had  O
a  O
partial  O
response  O
.  O

The  O
overall  O
median  O
time  O
to  O
progression  O
was  O
21  O
weeks  O
,  O
and  O
the  O
median  O
survival  O
time  O
for  O
all  O
patients  O
was  O
19.9  O
months  O
.  O

Major  O
grade  O
3  O
or  O
4  O
adverse  O
effects  O
were  O
thromboembolic  B-TOXI
disease  I-TOXI
(  O
in  O
25  O
%  O
of  O
patients  O
)  O
,  O
hyperglycemia  B-TOXI
(  O
in  O
38  O
%  O
)  O
,  O
and  O
hypophosphatemia  B-TOXI
(  O
in  O
42  O
%  O
)  O
.  O

Significant  O
leukopenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
,  O
and  O
peripheral  B-TOXI
neuropathy  I-TOXI
were  O
not  O
observed  O
.  O

TEC  O
has  O
significant  O
antitumor  O
activity  O
and  O
is  O
well  O
tolerated  O
in  O
patients  O
with  O
progressive  B-CANCER
androgen-independent  I-CANCER
prostate  I-CANCER
cancer  I-CANCER
.  O

Salvage  O
treatment  O
with  O
paclitaxel  B-DRUG
,  O
ifosfamide  B-DRUG
,  O
and  O
cisplatin  B-DRUG
plus  O
high-dose  O
carboplatin  B-DRUG
,  O
etoposide  B-DRUG
,  O
and  O
thiotepa  B-DRUG
followed  O
by  O
autologous  O
stem-cell  O
rescue  O
in  O
patients  O
with  O
relapsed  O
or  O
refractory  O
germ  B-CANCER
cell  I-CANCER
cancer  I-CANCER
.  O


To  O
study  O
feasibility  O
and  O
efficacy  O
of  O
a  O
new  O
salvage  O
regimen  O
in  O
patients  O
with  O
relapsed  O
and  O
/  O
or  O
refractory  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
.  O

Between  O
May  O
1995  O
and  O
February  O
1997  O
,  O
80  O
patients  O
were  O
entered  O
onto  O
a  O
phase  O
II  O
study  O
.  O

Conventional-dose  O
salvage  O
treatment  O
with  O
three  O
cycles  O
of  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
ifosfamide  B-DRUG
5  O
x  O
1.2  O
g  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
cisplatin  B-DRUG
5  O
x  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
TIP  B-DRUG
)  O
was  O
followed  O
by  O
one  O
cycle  O
of  O
high-dose  O
chemotherapy  O
(  O
HDCT  O
)  O
with  O
carboplatin  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
x  O
3  O
,  O
etoposide  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
x  O
4  O
,  O
and  O
thiotepa  B-DRUG
150  O
to  O
250  O
mg  O
/  O
m  O
(  O
2  O
)  O
x  O
3  O
(  O
CET  B-DRUG
)  O
.  O

In  O
23  O
patients  O
,  O
one  O
additional  O
cycle  O
of  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
ifosfamide  B-DRUG
5  O
g  O
/  O
m  O
(  O
2  O
)  O
(  O
TI  O
)  O
was  O
given  O
immediately  O
before  O
TIP  B-DRUG
to  O
improve  O
stem-cell  O
mobilization  O
.  O

Fifty-five  O
(  O
69  O
%  O
)  O
of  O
80  O
patients  O
responded  O
to  O
TIP  B-DRUG
,  O
24  O
(  O
30  O
%  O
)  O
of  O
80  O
patients  O
had  O
stable  O
disease  O
(  O
n  O
=  O
5  O
)  O
or  O
tumor  B-TOXI
progression  I-TOXI
(  O
n  O
=  O
19  O
)  O
,  O
and  O
one  O
patient  O
died  B-TOXI
.  O

Only  O
62  O
(  O
78  O
%  O
)  O
of  O
80  O
patients  O
received  O
subsequent  O
HDCT  O
.  O

Among  O
those  O
,  O
41  O
(  O
66  O
%  O
)  O
of  O
62  O
patients  O
responded  O
and  O
20  O
(  O
32  O
%  O
)  O
of  O
62  O
patients  O
had  O
stable  O
disease  O
(  O
n  O
=  O
3  O
)  O
or  O
tumor  B-TOXI
progression  I-TOXI
(  O
n  O
=  O
17  O
)  O
.  O

One  O
patient  O
died  B-TOXI
after  O
HDCT  O
from  O
multiorgan  O
failure  O
.  O

Survival  O
probabilities  O
at  O
3  O
years  O
were  O
30  O
%  O
for  O
overall  O
and  O
25  O
%  O
for  O
event-free  O
survival  O
.  O

Peripheral  B-TOXI
neurotoxicity  I-TOXI
with  O
sensorimotor  B-TOXI
impairment  I-TOXI
grade  O
2  O
through  O
4  O
in  O
29  O
%  O
,  O
paresthesias  B-TOXI
grade  O
2  O
through  O
4  O
in  O
24  O
%  O
,  O
and  O
skin  B-TOXI
toxicity  I-TOXI
grade  O
2  O
through  O
3  O
in  O
15  O
%  O
of  O
patients  O
were  O
the  O
most  O
relevant  O
side  O
effects  O
.  O

Treatment  O
with  O
TIP  B-DRUG
followed  O
by  O
high-dose  O
CET  B-DRUG
is  O
feasible  O
and  O
can  O
induce  O
long-term  O
remissions  O
in  O
25  O
%  O
of  O
patients  O
with  O
relapsed  O
or  O
refractory  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
.  O

Peripheral  B-TOXI
nervous  I-TOXI
toxicity  I-TOXI
in  O
approximately  O
one  O
third  O
of  O
patients  O
is  O
a  O
disadvantage  O
of  O
this  O
salvage  O
strategy  O
.  O

Phase  O
Ib  O
trial  O
of  O
intravenous  O
recombinant  B-DRUG
humanized  I-DRUG
monoclonal  I-DRUG
antibody  I-DRUG
to  O
vascular  O
endothelial  O
growth  O
factor  O
in  O
combination  O
with  O
chemotherapy  O
in  O
patients  O
with  O
advanced  B-CANCER
cancer  I-CANCER
:  O
pharmacologic  O
and  O
long-term  O
safety  O
data  O
.  O


Tumor  O
angiogenesis  O
mediated  O
by  O
vascular  B-DRUG
endothelial  I-DRUG
growth  I-DRUG
factor  I-DRUG
(  O
VEGF  B-DRUG
)  O
is  O
inhibited  O
by  O
the  O
recombinant  B-DRUG
humanized  I-DRUG
(  I-DRUG
rhu  I-DRUG
)  I-DRUG
monoclonal  I-DRUG
antibody  I-DRUG
(  I-DRUG
MAb  I-DRUG
)  I-DRUG
rhuMAbVEGF  I-DRUG
,  O
which  O
has  O
synergy  O
with  O
chemotherapy  O
in  O
animal  O
models  O
.  O

The  O
present  O
study  O
was  O
designed  O
to  O
assess  O
the  O
safety  O
and  O
pharmacokinetics  O
of  O
weekly  O
intravenous  O
(  O
IV  O
)  O
rhuMAbVEGF  B-DRUG
with  O
one  O
of  O
three  O
standard  O
chemotherapy  O
regimens  O
.  O

Twelve  O
adult  O
patients  O
were  O
enrolled  O
four  O
on  O
each  O
combination  O
.  O

rhuMAbVEGF  B-DRUG
,  O
3  O
mg  O
/  O
kg  O
IV  O
,  O
was  O
administered  O
weekly  O
for  O
8  O
weeks  O
with  O
(  O
1  O
)  O
doxorubicin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
4  O
weeks  O
;  O
(  O
2  O
)  O
carboplatin  B-DRUG
at  O
area  O
under  O
the  O
curve  O
of  O
6  O
plus  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
4  O
weeks  O
;  O
and  O
(  O
3  O
)  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
with  O
leucovorin  B-DRUG
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
weekly  O
,  O
weeks  O
1  O
to  O
6  O
every  O
8  O
weeks  O
.  O

The  O
median  O
number  O
of  O
rhuMAbVEGF  B-DRUG
doses  O
delivered  O
was  O
eight  O
(  O
range  O
,  O
four  O
to  O
eight  O
doses  O
)  O
.  O

Grade  O
3  O
toxicities  O
were  O
diarrhea  B-TOXI
(  O
one  O
5-FU  B-DRUG
patient  O
)  O
,  O
thrombocytopenia  B-TOXI
(  O
two  O
patients  O
on  O
carboplatin  B-DRUG
plus  O
paclitaxel  B-DRUG
)  O
,  O
and  O
leukopenia  B-TOXI
(  O
one  O
patient  O
on  O
carboplatin  B-DRUG
plus  O
paclitaxel  B-DRUG
)  O
.  O

These  O
toxicities  O
were  O
likely  O
attributable  O
to  O
the  O
chemotherapy  O
component  O
of  O
the  O
regimen  O
.  O

The  O
mean  O
(  O
+  O
/  O
-  O
SD  O
)  O
peak  O
serum  O
level  O
of  O
rhuMAbVEGF  B-DRUG
was  O
167  O
+  O
/  O
-  O
46  O
microg  O
/  O
mL  O
,  O
and  O
the  O
mean  O
terminal  O
half-life  O
was  O
13  O
days  O
.  O

Total  O
(  O
free  O
plus  O
bound  O
)  O
serum  O
VEGF  B-DRUG
levels  O
increased  O
from  O
51  O
+  O
/  O
-  O
39  O
pg  O
/  O
mL  O
(  O
day  O
0  O
)  O
to  O
211  O
+  O
/  O
-  O
112  O
(  O
day  O
49  O
)  O
pg  O
/  O
mL  O
.  O

Three  O
responding  O
patients  O
continued  O
treatment  O
with  O
rhuMAbVEGF  B-DRUG
and  O
chemotherapy  O
,  O
receiving  O
the  O
equivalent  O
of  O
36  O
,  O
20  O
,  O
and  O
40  O
total  O
rhuMAbVEGF  B-DRUG
doses  O
with  O
no  O
cumulative  O
or  O
late  O
toxicities  O
.  O

rhuMAbVEGF  B-DRUG
can  O
be  O
safely  O
combined  O
with  O
chemotherapy  O
at  O
doses  O
associated  O
with  O
VEGF  B-DRUG
blockade  O
and  O
without  O
apparent  O
synergistic  O
toxicity  O
.  O

Its  O
contribution  O
to  O
the  O
treatment  O
of  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
should  O
be  O
evaluated  O
in  O
randomized  O
treatment  O
trials  O
.  O

Phase  O
I  O
trial  O
of  O
escalating  O
doses  O
of  O
paclitaxel  B-DRUG
combined  O
with  O
fixed  O
doses  O
of  O
cisplatin  B-DRUG
and  O
doxorubicin  B-DRUG
in  O
advanced  B-CANCER
endometrial  I-CANCER
cancer  I-CANCER
and  O
other  O
gynecologic  B-CANCER
malignancies  I-CANCER
:  O
a  O
Gynecologic  O
Oncology  O
Group  O
study  O
.  O


The  O
primary  O
objective  O
of  O
this  O
phase  O
I  O
trial  O
was  O
to  O
determine  O
the  O
feasibility  O
of  O
administering  O
a  O
combination  O
of  O
paclitaxel  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
doxorubicin  B-DRUG
with  O
or  O
without  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
(  O
G-CSF  B-DRUG
)  O
in  O
patients  O
with  O
advanced  O
endometrial  B-CANCER
and  I-CANCER
other  I-CANCER
gynecologic  I-CANCER
cancers  I-CANCER
.  O

Patients  O
were  O
chemotherapy-naive  O
.  O

Doxorubicin  B-DRUG
was  O
administered  O
as  O
a  O
brief  O
infusion  O
,  O
paclitaxel  B-DRUG
for  O
3  O
hours  O
,  O
and  O
cisplatin  B-DRUG
for  O
60  O
minutes  O
.  O

Treatments  O
were  O
repeated  O
every  O
3  O
weeks  O
.  O

For  O
most  O
dose  O
levels  O
,  O
the  O
cisplatin  B-DRUG
and  O
doxorubicin  B-DRUG
were  O
fixed  O
at  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
45  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
whereas  O
the  O
paclitaxel  B-DRUG
was  O
escalated  O
in  O
successive  O
cohorts  O
from  O
90  O
to  O
250  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Patients  O
who  O
had  O
received  O
previous  O
radiotherapy  O
to  O
the  O
whole  O
pelvis  O
were  O
escalated  O
separately  O
from  O
those  O
who  O
had  O
not  O
.  O

Eighty  O
patients  O
received  O
320  O
cycles  O
of  O
therapy  O
.  O

When  O
G-CSF  B-DRUG
was  O
not  O
used  O
,  O
myelosuppression  O
prevented  O
escalation  O
beyond  O
the  O
starting  O
dose  O
for  O
patients  O
with  O
or  O
without  O
previous  O
pelvic  O
radiotherapy  O
.  O

When  O
G-CSF  B-DRUG
was  O
added  O
,  O
neurotoxicity  B-TOXI
became  O
dose-limiting  O
for  O
both  O
groups  O
.  O

Ten  O
patients  O
were  O
removed  O
from  O
the  O
study  O
for  O
asymptomatic  O
declines  O
in  O
ejection  O
fraction  O
,  O
but  O
no  O
symptomatic  O
congestive  B-TOXI
heart  I-TOXI
failure  I-TOXI
was  O
observed  O
.  O

Major  O
antitumor  O
responses  O
occurred  O
in  O
46  O
%  O
of  O
patients  O
(  O
six  O
of  O
13  O
)  O
with  O
measurable  O
endometrial  B-CANCER
carcinoma  I-CANCER
and  O
50  O
%  O
of  O
patients  O
(  O
eight  O
of  O
16  O
)  O
with  O
measurable  O
cervical  B-CANCER
carcinoma  I-CANCER
.  O

The  O
combination  O
of  O
paclitaxel  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
cisplatin  B-DRUG
at  O
relevant  O
single-agent  O
doses  O
is  O
active  O
and  O
feasible  O
with  O
the  O
addition  O
of  O
G-CSF  B-DRUG
.  O

A  O
regimen  O
of  O
cisplatin  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
doxorubicin  B-DRUG
45  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
paclitaxel  B-DRUG
160  O
mg  O
/  O
m  O
(  O
2  O
)  O
with  O
G-CSF  B-DRUG
support  O
is  O
recommended  O
for  O
further  O
testing  O
.  O

Phase  O
I  O
trial  O
of  O
the  O
combination  O
of  O
irinotecan  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
carboplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
maximum-tolerated  O
dose  O
,  O
toxicities  O
,  O
and  O
dose  O
suitable  O
for  O
phase  O
II  O
/  O
III  O
trials  O
of  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
combined  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

Patients  O
with  O
stage  O
IIIB  O
/  O
IV  O
NSCLC  B-CANCER
were  O
enrolled  O
to  O
this  O
multicenter  O
,  O
phase  O
I  O
study  O
.  O

The  O
initial  O
regimen  O
was  O
paclitaxel  B-DRUG
225  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
3  O
h  O
,  O
followed  O
by  O
carboplatin  B-DRUG
area  O
under  O
the  O
curve  O
(  O
AUC  O
)  O
6  O
over  O
30  O
minutes  O
on  O
day  O
1  O
,  O
and  O
CPT-11  B-DRUG
starting  O
at  O
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
over  O
90  O
minutes  O
,  O
days  O
1  O
and  O
8  O
,  O
every  O
3  O
weeks  O
.  O

Dose-limiting  O
toxicity  O
occurred  O
in  O
three  O
of  O
seven  O
patients  O
.  O

The  O
regimen  O
was  O
amended  O
,  O
with  O
doses  O
reduced  O
to  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
3  O
h  O
,  O
carboplatin  B-DRUG
AUC  O
5  O
and  O
CPT-11  B-DRUG
at  O
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
all  O
on  O
day  O
1  O
every  O
3  O
weeks  O
.  O

Dose  O
escalation  O
of  O
CPT-11  B-DRUG
proceeded  O
to  O
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
then  O
125  O
mg  O
/  O
m  O
(  O
2  O
)  O
before  O
dose-limiting  O
toxicities  O
were  O
experienced  O
.  O

Subsequent  O
patients  O
received  O
an  O
intermediate  O
CPT-11  B-DRUG
dose  O
of  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Thirty-three  O
patients  O
were  O
enrolled  O
;  O
32  O
patients  O
were  O
assessable  O
for  O
safety  O
,  O
and  O
31  O
were  O
assessable  O
for  O
tumor  O
response  O
.  O

The  O
primary  O
first-cycle  O
dose-limiting  O
toxicities  O
were  O
neutropenia  B-TOXI
and  O
diarrhea  B-TOXI
.  O

The  O
most  O
common  O
grade  O
3  O
/  O
4  O
toxicity  O
observed  O
during  O
all  O
cycles  O
was  O
neutropenia  B-TOXI
(  O
16  O
patients  O
[  O
50  O
%  O
]  O
,  O
with  O
six  O
[  O
19  O
%  O
]  O
developing  O
neutropenic  B-TOXI
fever  I-TOXI
)  O
.  O

Objective  O
tumor  O
response  O
was  O
observed  O
in  O
39  O
%  O
(  O
12  O
/  O
31  O
,  O
95  O
%  O
confidence  O
interval  O
,  O
22  O
%  O
to  O
58  O
%  O
)  O
.  O

The  O
median  O
time  O
to  O
tumor  B-TOXI
progression  I-TOXI
was  O
6.8  O
months  O
,  O
median  O
survival  O
11.0  O
months  O
,  O
and  O
1-year  O
survival  O
probability  O
0.46  O
.  O

CPT-11  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
carboplatin  B-DRUG
AUC  O
5  O
given  O
every  O
3  O
weeks  O
can  O
be  O
safely  O
administered  O
in  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

Neutropenia  B-TOXI
and  O
diarrhea  B-TOXI
are  O
the  O
dose-limiting  O
toxicities  O
.  O

The  O
combination  O
shows  O
appreciable  O
activity  O
,  O
and  O
survival  O
data  O
are  O
favorable  O
.  O

A  O
phase  O
II  O
study  O
of  O
sequential  O
chemotherapy  O
with  O
docetaxel  B-DRUG
after  O
the  O
weekly  O
PELF  B-DRUG
regimen  O
in  O
advanced  B-CANCER
gastric  I-CANCER
cancer.  I-CANCER
A  O
report  O
from  O
the  O
Italian  O
group  O
for  O
the  O
study  O
of  O
digestive  B-CANCER
tract  I-CANCER
cancer  I-CANCER
.  O


In  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
,  O
we  O
investigated  O
feasibility  O
and  O
activity  O
of  O
sequential  O
chemotherapy  O
with  O
docetaxel  B-DRUG
after  O
an  O
intensive  O
weekly  O
regimen  O
consisting  O
of  O
cisplatin  B-DRUG
,  O
epidoxorubicin  B-DRUG
,  O
fluorouracil  B-DRUG
,  O
leucovorin  B-DRUG
(  O
PELF  B-DRUG
)  O
plus  O
filgrastim  B-DRUG
.  O

Chemotherapy-naive  O
patients  O
with  O
relapsed  B-CANCER
or  I-CANCER
metastatic  I-CANCER
gastric  I-CANCER
cancer  I-CANCER
received  O
8  O
weekly  O
administrations  O
of  O
chemotherapy  O
with  O
cisplatin  B-DRUG
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
fluorouracil  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
epidoxorubicin  B-DRUG
35  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
6S-stereoisomer  O
of  O
leucovorin  B-DRUG
250  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
glutathione  B-DRUG
1.5  O
g  O
/  O
m  O
(  O
2  O
)  O
.  O

On  O
the  O
other  O
days  O
filgrastim  B-DRUG
5  O
microg  O
kg  O
(  O
-1  O
)  O
was  O
administered  O
by  O
subcutaneous  O
injection  O
.  O

Subsequently  O
,  O
patients  O
with  O
partial  O
response  O
or  O
stable  O
disease  O
received  O
3  O
cycles  O
of  O
docetaxel  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
3  O
weeks  O
.  O

40  O
patients  O
have  O
been  O
enrolled  O
and  O
they  O
are  O
evaluable  O
for  O
response  O
and  O
toxicity  O
.  O

After  O
the  O
PELF  B-DRUG
regimen  O
,  O
3  O
patients  O
achieved  O
complete  O
response  O
,  O
13  O
patients  O
showed  O
partial  O
response  O
,  O
21  O
patients  O
had  O
stable  O
disease  O
and  O
3  O
patients  O
progressed  O
(  O
40  O
%  O
response  O
rate  O
;  O
95  O
%  O
CI  O
25  O
%  O
to  O
55  O
%  O
)  O
.  O

After  O
docetaxel  B-DRUG
,  O
9  O
out  O
34  O
patients  O
improved  O
the  O
outcome  O
(  O
26.5  O
%  O
)  O
;  O
7  O
patients  O
with  O
stable  O
disease  O
achieved  O
partial  O
response  O
and  O
2  O
patients  O
with  O
partial  O
response  O
achieved  O
complete  O
response  O
.  O

The  O
overall  O
response  O
rate  O
in  O
the  O
40  O
patients  O
was  O
57.5  O
%  O
(  O
95  O
%  O
CI  O
,  O
42.5  O
%  O
to  O
72.5  O
%  O
)  O
.  O

The  O
PELF  B-DRUG
regimen  O
did  O
not  O
cause  O
any  O
grade  O
IV  O
toxicity  O
,  O
the  O
most  O
frequent  O
grade  O
III  O
acute  O
side-effects  O
were  O
thrombocytopenia  B-TOXI
and  O
vomiting  B-TOXI
which  O
occurred  O
in  O
the  O
10  O
%  O
of  O
320  O
PELF  B-DRUG
cycles  O
.  O

Docetaxel  B-DRUG
caused  O
grade  O
III-IV  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
in  O
the  O
10  O
%  O
and  O
the  O
19  O
%  O
of  O
cycles  O
respectively  O
.  O

Fatigue  O
was  O
a  O
frequent  O
side-effect  O
during  O
both  O
PELF  B-DRUG
and  O
docetaxel  B-DRUG
chemotherapy  O
.  O

The  O
sequential  O
application  O
of  O
docetaxel  B-DRUG
after  O
PELF  B-DRUG
chemotherapy  O
gained  O
major  O
objective  O
responses  O
with  O
manageable  O
toxicity  O
.  O

This  O
strategy  O
is  O
worth  O
of  O
further  O
investigation  O
in  O
the  O
setting  O
of  O
palliative  O
or  O
neoadjuvant  O
chemotherapy  O
.  O

Doxorubicin  B-DRUG
and  O
paclitaxel  B-DRUG
versus  O
fluorouracil  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
cyclophosphamide  B-DRUG
as  O
first-line  O
therapy  O
for  O
women  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
:  O
final  O
results  O
of  O
a  O
randomized  O
phase  O
III  O
multicenter  O
trial  O
.  O


This  O
phase  O
III  O
trial  O
compared  O
the  O
efficacy  O
and  O
safety  O
of  O
doxorubicin  B-DRUG
and  O
paclitaxel  B-DRUG
(  O
AT  B-DRUG
)  O
to  O
5-fluorouracil  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
cyclophosphamide  B-DRUG
(  O
FAC  B-DRUG
)  O
as  O
first-line  O
therapy  O
for  O
women  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O

A  O
total  O
of  O
267  O
women  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
were  O
randomized  O
to  O
receive  O
either  O
AT  B-DRUG
(  O
doxorubicin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
followed  O
24  O
hours  O
later  O
by  O
paclitaxel  B-DRUG
220  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
or  O
FAC  B-DRUG
(  O
5-fluorouracil  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
doxorubicin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
cyclophosphamide  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
,  O
each  O
administered  O
every  O
3  O
weeks  O
for  O
up  O
to  O
eight  O
cycles  O
.  O

Patients  O
had  O
to  O
have  O
measurable  O
disease  O
and  O
an  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
status  O
of  O
0  O
to  O
2.  O
Only  O
one  O
prior  O
non-anthracycline  O
,  O
nontaxane-containing  O
adjuvant  O
chemotherapy  O
regimen  O
was  O
allowed  O
.  O

Overall  O
response  O
rates  O
for  O
patients  O
randomized  O
to  O
AT  B-DRUG
and  O
FAC  B-DRUG
were  O
68  O
%  O
and  O
55  O
%  O
,  O
respectively  O
(  O
P  O
=.032  O
)  O
.  O

Median  O
time  O
to  O
progression  O
and  O
overall  O
survival  O
were  O
significantly  O
longer  O
for  O
AT  B-DRUG
compared  O
with  O
FAC  B-DRUG
(  O
time  O
to  O
progression  O
8.3  O
months  O
v  O
6.2  O
months  O
[  O
P  O
=.034  O
]  O
;  O
overall  O
survival  O
23.3  O
months  O
v  O
18.3  O
months  O
[  O
P  O
=.013  O
]  O
)  O
.  O

Therapy  O
was  O
generally  O
well-tolerated  O
(  O
median  O
of  O
eight  O
cycles  O
delivered  O
in  O
each  O
arm  O
)  O
.  O

Grade  O
3  O
or  O
4  O
neutropenia  B-TOXI
was  O
more  O
common  O
with  O
AT  B-DRUG
than  O
with  O
FAC  B-DRUG
(  O
89  O
%  O
v  O
65  O
%  O
;  O
P  O
&  O
lt  O
;  O
.001  O
)  O
;  O
however  O
,  O
the  O
incidence  O
of  O
fever  B-TOXI
and  O
infection  B-TOXI
was  O
low  O
.  O

Grade  O
3  O
or  O
4  O
arthralgia  B-TOXI
and  O
myalgia  B-TOXI
,  O
peripheral  B-TOXI
neuropathy  I-TOXI
,  O
and  O
diarrhea  B-TOXI
were  O
more  O
common  O
with  O
AT  B-DRUG
,  O
whereas  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
were  O
more  O
common  O
with  O
FAC  B-DRUG
.  O

The  O
incidence  O
of  O
cardiotoxicity  B-TOXI
was  O
low  O
in  O
both  O
arms  O
.  O

AT  O
conferred  O
a  O
significant  O
advantage  O
in  O
response  O
rate  O
,  O
time  O
to  O
progression  O
,  O
and  O
overall  O
survival  O
compared  O
with  O
FAC  B-DRUG
.  O

Treatment  O
was  O
well-tolerated  O
with  O
no  O
unexpected  O
toxicities  O
.  O

Concomitant  O
infusional  O
paclitaxel  B-DRUG
and  O
fluorouracil  B-DRUG
,  O
oral  B-DRUG
hydroxyurea  I-DRUG
,  O
and  O
hyperfractionated  O
radiation  O
for  O
locally  O
advanced  B-CANCER
squamous  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
.  O


To  O
improve  O
local  O
disease  O
control  O
and  O
survival  O
with  O
organ  O
preservation  O
,  O
we  O
conducted  O
a  O
phase  O
II  O
multi-institutional  O
trial  O
with  O
a  O
concomitant  O
taxane-based  O
chemotherapy  O
and  O
hyperfractionated  O
radiation  O
regimen  O
.  O

Sixty-four  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
squamous  I-CANCER
cancers  I-CANCER
(  O
stage  O
IV  O
,  O
98  O
%  O
;  O
N2  O
/  O
3  O
,  O
81  O
%  O
)  O
were  O
treated  O
on  O
an  O
intensive  O
regimen  O
consisting  O
of  O
5-day  O
(  O
120-hour  O
)  O
infusions  O
of  O
paclitaxel  B-DRUG
(  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
)  O
and  O
fluorouracil  B-DRUG
(  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
)  O
,  O
oral  B-DRUG
hydroxyurea  I-DRUG
500  O
mg  O
every  O
12  O
hours  O
for  O
11  O
doses  O
,  O
and  O
radiation  O
1.5  O
Gy  O
bid  O
(  O
T-FH2X  O
)  O
.  O

Chemoradiation  O
was  O
administered  O
concomitantly  O
on  O
days  O
1  O
to  O
5  O
of  O
each  O
14-day  O
cycle  O
.  O

A  O
full  O
treatment  O
course  O
consisted  O
of  O
five  O
cycles  O
during  O
a  O
10-week  O
period  O
to  O
a  O
total  O
radiation  O
dose  O
of  O
72  O
to  O
75  O
Gy  O
.  O

The  O
median  O
follow-up  O
for  O
the  O
group  O
is  O
34  O
months  O
.  O

At  O
3  O
years  O
,  O
progression-free  O
survival  O
is  O
63  O
%  O
,  O
locoregional  O
control  O
is  O
86  O
%  O
,  O
and  O
systemic  O
control  O
is  O
79  O
%  O
;  O
overall  O
survival  O
is  O
60  O
%  O
.  O

Seventeen  O
patients  O
died  B-TOXI
of  O
recurrent  O
cancer  O
,  O
two  O
died  B-TOXI
of  O
second  O
primary  O
cancers  O
,  O
and  O
four  O
died  B-TOXI
of  O
other  O
causes  O
.  O

Side  O
effects  O
observed  O
include  O
anemia  B-TOXI
(  O
22  O
%  O
required  O
transfusion  O
)  O
,  O
leucopenia  B-TOXI
(  O
34  O
%  O
,  O
grade  O
3  O
to  O
4  O
)  O
,  O
and  O
mucositis  B-TOXI
(  O
84  O
%  O
,  O
grade  O
3  O
to  O
4  O
)  O
.  O

Organ  O
preservation  O
principles  O
were  O
maintained  O
.  O

At  O
1  O
year  O
posttreatment  O
,  O
61  O
%  O
of  O
patients  O
had  O
severe  B-TOXI
xerostomia  I-TOXI
and  O
47  O
%  O
had  O
compromised  B-TOXI
swallowing  I-TOXI
.  O

There  O
was  O
little  O
disturbance  O
of  O
speech  O
quality  O
in  O
97  O
%  O
of  O
patients  O
at  O
the  O
same  O
follow-up  O
point  O
.  O

T-FH2X  O
is  O
a  O
highly  O
active  O
and  O
tolerable  O
concomitant  O
chemotherapy  O
and  O
hyperfractionated  O
radiation  O
regimen  O
that  O
induces  O
sustained  O
local  O
tumor  O
control  O
and  O
holds  O
promise  O
for  O
improved  O
survival  O
with  O
organ  O
preservation  O
in  O
high-risk  O
patients  O
.  O

Identification  O
of  O
less  O
toxic  O
therapy  O
and  O
improved  O
distant  O
disease  O
control  O
are  O
needed  O
.  O

T-FH2X  O
should  O
be  O
tested  O
in  O
a  O
randomized  O
trial  O
and  O
compared  O
with  O
a  O
less  O
intensive  O
concomitant  O
regimen  O
that  O
uses  O
once-daily  O
radiation  O
fractionation  O
.  O

Oxaliplatin  B-DRUG
plus  O
raltitrexed  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
:  O
results  O
of  O
a  O
Phase  O
I-II  O
trial  O
.  O


Oxaliplatin  B-DRUG
and  O
raltitrexed  B-DRUG
both  O
are  O
active  O
anticancer  O
agents  O
in  O
the  O
treatment  O
of  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
:  O
They  O
have  O
different  O
mechanisms  O
of  O
action  O
and  O
toxicity  O
profiles  O
and  O
have  O
shown  O
at  O
least  O
additive  O
effects  O
in  O
experimental  O
and  O
preliminary  O
clinical  O
studies  O
.  O

The  O
aim  O
of  O
this  O
disease  O
oriented  O
Phase  O
I-II  O
study  O
was  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
the  O
dose-limiting  O
toxicities  O
(  O
DLT  O
)  O
,  O
and  O
the  O
objective  O
response  O
rate  O
of  O
this  O
combination  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
.  O

Between  O
April  O
1998  O
and  O
March  O
1999  O
,  O
69  O
patients  O
with  O
measurable  O
metastatic  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
who  O
previously  O
were  O
unexposed  O
to  O
palliative  O
chemotherapy  O
were  O
enrolled  O
.  O

In  O
the  O
Phase  O
I  O
part  O
of  O
the  O
study  O
,  O
27  O
patients  O
were  O
treated  O
with  O
3-weekly  O
courses  O
of  O
a  O
fixed  O
dose  O
of  O
raltitrexed  B-DRUG
(  O
3  O
mg  O
/  O
m  O
(  O
2  O
)  O
given  O
as  O
a  O
15-minute  O
intravenous  O
infusion  O
)  O
followed  O
by  O
a  O
2-hour  O
infusion  O
of  O
oxaliplatin  B-DRUG
,  O
which  O
was  O
escalated  O
in  O
consecutive  O
cohorts  O
of  O
three  O
to  O
six  O
patients  O
from  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
120  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
130  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
140  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

After  O
having  O
defined  O
the  O
toxic  O
dose  O
,  O
42  O
additional  O
patients  O
were  O
entered  O
at  O
one  O
dose  O
level  O
below  O
to  O
define  O
the  O
therapeutic  O
index  O
of  O
this  O
combination  O
more  O
precisely  O
.  O

In  O
the  O
Phase  O
I  O
part  O
of  O
the  O
study  O
,  O
during  O
the  O
first  O
three  O
dose  O
levels  O
,  O
only  O
one  O
patient  O
each  O
experienced  O
DLT  O
(  O
Grade  O
3  O
increase  B-TOXI
in  I-TOXI
transaminases  I-TOXI
,  O
diarrhea  B-TOXI
,  O
and  O
stomatitis  B-TOXI
)  O
;  O
at  O
level  O
4  O
,  O
two  O
of  O
the  O
first  O
six  O
patients  O
entered  O
had  O
Grade  O
3  O
neutropenic  B-TOXI
infection  I-TOXI
or  O
peripheral  B-TOXI
neurotoxicity  I-TOXI
,  O
whereas  O
dose  O
level  O
5  O
(  O
oxaliplatin  B-DRUG
140  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
constituted  O
the  O
toxic  O
dose  O
with  O
three  O
of  O
three  O
patients  O
experiencing  O
DLT  O
(  O
Grade  O
3  O
asthenia  B-TOXI
,  O
transient  B-TOXI
amaurosis  I-TOXI
,  O
and  O
diarrhea  B-TOXI
with  O
Grade  O
4  O
neutropenia  B-TOXI
)  O
.  O

Externally  O
reviewed  O
objective  O
responses  O
were  O
noted  O
in  O
9  O
of  O
these  O
27  O
patients  O
(  O
33  O
%  O
)  O
,  O
and  O
stable  O
disease  O
occurred  O
in  O
12  O
patients  O
(  O
44.4  O
%  O
)  O
.  O

Among  O
the  O
42  O
patients  O
who  O
were  O
treated  O
subsequently  O
at  O
the  O
MTD  O
level  O
(  O
Phase  O
II  O
portion  O
)  O
,  O
20  O
patients  O
(  O
47.6  O
%  O
)  O
responded  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
32-62.6  O
%  O
)  O
,  O
and  O
21  O
patients  O
(  O
50  O
%  O
)  O
had  O
stable  O
disease  O
.  O

Their  O
median  O
progression  O
free  O
survival  O
was  O
9.0  O
months  O
,  O
and  O
the  O
median  O
overall  O
survival  O
,  O
with  O
42  O
patients  O
(  O
67  O
%  O
)  O
currently  O
alive  O
,  O
is  O
&  O
gt  O
;  O
14.5  O
months  O
.  O

Treatment  O
tolerance  O
at  O
the  O
MTD  O
was  O
acceptable  O
,  O
with  O
only  O
9  O
of  O
42  O
patients  O
(  O
21  O
%  O
)  O
experiencing  O
Grade  O
3-4  O
neutropenia  B-TOXI
;  O
Grade  O
3  O
nonhematologic  B-TOXI
adverse  I-TOXI
reactions  I-TOXI
included  O
increase  B-TOXI
in  I-TOXI
serum  I-TOXI
transaminases  I-TOXI
in  O
6  O
patients  O
,  O
peripheral  B-TOXI
neuropathy  I-TOXI
in  O
3  O
patients  O
,  O
diarrhea  B-TOXI
in  O
3  O
patients  O
,  O
and  O
both  O
stomatitis  B-TOXI
and  O
emesis  B-TOXI
in  O
only  O
1  O
patient  O
each  O
.  O

The  O
described  O
objective  O
response  O
and  O
toxicity  O
data  O
,  O
which  O
are  O
in  O
agreement  O
with  O
preliminary  O
results  O
of  O
other  O
Phase  O
I-II  O
studies  O
,  O
support  O
the  O
promising  O
therapeutic  O
potential  O
of  O
this  O
combination  O
in  O
the  O
treatment  O
of  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
.  O

Due  O
to  O
its  O
substantial  O
antitumor  O
activity  O
,  O
tolerance  O
(  O
at  O
the  O
recommended  O
MTD  O
level  O
)  O
,  O
and  O
convenient  O
3-weekly  O
outpatient  O
administration  O
schedule  O
,  O
further  O
evaluation  O
of  O
this  O
regimen  O
seems  O
warranted  O
.  O

Effect  O
of  O
food  O
on  O
the  O
oral  O
bioavailability  O
of  O
UFT  B-DRUG
and  O
leucovorin  B-DRUG
in  O
cancer  O
patients  O
.  O


UFT  B-DRUG
is  O
composed  O
of  O
tegafur  B-DRUG
(  O
FT  B-DRUG
)  O
,  O
a  O
prodrug  O
of  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
,  O
and  O
uracil  B-DRUG
in  O
a  O
fixed  O
combination  O
(  O
1:4  O
)  O
.  O

In  O
conjunction  O
with  O
leucovorin  B-DRUG
,  O
UFT  B-DRUG
is  O
being  O
developed  O
for  O
the  O
first-line  O
oral  O
treatment  O
of  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

The  O
effect  O
of  O
food  O
on  O
the  O
oral  O
bioavailability  O
of  O
UFT  B-DRUG
(  O
2  O
x  O
100  O
mg  O
capsules  O
;  O
dose  O
in  O
terms  O
of  O
FT  B-DRUG
)  O
and  O
leucovorin  B-DRUG
(  O
2  O
x  O
15  O
mg  O
tablets  O
)  O
was  O
evaluated  O
in  O
a  O
single-dose  O
,  O
randomized  O
,  O
two-way  O
crossover  O
study  O
.  O

Patients  O
(  O
n  O
=  O
25  O
)  O
were  O
assigned  O
to  O
receive  O
both  O
drugs  O
after  O
an  O
overnight  O
fast  O
or  O
5  O
min  O
after  O
completion  O
of  O
a  O
high-fat  O
meal  O
(  O
721  O
calories  O
)  O
with  O
a  O
3-day  O
washout  O
period  O
between  O
treatments  O
;  O
then  O
they  O
were  O
permitted  O
to  O
continue  O
on  O
oral  O
UFT  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
therapy  O
for  O
safety  O
assessment  O
.  O

UFT  B-DRUG
(  O
300  O
mg  O
/  O
m2  O
/  O
day  O
as  O
three  O
divided  O
doses  O
)  O
and  O
leucovorin  B-DRUG
(  O
90  O
mg  O
/  O
day  O
as  O
three  O
divided  O
doses  O
)  O
were  O
given  O
for  O
28  O
days  O
.  O

After  O
a  O
7-day  O
rest  O
,  O
the  O
28-day  O
cycle  O
was  O
repeated  O
.  O

Pharmacokinetics  O
(  O
n  O
=  O
22  O
patients  O
)  O
were  O
determined  O
for  O
FT  B-DRUG
,  O
5-FU  B-DRUG
,  O
uracil  B-DRUG
,  O
leucovorin  B-DRUG
,  O
and  O
5-methyltetrahydrofolate  B-DRUG
(  O
an  O
active  O
metabolite  O
of  O
leucovorin  B-DRUG
)  O
.  O

The  O
absence  O
of  O
food-effect  O
on  O
peak  O
plasma  O
concentration  O
(  O
CMAX  O
)  O
and  O
the  O
area  O
under  O
the  O
curve  O
(  O
AUC  O
)  O
was  O
concluded  O
if  O
the  O
90  O
%  O
confidence  O
interval  O
for  O
the  O
ratio  O
of  O
the  O
treatment  O
means  O
was  O
entirely  O
contained  O
in  O
0.75-1.33  O
.  O

Administration  O
of  O
UFT  B-DRUG
with  O
food  O
resulted  O
in  O
a  O
34  O
%  O
decrease  O
in  O
CMAX  O
of  O
FT  B-DRUG
,  O
whereas  O
the  O
AUC  O
of  O
FT  B-DRUG
remained  O
unchanged  O
.  O

Food  O
decreased  O
the  O
CMAX  O
and  O
AUC  O
values  O
of  O
uracil  O
and  O
5-FU  B-DRUG
by  O
37-76  O
%  O
.  O

On  O
the  O
contrary  O
,  O
the  O
CMAX  O
and  O
AUC  O
values  O
of  O
leucovorin  B-DRUG
and  O
5-methyltetrahydrofolate  B-DRUG
were  O
increased  O
by  O
14-60  O
%  O
with  O
food  O
.  O

Time  O
to  O
reach  O
CMAX  O
for  O
all  O
analytes  O
was  O
significantly  O
(  O
P  O
&  O
lt  O
;  O
or  O
=  O
0.001  O
)  O
delayed  O
by  O
food  O
.  O

Except  O
for  O
the  O
AUCs  O
of  O
FT  B-DRUG
,  O
the  O
statistical  O
criterion  O
for  O
concluding  O
a  O
lack  O
of  O
food-effect  O
was  O
not  O
met  O
.  O

These  O
data  O
suggest  O
that  O
UFT  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
should  O
not  O
be  O
dosed  O
simultaneously  O
with  O
food  O
.  O

It  O
is  O
recommended  O
that  O
food  O
should  O
not  O
be  O
consumed  O
for  O
1  O
h  O
before  O
and  O
after  O
an  O
oral  O
dose  O
of  O
UFT  B-DRUG
and  O
leucovorin  B-DRUG
in  O
a  O
manner  O
similar  O
to  O
pivotal  O
Phase  O
III  O
trials  O
.  O

The  O
28-day  O
oral  O
regimen  O
of  O
UFT  B-DRUG
and  O
leucovorin  B-DRUG
was  O
generally  O
well  O
tolerated  O
in  O
the  O
population  O
studied  O
.  O

5-fluorouracil  B-DRUG
modulated  O
by  O
leucovorin  B-DRUG
,  O
methotrexate  B-DRUG
and  O
mitomycin  B-DRUG
:  O
highly  O
effective  O
,  O
low-cost  O
chemotherapy  O
for  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


We  O
have  O
reported  O
that  O
an  O
alternating  O
regimen  O
of  O
bolus  O
and  O
continuous  O
infusion  O
5-fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
was  O
superior  O
to  O
bolus  O
FU  B-DRUG
in  O
terms  O
of  O
response  O
rate  O
and  O
progression-free  O
survival  O
in  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Biochemical  O
modulation  O
was  O
an  O
essential  O
part  O
of  O
this  O
regimen  O
and  O
it  O
was  O
selective  O
for  O
the  O
schedule  O
of  O
FU  B-DRUG
administration  O
:  O
bolus  O
FU  B-DRUG
was  O
in  O
fact  O
modulated  O
by  O
methotrexate  B-DRUG
(  O
MTX  B-DRUG
)  O
while  O
continuous  O
infusion  O
FU  B-DRUG
was  O
potentiated  O
by  O
6-s-leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
.  O

Considering  O
the  O
low  O
cost  O
and  O
the  O
favourable  O
report  O
on  O
the  O
activity  O
of  O
mitomycin  B-DRUG
C  I-DRUG
(  O
mito  O
)  O
added  O
to  O
CI  O
FU  B-DRUG
,  O
we  O
have  O
incorporated  O
this  O
agent  O
in  O
the  O
infusional  O
part  O
of  O
our  O
treatment  O
programme  O
.  O

105  O
patients  O
with  O
untreated  O
,  O
advanced  O
,  O
measurable  O
colorectal  B-CANCER
cancer  I-CANCER
were  O
accrued  O
from  O
13  O
Italian  O
centres  O
and  O
treated  O
with  O
the  O
following  O
regimen  O
.  O

2  O
biweekly  O
cycles  O
of  O
FU  B-DRUG
bolus  O
(  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
,  O
modulated  O
by  O
MTX  B-DRUG
(  O
24  O
h  O
earlier  O
,  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
were  O
alternated  O
with  O
a  O
3-week  O
continuous  O
infusion  O
of  O
FU  B-DRUG
(  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
daily  O
)  O
,  O
modulated  O
by  O
LV  B-DRUG
(  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
weekly  O
bolus  O
)  O
.  O

Mito  O
,  O
7  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
was  O
given  O
on  O
the  O
first  O
day  O
of  O
the  O
infusional  O
period  O
.  O

After  O
a  O
1  O
week  O
rest  O
,  O
the  O
whole  O
cycle  O
(  O
8  O
weeks  O
)  O
was  O
repeated  O
,  O
if  O
indicated  O
.  O

5  O
complete  O
and  O
34  O
partial  O
responses  O
were  O
obtained  O
(  O
response  O
rate  O
,  O
37  O
%  O
on  O
the  O
intention  O
to  O
treat  O
basis  O
;  O
95  O
%  O
confidence  O
limits  O
,  O
28-46  O
%  O
)  O
.  O

After  O
a  O
median  O
follow-up  O
time  O
of  O
26  O
months  O
,  O
37  O
patients  O
are  O
still  O
alive  O
.  O

The  O
median  O
progression-free  O
survival  O
is  O
7.7  O
months  O
with  O
an  O
overall  O
survival  O
of  O
18.8  O
months  O
and  O
a  O
2-year  O
survival  O
rate  O
of  O
30  O
%  O
.  O

The  O
regimen  O
was  O
very  O
well  O
tolerated  O
with  O
fewer  O
than  O
13  O
%  O
of  O
patients  O
experiencing  O
WHO  O
grade  O
III-IV  O
toxicity  O
.  O

These  O
results  O
are  O
consistent  O
with  O
those  O
obtained  O
by  O
our  O
group  O
in  O
3  O
previous  O
trials  O
of  O
schedule  O
specific  O
biochemical  O
modulation  O
of  O
FU  B-DRUG
.  O

They  O
also  O
indicate  O
a  O
highly  O
active  O
,  O
little  O
toxic  O
,  O
inexpensive  O
regimen  O
of  O
old  O
drugs  O
to  O
be  O
used  O
(  O
a  O
)  O
as  O
an  O
alternative  O
to  O
the  O
more  O
expensive  O
combinations  O
including  O
CPT-11  B-DRUG
or  O
oxaliplatin  B-DRUG
or  O
(  O
b  O
)  O
as  O
the  O
basis  O
for  O
combination  O
programmes  O
with  O
these  O
agents  O
.  O

Phase  O
I  O
study  O
of  O
gemcitabine  B-DRUG
and  O
carboplatin  B-DRUG
in  O
advanced  B-CANCER
non-small  I-CANCER
cell  I-CANCER
lung  I-CANCER
carcinoma  I-CANCER
.  O


This  O
phase  O
I  O
study  O
was  O
designed  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
of  O
carboplatin  B-DRUG
with  O
a  O
fixed  O
dose  O
of  O
gemcitabine  B-DRUG
without  O
growth  B-DRUG
factor  I-DRUG
or  O
hematopoietic  B-DRUG
precursor  I-DRUG
support  O
.  O

Nineteen  O
patients  O
with  O
previously  O
untreated  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
were  O
treated  O
at  O
three  O
dose  O
levels  O
.  O

Initially  O
,  O
the  O
gemcitabine  B-DRUG
dose  O
was  O
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
given  O
on  O
days  O
1  O
and  O
8.  O
Of  O
the  O
first  O
five  O
patients  O
treated  O
with  O
carboplatin  B-DRUG
AUC  O
4  O
,  O
three  O
experienced  O
dose  O
limiting  O
toxicity  O
(  O
DLT  O
)  O
.  O

The  O
study  O
was  O
,  O
therefore  O
,  O
amended  O
to  O
decrease  O
the  O
dose  O
of  O
gemcitabine  B-DRUG
to  O
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
given  O
on  O
days  O
1  O
and  O
8  O
in  O
a  O
21-day  O
cycle  O
.  O

Dose  O
limiting  O
toxicity  O
(  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
)  O
were  O
seen  O
at  O
dose  O
level  O
2A  O
(  O
carboplatin  B-DRUG
AUC=5  O
)  O
.  O

Thus  O
,  O
no  O
further  O
dose  O
escalation  O
was  O
performed  O
.  O

Grade  O
3  O
and  O
4  O
toxicities  O
were  O
seen  O
as  O
follows  O
:  O
leukopenia  B-TOXI
in  O
five  O
of  O
18  O
(  O
28  O
%  O
)  O
;  O
neutropenia  B-TOXI
,  O
four  O
of  O
18  O
(  O
22  O
%  O
)  O
;  O
and  O
thrombocytopenia  B-TOXI
,  O
four  O
of  O
18  O
(  O
22  O
%  O
)  O
evaluable  O
patients  O
.  O

Grade  O
3  O
or  O
4  O
anemia  B-TOXI
occurred  O
in  O
one  O
of  O
18  O
(  O
6  O
%  O
)  O
patients  O
and  O
no  O
neutropenic  B-TOXI
fever  I-TOXI
or  O
treatment  O
related  O
mortality  O
was  O
observed  O
.  O

Partial  O
responses  O
were  O
seen  O
in  O
six  O
patients  O
and  O
one  O
patient  O
with  O
evaluable  O
disease  O
had  O
an  O
objective  O
response  O
.  O

The  O
overall  O
response  O
rate  O
was  O
37  O
%  O
(  O
seven  O
of  O
19  O
)  O
.  O

Six  O
other  O
patients  O
had  O
stable  O
disease  O
.  O

A  O
total  O
of  O
89  O
courses  O
were  O
administered  O
with  O
a  O
median  O
of  O
five  O
courses  O
per  O
patient  O
(  O
range  O
:  O
two  O
to  O
six  O
courses  O
)  O
.  O

The  O
median  O
time  O
to  O
progression  O
for  O
all  O
patients  O
was  O
3.7  O
months  O
.  O

The  O
median  O
overall  O
survival  O
was  O
7.4  O
months  O
with  O
four  O
patients  O
still  O
alive  O
(  O
median  O
follow  O
up  O
13.5  O
months  O
)  O
.  O

The  O
survival  O
at  O
6  O
months  O
and  O
1  O
year  O
is  O
64  O
and  O
23  O
%  O
,  O
respectively  O
.  O

The  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
in  O
this  O
group  O
of  O
patients  O
was  O
defined  O
as  O
carboplatin  B-DRUG
AUC  O
4  O
when  O
administered  O
with  O
gemcitabine  B-DRUG
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
8  O
of  O
a  O
21-day  O
schedule  O
.  O

Addition  O
of  O
oxaliplatin  B-DRUG
to  O
continuous  O
fluorouracil  B-DRUG
,  O
l-folinic  B-DRUG
acid  I-DRUG
,  O
and  O
concomitant  O
radiotherapy  O
in  O
rectal  B-CANCER
cancer  I-CANCER
:  O
the  O
Lyon  O
R  O
97-03  O
phase  O
I  O
trial  O
.  O


Oxaliplatin  B-DRUG
could  O
increase  O
the  O
efficacy  O
of  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
/  O
folinic  B-DRUG
acid  I-DRUG
chemoradiotherapy  O
in  O
rectal  B-CANCER
cancer  I-CANCER
.  O

We  O
tested  O
three  O
dose  O
levels  O
to  O
identify  O
a  O
feasible  O
oxaliplatin  B-DRUG
dose  O
for  O
combination  O
therapy  O
.  O

Between  O
February  O
1998  O
and  O
April  O
2000  O
,  O
we  O
included  O
17  O
rectal  B-CANCER
adenocarcinoma  I-CANCER
patients  O
in  O
a  O
single-center  O
phase  O
I  O
study  O
.  O

Patients  O
had  O
T4  O
rectal  B-CANCER
carcinoma  I-CANCER
,  O
T1-T3  O
disease  O
with  O
colostomy  O
refusal  O
,  O
or  O
potentially  O
operable  O
T2  O
/  O
T3  O
M1  O
requiring  O
local  O
treatment  O
.  O

Pelvic  O
radiotherapy  O
was  O
45  O
Gy  O
over  O
5  O
weeks  O
,  O
1.8  O
Gy  O
/  O
fraction  O
,  O
with  O
concomitant  O
chemotherapy  O
weeks  O
1  O
and  O
5.  O
Chemotherapy  O
was  O
oxaliplatin  B-DRUG
80  O
,  O
100  O
,  O
or  O
130  O
mg  O
/  O
m2  O
2-hour  O
infusion  O
on  O
day  O
1  O
followed  O
by  O
L-folinic  B-DRUG
acid  I-DRUG
100  O
mg  O
/  O
m2  O
/  O
d  O
intravenous  O
bolus  O
,  O
and  O
5-FU  B-DRUG
350  O
mg  O
/  O
m2  O
/  O
d  O
continuous  O
infusion  O
on  O
days  O
1  O
to  O
5  O
(  O
FolfoR1  O
)  O
.  O

Six  O
patients  O
refusing  O
surgery  O
received  O
additional  O
contact  O
radiotherapy  O
+  O
/  O
-  O
brachytherapy  O
.  O

Dose  O
escalation  O
proceeded  O
if  O
less  O
than  O
two  O
of  O
six  O
patients  O
had  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
at  O
a  O
given  O
dose-level  O
.  O

All  O
except  O
two  O
patients  O
completed  O
treatment  O
;  O
patients  O
at  O
level  O
1  O
(  O
prolonged  O
grade  O
1  O
thrombocytopenia  B-TOXI
)  O
and  O
level  O
3  O
(  O
prolonged  B-TOXI
cold-related  I-TOXI
dysesthesia  I-TOXI
)  O
had  O
no  O
second  O
chemotherapy  O
course  O
.  O

Median  O
follow-up  O
is  O
14  O
months  O
(  O
range  O
,  O
2  O
to  O
28  O
months  O
)  O
.  O

One  O
elderly  O
patient  O
at  O
dose  O
level  O
1  O
had  O
DLT  O
asthenia  B-TOXI
,  O
severe  B-TOXI
diarrhea  I-TOXI
and  O
vomiting  B-TOXI
,  O
and  O
more  O
than  O
10  O
%  O
weight  B-TOXI
loss  I-TOXI
.  O

There  O
were  O
no  O
other  O
DLTs  O
and  O
no  O
severe  O
rectitis  O
or  O
gastrointestinal  O
toxicity  O
.  O

There  O
were  O
objective  O
responses  O
at  O
all  O
doses  O
and  O
no  O
progressions  O
.  O

Eight  O
patients  O
underwent  O
radical  O
surgery  O
after  O
chemoradiotherapy  O
.  O

Two  O
had  O
complete  O
pathologic  O
responses  O
.  O

FolfoR1  O
seems  O
feasible  O
and  O
effective  O
.  O

Dose  O
escalation  O
did  O
not  O
increase  O
toxicity  O
.  O

Although  O
the  O
MTD  O
was  O
not  O
reached  O
in  O
this  O
study  O
,  O
we  O
recommend  O
oxaliplatin  B-DRUG
130  O
mg  O
/  O
m2  O
for  O
phase  O
II  O
studies  O
because  O
it  O
is  O
the  O
dose  O
determined  O
from  O
studies  O
in  O
metastatic  O
patients  O
with  O
no  O
toxicity  O
when  O
given  O
concurrently  O
with  O
radiation  O
.  O

A  O
phase  O
I  O
study  O
of  O
a  O
fixed  O
dose  O
of  O
cisplatin  B-DRUG
with  O
increasing  O
doses  O
of  O
raltitrexed  B-DRUG
(  O
Tomudex  B-DRUG
)  O
in  O
the  O
treatment  O
of  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
or  I-CANCER
metastatic  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
.  O


A  O
phase  O
I  O
trial  O
of  O
raltitrexed  B-DRUG
in  O
combination  O
with  O
cisplatin  B-DRUG
in  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
or  I-CANCER
metastatic  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
(  O
SCCHN  B-CANCER
)  O
.  O

Eligible  O
patients  O
had  O
locally  B-CANCER
advanced  I-CANCER
or  I-CANCER
metastatic  I-CANCER
SCCHN  I-CANCER
.  O

Cohorts  O
of  O
patients  O
were  O
treated  O
with  O
escalating  O
doses  O
of  O
raltitrexed  B-DRUG
(  O
2.0  O
mg  O
/  O
m2  O
to  O
3.5  O
mg  O
/  O
m2  O
)  O
as  O
a  O
15-minute  O
intravenous  O
infusion  O
immediately  O
followed  O
by  O
cisplatin  B-DRUG
(  O
80  O
mg  O
/  O
m2  O
)  O
administered  O
over  O
four  O
hours  O
every  O
three  O
weeks  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
.  O

A  O
total  O
of  O
17  O
patients  O
was  O
administered  O
60  O
courses  O
of  O
an  O
escalating  O
dose  O
of  O
raltitrexed  B-DRUG
.  O

Starting  O
dose  O
of  O
cisplatin  B-DRUG
was  O
initially  O
100  O
mg  O
/  O
m2  O
in  O
the  O
first  O
three  O
patients  O
treated  O
at  O
the  O
first  O
dose  O
level  O
.  O

Due  O
to  O
cisplatin-induced  B-TOXI
nephrotoxicity  I-TOXI
expressed  O
as  O
a  O
creatinine  B-DRUG
clearance  O
decrease  O
by  O
more  O
than  O
50  O
%  O
,  O
the  O
cisplatin  B-DRUG
dose  O
was  O
reduced  O
to  O
80  O
mg  O
/  O
m2  O
for  O
all  O
subsequent  O
treatment  O
cycles  O
.  O

Dose-limiting  O
toxicity  O
was  O
observed  O
at  O
raltitrexed  B-DRUG
dose  O
of  O
3.5  O
mg  O
/  O
m2  O
in  O
two  O
out  O
of  O
five  O
patients  O
.  O

Dose-limiting  O
grade  O
4  O
(  O
CTC  O
)  O
neutropenia  B-TOXI
,  O
grade  O
4  O
diarrhoea  B-TOXI
,  O
grade  O
3  O
lethargy  B-TOXI
and  O
elevation  O
of  O
transaminases  B-TOXI
and  I-TOXI
bilirubine  I-TOXI
was  O
seen  O
in  O
these  O
two  O
patients  O
.  O

One  O
patient  O
treated  O
at  O
the  O
level  O
of  O
the  O
MTD  O
,  O
died  B-TOXI
23  O
days  O
after  O
the  O
first  O
cycle  O
with  O
unresolved  O
gastro-intestinal  B-TOXI
toxicity  I-TOXI
.  O

In  O
all  O
other  O
dose  O
levels  O
toxicity  O
was  O
very  O
limited  O
.  O

The  O
recommended  O
dose  O
for  O
further  O
study  O
was  O
raltitrexed  B-DRUG
3.0  O
mg  O
/  O
m2  O
in  O
combination  O
with  O
cisplatin  B-DRUG
80  O
mg  O
/  O
m2  O
.  O

In  O
15  O
evaluable  O
patients  O
,  O
we  O
observed  O
9  O
WHO  O
objective  O
responses  O
(  O
1  O
complete  O
and  O
8  O
partial  O
)  O
.  O

At  O
the  O
recommended  O
dose  O
level  O
3  O
partial  O
responses  O
were  O
observed  O
in  O
five  O
evaluable  O
patients  O
.  O

The  O
regimen  O
of  O
raltitrexed  B-DRUG
3.0  O
mg  O
/  O
m2  O
followed  O
by  O
cisplatin  B-DRUG
80  O
mg  O
/  O
m2  O
on  O
day  O
1  O
,  O
every  O
three  O
weeks  O
has  O
manageable  O
toxicity  O
and  O
these  O
doses  O
are  O
recommended  O
for  O
phase  O
II  O
evaluation  O
.  O

Results  O
indicate  O
that  O
this  O
combination  O
is  O
active  O
for  O
the  O
treatment  O
of  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
or  I-CANCER
metastatic  I-CANCER
SCCHN  I-CANCER
.  O

Recently  O
,  O
a  O
phase  O
II  O
study  O
has  O
been  O
started  O
.  O

Randomized  O
phase  O
III  O
trial  O
of  O
high-dose-intensity  O
methotrexate  B-DRUG
,  O
vinblastine  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
cisplatin  B-DRUG
(  O
MVAC  B-DRUG
)  O
chemotherapy  O
and  O
recombinant  O
human  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
versus  O
classic  O
MVAC  B-DRUG
in  O
advanced  B-CANCER
urothelial  I-CANCER
tract  I-CANCER
tumors  I-CANCER
:  O
European  O
Organization  O
for  O
Research  O
and  O
Treatment  O
of  O
Cancer  O
Protocol  O
no.  O
30924  O
.  O


This  O
randomized  O
trial  O
evaluated  O
antitumor  O
activity  O
of  O
and  O
survival  O
asociated  O
with  O
high-dose-intensity  O
chemotherapy  O
with  O
methotrexate  B-DRUG
,  O
vinblastine  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
cisplatin  B-DRUG
(  O
MVAC  B-DRUG
)  O
plus  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
(  O
HD-MVAC  B-DRUG
)  O
versus  O
MVAC  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
transitional-cell  I-CANCER
carcinoma  I-CANCER
(  O
TCC  B-CANCER
)  O
.  O

A  O
total  O
of  O
263  O
patients  O
with  O
metastatic  B-CANCER
or  I-CANCER
advanced  I-CANCER
TCC  I-CANCER
who  O
had  O
no  O
prior  O
chemotherapy  O
were  O
randomized  O
to  O
HD-MVAC  B-DRUG
(  O
2-week  O
cycles  O
)  O
or  O
MVAC  B-DRUG
(  O
4-week  O
cycles  O
)  O
.  O

Using  O
an  O
intent-to-treat  O
analysis  O
,  O
at  O
a  O
median  O
follow-up  O
of  O
38  O
months  O
,  O
on  O
the  O
HD-MVAC  B-DRUG
arm  O
there  O
were  O
28  O
complete  O
responses  O
(  O
CRs  O
)  O
(  O
21  O
%  O
)  O
and  O
55  O
partial  O
responses  O
(  O
PRs  O
)  O
(  O
41  O
%  O
)  O
,  O
for  O
an  O
overall  O
response  O
of  O
62  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
[  O
CI  O
]  O
,  O
54  O
%  O
to  O
70  O
%  O
)  O
.  O

On  O
the  O
MVAC  B-DRUG
arm  O
,  O
there  O
were  O
12  O
CRs  O
(  O
9  O
%  O
)  O
and  O
53  O
PRs  O
(  O
41  O
%  O
)  O
,  O
for  O
an  O
overall  O
response  O
of  O
50  O
%  O
(  O
95  O
%  O
CI  O
,  O
42  O
%  O
to  O
59  O
%  O
)  O
.  O

The  O
P  O
value  O
for  O
the  O
difference  O
in  O
CR  O
rate  O
was.009  O
;  O
and  O
for  O
the  O
overall  O
response  O
,  O
it  O
was.06  O
.  O

There  O
was  O
no  O
statistically  O
significant  O
difference  O
in  O
survival  O
(  O
P  O
=.122  O
)  O
or  O
time  O
to  O
progression  O
(  O
P  O
=.114  O
)  O
.  O

Progression-free  O
survival  O
was  O
significantly  O
better  O
with  O
HD-MVAC  B-DRUG
(  O
P=.037  O
;  O
hazard  O
ratio.75  O
;  O
95  O
%  O
CI.58  O
to.98  O
)  O
.  O

The  O
median  O
progression-free  O
survival  O
time  O
was  O
9.1  O
months  O
on  O
the  O
HD-MVAC  B-DRUG
arm  O
versus  O
8.2  O
months  O
on  O
the  O
MVAC  B-DRUG
arm  O
.  O

The  O
2-year  O
progression-free  O
survival  O
rate  O
was  O
24.7  O
%  O
for  O
HD-MVAC  B-DRUG
(  O
95  O
%  O
CI  O
,  O
17.1  O
%  O
to  O
32.3  O
%  O
)  O
versus  O
11.6  O
%  O
for  O
MVAC  B-DRUG
(  O
95  O
%  O
CI  O
,  O
5.9  O
%  O
to  O
17.4  O
%  O
)  O
.  O

With  O
HD-MVAC  B-DRUG
,  O
it  O
was  O
possible  O
to  O
deliver  O
twice  O
the  O
doses  O
of  O
cisplatin  B-DRUG
and  O
doxorubicin  B-DRUG
in  O
half  O
the  O
time  O
,  O
with  O
fewer  O
dose  O
delays  O
and  O
less  O
toxicity  O
.  O

Although  O
a  O
50  O
%  O
difference  O
in  O
median  O
overall  O
survival  O
was  O
not  O
detected  O
,  O
a  O
benefit  O
was  O
observed  O
in  O
progression-free  O
survival  O
,  O
CR  O
rates  O
,  O
and  O
overall  O
response  O
rates  O
with  O
HD-MVAC  B-DRUG
.  O

A  O
phase  O
II  O
study  O
of  O
sequential  O
5-fluorouracil  B-DRUG
,  O
epirubicin  B-DRUG
and  O
cyclophosphamide  B-DRUG
(  O
FEC  B-DRUG
)  O
and  O
paclitaxel  B-DRUG
in  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
(  O
Protocol  O
PV  O
BC  O
97  O
/  O
01  O
)  O
.  O


Sequential  O
administration  O
of  O
the  O
association  O
of  O
5-fluorouracil  B-DRUG
,  O
epirubicin  B-DRUG
and  O
cyclophosphamide  B-DRUG
(  O
FEC  B-DRUG
)  O
and  O
paclitaxel  B-DRUG
could  O
be  O
better  O
tolerated  O
than  O
the  O
association  O
of  O
an  O
anthracycline  B-DRUG
and  O
paclitaxel  B-DRUG
while  O
having  O
a  O
similar  O
antitumour  O
effect  O
.  O

69  O
patients  O
with  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
previously  O
untreated  O
with  O
anthracyclines  B-DRUG
or  O
paclitaxel  B-DRUG
entered  O
a  O
phase  O
II  O
multicentre  O
study  O
in  O
which  O
FEC  B-DRUG
was  O
followed  O
by  O
paclitaxel  B-DRUG
.  O

Both  O
regimens  O
were  O
administered  O
4  O
times  O
every  O
21  O
days  O
.  O

The  O
median  O
follow-up  O
is  O
20  O
months  O
and  O
38  O
/  O
69  O
patients  O
have  O
died  B-TOXI
.  O

Grade  O
III-IV  O
toxicity  O
was  O
acceptable  O
.  O

Leukopenia  B-TOXI
occurred  O
in  O
26  O
%  O
of  O
patients  O
,  O
thrombocytopenia  B-TOXI
in  O
2  O
%  O
and  O
anaemia  B-TOXI
in  O
4  O
%  O
.  O

One  O
patient  O
had  O
reversible  B-TOXI
heart  I-TOXI
failure  I-TOXI
during  O
FEC  B-DRUG
therapy  O
.  O

Peripheral  B-TOXI
neuropathy  I-TOXI
and  O
arthralgia-myalgia  B-TOXI
occurred  O
in  O
9  O
%  O
and  O
4  O
%  O
of  O
patients  O
,  O
respectively  O
and  O
one  O
patient  O
had  O
respiratory  B-TOXI
hypersensitivity  I-TOXI
during  O
paclitaxel  B-DRUG
treatment  O
.  O

9  O
patients  O
did  O
not  O
complete  O
therapy  O
because  O
of  O
:  O
treatment  O
refusal  O
(  O
n  O
=  O
1  O
)  O
,  O
cardiac  B-TOXI
toxicity  I-TOXI
(  O
n  O
=  O
1  O
)  O
,  O
early  B-TOXI
death  I-TOXI
during  O
FEC  B-DRUG
chemotherapy  O
(  O
n  O
=  O
1  O
)  O
,  O
major  O
protocol  O
violations  O
(  O
n  O
=  O
4  O
)  O
,  O
hypersensitivity  B-TOXI
reaction  I-TOXI
(  O
n  O
=  O
1  O
)  O
and  O
early  B-TOXI
death  I-TOXI
during  O
paclitaxel  B-DRUG
chemotherapy  O
(  O
n  O
=  O
1  O
)  O
.  O

The  O
overall  O
response  O
rate  O
was  O
65  O
%  O
(  O
95  O
%  O
CI  O
=  O
53-76  O
)  O
,  O
and  O
7  O
%  O
of  O
patients  O
had  O
stable  O
disease  O
.  O

Therapy  O
was  O
defined  O
as  O
having  O
failed  O
in  O
28  O
%  O
of  O
patients  O
because  O
they  O
were  O
not  O
evaluable  O
(  O
13  O
%  O
)  O
or  O
had  O
progressive  B-TOXI
disease  I-TOXI
(  O
15  O
%  O
)  O
.  O

The  O
median  O
time  O
to  O
progression  O
and  O
survival  O
are  O
13.2  O
and  O
23.5  O
months  O
,  O
respectively  O
.  O

Sequential  O
FEC-paclitaxel  B-DRUG
is  O
a  O
suitable  O
strategy  O
for  O
patients  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
who  O
have  O
not  O
been  O
previously  O
treated  O
with  O
anthracyclines  B-DRUG
and  O
/  O
or  O
taxanes  B-DRUG
.  O

In  O
fact  O
,  O
it  O
avoids  O
major  O
haematologic  B-TOXI
toxicity  I-TOXI
and  O
has  O
a  O
good  O
antitumour  O
effect  O
.  O

Multicenter  O
phase  O
II  O
trial  O
of  O
paclitaxel  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
etoposide  B-DRUG
with  O
concurrent  O
radiation  O
for  O
limited-stage  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


To  O
investigate  O
the  O
feasibility  O
,  O
efficacy  O
,  O
and  O
safety  O
of  O
adding  O
paclitaxel  B-DRUG
to  O
cisplatin  B-DRUG
/  I-DRUG
etoposide  I-DRUG
chemotherapy  O
and  O
concurrent  O
thoracic  O
radiotherapy  O
(  O
TRT  O
)  O
in  O
treatment  O
of  O
limited-stage  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
LD-SCLC  B-CANCER
)  O
.  O

Patients  O
received  O
five  O
courses  O
of  O
chemotherapy  O
(  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m2  O
1-hour  O
intravenous  O
[  O
IV  O
]  O
infusion  O
day  O
1  O
;  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
IV  O
day  O
1  O
;  O
etoposide  B-DRUG
100  O
mg  O
/  O
m2  O
IV  O
day  O
1  O
;  O
oral  B-DRUG
etoposide  I-DRUG
100  O
mg  O
bid  O
days  O
2  O
to  O
5  O
)  O
at  O
3-week  O
intervals  O
.  O

TRT  O
(  O
42  O
Gy  O
administered  O
in  O
15  O
fractions  O
)  O
was  O
administered  O
concurrent  O
with  O
chemotherapy  O
cycle  O
3.  O
All  O
patients  O
were  O
evaluated  O
before  O
starting  O
TRT  O
and  O
4  O
weeks  O
after  O
termination  O
of  O
chemotherapy  O
.  O

Patients  O
achieving  O
complete  O
remission  O
(  O
CR  O
)  O
were  O
administered  O
prophylactic  O
cranial  O
irradiation  O
.  O

Thirty-nine  O
patients  O
were  O
included  O
,  O
and  O
the  O
median  O
age  O
was  O
63  O
years  O
.  O

The  O
median  O
follow-up  O
was  O
36  O
months  O
(  O
range  O
,  O
19  O
to  O
57  O
months  O
)  O
.  O

The  O
overall  O
response  O
rate  O
was  O
92  O
%  O
(  O
CR  O
,  O
81  O
%  O
;  O
partial  O
response  O
,  O
11  O
%  O
)  O
,  O
and  O
the  O
median  O
survival  O
was  O
21  O
months  O
.  O

The  O
1-  O
and  O
2-year  O
disease-specific  O
survival  O
rates  O
were  O
69  O
%  O
and  O
37  O
%  O
,  O
respectively  O
.  O

Of  O
29  O
CR  O
patients  O
,  O
83  O
%  O
have  O
relapsed  O
.  O

Brain  B-CANCER
metastasis  I-CANCER
was  O
as  O
frequent  O
as  O
local  O
recurrences  O
(  O
42  O
%  O
)  O
.  O

Hematologic  B-TOXI
toxicity  I-TOXI
included  O
grade  O
3  O
to  O
4  O
leukopenia  B-TOXI
in  O
74  O
%  O
of  O
patients  O
and  O
grade  O
3  O
thrombocytopenia  B-TOXI
in  O
10  O
%  O
.  O

One  O
treatment-related  B-TOXI
death  I-TOXI
occurred  O
as  O
a  O
result  O
of  O
severe  B-TOXI
neutropenia  I-TOXI
and  O
septicemia  B-TOXI
.  O

Hematotoxicity  B-TOXI
caused  O
dose  O
reductions  O
in  O
31  O
%  O
of  O
courses  O
.  O

One  O
patient  O
had  O
an  O
anaphylactic  B-TOXI
reaction  I-TOXI
during  O
the  O
first  O
paclitaxel  B-DRUG
infusion  O
.  O

Paclitaxel-related  B-TOXI
neuropathy  I-TOXI
and  O
myalgia  B-TOXI
were  O
reversible  O
.  O

Grade  O
3  O
esophagitis  B-TOXI
was  O
seen  O
in  O
five  O
patients  O
during  O
and  O
shortly  O
after  O
TRT  O
.  O

This  O
novel  O
multimodal  O
regimen  O
is  O
effective  O
and  O
well  O
tolerated  O
in  O
patients  O
with  O
LD-SCLC  B-CANCER
.  O

It  O
compares  O
favorably  O
with  O
previously  O
published  O
phase  O
II  O
studies  O
.  O

Dexamethasone  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
etoposide  B-DRUG
,  O
cyclophosphamide  B-DRUG
(  O
d-TEC  B-DRUG
)  O
and  O
G-CSF  B-DRUG
for  O
stem  B-CANCER
cell  I-CANCER
mobilisation  I-CANCER
in  I-CANCER
multiple  I-CANCER
myeloma  I-CANCER
.  O


Forty-one  O
patients  O
with  O
multiple  O
myeloma  B-CANCER
were  O
treated  O
with  O
a  O
novel  O
stem  O
cell  O
mobilisation  O
regimen  O
.  O

The  O
primary  O
end  O
points  O
were  O
adequate  O
stem  O
cell  O
mobilising  O
ability  O
(  O
&  O
gt  O
;  O
1  O
%  O
circulating  O
CD34-positive  O
cells  O
)  O
and  O
collection  O
(  O
&  O
gt  O
;  O
or  O
=  O
4  O
x  O
10  O
(  O
6  O
)  O
CD34-positive  O
cells  O
/  O
kg  O
)  O
,  O
and  O
safety  O
.  O

The  O
secondary  O
end  O
point  O
was  O
activity  O
against  O
myeloma  B-CANCER
.  O

The  O
regimen  O
(  O
d-TEC  B-DRUG
)  O
consisted  O
of  O
dexamethasone  B-DRUG
,  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
i.v.  O
,  O
etoposide  B-DRUG
60  O
mg  O
/  O
kg  O
i.v.  O
,  O
cyclophosphamide  B-DRUG
3  O
g  O
/  O
m  O
(  O
2  O
)  O
i.v.  O
,  O
and  O
G-CSF  B-DRUG
5-10  O
microg  O
/  O
kg  O
/  O
day  O
i.v.  O
A  O
total  O
of  O
84  O
cycles  O
were  O
administered  O
to  O
these  O
41  O
individuals  O
.  O

Patient  O
characteristics  O
included  O
a  O
median  O
age  O
of  O
53  O
years  O
,  O
a  O
median  O
of  O
five  O
prior  O
chemotherapy  O
cycles  O
,  O
and  O
a  O
median  O
interval  O
of  O
10  O
months  O
from  O
diagnosis  O
of  O
myeloma  B-CANCER
to  O
first  O
cycle  O
of  O
d-TEC  B-DRUG
.  O

Seventy-five  O
percent  O
of  O
the  O
patients  O
had  O
stage  O
II  O
or  O
III  O
disease  O
,  O
50  O
%  O
had  O
received  O
carmustine  B-DRUG
and  O
/  O
or  O
melphalan  B-DRUG
previously  O
,  O
and  O
25  O
%  O
had  O
received  O
prior  O
radiation  O
therapy  O
.  O

Eighty-eight  O
percent  O
of  O
patients  O
mobilised  O
adequately  O
after  O
the  O
first  O
cycle  O
of  O
d-TEC  B-DRUG
and  O
91  O
%  O
mobilized  O
adequately  O
after  O
the  O
second  O
cycle  O
.  O

An  O
adequate  O
number  O
of  O
stem  O
cells  O
were  O
collected  O
in  O
32  O
patients  O
.  O

Of  O
the  O
remaining  O
nine  O
patients  O
,  O
three  O
mobilised  O
,  O
but  O
stem  O
cells  O
were  O
not  O
collected  O
,  O
two  O
mobilised  O
but  O
stem  O
cell  O
collection  O
was  O
&  O
lt  O
;  O
4  O
x  O
10  O
(  O
6  O
)  O
CD34-positive  O
cells  O
/  O
kg  O
,  O
three  O
did  O
not  O
mobilise  O
,  O
and  O
one  O
died  B-TOXI
of  I-TOXI
disease  I-TOXI
progression  I-TOXI
.  O

Major  O
toxicities  O
included  O
pancytopenia  B-TOXI
,  O
alopecia  B-TOXI
,  O
fever  B-TOXI
and  O
stomatitis  B-TOXI
.  O

One  O
patient  O
died  B-TOXI
from  I-TOXI
multi-organ  I-TOXI
failure  I-TOXI
and  O
progressive  B-TOXI
disease  I-TOXI
.  O

Fifty  O
percent  O
of  O
evaluable  O
patients  O
demonstrated  O
a  O
partial  O
response  O
and  O
28.6  O
%  O
of  O
patients  O
had  O
a  O
minor  O
response  O
.  O

This  O
novel  O
dose-intense  O
regimen  O
was  O
safe  O
,  O
capable  O
of  O
stem  O
cell  O
mobilisation  O
and  O
collection  O
,  O
even  O
in  O
heavily  O
pre-treated  O
patients  O
,  O
and  O
active  O
against  O
the  O
underlying  O
myeloma  B-CANCER
.  O

Multiple  O
cycles  O
of  O
dose-intensive  O
chemotherapy  O
with  O
repeated  O
stem  O
cell  O
support  O
as  O
induction  O
treatment  O
in  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
:  O
a  O
feasibility  O
study  O
.  O


The  O
purpose  O
of  O
this  O
trial  O
was  O
to  O
study  O
feasibility  O
and  O
tolerance  O
of  O
a  O
dose-intensive  O
multicyclic  O
alternating  O
induction  O
chemotherapy  O
with  O
repeated  O
stem  O
cell  O
support  O
in  O
a  O
series  O
of  O
43  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
.  O

Anthracycline-naive  O
patients  O
(  O
n  O
=  O
21  O
)  O
received  O
cyclophosphamide  B-DRUG
2.5  O
g  O
/  O
m  O
(  O
2  O
)  O
plus  O
doxorubicin  B-DRUG
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
alternating  O
every  O
14  O
days  O
with  O
paclitaxel  B-DRUG
200-350  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
cisplatin  B-DRUG
120  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Patients  O
who  O
had  O
previously  O
received  O
anthracyclines  B-DRUG
(  O
n  O
=  O
22  O
)  O
received  O
cisplatin  B-DRUG
120  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
etoposide  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
alternating  O
with  O
paclitaxel  B-DRUG
200-350  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
ifosfamide  B-DRUG
8  O
g  O
/  O
m  O
(  O
2  O
)  O
.  O

Peripheral  O
blood  O
stem  O
cells  O
were  O
infused  O
after  O
every  O
course  O
except  O
the  O
first  O
,  O
with  O
a  O
median  O
CD34  O
(  O
+  O
)  O
dose  O
of  O
2.1  O
x  O
10  O
(  O
6  O
)  O
/  O
kg  O
per  O
cycle  O
.  O

Positive  O
selection  O
of  O
CD34  O
(  O
+  O
)  O
cells  O
was  O
performed  O
in  O
good  O
mobilizers  O
.  O

The  O
median  O
number  O
of  O
cycles  O
administered  O
was  O
six  O
(  O
4-8  O
)  O
,  O
and  O
the  O
time  O
interval  O
between  O
them  O
was  O
17  O
days  O
.  O

Median  O
summation  O
dose  O
intensities  O
(  O
SDI  O
)  O
actually  O
administered  O
for  O
the  O
CA-TP  B-DRUG
and  O
PE-TI  B-DRUG
protocol  O
were  O
4.95  O
and  O
4.69  O
,  O
respectively  O
(  O
87  O
%  O
of  O
scheduled  O
SDI  O
)  O
.  O

There  O
were  O
15  O
complete  O
(  O
35  O
%  O
)  O
and  O
21  O
partial  O
responses  O
(  O
49  O
%  O
)  O
,  O
for  O
an  O
overall  O
response  O
rate  O
of  O
84  O
%  O
(  O
95  O
%  O
CI  O
,  O
73  O
%  O
-95  O
%  O
)  O
.  O

Infection  B-TOXI
or  O
neutropenic  B-TOXI
fever  I-TOXI
occurred  O
in  O
50  O
%  O
of  O
the  O
cycles  O
.  O

There  O
was  O
one  O
treatment-related  O
death  B-TOXI
.  O

After  O
a  O
median  O
follow-up  O
of  O
26  O
months  O
,  O
the  O
median  O
event-free-survival  O
was  O
12  O
months  O
(  O
95  O
%  O
CI  O
:  O
10-14  O
)  O
and  O
overall  O
survival  O
was  O
31  O
months  O
.  O

These  O
high  O
dose-intensity  O
induction  O
treatments  O
seem  O
to  O
be  O
feasible  O
with  O
sequential  O
stem  O
cell  O
support  O
.  O

Dose-finding  O
,  O
pharmacokinetic  O
and  O
phase  O
II  O
study  O
of  O
docetaxel  B-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
inoperable  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


The  O
good  O
efficacy-toxicity  O
ratio  O
of  O
both  O
docetaxel  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
stimulates  O
the  O
investigation  O
of  O
the  O
combination  O
of  O
these  O
drugs  O
as  O
a  O
first  O
line  O
chemotherapy  O
.  O

This  O
two-step  O
study  O
firstly  O
aimed  O
at  O
determining  O
the  O
maximum  O
tolerated  O
and  O
recommended  O
doses  O
of  O
docetaxel  B-DRUG
given  O
every  O
3  O
weeks  O
in  O
combination  O
with  O
a  O
fixed  O
dose  O
of  O
gemcitabine  B-DRUG
;  O
the  O
phase  O
I  O
study  O
paid  O
particular  O
attention  O
to  O
pharmacokinetics  O
.  O

Afterwards  O
,  O
the  O
safety  O
and  O
efficacy  O
of  O
the  O
recommended  O
dose  O
was  O
carefully  O
assessed  O
in  O
the  O
phase  O
II-step  O
.  O

The  O
following  O
range  O
of  O
docetaxel  B-DRUG
dosages  O
were  O
tested  O
in  O
the  O
phase  O
I  O
study  O
;  O
60  O
,  O
75  O
,  O
85  O
,  O
and  O
100  O
mg  O
m  O
(  O
-2  O
)  O
given  O
on  O
day  O
8  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
1000  O
mg  O
m  O
(  O
-2  O
)  O
delivered  O
on  O
days  O
1  O
and  O
8  O
of  O
a  O
3-week  O
cycle  O
.  O

Haematopoietic  B-DRUG
growth  I-DRUG
factors  I-DRUG
were  O
not  O
allowed  O
.  O

The  O
treatment  O
was  O
delivered  O
on  O
an  O
outpatient  O
basis  O
.  O

Main  O
eligibility  O
criteria  O
consisted  O
of  O
stage  O
III  O
b  O
or  O
IV  O
histologically  O
proven  O
NSCLC  B-CANCER
,  O
Eastern  O
Co-operative  O
Oncology  O
Group  O
(  O
ECOG  O
)  O
performance  O
status  O
PS  O
&  O
lt  O
;  O
or  O
=2  O
,  O
age  O
&  O
lt  O
;  O
or  O
=70  O
years  O
,  O
measurable  O
disease  O
,  O
adequate  O
blood  O
counts  O
,  O
chemistry  O
,  O
and  O
no  O
symptomatic  O
brain  O
metastasis  O
.  O

Four  O
centres  O
enrolled  O
49  O
patients  O
(  O
eight  O
having  O
been  O
pre-treated  O
)  O
;  O
16  O
in  O
phase  O
I  O
and  O
33  O
in  O
phase  O
II  O
.  O

The  O
maximal  O
tolerated  O
dose  O
was  O
almost  O
reached  O
at  O
the  O
last  O
dose  O
level  O
(  O
i.e.  O
docetaxel  O
,  O
100  O
mg  O
m  O
(  O
-2  O
)  O
)  O
.  O

Consequently  O
,  O
we  O
considered  O
the  O
85  O
mg  O
m  O
(  O
-2  O
)  O
level  O
as  O
the  O
recommended  O
dose  O
.  O

There  O
was  O
a  O
positive  O
relationship  O
of  O
the  O
docetaxel  B-DRUG
dose  O
to  O
the  O
area  O
under  O
the  O
curve  O
of  O
this  O
drug  O
.  O

Toxicity  O
was  O
assessable  O
in  O
all  O
patients  O
.  O

Among  O
the  O
200  O
cycles  O
delivered  O
,  O
192  O
were  O
assessable  O
for  O
this  O
feature  O
.  O

Main  O
toxicity  O
was  O
grade  O
3-4  O
neutropenia  B-TOXI
affecting  O
23  O
patients  O
(  O
47  O
%  O
of  O
the  O
population  O
;  O
23  O
%  O
of  O
the  O
cycles  O
)  O
.  O

Six  O
febrile  B-TOXI
episodes  I-TOXI
were  O
recorded  O
leading  O
to  O
two  O
treatment-related  B-TOXI
deaths  I-TOXI
.  O

Another  O
patient  O
died  B-TOXI
from  O
congestive  B-TOXI
cardiac  I-TOXI
failure  I-TOXI
.  O

In  O
addition  O
,  O
six  O
patients  O
experienced  O
interstitial  B-TOXI
pneumonitis  I-TOXI
,  O
(  O
one  O
half  O
considered  O
as  O
severe  O
)  O
,  O
two  O
of  O
them  O
having  O
received  O
the  O
recommended  O
dose  O
.  O

All  O
patients  O
recovered  O
from  O
this  O
toxicity  O
after  O
corticosteroids  B-DRUG
.  O

Fourteen  O
patients  O
out  O
of  O
the  O
whole  O
population  O
(  O
29  O
%  O
;  O
95  O
%  O
CI  O
[  O
17-43  O
]  O
,  O
including  O
ten  O
patients  O
receiving  O
the  O
recommended  O
dose  O
)  O
,  O
achieved  O
an  O
objective  O
response  O
.  O

Median  O
follow-up  O
was  O
14  O
months  O
(  O
range  O
,  O
0.3-29.4  O
)  O
.  O

Median  O
survival  O
was  O
11.2  O
months  O
(  O
95  O
%  O
CI  O
[  O
8.3-13.2  O
]  O
)  O
,  O
and  O
the  O
1-year  O
survival  O
rate  O
was  O
45  O
%  O
.  O

Gemcitabine  B-DRUG
,  O
1000  O
mg  O
m  O
(  O
-2  O
)  O
days  O
1  O
and  O
8  O
in  O
combination  O
with  O
docetaxel  B-DRUG
,  O
85  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
8  O
,  O
given  O
every  O
3  O
weeks  O
could  O
be  O
considered  O
as  O
an  O
active  O
regimen  O
with  O
manageable  O
toxicities  O
in  O
locally  B-CANCER
advanced  I-CANCER
or  I-CANCER
metastatic  I-CANCER
NSCLC  I-CANCER
.  O

This  O
study  O
deserves  O
further  O
comparisons  O
with  O
classical  O
platinum-based  B-DRUG
regimens  O
.  O

Phase  O
I  O
and  O
pharmacokinetic  O
study  O
of  O
two  O
sequences  O
of  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
administered  O
weekly  O
to  O
patients  O
with  O
advanced  B-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
,  O
and  O
effect  O
of  O
drug  O
sequence  O
on  O
toxicities  O
and  O
pharmacokinetics  O
of  O
the  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
.  O

A  O
total  O
of  O
34  O
patients  O
with  O
advanced  B-CANCER
cancers  I-CANCER
were  O
treated  O
with  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
on  O
days  O
1  O
and  O
8  O
of  O
each  O
21-day  O
cycle  O
according  O
to  O
the  O
following  O
dose  O
escalation  O
schedule  O
:  O
level  O
1  O
,  O
800  O
and  O
30  O
mg  O
/  O
m2  O
,  O
respectively  O
;  O
level  O
2  O
,  O
800  O
and  O
40  O
mg  O
/  O
m2  O
;  O
level  O
3  O
,  O
1,000  O
and  O
40  O
mg  O
/  O
m2  O
;  O
and  O
level  O
4  O
,  O
1,250  O
and  O
40  O
mg  O
/  O
m2  O
.  O

At  O
each  O
dose  O
level  O
,  O
at  O
least  O
three  O
patients  O
were  O
assigned  O
to  O
one  O
of  O
the  O
two  O
sequences  O
of  O
drug  O
administration  O
:  O
gemcitabine  B-DRUG
--  O
&  O
gt  O
;  O
docetaxel  B-DRUG
or  O
docetaxel  B-DRUG
--  O
&  O
gt  O
;  O
gemcitabine  B-DRUG
.  O

Once  O
the  O
MTD  O
had  O
been  O
reached  O
,  O
six  O
additional  O
patients  O
,  O
who  O
had  O
received  O
no  O
more  O
than  O
one  O
chemotherapy  O
regimen  O
,  O
were  O
enrolled  O
to  O
dose  O
levels  O
3  O
and  O
4  O
(  O
gemcitabine  B-DRUG
--  O
&  O
gt  O
;  O
docetaxel  B-DRUG
)  O
to  O
determine  O
the  O
MTD  O
in  O
minimally  O
pretreated  O
patients  O
.  O

Neutropenia  B-TOXI
was  O
the  O
most  O
frequent  O
DLT  O
with  O
an  O
overall  O
incidence  O
of  O
23.5  O
%  O
.  O

Grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
occurred  O
in  O
62  O
%  O
of  O
patients  O
(  O
8  O
/  O
13  O
)  O
who  O
had  O
received  O
two  O
or  O
more  O
prior  O
chemotherapy  O
regimens  O
,  O
but  O
not  O
at  O
all  O
(  O
0  O
/  O
15  O
)  O
in  O
patients  O
who  O
had  O
received  O
no  O
more  O
than  O
one  O
prior  O
chemotherapy  O
regimens  O
(  O
P  O
&  O
lt  O
;  O
0.001  O
)  O
.  O

Additional  O
DLTs  O
included  O
grade  O
4  O
diarrhea  B-TOXI
and  O
grade  O
4  O
stomatitis  B-TOXI
in  O
one  O
patient  O
each  O
.  O

The  O
MTD  O
was  O
determined  O
to  O
be  O
gemcitabine  B-DRUG
800  O
mg  O
/  O
m2  O
and  O
docetaxel  B-DRUG
40  O
mg  O
/  O
m2  O
in  O
patients  O
who  O
had  O
received  O
two  O
or  O
more  O
prior  O
chemotherapy  O
regimens  O
.  O

However  O
,  O
minimally  O
pretreated  O
patients  O
(  O
no  O
more  O
than  O
one  O
prior  O
chemotherapy  O
regimen  O
)  O
were  O
able  O
to  O
tolerate  O
higher  O
doses  O
with  O
an  O
MTD  O
of  O
gemcitabine  B-DRUG
1,250  O
mg  O
/  O
m2  O
and  O
docetaxel  B-DRUG
40  O
mg  O
/  O
m2  O
.  O

There  O
were  O
no  O
significant  O
differences  O
in  O
toxicities  O
or  O
pharmacokinetics  O
between  O
the  O
two  O
sequences  O
of  O
administration  O
.  O

Partial  O
and  O
minor  O
responses  O
were  O
observed  O
in  O
23.5  O
%  O
of  O
patients  O
:  O
non-small-cell  B-CANCER
lung  I-CANCER
(  O
two  O
of  O
eight  O
)  O
,  O
gastric  B-CANCER
(  O
two  O
of  O
three  O
)  O
,  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
(  O
one  O
of  O
two  O
)  O
,  O
bladder  B-CANCER
(  O
two  O
of  O
four  O
)  O
and  O
hepatocellular  B-CANCER
cancer  I-CANCER
(  O
one  O
of  O
one  O
)  O
.  O

The  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
administered  O
on  O
days  O
1  O
and  O
8  O
every  O
21  O
days  O
was  O
feasible  O
and  O
well  O
tolerated  O
in  O
patients  O
with  O
advanced  B-CANCER
malignancies  I-CANCER
.  O

The  O
sequence  O
of  O
administration  O
had  O
no  O
significant  O
effect  O
on  O
the  O
toxicity  O
or  O
pharmacokinetics  O
of  O
either  O
drug  O
.  O

Minimally  O
pretreated  O
patients  O
tolerated  O
higher  O
doses  O
of  O
this  O
combination  O
without  O
significant  O
toxicities  O
.  O

This  O
schedule  O
and  O
combination  O
demonstrated  O
activity  O
in  O
a  O
variety  O
of  O
solid  B-CANCER
tumors  I-CANCER
,  O
and  O
merits  O
further  O
evaluation  O
.  O

Dose  O
and  O
schedule-finding  O
study  O
of  O
oral  O
topotecan  B-DRUG
and  O
weekly  O
cisplatin  B-DRUG
in  O
patients  O
with  O
recurrent  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O


Both  O
weekly  O
cisplatin  B-DRUG
chemotherapy  O
and  O
single  O
agent  O
topotecan  B-DRUG
have  O
proven  O
to  O
be  O
effective  O
in  O
recurrent  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

Preclinical  O
data  O
show  O
synergism  O
between  O
cisplatin  B-DRUG
and  O
topotecan  B-DRUG
.  O

Side  O
effects  O
for  O
this  O
combination  O
are  O
drug  O
sequence  O
dependent  O
and  O
predominantly  O
haematologic  O
.  O

Since  O
preclinical  O
data  O
suggest  O
that  O
Cremophor  B-DRUG
EL  I-DRUG
(  O
CrEL  B-DRUG
)  O
,  O
the  O
formulation  O
vehicle  O
of  O
paclitaxel  B-DRUG
,  O
has  O
a  O
protective  O
effect  O
on  O
haematological  B-TOXI
toxicity  I-TOXI
of  O
cisplatin  B-DRUG
,  O
CrEL  B-DRUG
was  O
added  O
to  O
the  O
combination  O
cisplatin  B-DRUG
and  O
topotecan  B-DRUG
.  O

In  O
this  O
phase  O
I  O
study  O
,  O
escalating  O
doses  O
of  O
oral  O
topotecan  B-DRUG
administered  O
on  O
day  O
1  O
,  O
2  O
,  O
8  O
,  O
9  O
,  O
15  O
,  O
16  O
,  O
29  O
,  O
30  O
,  O
36  O
,  O
37  O
,  O
43  O
,  O
44  O
were  O
combined  O
with  O
weekly  O
cisplatin  B-DRUG
70  O
mg  O
m  O
(  O
-2  O
)  O
d  O
(  O
-1  O
)  O
on  O
day  O
1  O
,  O
8  O
,  O
15  O
,  O
29  O
,  O
36  O
,  O
43  O
(  O
scheme  O
A  O
)  O
or  O
with  O
the  O
presumably  O
less  O
myelotoxic  O
sequence  O
weekly  O
cisplatin  B-DRUG
day  O
2  O
,  O
9  O
,  O
16  O
,  O
30  O
,  O
37  O
,  O
44  O
(  O
scheme  O
B  O
)  O
.  O

In  O
scheme  O
C  O
,  O
CrEL  B-DRUG
12  O
ml  O
was  O
administered  O
prior  O
to  O
cisplatin  B-DRUG
in  O
the  O
sequence  O
of  O
Scheme  O
A.  O
18  O
patients  O
have  O
received  O
a  O
total  O
of  O
85  O
courses  O
.  O

In  O
scheme  O
A  O
4  O
/  O
10  O
patients  O
,  O
all  O
treated  O
with  O
topotecan  B-DRUG
0.45  O
mg  O
m  O
(  O
-2  O
)  O
d  O
(  O
-1  O
)  O
,  O
experienced  O
DLT  O
:  O
1  O
patient  O
had  O
vomiting  B-TOXI
grade  O
4  O
,  O
1  O
patient  O
had  O
grade  O
4  O
neutropenia  B-TOXI
&  O
gt  O
;  O
5  O
days  O
,  O
1  O
patient  O
had  O
&  O
gt  O
;  O
2  O
weeks  O
delay  O
due  O
to  O
thrombocytopenia  B-TOXI
and  O
1  O
patient  O
due  O
to  O
neutropenia  B-TOXI
.  O

Both  O
patients  O
in  O
scheme  O
B  O
(  O
topotecan  B-DRUG
0.45  O
mg  O
m  O
(  O
-2  O
)  O
d  O
(  O
-1  O
)  O
)  O
had  O
DLT  O
due  O
to  O
a  O
delay  O
&  O
gt  O
;  O
2  O
weeks  O
because  O
of  O
prolonged  O
haematological  B-TOXI
toxicity  I-TOXI
.  O

No  O
DLT  O
was  O
observed  O
in  O
the  O
first  O
3  O
patients  O
in  O
scheme  O
C  O
(  O
topotecan  B-DRUG
0.45  O
mg  O
m  O
(  O
-2  O
)  O
d  O
(  O
-1  O
)  O
)  O
.  O

However  O
,  O
2  O
out  O
of  O
3  O
patients  O
treated  O
at  O
dose  O
level  O
topotecan  B-DRUG
0.60  O
mg  O
m  O
(  O
-2  O
)  O
d  O
(  O
-1  O
)  O
in  O
scheme  O
C  O
experienced  O
DLT  O
due  O
to  O
&  O
gt  O
;  O
2  O
weeks  O
delay  O
because  O
of  O
persistent  O
thrombocytopenia  B-TOXI
or  O
neutropenia  B-TOXI
.  O

We  O
conclude  O
that  O
there  O
is  O
a  O
modest  O
clinical  O
effect  O
of  O
CrEL  B-DRUG
on  O
haematological  B-TOXI
toxicity  I-TOXI
for  O
this  O
cisplatin-based  B-DRUG
combination  O
regimen  O
,  O
which  O
seems  O
to  O
reduce  O
these  O
side  O
effects  O
but  O
does  O
not  O
really  O
enable  O
an  O
increase  O
of  O
the  O
oral  O
topotecan  B-DRUG
dose  O
.  O

Phase  O
I  O
study  O
to  O
evaluate  O
multiple  O
regimens  O
of  O
intravenous  O
5-fluorouracil  B-DRUG
administered  O
in  O
combination  O
with  O
weekly  O
gemcitabine  O
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
:  O
a  O
potential  O
broadly  O
active  O
regimen  O
for  O
advanced  B-CANCER
solid  I-CANCER
tumor  I-CANCER
malignancies  I-CANCER
.  O


The  O
purpose  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
and  O
toxicity  O
profile  O
of  O
gemcitabine  B-DRUG
given  O
on  O
a  O
weekly  O
schedule  O
with  O
continuous  O
infusion  O
5-fluorouracil  B-DRUG
.  O

Eligible  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
received  O
escalating  O
doses  O
of  O
gemcitabine  B-DRUG
200  O
and  O
300  O
mg  O
/  O
m  O
(  O
2  O
)  O
weekly  O
as  O
a  O
30-minute  O
infusion  O
on  O
Days  O
1  O
,  O
8  O
,  O
and  O
15  O
every  O
4  O
weeks  O
(  O
schedule  O
1  O
)  O
or  O
450  O
,  O
600  O
,  O
800  O
,  O
1000  O
,  O
1250  O
,  O
1500  O
,  O
1800  O
,  O
and  O
2200  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
Days  O
1  O
and  O
8  O
(  O
schedule  O
2  O
)  O
every  O
3  O
weeks  O
,  O
respectively  O
.  O

At  O
the  O
completion  O
of  O
gemcitabine  B-DRUG
infusion  O
(  O
Day  O
1  O
)  O
,  O
patients  O
received  O
fixed  O
dose  O
continuous  O
infusion  O
of  O
5-fluorouracil  B-DRUG
at  O
either  O
300  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
Days  O
1-21  O
)  O
or  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
Days  O
1-21  O
;  O
schedule  O
1  O
)  O
every  O
4  O
weeks  O
or  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
Days  O
1-14  O
;  O
schedule  O
2  O
]  O
every  O
3  O
weeks  O
,  O
respectively  O
.  O

Toxicity  O
assessments  O
were  O
performed  O
weekly  O
on  O
study  O
,  O
and  O
efficacy  O
measurements  O
were  O
performed  O
every  O
6-8  O
weeks  O
.  O

Seventy  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
malignancies  I-CANCER
received  O
a  O
total  O
of  O
220  O
cycles  O
of  O
combination  O
chemotherapy  O
.  O

Eleven  O
(  O
14.3  O
%  O
)  O
patients  O
received  O
no  O
more  O
than  O
1  O
treatment  O
cycle  O
of  O
combination  O
therapy  O
.  O

Schedule  O
1  O
maximum  O
tolerated  O
dose  O
of  O
gemcitabine  B-DRUG
was  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
when  O
combined  O
with  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
at  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
(  O
Days  O
1-21  O
)  O
repeated  O
every  O
4  O
weeks  O
.  O

The  O
schedule  O
2  O
maximum  O
tolerated  O
dose  O
of  O
gemcitabine  B-DRUG
was  O
2200  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
when  O
combined  O
with  O
5-FU  B-DRUG
dosed  O
at  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
(  O
Days  O
1-14  O
)  O
repeated  O
every  O
3  O
weeks  O
.  O

In  O
schedule  O
1  O
,  O
the  O
limiting  O
factor  O
for  O
gemcitabine  B-DRUG
delivery  O
was  O
the  O
Day  O
15  O
dose  O
that  O
often  O
was  O
omitted  O
because  O
of  O
myelosuppression  B-TOXI
and  O
/  O
or  O
mucositis  B-TOXI
.  O

In  O
schedule  O
1  O
cycle  O
1  O
,  O
nonhematologic  B-TOXI
toxicity  I-TOXI
was  O
common  O
and  O
included  O
Grade  O
3-4  O
toxicities  O
:  O
mucositis  B-TOXI
(  O
8  O
patients  O
)  O
,  O
fatigue  B-TOXI
(  O
2  O
patients  O
)  O
,  O
and  O
anorexia  B-TOXI
(  O
1  O
patient  O
)  O
.  O

One  O
patient  O
had  O
Grade  O
3-4  O
neutropenia  B-TOXI
at  O
dose  O
level  O
5  O
(  O
maximum  O
tolerated  O
dose  O
)  O
.  O

In  O
schedule  O
2  O
cycle  O
1  O
,  O
hematologic  B-TOXI
toxicities  I-TOXI
were  O
more  O
common  O
than  O
nonhematologic  B-TOXI
toxicity  I-TOXI
and  O
included  O
Grade  O
3  O
anemia  B-TOXI
(  O
3  O
patients  O
)  O
,  O
Grade  O
3  O
neutropenia  B-TOXI
(  O
4  O
patients  O
)  O
,  O
and  O
Grade  O
3  O
thrombocytopenia  B-TOXI
(  O
2  O
patients  O
)  O
.  O

The  O
nonhematologic  B-TOXI
toxicities  I-TOXI
included  O
Grade  O
3  O
mucositis  B-TOXI
(  O
3  O
patients  O
)  O
,  O
Grade  O
3  O
fatigue  B-TOXI
(  O
2  O
patients  O
)  O
,  O
and  O
Grade  O
3  O
dehydration  B-TOXI
(  O
1  O
patient  O
)  O
.  O

Overall  O
,  O
antitumor  O
activity  O
was  O
observed  O
in  O
seven  O
patients  O
.  O

Three  O
of  O
30  O
patients  O
with  O
cytokine  O
refractory  O
renal  B-CANCER
cell  I-CANCER
carcinoma  I-CANCER
(  O
RCC  B-CANCER
;  O
relative  O
risk  O
[  O
RR  O
]  O
10  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
[  O
CI  O
]  O
,  O
0.82-22  O
%  O
)  O
had  O
a  O
partial  O
response  O
.  O

Of  O
the  O
remaining  O
27  O
patients  O
with  O
RCC  B-CANCER
,  O
4  O
patients  O
had  O
a  O
minor  O
response  O
,  O
and  O
10  O
patients  O
had  O
stable  O
disease  O
lasting  O
a  O
median  O
of  O
6.4  O
(  O
range  O
,  O
4-12  O
)  O
months  O
.  O

The  O
remaining  O
5  O
responses  O
occurred  O
in  O
40  O
patients  O
(  O
RR  O
,  O
12.5  O
%  O
;  O
95  O
%  O
CI  O
,  O
4.2-26.8  O
%  O
)  O
:  O
2  O
patients  O
with  O
5-FU  B-DRUG
refractory  O
colon  B-CANCER
carcinoma  I-CANCER
,  O
1  O
patient  O
with  O
hepatoma  B-CANCER
,  O
1  O
patient  O
with  O
paclitaxel-cisplatin-resistant  B-DRUG
ovarian  B-CANCER
carcinoma  I-CANCER
,  O
and  O
1  O
patient  O
with  O
cisplatin-resistant  B-DRUG
head  B-CANCER
and  I-CANCER
neck  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
had  O
a  O
partial  O
response  O
.  O

For  O
Phase  O
II  O
development  O
,  O
gemcitabine  B-DRUG
450-600  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
Days  O
1  O
,  O
8  O
,  O
and  O
15  O
can  O
be  O
safely  O
combined  O
with  O
5-FU  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
given  O
as  O
a  O
continuous  O
infusion  O
(  O
Days  O
1-21  O
)  O
of  O
a  O
28-day  O
cycle  O
or  O
gemcitabine  B-DRUG
1800  O
mg  O
/  O
m  O
(  O
2  O
)  O
Days  O
1  O
and  O
8  O
given  O
with  O
5-FU  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
continuous  O
infusion  O
(  O
Days  O
1-14  O
)  O
of  O
a  O
21-day  O
cycle  O
.  O

The  O
observed  O
antitumor  O
activity  O
in  O
several  O
solid  B-CANCER
tumors  I-CANCER
,  O
especially  O
in  O
renal  B-CANCER
cell  I-CANCER
carcinoma  I-CANCER
,  O
warrants  O
broad  O
Phase  O
II  O
evaluation  O
.  O

Phase  O
I  O
study  O
of  O
combination  O
topotecan  B-DRUG
and  O
carboplatin  B-DRUG
in  O
pediatric  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


We  O
conducted  O
a  O
phase  O
I  O
trial  O
of  O
escalating  O
doses  O
of  O
topotecan  B-DRUG
(  O
TOPO  B-DRUG
)  O
in  O
association  O
with  O
a  O
fixed  O
systemic  O
exposure  O
of  O
carboplatin  B-DRUG
(  O
CARBO  B-DRUG
)  O
with  O
or  O
without  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
(  O
G-CSF  O
)  O
in  O
children  O
.  O

Two  O
separate  O
cohorts  O
of  O
patients  O
(  O
pts  O
)  O
with  O
solid  B-CANCER
tumors  I-CANCER
were  O
studied  O
:  O
(  O
A  O
)  O
pts  O
with  O
refractory  O
or  O
recurrent  O
disease  O
and  O
(  O
B  O
)  O
pts  O
with  O
no  O
prior  O
myelosuppressive  O
therapy  O
or  O
newly  B-CANCER
diagnosed  I-CANCER
tumors  I-CANCER
for  O
which  O
there  O
was  O
no  O
standard  O
chemotherapy  O
.  O

CARBO  B-DRUG
was  O
given  O
on  O
day  O
1  O
at  O
an  O
area  O
under  O
the  O
curve  O
of  O
6.5  O
,  O
followed  O
by  O
TOPO  B-DRUG
as  O
a  O
continuous  O
infusion  O
for  O
3  O
days  O
;  O
the  O
starting  O
dose  O
of  O
TOPO  B-DRUG
was  O
0.50  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d.  O
Cycles  O
were  O
repeated  O
every  O
21  O
days  O
.  O

G-CSF  B-DRUG
was  O
given  O
at  O
a  O
dose  O
of  O
5  O
microg  O
/  O
kg  O
/  O
d  O
starting  O
on  O
day  O
4.  O
Forty-eight  O
of  O
51  O
pts  O
were  O
assessable  O
for  O
toxicity  O
.  O

In  O
group  O
A  O
,  O
dose-limiting  O
myelosuppression  B-TOXI
persisted  O
despite  O
de-escalation  O
of  O
TOPO  B-DRUG
to  O
0.3  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
and  O
use  O
of  O
G-CSF  B-DRUG
.  O

In  O
group  O
B  O
,  O
the  O
maximum-tolerated  O
dose  O
of  O
TOPO  B-DRUG
was  O
0.5  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
for  O
3  O
days  O
,  O
and  O
0.6  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
for  O
3  O
days  O
with  O
G-CSF  B-DRUG
.  O

No  O
significant  O
nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
observed  O
.  O

Among  O
46  O
pts  O
assessable  O
for  O
response  O
,  O
one  O
had  O
complete  O
response  O
,  O
five  O
had  O
partial  O
response  O
,  O
and  O
18  O
had  O
stable  O
disease  O
.  O

Although  O
this  O
combination  O
possesses  O
antineoplastic  O
activity  O
in  O
pediatric  B-CANCER
solid  I-CANCER
tumors  I-CANCER
,  O
hematologic  B-TOXI
toxicity  I-TOXI
precluded  O
any  O
meaningful  O
TOPO  B-DRUG
dose  O
escalation  O
.  O

The  O
addition  O
of  O
G-CSF  B-DRUG
did  O
not  O
alter  O
this  O
.  O

The  O
potential  O
for  O
preservation  O
of  O
activity  O
and  O
diminution  O
of  O
toxicity  O
with  O
alternative  O
sequences  O
and  O
schedules  O
of  O
administration  O
(  O
topoisomerase  B-DRUG
followed  O
by  O
alkylating  B-DRUG
or  I-DRUG
platinating  I-DRUG
agents  I-DRUG
)  O
should  O
be  O
evaluated  O
.  O

A  O
phase  O
I-II  O
study  O
on  O
a  O
gemcitabine-cyclophosphamide-fluorouracil  B-DRUG
/  B-DRUG
folinic  I-DRUG
acid  I-DRUG
triplet  O
combination  O
in  O
anthracycline-  B-DRUG
and  O
taxane-refractory  B-DRUG
breast  B-CANCER
cancer  I-CANCER
patients  O
.  O


To  O
define  O
the  O
cyclophosphamide  B-DRUG
(  O
CTX  B-DRUG
)  O
maximal  O
tolerated  O
dose  O
when  O
combined  O
with  O
fixed  O
doses  O
of  O
gemcitabine  B-DRUG
,  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
and  O
folinic  B-DRUG
acid  I-DRUG
(  O
leucovorin  B-DRUG
,  O
LFA  B-DRUG
)  O
in  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
pretreated  O
with  O
anthracyclines  B-DRUG
and  O
taxanes  B-DRUG
.  O

Metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
aged  O
&  O
lt  O
;  O
or  O
=  O
75  O
years  O
,  O
with  O
ECOG  O
performance  O
status  O
0-2  O
,  O
were  O
eligible  O
,  O
provided  O
that  O
they  O
had  O
received  O
previous  O
anthracycline-  B-DRUG
and  O
taxane-based  B-DRUG
chemotherapy  O
for  O
the  O
advanced  O
disease  O
.  O

Chemotherapy  O
consisted  O
of  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
5-FU  O
425  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
LFA  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
escalating  O
doses  O
of  O
CTX  B-DRUG
,  O
starting  O
from  O
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
on  O
days  O
1  O
and  O
8  O
every  O
3  O
weeks  O
.  O

The  O
dose  O
escalation  O
was  O
stopped  O
if  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
occurred  O
in  O
&  O
gt  O
;  O
33  O
%  O
of  O
patients  O
of  O
a  O
given  O
cohort  O
.  O

After  O
the  O
definition  O
of  O
DLT  O
,  O
a  O
further  O
escalation  O
with  O
the  O
addition  O
of  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
(  O
G-CSF  B-DRUG
;  O
on  O
days  O
3-5  O
and  O
10-12  O
)  O
was  O
planned  O
.  O

Since  O
March  O
1999  O
,  O
69  O
patients  O
have  O
entered  O
this  O
trial  O
through  O
seven  O
different  O
cohorts  O
.  O

The  O
dose  O
escalation  O
was  O
stopped  O
at  O
the  O
CTX  B-DRUG
dose  O
of  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
since  O
3  O
/  O
6  O
patients  O
showed  O
DLT  O
.  O

A  O
further  O
dose  O
escalation  O
was  O
attempted  O
in  O
the  O
presence  O
of  O
G-CSF  B-DRUG
support  O
.  O

A  O
CTX  B-DRUG
dose  O
of  O
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
proved  O
to  O
be  O
safe  O
and  O
was  O
chosen  O
for  O
the  O
phase  O
II  O
.  O

A  O
total  O
of  O
33  O
patients  O
were  O
treated  O
at  O
this  O
dose  O
level  O
.  O

The  O
treatment  O
was  O
fairly  O
well  O
tolerated  O
,  O
grade  O
3-4  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
occurring  O
in  O
38  O
and  O
16  O
%  O
of  O
patients  O
,  O
respectively  O
.  O

No  O
cases  O
of  O
sepsis  B-TOXI
or  O
bleeding  B-TOXI
were  O
registered  O
.  O

Four  O
patients  O
required  O
a  O
packed  O
red  O
blood  O
cell  O
transfusion  O
.  O

Severe  O
nonhematologic  B-TOXI
toxicity  I-TOXI
was  O
also  O
uncommon  O
,  O
occurring  O
in  O
10  O
patients  O
.  O

Three  O
complete  O
and  O
24  O
partial  O
responses  O
were  O
recorded  O
for  O
an  O
overall  O
response  O
rate  O
of  O
38  O
%  O
(  O
95  O
%  O
CI  O
=  O
26-50  O
)  O
.  O

Two  O
complete  O
and  O
12  O
partial  O
responses  O
were  O
recorded  O
in  O
the  O
33  O
patients  O
treated  O
in  O
the  O
phase  O
II  O
for  O
an  O
overall  O
response  O
rate  O
(  O
ORR  O
)  O
of  O
42  O
%  O
(  O
95  O
%  O
CI  O
=  O
25-61  O
)  O
.  O

The  O
gemcitabine-CTX-5-FU  B-DRUG
/  B-DRUG
LFA  I-DRUG
combination  O
is  O
a  O
well-tolerated  O
treatment  O
for  O
poor-prognosis  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
with  O
previous  O
exposure  O
to  O
anthracyclines  B-DRUG
and  O
taxanes  B-DRUG
.  O

With  O
the  O
addition  O
of  O
G-CSF  B-DRUG
,  O
a  O
cumulative  O
CTX  B-DRUG
dose  O
of  O
1,600  O
mg  O
/  O
m  O
(  O
2  O
)  O
can  O
be  O
safely  O
delivered  O
every  O
3  O
weeks  O
.  O

The  O
evidence  O
of  O
an  O
ORR  O
approaching  O
40  O
%  O
is  O
very  O
promising  O
and  O
justifies  O
further  O
evaluations  O
in  O
this  O
subset  O
of  O
patients  O
.  O

Weekly  O
administration  O
of  O
gemcitabine  B-DRUG
plus  O
docetaxel  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
1  O
study  O
.  O


This  O
study  O
was  O
designed  O
to  O
determine  O
the  O
maximum  O
tolerable  O
dose  O
(  O
MTD  O
)  O
of  O
gemcitabine  B-DRUG
plus  O
docetaxel  B-DRUG
,  O
both  O
given  O
on  O
a  O
weekly  O
schedule  O
,  O
in  O
patients  O
with  O
pretreated  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
(  O
MBC  B-CANCER
)  O
.  O

Heavily  O
pretreated  O
patients  O
with  O
MBC  B-CANCER
,  O
aged  O
18-75  O
years  O
with  O
World  O
Health  O
Organization  O
performance  O
status  O
of  O
0-2  O
were  O
enrolled  O
.  O

Three  O
escalating  O
weekly  O
doses  O
of  O
docetaxel  B-DRUG
(  O
30  O
,  O
35  O
and  O
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
followed  O
by  O
a  O
weekly  O
fixed  O
dose  O
of  O
gemcitabine  B-DRUG
,  O
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
were  O
administered  O
on  O
days  O
1  O
,  O
8  O
and  O
15  O
of  O
a  O
28-day  O
cycle  O
.  O

Dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
included  O
grade  O
&  O
gt  O
;  O
3  O
hematologic  B-TOXI
toxicity  I-TOXI
and  O
grade  O
&  O
gt  O
;  O
2  O
stomatitis  B-TOXI
,  O
asthenia  B-TOXI
,  O
diarrhea  B-TOXI
or  O
organ-specific  B-TOXI
toxicity  I-TOXI
(  O
except  O
alopecia  B-TOXI
)  O
.  O

Dose  O
escalation  O
was  O
stopped  O
if  O
&  O
gt  O
;  O
or  O
=  O
3  O
of  O
5  O
patients  O
at  O
any  O
dose  O
level  O
experienced  O
DLT  O
.  O

Eighteen  O
patients  O
(  O
median  O
age  O
56  O
years  O
)  O
received  O
a  O
mean  O
of  O
4.1  O
(  O
range  O
1-6  O
)  O
cycles  O
.  O

Asthenia  B-TOXI
,  O
stomatitis  B-TOXI
and  O
leukopenia  B-TOXI
were  O
the  O
main  O
DLTs  O
.  O

One  O
of  O
5  O
patients  O
had  O
DLT  O
at  O
dose  O
level  O
1  O
and  O
2  O
of  O
5  O
patients  O
at  O
dose  O
level  O
2.  O
At  O
dose  O
level  O
3  O
,  O
3  O
of  O
5  O
patients  O
had  O
DLTs  O
.  O

Three  O
additional  O
patients  O
treated  O
at  O
dose  O
level  O
3  O
confirmed  O
that  O
the  O
MTD  O
had  O
been  O
reached  O
.  O

Therefore  O
,  O
the  O
recommended  O
docetaxel  B-DRUG
dose  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
for  O
phase  O
II  O
studies  O
was  O
established  O
at  O
the  O
next  O
lower  O
dose  O
,  O
35  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Of  O
12  O
evaluable  O
patients  O
,  O
7  O
(  O
58  O
%  O
)  O
achieved  O
an  O
objective  O
response  O
.  O

Gemcitabine  B-DRUG
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
docetaxel  B-DRUG
35  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
,  O
8  O
and  O
15  O
of  O
a  O
28-day  O
cycle  O
is  O
a  O
safe  O
regimen  O
which  O
shows  O
activity  O
in  O
heavily  O
pretreated  O
patients  O
with  O
MBC  B-CANCER
.  O

Further  O
phase  O
II  O
investigations  O
with  O
this  O
combination  O
are  O
now  O
warranted  O
.  O

Infusional  O
5-fluorouracil  B-DRUG
,  O
cisplatin  B-DRUG
and  O
mitomycin  B-DRUG
C  I-DRUG
in  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
:  O
a  O
low  O
cost  O
effective  O
regimen  O
.  O


Recently  O
,  O
we  O
reported  O
a  O
highly  O
active  O
regimen  O
in  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
including  O
a  O
weekly  O
administration  O
of  O
cisplatin  B-DRUG
,  O
epidoxorubicin  B-DRUG
,  O
leucovorin  B-DRUG
,  O
5-fluorouracil  B-DRUG
with  O
the  O
support  O
of  O
filgrastim  B-DRUG
.  O

In  O
order  O
to  O
simplify  O
the  O
administration  O
and  O
to  O
decrease  O
the  O
toxicity  O
of  O
these  O
drugs  O
,  O
mainly  O
epidoxorubicin-induced  B-DRUG
alopecia  B-TOXI
,  O
we  O
designed  O
a  O
regimen  O
including  O
an  O
infusional  O
5-fluorouracil  B-DRUG
schedule  O
according  O
to  O
the  O
de  O
Gramont  O
regimen  O
,  O
cisplatin  B-DRUG
and  O
mitomycin  B-DRUG
C  I-DRUG
replacing  O
epidoxorubicin  B-DRUG
.  O

Forty-five  O
patients  O
with  O
advanced  B-CANCER
or  I-CANCER
metastatic  I-CANCER
gastric  I-CANCER
cancer  I-CANCER
were  O
treated  O
with  O
cisplatin  B-DRUG
50  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
on  O
day  O
1  O
,  O
every  O
2  O
weeks  O
,  O
6S-stereoisomer-leucovorin  B-DRUG
100  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
followed  O
by  O
5-fluorouracil  B-DRUG
400  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
bolus  O
and  O
600  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
in  O
a  O
22-h  O
infusion  O
,  O
on  O
days  O
1  O
and  O
2  O
,  O
every  O
2  O
weeks  O
,  O
and  O
mitomycin  B-DRUG
C  I-DRUG
7  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
bolus  O
on  O
day  O
2  O
,  O
every  O
6  O
weeks  O
.  O

Grades  O
3-4  O
toxicities  O
(  O
National  O
Cancer  O
Institute-Common  O
Toxicity  O
Criteria  O
)  O
consisted  O
mainly  O
of  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
.  O

Five  O
patients  O
had  O
a  O
complete  O
response  O
and  O
16  O
had  O
a  O
partial  O
response  O
for  O
an  O
overall  O
response  O
rate  O
of  O
46.7  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
32.1-61.2  O
%  O
)  O
.  O

The  O
median  O
survival  O
was  O
11  O
months  O
.  O

The  O
combination  O
of  O
cisplatin  B-DRUG
,  O
5-fluorouracil  B-DRUG
and  O
leucovorin  B-DRUG
according  O
to  O
de  O
Gramont  O
,  O
and  O
mitomycin  B-DRUG
C  I-DRUG
seems  O
to  O
be  O
an  O
active  O
and  O
safe  O
regimen  O
in  O
the  O
treatment  O
of  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

Because  O
of  O
its  O
low  O
cost  O
it  O
may  O
be  O
suggested  O
for  O
patients  O
not  O
enrolled  O
into  O
clinical  O
trials  O
.  O

Multicentre  O
phase  O
II  O
study  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
malignant  B-CANCER
pleural  I-CANCER
mesothelioma  I-CANCER
.  O


Malignant  B-CANCER
pleural  I-CANCER
mesothelioma  I-CANCER
is  O
a  O
notoriously  O
chemoresistant  O
tumour  O
.  O

However  O
,  O
a  O
recent  O
single  O
institution  O
study  O
showed  O
an  O
impressive  O
activity  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
.  O

Our  O
aim  O
is  O
to  O
investigate  O
the  O
efficacy  O
and  O
toxicity  O
of  O
a  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
combination  O
in  O
selected  O
and  O
chemo-naive  O
patients  O
with  O
histologically  O
proven  O
malignant  B-CANCER
pleural  I-CANCER
mesothelioma  I-CANCER
.  O

Gemcitabine  B-DRUG
1250  O
mg  O
m  O
(  O
-2  O
)  O
was  O
administered  O
on  O
day  O
1  O
and  O
day  O
8  O
and  O
cisplatin  B-DRUG
80  O
mg  O
m  O
(  O
-2  O
)  O
was  O
administered  O
on  O
day  O
1  O
in  O
a  O
3-week  O
cycle  O
with  O
a  O
maximum  O
of  O
six  O
cycles  O
.  O

Response  O
and  O
toxicity  O
evaluations  O
were  O
performed  O
according  O
to  O
WHO  O
and  O
NCIC-CTC  O
criteria  O
.  O

Pathology  O
and  O
radiology  O
were  O
centrally  O
reviewed  O
.  O

Results  O
show  O
that  O
in  O
25  O
evaluable  O
patients  O
,  O
four  O
PR  O
were  O
observed  O
(  O
ORR  O
16  O
%  O
,  O
95  O
%  O
CI  O
1-31  O
%  O
)  O
.  O

Responses  O
of  O
seven  O
patients  O
were  O
unevaluable  O
.  O

No  O
unexpected  O
toxicity  O
occurred  O
.  O

Time  O
to  O
progression  O
was  O
6  O
months  O
(  O
5-7  O
months  O
)  O
with  O
a  O
median  O
survival  O
from  O
registration  O
of  O
9.6  O
months  O
(  O
95  O
%  O
CI  O
8-12  O
months  O
)  O
.  O

In  O
conclusion  O
this  O
trial  O
excludes  O
with  O
90  O
%  O
power  O
a  O
response  O
rate  O
of  O
greater  O
than  O
30  O
%  O
in  O
patients  O
with  O
malignant  B-CANCER
pleural  I-CANCER
mesothelioma  I-CANCER
using  O
a  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
at  O
the  O
proposed  O
dose  O
and  O
schedule  O
.  O

Phase  O
II  O
study  O
of  O
paclitaxel  B-DRUG
plus  O
gemcitabine  B-DRUG
in  O
refractory  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
(  O
E9897  O
)  O
:  O
a  O
trial  O
of  O
the  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
.  O


Despite  O
great  O
success  O
in  O
the  O
treatment  O
of  O
disseminated  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
,  O
20  O
%  O
of  O
patients  O
are  O
incurable  O
and  O
become  O
candidates  O
for  O
investigational  O
therapy  O
.  O

Paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
have  O
shown  O
activity  O
as  O
single  O
agents  O
in  O
refractory  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
and  O
can  O
be  O
combined  O
with  O
manageable  O
toxicity  O
.  O

Patients  O
with  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
believed  O
to  O
be  O
incurable  O
with  O
chemotherapy  O
or  O
surgery  O
were  O
treated  O
with  O
paclitaxel  B-DRUG
110  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenously  O
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
of  O
a  O
4-week  O
cycle  O
for  O
a  O
maximum  O
of  O
six  O
cycles  O
.  O

Patients  O
were  O
evaluated  O
for  O
response  O
and  O
toxicity  O
.  O

Twenty-eight  O
of  O
30  O
enrolled  O
patients  O
were  O
assessable  O
.  O

Toxicity  O
was  O
primarily  O
hematologic  O
but  O
was  O
manageable  O
with  O
only  O
a  O
single  O
case  O
of  O
neutropenic  B-TOXI
fever  I-TOXI
.  O

Six  O
(  O
21.4  O
%  O
)  O
of  O
28  O
patients  O
responded  O
,  O
including  O
three  O
complete  O
responses  O
.  O

Two  O
of  O
the  O
complete  O
responders  O
were  O
continuously  O
disease-free  O
at  O
15+  O
and  O
25+  O
months  O
.  O

Paclitaxel  B-DRUG
plus  O
gemcitabine  B-DRUG
is  O
an  O
active  O
regimen  O
in  O
refractory  O
germ  B-CANCER
cell  I-CANCER
tumors  I-CANCER
,  O
with  O
an  O
acceptable  O
toxicity  O
profile  O
.  O

This  O
regimen  O
has  O
the  O
possibility  O
for  O
long-term  O
disease-free  O
survival  O
in  O
this  O
refractory  O
patient  O
population  O
.  O

A  O
dose-finding  O
study  O
of  O
carboplatin-epirubicin-docetaxel  B-DRUG
in  O
advanced  B-CANCER
epithelial  I-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O


The  O
docetaxel-carboplatin  B-DRUG
combination  O
is  O
active  O
and  O
well  O
tolerated  O
in  O
patients  O
with  O
epithelial  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

We  O
added  O
epirubicin  B-DRUG
to  O
this  O
combination  O
to  O
investigate  O
additional  O
benefits  O
of  O
anthracyclines  B-DRUG
in  O
epithelial  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

Twenty-one  O
patients  O
,  O
FIGO  B-DRUG
Ic-IV  I-DRUG
,  O
performance  O
status  O
0-1  O
,  O
were  O
treated  O
in  O
four  O
dose  O
cohorts  O
.  O

Docetaxel  B-DRUG
was  O
fixed  O
at  O
75  O
mg  O
m  O
(  O
-2  O
)  O
,  O
carboplatin  B-DRUG
doses  O
were  O
AUC  O
4-5  O
and  O
epirubicin  B-DRUG
doses  O
were  O
50-60  O
mg  O
m  O
(  O
-2  O
)  O
.  O

Drugs  O
were  O
given  O
on  O
day  O
1  O
,  O
every  O
3  O
weeks  O
,  O
except  O
in  O
cohort  O
3  O
,  O
where  O
epirubicin  B-DRUG
was  O
given  O
on  O
day  O
8.  O
Dexamethasone  B-DRUG
was  O
given  O
prophylactically  O
.  O

One  O
dose-limiting  O
toxicity  O
occurred  O
in  O
cohorts  O
1  O
,  O
2  O
and  O
4  O
,  O
two  O
occurred  O
in  O
cohort  O
3.  O
Complicated  O
neutropenia  B-TOXI
occurred  O
in  O
two  O
patients  O
in  O
cohorts  O
1  O
and  O
2  O
and  O
one  O
patient  O
in  O
cohorts  O
3  O
and  O
4.  O
Two  O
patients  O
experienced  O
grade  O
III  O
diarrhoea  B-TOXI
or  O
stomatitis  B-TOXI
in  O
cohort  O
1  O
and  O
two  O
in  O
cohort  O
3.  O
There  O
were  O
no  O
treatment-related  B-TOXI
deaths  I-TOXI
.  O

Grade  O
II  O
sensory  B-TOXI
neuropathy  I-TOXI
occurred  O
in  O
one  O
patient  O
.  O

No  O
cardiac  O
toxicity  O
or  O
significant  O
oedema  B-TOXI
was  O
observed  O
.  O

The  O
overall  O
response  O
rate  O
was  O
36  O
%  O
,  O
and  O
62  O
%  O
were  O
CA125  O
responders  O
.  O

The  O
predefined  O
maximum  O
tolerated  O
dose  O
was  O
exceeded  O
in  O
cohort  O
3.  O
The  O
cohort  O
4  O
dose  O
level  O
(  O
epirubicin  B-DRUG
50  O
mg  O
m  O
(  O
-2  O
)  O
,  O
carboplatin  B-DRUG
AUC  O
4  O
,  O
docetaxel  B-DRUG
75  O
mg  O
m  O
(  O
-2  O
)  O
)  O
,  O
warrants  O
further  O
study  O
.  O

Schedule-selective  O
biochemical  O
modulation  O
of  O
5-fluorouracil  B-DRUG
in  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
--  O
a  O
phase  O
II  O
study  O
.  O


5-fluorouracil  B-DRUG
remains  O
the  O
standard  O
therapy  O
for  O
patients  O
with  O
advanced  B-CANCER
/  I-CANCER
metastatic  I-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Pre-clinical  O
studies  O
have  O
demonstrated  O
the  O
biological  O
modulation  O
of  O
5-fluorouracil  B-DRUG
by  O
methotrexate  B-DRUG
and  O
leucovorin  B-DRUG
.  O

This  O
phase  O
II  O
study  O
was  O
initiated  O
to  O
determine  O
the  O
activity  O
and  O
toxicity  O
of  O
sequential  O
methotrexate  B-DRUG
--  I-DRUG
leucovorin  I-DRUG
and  O
5-fluorouracil  B-DRUG
chemotherapy  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Ninety-seven  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
were  O
enrolled  O
onto  O
the  O
study  O
.  O

Methotrexate  B-DRUG
--  O
30  O
mg  O
/  O
m2  O
was  O
administered  O
every  O
6  O
hours  O
for  O
6  O
doses  O
followed  O
by  O
a  O
2  O
hour  O
infusion  O
of  O
LV  B-DRUG
--  O
500  O
mg  O
/  O
m2  O
.  O

Midway  O
through  O
the  O
leucovorin  B-DRUG
infusion  O
,  O
patients  O
received  O
5-fluorouracil  B-DRUG
--  O
600  O
mg  O
/  O
m2  O
.  O

This  O
constituted  O
a  O
cycle  O
of  O
therapy  O
and  O
was  O
repeated  O
every  O
2  O
weeks  O
until  O
progression  O
.  O

The  O
median  O
age  O
was  O
64  O
yrs  O
(  O
34-84  O
)  O
and  O
the  O
Eastern  O
Cooperative  O
Group  O
Oncology  O
performance  O
score  O
was  O
0  O
in  O
37  O
%  O
,  O
1  O
in  O
55  O
%  O
and  O
2  O
in  O
8  O
%  O
of  O
patients  O
.  O

Partial  O
and  O
complete  O
responses  O
were  O
seen  O
in  O
31  O
%  O
of  O
patients  O
with  O
a  O
median  O
duration  O
of  O
response  O
of  O
6.4  O
months  O
.  O

The  O
overall  O
median  O
survival  O
was  O
13.0  O
months  O
.  O

The  O
estimated  O
1-year  O
survival  O
was  O
53.7  O
%  O
.  O

Grade  O
III  O
and  O
IV  O
toxic  O
effects  O
were  O
modest  O
and  O
included  O
mucositis  B-TOXI
,  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
.  O

This  O
phase  O
II  O
study  O
supports  O
previously  O
reported  O
data  O
demonstrating  O
the  O
modest  O
clinical  O
benefit  O
of  O
5-FU  B-DRUG
modulation  O
utilizing  O
methotrexate  B-DRUG
and  O
leucovorin  B-DRUG
in  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Ongoing  O
studies  O
evaluating  O
5-fluorouracil  B-DRUG
modulation  O
with  O
more  O
novel  O
agents  O
(  O
Irinotecan  B-DRUG
and  O
/  O
or  O
oxaliplatin  B-DRUG
)  O
are  O
in  O
progress  O
and  O
may  O
prove  O
encouraging  O
.  O

Triplet  O
combination  O
with  O
irinotecan  B-DRUG
plus  O
oxaliplatin  B-DRUG
plus  O
continuous-infusion  O
fluorouracil  B-DRUG
and  O
leucovorin  B-DRUG
as  O
first-line  O
treatment  O
in  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
:  O
a  O
multicenter  O
phase  O
II  O
trial  O
.  O


To  O
evaluate  O
the  O
efficacy  O
and  O
tolerance  O
of  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
in  O
combination  O
with  O
oxaliplatin  B-DRUG
(  O
L-OHP  B-DRUG
)  O
plus  O
fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
/  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
(  O
de  O
Gramont  O
regimen  O
)  O
as  O
first-line  O
treatment  O
of  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
(  O
MCC  B-CANCER
)  O
.  O

Thirty-one  O
patients  O
with  O
MCC  B-CANCER
who  O
had  O
not  O
received  O
prior  O
therapy  O
for  O
metastatic  O
disease  O
were  O
enrolled  O
.  O

Their  O
median  O
age  O
was  O
60  O
years  O
;  O
performance  O
status  O
(  O
World  O
Health  O
Organization  O
)  O
was  O
0  O
in  O
12  O
,  O
1  O
in  O
14  O
,  O
and  O
2  O
in  O
five  O
patients  O
;  O
19  O
patients  O
(  O
61  O
%  O
)  O
had  O
prior  O
surgery  O
,  O
and  O
14  O
(  O
45  O
%  O
)  O
had  O
adjuvant  O
chemotherapy  O
.  O

CPT-11  B-DRUG
was  O
administered  O
on  O
day  O
1  O
at  O
150  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
90-minute  O
intravenous  O
(  O
IV  O
)  O
infusion  O
;  O
L-OHP  B-DRUG
was  O
administered  O
on  O
day  O
2  O
at  O
65  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
2-hour  O
IV  O
infusion  O
;  O
and  O
on  O
days  O
2  O
and  O
3  O
,  O
LV  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
preceded  O
5-FU  B-DRUG
administration  O
of  O
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
initial  O
IV  O
bolus  O
dose  O
followed  O
by  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
22-hour  O
IV  O
continuous  O
infusion  O
.  O

The  O
regimen  O
was  O
repeated  O
every  O
2  O
weeks  O
.  O

All  O
patients  O
were  O
assessable  O
for  O
toxicity  O
and  O
30  O
for  O
response  O
to  O
treatment  O
.  O

Complete  O
response  O
was  O
achieved  O
in  O
two  O
patients  O
(  O
6.5  O
%  O
)  O
and  O
partial  O
response  O
in  O
16  O
(  O
51.6  O
%  O
)  O
(  O
overall  O
response  O
rate  O
,  O
58.1  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
,  O
40.7  O
%  O
to  O
75.4  O
%  O
)  O
;  O
eight  O
patients  O
(  O
25.8  O
%  O
)  O
had  O
stable  O
disease  O
,  O
and  O
five  O
(  O
16.1  O
%  O
)  O
had  O
disease  B-TOXI
progression  I-TOXI
.  O

The  O
median  O
duration  O
of  O
response  O
was  O
9  O
months  O
,  O
and  O
the  O
median  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
was  O
13  O
months  O
.  O

Neutropenia  B-TOXI
grade  O
3  O
to  O
4  O
occurred  O
in  O
14  O
patients  O
(  O
45  O
%  O
)  O
and  O
febrile  B-TOXI
neutropenia  I-TOXI
in  O
two  O
(  O
6  O
%  O
)  O
.  O

Diarrhea  B-TOXI
grade  O
3  O
to  O
4  O
was  O
observed  O
in  O
10  O
patients  O
(  O
32  O
%  O
)  O
,  O
neurotoxicity  B-TOXI
grade  O
3  O
to  O
4  O
in  O
three  O
(  O
9  O
%  O
)  O
,  O
and  O
asthenia  B-TOXI
grade  O
3  O
in  O
two  O
(  O
10  O
%  O
)  O
.  O

No  O
treatment-related  O
death  B-TOXI
has  O
occurred  O
.  O

The  O
triplet  O
combination  O
of  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
+  I-DRUG
CPT-11  I-DRUG
+  I-DRUG
L-OHP  I-DRUG
is  O
a  O
highly  O
active  O
regimen  O
with  O
manageable  O
toxicity  O
as  O
front-line  O
treatment  O
in  O
MCC  B-CANCER
.  O

Phase  O
I  O
clinical  O
and  O
pharmacokinetic  O
study  O
of  O
combination  O
chemotherapy  O
with  O
topotecan  B-DRUG
and  O
ifosfamide  B-DRUG
in  O
patients  O
with  O
progressive  O
or  O
relapsed  O
solid  B-CANCER
tumors  I-CANCER
.  O


Topotecan  B-DRUG
and  O
ifosfamide  B-DRUG
are  O
effective  O
in  O
the  O
treatment  O
of  O
various  O
solid  B-CANCER
tumors  I-CANCER
.  O

Up  O
to  O
the  O
time  O
of  O
this  O
study  O
,  O
the  O
two  O
drugs  O
have  O
been  O
combined  O
just  O
once  O
(  O
Smith  O
et  O
al.  O
1998  O
)  O
.  O

Due  O
to  O
its  O
hematotoxicity  B-TOXI
,  O
topotecan  B-DRUG
has  O
been  O
used  O
predominantly  O
within  O
monochemotherapy  O
protocols  O
.  O

However  O
,  O
the  O
combination  O
of  O
topotecan  B-DRUG
and  O
alkylating  B-DRUG
agents  I-DRUG
is  O
supra-additive  O
in  O
many  O
preclinical  O
models  O
.  O

This  O
phase-I  O
trial  O
was  O
primarily  O
performed  O
to  O
evaluate  O
the  O
maximum  O
tolerable  O
dose  O
(  O
MTD  O
)  O
and  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
of  O
a  O
combination  O
chemotherapy  O
with  O
topotecan  B-DRUG
and  O
ifosfamide  B-DRUG
using  O
a  O
5-day  O
schedule  O
.  O

A  O
secondary  O
goal  O
was  O
to  O
estimate  O
the  O
response  O
rate  O
in  O
a  O
group  O
of  O
heavily  O
pretreated  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

The  O
pharmacokinetics  O
of  O
topotecan  B-DRUG
were  O
preliminarily  O
determined  O
in  O
some  O
of  O
the  O
patients  O
.  O

A  O
total  O
of  O
12  O
patients  O
(  O
three  O
female  O
/  O
nine  O
male  O
)  O
,  O
median  O
age  O
49  O
years  O
(  O
range  O
19-69  O
)  O
,  O
11  O
with  O
prior  O
chemotherapy  O
,  O
received  O
a  O
total  O
of  O
24  O
courses  O
of  O
chemotherapy  O
at  O
three  O
dose-levels  O
of  O
topotecan  B-DRUG
.  O

Ifosfamide  B-DRUG
was  O
administered  O
by  O
intravenous  O
infusion  O
over  O
3  O
h  O
immediately  O
followed  O
by  O
a  O
30-min  O
infusion  O
of  O
topotecan  B-DRUG
.  O

Mesna  B-DRUG
(  O
3  O
x  O
300  O
mg  O
x  O
m  O
(  O
2  O
)  O
x  O
day  O
)  O
was  O
given  O
routinely  O
during  O
chemotherapy  O
as  O
a  O
uroprotector  O
.  O

G-CSF  B-DRUG
(  O
filgrastim  B-DRUG
)  O
was  O
permitted  O
only  O
in  O
cases  O
of  O
febrile  B-TOXI
neutropenia  I-TOXI
(  O
FN  B-TOXI
)  O
.  O

The  O
major  O
toxicity  O
was  O
non-hematologic  O
;  O
severe  B-TOXI
liver  I-TOXI
and  I-TOXI
renal  I-TOXI
toxicity  I-TOXI
were  O
observed  O
in  O
three  O
out  O
of  O
11  O
patients  O
.  O

Two  O
treatment-related  B-TOXI
deaths  I-TOXI
occurred  O
.  O

No  O
clinical  O
remissions  O
occurred  O
in  O
11  O
evaluable  O
patients  O
.  O

The  O
pharmacokinetics  O
of  O
topotecan  B-DRUG
were  O
relatively  O
similar  O
in  O
our  O
patients  O
and  O
supported  O
findings  O
in  O
recent  O
literature  O
.  O

The  O
MTD  O
of  O
this  O
combination  O
was  O
defined  O
at  O
dose-level  O
2  O
(  O
1.0  O
mg  O
/  O
m  O
(  O
2  O
)  O
of  O
topotecan  B-DRUG
and  O
750  O
mg  O
/  O
m  O
(  O
2  O
)  O
of  O
ifosfamide  B-DRUG
)  O
.  O

Further  O
trials  O
should  O
not  O
exceed  O
this  O
dose  O
.  O

The  O
pharmacological  O
causes  O
for  O
the  O
pronounced  O
toxicity  O
have  O
to  O
be  O
clarified  O
.  O

Cisplatin  B-DRUG
,  O
gemcitabine  B-DRUG
,  O
and  O
ifosfamide  B-DRUG
as  O
weekly  O
therapy  O
:  O
a  O
feasibility  O
and  O
phase  O
II  O
study  O
of  O
salvage  O
treatment  O
for  O
advanced  B-CANCER
transitional-cell  I-CANCER
carcinoma  I-CANCER
.  O


We  O
investigated  O
the  O
feasibility  O
,  O
safety  O
,  O
and  O
antitumor  O
activity  O
of  O
weekly  O
gemcitabine  B-DRUG
given  O
in  O
combination  O
with  O
low  O
doses  O
of  O
cisplatin  B-DRUG
and  O
ifosfamide  B-DRUG
in  O
previously  O
treated  O
patients  O
with  O
advanced  B-CANCER
transitional-cell  I-CANCER
carcinoma  I-CANCER
(  O
TCC  B-CANCER
)  O
of  O
the  O
urothelium  O
.  O

Patients  O
with  O
measurable  O
,  O
metastatic  O
or  O
unresectable  O
TCC  B-CANCER
who  O
had  O
received  O
one  O
or  O
two  O
prior  O
chemotherapy  O
regimens  O
were  O
eligible  O
.  O

On  O
a  O
28-day  O
course  O
,  O
doses  O
of  O
cisplatin  B-DRUG
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
gemcitabine  B-DRUG
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
ifosfamide  B-DRUG
1  O
g  O
/  O
m  O
(  O
2  O
)  O
were  O
given  O
on  O
day  O
1  O
and  O
then  O
repeated  O
on  O
day  O
8  O
and  O
day  O
15  O
unless  O
there  O
was  O
dose-limiting  O
hematologic  B-TOXI
toxicity  I-TOXI
.  O

Fifty-one  O
patients  O
were  O
registered  O
;  O
10  O
patients  O
participated  O
in  O
a  O
pilot  O
study  O
,  O
after  O
which  O
41  O
patients  O
were  O
registered  O
onto  O
the  O
phase  O
II  O
protocol  O
.  O

Forty-eight  O
patients  O
(  O
94.1  O
%  O
)  O
had  O
dose-limiting  O
hematologic  B-TOXI
toxicity  I-TOXI
on  O
day  O
8  O
or  O
day  O
15  O
.  O

Nonhematologic  B-TOXI
toxicity  I-TOXI
of  O
grade  O
3  O
or  O
greater  O
consisted  O
mainly  O
of  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
(  O
seven  O
patients  O
,  O
13.7  O
%  O
)  O
and  O
infection  B-TOXI
(  O
seven  O
patients  O
,  O
13.7  O
%  O
)  O
.  O

Responses  O
could  O
be  O
assessed  O
in  O
49  O
of  O
51  O
eligible  O
patients  O
;  O
two  O
complete  O
responses  O
(  O
4.1  O
%  O
)  O
and  O
18  O
partial  O
responses  O
(  O
36.7  O
%  O
)  O
were  O
observed  O
for  O
an  O
overall  O
response  O
rate  O
of  O
40.8  O
%  O
(  O
exact  O
95  O
%  O
confidence  O
interval  O
,  O
27  O
%  O
to  O
56  O
%  O
)  O
.  O

This  O
regimen  O
of  O
cisplatin  B-DRUG
,  O
gemcitabine  B-DRUG
,  O
and  O
ifosfamide  B-DRUG
is  O
not  O
feasible  O
for  O
weekly  O
administration  O
because  O
of  O
hematologic  B-TOXI
toxicity  I-TOXI
.  O

Nevertheless  O
,  O
there  O
was  O
promising  O
activity  O
with  O
only  O
two  O
doses  O
per  O
28-day  O
cycle  O
.  O

On  O
the  O
basis  O
of  O
these  O
results  O
,  O
we  O
have  O
initiated  O
a  O
phase  O
II  O
trial  O
of  O
this  O
combination  O
given  O
as  O
a  O
single  O
dose  O
every  O
14  O
days  O
in  O
patients  O
with  O
untreated  O
,  O
metastatic  B-CANCER
urothelial  I-CANCER
carcinoma  I-CANCER
.  O

Pilot  O
study  O
of  O
gemcitabine  B-DRUG
(  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
min  O
)  O
and  O
cisplatin  B-DRUG
.  O


Gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
are  O
routinely  O
used  O
in  O
combination  O
.  O

In  O
this  O
combination  O
,  O
gemcitabine  B-DRUG
at  O
conventional  O
doses  O
of  O
1000-1500  O
mg  O
/  O
m  O
(  O
2  O
)  O
is  O
delivered  O
weekly  O
as  O
a  O
30-minute  O
bolus  O
.  O

Laboratory  O
data  O
suggest  O
that  O
the  O
synthesis  O
of  O
gemcitabine  B-DRUG
triphosphate  I-DRUG
is  O
saturable  O
,  O
and  O
that  O
gemcitabine  B-DRUG
infused  O
at  O
a  O
rate  O
of  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
min  O
optimizes  O
accumulation  O
of  O
the  O
triphosphate  B-DRUG
.  O

Early  O
clinical  O
experience  O
suggests  O
that  O
gemcitabine  B-DRUG
delivered  O
by  O
a  O
more  O
prolonged  O
infusion  O
is  O
more  O
myelosuppressive  O
.  O

In  O
this  O
pilot  O
study  O
,  O
we  O
wished  O
to  O
assess  O
if  O
full-dose  O
gemcitabine  B-DRUG
when  O
given  O
with  O
cisplatin  B-DRUG
could  O
be  O
delivered  O
by  O
this  O
more  O
prolonged  O
infusion  O
.  O

In  O
this  O
study  O
,  O
all  O
patients  O
received  O
cisplatin  B-DRUG
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

All  O
gemcitabine  B-DRUG
doses  O
were  O
delivered  O
at  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
min  O
.  O

For  O
the  O
initial  O
cohort  O
(  O
level  O
1  O
)  O
the  O
gemcitabine  B-DRUG
dose  O
was  O
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
min  O
.  O

Subsequent  O
escalations  O
were  O
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
min  O
(  O
level  O
2  O
)  O
,  O
and  O
1250  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
min  O
(  O
levels  O
3  O
and  O
4  O
)  O
.  O

For  O
the  O
first  O
three  O
cohorts  O
,  O
patients  O
received  O
gemcitabine  B-DRUG
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
and  O
cisplatin  B-DRUG
on  O
day  O
15  O
on  O
a  O
28-day  O
cycle  O
.  O

Patients  O
on  O
level  O
4  O
received  O
gemcitabine  B-DRUG
on  O
days  O
1  O
and  O
8  O
and  O
cisplatin  B-DRUG
on  O
day  O
8  O
on  O
a  O
21-day  O
cycle  O
.  O

Dose  O
omissions  O
or  O
delays  O
(  O
holds  O
)  O
were  O
mandated  O
for  O
NCI  O
CTC  O
grade  O
3  O
or  O
4  O
granulocytopenia  B-TOXI
or  O
grade  O
2-4  O
thrombocytopenia  B-TOXI
.  O

Entered  O
onto  O
this  O
dose-finding  O
study  O
were  O
23  O
patients  O
(  O
12  O
male  O
,  O
11  O
female  O
)  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

Seven  O
patients  O
were  O
treatment-naive  O
.  O

Six  O
patients  O
were  O
treated  O
on  O
level  O
1  O
,  O
five  O
each  O
on  O
levels  O
2  O
and  O
3  O
and  O
seven  O
on  O
level  O
4.  O
Patients  O
received  O
one  O
to  O
seven  O
cycles  O
of  O
treatment  O
.  O

Myelosuppression-related  O
dose  O
holds  O
occurred  O
at  O
all  O
levels  O
.  O

First-cycle  O
dose  O
holds  O
occurred  O
in  O
three  O
of  O
six  O
,  O
four  O
of  O
five  O
,  O
three  O
of  O
five  O
and  O
two  O
of  O
seven  O
patients  O
on  O
successive  O
levels  O
.  O

First-cycle  O
grade  O
3  O
or  O
4  O
granulocytopenia  B-TOXI
/  O
thrombocytopenia  B-TOXI
occurred  O
in  O
three  O
patients  O
on  O
level  O
1  O
,  O
one  O
patient  O
on  O
level  O
2  O
,  O
two  O
patients  O
on  O
level  O
3  O
and  O
three  O
patients  O
on  O
level  O
4.  O
There  O
were  O
no  O
partial  O
or  O
complete  O
responses  O
.  O

Four  O
patients  O
were  O
removed  O
for  O
toxicity  O
(  O
three  O
myelosuppression  B-TOXI
,  O
one  O
nephrotoxicity  B-TOXI
)  O
,  O
one  O
at  O
physician  O
discretion  O
,  O
and  O
15  O
with  O
disease  B-TOXI
progression  I-TOXI
.  O

Three  O
patients  O
stopped  O
therapy  O
with  O
stable  O
disease  O
after  O
5-6  O
months  O
.  O

On  O
level  O
3  O
,  O
three  O
of  O
five  O
patients  O
remained  O
on  O
therapy  O
for  O
4  O
months  O
or  O
more  O
,  O
compared  O
to  O
only  O
one  O
patient  O
on  O
each  O
of  O
the  O
other  O
three  O
levels  O
.  O

CONCLUSIONS  O
Weekly  O
gemcitabine  B-DRUG
1250  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
utilizing  O
a  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
min  O
infusion  O
rate  O
,  O
can  O
be  O
delivered  O
with  O
cisplatin  B-DRUG
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
with  O
tolerable  O
toxicity  O
.  O

When  O
used  O
in  O
combination  O
with  O
cisplatin  B-DRUG
,  O
however  O
,  O
the  O
benefit  O
of  O
this  O
fixed  O
dose  O
rate  O
infusion  O
gemcitabine  B-DRUG
compared  O
to  O
standard  O
bolus  O
gemcitabine  B-DRUG
remains  O
to  O
be  O
determined  O
.  O

Phase  O
I  O
study  O
of  O
weekly  O
CPT-11  B-DRUG
(  O
irinotecan  B-DRUG
)  O
/  O
docetaxel  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


Based  O
on  O
the  O
synergistic  O
cytotoxicity  O
demonstrated  O
in  O
vitro  O
by  O
topoisomerase  B-DRUG
I  O
inhibitors  O
followed  O
by  O
docetaxel  B-DRUG
and  O
the  O
feasibility  O
of  O
giving  O
both  O
drugs  O
on  O
a  O
weekly  O
schedule  O
avoiding  O
overlapping  O
toxicities  O
,  O
we  O
designed  O
a  O
phase  O
I  O
trial  O
of  O
weekly  O
CPT-11  B-DRUG
(  O
irinotecan  B-DRUG
)  O
/  O
docetaxel  B-DRUG
to  O
determine  O
the  O
dose-limiting  O
toxicities  O
(  O
DLT  O
)  O
and  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
this  O
combination  O
.  O

Eighteen  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
treated  O
with  O
at  O
least  O
one  O
prior  O
chemotherapy  O
regimen  O
were  O
included  O
in  O
this  O
trial  O
.  O

CPT-11  B-DRUG
was  O
administered  O
as  O
a  O
90-min  O
(  O
intravenous  O
)  O
IV  O
infusion  O
followed  O
immediately  O
by  O
docetaxel  B-DRUG
as  O
a  O
30-min  O
IV  O
infusion  O
.  O

Both  O
drugs  O
were  O
given  O
on  O
days  O
1  O
,  O
8  O
and  O
15  O
in  O
4-week  O
cycles  O
.  O

Four  O
escalating  O
dose  O
levels  O
of  O
CPT-11  B-DRUG
/  I-DRUG
docetaxel  I-DRUG
(  O
level  O
I  O
:  O
60  O
/  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
level  O
II  O
:  O
60  O
/  O
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
level  O
III  O
:  O
70  O
/  O
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
level  O
IV  O
:  O
70  O
/  O
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
were  O
studied  O
.  O

Forty-seven  O
cycles  O
were  O
administered  O
(  O
range  O
,  O
1-5  O
courses  O
)  O
with  O
a  O
median  O
number  O
of  O
2.6  O
cycles  O
per  O
patient  O
.  O

Grade  O
4  O
leukopenia  B-TOXI
was  O
the  O
DLT  O
reached  O
at  O
dose-level  O
IV  O
(  O
CPT-11  B-DRUG
/  I-DRUG
docetaxel  I-DRUG
70  O
/  O
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
.  O

Four  O
patients  O
had  O
grade  O
3  O
anemia  B-TOXI
at  O
dose  O
levels  O
III  O
(  O
two  O
patients  O
)  O
and  O
IV  O
(  O
two  O
patients  O
)  O
,  O
while  O
grade  O
3  O
/  O
4  O
thrombocytopenia  B-TOXI
was  O
not  O
seen  O
.  O

Grade  O
3  O
/  O
4  O
non-hematologic  B-TOXI
toxicities  I-TOXI
included  O
grade  O
3  O
diarrhea  B-TOXI
in  O
two  O
patients  O
(  O
dose  O
levels  O
II  O
and  O
IV  O
)  O
,  O
grade  O
3  O
asthenia  B-TOXI
in  O
one  O
patient  O
(  O
dose  O
level  O
II  O
)  O
and  O
grade  O
3  O
stomatitis  B-TOXI
in  O
one  O
patient  O
(  O
dose  O
level  O
I  O
)  O
.  O

The  O
recommended  O
dose  O
of  O
this  O
weekly  O
schedule  O
is  O
CPT-11  B-DRUG
70  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
docetaxel  B-DRUG
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

DLT  O
of  O
this  O
regimen  O
is  O
leukopenia  B-TOXI
,  O
although  O
toxicity  O
is  O
manageable  O
at  O
the  O
recommended  O
dose  O
level  O
.  O

The  O
activity  O
of  O
this  O
regimen  O
is  O
being  O
evaluated  O
in  O
a  O
phase  O
II  O
study  O
in  O
previously  O
treated  O
patients  O
with  O
advanced  B-CANCER
non-small  I-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

A  O
dose-escalation  O
study  O
of  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
non-small  I-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
previously  O
treated  O
with  O
a  O
cisplatin-based  B-DRUG
front  O
line  O
chemotherapy  O
.  O


CPT-11  B-DRUG
and  O
gemcitabine  B-DRUG
are  O
both  O
active  O
agents  O
against  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

We  O
conducted  O
a  O
phase  O
I  O
study  O
to  O
determine  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
the  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
their  O
combination  O
in  O
patients  O
with  O
previously  O
treated  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

Twenty-seven  O
patients  O
with  O
histologically  O
confirmed  O
NSCLC  B-CANCER
,  O
who  O
had  O
failed  O
cisplatin-based  B-DRUG
front-line  O
chemotherapy  O
,  O
were  O
enrolled  O
.  O

The  O
patients  O
'  O
median  O
age  O
was  O
56  O
years  O
,  O
24  O
were  O
male  O
and  O
22  O
had  O
a  O
performance  O
status  O
(  O
WHO  O
)  O
0-1  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
on  O
days  O
1  O
and  O
8  O
,  O
as  O
a  O
30-minute  O
i.v.  O
infusion  O
,  O
at  O
escalated  O
doses  O
ranging  O
from  O
900  O
to  O
1200  O
mg  O
/  O
m2  O
.  O

CPT-11  B-DRUG
was  O
given  O
over  O
a  O
60-minute  O
i.v.  O
infusion  O
on  O
day  O
8  O
at  O
escalated  O
doses  O
ranging  O
from  O
200  O
to  O
350  O
mg  O
/  O
m2  O
,  O
following  O
gemcitabine  B-DRUG
administration  O
.  O

The  O
treatment  O
was  O
repeated  O
every  O
three  O
weeks  O
.  O

The  O
MTD  O
was  O
exceeded  O
at  O
dose-level  O
7  O
with  O
CPT-11  B-DRUG
350  O
mg  O
/  O
m2  O
and  O
gemcitabine  B-DRUG
1200  O
mg  O
/  O
m2  O
,  O
where  O
all  O
three  O
enrolled  O
patients  O
presented  O
DLTs  O
(  O
one  O
patient  O
grade  O
4  O
thrombocytopenia  B-TOXI
,  O
one  O
grade  O
3  O
diarrhea  B-TOXI
and  O
one  O
grade  O
3  O
asthenia  B-TOXI
)  O
.  O

The  O
recommended  O
doses  O
for  O
future  O
phase  O
II  O
studies  O
are  O
CPT-11  B-DRUG
300  O
mg  O
/  O
m2  O
on  O
day  O
8  O
and  O
gemcitabine  B-DRUG
1200  O
mg  O
/  O
m2  O
on  O
days  O
1  O
and  O
8.  O
A  O
total  O
of  O
107  O
treatment  O
cycles  O
were  O
administered  O
.  O

Grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
was  O
observed  O
in  O
13  O
(  O
13  O
%  O
)  O
cycles  O
,  O
febrile  B-TOXI
neutropenia  I-TOXI
in  O
3  O
(  O
3  O
%  O
)  O
and  O
grade  O
3  O
/  O
4  O
thrombocytopenia  B-TOXI
in  O
2  O
(  O
2  O
%  O
)  O
.  O

Grade  O
2  O
/  O
3  O
diarrhea  B-TOXI
was  O
seen  O
in  O
6  O
(  O
6  O
%  O
)  O
cycles  O
,  O
grade  O
2  O
/  O
3  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
in  O
13  O
(  O
13  O
%  O
)  O
and  O
grade  O
2  O
/  O
3  O
asthenia  B-TOXI
in  O
8  O
(  O
8  O
%  O
)  O
.  O

Other  O
toxicities  O
were  O
mild  O
.  O

Among  O
23  O
patients  O
evaluable  O
for  O
response  O
,  O
PR  O
was  O
achieved  O
in  O
one  O
(  O
4.5  O
%  O
)  O
,  O
SD  O
in  O
12  O
(  O
52.5  O
%  O
)  O
and  O
PD  O
in  O
10  O
(  O
43  O
%  O
)  O
.  O

The  O
results  O
of  O
this  O
phase  O
I  O
study  O
clearly  O
demonstrate  O
that  O
gemcitabine  B-DRUG
and  O
CPT-11  B-DRUG
can  O
be  O
efficiently  O
combined  O
in  O
a  O
low-toxicity  O
regimen  O
with  O
doses  O
equal  O
or  O
near  O
monotherapy  O
levels  O
.  O

Further  O
studies  O
are  O
needed  O
to  O
evaluate  O
the  O
efficacy  O
of  O
this  O
combination  O
in  O
both  O
chemotherapy-naive  O
and  O
pre-treated  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

Modulation  O
of  O
the  O
Fas  O
signaling  O
pathway  O
by  O
IFN-gamma  B-DRUG
in  O
therapy  O
of  O
colon  B-CANCER
cancer  I-CANCER
:  O
phase  O
I  O
trial  O
and  O
correlative  O
studies  O
of  O
IFN-gamma  B-DRUG
,  O
5-fluorouracil  B-DRUG
,  O
and  O
leucovorin  B-DRUG
.  O


Potentiation  O
of  O
5-fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
(  O
FUra  B-DRUG
/  I-DRUG
LV  I-DRUG
)  O
cytotoxicity  O
by  O
IFN-gamma  B-DRUG
in  O
colon  B-CANCER
carcinoma  I-CANCER
cells  O
is  O
dependent  O
on  O
FUra-induced  B-DRUG
DNA  O
damage  O
,  O
the  O
Fas  O
death  O
receptor  O
,  O
and  O
independent  O
of  O
p53  O
and  O
RNA-mediated  O
FUra  B-DRUG
toxicity  O
,  O
which  O
occurs  O
in  O
normal  O
gastrointestinal  O
tissues  O
.  O

This  O
provides  O
a  O
rationale  O
for  O
enhancing  O
the  O
selective  O
action  O
of  O
FUra  B-DRUG
/  I-DRUG
LV  I-DRUG
by  O
IFN-gamma  B-DRUG
in  O
the  O
treatment  O
of  O
colorectal  B-CANCER
carcinoma  I-CANCER
.  O

Based  O
on  O
results  O
from  O
our  O
preclinical  O
studies  O
we  O
designed  O
a  O
Phase  O
I  O
trial  O
combining  O
FUra  B-DRUG
(  O
370  O
mg  O
/  O
m2  O
)  O
and  O
LV  B-DRUG
(  O
200  O
mg  O
/  O
m2  O
)  O
,  O
i.v.  O
bolus  O
daily  O
x  O
5  O
days  O
,  O
with  O
escalating  O
doses  O
of  O
IFN-gamma  B-DRUG
(  O
10-100  O
micro  O
g  O
/  O
m2  O
)  O
s.c.  O
on  O
days  O
1  O
,  O
3  O
,  O
and  O
5  O
,  O
every  O
28  O
days  O
.  O

Twenty-five  O
patients  O
with  O
carcinomas  B-CANCER
were  O
enrolled  O
;  O
6  O
patients  O
received  O
IFN-gamma  B-DRUG
on  O
days  O
1  O
and  O
3  O
only  O
.  O

The  O
dose-limiting  O
toxicity  O
,  O
stomatitis  B-TOXI
,  O
occurred  O
most  O
frequently  O
at  O
100  O
micro  O
g  O
/  O
m2  O
IFN-gamma  B-DRUG
.  O

Minor  O
response  O
or  O
SD  O
was  O
observed  O
in  O
2  O
of  O
9  O
patients  O
and  O
in  O
4  O
of  O
12  O
patients  O
at  O
dose  O
levels  O
of  O
&  O
lt  O
;  O
or  O
=50  O
micro  O
g  O
/  O
m2  O
and  O
&  O
gt  O
;  O
or  O
=75  O
micro  O
g  O
/  O
m2  O
IFN-gamma  B-DRUG
,  O
respectively  O
.  O

Three  O
evaluable  O
chemonaive  O
patients  O
demonstrated  O
partial  O
response  O
(  O
2  O
)  O
or  O
complete  O
response  O
(  O
1  O
)  O
.  O

Serial  O
plasma  O
samples  O
revealed  O
peak  O
FUra  B-DRUG
concentrations  O
of  O
&  O
gt  O
;  O
100  O
micro  O
M  O
;  O
at  O
100  O
micro  O
g  O
/  O
m2  O
IFN-gamma  B-DRUG
plasma  O
concentrations  O
&  O
gt  O
;  O
5  O
units  O
/  O
ml  O
persisted  O
for  O
6.5  O
h  O
and  O
&  O
gt  O
;  O
1  O
unit  O
/  O
ml  O
for  O
28.5  O
h.  O
The  O
pharmacokinetic  O
parameters  O
of  O
IFN-gamma  B-DRUG
correlated  O
with  O
a  O
2-3-fold  O
up-regulation  O
of  O
Fas  O
expression  O
at  O
24  O
h  O
in  O
CD15+  O
cells  O
in  O
peripheral  O
blood  O
samples  O
.  O

Furthermore  O
,  O
clinically  O
relevant  O
IFN-gamma  B-DRUG
concentrations  O
up-regulated  O
Fas  O
expression  O
and  O
sensitized  O
HT29  O
colon  B-CANCER
carcinoma  I-CANCER
cells  O
in  O
vitro  O
to  O
FUra  B-DRUG
/  I-DRUG
LV  I-DRUG
cytotoxicity  O
.  O

On  O
the  O
basis  O
of  O
the  O
modulation  O
of  O
Fas  O
signaling  O
,  O
FUra  B-DRUG
/  I-DRUG
LV  I-DRUG
combined  O
with  O
IFN-gamma  B-DRUG
has  O
shown  O
activity  O
in  O
a  O
Phase  O
I  O
trial  O
in  O
colorectal  B-CANCER
carcinoma  I-CANCER
and  O
warrants  O
additional  O
evaluation  O
in  O
Phase  O
II  O
.  O

A  O
'modified  O
de  O
Gramont  O
'  O
regimen  O
of  O
fluorouracil  B-DRUG
,  O
alone  O
and  O
with  O
oxaliplatin  B-DRUG
,  O
for  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


The  O
standard  O
de  O
Gramont  O
(  O
dG  O
)  O
regimen  O
of  O
fortnightly  O
leucovorin  B-DRUG
,  O
bolus  O
fluorouracil  B-DRUG
and  O
22-h  O
infusion  O
of  O
fluorouracil  B-DRUG
,  O
d1+2  O
,  O
and  O
the  O
same  O
regimen  O
plus  O
oxaliplatin  B-DRUG
,  O
are  O
effective  O
but  O
also  O
cumbersome  O
.  O

We  O
therefore  O
present  O
simplified  O
'Modified  O
de  O
Gramont  O
'  O
(  O
MdG  O
)  O
regimens  O
.  O

Forty-six  O
advanced  B-CANCER
gastrointestinal  I-CANCER
cancer  I-CANCER
patients  O
entered  O
a  O
dose-exploring  O
study  O
of  O
MdG  O
,  O
including  O
an  O
expanded  O
cohort  O
of  O
colorectal  B-CANCER
cancer  I-CANCER
patients  O
at  O
optimum  O
dose  O
.  O

Treatment  O
(  O
fortnightly  O
)  O
comprised  O
:  O
2-h  O
i.v.i.  O
leucovorin  B-DRUG
(  O
350  O
mg  O
d  O
,  O
l-LV  O
or  O
175  O
mg  O
l-LV  O
,  O
not  O
adjusted  O
for  O
patient  O
surface  O
area  O
)  O
;  O
bolus  O
fluorouracil  B-DRUG
(  O
400  O
mg  O
m  O
(  O
-2  O
)  O
)  O
,  O
then  O
ambulatory  O
46-h  O
fluorouracil  B-DRUG
infusion  O
(  O
2000-3600  O
mg  O
m  O
(  O
-2  O
)  O
,  O
cohort  O
escalation  O
)  O
.  O

Subsequently  O
,  O
62  O
colorectal  O
patients  O
(  O
25  O
unpretreated  O
;  O
37  O
fluorouracil-resistant  B-DRUG
)  O
received  O
MdG  O
plus  O
oxaliplatin  B-DRUG
(  O
OxMdG  O
)  O
85  O
mg  O
m  O
(  O
-2  O
)  O
.  O

Fluorouracil  B-DRUG
pharmacokinetics  O
during  O
MdG  O
were  O
compared  O
with  O
dG  O
.  O

The  O
optimum  O
fluorouracil  B-DRUG
doses  O
for  O
MdG  O
alone  O
were  O
determined  O
as  O
400  O
mg  O
m  O
(  O
-2  O
)  O
bolus  O
+  O
2800  O
mg  O
m  O
(  O
-2  O
)  O
46-h  O
infusion  O
.  O

A  O
lower  O
dose  O
of  O
400  O
mg  O
m  O
(  O
-2  O
)  O
bolus  O
+  O
2400  O
mg  O
m  O
(  O
-2  O
)  O
infusion  O
which  O
,  O
like  O
dG  O
produces  O
minimal  O
toxicity  O
,  O
was  O
chosen  O
for  O
the  O
OxMdG  O
combination  O
.  O

Fluorouracil  B-DRUG
exposure  O
(  O
AUC  O
(  O
0-48  O
h  O
)  O
)  O
at  O
this  O
lower  O
dose  O
is  O
equivalent  O
to  O
dG  O
.  O

With  O
OxMdG  O
,  O
grade  O
3-4  O
toxicity  O
was  O
rare  O
(  O
neutropenia  B-TOXI
2.8  O
%  O
cycles  O
;  O
vomiting  B-TOXI
or  O
diarrhoea  B-TOXI
&  O
lt  O
;  O
1  O
%  O
cycles  O
)  O
,  O
but  O
despite  O
this  O
there  O
were  O
two  O
infection-associated  B-TOXI
deaths  I-TOXI
.  O

Oxaliplatin  B-DRUG
was  O
omitted  O
for  O
cumulative  O
neurotoxicity  B-TOXI
in  O
17  O
out  O
of  O
62  O
patients  O
.  O

Objective  O
responses  O
in  O
colorectal  B-CANCER
cancer  I-CANCER
patients  O
were  O
:  O
1st-line  O
MdG  O
(  O
22  O
assessable  O
)  O
:  O
PR=36  O
%  O
,  O
NC=32  O
%  O
,  O
PD=32  O
%  O
.  O

1st-line  O
OxMdG  O
(  O
24  O
assessable  O
)  O
:  O
CR  O
/  O
PR=72  O
%  O
;  O
NC=20  O
%  O
;  O
PD=8  O
%  O
;  O
2nd  O
line  O
OxMdG  O
(  O
34  O
assessable  O
)  O
:  O
PR=12  O
%  O
;  O
NC=38  O
%  O
;  O
PD=50  O
%  O
.  O

MdG  O
and  O
OxMdG  O
are  O
convenient  O
and  O
well-tolerated  O
.  O

OxMdG  O
was  O
particularly  O
active  O
as  O
1st-line  O
treatment  O
of  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Both  O
regimens  O
are  O
being  O
further  O
evaluated  O
in  O
the  O
current  O
UK  O
MRC  B-CANCER
phase  O
III  O
trial  O
.  O

A  O
multicentre  O
phase  O
II  O
study  O
of  O
cisplatin  B-DRUG
and  O
gemcitabine  B-DRUG
for  O
malignant  B-CANCER
mesothelioma  I-CANCER
.  O


Our  O
previous  O
phase  O
II  O
study  O
of  O
cisplatin  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
malignant  B-CANCER
mesothelioma  I-CANCER
showed  O
a  O
47.6  O
%  O
(  O
95  O
%  O
CI  O
26.2-69.0  O
%  O
)  O
response  O
rate  O
with  O
symptom  O
improvement  O
in  O
responding  O
patients  O
.  O

Here  O
we  O
confirm  O
these  O
findings  O
in  O
a  O
multicentre  O
setting  O
,  O
and  O
assess  O
the  O
effect  O
of  O
this  O
treatment  O
on  O
quality  O
of  O
life  O
and  O
pulmonary  O
function  O
.  O

Fifty-three  O
patients  O
with  O
pleural  B-CANCER
malignant  I-CANCER
mesothelioma  I-CANCER
received  O
cisplatin  B-DRUG
100  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
day  O
1  O
and  O
gemcitabine  B-DRUG
1000  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
of  O
a  O
28  O
day  O
cycle  O
for  O
a  O
maximum  O
of  O
six  O
cycles  O
.  O

Quality  O
of  O
life  O
and  O
pulmonary  O
function  O
were  O
assessed  O
at  O
each  O
cycle  O
.  O

The  O
best  O
response  O
achieved  O
in  O
52  O
assessable  O
patients  O
was  O
:  O
partial  O
response  O
,  O
17  O
(  O
33  O
%  O
,  O
95  O
%  O
CI  O
20-46  O
%  O
)  O
;  O
stable  O
disease  O
,  O
31  O
(  O
60  O
%  O
)  O
;  O
and  O
progressive  B-TOXI
disease  I-TOXI
,  O
four  O
(  O
8  O
%  O
)  O
.  O

The  O
median  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
was  O
6.4  O
months  O
,  O
median  O
survival  O
from  O
start  O
of  O
treatment  O
11.2  O
months  O
,  O
and  O
median  O
survival  O
from  O
diagnosis  O
17.3  O
months  O
.  O

Vital  O
capacity  O
and  O
global  O
quality  O
of  O
life  O
remained  O
stable  O
in  O
all  O
patients  O
and  O
improved  O
significantly  O
in  O
responding  O
patients  O
.  O

Major  O
toxicities  O
were  O
haematological  B-TOXI
,  O
limiting  O
the  O
mean  O
relative  O
dose  O
intensity  O
of  O
gemcitabine  B-DRUG
to  O
75  O
%  O
.  O

This  O
schedule  O
of  O
cisplatin  B-DRUG
and  O
gemcitabine  B-DRUG
is  O
active  O
in  O
malignant  B-CANCER
mesothelioma  I-CANCER
in  O
a  O
multicentre  O
setting  O
.  O

Investigation  O
of  O
alternative  O
scheduling  O
is  O
needed  O
to  O
decrease  O
haematological  B-TOXI
toxicity  I-TOXI
and  O
increase  O
the  O
relative  O
dose  O
intensity  O
of  O
gemcitabine  B-DRUG
whilst  O
maintaining  O
response  O
rate  O
and  O
quality  O
of  O
life  O
.  O

A  O
phase  O
I  O
and  O
pharmacokinetic  O
study  O
of  O
capecitabine  B-DRUG
in  O
combination  O
with  O
epirubicin  B-DRUG
and  O
cisplatin  B-DRUG
in  O
patients  O
with  O
inoperable  O
oesophago-gastric  B-CANCER
adenocarcinoma  I-CANCER
.  O


The  O
purpose  O
of  O
this  O
study  O
was  O
to  O
evaluate  O
the  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
and  O
maximum  O
tolerated  O
dose  O
of  O
capecitabine  O
when  O
used  O
in  O
combination  O
with  O
epirubicin  B-DRUG
and  O
cisplatin  B-DRUG
(  O
ECC  B-DRUG
)  O
in  O
patients  O
with  O
oesophageal  B-CANCER
or  I-CANCER
gastric  I-CANCER
adenocarcinoma  I-CANCER
.  O

Response  O
rate  O
,  O
progression-free  O
survival  O
(  O
PFS  O
)  O
and  O
overall  O
survival  O
were  O
also  O
determined  O
,  O
and  O
the  O
effect  O
of  O
previous  O
oesophago-gastric  O
surgery  O
or  O
concurrent  O
oesophago-gastric  B-CANCER
cancer  I-CANCER
on  O
the  O
absorption  O
and  O
metabolism  O
of  O
capecitabine  B-DRUG
was  O
evaluated  O
.  O

Patients  O
with  O
inoperable  O
oesophago-gastric  B-CANCER
adenocarcinoma  I-CANCER
received  O
up  O
to  O
six  O
cycles  O
of  O
epirubicin  B-DRUG
(  O
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
i.v.  O
,  O
3-weekly  O
)  O
,  O
cisplatin  B-DRUG
(  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
i.v.  O
,  O
3-weekly  O
)  O
and  O
capecitabine  B-DRUG
,  O
the  O
latter  O
administered  O
orally  O
in  O
an  O
intermittent  O
schedule  O
(  O
14  O
days  O
treatment  O
;  O
7-day  O
rest  O
period  O
)  O
at  O
3-weekly  O
intervals  O
.  O

Patients  O
were  O
recruited  O
into  O
one  O
of  O
four  O
escalating  O
dose  O
cohorts  O
(  O
500  O
,  O
825  O
,  O
1000  O
and  O
1250  O
mg  O
/  O
m  O
(  O
2  O
)  O
bd  O
)  O
.  O

Dose  O
escalation  O
occurred  O
after  O
six  O
patients  O
had  O
completed  O
at  O
least  O
one  O
cycle  O
of  O
chemotherapy  O
at  O
the  O
previous  O
dose  O
level  O
,  O
with  O
DLT  O
assessed  O
on  O
the  O
toxicity  O
of  O
the  O
first  O
cycle  O
only  O
.  O

Blood  O
sampling  O
for  O
pharmacokinetic  O
analyses  O
was  O
performed  O
over  O
the  O
first  O
10  O
h  O
of  O
day  O
1  O
of  O
cycle  O
1.  O
Thirty-two  O
patients  O
,  O
median  O
age  O
63  O
years  O
(  O
range  O
32-76  O
years  O
)  O
,  O
ECOG  O
performance  O
status  O
&  O
lt  O
;  O
or  O
=2  O
with  O
locally  O
advanced  O
(  O
10  O
)  O
or  O
metastatic  O
(  O
22  O
)  O
disease  O
were  O
recruited  O
and  O
were  O
evaluable  O
for  O
toxicity  O
.  O

Two  O
of  O
five  O
patients  O
experienced  O
DLT  O
at  O
1250  O
mg  O
/  O
m  O
(  O
2  O
)  O
bd  O
with  O
grade  O
II  O
stomatitis  B-TOXI
(  O
one  O
patient  O
)  O
and  O
grade  O
III  O
diarrhoea  B-TOXI
with  O
febrile  B-TOXI
neutropenia  I-TOXI
(  O
one  O
patient  O
)  O
.  O

Cumulative  O
toxicity  O
for  O
all  O
cycles  O
(  O
n  O
=  O
140  O
)  O
(  O
worst  O
grade  O
per  O
patient  O
)  O
includes  O
grade  O
IV  O
oesophagitis  B-TOXI
(  O
one  O
patient  O
)  O
,  O
grade  O
III  O
diarrhoea  B-TOXI
(  O
five  O
)  O
,  O
grade  O
IV  O
neutropenia  B-TOXI
with  I-TOXI
infection  I-TOXI
(  O
seven  O
)  O
,  O
grade  O
II  O
stomatitis  B-TOXI
(  O
four  O
)  O
and  O
grade  O
IV  O
thrombocytopenia  B-TOXI
(  O
one  O
)  O
.  O

Of  O
29  O
patients  O
with  O
evaluable  O
disease  O
,  O
there  O
was  O
one  O
complete  O
response  O
and  O
six  O
partial  O
responses  O
[  O
24  O
%  O
response  O
rate  O
[  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
10  O
%  O
to  O
44  O
%  O
]  O
]  O
,  O
a  O
median  O
PFS  O
of  O
22  O
weeks  O
(  O
95  O
%  O
CI  O
17-27  O
weeks  O
)  O
and  O
median  O
overall  O
survival  O
of  O
34  O
weeks  O
(  O
95  O
%  O
CI  O
19-49  O
weeks  O
)  O
.  O

Capecitabine  B-DRUG
was  O
rapidly  O
absorbed  O
after  O
oral  O
administration  O
,  O
with  O
a  O
t  O
(  O
max  O
)  O
of  O
1-2  O
h  O
for  O
capecitabine  B-DRUG
,  O
DFCR  B-DRUG
(  O
5'-deoxy-5-fluorocytidine  B-DRUG
)  O
and  O
DFUR  B-DRUG
(  O
5'-deoxy-5-fluorouridine  B-DRUG
)  O
.  O

The  O
C  O
(  O
max  O
)  O
and  O
AUC  O
(  O
0-  O
)  O
(  O
infinity  O
)  O
for  O
capecitabine  B-DRUG
,  O
DFCR  B-DRUG
and  O
DFUR  B-DRUG
were  O
similar  O
to  O
those  O
observed  O
in  O
previous  O
monotherapy  O
studies  O
of  O
capecitabine  B-DRUG
taken  O
after  O
food  O
.  O

A  O
dose  O
of  O
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
bd  O
of  O
capecitabine  B-DRUG
is  O
recommended  O
for  O
use  O
on  O
an  O
intermittent  O
schedule  O
in  O
combination  O
with  O
these  O
doses  O
and  O
schedule  O
of  O
epirubicin  B-DRUG
and  O
cisplatin  B-DRUG
.  O

This  O
regimen  O
is  O
tolerable  O
and  O
active  O
in  O
oesophago-gastric  B-CANCER
adenocarcinoma  I-CANCER
.  O

A  O
randomised  O
phase  O
III  O
comparison  O
with  O
ECF  O
is  O
justified  O
.  O

Phase  O
I-II  O
and  O
pharmacokinetic  O
study  O
of  O
gemcitabine  B-DRUG
combined  O
with  O
oxaliplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
and  O
ovarian  B-CANCER
carcinoma  I-CANCER
.  O


The  O
aim  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
toxicity  O
profile  O
,  O
the  O
recommended  O
dose  O
(  O
RD  O
)  O
and  O
the  O
pharmacokinetic  O
parameters  O
,  O
and  O
to  O
evaluate  O
the  O
antitumor  O
activity  O
of  O
gemcitabine  B-DRUG
combined  O
with  O
oxaliplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
and  O
ovarian  B-CANCER
carcinoma  I-CANCER
(  O
OC  B-CANCER
)  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
as  O
a  O
30-min  O
infusion  O
followed  O
by  O
a  O
2-h  O
infusion  O
of  O
oxaliplatin  B-DRUG
,  O
repeated  O
every  O
2  O
weeks  O
.  O

Doses  O
of  O
gemcitabine  B-DRUG
and  O
oxaliplatin  B-DRUG
ranged  O
from  O
800  O
to  O
1500  O
and  O
70  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
respectively  O
.  O

Forty-four  O
patients  O
(  O
26  O
males  O
,  O
18  O
females  O
;  O
median  O
age  O
55  O
years  O
)  O
including  O
35  O
NSCLC  B-CANCER
(  O
five  O
platinum  O
pretreated  O
)  O
and  O
nine  O
OC  B-CANCER
patients  O
(  O
all  O
platinum  O
pretreated  O
)  O
received  O
a  O
total  O
of  O
355  O
cycles  O
.  O

All  O
patients  O
were  O
evaluable  O
for  O
toxicity  O
.  O

No  O
dose-limiting  O
toxicity  O
at  O
any  O
dose  O
level  O
occurred  O
during  O
the  O
first  O
two  O
cycles  O
;  O
therefore  O
,  O
the  O
highest  O
dose-level  O
of  O
gemcitabine  B-DRUG
(  O
1500  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
and  O
oxaliplatin  B-DRUG
(  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
was  O
considered  O
as  O
the  O
RD.  O
Hematological  B-TOXI
toxicity  I-TOXI
was  O
moderate  O
amongst  O
the  O
22  O
patients  O
treated  O
(  O
167  O
cycles  O
)  O
at  O
that  O
dose  O
level  O
.  O

Thirteen  O
cycles  O
were  O
associated  O
with  O
grade  O
3-4  O
non-febrile  B-TOXI
neutropenia  I-TOXI
in  O
six  O
patients  O
,  O
and  O
eight  O
cycles  O
with  O
grade  O
3-4  O
thrombocytopenia  B-TOXI
in  O
two  O
patients  O
.  O

Other  O
toxicities  O
were  O
mild  O
to  O
moderate  O
,  O
consisting  O
of  O
asthenia  B-TOXI
and  O
peripheral  B-TOXI
neurotoxicity  I-TOXI
.  O

Four  O
of  O
the  O
35  O
patients  O
treated  O
with  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
experienced  O
grade  O
3  O
neurotoxicity  B-TOXI
requiring  O
treatment  O
discontinuation  O
at  O
cycle  O
10  O
.  O

In  O
the  O
range  O
of  O
the  O
doses  O
used  O
,  O
gemcitabine  B-DRUG
and  O
its  O
main  O
metabolite  O
2',2'-difluorodeoxyuridine  B-DRUG
appeared  O
not  O
to  O
be  O
affected  O
by  O
oxaliplatin  B-DRUG
70-100  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Of  O
the  O
44  O
patients  O
evaluable  O
for  O
activity  O
,  O
12  O
NSCLC  B-CANCER
patients  O
experienced  O
objective  O
responses  O
(  O
one  O
complete  O
and  O
11  O
partial  O
responses  O
)  O
and  O
three  O
OC  B-CANCER
patients  O
showed  O
tumor  O
stabilization  O
lasting  O
for  O
6  O
months  O
with  O
a  O
50  O
%  O
decrease  O
of  O
CA  O
125  O
level  O
.  O

Two  O
partial  O
responses  O
(  O
NSCLC  B-CANCER
)  O
and  O
one  O
tumor  O
stabilization  O
(  O
OC  B-CANCER
)  O
occurred  O
in  O
platinum-resistant  B-DRUG
patients  O
.  O

The  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
oxaliplatin  B-DRUG
could  O
be  O
safely  O
administered  O
on  O
an  O
out-patient  O
schedule  O
in  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
and  I-CANCER
OC  I-CANCER
.  O

The  O
RD  O
was  O
gemcitabine  B-DRUG
1500  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
2  O
weeks  O
.  O

Promising  O
antitumor  O
activity  O
was  O
reported  O
in  O
patients  O
with  O
NSCLC  B-CANCER
and  O
platinum-pretreated  O
OC  B-CANCER
,  O
and  O
thus  O
,  O
deserves  O
further  O
evaluation  O
.  O

Paclitaxel  B-DRUG
plus  O
carboplatin  B-DRUG
versus  O
gemcitabine  B-DRUG
plus  O
paclitaxel  B-DRUG
in  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
III  O
randomized  O
trial  O
.  O


We  O
conducted  O
this  O
randomized  O
study  O
comparing  O
the  O
activity  O
and  O
toxicity  O
of  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
(  O
PG  B-DRUG
)  O
and  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
(  O
PC  B-DRUG
)  O
combinations  O
for  O
the  O
treatment  O
of  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

Chemotherapy-naive  O
patients  O
were  O
randomized  O
to  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
1  O
plus  O
either  O
carboplatin  B-DRUG
at  O
an  O
area  O
under  O
the  O
concentration-time  O
curve  O
of  O
6  O
on  O
day  O
1  O
(  O
group  O
A  O
)  O
or  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
8  O
(  O
group  O
B  O
)  O
every  O
3  O
weeks  O
.  O

A  O
retrospective  O
cost  O
analysis  O
was  O
conducted  O
using  O
Student  O
's  O
t  O
test  O
to  O
compare  O
independent  O
samples  O
between  O
groups  O
.  O

A  O
total  O
of  O
509  O
patients  O
(  O
group  O
A  O
,  O
252  O
patients  O
;  O
group  O
B  O
,  O
257  O
patients  O
)  O
were  O
enrolled  O
;  O
all  O
characteristics  O
were  O
well  O
balanced  O
.  O

The  O
median  O
survival  O
time  O
was  O
10.4  O
months  O
(  O
95  O
%  O
confidence  O
interval  O
[  O
CI  O
]  O
,  O
8.8  O
to  O
12  O
months  O
)  O
for  O
group  O
A  O
and  O
9.8  O
months  O
(  O
95  O
%  O
CI  O
,  O
8.0  O
to  O
11.7  O
months  O
)  O
for  O
group  O
B  O
(  O
P  O
=.32  O
)  O
.  O

Respective  O
1-year  O
survival  O
rates  O
were  O
41.7  O
%  O
and  O
41.4  O
%  O
.  O

The  O
response  O
rate  O
for  O
group  O
A  O
was  O
28.0  O
%  O
(  O
2  O
%  O
complete  O
response  O
[  O
CR  O
]  O
,  O
26  O
%  O
partial  O
response  O
[  O
PR  O
]  O
[  O
95  O
%  O
CI  O
,  O
22  O
%  O
to  O
34  O
%  O
]  O
)  O
,  O
and  O
the  O
response  O
rate  O
for  O
group  O
B  O
was  O
35.0  O
%  O
(  O
5  O
%  O
CR  O
,  O
30  O
%  O
PR  O
)  O
[  O
95  O
%  O
CI  O
,  O
29  O
%  O
to  O
41  O
%  O
]  O
)  O
(  O
P  O
=.12  O
)  O
.  O

Toxicity  O
was  O
mild  O
.  O

Grades  O
3  O
/  O
4  O
neutropenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
,  O
and  O
anemia  B-TOXI
for  O
groups  O
A  O
and  O
B  O
were  O
seen  O
in  O
15  O
%  O
and  O
15  O
%  O
,  O
2  O
%  O
and  O
1  O
%  O
,  O
and  O
5  O
%  O
and  O
2  O
%  O
,  O
respectively  O
.  O

The  O
mean  O
total  O
cost  O
(  O
outpatient  O
clinic  O
visits  O
plus  O
chemotherapy  O
drug  O
fee  O
)  O
for  O
group  O
A  O
(  O
euro  O
;  O
7,612.64  O
)  O
versus  O
group  O
B  O
(  O
euro  O
;  O
7,484.77  O
)  O
was  O
not  O
statistically  O
significant  O
(  O
P  O
&  O
lt  O
;  O
.66  O
)  O
.  O

The  O
PG  B-DRUG
combination  O
is  O
as  O
equally  O
active  O
and  O
well  O
tolerated  O
as  O
the  O
PC  B-DRUG
combination  O
in  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

Phase  O
II  O
multicenter  O
trial  O
of  O
a  O
weekly  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
regimen  O
in  O
patients  O
with  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
activity  O
of  O
weekly  O
paclitaxel  B-DRUG
plus  O
carboplatin  B-DRUG
as  O
first-line  O
therapy  O
in  O
patients  O
with  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
(  O
ABC  B-CANCER
)  O
by  O
assessing  O
response  O
rate  O
,  O
survival  O
,  O
and  O
safety  O
.  O

One  O
hundred  O
patients  O
with  O
ABC  B-CANCER
received  O
paclitaxel  B-DRUG
135  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
group  O
1  O
,  O
n  O
=  O
20  O
)  O
and  O
carboplatin  B-DRUG
area  O
under  O
the  O
concentration-time  O
curve  O
(  O
AUC  O
)  O
of  O
2.  O
Paclitaxel  B-DRUG
was  O
subsequently  O
reduced  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
group  O
2  O
,  O
n  O
=  O
80  O
)  O
because  O
of  O
toxicity  O
.  O

The  O
median  O
age  O
was  O
58.5  O
years  O
,  O
and  O
most  O
patients  O
had  O
an  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
status  O
of  O
&  O
lt  O
;  O
or=  O
2.  O
Estrogen  O
and  O
progesterone  O
receptor  O
status  O
were  O
evenly  O
distributed  O
among  O
both  O
groups  O
.  O

Sixty-one  O
patients  O
received  O
prior  O
chemotherapy  O
,  O
37  O
(  O
61  O
%  O
)  O
of  O
whom  O
received  O
prior  O
doxorubicin  B-DRUG
.  O

Among  O
47  O
patients  O
who  O
received  O
prior  O
hormonal  O
therapy  O
,  O
43  O
received  O
tamoxifen  B-DRUG
.  O

The  O
overall  O
response  O
rate  O
(  O
ORR  O
)  O
among  O
95  O
assessable  O
patients  O
was  O
62  O
%  O
,  O
including  O
8  O
%  O
complete  O
responses  O
and  O
54  O
%  O
partial  O
responses  O
.  O

The  O
median  O
time  O
to  O
response  O
was  O
1.8  O
months  O
,  O
and  O
the  O
median  O
duration  O
of  O
response  O
was  O
13.3  O
months  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
4.8  O
months  O
.  O

The  O
median  O
survival  O
was  O
16  O
months  O
.  O

Neutropenia  B-TOXI
and  O
leukopenia  B-TOXI
were  O
the  O
most  O
common  O
grade  O
3  O
and  O
4  O
toxicities  O
.  O

In  O
group  O
1  O
,  O
neutropenia  B-TOXI
(  O
50  O
%  O
)  O
and  O
leukopenia  B-TOXI
(  O
35  O
%  O
)  O
necessitated  O
dose  O
reductions  O
for  O
50  O
%  O
of  O
patients  O
during  O
the  O
first  O
three  O
cycles  O
,  O
prompting  O
the  O
reduction  O
in  O
paclitaxel  B-DRUG
dose  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Grade  O
3  O
and  O
4  O
nonhematologic  B-TOXI
toxicities  I-TOXI
for  O
all  O
patients  O
included  O
peripheral  B-TOXI
neuropathy  I-TOXI
(  O
11  O
%  O
)  O
,  O
infection  B-TOXI
(  O
6  O
%  O
)  O
,  O
anemia  B-TOXI
(  O
5  O
%  O
)  O
,  O
weakness  B-TOXI
(  O
6  O
%  O
)  O
,  O
and  O
paresthesia  B-TOXI
(  O
3  O
%  O
)  O
.  O

The  O
62  O
%  O
ORR  O
achieved  O
with  O
weekly  O
paclitaxel  B-DRUG
plus  O
carboplatin  B-DRUG
is  O
among  O
the  O
highest  O
achieved  O
with  O
chemotherapy  O
for  O
ABC  B-CANCER
.  O

This  O
high  O
response  O
rate  O
and  O
the  O
lack  O
of  O
cardiotoxicity  B-TOXI
suggest  O
that  O
the  O
regimen  O
should  O
be  O
considered  O
as  O
a  O
nonanthracycline  O
regimen  O
for  O
future  O
adjuvant  O
therapy  O
.  O

Phase  O
II  O
study  O
to  O
evaluate  O
combining  O
gemcitabine  B-DRUG
with  O
flutamide  B-DRUG
in  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
patients  O
.  O


A  O
phase  O
II  O
study  O
was  O
undertaken  O
to  O
determine  O
the  O
safety  O
of  O
combining  O
flutamide  B-DRUG
with  O
gemcitabine  B-DRUG
,  O
with  O
response  O
rate  O
being  O
the  O
primary  O
end  O
point  O
.  O

Twenty-seven  O
patients  O
with  O
histologically  O
proven  O
,  O
previously  O
untreated  O
,  O
unresectable  O
pancreatic  B-CANCER
adenocarcinoma  I-CANCER
received  O
gemcitabine  B-DRUG
,  O
1  O
g  O
m  O
(  O
-2  O
)  O
intravenously  O
on  O
days  O
1  O
,  O
8  O
and  O
15  O
of  O
a  O
28  O
day  O
cycle  O
,  O
and  O
flutamide  B-DRUG
250  O
mg  O
given  O
orally  O
three  O
times  O
daily  O
.  O

Treatment  O
was  O
halted  O
if  O
there  O
was  O
unacceptable  O
toxicity  O
,  O
or  O
evidence  O
of  O
disease  B-TOXI
progression  I-TOXI
.  O

Toxicity  O
was  O
documented  O
every  O
cycle  O
.  O

Tumour  O
assessment  O
was  O
undertaken  O
after  O
cycles  O
2  O
and  O
4  O
,  O
and  O
thereafter  O
at  O
least  O
every  O
additional  O
four  O
cycles  O
.  O

One  O
hundred  O
and  O
seventeen  O
cycles  O
of  O
treatment  O
were  O
administered  O
,  O
median  O
four  O
cycles  O
per  O
patient  O
(  O
range  O
1-18  O
)  O
.  O

Gemcitabine  B-DRUG
combined  O
with  O
flutamide  B-DRUG
was  O
well  O
tolerated  O
,  O
with  O
most  O
toxicities  O
being  O
recorded  O
as  O
grade  O
1  O
or  O
2  O
and  O
only  O
nine  O
treatment  O
cycles  O
associated  O
with  O
grade  O
3  O
toxicity  O
.  O

The  O
most  O
frequent  O
toxicity  O
was  O
myelosuppression  B-TOXI
.  O

One  O
case  O
of  O
transient  B-TOXI
jaundice  I-TOXI
was  O
recorded  O
.  O

The  O
commonest  O
symptomatic  O
toxicity  O
was  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
.  O

The  O
response  O
rate  O
was  O
15  O
%  O
(  O
four  O
partial  O
responses  O
)  O
,  O
median  O
survival  O
6  O
months  O
and  O
22  O
%  O
of  O
patients  O
were  O
alive  O
at  O
1  O
year  O
.  O

These  O
results  O
suggest  O
antitumour  O
activity  O
of  O
the  O
combination  O
therapy  O
to  O
be  O
equivalent  O
to  O
single  O
agent  O
gemcitabine  B-DRUG
.  O

Combination  O
chemotherapy  O
comprising  O
5-fluorouracil  B-DRUG
,  O
leucovorin  B-DRUG
,  O
etoposide  B-DRUG
,  O
and  O
cis-diamminedichloroplatinum  B-DRUG
for  O
the  O
treatment  O
of  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


The  O
FLEP  B-DRUG
regimen  O
(  O
5-FU  B-DRUG
,  O
LV  B-DRUG
,  O
ETP  B-DRUG
,  O
and  O
CDDP  B-DRUG
)  O
has  O
been  O
recommended  O
as  O
a  O
combination  O
chemotherapy  O
to  O
control  O
advanced  B-CANCER
and  I-CANCER
recurrent  I-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

We  O
performed  O
a  O
phase  O
II  O
study  O
of  O
this  O
regimen  O
in  O
49  O
patients  O
with  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

The  O
treatment  O
regimen  O
consisted  O
of  O
:  O
5-FU  B-DRUG
at  O
370  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
days  O
1-5  O
,  O
i.v.  O
24  O
h  O
)  O
;  O
LV  B-DRUG
at  O
a  O
dose  O
of  O
30  O
mg  O
(  O
days  O
1-5  O
,  O
i.v.  O
bolus  O
)  O
;  O
and  O
ETP  B-DRUG
and  O
CDDP  B-DRUG
each  O
at  O
70  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
days  O
7  O
and  O
21  O
,  O
i.a.  O
2  O
h  O
)  O
,  O
which  O
was  O
repeated  O
every  O
five  O
weeks  O
.  O

The  O
overall  O
response  O
rate  O
was  O
40.8  O
%  O
(  O
20  O
/  O
49  O
patients  O
)  O
and  O
the  O
median  O
survival  O
time  O
was  O
12.6  O
months  O
(  O
range  O
1.1-41.8  O
)  O
.  O

The  O
adverse  O
events  O
were  O
Grade  O
3  O
/  O
4  O
leukocytopenia  B-TOXI
(  O
16.3  O
%  O
)  O
,  O
Grade  O
3  O
/  O
4  O
thrombocytopenia  B-TOXI
(  O
8.2  O
%  O
)  O
,  O
Grade  O
3  O
nausea  B-TOXI
and  O
/  O
or  O
vomiting  B-TOXI
(  O
4.1  O
%  O
)  O
,  O
and  O
Grade  O
3  O
stomatitis  B-TOXI
(  O
2.0  O
%  O
)  O
.  O

Based  O
on  O
the  O
encouraging  O
response  O
rate  O
and  O
prognosis  O
,  O
we  O
recommend  O
applying  O
the  O
FLEP  B-DRUG
regimen  O
to  O
patients  O
with  O
primary  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

Chronomodulated  O
chemotherapy  O
in  O
metastatic  B-CANCER
gastrointestinal  I-CANCER
cancer  I-CANCER
combining  O
5-FU  B-DRUG
and  O
sodium  B-DRUG
folinate  I-DRUG
with  O
oxaliplatin  B-DRUG
,  O
irinotecan  B-DRUG
or  O
gemcitabine  B-DRUG
:  O
the  O
Jena  O
experience  O
in  O
79  O
patients  O
.  O


To  O
study  O
efficacy  O
and  O
tolerability  O
of  O
chronomodulated  O
(  O
CM  O
)  O
-chemotherapy  O
in  O
patients  O
with  O
metastatic  B-CANCER
or  I-CANCER
locally  I-CANCER
advanced  I-CANCER
tumors  I-CANCER
of  O
the  O
GI  O
tract  O
.  O

Furthermore  O
,  O
calcium  B-DRUG
folinate  I-DRUG
was  O
replaced  O
by  O
sodium  B-DRUG
folinate  I-DRUG
due  O
to  O
better  O
feasibility  O
.  O

We  O
treated  O
79  O
patients  O
with  O
metastatic  B-CANCER
or  I-CANCER
locally  I-CANCER
advanced  I-CANCER
colorectal  I-CANCER
cancer  I-CANCER
(  O
n=52  O
)  O
,  O
cancer  B-CANCER
of  I-CANCER
the  I-CANCER
pancreas  I-CANCER
/  I-CANCER
biliary  I-CANCER
tract  I-CANCER
(  O
n=14  O
)  O
,  O
and  O
other  O
malignancies  B-CANCER
(  O
n=14  O
)  O
with  O
a  O
total  O
of  O
592  O
courses  O
of  O
CM-therapy  O
.  O

Out  O
of  O
the  O
total  O
study  O
population  O
53  O
/  O
79  O
,  O
i.e.  O
,  O
67.1  O
%  O
had  O
received  O
prior  O
chemotherapy  O
.  O

Most  O
of  O
the  O
patients  O
(  O
77.2  O
%  O
)  O
received  O
sodium-folinate-5-FU-oxaliplatin-CM  B-DRUG
(  O
SOFOX-CM  B-DRUG
)  O
as  O
first-line  O
chronomodulated  O
therapy  O
,  O
20.3  O
%  O
received  O
sodium-folinate-5-FU-irinotecan-CM  B-DRUG
(  O
SOFIRI-CM  B-DRUG
)  O
,  O
and  O
2.5  O
%  O
(  O
n=1  O
)  O
received  O
sodium-folinate-5-FU-gemcitabine-CM  B-DRUG
(  O
SOFGEM-CM  B-DRUG
)  O
.  O

We  O
found  O
a  O
moderate  O
overall  O
toxicity  O
with  O
grade  O
3-4  O
neuropathy  B-TOXI
in  O
7.46  O
%  O
of  O
patients  O
during  O
a  O
total  O
of  O
433  O
courses  O
of  O
SOFOX-CM  B-DRUG
and  O
grade  O
3-4  O
diarrhea  B-TOXI
in  O
10.26  O
%  O
of  O
patients  O
after  O
154  O
courses  O
of  O
SOFIRI-CM  B-DRUG
.  O

SOFOX-CM  B-DRUG
had  O
to  O
be  O
stopped  O
only  O
in  O
one  O
patient  O
due  O
to  O
grade  O
3-4  O
sensory  B-TOXI
neuropathy  I-TOXI
.  O

CM-therapy  O
led  O
to  O
complete  O
response  O
(  O
CR  O
)  O
in  O
1.3  O
%  O
,  O
partial  O
response  O
(  O
PR  O
)  O
in  O
15.2  O
%  O
,  O
stable  O
disease  O
(  O
SD  O
)  O
in  O
32.9  O
%  O
,  O
and  O
progressive  B-TOXI
disease  I-TOXI
(  O
PD  O
)  O
in  O
44.3  O
%  O
of  O
all  O
patients  O
.  O

For  O
the  O
26  O
chemonaive  O
patients  O
remission  O
data  O
were  O
as  O
follows  O
:  O
CR  O
one  O
patient  O
(  O
3.8  O
%  O
)  O
,  O
PR  O
four  O
patients  O
(  O
15.4  O
%  O
)  O
,  O
SD  O
seven  O
patients  O
(  O
26.9  O
%  O
)  O
,  O
PD  O
12  O
patients  O
(  O
46.3  O
%  O
)  O
,  O
lost  O
to  O
follow-up  O
one  O
patient  O
(  O
3.8  O
%  O
)  O
,  O
and  O
too-early-for-analysis  O
one  O
patient  O
(  O
3.8  O
%  O
)  O
.  O

The  O
median  O
progression-free-survival  O
(  O
PFS  O
)  O
was  O
4  O
months  O
(  O
range  O
,  O
0-24  O
months  O
)  O
.  O

The  O
median  O
PFS  O
was  O
also  O
4  O
months  O
(  O
range  O
,  O
0-21  O
months  O
)  O
for  O
those  O
patients  O
receiving  O
SOFOX-CM  B-DRUG
as  O
first  O
CM-therapy  O
(  O
n=61  O
)  O
,  O
while  O
it  O
was  O
found  O
to  O
be  O
0  O
months  O
(  O
range  O
,  O
0-10  O
months  O
)  O
for  O
patients  O
(  O
n=16  O
)  O
receiving  O
SOFIRI-CM  B-DRUG
as  O
first  O
chronomodulated  O
therapy  O
.  O

We  O
found  O
CM-therapy  O
to  O
be  O
effective  O
and  O
safe  O
in  O
the  O
treatment  O
of  O
advanced  B-CANCER
malignancies  I-CANCER
of  I-CANCER
the  I-CANCER
GI  I-CANCER
tract  I-CANCER
.  O

Sodium  B-DRUG
folinate  I-DRUG
offers  O
superior  O
feasibility  O
and  O
compatibility  O
with  O
cytostatic  B-DRUG
drugs  I-DRUG
without  O
drawbacks  O
.  O

Folinic  B-DRUG
acid  I-DRUG
,  O
5-fluorouracil  B-DRUG
and  O
mitomycin  B-DRUG
C  I-DRUG
in  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
previously  O
treated  O
with  O
at  O
least  O
two  O
chemotherapy  O
regimens  O
.  O


To  O
assess  O
the  O
activity  O
and  O
safety  O
of  O
combined  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
,  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
and  O
mitomycin  B-DRUG
C  I-DRUG
(  O
MMC  B-DRUG
)  O
in  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
previously  O
treated  O
with  O
at  O
least  O
two  O
chemotherapy  O
regimens  O
.  O

A  O
total  O
of  O
104  O
consecutive  O
patients  O
were  O
enrolled  O
for  O
treatment  O
with  O
FA  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
5-FU  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
i.v.  O
on  O
days  O
1-5  O
,  O
and  O
MMC  B-DRUG
3  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
3-5  O
(  O
FFM  O
)  O
.  O

The  O
cycles  O
were  O
repeated  O
every  O
21  O
days  O
until  O
progression  B-TOXI
,  I-TOXI
severe  I-TOXI
toxicity  I-TOXI
or  O
patient  O
refusal  O
.  O

Of  O
the  O
104  O
patients  O
,  O
96  O
were  O
evaluable  O
for  O
response  O
and  O
toxicity  O
.  O

The  O
overall  O
response  O
rate  O
was  O
43  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
32.8-53.2  O
%  O
)  O
;  O
40  O
patients  O
achieved  O
stable  O
disease  O
(  O
42  O
%  O
)  O
and  O
15  O
progressed  O
(  O
15  O
%  O
)  O
.  O

In  O
a  O
retrospectively  O
defined  O
subgroup  O
of  O
patients  O
with  O
clinical  O
resistance  O
to  O
taxanes  B-DRUG
(  O
12  O
patients  O
)  O
or  O
anthracyclines  B-DRUG
(  O
14  O
patients  O
)  O
,  O
the  O
response  O
rate  O
was  O
42  O
%  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
8  O
months  O
(  O
3-18  O
months  O
)  O
,  O
and  O
the  O
median  O
overall  O
survival  O
was  O
10.5+  O
months  O
(  O
2-36  O
months  O
)  O
.  O

The  O
most  O
common  O
treatment-related  O
adverse  O
events  O
were  O
stomatitis  B-TOXI
,  O
neutropenia  B-TOXI
,  O
nausea  B-TOXI
/  O
vomiting  B-TOXI
and  O
diarrhea  B-TOXI
.  O

Stomatitis  B-TOXI
,  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
were  O
the  O
only  O
grade  O
4  O
treatment-related  O
adverse  O
events  O
,  O
and  O
occurred  O
in  O
no  O
more  O
than  O
3  O
%  O
of  O
patients  O
.  O

The  O
tested  O
FFM  O
regimen  O
seems  O
to  O
offer  O
a  O
valid  O
option  O
for  O
patients  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
who  O
have  O
been  O
pretreated  O
with  O
two  O
or  O
more  O
chemotherapeutic  O
lines  O
or  O
who  O
have  O
failed  O
on  O
regimens  O
containing  O
anthracyclines  B-DRUG
or  O
taxanes  B-DRUG
.  O

Intermittent  O
weekly  O
high-dose  O
capecitabine  B-DRUG
in  O
combination  O
with  O
oxaliplatin  B-DRUG
:  O
a  O
phase  O
I  O
/  O
II  O
study  O
in  O
first-line  O
treatment  O
of  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


The  O
aim  O
of  O
this  O
phase  O
I  O
study  O
was  O
to  O
determine  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
the  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
an  O
intermittent  O
weekly  O
capecitabine  B-DRUG
regimen  O
in  O
combination  O
with  O
oxaliplatin  B-DRUG
.  O

Furthermore  O
,  O
we  O
intended  O
to  O
explore  O
its  O
safety  O
at  O
the  O
recommended  O
dose  O
,  O
and  O
to  O
assess  O
its  O
principal  O
antitumor  O
activity  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Thirty  O
patients  O
with  O
measurable  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
who  O
previously  O
were  O
unexposed  O
to  O
palliative  O
chemotherapy  O
were  O
enrolled  O
on  O
to  O
this  O
disease-oriented  O
phase  O
I  O
trial  O
.  O

They  O
were  O
treated  O
with  O
a  O
fixed  O
dose  O
of  O
oxaliplatin  B-DRUG
(  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
as  O
a  O
2-h  O
intravenous  O
infusion  O
on  O
day  O
1  O
)  O
plus  O
escalating  O
doses  O
of  O
capecitabine  B-DRUG
(  O
given  O
at  O
two  O
divided  O
daily  O
doses  O
from  O
days  O
1  O
to  O
7  O
)  O
,  O
repeated  O
every  O
2  O
weeks  O
.  O

The  O
dose  O
of  O
oral  O
fluoropyrimidine  B-DRUG
was  O
escalated  O
in  O
consecutive  O
cohorts  O
of  O
three  O
to  O
six  O
patients  O
from  O
2500  O
to  O
4000  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
.  O

After  O
having  O
defined  O
the  O
toxic  O
dose  O
,  O
nine  O
additional  O
patients  O
were  O
entered  O
at  O
the  O
MTD  O
/  O
recommended  O
dose  O
to  O
confirm  O
its  O
safety  O
profile  O
,  O
and  O
assure  O
suitability  O
for  O
future  O
phase  O
II  O
/  O
III  O
studies  O
.  O

In  O
the  O
phase  O
I  O
part  O
of  O
the  O
study  O
,  O
21  O
patients  O
were  O
enrolled  O
,  O
and  O
a  O
total  O
of  O
222  O
courses  O
were  O
administered  O
through  O
four  O
dose  O
levels  O
of  O
capecitabine  B-DRUG
combined  O
with  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Gastrointestinal  B-TOXI
toxicities  I-TOXI
,  O
predominantly  O
diarrhea  B-TOXI
,  O
were  O
the  O
principal  O
DLTs  O
.  O

Other  O
severe  O
adverse  O
events  O
included  O
grade  O
3  O
asthenia  B-TOXI
,  O
acute  B-TOXI
neurological  I-TOXI
symptoms  I-TOXI
and  O
skin  B-TOXI
toxicity  I-TOXI
.  O

The  O
combination  O
was  O
not  O
myelosuppressive  O
,  O
eliciting  O
only  O
sporadically  O
grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
and  O
/  O
or  O
thrombocytopenia  B-TOXI
.  O

There  O
was  O
no  O
alopecia  B-TOXI
,  O
and  O
only  O
a  O
few  O
patients  O
experienced  O
mild  O
symptoms  O
of  O
hand-foot  B-TOXI
syndrome  I-TOXI
.  O

Externally  O
reviewed  O
objective  O
responses  O
were  O
noted  O
in  O
15  O
of  O
all  O
30  O
evaluable  O
patients  O
(  O
overall  O
response  O
rate  O
,  O
50  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
31  O
%  O
to  O
69  O
%  O
)  O
including  O
three  O
complete  O
remissions  O
and  O
median  O
progression-free  O
survival  O
was  O
8.8  O
months  O
(  O
range  O
7-14+  O
months  O
)  O
.  O

Overall  O
results  O
of  O
this  O
study  O
indicate  O
that  O
the  O
administration  O
of  O
clinically  O
relevant  O
single-agent  O
doses  O
of  O
both  O
capecitabine  B-DRUG
and  O
oxaliplatin  B-DRUG
is  O
feasible  O
and  O
seems  O
to  O
result  O
in  O
promising  O
therapeutic  O
activity  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

On  O
the  O
basis  O
of  O
the  O
toxicological  O
profile  O
of  O
the  O
combination  O
regimen  O
shown  O
in  O
the  O
present  O
study  O
,  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
2-h  O
intravenous  O
infusion  O
every  O
2  O
weeks  O
administered  O
in  O
combination  O
with  O
capecitabine  B-DRUG
3500  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
x7  O
in  O
two  O
divided  O
doses  O
is  O
recommended  O
for  O
further  O
evaluations  O
.  O

Phase  O
I  O
trial  O
of  O
gemcitabine  B-DRUG
,  O
administered  O
as  O
a  O
standard  O
and  O
constant  O
dose-rate  O
infusion  O
,  O
in  O
combination  O
with  O
paclitaxel  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
(  O
LOA-2  O
)  O
.  O


The  O
major  O
purposes  O
of  O
this  O
study  O
were  O
to  O
determine  O
the  O
maximally  O
tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
,  O
toxicity  O
profile  O
,  O
and  O
antitumor  O
activity  O
of  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
combination  O
therapy  O
when  O
administered  O
to  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
,  O
using  O
two  O
infusion  O
schedules  O
of  O
each  O
agent  O
.  O

Paclitaxel  B-DRUG
was  O
administered  O
on  O
day  O
1  O
,  O
followed  O
by  O
gemcitabine  B-DRUG
,  O
and  O
gemcitabine  B-DRUG
alone  O
was  O
administered  O
on  O
day  O
8  O
,  O
of  O
each  O
21-day  O
treatment  O
course  O
.  O

In  O
the  O
initial  O
phase  O
of  O
the  O
trial  O
,  O
paclitaxel  B-DRUG
was  O
administered  O
during  O
3  O
hours  O
and  O
gemcitabine  B-DRUG
during  O
30  O
minutes  O
(  O
schedule  O
A  O
)  O
.  O

After  O
the  O
MTD  O
was  O
determined  O
on  O
this  O
schedule  O
,  O
patients  O
were  O
then  O
treated  O
with  O
paclitaxel  B-DRUG
during  O
1  O
hour  O
and  O
gemcitabine  B-DRUG
at  O
a  O
fixed  O
dose-rate  O
of  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
min  O
(  O
schedule  O
B  O
)  O
.  O

Forty-six  O
patients  O
were  O
treated  O
with  O
176  O
courses  O
at  O
7  O
dose  O
levels  O
.  O

The  O
MTD  O
for  O
schedule  O
A  O
was  O
1,300  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
for  O
schedule  O
B  O
was  O
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
for  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
,  O
respectively  O
.  O

The  O
DLT  O
for  O
schedule  O
A  O
was  O
neutropenia  B-TOXI
and  O
for  O
schedule  O
B  O
was  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
.  O

Nonhematologic  B-TOXI
toxicity  I-TOXI
was  O
relatively  O
mild  O
.  O

Gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
,  O
using  O
both  O
schedules  O
of  O
administration  O
in  O
the  O
current  O
trial  O
,  O
is  O
a  O
promising  O
chemotherapeutic  O
regimen  O
.  O

Gemcitabine  B-DRUG
and  O
interferon-alpha  B-DRUG
2b  I-DRUG
in  O
solid  B-CANCER
tumors  I-CANCER
:  O
a  O
phase  O
I  O
study  O
in  O
patients  O
with  O
advanced  B-CANCER
or  I-CANCER
metastatic  I-CANCER
non-small  I-CANCER
cell  I-CANCER
lung  I-CANCER
,  I-CANCER
ovarian  I-CANCER
,  I-CANCER
pancreatic  I-CANCER
or  I-CANCER
renal  I-CANCER
cancer  I-CANCER
.  O


We  O
performed  O
a  O
phase  O
I  O
study  O
combining  O
gemcitabine  B-DRUG
and  O
interferon  B-DRUG
(  I-DRUG
IFN  I-DRUG
)  I-DRUG
-  I-DRUG
2b  I-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
recommended  O
doses  O
for  O
phase  O
II  O
trials  O
.  O

Five  O
dose  O
levels  O
of  O
gemcitabine  B-DRUG
(  O
mg  O
/  O
m  O
)  O
/  O
IFN-  B-DRUG
(  O
x10  O
IU  O
)  O
were  O
planned  O
:  O
500  O
/  O
5  O
,  O
1000  O
/  O
5  O
,  O
1000  O
/  O
7  O
,  O
1000  O
/  O
10  O
and  O
1200  O
/  O
10  O
.  O

Gemcitabine  B-DRUG
was  O
given  O
once  O
weekly  O
and  O
IFN  B-DRUG
3  O
x  O
weekly  O
for  O
3  O
consecutive  O
weeks  O
followed  O
by  O
1  O
week  O
of  O
rest  O
(  O
28-day  O
cycles  O
)  O
.  O

Between  O
February  O
1997  O
and  O
June  O
1999  O
,  O
21  O
patients  O
with  O
advanced  B-CANCER
pancreatic  I-CANCER
(  O
=3  O
)  O
,  O
ovarian  O
(  O
=1  O
)  O
,  O
renal  O
(  O
=10  O
)  O
and  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
;  O
=7  O
)  O
were  O
enrolled  O
.  O

The  O
MTD  O
was  O
reached  O
at  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m  O
and  O
IFN-  B-DRUG
7  O
x  O
10  O
IU  O
,  O
with  O
two  O
of  O
three  O
patients  O
having  O
dose-limiting  O
toxicity  O
(  O
thrombocytopenia  B-TOXI
)  O
.  O

The  O
predominant  O
hematologic  B-TOXI
toxicities  I-TOXI
(  O
grade  O
3  O
/  O
4  O
)  O
were  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
(  O
13  O
and  O
five  O
patients  O
,  O
respectively  O
)  O
.  O

Three  O
patients  O
had  O
moderate  O
neutropenic  B-TOXI
fever  I-TOXI
and  O
one  O
had  O
grade  O
4  O
AST  O
/  O
ALT  O
;  O
none  O
required  O
hospitalization  O
.  O

Of  O
the  O
18  O
evaluable  O
patients  O
,  O
responses  O
included  O
one  O
partial  O
response  O
(  O
NSCLC  B-CANCER
)  O
and  O
10  O
stable  O
diseases  O
(  O
eight  O
renal  B-CANCER
cancer  I-CANCER
)  O
.  O

We  O
conclude  O
that  O
the  O
recommended  O
phase  O
II  O
study  O
regimen  O
is  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m  O
and  O
IFN-  B-DRUG
5  O
x  O
10  O
IU  O
,  O
every  O
28  O
days  O
.  O

The  O
results  O
,  O
particularly  O
those  O
in  O
metastatic  B-CANCER
renal  I-CANCER
carcinoma  I-CANCER
,  O
are  O
encouraging  O
and  O
worthy  O
of  O
further  O
evaluation  O
in  O
phase  O
II  O
trials  O
.  O

Phase  O
I  O
study  O
of  O
pegylated  B-DRUG
liposomal  I-DRUG
doxorubicin  I-DRUG
and  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
malignancies  I-CANCER
.  O


Pegylated  B-DRUG
liposomal  I-DRUG
doxorubicin  I-DRUG
(  O
PEG-LD  B-DRUG
)  O
and  O
gemcitabine  B-DRUG
have  O
single-agent  O
activity  O
in  O
breast  B-CANCER
and  I-CANCER
ovarian  I-CANCER
carcinoma  I-CANCER
patients  O
.  O

We  O
conducted  O
a  O
Phase  O
I  O
trial  O
to  O
evaluate  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
toxicities  O
of  O
this  O
combination  O
in  O
patients  O
with  O
advanced  B-CANCER
malignancies  I-CANCER
.  O

Twenty-six  O
patients  O
with  O
refractory  O
or  O
recurrent  O
malignancies  B-CANCER
were  O
enrolled  O
in  O
this  O
dose  O
escalation  O
trial  O
.  O

Dose  O
escalation  O
proceeded  O
from  O
a  O
starting  O
level  O
of  O
PEG-LD  B-DRUG
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
on  O
Days  O
1  O
and  O
15  O
of  O
a  O
28-day  O
cycle  O
.  O

The  O
MTD  O
was  O
PEG-LD  B-DRUG
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
2000  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
on  O
Days  O
1  O
and  O
15  O
of  O
a  O
28-day  O
cycle  O
.  O

Dose-limiting  O
toxicity  O
,  O
a  O
Grade  O
3  O
rash  B-TOXI
,  O
was  O
observed  O
in  O
one  O
patient  O
during  O
Cycle  O
1  O
and  O
Grade  O
3  O
stomatitis  B-TOXI
and  O
a  O
rash  B-TOXI
were  O
observed  O
in  O
a  O
second  O
patient  O
during  O
Cycle  O
2  O
after  O
administration  O
of  O
PEG-LD  B-DRUG
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
2000  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Other  O
side  O
effects  O
included  O
palmar-plantar  B-TOXI
erythrodysesthesia  I-TOXI
,  O
nausea  B-TOXI
,  O
and  O
fatigue  B-TOXI
.  O

One  O
complete  O
and  O
two  O
partial  O
responses  O
were  O
observed  O
.  O

The  O
recommended  O
Phase  O
II  O
dose  O
is  O
PEG-LD  B-DRUG
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
with  O
gemcitabine  B-DRUG
2000  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
Days  O
1  O
and  O
15  O
of  O
a  O
28-day  O
cycle  O
.  O

A  O
trial  O
with  O
this  O
combination  O
is  O
currently  O
ongoing  O
at  O
this  O
institution  O
comprising  O
patients  O
with  O
refractory  O
ovarian  B-CANCER
carcinoma  I-CANCER
.  O

Phase  O
I  O
study  O
of  O
rubitecan  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
malignancies  I-CANCER
.  O


Rubitecan  B-DRUG
(  O
9-nitrocamptothecin  B-DRUG
,  O
9-NC  B-DRUG
,  O
Orathecin  B-DRUG
)  O
and  O
gemcitabine  B-DRUG
have  O
single-agent  O
activity  O
in  O
pancreatic  B-CANCER
and  I-CANCER
ovarian  I-CANCER
carcinoma  I-CANCER
.  O

We  O
conducted  O
a  O
phase  O
I  O
trial  O
to  O
evaluate  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
toxicities  O
of  O
this  O
combination  O
in  O
advanced  B-CANCER
malignancies  I-CANCER
.  O

Twenty-one  O
patients  O
with  O
refractory  O
or  O
recurrent  O
malignancies  B-CANCER
were  O
enrolled  O
in  O
this  O
dose  O
escalation  O
trial  O
.  O

Dose  O
escalation  O
proceeded  O
from  O
a  O
starting  O
level  O
of  O
rubitecan  B-DRUG
at  O
0.75  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
administered  O
orally  O
on  O
days  O
1-5  O
and  O
8-12  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
intravenously  O
on  O
days  O
1  O
and  O
8  O
of  O
a  O
21-day  O
cycle  O
.  O

The  O
MTD  O
was  O
defined  O
as  O
rubitecan  B-DRUG
1  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
orally  O
days  O
1-5  O
and  O
8-12  O
,  O
and  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
intravenously  O
over  O
30  O
min  O
days  O
1  O
and  O
8  O
,  O
given  O
every  O
21  O
days  O
.  O

Dose-limiting  O
toxicity  O
was  O
myelosuppression  B-TOXI
including  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
.  O

Other  O
side  O
effects  O
included  O
diarrhea  B-TOXI
,  O
nausea  B-TOXI
,  O
vomiting  B-TOXI
and  O
fatigue  B-TOXI
.  O

Five  O
patients  O
with  O
stable  O
disease  O
were  O
observed  O
among  O
18  O
evaluable  O
patients  O
.  O

The  O
recommended  O
phase  O
II  O
dose  O
is  O
rubitecan  B-DRUG
1  O
mg  O
/  O
m  O
(  O
2  O
)  O
given  O
orally  O
on  O
days  O
1-5  O
and  O
8-12  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
30-min  O
intravenous  O
infusion  O
on  O
days  O
1  O
and  O
8  O
of  O
a  O
21-day  O
cycle  O
.  O

A  O
phase  O
I  O
trial  O
of  O
weekly  O
docetaxel  B-DRUG
and  O
cisplatinum  B-DRUG
combined  O
to  O
concurrent  O
hyperfractionated  O
radiotherapy  O
for  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
and  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
.  O


We  O
conducted  O
a  O
phase  O
I  O
study  O
to  O
evaluate  O
the  O
activity  O
and  O
tolerability  O
of  O
concurrent  O
docetaxel  B-DRUG
and  O
cisplatinum  B-DRUG
radiosensitization  O
with  O
hyperfractionated  O
irradiation  O
,  O
in  O
patients  O
with  O
advanced  B-CANCER
non-small  I-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
and  O
squamous  B-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
(  O
SCCHN  B-CANCER
)  O
.  O

Nine  O
patients  O
(  O
5  O
stage  O
III  O
(  O
A  O
)  O
and  O
4  O
III  O
(  O
B  O
)  O
)  O
with  O
NSCLC  B-CANCER
,  O
and  O
15  O
with  O
SCCHN  B-CANCER
(  O
10  O
stage  O
III  O
and  O
5  O
IV  O
)  O
were  O
treated  O
with  O
a  O
b.i.d.  O
hyperfractionated  O
(  O
HF  O
)  O
radiotherapy  O
schedule  O
.  O

The  O
normalized  O
total  O
dose  O
for  O
alpha  O
/  O
beta  O
ratio  O
=  O
10  O
Gy  O
was  O
69.6  O
Gy  O
for  O
NSCLC  O
and  O
80.5  O
Gy  O
for  O
SCCHN  B-CANCER
patients  O
.  O

The  O
standard  O
dose  O
of  O
cisplatin  B-DRUG
(  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
was  O
given  O
combined  O
to  O
docetaxel  B-DRUG
on  O
a  O
weekly  O
basis  O
.  O

The  O
docetaxel  B-DRUG
starting  O
dose  O
level  O
was  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
and  O
was  O
escalated  O
by  O
3  O
mg  O
/  O
m  O
(  O
2  O
)  O
increments  O
in  O
cohorts  O
of  O
8  O
patients  O
(  O
5  O
SCCHN  B-CANCER
and  O
3  O
NSCLC  B-CANCER
)  O
.  O

DLT  O
(  O
grade  O
3  O
malaise  B-TOXI
)  O
was  O
observed  O
in  O
4  O
out  O
of  O
8  O
patients  O
treated  O
at  O
the  O
16  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
docetaxel  B-DRUG
dose  O
level  O
.  O

The  O
13  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
docetaxel  B-DRUG
dose  O
level  O
was  O
defined  O
as  O
the  O
MTD  O
causing  O
grade  O
3  O
mucositis  B-TOXI
in  O
4  O
out  O
of  O
8  O
patients  O
.  O

In  O
total  O
4  O
(  O
17  O
%  O
)  O
patients  O
developed  O
grade  O
3  O
neutropenia  B-TOXI
.  O

G-CSF  B-DRUG
support  O
was  O
given  O
in  O
1  O
/  O
8  O
,  O
4  O
/  O
8  O
,  O
and  O
5  O
/  O
8  O
patients  O
treated  O
at  O
the  O
10  O
,  O
13  O
and  O
16  O
mg  O
/  O
m  O
(  O
2  O
)  O
docetaxel  B-DRUG
dose  O
levels  O
respectively  O
.  O

Fatigue  B-TOXI
was  O
the  O
most  O
common  O
adverse  O
event  O
(  O
5  O
/  O
24  O
:  O
21  O
%  O
)  O
and  O
was  O
responsible  O
for  O
more  O
than  O
1  O
week  O
treatment  O
delay  O
in  O
4  O
out  O
of  O
8  O
patients  O
treated  O
at  O
the  O
16  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
docetaxel  B-DRUG
dose  O
level  O
.  O

Nine  O
(  O
3  O
NSCLC  B-CANCER
and  O
6  O
SCCHN  B-CANCER
patients  O
:  O
37.5  O
%  O
)  O
had  O
treatment  O
delay  O
of  O
1  O
week  O
,  O
while  O
7  O
(  O
3  O
NSCLC  B-CANCER
and  O
4  O
SCCHN  B-CANCER
:  O
29  O
%  O
)  O
had  O
delays  O
of  O
2  O
weeks  O
for  O
combined  O
chemoradiation  B-TOXI
sequelae  I-TOXI
.  O

Acute  B-TOXI
hypersensitivity  I-TOXI
reactions  I-TOXI
occurred  O
in  O
3  O
(  O
12.5  O
%  O
)  O
patients  O
,  O
and  O
grade  O
3  O
mucositis  B-TOXI
in  O
2  O
/  O
8  O
,  O
5  O
/  O
8  O
and  O
6  O
/  O
8  O
patients  O
,  O
treated  O
at  O
10  O
,  O
13  O
and  O
16  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
docetaxel  B-DRUG
dose  O
levels  O
respectively  O
.  O

The  O
overall  O
response  O
rate  O
was  O
79  O
%  O
(  O
CI  O
=  O
63-96  O
%  O
)  O
with  O
33  O
%  O
and  O
53  O
%  O
CRs  O
for  O
NSCLC  B-CANCER
and  O
SCCHN  B-CANCER
patients  O
respectively  O
.  O

There  O
were  O
3  O
deaths  B-TOXI
among  O
9  O
NSCLC  B-CANCER
and  O
4  O
among  O
15  O
SCCHN  B-CANCER
patients  O
.  O

Local  B-TOXI
and  I-TOXI
/  I-TOXI
or  I-TOXI
distant  I-TOXI
disease  I-TOXI
recurrences  I-TOXI
were  O
shown  O
in  O
4  O
NSCLC  B-CANCER
and  O
in  O
6  O
SCCHN  B-CANCER
patients  O
;  O
5  O
NSCLC  B-CANCER
and  O
9  O
SCCHN  B-CANCER
patients  O
are  O
alive  O
with  O
no  O
evidence  O
of  O
tumor  B-TOXI
progression  I-TOXI
at  O
8.5  O
months  O
mean  O
follow-up  O
time  O
.  O

Radiosensitization  O
with  O
docetaxel  B-DRUG
and  O
cisplatin  B-DRUG
given  O
concurrently  O
with  O
HF  O
(  O
b.i.d.  O
)  O
radiotherapy  O
on  O
a  O
weekly  O
basis  O
is  O
a  O
promising  O
approach  O
and  O
the  O
recommended  O
dose  O
for  O
further  O
phase  O
II  O
studies  O
is  O
10  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
week  O
for  O
both  O
drugs  O
.  O

The  O
antitumor  O
activity  O
shown  O
was  O
significant  O
in  O
both  O
types  O
of  O
tumors  O
.  O

The  O
incorporation  O
of  O
docetaxel  B-DRUG
in  O
chemoradiotherapy  O
regimens  O
for  O
future  O
treatment  O
of  O
squamous  B-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
lung  I-CANCER
and  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
,  O
merits  O
evaluation  O
in  O
phase  O
II  O
and  O
III  O
trials  O
.  O

Temozolomide  B-DRUG
in  O
combination  O
with  O
interferon  B-DRUG
alpha-2b  I-DRUG
in  O
patients  O
with  O
metastatic  B-CANCER
melanoma  I-CANCER
:  O
a  O
phase  O
I  O
dose-escalation  O
study  O
.  O


Metastatic  B-CANCER
melanoma  I-CANCER
(  O
MM  B-CANCER
)  O
is  O
associated  O
with  O
a  O
high  O
risk  O
of  O
central  O
nervous  O
system  O
(  O
CNS  O
)  O
metastases  O
,  O
and  O
current  O
chemotherapy  O
does  O
not  O
adequately  O
treat  O
or  O
protect  O
patients  O
with  O
MM  B-CANCER
against  O
CNS  O
metastases  O
.  O

Therefore  O
,  O
the  O
authors  O
initiated  O
a  O
Phase  O
I  O
study  O
to  O
determine  O
the  O
pharmacokinetics  O
and  O
safety  O
profile  O
of  O
temozolomide  B-DRUG
(  O
TMZ  O
)  O
,  O
a  O
novel  O
oral  O
alkylating  B-DRUG
agent  I-DRUG
known  O
to  O
cross  O
the  O
blood-brain  O
barrier  O
,  O
in  O
combination  O
with  O
interferon  B-DRUG
alpha-2b  I-DRUG
(  O
IFN-alpha2b  B-DRUG
)  O
.  O

Twenty-three  O
patients  O
with  O
MM  B-CANCER
were  O
enrolled  O
in  O
this  O
single-center  O
,  O
open-label  O
study  O
.  O

Patients  O
with  O
CNS  O
metastasis  O
were  O
excluded  O
.  O

One  O
cohort  O
(  O
n  O
=  O
6  O
patients  O
)  O
received  O
oral  O
TMZ  B-DRUG
(  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
day  O
)  O
for  O
5  O
days  O
every  O
28-day  O
cycle  O
plus  O
subcutaneous  O
IFN-alpha2b  B-DRUG
(  O
5  O
million  O
International  O
Units  O
[  O
MIU  O
]  O
/  O
m  O
(  O
2  O
)  O
per  O
day  O
,  O
3  O
times  O
per  O
week  O
)  O
.  O

A  O
second  O
cohort  O
(  O
n  O
=  O
17  O
patients  O
)  O
received  O
TMZ  B-DRUG
150  O
mg  O
/  O
m  O
(  O
2  O
)  O
per  O
day  O
on  O
the  O
same  O
schedule  O
plus  O
escalating  O
doses  O
of  O
IFN-alpha2b  B-DRUG
(  O
5.0  O
MIU  O
/  O
m  O
(  O
2  O
)  O
per  O
day  O
,  O
7.5  O
MIU  O
/  O
m  O
(  O
2  O
)  O
per  O
day  O
,  O
and  O
10  O
MIU  O
/  O
m  O
(  O
2  O
)  O
per  O
day  O
3  O
times  O
per  O
week  O
)  O
.  O

The  O
most  O
common  O
adverse  O
events  O
were  O
fatigue  B-TOXI
,  O
fever  B-TOXI
,  O
nausea  B-TOXI
/  O
emesis  B-TOXI
,  O
anxiety  B-TOXI
,  O
and  O
diarrhea  B-TOXI
.  O

Most  O
toxicity  O
was  O
mild  O
to  O
moderate  O
in  O
severity  O
.  O

The  O
primary  O
dose-limiting  O
toxicity  O
was  O
thrombocytopenia  B-TOXI
.  O

The  O
maximum  O
tolerated  O
dose  O
was  O
either  O
TMZ  B-DRUG
150  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
IFN-alpha2b  B-DRUG
7.5  O
MIU  O
/  O
m  O
(  O
2  O
)  O
or  O
TMZ  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
IFN-alpha2b  B-DRUG
5.0  O
MIU  O
/  O
m  O
(  O
2  O
)  O
.  O

Four  O
patients  O
(  O
17  O
%  O
)  O
had  O
objective  O
responses  O
(  O
one  O
complete  O
response  O
and  O
three  O
partial  O
responses  O
)  O
,  O
and  O
four  O
patients  O
had  O
stable  O
disease  O
.  O

The  O
median  O
survival  O
was  O
9  O
months  O
.  O

The  O
pharmacokinetics  O
of  O
TMZ  B-DRUG
were  O
not  O
affected  O
by  O
coadministration  O
of  O
IFN-alpha2b  B-DRUG
.  O

TMZ  B-DRUG
can  O
be  O
combined  O
safely  O
with  O
IFN-alpha2b  B-DRUG
.  O

This  O
regimen  O
demonstrated  O
clinical  O
activity  O
in  O
patients  O
with  O
MM  B-DRUG
and  O
merits  O
further  O
investigation  O
to  O
define  O
its  O
effect  O
on  O
the  O
incidence  O
of  O
brain  O
metastases  O
.  O

Phase  O
I  O
trial  O
of  O
weekly  O
docetaxel  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
refractory  O
malignancies  B-CANCER
.  O


A  O
Phase  O
I  O
study  O
using  O
weekly  O
docetaxel  B-DRUG
and  O
gemcitabine  B-DRUG
was  O
conducted  O
to  O
investigate  O
toxicity  O
;  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
each  O
agent  O
;  O
and  O
,  O
in  O
a  O
preliminary  O
fashion  O
,  O
to  O
determine  O
the  O
antitumor  O
activity  O
of  O
the  O
combination  O
.  O

Docetaxel  B-DRUG
and  O
gemcitabine  B-DRUG
were  O
administered  O
intravenously  O
on  O
Days  O
1  O
,  O
8  O
,  O
and  O
15  O
every  O
28  O
days  O
.  O

The  O
dose  O
levels  O
of  O
docetaxel  B-DRUG
and  O
gemcitabine  B-DRUG
were  O
as  O
follows  O
:  O
Level  O
I  O
,  O
docetaxel  B-DRUG
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
;  O
Level  O
II  O
,  O
docetaxel  B-DRUG
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
;  O
Level  O
III  O
,  O
docetaxel  B-DRUG
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
;  O
Level  O
IV  O
,  O
docetaxel  B-DRUG
36  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
;  O
and  O
Level  O
V  O
,  O
docetaxel  B-DRUG
36  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Thirty-three  O
eligible  O
patients  O
were  O
entered  O
.  O

The  O
diagnoses  O
were  O
as  O
follows  O
:  O
Eleven  O
patients  O
had  O
nonsmall  B-CANCER
cell  I-CANCER
lung  I-CANCER
carcinoma  I-CANCER
,  O
3  O
patients  O
had  O
carcinoma  B-CANCER
of  I-CANCER
the  I-CANCER
bladder  I-CANCER
,  O
3  O
patients  O
had  O
renal  B-CANCER
carcinoma  I-CANCER
,  O
2  O
patients  O
had  O
adrenal  B-CANCER
carcinoma  I-CANCER
,  O
5  O
patients  O
had  O
unknown  B-CANCER
primary  I-CANCER
tumors  I-CANCER
,  O
and  O
9  O
patients  O
had  O
miscellaneous  B-CANCER
malignancies  I-CANCER
.  O

Fifty-nine  O
percent  O
of  O
patients  O
had  O
received  O
prior  O
chemotherapy  O
.  O

The  O
median  O
age  O
was  O
62  O
years  O
(  O
range  O
,  O
27-77  O
years  O
)  O
,  O
and  O
the  O
median  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
status  O
was  O
1  O
(  O
range  O
,  O
0-1  O
)  O
.  O

Five  O
patients  O
were  O
treated  O
at  O
Dose  O
Levels  O
I  O
and  O
II  O
,  O
6  O
patients  O
were  O
treated  O
at  O
Dose  O
Levels  O
III  O
and  O
V  O
,  O
and  O
11  O
patients  O
were  O
treated  O
at  O
Dose  O
Level  O
IV  O
.  O

Grade  O
3-4  O
toxicities  O
during  O
Cycle  O
I  O
included  O
neutropenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
,  O
mucositis  B-TOXI
,  O
and  O
diarrhea  B-TOXI
.  O

Dose-limiting  O
toxicity  O
,  O
consisting  O
of  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
,  O
occurred  O
in  O
three  O
of  O
six  O
patients  O
at  O
Dose  O
Level  O
V.  O
The  O
combination  O
of  O
docetaxel  B-DRUG
36  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
Dose  O
Level  O
IV  O
)  O
was  O
determined  O
as  O
the  O
MTD  O
and  O
was  O
the  O
recommended  O
Phase  O
II  O
dose  O
.  O

Two  O
patients  O
had  O
a  O
partial  O
response  O
:  O
one  O
patient  O
with  O
bladder  B-CANCER
carcinoma  I-CANCER
(  O
Dose  O
Level  O
II  O
)  O
and  O
one  O
patient  O
with  O
nonsmall  B-CANCER
cell  I-CANCER
lung  I-CANCER
carcinoma  I-CANCER
(  O
Dose  O
Level  O
III  O
)  O
.  O

Overall  O
,  O
weekly  O
docetaxel  B-DRUG
and  O
gemcitabine  B-DRUG
were  O
well  O
tolerated  O
.  O

Further  O
studies  O
using  O
this  O
combination  O
are  O
planned  O
,  O
including  O
a  O
Phase  O
II  O
trial  O
in  O
patients  O
with  O
advanced  B-CANCER
nonsmall  I-CANCER
cell  I-CANCER
lung  I-CANCER
carcinoma  I-CANCER
.  O

A  O
dose-escalation  O
and  O
pharmacokinetic  O
study  O
of  O
gemcitabine  B-DRUG
and  O
oxaliplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


Gemcitabine  B-DRUG
and  O
oxaliplatin  B-DRUG
have  O
broad  O
antineoplastic  O
activity  O
and  O
favorable  O
toxicity  O
.  O

We  O
conducted  O
a  O
phase  O
I  O
study  O
to  O
determine  O
the  O
maximum  O
tolerated  O
doses  O
(  O
MTDs  O
)  O
and  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
the  O
combination  O
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

Sixty-eight  O
patients  O
with  O
advanced  B-CANCER
stage  I-CANCER
solid  I-CANCER
tumors  I-CANCER
were  O
enrolled  O
.  O

Treatment  O
was  O
first-line  O
for  O
35  O
%  O
of  O
patients  O
,  O
second-line  O
for  O
27  O
%  O
,  O
and  O
third-line  O
for  O
38  O
%  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
at  O
escalating  O
doses  O
of  O
1000-2000  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
30-min  O
intravenous  O
(  O
i.v.  O
)  O
infusion  O
on  O
days  O
1  O
and  O
8  O
and  O
oxaliplatin  B-DRUG
at  O
60-130  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
4-h  O
i.v.  O
infusion  O
on  O
day  O
8  O
every  O
21  O
days  O
without  O
growth  O
factor  O
support  O
.  O

The  O
MTD  O
was  O
defined  O
at  O
gemcitabine  B-DRUG
1800  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
8  O
and  O
oxaliplatin  B-DRUG
130  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
8.  O
Twelve  O
dose  O
levels  O
were  O
evaluated  O
and  O
DLTs  O
occurring  O
during  O
the  O
first  O
cycle  O
consisted  O
of  O
grade  O
4  O
neutropenia  B-TOXI
,  O
grade  O
3  O
asthenia  B-TOXI
or  O
mucositis  B-TOXI
and  O
grade  O
1-3  O
neutropenia  B-TOXI
or  O
thrombocytopenia  B-TOXI
resulting  O
in  O
treatment  O
delays  O
.  O

A  O
total  O
of  O
266  O
cycles  O
were  O
administered  O
with  O
only  O
one  O
episode  O
of  O
febrile  B-TOXI
neutropenia  I-TOXI
and  O
no  O
toxic  B-TOXI
deaths  I-TOXI
.  O

Seven  O
(  O
3  O
%  O
)  O
and  O
26  O
(  O
10  O
%  O
)  O
cycles  O
were  O
complicated  O
by  O
grade  O
4  O
and  O
3  O
neutropenia  B-TOXI
,  O
respectively  O
,  O
three  O
(  O
1  O
%  O
)  O
and  O
13  O
(  O
5  O
%  O
)  O
by  O
grade  O
4  O
and  O
3  O
thrombocytopenia  B-TOXI
,  O
and  O
eight  O
(  O
3  O
%  O
)  O
by  O
grade  O
3  O
anemia  B-TOXI
.  O

The  O
most  O
common  O
non-hematological  B-TOXI
toxicity  I-TOXI
was  O
grade  O
2  O
/  O
3  O
asthenia  B-TOXI
observed  O
in  O
23  O
%  O
of  O
cycles  O
.  O

Responses  O
were  O
observed  O
in  O
patients  O
with  O
a  O
variety  O
of  O
epithelial  B-CANCER
neoplasms  I-CANCER
.  O

The  O
pharmacokinetic  O
study  O
revealed  O
no  O
significant  O
interaction  O
between  O
the  O
two  O
drugs  O
.  O

The  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
oxaliplatin  B-DRUG
has  O
excellent  O
tolerability  O
and  O
promising  O
activity  O
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

As  O
the  O
MTD  O
exceeds  O
the  O
recommended  O
single-agent  O
dose  O
for  O
gemcitabine  B-DRUG
,  O
and  O
a  O
dose-response  O
effect  O
has  O
not  O
been  O
established  O
,  O
we  O
recommend  O
using  O
both  O
drugs  O
at  O
full  O
doses  O
,  O
e.g.  O
gemcitabine  B-DRUG
1200-1400  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
8  O
and  O
oxaliplatin  B-DRUG
130  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
8  O
for  O
further  O
phase  O
II  O
studies  O
.  O

Gemcitabine  B-DRUG
and  O
vinorelbine  B-DRUG
followed  O
by  O
docetaxel  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
a  O
multi-institutional  O
phase  O
II  O
trial  O
of  O
nonplatinum  O
sequential  O
triplet  O
combination  O
chemotherapy  O
(  O
JMTO  O
LC00-02  O
)  O
.  O


To  O
evaluate  O
the  O
efficacy  O
and  O
toxicity  O
of  O
the  O
sequential  O
nonplatinum  O
combination  O
chemotherapy  O
consisting  O
of  O
gemcitabine  B-DRUG
(  O
GEM  B-DRUG
)  O
and  O
vinorelbine  B-DRUG
(  O
VNR  B-DRUG
)  O
followed  O
by  O
docetaxel  B-DRUG
(  O
DOC  B-DRUG
)  O
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
,  O
we  O
conducted  O
the  O
multiinstitutional  O
phase  O
II  O
study  O
.  O

A  O
total  O
of  O
44  O
chemotherapy-naive  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
were  O
treated  O
with  O
GEM  B-DRUG
1000  O
mg  O
m  O
(  O
-2  O
)  O
and  O
VNR  B-DRUG
25  O
mg  O
m  O
(  O
-2  O
)  O
intravenously  O
on  O
days  O
1  O
and  O
8  O
every  O
3  O
weeks  O
for  O
three  O
cycles  O
.  O

DOC  B-DRUG
60  O
mg  O
m  O
(  O
-2  O
)  O
was  O
then  O
administrated  O
intravenously  O
at  O
3-week  O
intervals  O
for  O
three  O
cycles  O
.  O

Patients  O
were  O
evaluated  O
for  O
response  O
and  O
toxicity  O
with  O
each  O
cycle  O
of  O
the  O
treatment  O
.  O

The  O
major  O
objective  O
response  O
rate  O
was  O
47.7  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
,  O
33.8-62.1  O
%  O
)  O
.  O

Median  O
survival  O
time  O
(  O
MST  O
)  O
was  O
15.7  O
months  O
and  O
1-year  O
survival  O
rate  O
was  O
59  O
%  O
.  O

In  O
the  O
GEM  B-DRUG
/  I-DRUG
VNR  I-DRUG
cycle  O
,  O
grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
occurred  O
in  O
36.3  O
%  O
,  O
grade  O
3  O
/  O
4  O
anaemia  B-TOXI
in  O
two  O
patients  O
(  O
4.5  O
%  O
)  O
and  O
grade  O
3  O
thrombocytopenia  B-TOXI
in  O
one  O
patient  O
(  O
2.3  O
%  O
)  O
.  O

Grade  O
3  O
pneumonitis  B-TOXI
occurred  O
in  O
two  O
patients  O
(  O
4.5  O
%  O
)  O
in  O
GEM  B-DRUG
/  I-DRUG
VNR  I-DRUG
cycles  O
.  O

In  O
the  O
DOC  B-DRUG
cycles  O
,  O
grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
occurred  O
in  O
39.4  O
%  O
but  O
no  O
patient  O
experienced  O
grade  O
3  O
/  O
4  O
anaemia  B-TOXI
or  O
thrombocytopenia  B-TOXI
.  O

Of  O
the  O
44  O
eligible  O
patients  O
,  O
33  O
patients  O
completed  O
three  O
cycles  O
of  O
GEM  B-DRUG
/  I-DRUG
VNR  I-DRUG
and  O
22  O
patients  O
completed  O
six  O
cycles  O
of  O
planned  O
chemotherapy  O
(  O
three  O
cycles  O
of  O
GEM  B-DRUG
/  I-DRUG
VNR  I-DRUG
followed  O
by  O
three  O
cycles  O
of  O
DOC  B-DRUG
)  O
.  O

The  O
sequential  O
triplet  O
nonplatinum  O
chemotherapy  O
consisted  O
of  O
GEM  B-DRUG
/  I-DRUG
VNR  I-DRUG
followed  O
by  O
DOC  B-DRUG
,  O
and  O
was  O
very  O
active  O
and  O
well  O
tolerated  O
.  O

This  O
study  O
forms  O
the  O
basis  O
for  O
an  O
ongoing  O
phase  O
III  O
trial  O
that  O
compares  O
this  O
nonplatinum  O
triplet  O
and  O
standard  O
platinum  O
doublet  O
combination  O
(  O
carboplatin  B-DRUG
/  I-DRUG
paclitaxel  I-DRUG
)  O
.  O

Final  O
results  O
of  O
a  O
randomized  O
phase  O
III  O
trial  O
comparing  O
cyclophosphamide  B-DRUG
,  O
epirubicin  B-DRUG
,  O
and  O
fluorouracil  B-DRUG
with  O
a  O
dose-intensified  O
epirubicin  B-DRUG
and  O
cyclophosphamide  B-DRUG
+  I-DRUG
filgrastim  I-DRUG
as  O
neoadjuvant  O
treatment  O
in  O
locally  B-CANCER
advanced  I-CANCER
breast  I-CANCER
cancer  I-CANCER
:  O
an  O
EORTC-NCIC-SAKK  O
multicenter  O
study  O
.  O


To  O
compare  O
the  O
efficacy  O
of  O
a  O
standard  O
anthracycline-based  B-DRUG
regimen  O
to  O
a  O
dose-intensified  O
anthracycline  B-DRUG
regimen  O
in  O
locally  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O

Locally  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
were  O
randomly  O
assigned  O
onto  O
a  O
study  O
comparing  O
cyclophosphamide  B-DRUG
(  O
C  O
;  O
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
orally  O
days  O
1  O
to  O
14  O
)  O
,  O
epirubicin  B-DRUG
(  O
E  O
;  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenously  O
[  O
IV  O
]  O
days  O
1  O
,  O
8  O
)  O
,  O
and  O
fluorouracil  B-DRUG
(  O
F  O
;  O
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
IV  O
days  O
1  O
,  O
8  O
)  O
six  O
cycles  O
every  O
28  O
days  O
versus  O
E  O
(  O
120  O
mg  O
/  O
m  O
(  O
2  O
)  O
IV  O
day  O
1  O
)  O
,  O
C  O
(  O
830  O
mg  O
/  O
m  O
(  O
2  O
)  O
IV  O
day  O
1  O
)  O
,  O
and  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
(  O
filgrastim  B-DRUG
;  O
5  O
micro  O
g  O
/  O
kg  O
/  O
d  O
subcutaneously  O
days  O
2  O
to  O
13  O
)  O
six  O
cycles  O
every  O
14  O
days  O
.  O

The  O
study  O
was  O
designed  O
to  O
detect  O
a  O
15  O
%  O
improvement  O
;  O
that  O
is  O
,  O
from  O
50  O
%  O
to  O
65  O
%  O
in  O
median  O
progression-free  O
survival  O
(  O
PFS  O
)  O
in  O
favor  O
of  O
the  O
dose-intensified  O
regimen  O
.  O

A  O
total  O
of  O
448  O
patients  O
were  O
enrolled  O
over  O
a  O
period  O
of  O
3  O
years  O
.  O

The  O
median  O
dose  O
intensity  O
delivered  O
for  O
C  O
and  O
E  O
reached  O
,  O
respectively  O
,  O
85  O
%  O
and  O
87  O
%  O
of  O
that  O
planned  O
in  O
the  O
CEF  O
arm  O
and  O
96  O
%  O
and  O
95  O
%  O
of  O
that  O
planned  O
in  O
the  O
EC  O
arm  O
.  O

The  O
dose-intensified  O
arm  O
was  O
slightly  O
more  O
emetogenic  B-TOXI
and  O
generated  O
more  O
grade  O
3  O
to  O
4  O
anemia  B-TOXI
but  O
less  O
febrile  B-TOXI
neutropenia  I-TOXI
episodes  O
.  O

After  O
a  O
median  O
follow-up  O
of  O
5.5  O
years  O
,  O
277  O
events  O
have  O
been  O
reported  O
.  O

The  O
median  O
PFS  O
was  O
34  O
and  O
33.7  O
months  O
for  O
CEF  O
and  O
EC  O
,  O
respectively  O
(  O
P  O
=.68  O
)  O
,  O
and  O
the  O
5-year  O
survival  O
rate  O
was  O
53  O
%  O
and  O
51  O
%  O
for  O
CEF  O
and  O
EC  O
,  O
respectively  O
(  O
P  O
=.94  O
)  O
.  O

Dose-intensified  O
EC  O
does  O
not  O
provide  O
a  O
measurable  O
therapeutic  O
benefit  O
over  O
CEF  O
as  O
neoadjuvant  O
chemotherapy  O
for  O
unselected  O
locally  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
patients  O
.  O

High-dose  O
consolidation  O
chemotherapy  O
with  O
Idarubicin  B-DRUG
and  O
alkylating  B-DRUG
agents  I-DRUG
following  O
induction  O
with  O
gemcitabine-epirubicin-paclitaxel  B-DRUG
in  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
:  O
a  O
dose  O
finding  O
study  O
.  O


Preliminary  O
randomized  O
studies  O
have  O
failed  O
to  O
show  O
a  O
survival  O
benefit  O
of  O
high-dose  O
chemotherapy  O
with  O
alkylators  B-DRUG
in  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O

Idarubicin  B-DRUG
is  O
an  O
active  O
agent  O
in  O
breast  B-CANCER
cancer  I-CANCER
and  O
is  O
suitable  O
for  O
dose  O
escalation  O
.  O

We  O
designed  O
a  O
dose  O
finding  O
study  O
with  O
escalating  O
high-dose  O
idarubicin  B-DRUG
(  O
HD-Ida  B-DRUG
)  O
followed  O
by  O
fixed  O
high-dose  O
thiotepa+melphalan  B-DRUG
(  O
HD-TM  B-DRUG
)  O
with  O
peripheral  B-DRUG
blood  I-DRUG
progenitor  I-DRUG
cells  I-DRUG
(  O
PBPC  O
)  O
in  O
MBC  B-CANCER
patients  O
with  O
stable  O
disease  O
or  O
in  O
partial  O
response  O
after  O
six  O
courses  O
of  O
induction  O
chemotherapy  O
with  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
days  O
1  O
and  O
4  O
,  O
epirubicin  B-DRUG
90  O
mg  O
/  O
m  O
(  O
2  O
)  O
day  O
1  O
,  O
taxol  O
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
day  O
1  O
(  O
GET  B-DRUG
)  O
.  O

Aims  O
of  O
the  O
study  O
were  O
to  O
identify  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
idarubicin  O
,  O
to  O
evaluate  O
the  O
cardiac  O
safety  O
and  O
activity  O
of  O
HD-Ida  B-DRUG
and  O
HD-TM  B-DRUG
after  O
GET  B-DRUG
and  O
to  O
study  O
the  O
pharmacokinetic  O
profile  O
of  O
idarubicin  B-DRUG
and  O
idarubicinol  B-DRUG
.  O

A  O
total  O
of  O
14  O
patients  O
were  O
treated  O
.  O

Idarubicin  B-DRUG
was  O
administered  O
as  O
a  O
48  O
h  O
continuous  O
i.v.  O
infusion  O
at  O
the  O
following  O
dose  O
levels  O
:  O
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
three  O
patients  O
)  O
,  O
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
three  O
patients  O
)  O
,  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
five  O
patients  O
)  O
and  O
70  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
three  O
patients  O
)  O
.  O

Mucositis  B-TOXI
was  O
the  O
dose-limiting  O
toxicity  O
and  O
the  O
MTD  O
was  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

C  O
(  O
max  O
)  O
of  O
Idarubicin  B-DRUG
and  O
idarubicinol  B-DRUG
were  O
7.7+  O
/  O
-2.0  O
and  O
26.3+  O
/  O
-9.7  O
ng  O
/  O
ml  O
at  O
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
increased  O
to  O
14.8+3.0  O
and  O
47.4+12.6  O
ng  O
/  O
ml  O
at  O
70  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

AUCt  O
(  O
0-264  O
)  O
of  O
idarubicin  B-DRUG
and  O
idarubicinol  B-DRUG
increased  O
from  O
423.2+  O
/  O
-111.6  O
and  O
2581+  O
/  O
-606  O
hng  O
/  O
ml  O
at  O
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
to  O
732.8+  O
/  O
-140.2  O
and  O
4590+  O
/  O
-1258  O
hng  O
/  O
ml  O
at  O
70  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Conversion  O
rates  O
after  O
HD-Ida  B-DRUG
and  O
HD-TM  B-DRUG
were  O
28.6  O
and  O
38.5  O
%  O
,  O
respectively  O
.  O

No  O
episodes  O
of  O
cardiac  B-TOXI
toxicity  I-TOXI
were  O
observed  O
.  O

We  O
conclude  O
that  O
HD-Ida  B-DRUG
followed  O
by  O
HD-TM  B-DRUG
is  O
feasible  O
and  O
devoid  O
of  O
cardiac  B-TOXI
toxicity  I-TOXI
.  O

Moreover  O
,  O
the  O
activity  O
of  O
HD-Ida  B-DRUG
after  O
a  O
epirubicin-containing  B-DRUG
regimen  O
suggests  O
incomplete  O
cross-resistance  O
between  O
the  O
two  O
drugs  O
.  O

Preoperative  O
concurrent  O
chemoradiotherapy  O
in  O
locally  O
advanced  B-CANCER
rectal  I-CANCER
cancer  I-CANCER
with  O
high-dose  O
radiation  O
and  O
oxaliplatin-containing  B-DRUG
regimen  O
:  O
the  O
Lyon  O
R0-04  O
phase  O
II  O
trial  O
.  O


The  O
combination  O
of  O
radiation  O
,  O
fluorouracil  B-DRUG
,  O
and  O
oxaliplatin  B-DRUG
in  O
locally  O
advanced  B-CANCER
rectal  I-CANCER
cancer  I-CANCER
has  O
been  O
shown  O
to  O
be  O
feasible  O
in  O
a  O
phase  O
I  O
trial  O
.  O

The  O
purpose  O
of  O
this  O
phase  O
II  O
trial  O
was  O
to  O
assess  O
tolerance  O
and  O
efficacy  O
of  O
this  O
regimen  O
in  O
a  O
preoperative  O
setting  O
.  O

Between  O
May  O
2000  O
and  O
October  O
2001  O
,  O
40  O
operable  O
patients  O
were  O
entered  O
onto  O
the  O
study  O
.  O

Radiotherapy  O
was  O
delivered  O
with  O
a  O
three-field  O
technique  O
to  O
a  O
dose  O
of  O
50  O
Gy  O
over  O
5  O
weeks  O
with  O
a  O
concomitant  O
boost  O
approach  O
.  O

Two  O
cycles  O
of  O
chemotherapy  O
were  O
given  O
synchronously  O
on  O
weeks  O
1  O
and  O
5  O
,  O
with  O
oxaliplatin  B-DRUG
130  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
1  O
followed  O
by  O
5-day  O
continuous  O
infusion  O
of  O
fluorouracil  B-DRUG
350  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
L-folinic  B-DRUG
acid  I-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Surgery  O
was  O
planned  O
5  O
weeks  O
later  O
.  O

All  O
patients  O
completed  O
treatment  O
without  O
modification  O
except  O
one  O
who  O
experienced  O
grade  O
3  O
/  O
4  O
toxicity  O
.  O

Grade  O
3  O
toxicity  O
was  O
seen  O
in  O
seven  O
patients  O
.  O

Surgery  O
was  O
performed  O
in  O
all  O
patients  O
after  O
a  O
mean  O
interval  O
time  O
of  O
5  O
weeks  O
.  O

An  O
objective  O
clinical  O
response  O
was  O
seen  O
in  O
30  O
patients  O
(  O
75  O
%  O
)  O
.  O

Sphincter-saving  O
surgery  O
was  O
possible  O
in  O
26  O
patients  O
.  O

No  O
postoperative  O
deaths  B-TOXI
occurred  O
.  O

In  O
four  O
patients  O
(  O
10  O
%  O
)  O
,  O
a  O
reoperation  O
was  O
necessary  O
(  O
anastomotic  B-TOXI
fistula  I-TOXI
,  O
n  O
=  O
2  O
;  O
pelvic  B-TOXI
abscess  I-TOXI
,  O
n  O
=  O
2  O
)  O
.  O

In  O
six  O
cases  O
the  O
operative  O
specimen  O
was  O
sterilized  O
(  O
15  O
%  O
)  O
,  O
and  O
in  O
12  O
cases  O
(  O
30  O
%  O
)  O
,  O
only  O
few  O
residual  O
cells  O
were  O
detected  O
.  O

Such  O
a  O
combined  O
preoperative  O
chemoradiotherapy  O
and  O
oxaliplatin-containing  B-DRUG
regimen  O
is  O
well  O
tolerated  O
with  O
no  O
increase  O
in  O
surgical  O
toxicity  O
.  O

The  O
good  O
response  O
rate  O
observed  O
warrants  O
its  O
use  O
in  O
further  O
clinical  O
trials  O
.  O

Phase  O
I  O
trial  O
of  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
in  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


Gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
are  O
chemotherapeutic  O
agents  O
with  O
clinical  O
antitumor  O
activity  O
in  O
a  O
broad  O
range  O
of  O
malignant  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

Because  O
of  O
preclinical  O
synergy  O
,  O
unique  O
mechanisms  O
of  O
action  O
and  O
resistance  O
,  O
and  O
nonoverlapping  O
toxicities  O
,  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
combinations  O
are  O
attractive  O
for  O
testing  O
in  O
clinical  O
trials  O
.  O

Prior  O
weekly  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
regimens  O
administered  O
on  O
a  O
28-day  O
cycle  O
have  O
been  O
limited  O
by  O
cumulative  O
hematological  B-TOXI
toxicity  I-TOXI
on  O
day  O
15  O
,  O
thus  O
reducing  O
the  O
planned  O
gemcitabine  B-DRUG
dose  O
intensity  O
.  O

We  O
therefore  O
conducted  O
a  O
phase  O
I  O
trial  O
of  O
a  O
21-day  O
schedule  O
of  O
weekly  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
to  O
determine  O
the  O
tolerability  O
,  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
and  O
preliminary  O
estimates  O
of  O
efficacy  O
of  O
this  O
regimen  O
.  O

Forty-one  O
patients  O
with  O
advanced  B-CANCER
malignant  I-CANCER
solid  I-CANCER
tumors  I-CANCER
were  O
accrued  O
.  O

Gemcitabine  B-DRUG
was  O
given  O
at  O
a  O
fixed  O
dose  O
of  O
1000  O
mg  O
/  O
m2  O
while  O
paclitaxel  B-DRUG
was  O
administered  O
at  O
an  O
initial  O
dose  O
of  O
60  O
mg  O
/  O
m2  O
,  O
then  O
escalated  O
by  O
15  O
mg  O
/  O
m2  O
increments  O
over  O
seven  O
dose  O
levels  O
to  O
a  O
prospectively  O
planned  O
maximum  O
dose  O
of  O
150  O
mg  O
/  O
m2  O
.  O

Both  O
agents  O
were  O
infused  O
intravenously  O
on  O
days  O
one  O
and  O
eight  O
every  O
21  O
days  O
.  O

At  O
least  O
three  O
patients  O
were  O
enrolled  O
per  O
dose  O
level  O
.  O

No  O
intrapatient  O
dose  O
escalation  O
was  O
allowed  O
.  O

All  O
patients  O
were  O
assessable  O
for  O
toxicity  O
and  O
31  O
were  O
assessable  O
for  O
response  O
.  O

The  O
regimen  O
was  O
generally  O
well-tolerated  O
.  O

Dose-limiting  O
thrombocytopenia  B-DRUG
was  O
observed  O
in  O
one  O
patient  O
at  O
a  O
paclitaxel  B-DRUG
dose  O
of  O
135  O
mg  O
/  O
m2  O
/  O
week  O
(  O
dose  O
level  O
6  O
)  O
.  O

After  O
expansion  O
of  O
this  O
dose  O
level  O
by  O
14  O
additional  O
patients  O
,  O
no  O
further  O
dose-limiting  O
toxicities  O
were  O
observed  O
although  O
one  O
patient  O
at  O
dose  O
level  O
seven  O
died  B-TOXI
of  I-TOXI
neutropenic  I-TOXI
sepsis  I-TOXI
after  O
completing  O
three  O
cycles  O
.  O

There  O
were  O
eight  O
partial  O
responders  O
for  O
an  O
overall  O
response  O
proportion  O
of  O
26  O
%  O
(  O
95  O
%  O
CI  O
:  O
11  O
,  O
41  O
)  O
.  O

Twelve  O
patients  O
(  O
39  O
%  O
)  O
had  O
stable  O
disease  O
.  O

This  O
21-day  O
schedule  O
of  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
is  O
safe  O
,  O
well-tolerated  O
,  O
and  O
active  O
.  O

The  O
recommended  O
phase  O
II  O
dose  O
is  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m2  O
and  O
paclitaxel  B-DRUG
150  O
mg  O
/  O
m2  O
on  O
days  O
one  O
and  O
eight  O
every  O
21  O
days  O
.  O

The  O
antitumor  O
activity  O
observed  O
with  O
this  O
regimen  O
warrants  O
further  O
investigation  O
.  O

Phase  O
I  O
/  O
II  O
trial  O
of  O
weekly  O
cisplatin  B-DRUG
,  O
etoposide  B-DRUG
,  O
and  O
irinotecan  B-DRUG
chemotherapy  O
for  O
metastatic  B-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
JCOG  O
9507  O
.  O


Combinations  O
of  O
cisplatin-irinotecan  B-DRUG
and  O
cisplatin-etoposide  B-DRUG
are  O
active  O
and  O
well  O
tolerated  O
in  O
patients  O
with  O
both  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
SCLC  B-CANCER
)  O
and  O
nonsmall-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

To  O
define  O
the  O
recommended  O
dose  O
for  O
phase  O
II  O
trials  O
of  O
irinotecan  B-DRUG
combined  O
with  O
cisplatin  B-DRUG
and  O
etoposide  B-DRUG
in  O
chemonaive  O
patients  O
with  O
stage  O
IV  O
disease  O
,  O
56  O
patients  O
(  O
11  O
having  O
SCLC  B-CANCER
and  O
45  O
NSCLC  B-CANCER
)  O
received  O
cisplatin  B-DRUG
25  O
mg  O
m  O
(  O
-2  O
)  O
weekly  O
for  O
9  O
weeks  O
,  O
etoposide  B-DRUG
60  O
mg  O
m  O
(  O
-2  O
)  O
for  O
3  O
days  O
on  O
weeks  O
1  O
,  O
3  O
,  O
5  O
,  O
7  O
and  O
9  O
,  O
and  O
irinotecan  B-DRUG
20-100  O
mg  O
m  O
(  O
-2  O
)  O
(  O
levels  O
1-8  O
)  O
on  O
weeks  O
2  O
,  O
4  O
,  O
6  O
and  O
8  O
,  O
together  O
with  O
a  O
prophylactical  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
support  O
(  O
50  O
microg  O
m  O
(  O
-2  O
)  O
on  O
days  O
4-7  O
on  O
weeks  O
1  O
,  O
3  O
,  O
5  O
,  O
7  O
and  O
9  O
,  O
and  O
on  O
days  O
2-7  O
on  O
weeks  O
2  O
,  O
4  O
,  O
6  O
and  O
8  O
)  O
.  O

Grade  O
3-4  O
leukocytopenia  B-TOXI
,  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
were  O
noted  O
in  O
20  O
(  O
36  O
%  O
)  O
,  O
28  O
(  O
50  O
%  O
)  O
and  O
nine  O
(  O
16  O
%  O
)  O
patients  O
,  O
respectively  O
.  O

Grade  O
3  O
diarrhoea  B-TOXI
,  O
grade  O
3  O
cardiac  B-TOXI
toxicity  I-TOXI
,  O
and  O
grade  O
4  O
transaminase  B-TOXI
elevation  I-TOXI
developed  O
in  O
one  O
(  O
1.8  O
%  O
)  O
patient  O
each  O
.  O

Totally  O
,  O
four  O
of  O
56  O
patients  O
were  O
removed  O
from  O
the  O
study  O
because  O
of  O
toxicity  O
and  O
recovered  O
,  O
and  O
two  O
other  O
patients  O
died  B-TOXI
in  O
situations  O
where  O
drug  O
toxicity  O
might  O
contribute  O
to  O
their  O
death  B-TOXI
.  O

Dose-limiting  O
toxicity  O
was  O
noted  O
in  O
less  O
than  O
one-third  O
of  O
patients  O
at  O
dose  O
levels  O
1-7  O
,  O
but  O
in  O
all  O
patients  O
at  O
dose  O
level  O
8.  O
Thus  O
,  O
the  O
recommended  O
dose  O
was  O
determined  O
to  O
be  O
level  O
7  O
(  O
irinotecan  O
90  O
mg  O
m  O
(  O
-2  O
)  O
)  O
.  O

The  O
response  O
rates  O
for  O
SCLC  B-CANCER
and  O
NSCLC  B-CANCER
were  O
91  O
%  O
(  O
10  O
/  O
11  O
)  O
and  O
38  O
%  O
(  O
17  O
/  O
45  O
)  O
,  O
respectively  O
.  O

The  O
median  O
survival  O
time  O
and  O
1-year  O
survival  O
rate  O
were  O
11.9  O
months  O
and  O
46  O
%  O
for  O
SCLC  B-CANCER
and  O
10.1  O
months  O
and  O
40  O
%  O
for  O
NSCLC  B-CANCER
,  O
respectively  O
.  O

This  O
regimen  O
was  O
considered  O
to  O
be  O
feasible  O
and  O
promising  O
for  O
the  O
treatment  O
of  O
stage  O
IV  O
SCLC  B-CANCER
and  O
NSCLC  B-CANCER
.  O

Adjuvant  O
treatment  O
of  O
high-risk  O
stage  O
II  O
breast  B-CANCER
cancer  I-CANCER
with  O
doxorubicin  B-DRUG
followed  O
by  O
high-dose  O
chemotherapy  O
and  O
autologous  O
stem-cell  O
transplantation  O
:  O
a  O
single-institution  O
experience  O
with  O
132  O
consecutive  O
patients  O
.  O


Several  O
studies  O
have  O
shown  O
conflicting  O
results  O
with  O
the  O
use  O
of  O
intensive  O
consolidation  O
chemotherapy  O
for  O
breast  B-CANCER
cancer  I-CANCER
.  O

The  O
aim  O
of  O
the  O
present  O
study  O
was  O
to  O
investigate  O
the  O
efficacy  O
,  O
feasibility  O
and  O
toxicity  O
of  O
high-dose  O
chemotherapy  O
with  O
stem  O
cell  O
support  O
in  O
patients  O
with  O
high-risk  O
stage  O
II  O
breast  B-CANCER
cancer  I-CANCER
.  O

From  O
February  O
1994  O
to  O
November  O
1998  O
,  O
132  O
consecutive  O
patients  O
with  O
multinode  O
positive  O
breast  B-CANCER
cancer  I-CANCER
were  O
entered  O
to  O
the  O
study  O
.  O

In  O
total  O
,  O
86  O
patients  O
had  O
&  O
gt  O
;  O
or=10  O
positive  B-TOXI
axillary  I-TOXI
lymph  I-TOXI
nodes  I-TOXI
,  O
and  O
46  O
had  O
4-9  O
positive  B-TOXI
axillary  I-TOXI
lymph  I-TOXI
nodes  I-TOXI
with  I-TOXI
at  I-TOXI
least  I-TOXI
two  I-TOXI
additional  I-TOXI
predetermined  I-TOXI
risk  I-TOXI
factors  I-TOXI
at  O
diagnosis  O
.  O

All  O
patients  O
were  O
offered  O
adjuvant  O
chemotherapy  O
(  O
doxorubicin  B-DRUG
,  O
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
x  O
4  O
)  O
followed  O
by  O
high-dose  O
chemotherapy  O
(  O
cyclophosphamide  B-DRUG
6000  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
carboplatin  B-DRUG
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
thio-tepa  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
and  O
autologous  O
stem  O
cell  O
support  O
with  O
growth  O
factor  O
.  O

In  O
all  O
,  O
131  O
patients  O
also  O
received  O
local  O
radiation  O
therapy  O
and  O
tamoxifen  B-DRUG
based  O
on  O
receptor  O
status  O
.  O

After  O
a  O
median  O
follow-up  O
of  O
51  O
months  O
(  O
range  O
27-87  O
)  O
,  O
the  O
disease-free  O
and  O
overall  O
survival  O
rates  O
were  O
72  O
and  O
81  O
%  O
,  O
respectively  O
.  O

There  O
was  O
no  O
difference  O
in  O
the  O
outcome  O
for  O
high-risk  O
patients  O
with  O
&  O
gt  O
;  O
or  O
&  O
lt  O
;  O
than  O
10  O
positive  B-TOXI
axillary  I-TOXI
lymph  I-TOXI
nodes  I-TOXI
.  O

On  O
Cox  O
regression  O
analysis  O
only  O
progesterone  B-DRUG
receptor  O
status  O
was  O
predictive  O
of  O
disease-free  O
,  O
but  O
not  O
overall  O
survival  O
.  O

There  O
were  O
no  O
treatment-related  B-TOXI
deaths  I-TOXI
;  O
grades  O
III-IV  O
toxicity  O
was  O
relatively  O
low  O
.  O

This  O
combined  O
approach  O
of  O
doxorubicin  B-DRUG
followed  O
by  O
high-dose  O
chemotherapy  O
and  O
stem-cell  O
support  O
,  O
followed  O
by  O
locoregional  O
radiotherapy  O
,  O
was  O
safe  O
and  O
seems  O
to  O
be  O
effective  O
in  O
patients  O
with  O
multinode  O
positive  O
stage  O
II  O
breast  B-CANCER
cancer  I-CANCER
.  O

In  O
previous  O
trials  O
of  O
adjuvant  O
high-dose  O
therapy  O
in  O
this  O
patient  O
population  O
,  O
treatment-related  O
morbidity  O
and  O
mortality  O
markedly  O
influenced  O
the  O
outcome  O
.  O

For  O
this  O
high-risk  O
patient  O
population  O
,  O
further  O
testing  O
of  O
intensive  O
chemotherapy  O
regimens  O
with  O
a  O
lower  O
toxicity  O
profile  O
is  O
warranted  O
.  O

Randomized  O
phase  O
I  O
trial  O
of  O
recombinant  B-DRUG
human  I-DRUG
keratinocyte  I-DRUG
growth  I-DRUG
factor  I-DRUG
plus  O
chemotherapy  O
:  O
potential  O
role  O
as  O
mucosal  O
protectant  O
.  O


To  O
evaluate  O
the  O
safety  O
of  O
recombinant  B-DRUG
human  I-DRUG
keratinocyte  I-DRUG
growth  I-DRUG
factor  I-DRUG
(  O
KGF  B-DRUG
)  O
when  O
administered  O
with  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
in  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Patients  O
(  O
N  O
=  O
81  O
)  O
received  O
KGF  B-DRUG
by  O
intravenous  O
(  O
IV  O
)  O
bolus  O
on  O
days  O
1  O
to  O
3  O
,  O
followed  O
by  O
FU  B-DRUG
425  O
mg  O
/  O
m2  O
/  O
d  O
IV  O
bolus  O
plus  O
leucovorin  B-DRUG
20  O
mg  O
/  O
m2  O
/  O
d  O
IV  O
on  O
days  O
4  O
to  O
8.  O
KGF  B-DRUG
dose  O
levels  O
were  O
1  O
,  O
10  O
,  O
20  O
,  O
40  O
,  O
60  O
,  O
and  O
80  O
microg  O
/  O
kg  O
/  O
d.  O
A  O
randomized  O
,  O
placebo-controlled  B-DRUG
design  O
was  O
employed  O
(  O
2:1  O
randomization  O
of  O
KGF  B-DRUG
to  O
placebo  B-DRUG
)  O
.  O

Oral  B-TOXI
mucositis  I-TOXI
was  O
assessed  O
by  O
examination  O
on  O
days  O
1  O
,  O
4  O
,  O
8  O
,  O
15  O
,  O
and  O
28  O
.  O

In  O
addition  O
,  O
patients  O
provided  O
daily  O
assessments  O
of  O
oral  B-TOXI
symptoms  I-TOXI
using  O
a  O
self-administered  O
questionnaire  O
.  O

Skin  B-TOXI
and  I-TOXI
oral  I-TOXI
events  I-TOXI
occurred  O
in  O
13  O
of  O
18  O
patients  O
(  O
eight  O
patients  O
,  O
grade  O
1  O
;  O
four  O
patients  O
,  O
grade  O
2  O
;  O
and  O
one  O
patient  O
,  O
grade  O
3  O
)  O
treated  O
with  O
60  O
and  O
80  O
microg  O
/  O
kg  O
of  O
KGF  B-DRUG
and  O
three  O
of  O
11  O
patients  O
treated  O
with  O
40  O
microg  O
/  O
kg  O
(  O
grade  O
1  O
)  O
.  O

These  O
symptoms  O
were  O
dose  O
limiting  O
in  O
three  O
cases  O
(  O
ie  O
,  O
in  O
two  O
of  O
10  O
patients  O
treated  O
with  O
80  O
microg  O
/  O
kg  O
and  O
in  O
one  O
of  O
eight  O
patients  O
treated  O
with  O
60  O
microg  O
/  O
kg  O
)  O
.  O

The  O
frequency  O
of  O
grade  O
2  O
to  O
4  O
mucositis  B-TOXI
was  O
43  O
%  O
in  O
patients  O
treated  O
with  O
KGF  B-DRUG
,  O
compared  O
with  O
67  O
%  O
in  O
patients  O
treated  O
with  O
placebo  B-DRUG
(  O
P  O
=.06  O
)  O
.  O

Patient  O
self-assessments  O
of  O
oral  O
pain  O
and  O
clinical  O
assessments  O
of  O
mucositis  B-TOXI
showed  O
good  O
correlation  O
(  O
Kendall  O
's  O
tau  O
=  O
0.75  O
)  O
.  O

KGF  B-DRUG
is  O
generally  O
well  O
tolerated  O
when  O
administered  O
IV  O
at  O
doses  O
up  O
to  O
40  O
microg  O
/  O
kg  O
/  O
d  O
for  O
3  O
days  O
before  O
a  O
5-day  O
course  O
of  O
FU  B-DRUG
plus  O
leucovorin  B-DRUG
.  O

A  O
clinically  O
meaningful  O
biologic  O
effect  O
was  O
also  O
suggested  O
in  O
that  O
patients  O
treated  O
with  O
the  O
epithelial  B-DRUG
growth  I-DRUG
factor  I-DRUG
KGF  B-DRUG
had  O
a  O
lower  O
rate  O
of  O
grade  O
2  O
to  O
4  O
mucositis  B-TOXI
than  O
did  O
patients  O
treated  O
with  O
placebo  B-DRUG
.  O

Phase  O
I-II  O
study  O
of  O
docetaxel  B-DRUG
and  O
ifosfamide  B-DRUG
combination  O
in  O
patients  O
with  O
anthracycline  B-DRUG
pretreated  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O


Given  O
the  O
established  O
individual  O
activity  O
of  O
docetaxel  B-DRUG
and  O
ifosfamide  B-DRUG
in  O
anthracycline  B-DRUG
pretreated  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
,  O
the  O
present  O
phase  O
I-II  O
study  O
aimed  O
to  O
define  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
the  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
,  O
and  O
activity  O
of  O
the  O
docetaxel-ifosfamide  B-DRUG
combination  O
in  O
this  O
setting  O
.  O

Cohorts  O
of  O
three  O
to  O
six  O
patients  O
with  O
histologically  O
confirmed  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
after  O
prior  O
anthracycline-based  B-DRUG
chemotherapy  O
were  O
treated  O
at  O
successive  O
dose  O
levels  O
(  O
DLs  O
)  O
with  O
escalated  O
doses  O
of  O
docetaxel  B-DRUG
70-100  O
mg  O
x  O
m  O
(  O
-2  O
)  O
over  O
1  O
h  O
on  O
day  O
1  O
followed  O
by  O
ifosfamide  B-DRUG
5-6  O
g  O
x  O
m  O
(  O
-2  O
)  O
divided  O
over  O
days  O
1  O
and  O
2  O
(  O
2.5-3.0  O
g  O
x  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
over  O
1  O
h  O
)  O
,  O
and  O
recycled  O
every  O
21  O
days  O
.  O

G-CSF  B-DRUG
was  O
added  O
once  O
dose-limiting  O
neutropenia  B-TOXI
was  O
encountered  O
at  O
a  O
certain  O
DL  O
and  O
planned  O
to  O
be  O
incorporated  O
prophylactically  O
in  O
subsequent  O
higher  O
DLs  O
.  O

In  O
total  O
,  O
56  O
patients  O
with  O
a  O
median  O
age  O
of  O
54.5  O
(  O
range  O
,  O
32-72  O
)  O
years  O
and  O
performance  O
status  O
(  O
WHO  O
)  O
of  O
1  O
(  O
range  O
,  O
0-2  O
)  O
were  O
treated  O
at  O
five  O
DLs  O
as  O
follows  O
:  O
21  O
in  O
phase  O
I  O
DLs  O
(  O
DL1  O
:  O
3  O
,  O
DL2  O
:  O
6  O
,  O
DL3  O
:  O
3  O
,  O
DL4  O
:  O
6  O
,  O
and  O
DL5  O
:  O
3  O
)  O
and  O
the  O
remaining  O
35  O
were  O
treated  O
at  O
DL4  O
(  O
total  O
of  O
41  O
patients  O
at  O
DL4  O
)  O
,  O
which  O
was  O
defined  O
as  O
the  O
level  O
for  O
phase  O
II  O
testing  O
.  O

All  O
patients  O
were  O
assessable  O
for  O
toxicity  O
and  O
53  O
for  O
response  O
.  O

Dose-limiting  O
toxicity  O
(  O
with  O
the  O
addition  O
of  O
G-CSF  B-DRUG
after  O
DL2  O
)  O
was  O
reached  O
at  O
DL5  O
with  O
two  O
out  O
of  O
three  O
initial  O
patients  O
developing  O
febrile  B-TOXI
neutropenia  I-TOXI
(  O
FN  B-TOXI
)  O
.  O

Clinical  O
response  O
rates  O
,  O
on  O
an  O
intention-to-treat  O
basis  O
,  O
in  O
phase  O
II  O
were  O
:  O
53.6  O
%  O
(  O
95  O
%  O
CI  O
,  O
38.3-68.9  O
%  O
)  O
;  O
three  O
complete  O
remissions  O
,  O
19  O
partial  O
remissions  O
,  O
seven  O
stable  O
disease  O
,  O
and  O
12  O
progressive  B-TOXI
disease  I-TOXI
.  O

The  O
median  O
response  O
duration  O
was  O
7  O
months  O
(  O
3-24  O
months  O
)  O
,  O
median  O
time  O
to  O
progression  O
6.5  O
month  O
(  O
0.1-26  O
month  O
)  O
,  O
and  O
median  O
overall  O
survival  O
13  O
months  O
(  O
0.1-33  O
months  O
)  O
.  O

Grade  O
3  O
/  O
4  O
toxicities  O
included  O
time  O
to  O
progression  O
neutropenia  B-TOXI
in  O
78  O
%  O
of  O
patients-with  O
63  O
%  O
developing  O
grade  O
4  O
neutropenia  B-TOXI
(  O
&  O
lt  O
;  O
or=7  O
days  O
)  O
and  O
in  O
12  O
%  O
of  O
these  O
FN  B-TOXI
,  O
while  O
no  O
grade  O
3  O
/  O
4  O
thrombocytopenia  B-TOXI
was  O
observed  O
.  O

Other  O
toxicities  O
included  O
peripheral  B-TOXI
neuropathy  I-TOXI
grade  O
2  O
only  O
in  O
12  O
%  O
,  O
grade  O
1  O
/  O
2  O
reversible  B-TOXI
CNS  I-TOXI
toxicity  I-TOXI
in  O
17  O
%  O
,  O
no  O
renal  O
toxicity  O
,  O
grade  O
2  O
myalgias  B-TOXI
in  O
10  O
%  O
,  O
grade  O
3  O
diarrhoea  B-TOXI
in  O
10  O
%  O
,  O
skin  B-TOXI
/  I-TOXI
nail  I-TOXI
toxicity  I-TOXI
in  O
17  O
%  O
,  O
and  O
grade  O
2  O
fluid  B-TOXI
retention  I-TOXI
in  O
2  O
%  O
of  O
patients  O
.  O

One  O
patient  O
in  O
the  O
study  O
treated  O
at  O
phase  O
II  O
died  O
as  O
a  O
result  O
of  O
acute  B-TOXI
liver  I-TOXI
failure  I-TOXI
after  O
the  O
first  O
cycle  O
.  O

In  O
conclusion  O
,  O
the  O
present  O
phase  O
I-II  O
study  O
determined  O
the  O
feasibility  O
of  O
the  O
docetaxel-ifosfamide  B-DRUG
combination  O
,  O
defined  O
the  O
MTD  O
and  O
demonstrated  O
the  O
encouraging  O
activity  O
of  O
the  O
regimen  O
in  O
phase  O
II  O
,  O
thus  O
warranting  O
further  O
randomised  O
phase  O
III  O
comparisons  O
to  O
single-agent  O
docetaxel  B-DRUG
or  O
combinations  O
of  O
the  O
latter  O
with  O
other  O
active  O
agents  O
.  O

Combination  O
second-line  O
chemotherapy  O
with  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
for  O
recurrent  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
after  O
platinum-containing  B-DRUG
chemotherapy  O
:  O
a  O
phase  O
I  O
/  O
II  O
trial  O
.  O


In  O
a  O
randomized  O
trial  O
,  O
docetaxel  B-DRUG
monotherapy  O
yielded  O
longer  O
survival  O
than  O
the  O
best  O
supportive  O
care  O
in  O
patients  O
with  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
previously  O
treated  O
with  O
platinum-based  B-DRUG
chemotherapy  O
,  O
and  O
combination  O
chemotherapy  O
regimens  O
containing  O
docetaxel  B-DRUG
have  O
been  O
assessed  O
to  O
enhance  O
the  O
efficacy  O
of  O
second-line  O
chemotherapy  O
.  O

We  O
conducted  O
a  O
phase  O
I  O
/  O
II  O
trial  O
of  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
in  O
patients  O
with  O
recurrent  B-CANCER
NSCLC  I-CANCER
after  O
platinum-based  B-DRUG
chemotherapy  O
and  O
with  O
an  O
ECOG  O
performance  O
status  O
(  O
PS  O
)  O
of  O
0  O
or  O
1.  O
Docetaxel  B-DRUG
administration  O
was  O
fixed  O
at  O
a  O
dosage  O
of  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
8  O
,  O
and  O
gemcitabine  B-DRUG
was  O
administered  O
on  O
days  O
1  O
and  O
8.  O
The  O
starting  O
dose  O
level  O
of  O
gemcitabine  B-DRUG
was  O
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
level  O
0  O
)  O
,  O
and  O
the  O
subsequent  O
dose  O
level  O
of  O
gemcitabine  B-DRUG
was  O
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
level  O
+1  O
)  O
.  O

Treatment  O
was  O
repeated  O
every  O
3  O
weeks  O
.  O

In  O
the  O
phase  O
I  O
study  O
,  O
13  O
patients  O
were  O
enrolled  O
,  O
and  O
in  O
the  O
phase  O
II  O
study  O
,  O
29  O
patients  O
were  O
enrolled  O
.  O

Neutropenic  B-TOXI
fever  I-TOXI
and  O
omission  O
of  O
treatment  O
on  O
day  O
8  O
due  O
to  O
leukopenia  B-TOXI
(  O
leukocyte  O
count  O
less  O
than  O
3000  O
/  O
mm  O
(  O
3  O
)  O
)  O
were  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
.  O

Three  O
of  O
six  O
patients  O
experienced  O
DLTs  O
at  O
level  O
+1  O
,  O
which  O
was  O
the  O
maximum  O
tolerated  O
dose  O
.  O

Gemcitabine  B-DRUG
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
8  O
plus  O
docetaxel  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
8  O
(  O
level  O
0  O
)  O
was  O
recommended  O
for  O
the  O
phase  O
II  O
study  O
.  O

An  O
objective  O
response  O
was  O
observed  O
in  O
8  O
(  O
28  O
%  O
)  O
of  O
the  O
29  O
patients  O
.  O

The  O
median  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
was  O
4.2  O
months  O
(  O
95  O
%  O
CI  O
0.9-7.7  O
months  O
)  O
.  O

The  O
median  O
survival  O
time  O
was  O
11.1  O
months  O
(  O
95  O
%  O
CI  O
9.9-12.4  O
months  O
)  O
,  O
and  O
the  O
1-year  O
survival  O
rate  O
was  O
41  O
%  O
.  O

The  O
most  O
common  O
toxicity  O
,  O
though  O
mild  O
,  O
was  O
hematologic  O
,  O
and  O
consisted  O
of  O
grade  O
4  O
neutropenia  B-TOXI
(  O
18  O
%  O
)  O
,  O
grade  O
3  O
febrile  B-TOXI
neutropenia  I-TOXI
(  O
11  O
%  O
)  O
,  O
and  O
grade  O
3  O
thrombocytopenia  B-TOXI
(  O
11  O
%  O
)  O
.  O

There  O
were  O
no  O
toxic  B-TOXI
deaths  I-TOXI
.  O

Grade  O
3  O
non-hematologic  B-TOXI
toxicities  I-TOXI
included  O
nausea  B-TOXI
(  O
4  O
%  O
)  O
and  O
rash  B-TOXI
(  O
4  O
%  O
)  O
.  O

The  O
combination  O
chemotherapy  O
of  O
gemcitabine  B-DRUG
and  O
docetaxel  B-DRUG
is  O
active  O
and  O
well  O
tolerated  O
in  O
patients  O
with  O
recurrent  B-CANCER
NSCLC  I-CANCER
after  O
platinum-based  B-DRUG
chemotherapy  O
and  O
with  O
a  O
good  O
PS  O
.  O

Phase  O
I  O
and  O
pharmacokinetic  O
study  O
of  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
with  O
a  O
biweekly  O
schedule  O
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


A  O
phase  O
I  O
study  O
was  O
conducted  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
of  O
carboplatin  B-DRUG
in  O
combination  O
with  O
paclitaxel  B-DRUG
using  O
a  O
biweekly  O
schedule  O
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

The  O
pharmacokinetics  O
of  O
paclitaxel  B-DRUG
were  O
determined  O
preliminarily  O
in  O
some  O
patients  O
.  O

The  O
criteria  O
for  O
eligibility  O
for  O
study  O
entry  O
included  O
histologically  O
and  O
/  O
or  O
cytologically  O
confirmed  O
NSCLC  B-CANCER
(  O
stage  O
IIIb  O
or  O
IV  O
)  O
,  O
no  O
prior  O
treatment  O
,  O
and  O
measurable  O
disease  O
.  O

Paclitaxel  B-DRUG
was  O
given  O
in  O
combination  O
with  O
a  O
fixed  O
dose  O
of  O
carboplatin  B-DRUG
at  O
an  O
area  O
under  O
the  O
concentration-time  O
curve  O
(  O
AUC  O
)  O
of  O
3  O
mg  O
/  O
ml  O
x  O
min  O
,  O
every  O
2  O
weeks  O
.  O

The  O
starting  O
dose  O
of  O
paclitaxel  B-DRUG
was  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
the  O
dose  O
was  O
increased  O
in  O
increments  O
of  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Three  O
to  O
six  O
patients  O
were  O
allocated  O
to  O
each  O
dose  O
level  O
.  O

A  O
total  O
of  O
19  O
patients  O
(  O
11  O
male  O
and  O
8  O
female  O
)  O
with  O
a  O
median  O
age  O
of  O
61  O
years  O
(  O
range  O
43-74  O
years  O
)  O
and  O
a  O
median  O
ECOG  O
performance  O
status  O
of  O
0  O
(  O
range  O
0-1  O
)  O
were  O
enrolled  O
.  O

The  O
MTD  O
of  O
paclitaxel  B-DRUG
proved  O
to  O
be  O
160  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
the  O
DLT  O
was  O
neutropenia  B-TOXI
,  O
which  O
improved  O
well  O
following  O
treatment  O
with  O
G-CSF  B-DRUG
.  O

Gastrointestinal  B-TOXI
toxicity  I-TOXI
was  O
well  O
tolerated  O
.  O

Of  O
17  O
patients  O
who  O
received  O
four  O
cycles  O
or  O
more  O
,  O
7  O
(  O
41  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
18.4-67.1  O
%  O
)  O
responded  O
to  O
this  O
combination  O
therapy  O
.  O

The  O
pharmacokinetics  O
of  O
paclitaxel  B-DRUG
did  O
not  O
differ  O
from  O
published  O
data  O
.  O

The  O
recommended  O
dose  O
for  O
phase  O
II  O
study  O
is  O
paclitaxel  B-DRUG
140  O
mg  O
/  O
m  O
(  O
2  O
)  O
with  O
a  O
carboplatin  B-DRUG
AUC  O
of  O
3  O
mg  O
/  O
ml.min  O
.  O

This  O
biweekly  O
regimen  O
is  O
highly  O
effective  O
and  O
acceptable  O
,  O
and  O
the  O
present  O
data  O
indicate  O
that  O
the  O
regimen  O
may  O
be  O
suitable  O
for  O
use  O
on  O
an  O
outpatient  O
basis  O
.  O

Pilot  O
trial  O
of  O
the  O
epidermal  B-DRUG
growth  I-DRUG
factor  I-DRUG
receptor  I-DRUG
tyrosine  I-DRUG
kinase  I-DRUG
inhibitor  I-DRUG
gefitinib  I-DRUG
plus  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
in  O
patients  O
with  O
stage  O
IIIB  O
or  O
IV  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Gefitinib  B-DRUG
is  O
an  O
oral  O
agent  O
that  O
inhibits  O
the  O
tyrosine  B-DRUG
kinase  I-DRUG
of  I-DRUG
the  I-DRUG
epidermal  I-DRUG
growth  I-DRUG
factor  I-DRUG
receptor  I-DRUG
.  O

In  O
phase  O
I  O
trials  O
gefitinib  B-DRUG
was  O
well  O
tolerated  O
and  O
antitumor  O
activity  O
was  O
seen  O
in  O
pretreated  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
patients  O
.  O

Preclinical  O
studies  O
indicated  O
enhanced  O
effects  O
when  O
gefitnib  B-DRUG
was  O
added  O
to  O
carboplatin  B-DRUG
or  O
paclitaxel  B-DRUG
.  O

This  O
pilot  O
trial  O
combined  O
gefitinib  B-DRUG
with  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
to  O
define  O
the  O
toxicities  O
of  O
the  O
combination  O
and  O
assess  O
drug-drug  O
interactions  O
in  O
untreated  O
advanced  B-CANCER
NSCLC  I-CANCER
patients  O
.  O

Initially  O
(  O
part  O
1  O
)  O
patients  O
were  O
randomly  O
assigned  O
to  O
receive  O
intermittent  O
gefitinib  B-DRUG
with  O
cycle  O
1  O
or  O
2  O
of  O
chemotherapy  O
.  O

Thereafter  O
(  O
part  O
2  O
)  O
,  O
the  O
highest  O
dose  O
of  O
gefitinib  B-DRUG
that  O
was  O
given  O
without  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
from  O
part  O
1  O
was  O
administered  O
continuously  O
beginning  O
with  O
the  O
first  O
cycle  O
of  O
chemotherapy  O
.  O

Three  O
sequentially  O
enrolled  O
cohorts  O
received  O
gefitinib  B-DRUG
250  O
and  O
500  O
mg  O
(  O
intermittently  O
)  O
and  O
500  O
mg  O
(  O
continuously  O
)  O
.  O

We  O
treated  O
24  O
patients  O
;  O
nine  O
patients  O
with  O
250  O
mg  O
and  O
15  O
patients  O
with  O
500  O
mg  O
(  O
nine  O
patients  O
continuous  O
)  O
.  O

Two  O
occurrences  O
of  O
DLT  O
were  O
observed  O
.  O

One  O
patient  O
(  O
500  O
mg  O
,  O
part  O
1  O
)  O
developed  O
grade  O
3  O
rash  B-TOXI
and  O
another  O
patient  O
(  O
part  O
2  O
)  O
developed  O
prolonged  B-TOXI
neutropenia  I-TOXI
.  O

Steady-state  O
gefitinib  B-DRUG
levels  O
did  O
not  O
affect  O
exposure  O
to  O
chemotherapy  O
.  O

In  O
a  O
limited  O
sample  O
,  O
chemotherapy  O
modestly  O
increased  O
the  O
gefitinib  B-DRUG
area  O
under  O
concentration-time  O
curve  O
at  O
steady-state  O
and  O
minimum  O
steady-state  O
trough  O
concentration  O
.  O

Partial  O
responses  O
were  O
observed  O
in  O
five  O
of  O
24  O
patients  O
.  O

The  O
median  O
survival  O
was  O
8  O
months  O
.  O

The  O
gefitinib  B-DRUG
with  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
regimen  O
was  O
generally  O
well  O
tolerated  O
and  O
no  O
unanticipated  O
toxicities  O
or  O
clinically  O
relevant  O
pharmacokinetic  O
interactions  O
were  O
observed  O
.  O

Both  O
doses  O
of  O
gefitinib  B-DRUG
were  O
believed  O
to  O
be  O
safe  O
for  O
further  O
study  O
with  O
chemotherapy  O
.  O

This  O
regimen  O
was  O
thus  O
tested  O
in  O
a  O
completed  O
randomized  O
phase  O
III  O
trial  O
.  O

Combination  O
of  O
low-dose  O
cisplatin  B-DRUG
and  O
gemcitabine  B-DRUG
for  O
treatment  O
of  O
elderly  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


To  O
evaluate  O
the  O
feasibility  O
,  O
toxicity  O
and  O
efficacy  O
of  O
the  O
combination  O
of  O
low-dose  O
cisplatin  B-DRUG
(  O
CDDP  B-DRUG
)  O
and  O
gemcitabine  B-DRUG
(  O
GEM  B-DRUG
)  O
in  O
elderly  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

This  O
phase  O
II  O
trial  O
included  O
46  O
patients  O
aged  O
70  O
years  O
or  O
older  O
with  O
previously  O
untreated  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

All  O
patients  O
were  O
evaluable  O
for  O
response  O
and  O
toxicity  O
.  O

Treatment  O
consisted  O
of  O
CDDP  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
1  O
plus  O
GEM  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
8.  O
The  O
regimen  O
was  O
repeated  O
every  O
21  O
days  O
.  O

Patients  O
received  O
a  O
minimum  O
of  O
three  O
courses  O
unless  O
progressive  B-TOXI
disease  I-TOXI
was  O
detected  O
.  O

A  O
total  O
of  O
190  O
GEM-CDDP  B-DRUG
courses  O
were  O
administered  O
(  O
median  O
4.1  O
courses  O
per  O
patient  O
)  O
.  O

The  O
chemotherapy  O
regimen  O
was  O
well  O
tolerated  O
.  O

No  O
patients  O
developed  O
grade  O
4  O
toxicity  O
.  O

Grade  O
3  O
toxicities  O
were  O
as  O
follows  O
:  O
neutropenia  B-TOXI
in  O
six  O
patients  O
(  O
13  O
%  O
)  O
,  O
and  O
anemia  B-TOXI
,  O
thrombopenia  B-TOXI
and  O
nausea  B-TOXI
/  O
vomiting  B-TOXI
in  O
one  O
(  O
2  O
%  O
)  O
each  O
.  O

Two  O
patients  O
(  O
4  O
%  O
)  O
had  O
mild  O
nephrotoxicity  B-TOXI
.  O

Of  O
the  O
46  O
patients  O
,  O
16  O
had  O
a  O
partial  O
response  O
(  O
35  O
%  O
,  O
95  O
%  O
confidence  O
interval  O
,  O
CI  O
,  O
28-52  O
%  O
)  O
,  O
17  O
(  O
37  O
%  O
)  O
remained  O
stable  O
and  O
13  O
(  O
28  O
%  O
)  O
had  O
disease  B-TOXI
progression  I-TOXI
.  O

Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
status  O
improved  O
in  O
17  O
patients  O
(  O
37  O
%  O
)  O
,  O
whereas  O
25  O
(  O
54  O
%  O
,  O
95  O
%  O
CI  O
44-74  O
%  O
)  O
showed  O
a  O
clinical  O
benefit  O
.  O

Median  O
time  O
to  O
progression  O
was  O
20  O
weeks  O
.  O

Overall  O
median  O
survival  O
was  O
44  O
weeks  O
,  O
with  O
a  O
1-year  O
actuarial  O
survival  O
rate  O
of  O
35  O
%  O
.  O

The  O
combination  O
of  O
low-dose  O
CDDP  B-DRUG
and  O
GEM  B-DRUG
for  O
elderly  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
is  O
an  O
effective  O
and  O
well-tolerated  O
chemotherapeutic  O
approach  O
.  O

A  O
Phase  O
I  O
trial  O
of  O
the  O
farnesyl  B-DRUG
protein  I-DRUG
transferase  I-DRUG
inhibitor  I-DRUG
R115777  I-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
cancer  I-CANCER
.  O


This  O
Phase  O
I  O
study  O
was  O
undertaken  O
to  O
define  O
the  O
toxicity  O
,  O
pharmacodynamics  O
,  O
and  O
maximum  O
tolerated  O
dose  O
of  O
the  O
combination  O
of  O
R115777  B-DRUG
,  O
a  O
farnesyl  B-DRUG
transferase  I-DRUG
inhibitor  I-DRUG
,  O
with  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

Thirty  O
patients  O
with  O
solid  B-CANCER
tumors  I-CANCER
received  O
a  O
median  O
of  O
2.5  O
cycles  O
(  O
range  O
1-30+  O
)  O
through  O
five  O
dose  O
levels  O
.  O

R115777  B-DRUG
was  O
administered  O
p.o.  O
twice  O
daily  O
for  O
14  O
days  O
.  O

Gemcitabine  B-DRUG
was  O
infused  O
15  O
min  O
after  O
the  O
ingestion  O
of  O
R115777  B-DRUG
on  O
days  O
1  O
and  O
8.  O
Cisplatin  B-DRUG
was  O
administered  O
starting  O
30  O
min  O
after  O
completion  O
of  O
the  O
gemcitabine  B-DRUG
infusion  O
on  O
day  O
1.  O
Cycles  O
were  O
repeated  O
every  O
21  O
days  O
.  O

Toxicities  O
were  O
graded  O
by  O
the  O
National  O
Cancer  O
Institute  O
Common  O
Toxicity  O
Criteria  O
and  O
recorded  O
as  O
maximum  O
grade  O
per  O
patient  O
for  O
each  O
treatment  O
cycle  O
.  O

At  O
the  O
maximum  O
tolerated  O
dose  O
,  O
accumulation  O
of  O
prelamin  O
A  O
in  O
buccal  O
mucosa  O
cells  O
of  O
patients  O
was  O
evaluated  O
as  O
a  O
marker  O
of  O
farnesyl  O
transferase  O
inhibition  O
by  O
R115777  B-DRUG
.  O

Neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
were  O
the  O
most  O
common  O
toxicities  O
.  O

Dose-limiting  O
toxicity  O
in  O
cycle  O
1  O
was  O
myelosuppression  B-TOXI
with  O
thrombocytopenia  B-TOXI
alone  O
(  O
4  O
patients  O
)  O
,  O
neutropenia  B-TOXI
alone  O
(  O
1  O
patient  O
)  O
,  O
or  O
a  O
combination  O
of  O
both  O
(  O
3  O
patients  O
)  O
.  O

Common  O
nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
anorexia  B-TOXI
,  O
rash  B-TOXI
,  O
nausea  B-TOXI
,  O
vomiting  B-TOXI
,  O
and  O
fatigue  B-TOXI
,  O
none  O
of  O
which  O
was  O
dose  O
limiting  O
in  O
the  O
first  O
cycle  O
.  O

At  O
the  O
maximum  O
tolerated  O
dose  O
,  O
defined  O
as  O
R115777  B-DRUG
300  O
mg  O
twice  O
daily  O
p.o.  O
,  O
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
gemcitabine  B-DRUG
,  O
and  O
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
cisplatin  B-DRUG
,  O
inhibition  O
of  O
prelamin  O
A  O
farnesylation  O
in  O
buccal  O
mucosa  O
cells  O
of  O
patients  O
was  O
demonstrated  O
,  O
confirming  O
that  O
R115777  B-DRUG
inhibits  O
protein  O
farnesylation  O
in  O
vivo  O
.  O

Nine  O
objective  O
responses  O
(  O
one  O
complete  O
response  O
and  O
eight  O
partial  O
responses  O
)  O
were  O
documented  O
in  O
27  O
evaluable  O
patients  O
.  O

The  O
combination  O
of  O
R115777  B-DRUG
with  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
was  O
well  O
tolerated  O
and  O
showed  O
evidence  O
of  O
antitumor  O
activity  O
.  O

The  O
maximum  O
tolerated  O
dose  O
of  O
R115777  B-DRUG
successfully  O
inhibits  O
farnesyltransferase  O
in  O
patients  O
in  O
vivo  O
.  O

This  O
combination  O
warrants  O
further  O
evaluation  O
in  O
a  O
number  O
of  O
tumor  O
types  O
.  O

Oxaliplatin  B-DRUG
with  O
weekly  O
bolus  O
fluorouracil  B-DRUG
and  O
low-dose  O
leucovorin  B-DRUG
as  O
first-line  O
therapy  O
for  O
patients  O
with  O
colorectal  B-CANCER
cancer  I-CANCER
.  O


To  O
determine  O
the  O
activity  O
of  O
biweekly  O
oxaliplatin  B-DRUG
,  O
combined  O
with  O
weekly  O
bolus  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
and  O
low-dose  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
chemotherapy  O
(  O
bFOL  O
)  O
,  O
as  O
first-line  O
therapy  O
for  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Patients  O
with  O
measurable  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
;  O
no  O
previous  O
therapy  O
for  O
advanced  O
disease  O
(  O
adjuvant  O
therapy  O
allowed  O
if  O
&  O
gt  O
;  O
6  O
months  O
since  O
completion  O
)  O
;  O
and  O
performance  O
status  O
0  O
,  O
1  O
,  O
or  O
2  O
were  O
eligible  O
and  O
were  O
treated  O
with  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m2  O
days  O
1  O
and  O
15  O
plus  O
LV  B-DRUG
20  O
mg  O
/  O
m2  O
over  O
10  O
to  O
20  O
minutes  O
,  O
followed  O
by  O
a  O
500  O
mg  O
/  O
m2  O
bolus  O
dose  O
of  O
FU  B-DRUG
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
every  O
28  O
days  O
.  O

Patients  O
underwent  O
response  O
evaluation  O
by  O
computed  O
tomographic  O
scan  O
every  O
2  O
months  O
.  O

Forty-two  O
patients  O
were  O
entered  O
,  O
and  O
41  O
patients  O
were  O
treated  O
,  O
including  O
20  O
men  O
and  O
22  O
women  O
,  O
nine  O
with  O
previous  O
adjuvant  O
chemotherapy  O
and  O
four  O
with  O
radiation  O
therapy  O
.  O

Three  O
patients  O
achieved  O
complete  O
response  O
,  O
and  O
23  O
patients  O
achieved  O
partial  O
response  O
,  O
for  O
a  O
response  O
rate  O
of  O
63  O
%  O
(  O
95  O
%  O
CI  O
,  O
49  O
%  O
to  O
78  O
%  O
)  O
.  O

Major  O
toxicities  O
included  O
cumulative  O
neuropathy  B-TOXI
grade  O
2  O
(  O
24  O
%  O
)  O
and  O
grade  O
3  O
(  O
12  O
%  O
;  O
requiring  O
discontinuation  O
of  O
oxaliplatin  B-DRUG
)  O
,  O
diarrhea  B-TOXI
grade  O
3  O
to  O
4  O
(  O
29  O
%  O
)  O
and  O
grade  O
3  O
to  O
4  O
hematologic  B-TOXI
toxicity  I-TOXI
(  O
10  O
%  O
)  O
.  O

Median  O
time  O
to  O
progression  O
was  O
9.0  O
months  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
7.1  O
to  O
10.8  O
months  O
)  O
with  O
median  O
survival  O
of  O
15.9  O
months  O
(  O
95  O
%  O
confidence  O
interval  O
,  O
11.4  O
to  O
19.7  O
months  O
)  O
.  O

The  O
bFOL  O
regimen  O
seems  O
to  O
have  O
activity  O
comparable  O
to  O
be  O
infusional  O
programs  O
of  O
FU  B-DRUG
combined  O
with  O
oxaliplatin  B-DRUG
.  O

Prospective  O
trials  O
are  O
warranted  O
to  O
determine  O
the  O
relative  O
merits  O
of  O
this  O
schedule  O
compared  O
with  O
the  O
currently  O
indicated  O
schedules  O
.  O

A  O
phase  O
I  O
study  O
of  O
capecitabine  B-DRUG
in  O
combination  O
with  O
vinorelbine  B-DRUG
in  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O


A  O
phase  O
I  O
study  O
was  O
conducted  O
in  O
order  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
the  O
combination  O
of  O
vinorelbine  B-DRUG
and  O
capecitabine  B-DRUG
in  O
patients  O
affected  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O

Eighteen  O
patients  O
with  O
histologically  O
confirmed  O
advanced  B-CANCER
breast  I-CANCER
cancer  I-CANCER
,  O
who  O
had  O
failed  O
=1  O
prior  O
chemotherapy  O
regimen  O
,  O
were  O
enrolled  O
.  O

The  O
median  O
age  O
was  O
56  O
years  O
(  O
range  O
,  O
39-70  O
years  O
)  O
.  O

All  O
but  O
1  O
had  O
previously  O
received  O
a  O
combination  O
of  O
anthracyclines  B-DRUG
and  O
taxanes  B-DRUG
;  O
performance  O
status  O
(  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
)  O
was  O
0  O
/  O
1  O
or  O
2  O
in  O
13  O
and  O
5  O
patients  O
,  O
respectively  O
.  O

Vinorelbine  B-DRUG
was  O
administered  O
at  O
a  O
fixed  O
dosage  O
of  O
25  O
mg  O
/  O
m2  O
on  O
days  O
1  O
and  O
8  O
every  O
3  O
weeks  O
.  O

Capecitabine  B-DRUG
was  O
administered  O
orally  O
,  O
at  O
an  O
escalated  O
dose  O
ranging  O
from  O
1400  O
mg  O
/  O
m2  O
to  O
2250  O
mg  O
/  O
m2  O
for  O
14  O
consecutive  O
days  O
starting  O
on  O
day  O
1  O
of  O
the  O
cycle  O
,  O
divided  O
into  O
2  O
daily  O
doses  O
delivered  O
half  O
an  O
hour  O
after  O
eating  O
at  O
12-hour  O
intervals  O
.  O

Three  O
patients  O
were  O
treated  O
at  O
each  O
dose  O
level  O
:  O
if  O
1  O
patient  O
developed  O
a  O
DLT  O
,  O
an  O
additional  O
3  O
patients  O
were  O
treated  O
at  O
the  O
same  O
dose  O
level  O
.  O

If  O
2  O
additional  O
patients  O
experienced  O
DLT  O
,  O
no  O
further  O
escalation  O
was  O
allowed  O
and  O
the  O
previous  O
dose  O
level  O
was  O
declared  O
MTD  O
.  O

Dose-limiting  O
toxicity  O
was  O
reached  O
at  O
2250  O
mg  O
/  O
m2  O
of  O
capecitabine  B-DRUG
with  O
3  O
out  O
of  O
3  O
patients  O
experiencing  O
grade  O
4  O
neutropenia  B-TOXI
plus  O
grade  O
3  O
diarrhea  B-TOXI
and  O
grade  O
3  O
oral  B-TOXI
mucositis  I-TOXI
in  O
1  O
patient  O
)  O
.  O

Thus  O
,  O
MTD  O
was  O
defined  O
at  O
2000  O
mg  O
/  O
m2  O
capecitabine  O
.  O

Other  O
observed  O
grade  O
2  O
side  O
effects  O
were  O
:  O
1  O
patient  O
with  O
neutropenia  B-TOXI
,  O
1  O
with  O
hand-foot  B-TOXI
syndrome  I-TOXI
,  O
2  O
with  O
mucositis  B-TOXI
,  O
1  O
with  O
cutaneous  B-TOXI
rash  I-TOXI
,  O
and  O
1  O
with  O
thrombocytopenia  B-TOXI
.  O

With  O
regard  O
to  O
response  O
rate  O
,  O
we  O
observed  O
1  O
complete  O
response  O
(  O
5.5  O
%  O
)  O
,  O
6  O
partial  O
responses  O
(  O
33  O
%  O
)  O
,  O
and  O
4  O
disease  O
stabilizations  O
(  O
22  O
%  O
)  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
12  O
weeks  O
and  O
the  O
median  O
survival  O
41  O
weeks  O
.  O

The  O
MTD  O
of  O
capecitabine  B-DRUG
in  O
combination  O
with  O
vinorelbine  B-DRUG
at  O
25  O
mg  O
/  O
m2  O
dosage  O
on  O
days  O
1  O
and  O
8  O
of  O
a  O
3-week  O
schedule  O
is  O
2000  O
mg  O
/  O
m2  O
/  O
day  O
for  O
14  O
consecutive  O
days  O
.  O

Moreover  O
,  O
this  O
regimen  O
showed  O
interesting  O
activity  O
with  O
61  O
%  O
overall  O
disease  O
control  O
(  O
complete  O
plus  O
partial  O
response  O
plus  O
disease  O
stabilization  O
)  O
in  O
patients  O
pretreated  O
with  O
anthracyclines  B-DRUG
and  O
taxanes  B-DRUG
warranting  O
further  O
investigations  O
in  O
a  O
large  O
,  O
multicenter  O
phase  O
II  O
study  O
.  O

Safety  O
and  O
toxicity  O
analysis  O
of  O
oxaliplatin  B-DRUG
combined  O
with  O
fluorouracil  B-DRUG
or  O
as  O
a  O
single  O
agent  O
in  O
patients  O
with  O
previously  O
treated  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


Two  O
consecutive  O
compassionate  O
use  O
studies  O
of  O
oxaliplatin  B-DRUG
were  O
conducted  O
in  O
the  O
United  O
States  O
and  O
Canada  O
in  O
more  O
than  O
5000  O
patients  O
with  O
locally  O
advanced  B-CANCER
or  I-CANCER
metastatic  I-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
who  O
had  O
experienced  O
treatment  O
failure  O
after  O
at  O
least  O
one  O
prior  O
chemotherapy  O
regimen  O
.  O

The  O
main  O
focus  O
was  O
safety  O
.  O

Patients  O
were  O
assigned  O
to  O
treatment  O
with  O
either  O
single-agent  O
oxaliplatin  B-DRUG
or  O
oxaliplatin  B-DRUG
in  O
combination  O
with  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
and  O
with  O
or  O
without  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
in  O
various  O
regimens  O
.  O

Response  O
data  O
collection  O
was  O
not  O
a  O
trial  O
objective  O
,  O
but  O
time  O
to  O
treatment  O
failure  O
(  O
TTF  O
)  O
was  O
recorded  O
in  O
the  O
first  O
cohort  O
(  O
1370  O
patients  O
)  O
.  O

All  O
treatment  O
regimens  O
were  O
well  O
tolerated  O
,  O
with  O
an  O
overall  O
incidence  O
of  O
grade  O
3  O
or  O
4  O
hematologic  B-TOXI
toxicity  I-TOXI
of  O
23.2  O
%  O
,  O
grade  O
3  O
or  O
4  O
treatment-related  O
gastrointestinal  B-TOXI
toxicity  I-TOXI
of  O
26.4  O
%  O
(  O
including  O
diarrhea  O
,  O
vomiting  O
,  O
and  O
mucositis  O
)  O
,  O
and  O
grade  O
3  O
neurosensory  B-TOXI
toxicity  I-TOXI
3.9  O
%  O
.  O

Similar  O
results  O
were  O
reported  O
in  O
the  O
second  O
cohort  O
(  O
3806  O
patients  O
)  O
,  O
in  O
which  O
the  O
eligibility  O
criteria  O
were  O
much  O
less  O
restrictive  O
.  O

In  O
the  O
first  O
cohort  O
(  O
in  O
which  O
83  O
%  O
received  O
prior  O
irinotecan  B-DRUG
)  O
,  O
median  O
TTF  O
was  O
14  O
weeks  O
,  O
and  O
was  O
similar  O
for  O
the  O
five  O
regimens  O
combining  O
oxaliplatin  B-DRUG
and  O
FU  B-DRUG
with  O
or  O
without  O
LV  B-DRUG
,  O
but  O
significantly  O
shorter  O
for  O
the  O
single-agent  O
oxaliplatin  B-DRUG
arm  O
.  O

The  O
overall  O
dose-intensity  O
of  O
oxaliplatin  B-DRUG
was  O
maintained  O
at  O
85.5  O
%  O
(  O
range  O
,  O
80.6  O
%  O
to  O
94.3  O
%  O
)  O
of  O
that  O
prescribed  O
by  O
protocol  O
(  O
average  O
36.7  O
mg  O
/  O
m2  O
/  O
wk  O
)  O
.  O

These  O
data  O
in  O
a  O
heavily  O
pretreated  O
patient  O
population  O
confirm  O
that  O
oxaliplatin  B-DRUG
is  O
safe  O
when  O
used  O
as  O
a  O
single  O
agent  O
or  O
with  O
a  O
variety  O
of  O
FU-based  B-DRUG
regimens  O
as  O
salvage  O
therapy  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

A  O
phase  O
I  O
and  O
pharmacologic  O
study  O
of  O
weekly  O
gemcitabine  B-DRUG
in  O
combination  O
with  O
infusional  O
5-fluorodeoxyuridine  B-DRUG
and  O
oral  O
calcium  B-DRUG
leucovorin  I-DRUG
.  O


Since  O
preclinical  O
studies  O
have  O
shown  O
more  O
than  O
additive  O
cytotoxicity  O
and  O
DNA  O
damage  O
with  O
the  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
5-fluoro-2'-deoxyuridine  B-DRUG
(  O
FUDR  B-DRUG
)  O
,  O
we  O
studied  O
this  O
combination  O
in  O
a  O
phase  O
I  O
trial  O
.  O

Gemcitabine  B-DRUG
alone  O
was  O
given  O
in  O
cycle  O
1  O
as  O
a  O
24-h  O
,  O
2-h  O
or  O
1-h  O
i.v.  O
infusion  O
weekly  O
for  O
3  O
of  O
4  O
weeks  O
;  O
if  O
tolerated  O
,  O
a  O
24-h  O
i.v.  O
infusion  O
of  O
FUDR  B-DRUG
was  O
added  O
with  O
oral  O
leucovorin  B-DRUG
.  O

The  O
cycle  O
was  O
aborted  O
for  O
grade  O
3  O
thrombocytopenia  B-TOXI
,  O
grade  O
4  O
neutropenia  B-TOXI
,  O
and  O
grade  O
2  O
or  O
worse  O
nonhematologic  B-TOXI
toxicity  I-TOXI
.  O

During  O
cycle  O
1  O
,  O
six  O
of  O
eight  O
patients  O
who  O
received  O
150  O
or  O
100  O
mg  O
/  O
m2  O
over  O
24  O
h  O
had  O
dose-limiting  O
neutropenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
,  O
fatigue  B-TOXI
or  O
mucositis  B-TOXI
.  O

Six  O
of  O
seven  O
patients  O
treated  O
with  O
1000  O
mg  O
/  O
m2  O
over  O
2  O
h  O
required  O
a  O
gemcitabine  B-DRUG
dose  O
reduction  O
for  O
cycle  O
2  O
(  O
thrombocytopenia  B-TOXI
,  O
neutropenia  B-TOXI
,  O
fatigue  B-TOXI
)  O
.  O

Of  O
25  O
assessable  O
patients  O
who  O
received  O
gemcitabine  B-DRUG
1000  O
mg  O
/  O
m2  O
over  O
1  O
h  O
,  O
7  O
did  O
not  O
complete  O
cycle  O
1  O
due  O
to  O
thrombocytopenia  B-TOXI
(  O
n=6  O
)  O
or  O
diarrhea  B-TOXI
(  O
n=1  O
)  O
.  O

Of  O
42  O
patients  O
entered  O
,  O
27  O
received  O
at  O
least  O
one  O
course  O
of  O
gemcitabine  B-DRUG
/  I-DRUG
FUDR  I-DRUG
(  O
5-19.5  O
mg  O
/  O
m2  O
over  O
24  O
h  O
)  O
without  O
appreciable  O
toxicity  O
.  O

Due  O
to  O
a  O
shortage  O
of  O
FUDR  B-DRUG
,  O
the  O
protocol  O
was  O
closed  O
early  O
.  O

Gemcitabine  B-DRUG
plasma  O
concentrations  O
averaged  O
0.061  O
micro  O
M  O
(  O
24  O
h  O
)  O
,  O
16.3  O
micro  O
M  O
(  O
2  O
h  O
)  O
,  O
and  O
31.9  O
micro  O
M  O
(  O
1  O
h  O
)  O
.  O

In  O
21  O
paired  O
bone  O
marrow  O
mononuclear  O
cell  O
samples  O
obtained  O
before  O
treatment  O
and  O
during  O
FUDR  B-DRUG
infusion  O
,  O
thymidylate  O
synthase  O
ternary  O
complex  O
was  O
only  O
seen  O
during  O
FUDR  B-DRUG
infusion  O
.  O

Gemcitabine  B-DRUG
100-150  O
mg  O
/  O
m2  O
over  O
24  O
h  O
was  O
poorly  O
tolerated  O
,  O
whereas  O
toxicity  O
was  O
acceptable  O
with  O
800-1000  O
mg  O
/  O
m2  O
over  O
1  O
h.  O
Inhibition  O
of  O
the  O
target  O
enzyme  O
was  O
demonstrated  O
at  O
all  O
FUDR  B-DRUG
doses  O
.  O

Phase  O
I  O
and  O
pharmacokinetic  O
study  O
of  O
two  O
different  O
schedules  O
of  O
oxaliplatin  B-DRUG
,  O
irinotecan  B-DRUG
,  O
Fluorouracil  B-DRUG
,  O
and  O
leucovorin  B-DRUG
in  O
patients  O
with  O
solid  B-CANCER
tumors  I-CANCER
.  O


We  O
sought  O
to  O
determine  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
evaluate  O
the  O
toxicities  O
and  O
clinical  O
activity  O
of  O
two  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
,  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
,  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
,  O
and  O
oxaliplatin  B-DRUG
schedules  O
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

Additionally  O
,  O
we  O
investigated  O
the  O
effect  O
of  O
CPT-11  B-DRUG
on  O
oxaliplatin  B-DRUG
pharmacokinetics  O
.  O

Thirteen  O
patients  O
(  O
cohort  O
1  O
)  O
received  O
intravenous  O
CPT-11  B-DRUG
(  O
infusion  O
)  O
and  O
FU  B-DRUG
/  I-DRUG
LV  I-DRUG
(  O
bolus  O
)  O
on  O
days  O
1  O
,  O
8  O
,  O
15  O
,  O
and  O
22  O
and  O
oxaliplatin  B-DRUG
(  O
infusion  O
)  O
on  O
days  O
1  O
and  O
15  O
every  O
6  O
weeks  O
for  O
a  O
total  O
37  O
courses  O
(  O
median  O
,  O
three  O
courses  O
)  O
at  O
three  O
dose  O
levels  O
.  O

Twenty-two  O
cohort  O
2  O
patients  O
received  O
intravenous  O
CPT-11  B-DRUG
/  I-DRUG
oxaliplatin  I-DRUG
(  O
infusion  O
,  O
day  O
1  O
)  O
and  O
FU  B-DRUG
/  I-DRUG
LV  I-DRUG
(  O
90-minute  O
bolus  O
infusion  O
,  O
days  O
2  O
to  O
5  O
)  O
every  O
3  O
weeks  O
for  O
a  O
total  O
of  O
122  O
courses  O
(  O
median  O
,  O
four  O
courses  O
)  O
at  O
three  O
dose  O
levels  O
.  O

Pharmacokinetic  O
and  O
neurotoxicity  B-TOXI
assessments  O
were  O
performed  O
at  O
the  O
cohort  O
2  O
MTD  O
.  O

Dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
seen  O
in  O
both  O
cohorts  O
at  O
the  O
starting  O
dose  O
required  O
dose  O
de-escalation  O
.  O

Cohort  O
1  O
DLT  O
included  O
diarrhea  B-TOXI
and  O
neutropenia  B-TOXI
.  O

In  O
cohort  O
2  O
,  O
diarrhea  B-TOXI
,  O
vomiting  B-TOXI
,  O
dehydration  B-TOXI
,  O
neutropenia  B-TOXI
,  O
febrile  B-TOXI
neutropenia  I-TOXI
,  O
and  O
paresthesias  B-TOXI
were  O
DLTs  O
.  O

Antitumor  O
activity  O
was  O
seen  O
in  O
both  O
cohorts  O
.  O

In  O
cohort  O
2  O
,  O
the  O
total  O
platinum  B-DRUG
area  O
under  O
the  O
curve  O
of  O
patients  O
increased  O
17  O
%  O
in  O
cycle  O
2  O
(  O
P  O
=.048  O
)  O
,  O
but  O
objective  O
neurotoxicity  B-TOXI
was  O
not  O
seen  O
.  O

The  O
toxicities  O
resulting  O
from  O
the  O
addition  O
of  O
oxaliplatin  B-DRUG
to  O
CPT-11  B-DRUG
/  I-DRUG
FU  I-DRUG
/  I-DRUG
LV  I-DRUG
are  O
significant  O
but  O
manageable  O
.  O

The  O
MTDs  O
for  O
the  O
weekly  O
schedule  O
are  O
CPT-11  B-DRUG
(  O
75  O
mg  O
/  O
m2  O
)  O
,  O
oxaliplatin  B-DRUG
(  O
50  O
mg  O
/  O
m2  O
)  O
,  O
FU  O
(  O
320  O
mg  O
/  O
m2  O
)  O
,  O
and  O
LV  B-DRUG
(  O
20  O
mg  O
/  O
m2  O
)  O
;  O
and  O
,  O
for  O
the  O
3-weekly  O
schedule  O
,  O
the  O
MTDs  O
are  O
CPT-11  B-DRUG
(  O
175  O
mg  O
/  O
m2  O
)  O
,  O
oxaliplatin  B-DRUG
(  O
85  O
mg  O
/  O
m2  O
)  O
,  O
FU  B-DRUG
(  O
240  O
mg  O
/  O
m2  O
)  O
,  O
and  O
LV  B-DRUG
(  O
20  O
mg  O
/  O
m2  O
)  O
.  O

Second-cycle  O
platinum  B-DRUG
accumulation  O
raises  O
the  O
possibility  O
for  O
enhanced  O
cumulative  O
neurotoxicity  B-TOXI
with  O
CPT-11  B-DRUG
/  I-DRUG
oxaliplatin  I-DRUG
combinations  O
.  O

High-dose  O
tamoxifen  B-DRUG
as  O
an  O
enhancer  O
of  O
etoposide  B-TOXI
cytotoxicity.  I-TOXI
Clinical  O
effects  O
and  O
in  O
vitro  O
assessment  O
in  O
p-glycoprotein  O
expressing  O
cell  O
lines  O
.  O


Twenty-six  O
patients  O
with  O
relapsed  B-CANCER
or  I-CANCER
drug-resistant  I-CANCER
cancer  I-CANCER
were  O
treated  O
with  O
a  O
combination  O
of  O
oral  O
etoposide  B-DRUG
(  O
300  O
mg  O
day-1  O
for  O
3  O
days  O
)  O
and  O
high-dose  O
oral  O
tamoxifen  B-DRUG
as  O
a  O
potential  O
modulator  O
of  O
drug  O
resistance  O
(  O
480  O
or  O
720  O
mg  O
day-1  O
for  O
6  O
days  O
beginning  O
3  O
days  O
before  O
etoposide  B-DRUG
)  O
.  O

One  O
patient  O
with  O
relapsed  O
high-grade  O
lymphoma  B-TOXI
and  O
one  O
with  O
adenocarcinoma  B-TOXI
of  O
unknown  O
primary  O
site  O
has  O
a  O
partial  O
response  O
.  O

Toxicity  O
consisting  O
of  O
nausea  B-TOXI
,  O
vomiting  B-TOXI
and  O
subjective  B-TOXI
dizziness  I-TOXI
,  O
unsteadiness  B-TOXI
of  I-TOXI
gait  I-TOXI
and  O
malaise  B-TOXI
occurred  O
during  O
tamoxifen  B-DRUG
treatment  O
.  O

Serum  O
levels  O
of  O
tamoxifen  B-DRUG
averaged  O
3-3.5  O
microM  O
on  O
day  O
4  O
of  O
all  O
courses  O
of  O
treatment  O
at  O
both  O
480  O
and  O
720  O
mg  O
day-1  O
.  O

N-desmethyltamoxifen  B-DRUG
levels  O
were  O
lower  O
than  O
tamoxifen  B-DRUG
during  O
the  O
first  O
course  O
(  O
2  O
microM  O
)  O
but  O
increased  O
to  O
equal  O
tamoxifen  B-DRUG
levels  O
during  O
the  O
second  O
course  O
.  O

Didesmethyltamoxifen  B-DRUG
levels  O
remained  O
below  O
1  O
microM  O
.  O

In  O
vitro  O
,  O
both  O
tamoxifen  B-DRUG
and  O
the  O
standard  O
modulator  O
of  O
multidrug  O
resistance  O
,  O
verapamil  B-DRUG
,  O
produced  O
minor  O
enhancement  O
of  O
etoposide  B-TOXI
cytotoxicity  I-TOXI
in  O
the  O
MCF-7  O
wt  O
cell  O
line  O
but  O
produced  O
no  O
enhancement  O
with  O
any  O
other  O
cell  O
line  O
.  O

High  O
,  O
intermittent  O
doses  O
of  O
tamoxifen  B-DRUG
can  O
be  O
given  O
with  O
acceptable  O
toxicity  O
and  O
produce  O
serum  O
levels  O
that  O
have  O
been  O
shown  O
to  O
modulate  O
drug  O
resistance  O
in  O
vitro  O
.  O

In  O
vitro  O
,  O
however  O
,  O
such  O
levels  O
have  O
no  O
significant  O
effect  O
on  O
etoposide  B-TOXI
cytotoxicity  I-TOXI
towards  O
a  O
range  O
of  O
wild-type  O
and  O
MDR  O
cell  O
lines  O
.  O

Induction  O
chemotherapy  O
in  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
:  O
results  O
of  O
a  O
phase  O
III  O
trial  O
.  O


Between  O
December  O
1982  O
and  O
October  O
1986  O
,  O
131  O
patients  O
with  O
stage  O
II-III-IV  O
squamous  B-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
oropharynx  I-CANCER
or  I-CANCER
oral  I-CANCER
cavity  O
were  O
randomized  O
to  O
induction  O
chemotherapy  O
,  O
consisting  O
of  O
bleomycin  B-DRUG
(  O
10  O
mg  O
/  O
m2  O
/  O
day  O
in  O
continuous  O
infusion  O
from  O
day  O
1  O
to  O
day  O
5  O
)  O
,  O
methotrexate  B-DRUG
(  O
120  O
mg  O
/  O
m2  O
on  O
day  O
2  O
)  O
followed  O
by  O
folinic  B-DRUG
acid  I-DRUG
,  O
5-fluorouracil  B-DRUG
(  O
5  B-DRUG
FU  I-DRUG
)  O
(  O
600  O
mg  O
/  O
m2  O
on  O
day  O
2  O
)  O
,  O
and  O
cisplatin  B-DRUG
(  O
120  O
mg  O
/  O
m2  O
on  O
day  O
4  O
)  O
every  O
4  O
weeks  O
for  O
a  O
total  O
of  O
three  O
cycles  O
followed  O
by  O
definitive  O
locoregional  O
treatment  O
versus  O
locoregional  O
treatment  O
alone  O
.  O

The  O
modalities  O
of  O
definitive  O
treatment  O
(  O
radiotherapy  O
+  O
/  O
-  O
surgery  O
)  O
were  O
chosen  O
prior  O
to  O
randomization  O
.  O

A  O
total  O
of  O
116  O
patients  O
were  O
evaluable  O
.  O

Of  O
55  O
patients  O
in  O
the  O
chemotherapy  O
arm  O
,  O
four  O
(  O
7  O
%  O
)  O
had  O
a  O
complete  O
response  O
(  O
CR  O
)  O
and  O
23  O
(  O
42  O
%  O
)  O
a  O
partial  O
response  O
(  O
PR  O
)  O
following  O
the  O
induction  O
regimen  O
.  O

At  O
the  O
completion  O
of  O
locoregional  O
treatment  O
,  O
76  O
%  O
(  O
42  O
of  O
55  O
)  O
of  O
patients  O
in  O
the  O
experimental  O
group  O
were  O
in  O
CR  O
compared  O
to  O
89  O
%  O
(  O
54  O
of  O
61  O
)  O
in  O
the  O
control  O
group  O
.  O

There  O
was  O
no  O
difference  O
in  O
survival  O
,  O
cause-specific  O
survival  O
,  O
and  O
pattern  O
of  O
relapse  O
between  O
both  O
groups  O
.  O

The  O
median  O
survival  O
was  O
22  O
months  O
in  O
the  O
chemotherapy  O
group  O
and  O
29  O
months  O
in  O
the  O
control  O
group  O
.  O

Responders  O
to  O
chemotherapy  O
did  O
not  O
fare  O
better  O
than  O
nonresponders  O
.  O

Chemotherapy-related  B-TOXI
toxicities  I-TOXI
were  O
few  O
and  O
most  O
of  O
them  O
related  O
to  O
cisplatin  B-DRUG
which  O
was  O
reduced  O
to  O
100  O
mg  O
/  O
m2  O
for  O
35  O
patients  O
.  O

There  O
were  O
no  O
treatment-related  B-TOXI
deaths  I-TOXI
and  O
,  O
in  O
the  O
experimental  O
arm  O
of  O
the  O
trial  O
,  O
no  O
increased  O
morbidity  O
from  O
locoregional  O
treatment  O
.  O

This  O
induction  O
regimen  O
does  O
not  O
offer  O
any  O
advantages  O
over  O
standard  O
treatment  O
.  O

Etoposide  B-DRUG
and  O
carboplatin  B-DRUG
in  O
neuroblastoma  B-TOXI
:  O
a  O
French  O
Society  O
of  O
Pediatric  O
Oncology  O
phase  O
II  O
study  O
.  O


A  O
phase  O
II  O
study  O
of  O
etoposide  B-DRUG
(  O
VP  B-DRUG
16  I-DRUG
)  O
and  O
carboplatin  B-DRUG
(  O
CBDCA  B-DRUG
)  O
was  O
performed  O
in  O
patients  O
with  O
metastatic  B-CANCER
neuroblastoma  I-CANCER
(  O
NB  B-CANCER
)  O
.  O

The  O
aim  O
of  O
the  O
study  O
was  O
to  O
find  O
an  O
alternative  O
treatment  O
for  O
induction  O
with  O
different  O
toxicities  O
than  O
the  O
VP  B-DRUG
16  I-DRUG
/  I-DRUG
cisplatin  I-DRUG
(  O
CDDP  B-DRUG
)  O
combination  O
.  O

Forty-seven  O
patients  O
who  O
were  O
from  O
6  O
months  O
to  O
16  O
years  O
of  O
age  O
,  O
with  O
either  O
relapsed  O
(  O
29  O
)  O
or  O
primary  O
resistant  O
(  O
18  O
)  O
NB  B-DRUG
,  O
were  O
included  O
in  O
a  O
cooperative  O
multicenter  O
phase  O
II  O
study  O
of  O
the  O
French  O
Society  O
of  O
Pediatric  O
Oncology  O
(  O
SFOP  O
)  O
.  O

The  O
schedule  O
consisted  O
of  O
5  O
consecutive  O
days  O
of  O
VP  B-DRUG
16  I-DRUG
100  O
mg  O
/  O
m2  O
/  O
d  O
and  O
CBDCA  B-DRUG
160  O
mg  O
/  O
m2  O
/  O
d.  O
The  O
response  O
rate  O
for  O
the  O
39  O
assessable  O
patients  O
was  O
43  O
%  O
;  O
there  O
were  O
four  O
complete  O
remissions  O
and  O
13  O
partial  O
remissions  O
.  O

Neither  O
the  O
status  O
of  O
the  O
patients  O
nor  O
the  O
total  O
dose  O
of  O
CDDP  B-DRUG
that  O
was  O
received  O
previously  O
influenced  O
response  O
.  O

Hematologic  B-TOXI
toxicity  I-TOXI
was  O
marked  O
and  O
caused  O
considerable  O
delay  O
between  O
courses  O
(  O
median  O
interval  O
,  O
39  O
days  O
)  O
.  O

In  O
these  O
heavily  O
pretreated  O
patients  O
,  O
16  O
%  O
had  O
a  O
more  O
than  O
50  O
%  O
decrease  O
in  O
creatinine  O
clearance  O
and  O
a  O
22  O
%  O
World  O
Health  O
Organization  O
(  O
WHO  O
)  O
grade  O
2  O
ototoxicity  B-TOXI
.  O

This  O
VP  B-DRUG
16  I-DRUG
/  I-DRUG
CBDCA  I-DRUG
combination  O
deserves  O
further  O
evaluation  O
for  O
efficacy  O
and  O
toxicity  O
in  O
newly  O
diagnosed  O
patients  O
,  O
and  O
the  O
combination  O
of  O
both  O
drugs  O
should  O
be  O
considered  O
for  O
high-dose  O
therapy  O
with  O
bone  O
marrow  O
transplantation  O
.  O

Phase  O
I  O
and  O
II  O
study  O
of  O
high-dose  O
ifosfamide  B-DRUG
,  O
carboplatin  B-DRUG
,  O
and  O
etoposide  B-DRUG
with  O
autologous  O
bone  O
marrow  O
rescue  O
in  O
lymphomas  B-CANCER
and  I-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O


High-dose  O
chemotherapy  O
produces  O
durable  O
disease-free  O
remissions  O
in  O
a  O
minority  O
of  O
patients  O
with  O
resistant  B-CANCER
lymphomas  I-CANCER
and  I-CANCER
solid  I-CANCER
tumors  I-CANCER
.  O

In  O
an  O
attempt  O
to  O
improve  O
on  O
the  O
available  O
regimens  O
,  O
ifosfamide  B-DRUG
,  O
carboplatin  B-DRUG
,  O
and  O
etoposide  B-DRUG
(  O
ICE  B-DRUG
)  O
were  O
selected  O
for  O
a  O
new  O
high-dose  O
regimen  O
because  O
of  O
their  O
favorable  O
spectrum  O
of  O
nonhematopoietic  B-TOXI
toxicity  I-TOXI
and  O
evidence  O
of  O
synergy  O
in  O
in  O
vitro  O
systems  O
.  O

Forty-one  O
patients  O
with  O
drug-resistant  B-TOXI
Hodgkin  I-TOXI
's  I-TOXI
and  I-TOXI
non-Hodgkin  I-TOXI
's  I-TOXI
lymphomas  I-TOXI
,  O
and  O
breast  B-TOXI
and  I-TOXI
testicular  I-TOXI
cancers  I-TOXI
were  O
entered  O
onto  O
a  O
phase  O
I  O
and  O
II  O
trial  O
of  O
a  O
single  O
course  O
of  O
ICE  B-DRUG
with  O
autologous  O
bone  O
marrow  O
rescue  O
.  O

Before  O
transplantation  O
,  O
all  O
patients  O
received  O
combination  O
chemotherapy  O
until  O
maximal  O
tumor  O
response  O
was  O
achieved  O
.  O

Patients  O
received  O
total  O
doses  O
of  O
ifosfamide  B-DRUG
from  O
10  O
to  O
18  O
g  O
/  O
m2  O
,  O
carboplatin  B-DRUG
from  O
0.9  O
to  O
1.98  O
g  O
/  O
m2  O
,  O
and  O
etoposide  B-DRUG
from  O
0.6  O
to  O
1.5  O
g  O
/  O
m2  O
administered  O
during  O
a  O
4-day  O
period  O
,  O
with  O
a  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
ifosfamide  B-DRUG
16  O
g  O
/  O
m2  O
,  O
carboplatin  B-DRUG
1.8  O
g  O
/  O
m2  O
,  O
and  O
etoposide  B-DRUG
1.5  O
g  O
/  O
m2  O
.  O

The  O
dose-limiting  O
toxicities  O
included  O
irreversible  B-TOXI
renal  I-TOXI
,  O
cardiac  B-TOXI
,  O
and  O
CNS  B-TOXI
dysfunction  I-TOXI
.  O

There  O
were  O
three  O
toxic  B-TOXI
deaths  I-TOXI
(  O
7  O
%  O
)  O
,  O
and  O
all  O
occurred  O
above  O
the  O
MTD  O
.  O

Thirteen  O
patients  O
who  O
were  O
treated  O
at  O
the  O
MTD  O
tolerated  O
the  O
regimen  O
well  O
;  O
reversible  O
renal  B-TOXI
dysfunction  I-TOXI
and  O
grade  O
2  O
mucositis  B-TOXI
commonly  O
were  O
observed  O
.  O

Of  O
23  O
heavily  O
pretreated  O
patients  O
with  O
persistent  O
disease  O
at  O
the  O
time  O
of  O
transplant  O
,  O
10  O
(  O
43  O
%  O
)  O
achieved  O
complete  O
remissions  O
(  O
CRs  O
)  O
and  O
11  O
(  O
48  O
%  O
)  O
achieved  O
partial  O
remissions  O
(  O
PRs  O
)  O
.  O

Hodgkin  B-CANCER
's  I-CANCER
and  I-CANCER
non-Hodgkin  I-CANCER
's  I-CANCER
lymphoma  I-CANCER
patients  O
who  O
were  O
treated  O
at  O
or  O
below  O
the  O
MTD  O
had  O
a  O
median  O
potential  O
follow-up  O
of  O
11.9  O
months  O
,  O
and  O
12-month  O
progression-free  O
survivals  O
of  O
62  O
%  O
and  O
48  O
%  O
,  O
respectively  O
.  O

High-dose  O
ICE  B-DRUG
with  O
bone  O
marrow  O
rescue  O
was  O
well  O
tolerated  O
with  O
a  O
high  O
response  O
rate  O
,  O
and  O
should  O
be  O
considered  O
for  O
further  O
testing  O
.  O

Neoadjuvant  O
chemotherapy  O
with  O
cisplatin  B-DRUG
,  O
5-FU  B-DRUG
,  O
and  O
leucovorin  B-DRUG
(  O
PLF  B-DRUG
)  O
in  O
locally  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
:  O
a  O
prospective  O
phase  O
II  O
study  O
.  O


Patients  O
with  O
locally  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
(  O
cT3  O
,  O
cT4  O
,  O
N+  O
,  O
M0  O
)  O
have  O
a  O
dismal  O
prognosis  O
,  O
despite  O
complete  O
resection  O
.  O

The  O
objective  O
of  O
this  O
study  O
was  O
to  O
evaluate  O
the  O
toxicity  O
and  O
efficacy  O
of  O
neoadjuvant  O
chemotherapy  O
using  O
the  O
PLF  B-DRUG
(  O
cisplatin  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
[  O
folinic  B-DRUG
acid  I-DRUG
]  O
/  O
5-fluorouracil  B-DRUG
[  O
FU  B-DRUG
]  O
)  O
regimen  O
in  O
these  O
patients  O
.  O

Primary  O
endpoints  O
of  O
the  O
study  O
were  O
the  O
toxicity  O
and  O
the  O
response  O
to  O
chemotherapy  O
.  O

Secondary  O
endpoints  O
were  O
the  O
rate  O
of  O
complete  O
resection  O
,  O
survival  O
,  O
and  O
first  O
site  O
of  O
failure  O
.  O

Forty-nine  O
patients  O
with  O
adenocarcinoma  B-CANCER
of  I-CANCER
the  I-CANCER
stomach  I-CANCER
were  O
enrolled  O
.  O

Staging  O
was  O
based  O
on  O
abdominal  O
computed  O
tomography  O
(  O
CT  O
)  O
scans  O
,  O
endosonography  O
,  O
and  O
laparoscopy  O
.  O

The  O
intention  O
was  O
to  O
administer  O
two  O
cycles  O
(  O
each  O
containing  O
six  O
courses  O
)  O
of  O
preoperative  O
chemotherapy  O
,  O
consisting  O
of  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
high-dose  O
folinic  B-DRUG
acid  I-DRUG
(  O
HD-FA  O
)  O
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
and  O
HD  O
5-FU  B-DRUG
(  O
HD-5-FU  O
)  O
2000  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
PLF  O
)  O
.  O

Following  O
chemotherapy  O
all  O
patients  O
were  O
referred  O
to  O
surgery  O
.  O

To  O
be  O
evaluable  O
for  O
response  O
,  O
survival  O
,  O
and  O
first  O
site  O
of  O
failure  O
,  O
the  O
patient  O
had  O
to  O
receive  O
at  O
least  O
one  O
cycle  O
of  O
chemotherapy  O
.  O

Toxicity  O
observed  O
was  O
low  O
,  O
with  O
grade  O
3  O
toxicity  O
in  O
fewer  O
than  O
5  O
%  O
of  O
the  O
patients  O
and  O
two  O
events  O
of  O
grade  O
4  O
toxicity  O
(  O
diarrhea  B-TOXI
and  O
pulmonary  B-TOXI
embolism  I-TOXI
)  O
.  O

Forty-two  O
of  O
the  O
patients  O
(  O
86  O
%  O
)  O
received  O
at  O
least  O
one  O
cycle  O
of  O
chemotherapy  O
.  O

The  O
clinical  O
response  O
rate  O
in  O
these  O
patients  O
was  O
26  O
%  O
(  O
11  O
/  O
42  O
patients  O
)  O
.  O

In  O
76  O
%  O
of  O
the  O
patients  O
(  O
32  O
/  O
42  O
)  O
,  O
a  O
complete  O
resection  O
was  O
possible  O
.  O

The  O
median  O
duration  O
of  O
follow-up  O
for  O
the  O
surviving  O
patients  O
was  O
58  O
months  O
(  O
range  O
,  O
38  O
to  O
80+  O
months  O
)  O
.  O

The  O
median  O
survival  O
time  O
for  O
the  O
42  O
patients  O
assessable  O
for  O
response  O
was  O
25.4  O
months  O
(  O
range  O
,  O
6  O
to  O
80+  O
months  O
)  O
.  O

After  O
complete  O
resection  O
,  O
median  O
survival  O
time  O
was  O
32  O
months  O
(  O
range  O
,  O
7.6  O
to  O
80+  O
months  O
)  O
.  O

The  O
median  O
survival  O
time  O
for  O
clinically  O
responding  O
patients  O
has  O
not  O
yet  O
been  O
determined  O
,  O
but  O
5-year  O
survival  O
is  O
90  O
%  O
.  O

Twenty  O
of  O
the  O
32  O
completely  O
resected  O
patients  O
(  O
62.5  O
%  O
)  O
had  O
recurrences  O
.  O

First  O
site  O
of  O
failure  O
was  O
peritoneal  B-TOXI
dissemination  I-TOXI
in  O
10  O
patients  O
;  O
locoregional  B-TOXI
and  I-TOXI
distant  I-TOXI
recurrences  I-TOXI
were  O
rare  O
.  O

Neoadjuvant  O
chemotherapy  O
with  O
PLF  B-DRUG
in  O
patients  O
with  O
locally  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
has  O
low  O
toxicity  O
and  O
reasonable  O
efficacy  O
,  O
allowing  O
administration  O
on  O
an  O
outpatient  O
basis  O
.  O

Clinically  O
responding  O
patients  O
have  O
an  O
excellent  O
outcome  O
after  O
complete  O
resection  O
.  O

The  O
development  O
of  O
peritoneal  O
dissemination  O
even  O
after  O
neoadjuvant  O
chemotherapy  O
and  O
complete  O
resection  O
remains  O
an  O
unsolved  O
problem  O
in  O
patients  O
with  O
nonintestinal  B-CANCER
type  I-CANCER
tumors  I-CANCER
.  O

A  O
phase  O
II  O
study  O
of  O
weekly  O
cisplatin  B-DRUG
,  O
6S-stereoisomer  B-DRUG
leucovorin  I-DRUG
and  O
fluorouracil  B-DRUG
as  O
first-line  O
chemotherapy  O
for  O
elderly  O
patients  O
with  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


The  O
incidence  O
of  O
gastric  B-CANCER
cancer  I-CANCER
(  O
GC  B-CANCER
)  O
increases  O
significantly  O
after  O
the  O
fifth  O
decade  O
and  O
palliative  O
chemotherapy  O
is  O
the  O
ultimate  O
treatment  O
in  O
the  O
majority  O
of  O
patients  O
.  O

We  O
investigated  O
safety  O
and  O
efficacy  O
of  O
a  O
weekly  O
regimen  O
with  O
cisplatin  B-DRUG
,  O
fluorouracil  B-DRUG
and  O
leucovorin  B-DRUG
as  O
first-line  O
chemotherapy  O
for  O
elderly  O
patients  O
with  O
advanced  B-CANCER
GC  I-CANCER
.  O

Chemotherapy-naive  O
patients  O
older  O
than  O
65  O
years  O
were  O
considered  O
eligible  O
for  O
study  O
entry  O
.  O

Frail  O
elderly  O
patients  O
were  O
identified  O
and  O
excluded  O
according  O
to  O
the  O
following  O
criteria  O
:  O
age  O
&  O
gt  O
;  O
85  O
years  O
,  O
dependence  O
in  O
one  O
or  O
more  O
activities  O
of  O
daily  O
living  O
(  O
activities  O
of  O
daily  O
living  O
and  O
instrumental  O
activities  O
of  O
daily  O
living  O
scales  O
)  O
,  O
three  O
or  O
more  O
comorbid  O
conditions  O
,  O
one  O
or  O
more  O
geriatric  B-CANCER
syndromes  I-CANCER
.  O

Chemotherapy  O
consisted  O
of  O
1-day  O
per  O
week  O
administration  O
of  O
intravenous  O
cisplatin  B-DRUG
35  O
mg  O
m  O
(  O
-2  O
)  O
,  O
6S-stereoisomer  B-DRUG
leucovorin  I-DRUG
250  O
mg  O
m  O
(  O
-2  O
)  O
and  O
fluorouracil  B-DRUG
500  O
mg  O
m  O
(  O
-2  O
)  O
(  O
PLF  O
)  O
.  O

Patients  O
were  O
re-evaluated  O
after  O
eight  O
weekly  O
cycles  O
and  O
six  O
additional  O
weekly  O
administrations  O
were  O
planned  O
for  O
patients  O
without  O
disease  B-TOXI
progression  I-TOXI
.  O

A  O
5-day  O
subcutaneous  O
filgrastim  B-DRUG
(  O
5  O
mug  O
Kg  O
(  O
-1  O
)  O
day  O
(  O
-1  O
)  O
,  O
days  O
+1-+5  O
)  O
was  O
used  O
after  O
the  O
first  O
treatment  O
delay  O
for  O
neutropenia  B-TOXI
and  O
maintained  O
thereafter  O
.  O

In  O
the  O
whole  O
group  O
,  O
the  O
best  O
intention-to-treat  O
overall  O
response  O
rate  O
was  O
43  O
%  O
(  O
95  O
%  O
CI  O
:  O
30-56  O
%  O
)  O
.  O

The  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
and  O
the  O
median  O
survival  O
time  O
were  O
5.3  O
and  O
8.6  O
months  O
,  O
respectively  O
.  O

Fatigue  B-TOXI
was  O
the  O
commonest  O
nonhaematologic  B-TOXI
toxicity  I-TOXI
(  O
71  O
%  O
of  O
the  O
patients  O
)  O
.  O

Filgrastim  B-DRUG
was  O
used  O
in  O
30  O
patients  O
who  O
showed  O
grade  O
II  O
(  O
20  O
patients  O
)  O
or  O
grade  O
III  O
(  O
10  O
patients  O
)  O
neutropenia  B-TOXI
.  O

Neither  O
grade  O
IV  O
toxicity  O
nor  O
toxic  B-TOXI
deaths  I-TOXI
were  O
observed  O
.  O

The  O
weekly  O
PLF  B-DRUG
regimen  O
resulted  O
safe  O
and  O
effective  O
in  O
elderly  O
patients  O
with  O
advanced  B-CANCER
GC  I-CANCER
.  O

This  O
outpatient  O
regimen  O
is  O
based  O
on  O
old  O
and  O
low-cost  O
drugs  O
and  O
it  O
may  O
represent  O
an  O
alternative  O
to  O
new  O
and  O
more  O
expensive  O
combinations  O
.  O

Aggressive  O
simultaneous  O
radiochemotherapy  O
with  O
cisplatin  B-DRUG
and  O
paclitaxel  B-DRUG
in  O
combination  O
with  O
accelerated  O
hyperfractionated  O
radiotherapy  O
in  O
locally  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
tumors.  I-CANCER
Results  O
of  O
a  O
phase  O
I-II  O
trial  O
.  O


Simultaneous  O
radiochemotherapy  O
(  O
sRCT  O
)  O
is  O
the  O
treatment  O
of  O
first  O
choice  O
in  O
locally  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
cancers  I-CANCER
.  O

We  O
have  O
tested  O
a  O
very  O
aggressive  O
combination  O
protocol  O
with  O
cisplatin  B-DRUG
and  O
escalated  O
paclitaxel  B-DRUG
in  O
combination  O
with  O
accelerated  O
hyperfractionated  O
radiotherapy  O
to  O
assess  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
,  O
overall  O
toxicity  O
,  O
and  O
response  O
rate  O
.  O

The  O
trial  O
recruited  O
24  O
patients  O
(  O
21  O
males  O
,  O
three  O
females  O
,  O
mean  O
age  O
57  O
years  O
)  O
treated  O
at  O
our  O
department  O
from  O
1998  O
through  O
2001  O
.  O

Irradiation  O
was  O
administered  O
in  O
daily  O
doses  O
of  O
2  O
Gy  O
up  O
to  O
30  O
Gy  O
followed  O
by  O
1.4  O
Gy  O
twice  O
daily  O
up  O
to  O
70.6  O
Gy  O
to  O
the  O
primary  O
tumor  O
and  O
involved  O
nodes  O
and  O
51  O
Gy  O
to  O
the  O
clinically  O
negative  O
regional  O
nodes  O
.  O

The  O
chemotherapy  O
schedule  O
included  O
cisplatin  B-DRUG
in  O
a  O
fixed  O
dose  O
of  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1-5  O
and  O
29-33  O
and  O
paclitaxel  B-DRUG
at  O
increasing  O
dose  O
levels  O
of  O
20  O
,  O
25  O
,  O
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
twice  O
weekly  O
over  O
the  O
whole  O
treatment  O
time  O
.  O

Patients  O
were  O
recruited  O
in  O
cohorts  O
of  O
three  O
to  O
six  O
,  O
and  O
the  O
MTD  O
was  O
reached  O
if  O
two  O
out  O
of  O
six  O
patients  O
in  O
one  O
cohort  O
developed  O
DLT  O
.  O

DLT  O
was  O
defined  O
as  O
any  O
grade  O
4  O
toxicity  O
or  O
any  O
grade  O
3  O
toxicity  O
requiring  O
treatment  O
interruption  O
or  O
unplanned  O
hospitalization  O
or  O
any  O
grade  O
3  O
neurotoxicity  B-TOXI
.  O

We  O
recruited  O
mainly  O
patients  O
with  O
large  O
tumors  O
for  O
this  O
protocol  O
;  O
all  O
patients  O
were  O
stage  O
IV  O
,  O
and  O
the  O
mean  O
tumor  O
volume  O
(  O
primary  O
+  O
metastases  O
)  O
amounted  O
to  O
72  O
+  O
/  O
-  O
61  O
cm  O
(  O
3  O
)  O
.  O

The  O
mean  O
follow-up  O
was  O
30  O
months  O
(  O
range  O
4-39  O
months  O
)  O
.  O

One  O
early  O
death  B-TOXI
(  O
peritonitis  B-TOXI
and  O
sepsis  B-TOXI
at  O
day  O
10  O
)  O
occurred  O
,  O
and  O
23  O
patients  O
were  O
evaluable  O
for  O
acute  B-TOXI
toxicity  I-TOXI
and  I-TOXI
response  I-TOXI
.  O

The  O
MTD  O
of  O
paclitaxel  B-DRUG
was  O
reached  O
at  O
the  O
third  O
dose  O
level  O
(  O
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
paclitaxel  B-DRUG
twice  O
weekly  O
)  O
.  O

The  O
DLT  O
was  O
severe  B-TOXI
mucositis  I-TOXI
grade  O
3  O
(  O
n  O
=  O
1  O
)  O
and  O
skin  B-TOXI
erythema  I-TOXI
grade  O
4  O
(  O
n  O
=  O
2  O
)  O
.  O

After  O
determining  O
the  O
MTD  O
,  O
another  O
14  O
patients  O
were  O
treated  O
at  O
the  O
recommended  O
dose  O
level  O
of  O
paclitaxel  B-DRUG
with  O
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
twice  O
weekly  O
.  O

In  O
summary  O
,  O
13  O
/  O
23  O
patients  O
(  O
57  O
%  O
)  O
developed  O
grade  O
3  O
and  O
10  O
/  O
23  O
(  O
43  O
%  O
)  O
grade  O
2  O
mucositis  B-TOXI
.  O

Two  O
patients  O
(  O
9  O
%  O
)  O
had  O
grade  O
4  O
,  O
five  O
(  O
22  O
%  O
)  O
grade  O
3  O
,  O
and  O
16  O
(  O
69  O
%  O
)  O
grade  O
2  O
dermatitis  B-TOXI
.  O

One  O
patient  O
died  B-TOXI
at  O
day  O
30  O
of  O
neutropenic  B-TOXI
infection  I-TOXI
.  O

In  O
one  O
patient  O
,  O
a  O
grade  O
2  O
nephrotoxicity  B-TOXI
appeared  O
requiring  O
cessation  O
of  O
cisplatin  B-DRUG
chemotherapy  O
.  O

18  O
/  O
23  O
patients  O
(  O
78  O
%  O
)  O
required  O
blood  O
transfusion  O
(  O
1-3  O
units  O
)  O
and  O
16  O
/  O
23  O
(  O
70  O
%  O
)  O
i.v.  O
antibiotics  O
.  O

14  O
patients  O
(  O
61  O
%  O
)  O
achieved  O
a  O
complete  O
and  O
nine  O
(  O
39  O
%  O
)  O
a  O
partial  O
remission  O
,  O
yielding  O
an  O
overall  O
response  O
rate  O
of  O
100  O
%  O
.  O

In  O
summary  O
,  O
six  O
patients  O
died  B-TOXI
of  I-TOXI
local  I-TOXI
tumor  I-TOXI
progression  I-TOXI
(  O
n  O
=  O
2  O
)  O
,  O
distant  B-TOXI
metastases  I-TOXI
(  O
n  O
=  O
2  O
)  O
,  O
or  O
therapy-related  O
complications  B-TOXI
(  O
n  O
=  O
2  O
)  O
during  O
follow-up  O
.  O

The  O
3-year  O
overall  O
survival  O
was  O
71  O
%  O
.  O

Tumor  O
volume  O
was  O
not  O
a  O
risk  O
factor  O
for  O
failure  O
in  O
this  O
protocol  O
(  O
mean  O
tumor  O
volume  O
in  O
relapse-free  O
vs.  O
progressive  O
patients  O
71  O
+  O
/  O
-  O
65  O
cm  O
(  O
3  O
)  O
vs.  O
64  O
+  O
/  O
-  O
38  O
cm  O
(  O
3  O
)  O
)  O
.  O

All  O
patients  O
have  O
,  O
so  O
far  O
,  O
developed  O
only  O
slight  O
late  O
effects  O
(  O
fibrosis  B-TOXI
,  O
lymphedema  B-TOXI
)  O
with  O
no  O
grade  O
3-4  O
late  B-TOXI
sequelae  I-TOXI
.  O

This  O
very  O
aggressive  O
sRCT  O
protocol  O
yielded  O
excellent  O
response  O
and  O
survival  O
figures  O
but  O
was  O
associated  O
with  O
a  O
very  O
high  O
rate  O
of  O
acute  B-TOXI
toxicity  I-TOXI
(  O
8  O
%  O
therapy-related  B-TOXI
deaths  I-TOXI
)  O
.  O

A  O
maximal  O
supportive  O
treatment  O
is  O
therefore  O
required  O
.  O

Phase  O
I  O
clinical  O
study  O
of  O
infusional  O
5-fluorouracil  B-DRUG
with  O
oxaliplatin  B-DRUG
and  O
gemcitabine  B-DRUG
(  O
FOG  B-DRUG
regimen  O
)  O
in  O
patients  O
with  O
solid  B-CANCER
tumors  I-CANCER
.  O


The  O
aim  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
,  O
recommended  O
phase  O
II  O
dose  O
(  O
RPTD  O
)  O
and  O
toxicities  O
of  O
the  O
FOG  B-DRUG
regimen  O
(  O
infusional  O
5-fluorouracil  B-DRUG
,  O
oxaliplatin  B-DRUG
,  O
gemcitabine  B-DRUG
)  O
.  O

Patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
were  O
treated  O
in  O
an  O
accelerated  O
titration  O
scheme  O
.  O

5-Fluorouracil  B-DRUG
was  O
administered  O
intravenously  O
at  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
for  O
14  O
days  O
and  O
repeated  O
every  O
21  O
days  O
(  O
one  O
cycle  O
)  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
on  O
days  O
1  O
and  O
8  O
over  O
30  O
min  O
at  O
450-650  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

Oxaliplatin  B-DRUG
was  O
administered  O
on  O
day  O
1  O
over  O
2  O
h  O
at  O
85-130  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

For  O
cycles  O
1  O
,  O
3  O
and  O
beyond  O
,  O
gemcitabine  B-DRUG
followed  O
oxaliplatin  B-DRUG
;  O
for  O
cycle  O
2  O
,  O
gemcitabine  B-DRUG
preceded  O
oxaliplatin  B-DRUG
.  O

Forty-five  O
and  O
39  O
patients  O
were  O
assessable  O
for  O
toxicity  O
and  O
response  O
,  O
respectively  O
.  O

Cycle  O
1  O
dose-limiting  O
toxicities  O
(  O
DLT  O
)  O
included  O
neutropenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
and  O
diarrhea  B-TOXI
.  O

No  O
DLT  O
was  O
observed  O
in  O
cycle  O
1  O
at  O
the  O
first  O
four  O
dose  O
levels  O
(  O
DL  O
)  O
.  O

At  O
DL-5  O
,  O
two  O
of  O
four  O
(  O
50  O
%  O
)  O
patients  O
experienced  O
DLT  O
in  O
cycle  O
1.  O
Expanding  O
DL-4  O
,  O
nine  O
of  O
26  O
(  O
35  O
%  O
)  O
patients  O
experienced  O
DLT  O
in  O
cycle  O
1.  O
Because  O
recurrent  O
grade  O
3  O
toxicities  O
were  O
observed  O
in  O
three  O
of  O
six  O
(  O
50  O
%  O
)  O
patients  O
at  O
DL-3  O
,  O
DL-2  O
was  O
considered  O
the  O
RPTD  O
.  O

At  O
the  O
RPTD  O
,  O
three  O
patients  O
had  O
a  O
partial  O
response  O
(  O
response  O
rate  O
23  O
%  O
)  O
.  O

The  O
RPTD  O
for  O
the  O
5-fluorouracil-oxaliplatin-gemcitabine  B-DRUG
combination  O
is  O
200  O
/  O
100  O
/  O
450  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

This  O
novel  O
regimen  O
has  O
demonstrated  O
activity  O
in  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
and  O
merits  O
further  O
investigation  O
.  O

A  O
phase  O
II  O
study  O
of  O
irinotecan  B-DRUG
plus  O
chronomodulated  O
oxaliplatin  B-DRUG
,  O
5-fluorouracil  B-DRUG
and  O
folinic  B-DRUG
acid  I-DRUG
in  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
patients  O
.  O


The  O
combination  O
of  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
,  O
oxaliplatin  B-DRUG
(  O
L-OHP  B-DRUG
)  O
,  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
and  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
is  O
one  O
of  O
the  O
possibilities  O
to  O
overcome  O
chemoresistance  O
in  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
(  O
ACRC  B-CANCER
)  O
patients  O
.  O

The  O
aim  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
tolerability  O
and  O
activity  O
of  O
CPT-11  B-DRUG
plus  O
chronomodulated  O
infusion  O
of  O
L-OHP  B-DRUG
,  O
5-FU  B-DRUG
and  O
FA  B-DRUG
in  O
ACRC  B-CANCER
patients  O
.  O

A  O
total  O
of  O
35  O
patients  O
(  O
91  O
%  O
pretreated  O
,  O
77  O
%  O
with  O
CPT-11  B-DRUG
,  O
54  O
%  O
with  O
L-OHP  B-DRUG
,  O
42  O
%  O
with  O
both  O
)  O
were  O
treated  O
every  O
3  O
weeks  O
with  O
CPT-11  B-DRUG
,  O
180  O
mg  O
m  O
(  O
-2  O
)  O
day  O
1  O
i.v.  O
,  O
plus  O
L-OHP  B-DRUG
,  O
20  O
mg  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
,  O
5-FU  B-DRUG
,  O
700  O
mg  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
and  O
FA  B-DRUG
,  O
150  O
mg  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
,  O
all  O
three  O
drugs  O
from  O
day  O
2  O
to  O
day  O
5  O
by  O
chronomodulated  O
infusion  O
.  O

The  O
patients  O
'  O
(  O
pt  O
)  O
data  O
were  O
as  O
follows  O
:  O
male  O
/  O
female  O
21  O
/  O
14  O
;  O
median  O
age  O
58  O
years  O
(  O
range  O
:  O
38-70  O
)  O
;  O
PS  O
0  O
:  O
26  O
pts  O
(  O
74  O
%  O
)  O
,  O
PS  O
1  O
:  O
8  O
pts  O
(  O
23  O
%  O
)  O
,  O
PS  O
2  O
:  O
1  O
pt  O
(  O
3  O
%  O
)  O
;  O
primary  O
tumour  B-CANCER
colon  I-CANCER
/  I-CANCER
rectum  I-CANCER
26  O
/  O
9  O
;  O
involved  O
organs  O
:  O
1  O
,  O
14  O
pts  O
(  O
40  O
%  O
)  O
;  O
2  O
,  O
17  O
pts  O
(  O
48  O
%  O
)  O
;  O
&  O
gt  O
;  O
or=3  O
:  O
4  O
pts  O
(  O
11  O
%  O
)  O
;  O
previous  O
chemotherapy  O
lines  O
1  O
:  O
12  O
pts  O
(  O
34  O
%  O
)  O
,  O
2  O
:  O
10  O
pts  O
(  O
28  O
%  O
)  O
,  O
&  O
gt  O
;  O
or=3  O
:  O
10  O
pts  O
(  O
28  O
%  O
)  O
.  O

A  O
total  O
of  O
221  O
courses  O
(  O
c  O
)  O
were  O
performed  O
;  O
no  O
grade  O
4  O
toxicity  O
was  O
observed  O
with  O
only  O
one  O
grade  O
3  O
(  O
G3  O
)  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
(  O
3  O
%  O
)  O
in  O
one  O
out  O
of  O
221  O
courses  O
(  O
&  O
lt  O
;  O
1  O
%  O
)  O
.  O

Maximal  O
toxicity  O
(  O
G3  O
)  O
was  O
nausea  B-TOXI
and  O
diarrhoea  B-TOXI
in  O
10  O
pts  O
(  O
28  O
%  O
)  O
,  O
occurring  O
in  O
14  O
out  O
of  O
221  O
c  O
(  O
6  O
%  O
)  O
and  O
12  O
out  O
of  O
221  O
c  O
(  O
5  O
%  O
)  O
respectively  O
.  O

Seven  O
patients  O
achieved  O
a  O
partial  O
response  O
(  O
20  O
%  O
,  O
confidence  O
interval  O
(  O
c.i.  O
)  O
6.8-33.3  O
)  O
and  O
one  O
patient  O
a  O
complete  O
response  O
(  O
2.9  O
%  O
,  O
c.i.  O
0-8.4  O
)  O
,  O
for  O
a  O
total  O
overall  O
response  O
rate  O
of  O
22.9  O
%  O
(  O
c.i.  O
9-36.8  O
)  O
;  O
15  O
out  O
of  O
35  O
(  O
42.9  O
%  O
,  O
c.i.  O
26.5-59.3  O
)  O
had  O
stable  O
disease  O
and  O
12  O
out  O
of  O
35  O
(  O
34.3  O
%  O
,  O
c.i.  O
18.6-50  O
)  O
patients  O
underwent  O
a  O
progression  O
.  O

In  O
conclusion  O
,  O
this  O
four-drug  O
regimen  O
is  O
feasible  O
in  O
advanced  B-CANCER
pretreated  I-CANCER
ACRC  I-CANCER
patients  O
with  O
no  O
significant  O
haematological  B-TOXI
toxicity  I-TOXI
and  O
acceptable  O
diarrhoea  B-TOXI
.  O

The  O
activity  O
of  O
this  O
combination  O
is  O
currently  O
studied  O
in  O
EORTC  O
05011  O
study  O
.  O

FOLFIRI  B-DRUG
followed  O
by  O
FOLFOX6  B-DRUG
or  O
the  O
reverse  O
sequence  O
in  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
:  O
a  O
randomized  O
GERCOR  O
study  O
.  O


In  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
,  O
phase  O
III  O
studies  O
have  O
demonstrated  O
the  O
superiority  O
of  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
with  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
in  O
combination  O
with  O
irinotecan  B-DRUG
or  O
oxaliplatin  B-DRUG
over  O
FU  B-DRUG
+  I-DRUG
LV  I-DRUG
alone  O
.  O

This  O
phase  O
III  O
study  O
investigated  O
two  O
sequences  O
:  O
folinic  B-DRUG
acid  I-DRUG
,  O
FU  B-DRUG
,  O
and  O
irinotecan  B-DRUG
(  O
FOLFIRI  B-DRUG
)  O
followed  O
by  O
folinic  B-DRUG
acid  I-DRUG
,  O
FU  B-DRUG
,  O
and  O
oxaliplatin  B-DRUG
(  O
FOLFOX6  B-DRUG
;  O
arm  O
A  O
)  O
,  O
and  O
FOLFOX6  B-DRUG
followed  O
by  O
FOLFIRI  B-DRUG
(  O
arm  O
B  O
)  O
.  O

Previously  O
untreated  O
patients  O
with  O
assessable  O
disease  O
were  O
randomly  O
assigned  O
to  O
receive  O
a  O
2-hour  O
infusion  O
of  O
l-LV  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
or  O
dl-LV  O
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
followed  O
by  O
a  O
FU  B-DRUG
bolus  O
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
46-hour  O
infusion  O
2,400  O
to  O
3,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
46  O
hours  O
every  O
2  O
weeks  O
,  O
either  O
with  O
irinotecan  B-DRUG
180  O
mg  O
/  O
m  O
(  O
2  O
)  O
or  O
with  O
oxaliplatin  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
2-hour  O
infusion  O
on  O
day  O
1.  O
At  O
progression  O
,  O
irinotecan  B-DRUG
was  O
replaced  O
by  O
oxaliplatin  B-DRUG
(  O
arm  O
A  O
)  O
,  O
or  O
oxaliplatin  B-DRUG
by  O
irinotecan  B-DRUG
(  O
arm  O
B  O
)  O
.  O

Median  O
survival  O
was  O
21.5  O
months  O
in  O
109  O
patients  O
allocated  O
to  O
FOLFIRI  B-DRUG
then  O
FOLFOX6  B-DRUG
versus  O
20.6  O
months  O
in  O
111  O
patients  O
allocated  O
to  O
FOLFOX6  B-DRUG
then  O
FOLFIRI  B-DRUG
(  O
P  O
=.99  O
)  O
.  O

Median  O
second  O
progression-free  O
survival  O
(  O
PFS  O
)  O
was  O
14.2  O
months  O
in  O
arm  O
A  O
versus  O
10.9  O
in  O
arm  O
B  O
(  O
P  O
=.64  O
)  O
.  O

In  O
first-line  O
therapy  O
,  O
FOLFIRI  B-DRUG
achieved  O
56  O
%  O
response  O
rate  O
(  O
RR  O
)  O
and  O
8.5  O
months  O
median  O
PFS  O
,  O
versus  O
FOLFOX6  B-DRUG
which  O
achieved  O
54  O
%  O
RR  O
and  O
8.0  O
months  O
median  O
PFS  O
(  O
P  O
=.26  O
)  O
.  O

Second-line  O
FOLFIRI  B-DRUG
achieved  O
4  O
%  O
RR  O
and  O
2.5  O
months  O
median  O
PFS  O
,  O
versus  O
FOLFOX6  B-DRUG
which  O
achieved  O
15  O
%  O
RR  O
and  O
4.2  O
months  O
PFS  O
.  O

In  O
first-line  O
therapy  O
,  O
National  O
Cancer  O
Institute  O
Common  O
Toxicity  O
Criteria  O
grade  O
3  O
/  O
4  O
mucositis  B-TOXI
,  O
nausea  B-TOXI
/  O
vomiting  B-TOXI
,  O
and  O
grade  O
2  O
alopecia  B-TOXI
were  O
more  O
frequent  O
with  O
FOLFIRI  B-DRUG
,  O
and  O
grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
and  O
neurosensory  B-TOXI
toxicity  I-TOXI
were  O
more  O
frequent  O
with  O
FOLFOX6  B-DRUG
.  O

Both  O
sequences  O
achieved  O
a  O
prolonged  O
survival  O
and  O
similar  O
efficacy  O
.  O

The  O
toxicity  O
profiles  O
were  O
different  O
.  O

Multicenter  O
phase  O
II  O
study  O
of  O
Nordic  O
fluorouracil  B-DRUG
and  O
folinic  B-DRUG
acid  I-DRUG
bolus  O
schedule  O
combined  O
with  O
oxaliplatin  B-DRUG
as  O
first-line  O
treatment  O
of  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


This  O
Nordic  O
multicenter  O
phase  O
II  O
study  O
evaluated  O
the  O
efficacy  O
and  O
safety  O
of  O
oxaliplatin  B-DRUG
combined  O
with  O
the  O
Nordic  O
bolus  O
schedule  O
of  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
and  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
as  O
first-line  O
treatment  O
in  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Eighty-five  O
patients  O
were  O
treated  O
with  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
2-hour  O
infusion  O
on  O
day  O
1  O
,  O
followed  O
by  O
a  O
3-minute  O
bolus  O
injection  O
with  O
FU  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
,  O
30  O
minutes  O
later  O
,  O
by  O
a  O
bolus  O
injection  O
with  O
FA  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
second  O
week  O
.  O

The  O
same  O
doses  O
of  O
FU  B-DRUG
and  O
FA  B-DRUG
were  O
also  O
given  O
on  O
day  O
2.  O
Fifty-one  O
of  O
82  O
assessable  O
patients  O
achieved  O
a  O
complete  O
(  O
n  O
=  O
4  O
)  O
or  O
partial  O
(  O
n  O
=  O
47  O
)  O
response  O
,  O
leading  O
to  O
a  O
response  O
rate  O
of  O
62  O
%  O
(  O
95  O
%  O
CI  O
,  O
52  O
%  O
to  O
72  O
%  O
)  O
.  O

Nineteen  O
patients  O
showed  O
stable  O
disease  O
,  O
and  O
12  O
patients  O
had  O
progressive  B-TOXI
disease  I-TOXI
.  O

Thirty-eight  O
of  O
the  O
51  O
responses  O
were  O
radiologically  O
confirmed  O
8  O
weeks  O
later  O
(  O
confirmed  O
response  O
rate  O
,  O
46  O
%  O
;  O
95  O
%  O
CI  O
,  O
36  O
%  O
to  O
58  O
%  O
)  O
.  O

The  O
estimated  O
median  O
time  O
to  O
progression  O
was  O
7.0  O
months  O
(  O
95  O
%  O
CI  O
,  O
6.3  O
to  O
7.7  O
months  O
)  O
,  O
and  O
the  O
median  O
overall  O
survival  O
was  O
16.1  O
months  O
(  O
95  O
%  O
CI  O
,  O
12.7  O
to  O
19.6  O
months  O
)  O
in  O
the  O
intent-to-treat  O
population  O
.  O

Neutropenia  B-TOXI
was  O
the  O
main  O
adverse  O
event  O
,  O
with  O
grade  O
3  O
to  O
4  O
toxicity  O
in  O
58  O
%  O
of  O
patients  O
.  O

Febrile  B-TOXI
neutropenia  I-TOXI
developed  O
in  O
seven  O
patients  O
.  O

Nonhematologic  B-TOXI
toxicity  I-TOXI
consisted  O
mainly  O
of  O
neuropathy  B-TOXI
(  O
grade  O
3  O
in  O
11  O
patients  O
and  O
grade  O
2  O
in  O
another  O
27  O
patients  O
)  O
.  O

Oxaliplatin  B-DRUG
combined  O
with  O
the  O
bolus  O
Nordic  O
schedule  O
of  O
FU+FA  B-DRUG
(  O
Nordic  O
FLOX  B-DRUG
)  O
is  O
a  O
well-tolerated  O
,  O
effective  O
,  O
and  O
feasible  O
bolus  O
schedule  O
as  O
first-line  O
treatment  O
of  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
that  O
yields  O
comparable  O
results  O
compared  O
with  O
more  O
complex  O
schedules  O
.  O

Phase  O
II  O
trial  O
of  O
cisplatin  B-DRUG
/  I-DRUG
etoposide  I-DRUG
and  O
concurrent  O
radiotherapy  O
followed  O
by  O
paclitaxel  B-DRUG
/  I-DRUG
carboplatin  I-DRUG
consolidation  O
for  O
limited  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
Southwest  O
Oncology  O
Group  O
9713  O
.  O


Limited  B-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
LSCLC  B-CANCER
)  O
is  O
characterized  O
by  O
a  O
high  O
initial  O
response  O
rate  O
to  O
chemoradiotherapy  O
,  O
but  O
local  O
or  O
systemic  O
relapse  O
occurs  O
in  O
the  O
majority  O
of  O
patients  O
.  O

Previous  O
Southwest  O
Oncology  O
Group  O
trials  O
in  O
LSCLC  B-CANCER
have  O
utilized  O
cisplatin  B-DRUG
and  O
etoposide  B-DRUG
(  O
PE  B-DRUG
)  O
delivered  O
concurrently  O
with  O
thoracic  O
radiotherapy  O
followed  O
by  O
two  O
consolidation  O
cycles  O
.  O

Newer  O
chemotherapy  O
regimens  O
such  O
as  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
are  O
active  O
in  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
and  O
hold  O
the  O
promise  O
of  O
improving  O
both  O
local  O
and  O
systemic  O
control  O
.  O

S9713  O
evaluated  O
the  O
substitution  O
of  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
for  O
PE  B-DRUG
consolidation  O
in  O
LSCLC  B-CANCER
.  O

Between  O
July  O
1998  O
and  O
August  O
1999  O
,  O
96  O
patients  O
were  O
accrued  O
from  O
43  O
institutions  O
.  O

Eighty-nine  O
patients  O
were  O
eligible  O
;  O
87  O
were  O
assessable  O
for  O
survival  O
and  O
response  O
.  O

Treatment  O
consisted  O
of  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
,  O
8  O
,  O
29  O
,  O
and  O
36  O
,  O
and  O
etoposide  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
to  O
5  O
and  O
days  O
29  O
to  O
33  O
,  O
with  O
concurrent  O
radiotherapy  O
of  O
61  O
Gy  O
beginning  O
on  O
day  O
1.  O
Consolidation  O
therapy  O
was  O
carboplatin  B-DRUG
(  O
area  O
under  O
the  O
curve  O
=  O
6  O
)  O
and  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
both  O
drugs  O
administered  O
on  O
day  O
1  O
of  O
a  O
21  O
day  O
cycle  O
for  O
three  O
cycles  O
.  O

The  O
response  O
rate  O
was  O
86  O
%  O
(  O
complete  O
response  O
,  O
33  O
%  O
;  O
partial  O
response  O
,  O
53  O
%  O
)  O
.  O

Median  O
overall  O
survival  O
was  O
17  O
months  O
(  O
95  O
%  O
CI  O
,  O
12.7  O
to  O
19.0  O
)  O
.  O

One-  O
and  O
2-year  O
overall  O
survivals  O
were  O
61  O
%  O
and  O
33  O
%  O
,  O
respectively  O
.  O

Median  O
progression-free  O
survival  O
(  O
PFS  O
)  O
was  O
9  O
months  O
,  O
1-year  O
PFS  O
was  O
40  O
%  O
,  O
and  O
2-year  O
PFS  O
was  O
21  O
%  O
.  O

Consolidation  O
therapy  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
in  O
LSCLC  B-CANCER
resulted  O
in  O
an  O
outcome  O
similar  O
to  O
that  O
seen  O
in  O
prior  O
Southwest  O
Oncology  O
Group  O
trials  O
.  O

This  O
study  O
and  O
others  O
which  O
have  O
tested  O
paclitaxel  B-DRUG
in  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
dampens  O
enthusiasm  O
for  O
this  O
agent  O
in  O
the  O
primary  O
management  O
of  O
LSCLC  B-CANCER
.  O

Multicentric  O
phase  O
II  O
trial  O
of  O
gemcitabine  B-DRUG
plus  O
epirubicin  B-DRUG
plus  O
paclitaxel  B-DRUG
as  O
first-line  O
chemotherapy  O
in  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O


In  O
this  O
phase  O
II  O
,  O
multicentre  O
trial  O
,  O
patients  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
(  O
MBC  B-CANCER
)  O
were  O
treated  O
with  O
a  O
combination  O
of  O
gemcitabine  B-DRUG
,  O
epirubicin  B-DRUG
and  O
paclitaxel  B-DRUG
(  O
GET  B-DRUG
)  O
.  O

The  O
primary  O
objective  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
tolerability  O
and  O
activity  O
in  O
terms  O
of  O
complete  O
responce  O
(  O
CR  O
)  O
and  O
overall  O
response  O
rate  O
of  O
the  O
GET  B-DRUG
combination  O
in  O
this  O
patient  O
population  O
.  O

Patients  O
with  O
no  O
prior  O
treatment  O
for  O
MBC  B-CANCER
,  O
and  O
at  O
least  O
one  O
bidimensionally  O
measurable  O
lesion  O
received  O
gemcitabine  B-DRUG
1000  O
mg  O
m  O
(  O
-2  O
)  O
intravenously  O
(  O
i.v.  O
)  O
over  O
30  O
min  O
on  O
days  O
1  O
and  O
4  O
,  O
followed  O
by  O
epirubicin  B-DRUG
i.v.  O
at  O
90  O
mg  O
m  O
(  O
-2  O
)  O
on  O
day  O
1  O
,  O
and  O
paclitaxel  B-DRUG
175  O
mg  O
m  O
(  O
-2  O
)  O
over  O
3  O
h  O
on  O
day  O
1  O
,  O
every  O
21  O
days  O
,  O
up  O
to  O
eight  O
courses  O
.  O

From  O
May  O
1999  O
to  O
June  O
2000  O
,  O
48  O
patients  O
were  O
enrolled  O
from  O
seven  O
Italian  O
institutions  O
.  O

A  O
total  O
of  O
297  O
chemotherapy  O
courses  O
were  O
administered  O
with  O
a  O
median  O
of  O
six  O
cycles  O
patient  O
(  O
-1  O
)  O
(  O
range  O
1-8  O
)  O
.  O

Seven  O
patients  O
(  O
15  O
%  O
)  O
obtained  O
CR  O
and  O
27  O
patients  O
(  O
56  O
%  O
)  O
had  O
partial  O
responce  O
,  O
for  O
an  O
overall  O
response  O
rate  O
of  O
71  O
%  O
(  O
95  O
%  O
CI  O
:  O
58.3-83.7  O
)  O
.  O

After  O
a  O
median  O
follow-up  O
of  O
23.7  O
months  O
(  O
range  O
7.0-34.4  O
)  O
,  O
median  O
progression-free  O
survival  O
was  O
10.5  O
months  O
(  O
95  O
%  O
CI  O
:  O
9.2-11.7  O
)  O
,  O
and  O
median  O
overall  O
survival  O
25.9  O
months  O
.  O

The  O
main  O
haematological  B-TOXI
toxicity  I-TOXI
consisted  O
of  O
grade  O
3  O
or  O
4  O
neutropenia  B-TOXI
that  O
occurred  O
in  O
62  O
%  O
of  O
cycles  O
(  O
22  O
%  O
grade  O
4  O
and  O
40  O
%  O
grade  O
3  O
)  O
.  O

The  O
GET  B-DRUG
combination  O
is  O
active  O
and  O
well  O
tolerated  O
as  O
first-line  O
chemotherapy  O
for  O
MBC  B-CANCER
.  O

A  O
randomised  O
phase  O
II  O
study  O
of  O
weekly  O
paclitaxel  B-DRUG
or  O
vinorelbine  B-DRUG
in  O
combination  O
with  O
cisplatin  B-DRUG
against  O
inoperable  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
previously  O
untreated  O
.  O


Phase  O
II  O
studies  O
have  O
suggested  O
that  O
weekly  O
paclitaxel  B-DRUG
has  O
a  O
higher  O
response  O
rate  O
and  O
better  O
toxicity  O
profile  O
than  O
the  O
conventional  O
schedule  O
of  O
once  O
every  O
3  O
or  O
4  O
weeks  O
.  O

Our  O
aim  O
was  O
to  O
evaluate  O
the  O
efficacy  O
of  O
weekly  O
paclitaxel  B-DRUG
plus  O
cisplatin  B-DRUG
(  O
PC  B-DRUG
)  O
vs  O
vinorelbine  B-DRUG
plus  O
cisplatin  B-DRUG
(  O
VC  B-DRUG
)  O
in  O
chemona√Øve  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
patients  O
.  O

From  O
October  O
2000  O
to  O
May  O
2002  O
,  O
140  O
patients  O
were  O
enrolled  O
.  O

The  O
treatment  O
dose  O
was  O
P  O
66  O
mg  O
m  O
(  O
-2  O
)  O
intravenous  O
infusion  O
(  O
i.v.  O
)  O
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
,  O
and  O
C  O
60  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
on  O
day  O
15  O
,  O
or  O
V  O
23  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
,  O
and  O
C  O
60  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
on  O
day  O
15  O
,  O
every  O
4  O
weeks  O
.  O

In  O
all  O
,  O
281  O
cycles  O
of  O
PC  B-DRUG
and  O
307  O
cycles  O
of  O
VC  B-DRUG
were  O
given  O
to  O
the  O
patients  O
in  O
the  O
PC  B-DRUG
and  O
VC  B-DRUG
arms  O
,  O
respectively  O
.  O

There  O
were  O
26  O
partial  O
responses  O
and  O
one  O
complete  O
response  O
(  O
overall  O
38.6  O
%  O
)  O
in  O
the  O
PC  O
arm  O
,  O
and  O
no  O
complete  O
responses  O
,  O
but  O
27  O
partial  O
responses  O
(  O
overall  O
38.6  O
%  O
)  O
in  O
the  O
VC  B-DRUG
arm  O
.  O

Myelosuppression  B-TOXI
was  O
more  O
common  O
in  O
the  O
VC  B-DRUG
arm  O
(  O
P  O
&  O
lt  O
;  O
0.001  O
)  O
.  O

Peripheral  B-TOXI
neuropathy  I-TOXI
and  O
myalgia  B-TOXI
were  O
significantly  O
more  O
common  O
in  O
the  O
PC  B-DRUG
arm  O
(  O
P  O
&  O
lt  O
;  O
0.001  O
)  O
.  O

The  O
median  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
was  O
6  O
months  O
in  O
the  O
PC  B-DRUG
arm  O
and  O
8.4  O
months  O
in  O
the  O
VC  B-DRUG
arm  O
(  O
P=0.0344  O
)  O
.  O

The  O
median  O
survival  O
time  O
was  O
11.7  O
months  O
in  O
the  O
PC  B-DRUG
arm  O
and  O
15.4  O
months  O
in  O
the  O
VC  B-DRUG
arm  O
(  O
P=0.297  O
)  O
.  O

We  O
concluded  O
that  O
weekly  O
PC  B-DRUG
is  O
not  O
suggested  O
for  O
NSCLC  B-CANCER
patients  O
due  O
to  O
the  O
relatively  O
shorter  O
progression-free  O
survival  O
and  O
more  O
common  O
nonhaematological  B-TOXI
toxicities  I-TOXI
.  O

British  O
Journal  O
of  O
Cancer  O
(  O
2004  O
)  O
90  O
,  O
359-365  O
.  O

doi:10.1038  O
/  O
sj.bjc.6601526  O
www.bjcancer.com  O

Phase  O
II  O
trial  O
of  O
biweekly  O
infusional  O
fluorouracil  B-DRUG
,  O
folinic  B-DRUG
acid  I-DRUG
,  O
and  O
oxaliplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


To  O
evaluate  O
the  O
toxicity  O
and  O
activity  O
of  O
infusional  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
,  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
,  O
and  O
oxaliplatin  B-DRUG
,  O
administered  O
every  O
2  O
weeks  O
in  O
patients  O
with  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

Forty-one  O
previously  O
untreated  O
patients  O
with  O
measurable  O
adenocarcinoma  B-TOXI
of  I-TOXI
the  I-TOXI
stomach  I-TOXI
were  O
eligible  O
for  O
the  O
study  O
.  O

Patients  O
received  O
FU  B-DRUG
2.6  O
g  O
/  O
m  O
(  O
2  O
)  O
(  O
24-hour  O
continuous  O
infusion  O
)  O
,  O
FA  B-DRUG
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
2-hour  O
intravenous  O
infusion  O
)  O
,  O
and  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
2-hour  O
intravenous  O
infusion  O
)  O
every  O
2  O
weeks  O
for  O
6  O
weeks  O
.  O

Treatment  O
was  O
continued  O
until  O
progression  B-TOXI
of  I-TOXI
disease  I-TOXI
was  O
observed  O
.  O

All  O
patients  O
were  O
assessable  O
for  O
toxicity  O
and  O
37  O
of  O
41  O
patients  O
were  O
assessable  O
for  O
response  O
.  O

Patient  O
characteristics  O
were  O
:  O
sex  O
(  O
male  O
,  O
28  O
;  O
female,13  O
)  O
,  O
median  O
age  O
60  O
years  O
(  O
range  O
,  O
20  O
to  O
77  O
years  O
)  O
,  O
and  O
median  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
status  O
of  O
1.  O
Response  O
was  O
evaluated  O
every  O
6  O
weeks  O
.  O

Of  O
37  O
assessable  O
patients  O
,  O
one  O
complete  O
and  O
15  O
partial  O
remissions  O
were  O
observed  O
(  O
overall  O
response  O
rate  O
,  O
43  O
%  O
)  O
.  O

Stable  O
disease  O
was  O
observed  O
in  O
12  O
patients  O
(  O
32  O
%  O
)  O
and  O
progressive  B-TOXI
disease  I-TOXI
in  O
nine  O
patients  O
(  O
24  O
%  O
)  O
.  O

The  O
median  O
overall  O
survival  O
was  O
9.6  O
months  O
.  O

WHO  O
grade  O
3  O
or  O
4  O
hematologic  B-TOXI
toxicities  I-TOXI
included  O
neutropenia  B-TOXI
in  O
two  O
patients  O
(  O
4.9  O
%  O
)  O
and  O
thrombocytopenia  B-TOXI
in  O
one  O
patient  O
(  O
2.4  O
%  O
)  O
.  O

Other  O
WHO  O
grade  O
3  O
or  O
4  O
toxicities  O
included  O
diarrhea  B-TOXI
in  O
three  O
patients  O
(  O
7.3  O
%  O
)  O
and  O
vomiting  B-TOXI
in  O
two  O
patients  O
(  O
4.9  O
%  O
)  O
.  O

There  O
were  O
no  O
cases  O
of  O
grade  O
3  O
peripheral  B-TOXI
neuropathy  I-TOXI
and  O
no  O
treatment-related  B-TOXI
deaths  I-TOXI
.  O

Biweekly  O
fluorouracil  B-DRUG
,  O
folinic  B-DRUG
acid  I-DRUG
,  O
and  O
oxaliplatin  B-DRUG
is  O
active  O
and  O
well-tolerated  O
in  O
patients  O
with  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

Response  O
rates  O
,  O
time  O
to  O
progression  O
,  O
and  O
overall  O
survival  O
were  O
comparable  O
to  O
those  O
achieved  O
with  O
other  O
combination  O
chemotherapy  O
regimens  O
,  O
including  O
FOLFOX6  B-DRUG
,  O
with  O
significantly  O
less  O
toxicity  O
.  O

Gefitinib  B-DRUG
in  O
combination  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
in  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
III  O
trial  O
--  O
INTACT  O
2  O
.  O


Preclinical  O
studies  O
indicate  O
that  O
gefitinib  B-DRUG
(  O
Iressa  O
,  O
ZD1839  O
;  O
AstraZeneca  O
,  O
Wilmington  O
,  O
DE  O
)  O
,  O
an  O
orally  B-DRUG
active  I-DRUG
epidermal  I-DRUG
growth  I-DRUG
factor  I-DRUG
receptor  I-DRUG
tyrosine  I-DRUG
kinase  I-DRUG
inhibitor  I-DRUG
,  O
may  O
enhance  O
antitumor  O
efficacy  O
of  O
cytotoxics  O
,  O
and  O
combination  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
had  O
acceptable  O
tolerability  O
in  O
a  O
phase  O
I  O
trial  O
.  O

Gefitinib  B-DRUG
monotherapy  O
demonstrated  O
unparalleled  O
antitumor  O
activity  O
for  O
a  O
biologic  O
agent  O
,  O
with  O
less  O
toxicity  O
than  O
docetaxel  B-DRUG
,  O
in  O
phase  O
II  O
trials  O
in  O
refractory  O
,  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

This  O
phase  O
III  O
,  O
randomized  O
,  O
placebo-controlled  O
,  O
double-blind  O
trial  O
evaluated  O
gefitinib  B-DRUG
plus  O
paclitaxel  B-DRUG
and  O
carboplatin  O
in  O
chemotherapy-naive  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

Patients  O
received  O
paclitaxel  B-DRUG
225  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
carboplatin  B-DRUG
area  O
under  O
concentration  O
/  O
time  O
curve  O
of  O
6  O
mg  O
/  O
min  O
/  O
mL  O
(  O
day  O
1  O
every  O
3  O
weeks  O
)  O
plus  O
gefitinib  B-DRUG
500  O
mg  O
/  O
d  O
,  O
gefitinib  B-DRUG
250  O
mg  O
/  O
d  O
,  O
or  O
placebo  B-DRUG
.  O

After  O
a  O
maximum  O
of  O
six  O
cycles  O
,  O
daily  O
gefitinib  B-DRUG
or  O
placebo  B-DRUG
continued  O
until  O
disease  B-TOXI
progression  I-TOXI
.  O

End  O
points  O
included  O
overall  O
survival  O
,  O
time  O
to  O
progression  O
(  O
TTP  O
)  O
,  O
response  O
rate  O
(  O
RR  O
)  O
,  O
and  O
safety  O
evaluation  O
.  O

Results  O
A  O
total  O
of  O
1,037  O
patients  O
were  O
recruited  O
.  O

Baseline  O
demographic  O
characteristics  O
were  O
well  O
balanced  O
.  O

There  O
was  O
no  O
difference  O
in  O
overall  O
survival  O
(  O
median  O
,  O
8.7  O
,  O
9.8  O
,  O
and  O
9.9  O
months  O
for  O
gefitinib  B-DRUG
500  O
mg  O
/  O
d  O
,  O
250  O
mg  O
/  O
d  O
,  O
and  O
placebo  B-DRUG
,  O
respectively  O
;  O
P  O
=.64  O
)  O
,  O
TTP  O
,  O
or  O
RR  O
between  O
arms  O
.  O

Expected  O
dose-related  O
diarrhea  B-TOXI
and  O
skin  B-TOXI
toxicity  I-TOXI
were  O
observed  O
in  O
gefitinib-treated  B-DRUG
patients  O
,  O
with  O
no  O
new  O
significant  O
/  O
unexpected  O
safety  O
findings  O
from  O
combination  O
with  O
chemotherapy  O
.  O

Subset  O
analysis  O
of  O
patients  O
with  O
adenocarcinoma  B-TOXI
who  O
received  O
&  O
gt  O
;  O
or  O
=  O
90  O
days  O
'  O
chemotherapy  O
demonstrated  O
statistically  O
significant  O
prolonged  O
survival  O
,  O
suggesting  O
a  O
gefitinib  B-DRUG
maintenance  O
effect  O
.  O

Gefitinib  B-DRUG
showed  O
no  O
added  O
benefit  O
in  O
survival  O
,  O
TTP  O
,  O
or  O
RR  O
compared  O
with  O
standard  O
chemotherapy  O
alone  O
.  O

This  O
large  O
,  O
placebo-controlled  B-DRUG
trial  O
confirmed  O
the  O
favorable  O
gefitinib  B-DRUG
safety  O
profile  O
observed  O
in  O
phase  O
I  O
and  O
II  O
monotherapy  O
trials  O
.  O

Phase  O
I  O
dose-finding  O
study  O
of  O
biweekly  O
irinotecan  B-DRUG
in  O
combination  O
with  O
fixed  O
doses  O
of  O
5-fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
,  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
(  O
G-FLIP  B-DRUG
)  O
in  O
patients  O
with  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
or  O
other  O
solid  B-CANCER
tumors  I-CANCER
.  O


This  O
phase  O
I  O
trial  O
was  O
initiated  O
based  O
on  O
encouraging  O
clinical  O
data  O
with  O
5-fluorouracil  B-DRUG
(  I-DRUG
5-FU  I-DRUG
)  I-DRUG
/  I-DRUG
leucovorin  I-DRUG
(  I-DRUG
LV  I-DRUG
)  I-DRUG
,  I-DRUG
gemcitabine  B-DRUG
and  I-DRUG
cisplatin  I-DRUG
(  I-DRUG
G-FLIP  I-DRUG
)  I-DRUG
in  O
the  O
therapy  O
of  O
solid  B-CANCER
tumors  I-CANCER
.  O

In  O
this  O
trial  O
,  O
G-FLIP  B-DRUG
has  O
been  O
modified  O
to  O
facilitate  O
outpatient  O
administration  O
and  O
to  O
optimize  O
sequence-dependent  O
synergistic  O
activity  O
.  O

Treatment  O
consisted  O
of  O
biweekly  O
(  O
once  O
every  O
14  O
days  O
)  O
cycles  O
of  O
sequential  O
gemcitabine  B-DRUG
500  O
mg  O
/  O
m  O
,  O
irinotecan  B-DRUG
per  O
dose  O
escalation  O
schedule  O
,  O
bolus  O
5-FU  B-DRUG
400  O
mg  O
/  O
m  O
and  O
LV  B-DRUG
300  O
mg  O
on  O
day  O
1  O
followed  O
by  O
a  O
24-h  O
5-FU  B-DRUG
infusion  O
1500  O
mg  O
/  O
m  O
,  O
followed  O
by  O
cisplatin  B-DRUG
35  O
mg  O
/  O
m  O
on  O
day  O
2.  O
The  O
irinotecan  B-DRUG
starting  O
dose  O
was  O
80  O
mg  O
/  O
m  O
and  O
escalated  O
by  O
20  O
mg  O
/  O
m  O
in  O
cohorts  O
of  O
three  O
patients  O
until  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
was  O
defined  O
.  O

Twenty-three  O
patients  O
were  O
enrolled  O
(  O
13  O
men  O
/  O
10  O
women  O
)  O
with  O
the  O
following  O
cancers  O
:  O
11  O
pancreatic  O
,  O
five  O
gallbladder  O
,  O
three  O
squamous  B-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
,  O
one  O
hepatocellular  B-CANCER
carcinoma  I-CANCER
,  O
one  O
melanoma  B-CANCER
,  O
one  O
gastric  O
,  O
and  O
one  O
breast  B-CANCER
cancer  I-CANCER
.  O

Median  O
patient  O
age  O
was  O
63  O
years  O
(  O
range  O
44-78  O
)  O
and  O
median  O
Karnofsky  O
performance  O
status  O
(  O
KPS  O
)  O
was  O
80  O
.  O

Patients  O
received  O
a  O
median  O
of  O
8  O
cycles  O
(  O
range  O
1-16  O
)  O
over  O
five  O
irinotecan  B-DRUG
dose  O
levels  O
(  O
80  O
,  O
100  O
,  O
120  O
,  O
140  O
and  O
160  O
mg  O
/  O
m  O
)  O
.  O

Dose-limiting  O
toxicity  O
consisting  O
of  O
grade  O
3  O
nausea  B-TOXI
/  I-TOXI
vomiting  I-TOXI
despite  O
aggressive  O
anti-emetic  O
therapy  O
occurred  O
in  O
one  O
patient  O
at  O
dose  O
level  O
1  O
and  O
three  O
patients  O
at  O
dose  O
level  O
3.  O
Grade  O
3-4  O
hematological  B-TOXI
toxicities  I-TOXI
per  O
patient  O
consisted  O
of  O
thrombocytopenia  B-TOXI
(  O
3  O
%  O
)  O
,  O
anemia  B-TOXI
(  O
6  O
%  O
)  O
,  O
thrombosis  B-TOXI
(  O
23  O
%  O
)  O
,  O
neutropenia  B-TOXI
(  O
16  O
%  O
)  O
and  O
neutropenic  B-TOXI
fever  I-TOXI
(  O
10  O
%  O
)  O
.  O

Of  O
18  O
patients  O
evaluable  O
for  O
response  O
,  O
one  O
complete  O
response  O
(  O
pancreatic  O
)  O
and  O
eight  O
partial  O
responses  O
(  O
three  O
gallbladder  O
,  O
two  O
pancreatic  O
,  O
two  O
head  O
and  O
neck  O
,  O
and  O
one  O
breast  O
)  O
were  O
attained  O
.  O

Seven  O
patients  O
had  O
disease  O
stabilization  O
(  O
five  O
pancreatic  O
,  O
one  O
hepatocellular  O
and  O
one  O
gastric  O
)  O
for  O
a  O
median  O
of  O
16  O
weeks  O
(  O
range  O
10-22  O
)  O
.  O

Median  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
among  O
all  O
23  O
patients  O
enrolled  O
to  O
the  O
phase  O
I  O
portion  O
of  O
the  O
trial  O
was  O
20.5  O
weeks  O
(  O
range  O
4-37  O
)  O
.  O

We  O
conclude  O
that  O
G-FLIP  B-DRUG
is  O
a  O
novel  O
outpatient  O
chemotherapy  O
regimen  O
with  O
acceptable  O
toxicity  O
at  O
the  O
maximum  O
tolerated  O
irinotecan  B-DRUG
dose  O
of  O
120  O
mg  O
/  O
m.  O
The  O
phase  O
II  O
trial  O
of  O
G-FLIP  B-DRUG
using  O
an  O
irinotecan  B-DRUG
dose  O
of  O
120  O
mg  O
/  O
m  O
for  O
patients  O
with  O
metastatic  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
is  O
ongoing  O
.  O

Phase  O
I  O
and  O
pharmacokinetic  O
study  O
of  O
the  O
polyamine  B-DRUG
synthesis  I-DRUG
inhibitor  I-DRUG
SAM486A  I-DRUG
in  O
combination  O
with  O
5-fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
in  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


The  O
purpose  O
of  O
our  O
study  O
was  O
to  O
determine  O
the  O
maximum-tolerated  O
dose  O
,  O
dose-limiting  O
toxicity  O
,  O
safety  O
profile  O
,  O
and  O
pharmacokinetics  O
of  O
the  O
polyamine  B-DRUG
synthesis  I-DRUG
inhibitor  I-DRUG
SAM486A  I-DRUG
given  O
in  O
combination  O
with  O
5-fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
(  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
)  O
in  O
cancer  O
patients  O
.  O

Patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
were  O
treated  O
with  O
5-FU  B-DRUG
[  O
bolus  O
(  O
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
followed  O
by  O
a  O
22-h  O
infusion  O
(  O
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
]  O
and  O
LV  B-DRUG
(  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
and  O
escalating  O
doses  O
of  O
SAM486A  B-DRUG
,  O
1-3-h  O
infusion  O
daily  O
for  O
3  O
days  O
.  O

Plasma  O
sampling  O
was  O
performed  O
to  O
characterize  O
the  O
pharmacokinetics  O
and  O
pharmacodynamics  O
of  O
the  O
combination  O
Twenty-seven  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
and  O
1  O
with  O
pseudomyxoma  B-CANCER
peritonei  I-CANCER
were  O
treated  O
.  O

Twenty-six  O
patients  O
received  O
SAM486A  B-DRUG
in  O
the  O
combination  O
at  O
doses  O
ranging  O
from  O
25  O
to  O
150  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
.  O

Dose-limiting  O
toxicity  O
consisting  O
of  O
fatigue  B-TOXI
grade  O
3  O
was  O
seen  O
at  O
150  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
.  O

Other  O
adverse  O
events  O
included  O
neutropenia  B-TOXI
,  O
hand  B-TOXI
and  I-TOXI
foot  I-TOXI
syndrome  I-TOXI
,  O
nausea  B-TOXI
,  O
vomiting  B-TOXI
,  O
diarrhea  B-TOXI
,  O
and  O
constipation  B-TOXI
.  O

Fifteen  O
of  O
26  O
patients  O
evaluable  O
for  O
best  O
response  O
according  O
to  O
the  O
Southwest  O
Oncology  O
Group  O
criteria  O
achieved  O
a  O
partial  O
response  O
[  O
8  O
(  O
30  O
%  O
)  O
of  O
26  O
]  O
or  O
stable  O
disease  O
[  O
9  O
(  O
35  O
%  O
)  O
of  O
26  O
]  O
.  O

SAM486A  B-DRUG
did  O
not  O
influence  O
the  O
pharmacokinetics  O
of  O
5-FU  B-DRUG
,  O
and  O
SAM486A  B-DRUG
clearance  O
was  O
similar  O
to  O
that  O
when  O
used  O
as  O
a  O
single  O
agent  O
.  O

The  O
novel  O
molecular  O
agent  O
SAM486A  B-DRUG
is  O
tolerable  O
and  O
safe  O
in  O
combination  O
with  O
a  O
standard  O
5-FU  B-DRUG
regimen  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

The  O
dose  O
of  O
SAM486A  B-DRUG
recommended  O
for  O
additional  O
studies  O
with  O
this  O
combination  O
is  O
125  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
day  O
.  O

A  O
disease-directed  O
evaluation  O
of  O
SAM486A  B-DRUG
using  O
this  O
regimen  O
is  O
warranted  O
.  O

[  O
A  O
phase  O
I  O
study  O
of  O
combination  O
chemotherapy  O
using  O
TS-1  B-DRUG
and  O
pirarubicin  B-DRUG
(  O
THP  B-DRUG
)  O
for  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
]  O
.  O


The  O
safety  O
of  O
chemotherapy  O
combining  O
TS-1  B-DRUG
and  O
pirarubicin  B-DRUG
(  O
THP  B-DRUG
)  O
for  O
treatment  O
of  O
recurrent  O
or  O
locally  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
was  O
evaluated  O
.  O

THP  B-DRUG
was  O
administered  O
by  O
intravenous  O
drip  O
infusion  O
at  O
a  O
dose  O
of  O
14  O
mg  O
/  O
m2  O
every  O
other  O
week  O
.  O

TS-1  B-DRUG
was  O
administered  O
orally  O
at  O
a  O
dose  O
of  O
40  O
mg  O
/  O
m2  O
twice  O
a  O
day  O
for  O
2  O
weeks  O
followed  O
by  O
2  O
weeks  O
of  O
rest  O
(  O
level  O
1  O
)  O
,  O
for  O
3  O
weeks  O
followed  O
by  O
2  O
weeks  O
of  O
rest  O
(  O
level  O
2  O
)  O
,  O
and  O
for  O
4  O
weeks  O
followed  O
by  O
2  O
weeks  O
of  O
rest  O
(  O
level  O
3  O
)  O
.  O

Three  O
patients  O
were  O
treated  O
with  O
the  O
level  O
1  O
schedule  O
.  O

One  O
patient  O
with  O
peritoneal  B-DRUG
dissemination  O
received  O
22  O
courses  O
of  O
the  O
treatment  O
,  O
and  O
benefited  O
from  O
a  O
long-term  B-CANCER
NC  I-CANCER
.  O

However  O
the  O
remaining  O
2  O
cases  O
were  O
diagnosed  O
as  O
PD  O
after  O
4  O
courses  O
and  O
were  O
withdrawn  O
from  O
further  O
treatment  O
.  O

Two  O
patients  O
in  O
this  O
group  O
suffered  O
from  O
grade  O
2  O
adverse  O
events  O
according  O
to  O
the  O
NCI-CTC  O
.  O

Only  O
1  O
patient  O
who  O
had  O
liver  B-CANCER
metastasis  I-CANCER
was  O
treated  O
at  O
level  O
2.  O
Fourteen  O
courses  O
were  O
administered  O
,  O
and  O
a  O
PR  O
was  O
achieved  O
while  O
grade  O
2  O
adverse  O
events  O
were  O
observed  O
.  O

One  O
of  O
3  O
patients  O
who  O
were  O
treated  O
with  O
level  O
3  O
had  O
grade  O
3  O
adverse  O
events  O
.  O

Consequently  O
,  O
3  O
more  O
cases  O
were  O
added  O
to  O
this  O
dose  O
level  O
,  O
and  O
no  O
additional  O
grade  O
3  O
adverse  O
events  O
were  O
observed  O
,  O
while  O
grade  O
2  O
adverse  O
events  O
were  O
seen  O
in  O
4  O
cases  O
.  O

Urinary  B-TOXI
urgency  I-TOXI
had  O
completely  O
disappeared  O
in  O
1  O
patient  O
with  O
peritoneal  B-TOXI
recurrence  I-TOXI
.  O

Myelosuppression  B-TOXI
,  O
which  O
was  O
the  O
main  O
observed  O
adverse  O
event  O
,  O
was  O
well  O
controlled  O
and  O
of  O
brief  O
duration  O
.  O

The  O
response  O
,  O
including  O
alleviation  O
of  O
clinical  O
symptoms  O
,  O
was  O
confirmed  O
in  O
3  O
of  O
5  O
chemo-naive  O
patients  O
.  O

A  O
phase  O
II  O
study  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
chemotherapy-naive  O
,  O
unresectable  B-CANCER
gall  I-CANCER
bladder  I-CANCER
cancer  I-CANCER
.  O


The  O
primary  O
objective  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
response  O
rates  O
of  O
the  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
combination  O
in  O
unresectable  B-CANCER
gall  I-CANCER
bladder  I-CANCER
cancer  I-CANCER
patients  O
.  O

The  O
secondary  O
objectives  O
were  O
to  O
evaluate  O
the  O
toxicity  O
,  O
time  O
to  O
progressive  B-TOXI
disease  I-TOXI
,  O
and  O
overall  O
survival  O
.  O

Chemona√Øve  O
patients  O
with  O
histologically  O
proven  O
,  O
unresectable  O
bidimensionally  O
measurable  O
gall  B-CANCER
bladder  I-CANCER
cancer  I-CANCER
were  O
enrolled  O
into  O
this  O
study  O
.  O

All  O
patients  O
were  O
required  O
to  O
have  O
a  O
Zubrod  O
's  O
performance  O
status  O
&  O
lt  O
;  O
or=2  O
,  O
no  O
prior  O
radiotherapy  O
,  O
and  O
adequate  O
major  O
organ  O
function  O
.  O

Patients  O
received  O
gemcitabine  B-DRUG
(  O
1000  O
mg  O
x  O
m  O
(  O
-2  O
)  O
intravenously  O
over  O
30-60  O
min  O
)  O
on  O
days  O
1  O
and  O
8  O
,  O
and  O
cisplatin  B-DRUG
(  O
70  O
mg  O
x  O
m  O
(  O
-2  O
)  O
intravenously  O
over  O
2  O
h  O
)  O
on  O
day  O
1  O
,  O
every  O
21  O
days  O
.  O

Response  O
assessment  O
was  O
done  O
by  O
a  O
CT  O
scan  O
after  O
every  O
other  O
cycle  O
of  O
chemotherapy  O
.  O

In  O
all  O
,  O
30  O
patients  O
were  O
eligible  O
for  O
efficacy  O
and  O
toxicity  O
analysis  O
.  O

There  O
were  O
four  O
(  O
13.3  O
%  O
)  O
complete  O
responders  O
,  O
seven  O
(  O
23.3  O
%  O
)  O
partial  O
responders  O
,  O
and  O
seven  O
(  O
23.3  O
%  O
)  O
with  O
stable  O
disease  O
,  O
with  O
four  O
(  O
13.2  O
%  O
)  O
patients  O
showing  O
disease  B-TOXI
progression  I-TOXI
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
18  O
weeks  O
(  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
14-24  O
weeks  O
)  O
,  O
and  O
the  O
median  O
duration  O
of  O
response  O
was  O
13.5  O
weeks  O
(  O
range  O
5.5-104  O
weeks  O
)  O
.  O

The  O
median  O
overall  O
survival  O
was  O
20  O
weeks  O
(  O
95  O
%  O
CI  O
14-31  O
weeks  O
)  O
,  O
with  O
1-year  O
survival  O
rate  O
of  O
18.6  O
%  O
.  O

WHO  O
grade  O
3  O
or  O
4  O
anaemia  B-TOXI
was  O
seen  O
in  O
seven  O
(  O
23.3  O
%  O
)  O
and  O
four  O
(  O
13.3  O
%  O
)  O
patients  O
,  O
respectively  O
.  O

Five  O
(  O
16.6  O
%  O
)  O
patients  O
each  O
experienced  O
grade  O
3  O
or  O
4  O
neutropenia  B-TOXI
,  O
and  O
grade  O
3  O
or  O
4  O
thrombocytopenia  B-TOXI
was  O
seen  O
in  O
three  O
(  O
10  O
%  O
)  O
and  O
two  O
(  O
6.6  O
%  O
)  O
patients  O
,  O
respectively  O
.  O

The  O
present  O
study  O
shows  O
that  O
gemcitabine  B-DRUG
/  O
cisplatin  B-DRUG
combination  O
is  O
well  O
tolerated  O
and  O
active  O
in  O
advanced  B-CANCER
unresectable  I-CANCER
gall  I-CANCER
bladder  I-CANCER
cancer  I-CANCER
.  O

Pegylated  B-DRUG
liposomal  I-DRUG
doxorubicin  I-DRUG
in  O
combination  O
with  O
mitomycin  B-DRUG
C  I-DRUG
,  O
infusional  O
5-fluorouracil  B-DRUG
and  O
sodium  B-DRUG
folinic  I-DRUG
acid.  I-DRUG
A  O
phase-I-study  O
in  O
patients  O
with  O
upper  O
gastrointestinal  B-CANCER
cancer  I-CANCER
.  O


Mitomycin  B-DRUG
C  I-DRUG
(  O
MMC  B-DRUG
)  O
in  O
combination  O
with  O
infusional  O
5-fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
plus  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
is  O
an  O
effective  O
treatment  O
for  O
metastatic  B-CANCER
gastrointestinal  I-CANCER
cancer  I-CANCER
.  O

Anthracyclines  B-DRUG
are  O
commonly  O
used  O
in  O
the  O
treatment  O
of  O
upper  O
gastrointestinal  B-CANCER
cancer  I-CANCER
.  O

The  O
aim  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
of  O
liposomal  B-DRUG
,  O
pegylated  B-DRUG
doxorubicin  I-DRUG
(  O
Caelyx  B-DRUG
)  O
in  O
combination  O
with  O
infusional  O
5-FU  B-DRUG
/  I-DRUG
sodium  I-DRUG
FA  I-DRUG
and  O
MMC  B-DRUG
.  O

Escalating  O
doses  O
of  O
Caelyx  B-DRUG
(  O
15-25-30-35  O
mg  O
m  O
(  O
-2  O
)  O
corresponding  O
to  O
dose  O
levels  O
I-IV  O
)  O
were  O
applied  O
on  O
days  O
1  O
and  O
29  O
,  O
given  O
to  O
fixed  O
doses  O
of  O
24-h  O
5-FU  B-DRUG
(  O
2000  O
mg  O
m  O
(  O
-2  O
)  O
)  O
and  O
sodium  B-DRUG
FA  I-DRUG
(  O
500  O
mg  O
m  O
(  O
-2  O
)  O
,  O
mixed  O
with  O
5-FU  B-DRUG
in  O
one  O
pump  O
)  O
weekly  O
for  O
6  O
weeks  O
,  O
and  O
MMC  B-DRUG
7  O
mg  O
m  O
(  O
-2  O
)  O
on  O
days  O
8  O
and  O
36  O
.  O

At  O
least  O
three  O
patients  O
were  O
treated  O
at  O
each  O
dose  O
level  O
.  O

A  O
total  O
of  O
25  O
patients  O
are  O
evaluable  O
.  O

No  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
was  O
observed  O
on  O
level  O
I  O
(  O
n=3  O
)  O
.  O

On  O
level  O
II  O
,  O
DLT  O
occurred  O
in  O
three  O
out  O
of  O
five  O
patients  O
(  O
mucositis  B-TOXI
and  O
leucopenia  B-TOXI
)  O
.  O

Owing  O
to  O
the  O
early  O
DLTs  O
at  O
this  O
dose  O
,  O
we  O
added  O
a  O
20  O
mg  O
m  O
(  O
-2  O
)  O
Caelyx  B-DRUG
dose  O
level  O
(  O
Ia  O
)  O
.  O

In  O
total  O
,  O
17  O
patients  O
were  O
treated  O
at  O
this  O
dose  O
level  O
.  O

Among  O
these  O
,  O
only  O
two  O
patients  O
experienced  O
DLT  O
in  O
cycle  O
one  O
and  O
37  O
complete  O
cycles  O
have  O
been  O
administered  O
in  O
association  O
with  O
a  O
low  O
toxicity  O
profile  O
.  O

The  O
median  O
dose  O
intensity  O
was  O
100  O
%  O
for  O
each  O
drug  O
during  O
the  O
first  O
course  O
and  O
no  O
treatment  O
delay  O
exceeding  O
7  O
days  O
was  O
required  O
.  O

The  O
recommended  O
dose  O
of  O
4-weekly  O
Caelyx  B-DRUG
in  O
combination  O
with  O
weekly  O
24-h  O
5-FU  B-DRUG
/  I-DRUG
sodium  I-DRUG
FA  I-DRUG
and  O
4-weekly  O
MMC  B-DRUG
is  O
20  O
mg  O
m  O
(  O
-2  O
)  O
.  O

Preliminary  O
antitumour  O
activity  O
has  O
been  O
observed  O
in  O
patients  O
with  O
pretreated  O
pancreatic  B-CANCER
cancer  I-CANCER
and  O
in  O
untreated  O
gastric  B-CANCER
cancer  I-CANCER
.  O

A  O
novel  O
biweekly  O
multidrug  O
regimen  O
of  O
gemcitabine  B-DRUG
,  O
oxaliplatin  B-DRUG
,  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
,  O
and  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
in  O
pretreated  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
.  O


Previous  O
results  O
suggest  O
that  O
GEM  O
affects  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
metabolism  O
and  O
pharmacokinetics  O
in  O
cancer  O
patients  O
,  O
while  O
combined  O
with  O
oxaliplatin  B-DRUG
,  O
levo-folinic  B-DRUG
acid  I-DRUG
,  O
and  O
5-FU  B-DRUG
(  O
GOLF  B-DRUG
regimen  O
)  O
,  O
at  O
doses  O
achievable  O
in  O
cancer  O
patients  O
,  O
determines  O
high  O
cytotoxic  O
and  O
proapoptotic  O
antitumour  O
activity  O
in  O
colon  B-CANCER
cancer  I-CANCER
cells  O
in  O
vitro  O
.  O

On  O
these  O
bases  O
we  O
designed  O
a  O
phase  O
I-II  O
clinical  O
trial  O
testing  O
the  O
GOLF  B-DRUG
regimen  O
in  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
,  O
who  O
had  O
received  O
at  O
least  O
a  O
prior  O
line  O
of  O
chemotherapy  O
.  O

In  O
total  O
,  O
29  O
patients  O
(  O
20  O
males  O
and  O
nine  O
females  O
)  O
enrolled  O
in  O
the  O
study  O
received  O
every  O
2  O
weeks  O
,  O
gemcitabine  B-DRUG
(  O
patients  O
#  O
1-3  O
received  O
600  O
mg  O
m  O
(  O
-2  O
)  O
;  O
patients  O
#  O
4-6  O
received  O
850  O
mg  O
m  O
(  O
-2  O
)  O
;  O
while  O
patients  O
#  O
7-29  O
received  O
1000  O
mg  O
m  O
(  O
-2  O
)  O
)  O
on  O
the  O
day  O
1  O
,  O
levo-folinic  B-DRUG
acid  I-DRUG
(  O
100  O
mg  O
m  O
(  O
-2  O
)  O
)  O
on  O
the  O
days  O
1  O
and  O
2  O
;  O
5-fluorouracil  B-DRUG
(  O
400  O
mg  O
m  O
(  O
-2  O
)  O
)  O
in  O
bolus  O
injection  O
,  O
followed  O
by  O
a  O
22-h  O
continuous  O
infusion  O
(  O
800  O
mg  O
m  O
(  O
-2  O
)  O
)  O
on  O
the  O
days  O
1  O
and  O
2  O
,  O
and  O
oxaliplatin  B-DRUG
(  O
85  O
mg  O
m  O
(  O
-2  O
)  O
)  O
,  O
6  O
h  O
after  O
the  O
5-FU  B-DRUG
bolus  O
on  O
day  O
2.  O
The  O
most  O
frequent  O
side  O
effect  O
was  O
grade  O
I-II  O
haematological  B-TOXI
toxicity  I-TOXI
.  O

In  O
total  O
,  O
28  O
patients  O
were  O
evaluable  O
for  O
response  O
:  O
three  O
achieved  O
a  O
complete  O
response  O
,  O
nine  O
a  O
partial  O
response  O
,  O
10  O
had  O
a  O
stable  O
disease  O
,  O
and  O
six  O
progressed  O
.  O

The  O
average  O
time  O
to  O
progression  O
and  O
overall  O
survival  O
of  O
the  O
patients  O
was  O
,  O
respectively  O
,  O
7.26  O
and  O
22  O
months  O
.  O

Our  O
GOLF  B-DRUG
combination  O
is  O
well  O
tolerated  O
and  O
seems  O
promising  O
for  O
the  O
treatment  O
of  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

XELOX  B-DRUG
(  O
capecitabine  B-DRUG
plus  O
oxaliplatin  B-DRUG
)  O
:  O
active  O
first-line  O
therapy  O
for  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


Capecitabine  B-DRUG
has  O
demonstrated  O
high  O
efficacy  O
as  O
first-line  O
treatment  O
for  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
(  O
MCRC  B-CANCER
)  O
.  O

Oxaliplatin  B-DRUG
shows  O
synergy  O
with  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
,  O
with  O
little  O
toxicity  O
overlap  O
.  O

The  O
XELOX  B-DRUG
regimen  O
(  O
capecitabine  B-DRUG
plus  O
oxaliplatin  B-DRUG
)  O
,  O
established  O
in  O
a  O
previous  O
dose-finding  O
study  O
,  O
should  O
improve  O
on  O
infused  O
oxaliplatin  B-DRUG
with  O
FU  B-DRUG
and  O
leucovorin  B-DRUG
(  O
FOLFOX  B-DRUG
)  O
regimens  O
.  O

The  O
present  O
studies  O
further  O
characterize  O
efficacy  O
and  O
safety  O
of  O
the  O
XELOX  B-DRUG
regimen  O
.  O

The  O
antitumor  O
activity  O
of  O
XELOX  B-DRUG
was  O
investigated  O
in  O
a  O
colon  B-CANCER
cancer  I-CANCER
xenograft  O
model  O
.  O

Patients  O
with  O
MCRC  B-CANCER
received  O
first-line  O
XELOX  B-DRUG
in  O
3-week  O
treatment  O
cycles  O
:  O
intravenous  O
oxaliplatin  B-DRUG
130  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
day  O
1  O
)  O
followed  O
by  O
oral  O
capecitabine  B-DRUG
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
twice  O
daily  O
(  O
day  O
1  O
,  O
evening  O
,  O
to  O
day  O
15  O
,  O
morning  O
)  O
.  O

A  O
preclinical  O
study  O
confirmed  O
that  O
capecitabine  B-DRUG
has  O
supra-additive  O
activity  O
with  O
oxaliplatin  B-DRUG
.  O

In  O
the  O
clinical  O
study  O
,  O
53  O
of  O
96  O
patients  O
(  O
55  O
%  O
)  O
achieved  O
an  O
objective  O
response  O
,  O
and  O
30  O
(  O
31  O
%  O
)  O
experienced  O
disease  O
stabilization  O
for  O
&  O
gt  O
;  O
/  O
=  O
3  O
months  O
following  O
treatment  O
.  O

After  O
24  O
months  O
'  O
minimum  O
follow-up  O
,  O
median  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
(  O
TTP  O
)  O
and  O
median  O
overall  O
survival  O
were  O
7.7  O
and  O
19.5  O
months  O
,  O
respectively  O
.  O

XELOX  B-DRUG
safety  O
was  O
predictable  O
and  O
similar  O
to  O
the  O
FOLFOX4  B-DRUG
regimen  O
,  O
except  O
that  O
myelosuppression  B-TOXI
was  O
uncommon  O
with  O
XELOX  B-DRUG
(  O
grade  O
3  O
or  O
4  O
neutropenia  B-TOXI
,  O
7  O
%  O
)  O
.  O

Most  O
adverse  O
events  O
were  O
mild  O
to  O
moderate  O
,  O
the  O
most  O
common  O
being  O
acute  B-TOXI
sensory  I-TOXI
neuropathy  I-TOXI
(  O
85  O
%  O
)  O
.  O

Sixty-day  O
,  O
all-cause  O
mortality  O
was  O
2  O
%  O
.  O

XELOX  B-DRUG
is  O
a  O
highly  O
effective  O
first-line  O
treatment  O
for  O
MCRC  B-CANCER
.  O

Response  O
rates  O
,  O
TTP  O
,  O
and  O
overall  O
survival  O
are  O
similar  O
to  O
those  O
observed  O
with  O
FU  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
/  I-DRUG
oxaliplatin  I-DRUG
combinations  O
.  O

XELOX  B-DRUG
provides  O
a  O
more  O
convenient  O
regimen  O
,  O
likely  O
to  O
be  O
preferred  O
by  O
both  O
patients  O
and  O
healthcare  O
providers  O
.  O

Capecitabine  B-DRUG
has  O
the  O
potential  O
to  O
replace  O
FU  B-DRUG
/  I-DRUG
LV  I-DRUG
in  O
combination  O
with  O
oxaliplatin  B-DRUG
for  O
MCRC  B-CANCER
.  O

Phase  O
III  O
trial  O
of  O
doxorubicin  B-DRUG
plus  O
cisplatin  B-DRUG
with  O
or  O
without  O
paclitaxel  B-DRUG
plus  O
filgrastim  B-DRUG
in  O
advanced  B-CANCER
endometrial  I-CANCER
carcinoma  I-CANCER
:  O
a  O
Gynecologic  O
Oncology  O
Group  O
Study  O
.  O


To  O
determine  O
whether  O
the  O
addition  O
of  O
paclitaxel  B-DRUG
to  O
doxorubicin  B-DRUG
plus  O
cisplatin  B-DRUG
improves  O
overall  O
survival  O
(  O
OS  O
)  O
in  O
women  O
with  O
advanced  O
or  O
recurrent  O
endometrial  B-CANCER
carcinoma  I-CANCER
.  O

Secondary  O
comparisons  O
included  O
progression-free  O
survival  O
(  O
PFS  O
)  O
,  O
response  O
rate  O
(  O
RR  O
)  O
,  O
and  O
toxicities  O
.  O

Eligible  O
,  O
consenting  O
patients  O
received  O
doxorubicin  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
AP  O
)  O
,  O
or  O
doxorubicin  B-DRUG
45  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
day  O
1  O
)  O
,  O
followed  O
by  O
paclitaxel  B-DRUG
160  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
day  O
2  O
)  O
with  O
filgrastim  B-DRUG
support  O
(  O
TAP  B-DRUG
)  O
.  O

The  O
initial  O
doxorubicin  B-DRUG
dose  O
in  O
the  O
AP  O
arm  O
was  O
reduced  O
to  O
45  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
patients  O
with  O
prior  O
pelvic  O
radiotherapy  O
and  O
those  O
older  O
than  O
65  O
years  O
.  O

Both  O
regimens  O
were  O
repeated  O
every  O
3  O
weeks  O
to  O
a  O
maximum  O
of  O
seven  O
cycles  O
.  O

Patients  O
completed  O
a  O
neurotoxicity  B-TOXI
questionnaire  O
before  O
each  O
cycle  O
.  O

Two  O
hundred  O
seventy-three  O
women  O
(  O
10  O
ineligible  O
)  O
were  O
registered  O
.  O

Objective  O
response  O
(  O
57  O
%  O
v  O
34  O
%  O
;  O
P  O
&  O
lt  O
;  O
.01  O
)  O
,  O
PFS  O
(  O
median  O
,  O
8.3  O
v  O
5.3  O
months  O
;  O
P  O
&  O
lt  O
;  O
.01  O
)  O
,  O
and  O
OS  O
(  O
median  O
,  O
15.3  O
v  O
12.3  O
months  O
;  O
P  O
=.037  O
)  O
were  O
improved  O
with  O
TAP  B-DRUG
.  O

Treatment  O
was  O
hematologically  O
well  O
tolerated  O
,  O
with  O
only  O
2  O
%  O
of  O
patients  O
receiving  O
AP  O
,  O
and  O
3  O
%  O
of  O
patients  O
receiving  O
TAP  B-DRUG
experiencing  O
neutropenic  B-TOXI
fever  I-TOXI
.  O

Neurologic  B-TOXI
toxicity  I-TOXI
was  O
worse  O
for  O
those  O
receiving  O
TAP  B-DRUG
,  O
with  O
12  O
%  O
grade  O
3  O
,  O
and  O
27  O
%  O
grade  O
2  O
peripheral  B-TOXI
neuropathy  I-TOXI
,  O
compared  O
with  O
1  O
%  O
and  O
4  O
%  O
,  O
respectively  O
,  O
in  O
those  O
receiving  O
AP  O
.  O

Patient-reported  O
neurotoxicity  B-TOXI
was  O
significantly  O
higher  O
in  O
the  O
TAP  B-DRUG
arm  O
following  O
two  O
cycles  O
of  O
therapy  O
.  O

TAP  B-DRUG
significantly  O
improves  O
RR  O
,  O
PFS  O
,  O
and  O
OS  O
compared  O
with  O
AP  O
.  O

Evaluation  O
of  O
this  O
regimen  O
in  O
the  O
high-risk  O
adjuvant  O
setting  O
is  O
warranted  O
,  O
but  O
close  O
attention  O
should  O
be  O
paid  O
to  O
the  O
increased  O
risk  O
of  O
peripheral  B-TOXI
neuropathy  I-TOXI
.  O

Randomized  O
phase  O
II  O
trial  O
comparing  O
bevacizumab  B-DRUG
plus  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
with  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
alone  O
in  O
previously  O
untreated  O
locally  O
advanced  B-CANCER
or  I-CANCER
metastatic  I-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


To  O
investigate  O
the  O
efficacy  O
and  O
safety  O
of  O
bevacizumab  B-DRUG
plus  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
in  O
patients  O
with  O
advanced  O
or  O
recurrent  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

In  O
a  O
phase  O
II  O
trial  O
,  O
99  O
patients  O
were  O
randomly  O
assigned  O
to  O
bevacizumab  B-DRUG
7.5  O
(  O
n  O
=  O
32  O
)  O
or  O
15  O
mg  O
/  O
kg  O
(  O
n  O
=  O
35  O
)  O
plus  O
carboplatin  B-DRUG
(  O
area  O
under  O
the  O
curve  O
=  O
6  O
)  O
and  O
paclitaxel  B-DRUG
(  O
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
every  O
3  O
weeks  O
or  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
alone  O
(  O
n  O
=  O
32  O
)  O
.  O

Primary  O
efficacy  O
end  O
points  O
were  O
time  O
to  O
disease  B-TOXI
progression  I-TOXI
and  O
best  O
confirmed  O
response  O
rate  O
.  O

On  O
disease  B-TOXI
progression  I-TOXI
,  O
patients  O
in  O
the  O
control  O
arm  O
had  O
the  O
option  O
to  O
receive  O
single-agent  O
bevacizumab  B-DRUG
15  O
mg  O
/  O
kg  O
every  O
3  O
weeks  O
.  O

Compared  O
with  O
the  O
control  O
arm  O
,  O
treatment  O
with  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
plus  O
bevacizumab  B-DRUG
(  O
15  O
mg  O
/  O
kg  O
)  O
resulted  O
in  O
a  O
higher  O
response  O
rate  O
(  O
31.5  O
%  O
v  O
18.8  O
%  O
)  O
,  O
longer  O
median  O
time  O
to  O
progression  O
(  O
7.4  O
v  O
4.2  O
months  O
)  O
and  O
a  O
modest  O
increase  O
in  O
survival  O
(  O
17.7  O
v  O
14.9  O
months  O
)  O
.  O

Of  O
the  O
19  O
control  O
patients  O
that  O
crossed  O
over  O
to  O
single-agent  O
bevacizumab  B-DRUG
,  O
five  O
experienced  O
stable  O
disease  O
,  O
and  O
1-year  O
survival  O
was  O
47  O
%  O
.  O

Bleeding  B-TOXI
was  O
the  O
most  O
prominent  O
adverse  O
event  O
and  O
was  O
manifested  O
in  O
two  O
distinct  O
clinical  O
patterns  O
;  O
minor  B-TOXI
mucocutaneous  I-TOXI
hemorrhage  I-TOXI
and  O
major  B-TOXI
hemoptysis  I-TOXI
.  O

Major  B-TOXI
hemoptysis  I-TOXI
was  O
associated  O
with  O
squamous  O
cell  O
histology  O
,  O
tumor  B-TOXI
necrosis  I-TOXI
and  I-TOXI
cavitation  I-TOXI
,  O
and  O
disease  O
location  O
close  O
to  O
major  O
blood  O
vessels  O
.  O

Bevacizumab  B-DRUG
in  O
combination  O
with  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
improved  O
overall  O
response  O
and  O
time  O
to  O
progression  O
in  O
patients  O
with  O
advanced  O
or  O
recurrent  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

Patients  O
with  O
nonsquamous  O
cell  O
histology  O
appear  O
to  O
be  O
a  O
subpopulation  O
with  O
improved  O
outcome  O
and  O
acceptable  O
safety  O
risks  O
.  O

Topotecan  B-DRUG
compared  O
with  O
no  O
therapy  O
after  O
response  O
to  O
surgery  O
and  O
carboplatin  B-DRUG
/  I-DRUG
paclitaxel  I-DRUG
in  O
patients  O
with  O
ovarian  B-CANCER
cancer  I-CANCER
:  O
Multicenter  O
Italian  O
Trials  O
in  O
Ovarian  O
Cancer  O
(  O
MITO-1  O
)  O
randomized  O
study  O
.  O


Topotecan  B-DRUG
is  O
an  O
active  O
second-line  O
treatment  O
for  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

Its  O
efficacy  O
as  O
consolidation  O
treatment  O
after  O
first-line  O
standard  O
chemotherapy  O
is  O
unknown  O
.  O

To  O
investigate  O
whether  O
topotecan  B-DRUG
(  O
1.5  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
through  O
5  O
,  O
four  O
cycles  O
,  O
every  O
3  O
weeks  O
)  O
prolonged  O
progression-free  O
survival  O
(  O
PFS  O
)  O
for  O
patients  O
responding  O
to  O
standard  O
carboplatin  B-DRUG
(  O
area  O
under  O
the  O
curve  O
5  O
)  O
and  O
paclitaxel  B-DRUG
(  O
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
administered  O
as  O
a  O
3-hour  O
infusion  O
in  O
six  O
cycles  O
;  O
CP  B-DRUG
)  O
,  O
a  O
multicenter  O
phase  O
III  O
study  O
was  O
performed  O
with  O
an  O
80  O
%  O
power  O
to  O
detect  O
a  O
50  O
%  O
prolongation  O
of  O
median  O
PFS  O
.  O

Patients  O
were  O
registered  O
at  O
diagnosis  O
and  O
randomized  O
after  O
the  O
end  O
of  O
CP  B-DRUG
.  O

Two  O
hundred  O
seventy-three  O
patients  O
were  O
randomly  O
assigned  O
(  O
topotecan  B-DRUG
,  O
n  O
=  O
137  O
;  O
observation  O
,  O
n  O
=  O
136  O
)  O
,  O
with  O
a  O
median  O
age  O
of  O
56  O
years  O
.  O

Stage  O
at  O
diagnosis  O
was  O
advanced  O
in  O
three  O
fourths  O
of  O
patients  O
(  O
stage  O
III  O
in  O
65  O
%  O
of  O
patients  O
;  O
stage  O
IV  O
in  O
10  O
%  O
)  O
;  O
after  O
primary  O
surgery  O
,  O
46  O
%  O
had  O
no  O
residual  O
disease  O
and  O
20  O
%  O
were  O
optimally  O
debulked  O
.  O

After  O
CP  B-DRUG
,  O
87  O
%  O
reached  O
a  O
clinical  O
complete  O
response  O
,  O
and  O
13  O
%  O
achieved  O
a  O
partial  O
response  O
.  O

Neutropenia  B-TOXI
(  O
grade  O
3  O
/  O
4  O
in  O
58  O
%  O
of  O
the  O
patients  O
)  O
and  O
thrombocytopenia  B-TOXI
(  O
grade  O
3  O
in  O
21  O
%  O
;  O
grade  O
4  O
in  O
3  O
%  O
)  O
were  O
the  O
most  O
frequent  O
toxicities  O
attributed  O
to  O
topotecan  B-DRUG
.  O

There  O
was  O
no  O
statistically  O
significant  O
difference  O
in  O
PFS  O
between  O
the  O
arms  O
(  O
P  O
=.83  O
;  O
log-rank  O
test  O
)  O
:  O
median  O
PFS  O
was  O
18.2  O
months  O
in  O
the  O
topotecan  B-DRUG
arm  O
and  O
28.4  O
in  O
the  O
control  O
arm  O
.  O

Hazard  O
ratio  O
of  O
progression  O
for  O
patients  O
receiving  O
topotecan  B-DRUG
was  O
1.18  O
(  O
95  O
%  O
CI  O
,  O
0.86  O
to  O
1.63  O
)  O
after  O
adjustment  O
for  O
residual  O
disease  O
,  O
interval  O
debulking  O
surgery  O
,  O
and  O
response  O
to  O
CP  B-DRUG
.  O

The  O
present  O
analysis  O
indicates  O
that  O
consolidation  O
with  O
topotecan  B-DRUG
does  O
not  O
improve  O
PFS  O
for  O
patients  O
with  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
who  O
respond  O
to  O
initial  O
chemotherapy  O
with  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
.  O

Phase  O
I  O
/  O
II  O
study  O
of  O
first-line  O
irinotecan  B-DRUG
combined  O
with  O
5-fluorouracil  B-DRUG
and  O
folinic  B-DRUG
acid  I-DRUG
Mayo  O
Clinic  O
schedule  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


This  O
multicentre  O
phase  O
I  O
/  O
II  O
study  O
was  O
designed  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
of  O
irinotecan  B-DRUG
when  O
combined  O
with  O
5-fluorouracil  B-DRUG
and  O
folinic  B-DRUG
acid  I-DRUG
according  O
to  O
the  O
Mayo  O
Clinic  O
schedule  O
and  O
to  O
evaluate  O
the  O
activity  O
of  O
this  O
combination  O
as  O
first-line  O
therapy  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

Sixty-three  O
patients  O
received  O
irinotecan  B-DRUG
(  O
250  O
or  O
300  O
mg  O
/  O
m2  O
,  O
30-  O
to  O
90-minute  O
intravenous  O
infusion  O
on  O
day  O
1  O
)  O
,  O
immediately  O
followed  O
by  O
folinic  B-DRUG
acid  I-DRUG
(  O
20  O
mg  O
/  O
m2  O
/  O
day  O
)  O
and  O
5-fluorouracil  B-DRUG
(  O
425  O
mg  O
/  O
m2  O
,  O
15-minute  O
bolus  O
infusion  O
)  O
days  O
1  O
to  O
5  O
,  O
every  O
four  O
weeks  O
.  O

Diarrhoea  B-TOXI
was  O
dose  O
limiting  O
at  O
300  O
mg  O
/  O
m2  O
irinotecan  B-DRUG
in  O
combination  O
with  O
5-fluorouracil  B-DRUG
and  O
folinic  B-DRUG
acid  I-DRUG
,  O
and  O
this  O
was  O
determined  O
to  O
be  O
the  O
maximum  O
tolerated  O
dose  O
.  O

Grade  O
3-4  O
neutropenia  B-TOXI
was  O
the  O
most  O
frequently  O
reported  O
toxicity  O
.  O

The  O
recommended  O
dose  O
of  O
irinotecan  B-DRUG
for  O
the  O
phase  O
II  O
part  O
of  O
the  O
study  O
was  O
250  O
mg  O
/  O
m2  O
.  O

The  O
response  O
rate  O
for  O
the  O
evaluable  O
patient  O
population  O
was  O
36  O
%  O
(  O
13  O
/  O
36  O
)  O
,  O
and  O
44  O
%  O
(  O
16  O
patients  O
)  O
had  O
stable  O
disease  O
(  O
including  O
19  O
%  O
of  O
minor  O
response  O
)  O
.  O

For  O
the  O
intention-to-treat  O
population  O
,  O
the  O
response  O
rate  O
was  O
29  O
%  O
(  O
14  O
/  O
49  O
)  O
and  O
35  O
%  O
(  O
17  O
patients  O
)  O
stable  O
disease  O
(  O
including  O
14  O
%  O
of  O
minor  O
response  O
)  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
7.0  O
months  O
and  O
the  O
median  O
survival  O
was  O
12.0  O
months  O
.  O

Grade  O
3-4  O
non-haematological  B-TOXI
drug-related  I-TOXI
toxicities  I-TOXI
included  O
delayed  B-TOXI
diarrhoea  I-TOXI
,  O
stomatitis  B-TOXI
,  O
fatigue  B-TOXI
,  O
and  O
nausea  B-TOXI
/  I-TOXI
vomiting  I-TOXI
.  O

There  O
were  O
three  O
deaths  B-TOXI
due  O
to  O
septic  B-TOXI
shock  I-TOXI
that  O
were  O
possibly  O
or  O
probably  O
treatment-related  O
.  O

This  O
regimen  O
of  O
irinotecan  B-DRUG
in  O
combination  O
with  O
the  O
Mayo  O
Clinic  O
schedule  O
of  O
bolus  O
5-fluorouracil  B-DRUG
/  I-DRUG
folinic  I-DRUG
acid  I-DRUG
every  O
four  O
weeks  O
showed  O
activity  O
as  O
first-line  O
therapy  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O

In  O
keeping  O
with  O
other  O
published  O
results  O
of  O
studies  O
using  O
bolus  O
5-fluorouracil  B-DRUG
combined  O
with  O
irinotecan  B-DRUG
,  O
the  O
use  O
of  O
this  O
regimen  O
is  O
limited  O
by  O
a  O
relatively  O
high  O
rate  O
of  O
grade  O
3-4  O
neutropenia  B-TOXI
,  O
and  O
the  O
combination  O
of  O
irinotecan  B-DRUG
and  O
infusional  O
5-fluorouracil  B-DRUG
/  I-DRUG
folinic  I-DRUG
acid  I-DRUG
should  O
remain  O
the  O
regimen  O
of  O
first  O
choice  O
.  O

Multi-institutional  O
phase  O
II  O
trial  O
of  O
irinotecan  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
etoposide  B-DRUG
for  O
sensitive  B-CANCER
relapsed  I-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
has  O
been  O
shown  O
to  O
exhibit  O
excellent  O
antitumour  O
activity  O
against  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
SCLC  B-CANCER
)  O
.  O

A  O
multi-institutional  O
phase  O
II  O
study  O
was  O
therefore  O
conducted  O
to  O
evaluate  O
the  O
efficacy  O
and  O
toxicity  O
of  O
CPT-11  B-DRUG
combined  O
with  O
cisplatin  B-DRUG
(  O
CDDP  B-DRUG
)  O
and  O
etoposide  B-DRUG
(  O
ETOP  B-DRUG
)  O
(  O
PEI  O
regimen  O
)  O
for  O
the  O
treatment  O
of  O
sensitive  O
relapsed  O
SCLC  B-CANCER
.  O

Patients  O
who  O
responded  O
to  O
first-line  O
chemotherapy  O
but  O
relapsed  O
more  O
than  O
8  O
weeks  O
after  O
the  O
completion  O
of  O
first-line  O
therapy  O
(  O
n=40  O
)  O
were  O
treated  O
using  O
the  O
PEI  O
regimen  O
,  O
which  O
consisted  O
of  O
CDDP  B-DRUG
(  O
25  O
mg  O
m  O
(  O
-2  O
)  O
)  O
weekly  O
for  O
9  O
weeks  O
,  O
ETOP  B-DRUG
(  O
60  O
mg  O
m  O
(  O
-2  O
)  O
)  O
for  O
3  O
days  O
on  O
weeks  O
1  O
,  O
3  O
,  O
5  O
,  O
7  O
,  O
and  O
9  O
,  O
and  O
CPT-11  B-DRUG
(  O
90  O
mg  O
m  O
(  O
-2  O
)  O
)  O
on  O
weeks  O
2  O
,  O
4  O
,  O
6  O
,  O
and  O
8  O
with  O
granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
support  I-DRUG
.  O

Five  O
complete  O
responses  O
and  O
26  O
partial  O
responses  O
were  O
observed  O
,  O
and  O
the  O
overall  O
response  O
rate  O
was  O
78  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
61.5-89.2  O
%  O
)  O
.  O

The  O
median  O
survival  O
time  O
was  O
11.8  O
months  O
,  O
and  O
the  O
estimated  O
1-year  O
survival  O
rate  O
was  O
49  O
%  O
.  O

Grade  O
3  O
/  O
4  O
leucocytopenia  B-TOXI
,  O
neutropenia  B-TOXI
,  O
and  O
thrombocytopenia  B-TOXI
were  O
observed  O
in  O
55  O
,  O
73  O
,  O
and  O
33  O
%  O
of  O
the  O
patients  O
,  O
respectively  O
.  O

Nonhaematological  B-TOXI
toxicities  I-TOXI
were  O
mild  O
and  O
transient  O
in  O
all  O
patients  O
.  O

In  O
conclusion  O
,  O
the  O
PEI  O
regimen  O
is  O
considered  O
to  O
be  O
highly  O
active  O
and  O
well  O
tolerated  O
for  O
the  O
treatment  O
of  O
sensitive  B-CANCER
relapsed  I-CANCER
SCLC  I-CANCER
.  O

Cisplatin  B-DRUG
,  O
fluorouracil  B-DRUG
,  O
and  O
leucovorin  B-DRUG
induction  O
chemotherapy  O
followed  O
by  O
concurrent  O
cisplatin  B-DRUG
chemoradiotherapy  O
for  O
organ  O
preservation  O
and  O
cure  O
in  O
patients  O
with  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
:  O
long-term  O
follow-up  O
.  O


The  O
poor  O
functional  O
outcome  O
in  O
patients  O
with  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
(  O
HNSCC  B-CANCER
)  O
with  O
surgery  O
and  O
radiation  O
has  O
led  O
to  O
alternative  O
approaches  O
to  O
advanced  O
disease  O
.  O

We  O
conducted  O
a  O
phase  O
II  O
study  O
of  O
induction  O
chemotherapy  O
followed  O
by  O
concurrent  O
chemoradiotherapy  O
for  O
organ  O
preservation  O
in  O
patients  O
with  O
advanced  B-CANCER
resectable  I-CANCER
and  I-CANCER
unresectable  I-CANCER
(  I-CANCER
nasopharyngeal  I-CANCER
)  I-CANCER
tumors  I-CANCER
.  O

Forty-two  O
patients  O
with  O
stage  O
III  O
to  O
IV  O
resectable  O
HNSCC  B-CANCER
and  O
nasopharyngeal  B-CANCER
tumors  I-CANCER
received  O
induction  O
chemotherapy  O
with  O
two  O
courses  O
of  O
cisplatin  B-DRUG
(  O
20  O
mg  O
/  O
m2  O
/  O
d  O
continuous  O
infusion  O
[  O
CI  O
]  O
)  O
,  O
fluorouracil  B-DRUG
(  O
800  O
mg  O
/  O
m2  O
/  O
d  O
CI  O
)  O
,  O
and  O
leucovorin  B-DRUG
(  O
500  O
mg  O
/  O
m2  O
/  O
d  O
CI  O
;  O
PFL  O
)  O
for  O
4  O
days  O
followed  O
by  O
concurrent  O
therapy  O
with  O
cisplatin  B-DRUG
(  O
100  O
mg  O
/  O
m2  O
/  O
d  O
on  O
days  O
1  O
and  O
22  O
)  O
and  O
approximately  O
70  O
Gy  O
of  O
external-beam  O
radiotherapy  O
.  O

Response  O
to  O
induction  O
chemotherapy  O
included  O
partial  O
response  O
rate  O
of  O
52  O
%  O
and  O
complete  O
response  O
rate  O
of  O
24  O
%  O
.  O

The  O
most  O
common  O
grade  O
3  O
or  O
4  O
toxicity  O
was  O
neutropenia  B-TOXI
(  O
59  O
%  O
)  O
.  O

After  O
cisplatin  B-DRUG
chemoradiotherapy  O
the  O
complete  O
response  O
rate  O
was  O
67  O
%  O
.  O

Toxicities  O
of  O
cisplatin  B-DRUG
chemoradiotherapy  O
consisted  O
of  O
grade  O
3  O
or  O
4  O
mucositis  B-TOXI
(  O
79  O
%  O
)  O
and  O
neutropenia  B-TOXI
(  O
51  O
%  O
)  O
.  O

At  O
a  O
median  O
follow-up  O
of  O
71.5  O
months  O
,  O
43  O
%  O
of  O
the  O
patients  O
are  O
still  O
alive  O
and  O
disease-free  O
.  O

The  O
5-year  O
progression-free  O
survival  O
(  O
PFS  O
)  O
rate  O
was  O
60  O
%  O
,  O
and  O
the  O
2-  O
and  O
5-year  O
overall  O
survival  O
(  O
OS  O
)  O
rates  O
were  O
67  O
%  O
and  O
52  O
%  O
,  O
respectively  O
.  O

Three  O
patients  O
died  B-TOXI
of  I-TOXI
second  I-TOXI
primaries  I-TOXI
.  O

Late  O
complications  O
of  O
treatment  O
included  O
xerostomia  B-TOXI
and  O
hoarseness  B-TOXI
.  O

One  O
patient  O
had  O
persistent  O
dysphagia  B-TOXI
and  O
required  O
laser  O
epiglotectomy  O
108  O
months  O
after  O
treatment  O
.  O

Induction  O
chemotherapy  O
with  O
PFL  O
followed  O
by  O
concurrent  O
cisplatin  B-DRUG
chemoradiotherapy  O
is  O
well  O
tolerated  O
and  O
results  O
in  O
a  O
good  O
likelihood  O
of  O
organ  O
preservation  O
and  O
excellent  O
PFS  O
and  O
OS  O
.  O

Phase  O
II  O
trial  O
of  O
carboplatin  B-DRUG
and  O
etoposide  B-DRUG
for  O
patients  O
with  O
recurrent  B-CANCER
high-grade  I-CANCER
glioma  I-CANCER
.  O


We  O
present  O
the  O
results  O
of  O
a  O
phase  O
II  O
trial  O
of  O
carboplatin  B-DRUG
and  O
etoposide  B-DRUG
(  O
CE  B-DRUG
)  O
combination  O
as  O
first-line  O
chemotherapy  O
in  O
patients  O
with  O
recurrent  B-CANCER
glioblastoma  I-CANCER
multiforme  I-CANCER
(  O
GBM  B-CANCER
)  O
and  O
anaplastic  B-CANCER
astrocytoma  I-CANCER
(  O
AA  B-CANCER
)  O
after  O
surgery  O
and  O
radiotherapy  O
.  O

We  O
assess  O
the  O
activity  O
and  O
the  O
tolerability  O
of  O
this  O
combination  O
.  O

30  O
patients  O
with  O
GBM  B-CANCER
(  O
25  O
)  O
and  O
AA  B-CANCER
(  O
5  O
)  O
were  O
treated  O
with  O
VP-16  B-DRUG
(  O
etoposide  B-DRUG
)  O
120  O
mg  O
m  O
(  O
-2  O
)  O
and  O
CBCDA  B-DRUG
(  O
carboplatin  B-DRUG
)  O
100  O
mg  O
m  O
(  O
-2  O
)  O
for  O
3  O
days  O
every  O
4  O
weeks  O
.  O

Moreover  O
,  O
we  O
performed  O
a  O
retrospective  O
analysis  O
of  O
topoisomerase  O
IIalpha  O
gene  O
status  O
using  O
chromogenic  O
in  O
situ  O
hybridisation  O
.  O

The  O
median  O
age  O
was  O
54  O
years  O
(  O
21-73  O
years  O
)  O
;  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
score  O
was  O
0-1  O
in  O
25  O
patients  O
and  O
2  O
in  O
five  O
patients  O
.  O

All  O
patients  O
had  O
been  O
previously  O
treated  O
with  O
surgical  O
resection  O
(  O
21  O
radical  O
resections  O
)  O
followed  O
by  O
radiation  O
therapy  O
(  O
40-60  O
Gy  O
)  O
.  O

We  O
observed  O
six  O
(  O
20  O
%  O
)  O
complete  O
responses  O
,  O
three  O
(  O
10  O
%  O
)  O
partial  O
responses  O
and  O
12  O
(  O
40  O
%  O
)  O
stable  O
diseases  O
,  O
with  O
a  O
response  O
rate  O
of  O
30  O
%  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
4  O
months  O
,  O
while  O
progression-free  O
survival  O
at  O
6  O
months  O
was  O
33.3  O
%  O
.  O

The  O
median  O
survival  O
time  O
was  O
10  O
months  O
.  O

Neutropenia  B-TOXI
occurred  O
in  O
9  O
patients  O
:  O
four  O
patients  O
had  O
grade  O
4  O
,  O
two  O
patients  O
grade  O
3  O
and  O
three  O
patients  O
grade  O
2.  O
In  O
the  O
conclusion  O
of  O
this  O
clinical  O
trial  O
,  O
the  O
CE  B-DRUG
combination  O
has  O
shown  O
activity  O
in  O
recurrent  O
GBM  B-CANCER
and  O
AA  B-CANCER
,  O
with  O
a  O
good  O
toxicity  O
profile  O
.  O

Alterations  O
in  O
the  O
copy  O
number  O
of  O
topoisomerase  O
IIalpha  O
gene  O
seem  O
to  O
be  O
a  O
rare  O
event  O
and  O
in  O
our  O
series  O
do  O
not  O
influence  O
response  O
to  O
the  O
CE  B-DRUG
combination  O
.  O

A  O
phase  O
I  O
trial  O
of  O
gemcitabine  B-DRUG
plus  O
cladribine  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
hematologic  I-CANCER
malignant  I-CANCER
diseases  O
.  O


Gemcitabine  B-DRUG
and  O
cladribine  B-DRUG
(  O
2CdA  B-DRUG
)  O
are  O
nucleoside  O
analogues  O
that  O
decrease  O
DNA  O
synthesis  O
via  O
inhibition  O
of  O
ribonucleotide  O
reductase  O
;  O
the  O
combination  O
could  O
be  O
additive  O
or  O
synergistic  O
.  O

We  O
conducted  O
a  O
dose  O
escalation  O
study  O
to  O
establish  O
the  O
maximum  O
tolerable  O
doses  O
(  O
MTD  O
)  O
of  O
gemcitabine  B-DRUG
and  O
2CdA  B-DRUG
when  O
given  O
in  O
combination  O
in  O
patients  O
with  O
advanced  B-CANCER
hematologic  I-CANCER
malignancies  I-CANCER
and  O
to  O
describe  O
the  O
toxicity  O
profile  O
of  O
this  O
combination  O
.  O

A  O
total  O
of  O
45  O
patients  O
with  O
advanced  B-CANCER
hematologic  I-CANCER
diseases  I-CANCER
were  O
enrolled  O
into  O
two  O
groups  O
.  O

Group  O
A  O
had  O
adequate  O
baseline  O
hematopoiesis  O
,  O
defined  O
as  O
absolute  O
neutrophil  O
count  O
(  O
ANC  O
)  O
&  O
gt  O
;  O
1  O
x  O
10  O
(  O
9  O
)  O
/  O
l  O
and  O
platelet  O
count  O
&  O
gt  O
;  O
50  O
x  O
10  O
(  O
9  O
)  O
/  O
l.  O
Group  O
B  O
did  O
not  O
meet  O
these  O
criteria  O
.  O

Hematologic  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
for  O
group  O
A  O
was  O
defined  O
as  O
grade  O
4  O
neutropenia  B-TOXI
or  O
thrombocytopenia  B-TOXI
lasting  O
&  O
gt  O
;  O
28  O
days  O
;  O
group  O
B  O
was  O
not  O
evaluated  O
for  O
hematologic  B-TOXI
toxicity  I-TOXI
.  O

Nonhematologic  O
DLT  O
was  O
defined  O
similarly  O
for  O
both  O
groups  O
.  O

Death  B-TOXI
occurring  O
during  O
the  O
first  O
cycle  O
of  O
treatment  O
was  O
considered  O
a  O
DLT  O
event  O
only  O
if  O
it  O
was  O
related  O
to  O
drug  O
toxicity  O
.  O

Gemcitabine  B-DRUG
was  O
administered  O
as  O
a  O
4-h  O
intravenous  O
infusion  O
once  O
every  O
28  O
days  O
.  O

2CdA  B-DRUG
was  O
administered  O
over  O
1  O
h  O
daily  O
for  O
the  O
first  O
3  O
days  O
of  O
each  O
28-day  O
cycle  O
.  O

The  O
MTD  O
was  O
not  O
reached  O
in  O
either  O
group  O
.  O

Myelosuppression  B-TOXI
was  O
common  O
,  O
but  O
not  O
dose-limiting  O
.  O

Febrile  B-TOXI
neutropenia  I-TOXI
and  O
infections  O
were  O
also  O
common  O
,  O
particularly  O
in  O
group  O
B  O
,  O
and  O
judged  O
in  O
most  O
cases  O
to  O
be  O
due  O
to  O
bone  O
marrow  O
failure  O
at  O
baseline  O
.  O

Nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
generally  O
mild  O
,  O
and  O
skin  B-TOXI
rash  I-TOXI
,  O
the  O
most  O
frequently  O
observed  O
,  O
was  O
dose-limiting  O
in  O
one  O
patient  O
enrolled  O
in  O
each  O
group  O
.  O

Four  O
deaths  B-TOXI
(  O
three  O
during  O
the  O
first  O
cycle  O
of  O
treatment  O
)  O
occurred  O
at  O
the  O
highest  O
dose  O
level  O
tested  O
in  O
group  O
B  O
(  O
gemcitabine  B-DRUG
5000  O
mg  O
/  O
m2  O
and  O
2CdA  B-DRUG
16  O
mg  O
/  O
m2  O
)  O
.  O

Although  O
only  O
one  O
of  O
these  O
deaths  B-TOXI
was  O
dose-limiting  O
by  O
stated  O
criteria  O
,  O
this  O
dose  O
level  O
did  O
not  O
appear  O
to  O
be  O
safely  O
tolerated  O
in  O
this  O
patient  O
population  O
.  O

Several  O
responses  O
were  O
observed  O
in  O
patients  O
with  O
Hodgkin  B-CANCER
's  I-CANCER
disease  I-CANCER
.  O

The  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
2CdA  B-DRUG
is  O
feasible  O
in  O
patients  O
with  O
hematologic  B-CANCER
malignancies  I-CANCER
.  O

Phase  O
II  O
studies  O
of  O
this  O
combination  O
should  O
be  O
considered  O
,  O
particularly  O
in  O
patients  O
with  O
Hodgkin  B-CANCER
's  I-CANCER
disease  I-CANCER
.  O

Phase  O
I  O
trial  O
of  O
topotecan  B-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
in  O
refractory  O
solid  B-CANCER
tumor  I-CANCER
patients  O
.  O


To  O
determine  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
evidence  O
of  O
antitumor  O
activity  O
of  O
topotecan  B-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
in  O
refractory  O
cancer  O
patients  O
.  O

To  O
determine  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
evidence  O
of  O
antitumor  O
activity  O
of  O
topotecan  B-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
in  O
refractory  B-CANCER
cancer  I-CANCER
patients  O
.  O

This  O
was  O
a  O
Phase  O
I  O
,  O
prospective  O
,  O
dose-escalation  O
trial  O
that  O
employed  O
a  O
novel-dosing  O
schema  O
to  O
investigate  O
clinical  O
safety  O
.  O

Patients  O
were  O
treated  O
in  O
six  O
cohorts  O
with  O
topotecan  B-DRUG
(  O
T  O
)  O
+gemcitabine  B-DRUG
(  O
G  O
)  O
.  O

The  O
doses  O
of  O
T  O
and  O
G  O
were  O
administered  O
by  O
30-minute  O
IV  O
infusion  O
,  O
T  O
on  O
days  O
one  O
through  O
five  O
(  O
0.3  O
mg  O
/  O
m2  O
to  O
1  O
mg  O
/  O
m2  O
)  O
and  O
G  O
on  O
days  O
one  O
and  O
15  O
of  O
a  O
28-day  O
cycle  O
(  O
1000  O
mg  O
/  O
m2  O
to  O
1500  O
mg  O
/  O
m2  O
)  O
.  O

Toxicity  O
was  O
monitored  O
.  O

Twenty-three  O
cancer  O
patients  O
were  O
enrolled  O
(  O
colorectal  O
,  O
n=5  O
;  O
lung  O
,  O
n=4  O
;  O
gastric  O
,  O
n=4  O
;  O
esophageal  O
,  O
n=2  O
;  O
other  O
,  O
n=8  O
)  O
.  O

Two  O
of  O
three  O
patients  O
developed  O
grade  O
3  O
nonhematologic  B-TOXI
toxicity  I-TOXI
attributed  O
to  O
study  O
regimen  O
,  O
thereby  O
fulfilling  O
dose  O
limiting  O
toxicity  O
requirements  O
at  O
cohort  O
6  O
(  O
T  O
,  O
1  O
mg  O
/  O
m2  O
,  O
G  O
,  O
1500  O
mg  O
/  O
m2  O
)  O
.  O

Maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
was  O
established  O
at  O
cohort  O
5  O
(  O
T  O
,  O
1  O
mg  O
/  O
m2  O
,  O
G  O
,  O
1250  O
mg  O
/  O
m2  O
)  O
.  O

Ten  O
patients  O
were  O
treated  O
at  O
cohort  O
5.  O
Nonhematologic  B-TOXI
adverse  I-TOXI
effects  I-TOXI
(  O
AEs  O
)  O
&  O
gt  O
;  O
grade  O
3  O
attributed  O
to  O
the  O
study  O
regimen  O
were  O
not  O
observed  O
.  O

Hematologic  B-TOXI
toxicity  I-TOXI
was  O
frequent  O
.  O

Twenty-five  O
percent  O
of  O
patients  O
in  O
cohort  O
2  O
and  O
50  O
%  O
of  O
patients  O
in  O
cohorts  O
4  O
,  O
5  O
,  O
and  O
6  O
had  O
a  O
reduction  O
of  O
ANC  O
to  O
&  O
lt  O
;  O
500  O
mm3  O
.  O

All  O
neutropenic  B-TOXI
episodes  I-TOXI
were  O
less  O
than  O
one  O
week  O
in  O
duration  O
.  O

Five  O
of  O
the  O
patients  O
in  O
the  O
last  O
three  O
cohorts  O
required  O
delay  O
and  O
/  O
or  O
dose-reduction  O
of  O
G.  O
Nineteen  O
of  O
23  O
enrolled  O
patients  O
were  O
evaluable  O
for  O
response  O
.  O

Two  O
patients  O
achieved  O
a  O
minimal  O
response  O
.  O

The  O
MTD  O
was  O
observed  O
at  O
a  O
T  O
dose  O
of  O
1  O
mg  O
/  O
m2  O
administered  O
on  O
days  O
1  O
through  O
15  O
,  O
and  O
a  O
G  O
dose  O
of  O
1250  O
mg  O
/  O
m2  O
administered  O
on  O
days  O
1  O
and  O
15  O
via  O
30  O
minute  O
intravenous  O
(  O
IV  O
)  O
infusion  O
.  O

Phase  O
I  O
/  O
II  O
study  O
of  O
DHA-paclitaxel  B-DRUG
in  O
combination  O
with  O
carboplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
malignant  I-CANCER
solid  I-CANCER
tumours  I-CANCER
.  O


DHA-paclitaxel  B-DRUG
is  O
a  O
conjugate  O
of  O
paclitaxel  B-DRUG
and  O
the  O
fatty  B-DRUG
acid  I-DRUG
,  O
docosahexaenoic  B-DRUG
acid  I-DRUG
.  O

Preclinical  O
studies  O
have  O
demonstrated  O
increased  O
activity  O
,  O
relative  O
to  O
paclitaxel  B-DRUG
,  O
with  O
the  O
potential  O
for  O
an  O
improved  O
therapeutic  O
ratio  O
.  O

We  O
conducted  O
a  O
phase  O
I  O
study  O
to  O
determine  O
the  O
maximum  O
tolerated  O
doses  O
of  O
DHA-paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
when  O
administered  O
in  O
combination  O
.  O

Two  O
cohorts  O
of  O
patients  O
were  O
treated  O
:  O
carboplatin  B-DRUG
AUC  O
5  O
with  O
DHA-paclitaxel  B-DRUG
660  O
mg  O
m  O
(  O
-2  O
)  O
and  O
carboplatin  B-DRUG
AUC  O
5  O
with  O
DHA-paclitaxel  B-DRUG
880  O
mg  O
m  O
(  O
-2  O
)  O
.  O

Both  O
drugs  O
were  O
given  O
on  O
day  O
1  O
every  O
21  O
days  O
.  O

A  O
total  O
of  O
15  O
patients  O
were  O
enrolled  O
with  O
a  O
median  O
age  O
of  O
59  O
years  O
(  O
range  O
33-71  O
)  O
.  O

All  O
patients  O
had  O
advanced  B-CANCER
cancer  I-CANCER
refractory  O
to  O
standard  O
treatment  O
,  O
performance  O
status  O
0-2  O
and  O
were  O
without  O
major  B-TOXI
organ  I-TOXI
dysfunction  I-TOXI
.  O

A  O
total  O
of  O
54  O
cycles  O
of  O
treatment  O
were  O
delivered  O
.  O

No  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
was  O
seen  O
in  O
the  O
first  O
cohort  O
of  O
three  O
patients  O
.  O

In  O
an  O
expanded  O
second  O
cohort  O
,  O
neutropenia  B-TOXI
was  O
the  O
main  O
DLT  O
,  O
occurring  O
in  O
the  O
first  O
cycle  O
of  O
treatment  O
in  O
five  O
of  O
12  O
patients  O
:  O
three  O
of  O
these  O
patients  O
and  O
one  O
additional  O
patient  O
also  O
experienced  O
dose-limiting  O
grade  O
3  O
transient  B-TOXI
rises  I-TOXI
in  I-TOXI
liver  I-TOXI
transaminases  I-TOXI
.  O

No  O
alopecia  B-TOXI
was  O
seen  O
and  O
one  O
patient  O
developed  O
clinically  O
significant  O
neuropathy  B-TOXI
.  O

One  O
partial  O
response  O
was  O
seen  O
in  O
a  O
patient  O
with  O
advanced  B-CANCER
adenocarcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
oesophago-gastric  I-CANCER
junction  I-CANCER
and  O
12  O
patients  O
had  O
stable  O
disease  O
with  O
a  O
median  O
time  O
to  O
progression  O
of  O
184  O
days  O
(  O
range  O
60-506  O
days  O
)  O
.  O

The  O
recommended  O
phase  O
II  O
dose  O
in  O
pretreated  O
patients  O
is  O
Carboplatin  B-DRUG
AUC  O
5  O
and  O
DHA-paclitaxel  B-DRUG
660  O
mg  O
m  O
(  O
-2  O
)  O
given  O
every  O
21  O
days  O
.  O

Further  O
studies  O
with  O
Carboplatin  B-DRUG
AUC  O
5  O
and  O
DHA-paclitaxel  B-DRUG
880  O
mg  O
m  O
(  O
-2  O
)  O
,  O
given  O
every  O
28  O
days  O
,  O
are  O
warranted  O
in  O
chemo-naive  O
patients  O
.  O

Randomised  O
phase  O
2  O
trial  O
of  O
SIR-Spheres  O
plus  O
fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
chemotherapy  O
versus  O
fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
chemotherapy  O
alone  O
in  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


Selective  O
internal  O
radiation  O
therapy  O
(  O
SIRT  O
)  O
with  O
SIR-Spheres  O
(  O
R  O
)  O
is  O
a  O
new  O
technique  O
for  O
selectively  O
targeting  O
high  O
doses  O
of  O
radiation  O
to  O
tumours  B-CANCER
within  I-CANCER
the  I-CANCER
liver  I-CANCER
.  O

The  O
primary  O
objectives  O
of  O
this  O
randomised  O
trial  O
were  O
to  O
compare  O
the  O
response  O
rate  O
,  O
time  O
to  O
progressive  B-TOXI
disease  I-TOXI
(  O
PD  O
)  O
,  O
and  O
toxicity  O
of  O
a  O
regimen  O
of  O
systemic  O
fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
chemotherapy  O
versus  O
the  O
same  O
chemotherapy  O
plus  O
a  O
single  O
administration  O
of  O
SIR-Spheres  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
liver  I-CANCER
metastases  I-CANCER
.  O

The  O
trial  O
was  O
designed  O
to  O
presage  O
a  O
larger  O
trial  O
that  O
would  O
have  O
survival  O
as  O
the  O
primary  O
outcome  O
.  O

Twenty-one  O
patients  O
with  O
previously  O
untreated  O
advanced  B-CANCER
colorectal  I-CANCER
liver  I-CANCER
metastases  I-CANCER
,  O
with  O
or  O
without  O
extrahepatic  B-CANCER
metastases  I-CANCER
,  O
were  O
randomised  O
into  O
the  O
study  O
.  O

Using  O
RECIST  O
criteria  O
,  O
the  O
response  O
rate  O
for  O
11  O
patients  O
receiving  O
the  O
combination  O
treatment  O
was  O
significantly  O
greater  O
than  O
for  O
10  O
patients  O
receiving  O
chemotherapy  O
alone  O
(  O
First  O
Integrated  O
Response  O
;  O
10  O
PR  O
,  O
1  O
SD  O
vs.  O
0  O
PR  O
,  O
6  O
SD  O
,  O
4  O
PD  O
,  O
P  O
&  O
lt  O
;  O
0.001  O
and  O
Best  O
Confirmed  O
Response  O
;  O
8  O
PR  O
,  O
3  O
SD  O
vs.  O
0  O
PR  O
,  O
6  O
SD  O
,  O
4  O
PD  O
P  O
&  O
lt  O
;  O
0.001  O
)  O
.  O

The  O
time  O
to  O
PD  O
was  O
greater  O
for  O
patients  O
receiving  O
the  O
combination  O
treatment  O
(  O
18.6  O
months  O
vs.  O
3.6  O
months  O
,  O
P  O
&  O
lt  O
;  O
0.0005  O
)  O
.  O

Median  O
survival  O
was  O
significantly  O
longer  O
for  O
patients  O
receiving  O
the  O
combination  O
treatment  O
(  O
29.4  O
months  O
vs.  O
12.8  O
months  O
,  O
P  O
=  O
0.02  O
)  O
.  O

One  O
patient  O
in  O
the  O
combination  O
arm  O
died  B-TOXI
from  O
chemotherapy  O
induced  O
neutropenic  B-TOXI
sepsis  I-TOXI
after  O
the  O
fourth  O
chemotherapy  O
cycle  O
.  O

There  O
were  O
more  O
Grade  O
3  O
and  O
4  O
toxicity  O
events  O
in  O
patients  O
receiving  O
the  O
combination  O
treatment  O
.  O

There  O
was  O
no  O
difference  O
in  O
quality-of-life  O
over  O
a  O
3  O
month  O
period  O
between  O
the  O
two  O
treatments  O
when  O
rated  O
by  O
patients  O
(  O
P  O
=  O
0.96  O
)  O
or  O
physicians  O
(  O
P  O
=  O
0.98  O
)  O
.  O

This  O
small  O
phase  O
2  O
randomised  O
trial  O
demonstrated  O
that  O
the  O
addition  O
of  O
a  O
single  O
administration  O
of  O
SIR-Spheres  O
to  O
a  O
regimen  O
of  O
systemic  O
fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
chemotherapy  O
significantly  O
increased  O
both  O
treatment  O
related  O
response  O
,  O
time  O
to  O
PD  O
,  O
and  O
survival  O
with  O
acceptable  O
toxicity  O
.  O

The  O
combination  O
of  O
SIR-Spheres  O
plus  O
systemic  O
chemotherapy  O
is  O
now  O
the  O
subject  O
of  O
ongoing  O
trials  O
to  O
further  O
define  O
patient  O
benefit  O
.  O

Randomized  O
multicenter  O
phase  O
II  O
trial  O
of  O
a  O
biweekly  O
regimen  O
of  O
fluorouracil  B-DRUG
and  O
leucovorin  B-DRUG
(  O
LV5FU2  B-DRUG
)  O
,  O
LV5FU2  B-DRUG
plus  O
cisplatin  B-DRUG
,  O
or  O
LV5FU2  B-DRUG
plus  O
irinotecan  B-DRUG
in  O
patients  O
with  O
previously  O
untreated  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
:  O
a  O
Federation  O
Francophone  O
de  O
Cancerologie  O
Digestive  O
Group  O
Study  O
--  O
FFCD  O
9803  O
.  O


To  O
determine  O
the  O
efficacy  O
and  O
safety  O
of  O
a  O
biweekly  O
regimen  O
of  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
plus  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
alone  O
or  O
in  O
combination  O
with  O
cisplatin  B-DRUG
or  O
irinotecan  B-DRUG
in  O
patients  O
with  O
previously  O
untreated  O
metastatic  B-DRUG
gastric  I-DRUG
adenocarcinoma  I-DRUG
and  O
to  O
select  O
the  O
best  O
arm  O
for  O
a  O
phase  O
III  O
study  O
.  O

One  O
hundred  O
thirty-six  O
patients  O
(  O
two  O
were  O
ineligible  O
)  O
were  O
enrolled  O
onto  O
the  O
randomized  O
multicenter  O
phase  O
II  O
trial  O
.  O

Patients  O
received  O
LV  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
2-hour  O
infusion  O
)  O
followed  O
by  O
FU  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
bolus  O
)  O
and  O
FU  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
22-hour  O
continuous  O
infusion  O
)  O
on  O
days  O
1  O
and  O
2  O
every  O
14  O
days  O
(  O
LV5FU2  B-DRUG
;  O
arm  O
A  O
)  O
,  O
LV5FU2  B-DRUG
plus  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
1-hour  O
infusion  O
)  O
on  O
day  O
1  O
or  O
2  O
(  O
arm  O
B  O
)  O
,  O
or  O
LV5FU2  B-DRUG
plus  O
irinotecan  B-DRUG
180  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
2-hour  O
infusion  O
)  O
on  O
day  O
1  O
(  O
arm  O
C  O
)  O
.  O

The  O
overall  O
response  O
rates  O
,  O
which  O
were  O
confirmed  O
by  O
an  O
independent  O
expert  O
panel  O
,  O
were  O
13  O
%  O
(  O
95  O
%  O
CI  O
,  O
3.4  O
%  O
to  O
23.3  O
%  O
)  O
,  O
27  O
%  O
(  O
95  O
%  O
CI  O
,  O
14.1  O
%  O
to  O
40.4  O
%  O
)  O
,  O
and  O
40  O
%  O
(  O
95  O
%  O
CI  O
,  O
25.7  O
%  O
to  O
54.3  O
%  O
)  O
for  O
arms  O
A  O
,  O
B  O
,  O
and  O
C  O
,  O
respectively  O
.  O

Median  O
progression-free  O
survival  O
and  O
overall  O
survival  O
times  O
were  O
3.2  O
months  O
(  O
95  O
%  O
CI  O
,  O
1.8  O
to  O
4.6  O
months  O
)  O
and  O
6.8  O
months  O
(  O
95  O
%  O
CI  O
,  O
2.6  O
to  O
11.1  O
months  O
)  O
with  O
LV5FU2  B-DRUG
,  O
respectively  O
;  O
4.9  O
months  O
(  O
95  O
%  O
CI  O
,  O
3.5  O
to  O
6.3  O
months  O
)  O
and  O
9.5  O
months  O
(  O
95  O
%  O
CI  O
,  O
6.9  O
to  O
12.2  O
months  O
)  O
with  O
LV5FU2-cisplatin  B-DRUG
,  O
respectively  O
;  O
and  O
6.9  O
months  O
(  O
95  O
%  O
CI  O
,  O
5.5  O
to  O
8.3  O
months  O
)  O
and  O
11.3  O
months  O
(  O
95  O
%  O
CI  O
,  O
9.3  O
to  O
13.3  O
months  O
)  O
with  O
LV5FU2-irinotecan  B-DRUG
,  O
respectively  O
.  O

Of  O
the  O
three  O
regimens  O
tested  O
,  O
the  O
combination  O
of  O
LV5FU2-irinotecan  B-DRUG
is  O
the  O
most  O
promising  O
and  O
will  O
be  O
assessed  O
in  O
a  O
phase  O
III  O
trial  O
.  O

Carboplatin  B-DRUG
/  I-DRUG
paclitaxel  I-DRUG
or  O
carboplatin  B-DRUG
/  I-DRUG
vinorelbine  I-DRUG
followed  O
by  O
accelerated  O
hyperfractionated  O
conformal  O
radiation  O
therapy  O
:  O
report  O
of  O
a  O
prospective  O
phase  O
I  O
dose  O
escalation  O
trial  O
from  O
the  O
Carolina  O
Conformal  O
Therapy  O
Consortium  O
.  O


To  O
prospectively  O
determine  O
the  O
maximum-tolerated  O
dose  O
of  O
accelerated  O
hyperfractionated  O
conformal  O
radiotherapy  O
(  O
RT  O
;  O
1.6  O
Gy  O
bid  O
)  O
for  O
unresectable  O
locally  B-CANCER
advanced  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
IIB  O
to  O
IIIA  O
/  O
B  O
)  O
following  O
induction  O
carboplatin  B-DRUG
/  I-DRUG
paclitaxel  I-DRUG
(  O
C  O
/  O
T  O
)  O
or  O
carboplatin  B-DRUG
/  I-DRUG
vinorelbine  I-DRUG
(  O
C  O
/  O
N  O
)  O
.  O

Induction  O
chemotherapy  O
,  O
C  O
/  O
T  O
or  O
C  O
/  O
N  O
,  O
was  O
followed  O
by  O
escalating  O
doses  O
of  O
conformally-planned  O
RT  O
(  O
73.6  O
to  O
86.4  O
Gy  O
in  O
6.4-Gy  O
increments  O
)  O
.  O

Concurrent  O
boost  O
methods  O
delivered  O
1.6  O
and  O
1.25  O
Gy  O
bid  O
to  O
the  O
gross  O
and  O
clinical  O
target  O
volumes  O
,  O
respectively  O
.  O

Between  O
November  O
1997  O
and  O
February  O
2002  O
,  O
44  O
patients  O
were  O
enrolled  O
(  O
median  O
age  O
,  O
59  O
years  O
;  O
59  O
%  O
male  O
;  O
stage  O
III  O
,  O
98  O
%  O
;  O
median  O
tumor  O
size  O
,  O
4  O
cm  O
)  O
.  O

Thirty-nine  O
patients  O
completed  O
induction  O
chemotherapy  O
:  O
19  O
had  O
a  O
partial  O
response  O
,  O
seven  O
progressed  O
,  O
15  O
had  O
no  O
response  O
,  O
and  O
three  O
were  O
not  O
assessable  O
.  O

Chemotherapy-associated  B-TOXI
toxicities  I-TOXI
were  O
similar  O
in  O
the  O
two  O
chemotherapy  O
groups  O
.  O

The  O
incidence  O
of  O
grade  O
&  O
gt  O
;  O
or  O
=  O
3  O
RT-induced  O
toxicity  O
was  O
1  O
/  O
13  O
,  O
2  O
/  O
14  O
,  O
and  O
4  O
/  O
12  O
at  O
73.6  O
,  O
80  O
,  O
and  O
86.4  O
Gy  O
,  O
respectively  O
,  O
thus  O
defining  O
the  O
maximum  O
tolerated  O
dose  O
at  O
approximately  O
80  O
Gy  O
.  O

Toxicities  O
were  O
in  O
both  O
lung  O
and  O
esophagus  O
and  O
were  O
similar  O
in  O
the  O
two  O
chemotherapy  O
arms  O
.  O

With  O
a  O
median  O
followup  O
of  O
34  O
months  O
in  O
the  O
survivors  O
,  O
the  O
actuarial  O
2-year  O
survival  O
was  O
47  O
%  O
,  O
the  O
median  O
survival  O
was  O
18  O
months  O
.  O

Fifteen  O
patients  O
had  O
tumor  B-TOXI
relapse  I-TOXI
:  O
5  O
local  O
failures  O
in  O
the  O
high-dose  O
volume  O
,  O
2  O
regional  O
failures  O
outside  O
of  O
the  O
high-dose  O
volume  O
,  O
and  O
8  O
distant  B-TOXI
metastases  I-TOXI
.  O

High-dose  O
conformal  O
twice-daily  O
radiation  O
therapy  O
to  O
approximately  O
80  O
Gy  O
appears  O
tolerable  O
in  O
well-selected  O
patients  O
with  O
unresectable  B-CANCER
lung  I-CANCER
cancer  I-CANCER
following  O
either  O
C  O
/  O
T  O
or  O
C  O
/  O
N.  O
Dose-limiting  O
toxicities  O
are  O
mainly  O
pulmonary  O
and  O
esophageal  O
.  O

Results  O
of  O
a  O
planned  O
interim  O
toxicity  O
analysis  O
with  O
trimodality  O
therapy  O
,  O
including  O
carboplatin  B-DRUG
AUC  O
=  O
4  O
,  O
paclitaxel  B-DRUG
,  O
5-fluorouracil  B-DRUG
,  O
amifostine  B-DRUG
,  O
and  O
radiation  O
for  O
locally  B-CANCER
advanced  I-CANCER
esophageal  I-CANCER
cancer  I-CANCER
:  O
preliminary  O
analyses  O
and  O
treatment  O
recommendations  O
from  O
the  O
North  O
Central  O
Cancer  O
Treatment  O
Group  O
.  O


PURPOSE  O
:  O
An  O
aggressive  O
trimodality  O
approach  O
from  O
the  O
Minnie  O
Pearl  O
Cancer  O
Research  O
Network  O
[  O
carboplatin  B-DRUG
AUC  O
=  O
6  O
,  O
days  O
1  O
and  O
22  O
;  O
5-fluorouracil  B-DRUG
225  O
mg  O
/  O
m2  O
continuous  O
infusion  O
,  O
days  O
1-42  O
,  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m2  O
,  O
days  O
1  O
and  O
22  O
;  O
45  O
Gy  O
]  O
has  O
resulted  O
in  O
remarkable  O
pathologic  O
response  O
rates  O
but  O
notable  O
toxicity  O
.  O

This  O
trial  O
was  O
designed  O
to  O
mitigate  O
this  O
toxicity  O
by  O
starting  O
with  O
a  O
lower  O
carboplatin  B-DRUG
dose  O
,  O
AUC  O
=  O
4  O
,  O
and  O
by  O
adding  O
subcutaneous  O
amifostine  B-DRUG
.  O

METHODS  O
:  O
This  O
phase  O
II  O
trial  O
included  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
,  I-CANCER
potentially  I-CANCER
resectable  I-CANCER
esophageal  I-CANCER
cancer  I-CANCER
.  O

All  O
were  O
to  O
receive  O
the  O
above  O
regimen  O
with  O
modifications  O
of  O
carboplatin  B-DRUG
AUC  O
=  O
4  O
and  O
amifostine  B-DRUG
500  O
mg  O
subcutaneously  O
before  O
radiation  O
.  O

All  O
were  O
then  O
to  O
undergo  O
an  O
esophagectomy  O
.  O

A  O
planned  O
interim  O
toxicity  O
analysis  O
after  O
the  O
first  O
10  O
patients  O
was  O
to  O
determine  O
whether  O
the  O
carboplatin  B-DRUG
dose  O
should  O
escalate  O
to  O
AUC  O
=  O
6.  O
RESULTS  O
:  O
Ten  O
patients  O
were  O
enrolled  O
,  O
and  O
all  O
required  O
dose  O
reductions  O
/  O
omissions  O
during  O
neoadjuvant  O
therapy  O
.  O

One  O
patient  O
died  B-TOXI
from  O
paclitaxel  B-TOXI
anaphylaxis  I-TOXI
.  O

Six  O
patients  O
manifested  O
a  O
complete  O
pathologic  O
response  O
.  O

CONCLUSION  O
:  O
With  O
this  O
regimen  O
,  O
carboplatin  B-DRUG
AUC  O
=  O
4  O
for  O
patients  O
with  O
locally  B-CANCER
advanced  I-CANCER
esophageal  I-CANCER
cancer  I-CANCER
is  O
appropriate  O
.  O

A  O
phase  O
IB  O
clinical  O
and  O
pharmacokinetic  O
study  O
of  O
the  O
angiogenesis  O
inhibitor  O
SU5416  O
and  O
paclitaxel  B-DRUG
in  O
recurrent  B-CANCER
or  I-CANCER
metastatic  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
.  O


SU5416  B-DRUG
is  O
a  O
novel  O
small  O
organic  O
molecule  O
that  O
non-competitively  O
inhibits  O
the  O
phosphorylation  O
of  O
the  O
VEGF  O
tyrosine  O
kinase  O
receptor  O
,  O
Flk-1  O
.  O

This  O
phase  O
IB  O
study  O
was  O
performed  O
to  O
determine  O
the  O
safety  O
,  O
pharmacokinetics  O
,  O
and  O
preliminary  O
efficacy  O
of  O
the  O
combination  O
of  O
SU5416  B-DRUG
and  O
paclitaxel  B-DRUG
in  O
recurrent  B-CANCER
or  I-CANCER
metastatic  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
.  O

Enrolled  O
in  O
the  O
study  O
were  O
12  O
patients  O
with  O
biopsy-proven  O
recurrent  B-CANCER
or  I-CANCER
metastatic  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
.  O

Six  O
patients  O
received  O
intravenous  O
SU5416  B-DRUG
110  O
mg  O
/  O
m2  O
on  O
days  O
1  O
,  O
15  O
,  O
18  O
,  O
22  O
and  O
25  O
,  O
and  O
paclitaxel  B-DRUG
70  O
mg  O
/  O
m2  O
on  O
days  O
8  O
,  O
15  O
and  O
22  O
.  O

Since  O
two  O
patients  O
experienced  O
a  O
dose-limiting  O
toxicity  O
(  O
DLT  O
)  O
in  O
cohort  O
1  O
,  O
the  O
next  O
six  O
patients  O
received  O
identical  O
treatment  O
as  O
above  O
except  O
the  O
paclitaxel  B-DRUG
dose  O
was  O
reduced  O
to  O
55  O
mg  O
/  O
m2  O
per  O
week  O
.  O

A  O
total  O
of  O
42  O
cycles  O
at  O
two  O
different  O
dose  O
levels  O
were  O
given  O
.  O

In  O
cohort  O
1  O
there  O
were  O
two  O
deep  B-TOXI
venous  I-TOXI
thromboses  I-TOXI
that  O
were  O
DLTs  O
.  O

In  O
the  O
second  O
cohort  O
there  O
was  O
a  O
DLT  O
consisting  O
of  O
a  O
transient  B-TOXI
ischemic  I-TOXI
attack  O
after  O
receiving  O
SU5416  B-DRUG
.  O

Most  O
of  O
the  O
other  O
toxicities  O
seen  O
were  O
grade  O
1  O
or  O
2  O
in  O
nature  O
and  O
consisted  O
of  O
headache  B-TOXI
,  O
facial  B-TOXI
flushing  I-TOXI
,  O
and  O
fatigue  B-TOXI
.  O

Two  O
patients  O
developed  O
extensive  O
ulcerative  B-TOXI
cavities  I-TOXI
at  O
sites  O
of  O
prior  O
radiation  O
.  O

There  O
were  O
no  O
significant  O
changes  O
in  O
the  O
pharmacokinetic  O
parameters  O
of  O
SU5416  B-DRUG
given  O
with  O
paclitaxel  B-DRUG
.  O

Four  O
patients  O
had  O
prolonged  O
freedom  O
from  O
progression  O
of  O
18  O
,  O
28  O
,  O
42  O
,  O
and  O
60  O
weeks  O
duration  O
.  O

The  O
combination  O
of  O
SU5416  B-DRUG
with  O
paclitaxel  B-DRUG
had  O
a  O
higher  O
than  O
expected  O
incidence  O
of  O
thromboembolic  B-TOXI
events  I-TOXI
and  O
prophylactic  B-TOXI
anticoagulation  I-TOXI
should  O
be  O
considered  O
for  O
future  O
trials  O
that  O
combine  O
an  O
angiogenesis  O
inhibitor  O
with  O
cytotoxic  O
chemotherapy  O
.  O

Although  O
the  O
future  O
development  O
of  O
SU5416  B-DRUG
as  O
a  O
chemotherapeutic  O
agent  O
is  O
unclear  O
,  O
there  O
was  O
a  O
clinical  O
benefit  O
seen  O
with  O
this  O
combination  O
in  O
36  O
%  O
of  O
the  O
patients  O
.  O

This  O
trial  O
supports  O
the  O
use  O
of  O
developing  O
antiangiogenic  O
combinations  O
,  O
using  O
molecular  O
targeted  O
agents  O
,  O
in  O
head  B-CANCER
and  I-CANCER
neck  I-CANCER
carcinoma  I-CANCER
.  O

Results  O
of  O
paclitaxel  B-DRUG
(  O
day  O
1  O
and  O
8  O
)  O
and  O
carboplatin  B-DRUG
given  O
on  O
every  O
three  O
weeks  O
in  O
advanced  O
(  O
stage  O
III-IV  O
)  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Both  O
paclitaxel  B-DRUG
(  O
P  O
)  O
and  O
carboplatin  B-DRUG
(  O
C  O
)  O
have  O
significant  O
activity  O
in  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

The  O
weekly  O
administration  O
of  O
P  O
is  O
active  O
,  O
dose  O
intense  O
,  O
and  O
has  O
a  O
favorable  O
toxicity  O
profile  O
.  O

We  O
retrospectively  O
reviewed  O
the  O
data  O
of  O
51  O
consecutive  O
patients  O
receiving  O
C  O
and  O
day  O
1  O
and  O
8  O
P  O
chemotherapy  O
(  O
CT  O
)  O
regimen  O
in  O
advanced  B-CANCER
stage  I-CANCER
NSCLC  I-CANCER
to  O
evaluate  O
the  O
efficacy  O
and  O
toxicity  O
.  O

Patients  O
treated  O
in  O
our  O
institutions  O
having  O
pathologically  O
proven  O
NSCLC  B-CANCER
,  O
no  O
CNS  O
metastases  O
,  O
adequate  O
organ  O
function  O
and  O
performance  O
status  O
(  O
PS  O
)  O
ECOG  O
0-2  O
were  O
given  O
P  O
112.5  O
mg  O
/  O
m2  O
intravenously  O
(  O
IV  O
)  O
over  O
1  O
hour  O
on  O
day  O
1  O
and  O
8  O
,  O
followed  O
by  O
C  O
AUC  O
5  O
IV  O
over  O
1  O
hour  O
,  O
repeated  O
in  O
every  O
three  O
weeks  O
.  O

PC  O
was  O
given  O
for  O
maximum  O
of  O
6  O
cycles  O
.  O

Median  O
age  O
was  O
58  O
(  O
age  O
range  O
39-77  O
)  O
and  O
41  O
patients  O
(  O
80  O
%  O
)  O
were  O
male  O
.  O

PS  O
was  O
0  O
/  O
1  O
/  O
2  O
in  O
29  O
/  O
17  O
/  O
5  O
patients  O
and  O
stage  O
was  O
IIIA  O
/  O
IIIB  O
/  O
IV  O
in  O
3  O
/  O
14  O
/  O
34  O
patients  O
respectively  O
.  O

The  O
median  O
number  O
of  O
cycles  O
administered  O
was  O
3  O
(  O
1-6  O
)  O
.  O

Seven  O
patients  O
(  O
14  O
%  O
)  O
did  O
not  O
complete  O
the  O
first  O
3  O
cycles  O
either  O
due  O
to  O
death  B-TOXI
,  O
progression  O
,  O
grade  O
3  O
hypersensitivity  B-TOXI
reactions  I-TOXI
to  O
P  O
or  O
lost  O
to  O
follow  O
up  O
.  O

Best  O
evaluable  O
response  O
was  O
partial  O
response  O
(  O
PR  O
)  O
in  O
45  O
%  O
and  O
stable  O
disease  O
(  O
SD  O
)  O
in  O
18  O
%  O
.  O

Twelve  O
patients  O
(  O
24  O
%  O
)  O
received  O
local  O
RT.  O
Thirteen  O
patients  O
(  O
25  O
%  O
)  O
received  O
2nd  O
line  O
CT  O
at  O
progression  O
.  O

At  O
a  O
median  O
follow-up  O
of  O
7  O
months  O
(  O
range  O
,  O
1-20  O
)  O
,  O
25  O
(  O
49  O
%  O
)  O
patients  O
died  B-TOXI
and  O
35  O
patients  O
(  O
69  O
%  O
)  O
progressed  O
.  O

Median  O
overall  O
survival  O
(  O
OS  O
)  O
was  O
11  O
+  O
/  O
-  O
2  O
months  O
(  O
95  O
%  O
CI  O
;  O
6  O
to  O
16  O
)  O
,  O
1-year  O
OS  O
ratio  O
was  O
44  O
%  O
.  O

Median  O
time  O
to  O
progression  O
(  O
TTP  O
)  O
was  O
6  O
+  O
/  O
-  O
1  O
months  O
(  O
95  O
%  O
CI  O
;  O
4  O
to  O
8  O
)  O
,  O
1-year  O
progression  O
free  O
survival  O
(  O
PFS  O
)  O
ratio  O
was  O
20  O
%  O
.  O

We  O
observed  O
following  O
grade  O
3  O
toxicities  O
:  O
asthenia  B-TOXI
(  O
10  O
%  O
)  O
,  O
neuropathy  B-TOXI
(  O
4  O
%  O
)  O
,  O
anorexia  B-TOXI
(  O
4  O
%  O
)  O
,  O
anemia  B-TOXI
(  O
4  O
%  O
)  O
,  O
hypersensitivity  B-TOXI
to  O
P  O
(  O
2  O
%  O
)  O
,  O
nausea  B-TOXI
/  I-TOXI
vomiting  I-TOXI
(  O
2  O
%  O
)  O
,  O
diarrhea  B-TOXI
(  O
2  O
%  O
)  O
and  O
neutropenia  B-TOXI
(  O
2  O
%  O
)  O
.  O

Two  O
patients  O
(  O
4  O
%  O
)  O
died  B-TOXI
of  I-TOXI
febrile  I-TOXI
neutropenia  I-TOXI
.  O

Doses  O
of  O
CT  O
were  O
reduced  O
or  O
delayed  O
in  O
12  O
patients  O
(  O
24  O
%  O
)  O
.  O

P  O
on  O
day  O
1  O
and  O
8  O
and  O
C  O
every  O
three  O
weeks  O
is  O
practical  O
and  O
fairly  O
well  O
tolerated  O
outpatient  O
regimen  O
.  O

This  O
regimen  O
seems  O
to  O
be  O
comparably  O
active  O
to  O
regimens  O
given  O
once  O
in  O
every  O
three  O
weeks  O
.  O

Rituximab  B-DRUG
in  O
combination  O
with  O
fludarabine  B-DRUG
chemotherapy  O
in  O
low-grade  O
or  O
follicular  B-CANCER
lymphoma  I-CANCER
.  O


To  O
evaluate  O
the  O
safety  O
and  O
efficacy  O
of  O
fludarabine  B-DRUG
plus  O
rituximab  B-DRUG
in  O
treatment-naive  O
or  O
relapsed  O
patients  O
with  O
low-grade  O
and  O
/  O
or  O
follicular  B-CANCER
non-Hodgkin  I-CANCER
's  I-CANCER
lymphoma  I-CANCER
.  O

This  O
was  O
an  O
open-label  O
,  O
single-arm  O
,  O
single-center  O
phase  O
II  O
study  O
enrolling  O
40  O
patients  O
.  O

During  O
the  O
first  O
week  O
of  O
the  O
study  O
,  O
patients  O
received  O
two  O
infusions  O
of  O
rituximab  B-DRUG
375  O
mg  O
/  O
m2  O
administered  O
4  O
days  O
apart  O
.  O

Seventy-two  O
hours  O
after  O
the  O
second  O
infusion  O
of  O
rituximab  B-DRUG
,  O
patients  O
received  O
the  O
first  O
of  O
six  O
cycles  O
of  O
fludarabine  B-DRUG
chemotherapy  O
(  O
25  O
mg  O
/  O
m2  O
/  O
d  O
for  O
5  O
days  O
on  O
a  O
28-day  O
cycle  O
)  O
.  O

Single  O
infusions  O
of  O
rituximab  B-DRUG
were  O
administered  O
72  O
hours  O
before  O
the  O
second  O
,  O
fourth  O
,  O
and  O
sixth  O
cycles  O
of  O
fludarabine  B-DRUG
,  O
and  O
two  O
infusions  O
of  O
rituximab  B-DRUG
were  O
given  O
4  O
weeks  O
after  O
the  O
last  O
cycle  O
of  O
fludarabine  B-DRUG
.  O

Treatment  O
duration  O
was  O
26  O
weeks  O
.  O

An  O
overall  O
response  O
rate  O
of  O
90  O
%  O
(  O
80  O
%  O
complete  O
response  O
rate  O
)  O
was  O
achieved  O
in  O
the  O
intent-to-treat  O
population  O
.  O

Similar  O
response  O
rates  O
were  O
seen  O
in  O
treatment-naive  O
and  O
previously  O
treated  O
patients  O
.  O

The  O
median  O
duration  O
of  O
response  O
has  O
not  O
been  O
reached  O
at  O
40+  O
months  O
.  O

The  O
median  O
follow-up  O
time  O
in  O
this  O
study  O
is  O
44  O
months  O
(  O
range  O
,  O
15  O
to  O
66  O
months  O
)  O
.  O

In  O
patients  O
positive  O
for  O
the  O
14  O
;  O
18  O
translocation  B-TOXI
in  I-TOXI
blood  I-TOXI
and  I-TOXI
/  I-TOXI
or  I-TOXI
marrow  I-TOXI
at  O
enrollment  O
,  O
molecular  O
remission  O
was  O
achieved  O
in  O
88  O
%  O
of  O
cases  O
,  O
with  O
patients  O
remaining  O
negative  O
for  O
up  O
to  O
4  O
years  O
to  O
date  O
.  O

Hematologic  B-TOXI
toxicity  I-TOXI
was  O
manageable  O
,  O
and  O
except  O
for  O
a  O
15  O
%  O
incidence  O
of  O
herpes  B-TOXI
simplex  I-TOXI
/  I-TOXI
zoster  I-TOXI
infections  I-TOXI
,  O
infectious  B-TOXI
complications  I-TOXI
were  O
rare  O
.  O

Nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
minimal  O
.  O

Rituximab  B-DRUG
plus  O
fludarabine  B-DRUG
was  O
well  O
tolerated  O
and  O
associated  O
with  O
an  O
excellent  O
complete  O
response  O
rate  O
,  O
including  O
molecular  O
remissions  O
,  O
in  O
patients  O
with  O
low-grade  O
or  O
follicular  B-CANCER
lymphoma  I-CANCER
.  O

Phase  O
III  O
study  O
of  O
matrix  B-DRUG
metalloproteinase  I-DRUG
inhibitor  O
prinomastat  B-DRUG
in  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Matrix  B-DRUG
metalloproteinases  I-DRUG
(  O
MMPs  B-DRUG
)  O
degrade  O
extracellular  O
proteins  O
and  O
facilitate  B-CANCER
tumor  I-CANCER
growth  O
,  O
invasion  O
,  O
metastasis  O
,  O
and  O
angiogenesis  O
.  O

This  O
trial  O
was  O
undertaken  O
to  O
determine  O
the  O
effect  O
of  O
prinomastat  O
,  O
an  O
inhibitor  O
of  O
selected  O
MMPs  B-DRUG
,  O
on  O
the  O
survival  O
of  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
,  O
when  O
given  O
in  O
combination  O
with  O
gemcitabine-cisplatin  B-DRUG
chemotherapy  O
.  O

Chemotherapy-naive  O
patients  O
were  O
randomly  O
assigned  O
to  O
receive  O
prinomastat  B-DRUG
15  O
mg  O
or  O
placebo  B-DRUG
twice  O
daily  O
orally  O
continuously  O
,  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
1,250  O
mg  O
/  O
m2  O
days  O
1  O
and  O
8  O
plus  O
cisplatin  B-DRUG
75  O
mg  O
/  O
m2  O
day  O
1  O
,  O
every  O
21  O
days  O
for  O
up  O
to  O
six  O
cycles  O
.  O

The  O
planned  O
sample  O
size  O
was  O
420  O
patients  O
.  O

Study  O
results  O
at  O
an  O
interim  O
analysis  O
and  O
lack  O
of  O
efficacy  O
in  O
another  O
phase  O
III  O
trial  O
prompted  O
early  O
closure  O
of  O
this  O
study  O
.  O

There  O
were  O
362  O
patients  O
randomized  O
(  O
181  O
on  O
prinomastat  B-DRUG
and  O
181  O
on  O
placebo  B-DRUG
)  O
.  O

One  O
hundred  O
thirty-four  O
patients  O
had  O
stage  O
IIIB  O
disease  O
with  O
T4  O
primary  O
tumor  O
,  O
193  O
had  O
stage  O
IV  O
disease  O
,  O
and  O
34  O
had  O
recurrent  O
disease  O
(  O
one  O
enrolled  O
patient  O
was  O
ineligible  O
with  O
stage  O
IIIA  O
disease  O
)  O
.  O

Overall  O
response  O
rates  O
for  O
the  O
two  O
treatment  O
arms  O
were  O
similar  O
(  O
27  O
%  O
for  O
prinomastat  B-DRUG
v  O
26  O
%  O
for  O
placebo  B-DRUG
;  O
P  O
=  O
.81  O
)  O
.  O

There  O
was  O
no  O
difference  O
in  O
overall  O
survival  O
or  O
time  O
to  O
progression  O
;  O
for  O
prinomastat  B-DRUG
versus  O
placebo  B-DRUG
patients  O
,  O
the  O
median  O
overall  O
survival  O
times  O
were  O
11.5  O
versus  O
10.8  O
months  O
(  O
P  O
=  O
.82  O
)  O
,  O
1-year  O
survival  O
rates  O
were  O
43  O
%  O
v  O
38  O
%  O
(  O
P  O
=  O
.45  O
)  O
,  O
and  O
progression-free  O
survival  O
times  O
were  O
6.1  O
v  O
5.5  O
months  O
(  O
P  O
=  O
.11  O
)  O
,  O
respectively  O
.  O

The  O
toxicities  O
of  O
prinomastat  B-DRUG
were  O
arthralgia  B-TOXI
,  O
stiffness  B-TOXI
,  O
and  O
joint  B-TOXI
swelling  I-TOXI
.  O

Treatment  O
interruption  O
was  O
required  O
in  O
38  O
%  O
of  O
prinomastat  B-DRUG
patients  O
and  O
12  O
%  O
of  O
placebo  B-DRUG
patients  O
.  O

Prinomastat  B-DRUG
does  O
not  O
improve  O
the  O
outcome  O
of  O
chemotherapy  O
in  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

Weekly  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
advanced  B-CANCER
transitional-cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
urothelium  I-CANCER
:  O
a  O
phase  O
II  O
Hoosier  O
Oncology  O
Group  O
study  O
.  O


To  O
evaluate  O
the  O
efficacy  O
and  O
toxicity  O
of  O
weekly  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
transitional-cell  I-CANCER
carcinoma  I-CANCER
(  I-CANCER
TCC  I-CANCER
)  I-CANCER
of  I-CANCER
the  I-CANCER
urothelial  I-CANCER
tract  I-CANCER
.  O

Patients  O
with  O
advanced  O
unresectable  O
TCC  B-CANCER
were  O
enrolled  O
onto  O
this  O
multicenter  O
,  O
community-based  O
,  O
phase  O
II  O
trial  O
.  O

Initially  O
,  O
patients  O
were  O
treated  O
with  O
paclitaxel  B-DRUG
110  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
by  O
intravenous  O
infusion  O
on  O
days  O
1  O
,  O
8  O
,  O
and  O
15  O
every  O
28  O
days  O
.  O

Patients  O
who  O
had  O
an  O
objective  O
response  O
or  O
stable  O
disease  O
continued  O
treatment  O
for  O
a  O
maximum  O
of  O
six  O
courses  O
.  O

Paclitaxel  B-DRUG
was  O
decreased  O
to  O
90  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
gemcitabine  B-DRUG
was  O
decreased  O
to  O
800  O
mg  O
/  O
m  O
(  O
2  O
)  O
for  O
the  O
last  O
12  O
patients  O
because  O
of  O
a  O
concerning  O
incidence  O
of  O
pulmonary  B-TOXI
toxicity  I-TOXI
in  O
the  O
first  O
24  O
patients  O
.  O

Thirty-six  O
patients  O
were  O
enrolled  O
between  O
September  O
1998  O
and  O
March  O
2003  O
.  O

Twenty-four  O
patients  O
received  O
the  O
higher  O
doses  O
of  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
,  O
and  O
12  O
patients  O
received  O
the  O
lower  O
doses  O
.  O

Twenty-five  O
(  O
69.4  O
%  O
)  O
of  O
36  O
patients  O
had  O
major  O
responses  O
to  O
treatment  O
,  O
including  O
15  O
patients  O
(  O
41.7  O
%  O
)  O
with  O
complete  O
responses  O
.  O

With  O
a  O
median  O
follow-up  O
time  O
of  O
38.7  O
months  O
,  O
the  O
median  O
survival  O
time  O
was  O
15.8  O
months  O
.  O

Grade  O
3  O
and  O
4  O
toxicities  O
included  O
granulocytopenia  B-TOXI
(  O
36.1  O
%  O
)  O
,  O
thrombocytopenia  B-TOXI
(  O
8.3  O
%  O
)  O
,  O
and  O
neuropathy  B-TOXI
(  O
16.7  O
%  O
)  O
.  O

Five  O
patients  O
(  O
13.9  O
%  O
)  O
had  O
grades  O
3  O
to  O
5  O
pulmonary  B-TOXI
toxicity  I-TOXI
,  O
and  O
one  O
patient  O
had  O
grade  O
2  O
pulmonary  B-TOXI
toxicity  I-TOXI
.  O

Weekly  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
is  O
an  O
active  O
regimen  O
in  O
the  O
treatment  O
of  O
patients  O
with  O
advanced  B-CANCER
TCC  I-CANCER
.  O

However  O
,  O
because  O
of  O
the  O
high  O
incidence  O
of  O
pulmonary  B-TOXI
toxicity  I-TOXI
associated  O
with  O
this  O
schedule  O
of  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
,  O
we  O
recommend  O
against  O
the  O
use  O
of  O
this  O
regimen  O
in  O
this  O
patient  O
population  O
.  O

Irinotecan  B-DRUG
plus  O
oxaliplatin  B-DRUG
and  O
leucovorin-modulated  B-DRUG
fluorouracil  I-DRUG
in  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
--  O
a  O
Groupe  O
Tumeurs  O
Digestives  O
of  O
the  O
Federation  O
Nationale  O
des  O
Centres  O
de  O
Lutte  O
Contre  O
le  O
Cancer  O
study  O
.  O


To  O
evaluate  O
response  O
rate  O
and  O
toxicity  O
of  O
irinotecan  B-DRUG
and  O
oxaliplatin  B-DRUG
plus  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
and  O
leucovorin  B-DRUG
(  O
Folfirinox  B-DRUG
)  O
in  O
advanced  B-CANCER
pancreatic  I-CANCER
adenocarcinoma  I-CANCER
(  O
APA  B-CANCER
)  O
.  O

Chemotherapy-naive  O
patients  O
with  O
histologically  O
proven  O
APA  B-CANCER
and  O
bidimensionally  O
measurable  O
disease  O
were  O
treated  O
with  O
Folfirinox  B-DRUG
therapy  O
every  O
2  O
weeks  O
,  O
which  O
comprised  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
irinotecan  B-DRUG
180  O
mg  O
/  O
m  O
(  O
2  O
)  O
plus  O
leucovorin  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
followed  O
by  O
bolus  O
FU  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
1  O
,  O
then  O
FU  B-DRUG
2,400  O
mg  O
/  O
m  O
(  O
2  O
)  O
as  O
a  O
46-hour  O
continuous  O
infusion  O
.  O

Quality  O
of  O
life  O
(  O
QOL  O
)  O
was  O
assessed  O
using  O
European  O
Organisation  O
for  O
Research  O
and  O
Treatment  O
of  O
Cancer  O
Quality  O
of  O
Life  O
Questionnaire  O
C30  O
(  O
EORTC  O
QLQ-C30  O
)  O
.  O

Forty-seven  O
patients  O
were  O
entered  O
,  O
and  O
46  O
received  O
treatment  O
.  O

Thirty-five  O
patients  O
(  O
76  O
%  O
)  O
had  O
metastatic  B-TOXI
disease  I-TOXI
.  O

A  O
total  O
of  O
356  O
cycles  O
were  O
delivered  O
,  O
with  O
a  O
median  O
of  O
eight  O
cycles  O
per  O
patient  O
(  O
range  O
,  O
one  O
to  O
24  O
cycles  O
)  O
.  O

All  O
patients  O
were  O
assessable  O
for  O
safety  O
.  O

No  O
toxic  B-TOXI
death  I-TOXI
occurred  O
.  O

Grade  O
3  O
to  O
4  O
neutropenia  B-TOXI
occurred  O
in  O
52  O
%  O
of  O
patients  O
,  O
including  O
two  O
patients  O
with  O
febrile  B-TOXI
neutropenia  I-TOXI
.  O

Other  O
relevant  O
toxicities  O
included  O
grade  O
3  O
to  O
4  O
nausea  B-TOXI
(  O
20  O
%  O
)  O
,  O
vomiting  B-TOXI
(  O
17  O
%  O
)  O
,  O
and  O
diarrhea  B-TOXI
(  O
17  O
%  O
)  O
and  O
grade  O
3  O
neuropathy  B-TOXI
(  O
15  O
%  O
;  O
Levi  O
's  O
scale  O
)  O
.  O

The  O
confirmed  O
response  O
rate  O
was  O
26  O
%  O
(  O
95  O
%  O
CI  O
,  O
13  O
%  O
to  O
39  O
%  O
)  O
,  O
including  O
4  O
%  O
complete  O
responses  O
.  O

Median  O
time  O
to  O
progression  O
was  O
8.2  O
months  O
(  O
95  O
%  O
CI  O
,  O
5.3  O
to  O
11.6  O
months  O
)  O
,  O
and  O
median  O
overall  O
survival  O
was  O
10.2  O
months  O
(  O
95  O
%  O
CI  O
,  O
8.1  O
to  O
14.4  O
months  O
)  O
.  O

Between  O
baseline  O
and  O
end  O
of  O
treatment  O
,  O
patients  O
had  O
improvement  O
in  O
all  O
functional  O
scales  O
of  O
the  O
EORTC  O
QLQ-C30  O
,  O
except  O
cognitive  O
functioning  O
.  O

Responders  O
had  O
major  O
improvement  O
in  O
global  O
QOL  O
.  O

With  O
a  O
good  O
safety  O
profile  O
,  O
a  O
promising  O
response  O
rate  O
,  O
and  O
an  O
improvement  O
in  O
QOL  O
,  O
Folfirinox  B-DRUG
will  O
be  O
further  O
assessed  O
in  O
a  O
phase  O
III  O
trial  O
.  O

Docetaxel  B-DRUG
(  O
Taxotere  B-DRUG
)  O
,  O
cisplatin  B-DRUG
,  O
UFT  B-DRUG
,  O
and  O
leucovorin  B-DRUG
combination  O
chemotherapy  O
in  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


We  O
conducted  O
this  O
study  O
to  O
ascertain  O
the  O
efficacy  O
and  O
toxicity  O
of  O
docetaxel  B-DRUG
and  O
cisplatin  B-DRUG
combined  O
with  O
oral  O
UFT  B-DRUG
and  O
leucovorin  B-DRUG
as  O
a  O
first-line  O
treatment  O
for  O
patients  O
with  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

In  O
all  O
,  O
52  O
patients  O
received  O
courses  O
of  O
docetaxel  B-DRUG
60  O
mg  O
m  O
(  O
-2  O
)  O
intravenously  O
(  O
i.v.  O
)  O
for  O
1  O
h  O
and  O
then  O
cisplatin  B-DRUG
75  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
for  O
2  O
h  O
on  O
day  O
1.  O
Oral  O
UFT  B-DRUG
at  O
400-600  O
mg  O
day  O
(  O
-1  O
)  O
,  O
as  O
determined  O
by  O
body  O
surface  O
area  O
,  O
and  O
leucovorin  B-DRUG
at  O
75  O
mg  O
day  O
(  O
-1  O
)  O
were  O
administered  O
for  O
21  O
consecutive  O
days  O
from  O
day  O
1  O
,  O
and  O
this  O
was  O
followed  O
by  O
a  O
7-day  O
drug-free  O
interval  O
.  O

A  O
total  O
of  O
225  O
courses  O
were  O
administered  O
,  O
and  O
the  O
median  O
number  O
of  O
courses  O
per  O
patient  O
was  O
four  O
.  O

Four  O
complete  O
responses  O
(  O
7.7  O
%  O
)  O
and  O
22  O
partial  O
responses  O
(  O
42.3  O
%  O
)  O
were  O
achieved  O
,  O
giving  O
an  O
overall  O
response  O
rate  O
of  O
50  O
%  O
(  O
95  O
%  O
Confidence  O
Interval  O
:  O
36.4-63.6  O
%  O
)  O
.  O

The  O
major  O
toxicity  O
was  O
neutropenia  B-TOXI
,  O
which  O
reached  O
grade  O
3  O
/  O
4  O
in  O
36  O
patients  O
(  O
69.3  O
%  O
)  O
.  O

Grade  O
3  O
/  O
4  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
was  O
observed  O
in  O
12  O
patients  O
(  O
23.1  O
%  O
)  O
.  O

Median  O
time  O
to  O
progression  O
was  O
22  O
weeks  O
(  O
4  O
to  O
156+  O
weeks  O
)  O
,  O
median  O
survival  O
duration  O
was  O
48  O
weeks  O
(  O
4  O
to  O
156+  O
weeks  O
)  O
,  O
and  O
median  O
response  O
duration  O
was  O
24  O
weeks  O
(  O
6-152  O
weeks  O
)  O
.  O

We  O
conclude  O
that  O
docetaxel  B-DRUG
,  O
cisplatin  B-DRUG
,  O
oral  O
UFT  B-DRUG
,  O
and  O
leucovorin  B-DRUG
combination  O
chemotherapy  O
is  O
effective  O
and  O
tolerable  O
for  O
the  O
treatment  O
of  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

The  O
evaluation  O
of  O
amifostine  B-DRUG
for  O
mucosal  O
protection  O
in  O
patients  O
with  O
advanced  B-CANCER
loco-regional  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinomas  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
(  O
SCCHN  B-CANCER
)  O
treated  O
with  O
concurrent  O
weekly  O
carboplatin  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
daily  O
radiotherapy  O
(  O
RT  O
)  O
.  O


Concurrent  O
chemotherapy  O
and  O
radiation  O
has  O
improved  O
the  O
outcome  O
for  O
patients  O
presenting  O
with  O
locally  B-CANCER
advanced  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinomas  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
(  O
SCCHN  B-CANCER
)  O
.  O

These  O
improvements  O
have  O
come  O
at  O
a  O
cost  O
of  O
increased  O
treatment-related  B-TOXI
toxicities  I-TOXI
.  O

We  O
previously  O
reported  O
the  O
results  O
of  O
a  O
phase  O
II  O
trial  O
examining  O
the  O
role  O
of  O
concurrent  O
carboplatin  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
daily  O
radiotherapy  O
(  O
RT  O
)  O
in  O
SCCHN  B-CANCER
.  O

In  O
an  O
attempt  O
to  O
decrease  O
these  O
side  O
effects  O
,  O
we  O
conducted  O
a  O
prospective  O
phase  O
II  O
trial  O
evaluating  O
the  O
role  O
of  O
amifostine  B-DRUG
(  O
Ethyol  O
,  O
MedImmune  O
Oncology  O
,  O
Inc  O
,  O
Gaithersburg  O
,  O
MD  O
)  O
in  O
patients  O
treated  O
with  O
this  O
concurrent  O
chemoRT  O
scheme  O
.  O

From  O
April  O
2002  O
to  O
September  O
2004  O
,  O
19  O
patients  O
with  O
stage  O
III-IV  O
SCCHN  B-CANCER
were  O
enrolled  O
on  O
a  O
prospective  O
phase  O
II  O
trial  O
.  O

Treatment  O
consisted  O
of  O
daily  O
RT  O
delivered  O
to  O
70.2  O
Gy  O
(  O
1.8  O
Gy  O
/  O
fx  O
)  O
with  O
amifostine  B-DRUG
500  O
mg  O
IV  O
(  O
&  O
lt  O
;  O
1  O
hour  O
before  O
RT  O
)  O
,  O
and  O
concurrent  O
weekly  O
carboplatin  B-DRUG
(  O
100  O
mg  O
/  O
m2  O
)  O
and  O
paclitaxel  B-DRUG
(  O
40  O
mg  O
/  O
m2  O
)  O
.  O

Median  O
age  O
was  O
58.5  O
years  O
(  O
range  O
,  O
48  O
to  O
70  O
years  O
)  O
;  O
male  O
to  O
female  O
ratio  O
was  O
,  O
83  O
%  O
:17  O
%  O
;  O
Caucasian  O
versus  O
other  O
was  O
,  O
61  O
%  O
/  O
39  O
%  O
.  O

Tumor  O
characteristics  O
based  O
on  O
histology  O
were  O
:  O
primary  O
cancers  B-CANCER
of  I-CANCER
the  I-CANCER
oropharynx  I-CANCER
(  O
55.6  O
%  O
)  O
;  O
supraglottic  B-CANCER
larynx  I-CANCER
(  O
16.7  O
%  O
)  O
;  O
hypopharynx  O
(  O
16.7  O
%  O
)  O
;  O
oral  O
cavity  O
(  O
5.6  O
%  O
)  O
;  O
and  O
unknown  O
primaries  O
(  O
5.6  O
%  O
)  O
.  O

All  O
patients  O
presented  O
with  O
locally  O
advanced  O
,  O
unresectable  O
disease  O
T4  O
(  O
50  O
%  O
)  O
,  O
T3  O
(  O
27.8  O
%  O
)  O
,  O
and  O
advanced  B-CANCER
nodal  I-CANCER
disease  I-CANCER
(  O
N2b-N3  O
)  O
(  O
78  O
%  O
)  O
.  O

Toxicities  O
were  O
measured  O
weekly  O
during  O
treatment  O
and  O
at  O
each  O
follow-up  O
visit  O
.  O

Disease  O
response  O
to  O
therapy  O
was  O
determined  O
2  O
months  O
after  O
completion  O
of  O
therapy  O
.  O

Seventeen  O
patients  O
are  O
evaluable  O
for  O
response  O
and  O
survival  O
at  O
2  O
months  O
following  O
completion  O
of  O
RT.  O
Eighty-four  O
percent  O
completed  O
the  O
prescribed  O
radiation  O
treatment  O
,  O
and  O
84  O
%  O
of  O
patients  O
received  O
more  O
than  O
six  O
cycles  O
of  O
chemotherapy  O
.  O

The  O
median  O
number  O
of  O
missed  O
chemotherapy  O
cycles  O
was  O
1.5  O
(  O
range  O
,  O
0  O
to  O
5  O
cycles  O
)  O
.  O

Fifty-six  O
percent  O
of  O
patients  O
received  O
more  O
than  O
90  O
%  O
of  O
prescribed  O
amifostine  B-DRUG
doses  O
,  O
with  O
chemoRT-related  B-TOXI
toxicity  I-TOXI
being  O
the  O
most  O
common  O
reason  O
for  O
withholding  O
the  O
dose  O
(  O
77  O
%  O
)  O
.  O

Median  O
doses  O
of  O
missed  O
amifostine  B-DRUG
were  O
three  O
(  O
range  O
,  O
0  O
to  O
30  O
doses  O
)  O
.  O

Grade  O
3  O
toxicities  O
associated  O
with  O
therapy  O
were  O
:  O
mucositis  B-TOXI
and  O
dysphagia  B-TOXI
(  O
40  O
%  O
of  O
patients  O
each  O
)  O
,  O
dehydration  B-TOXI
(  O
27  O
%  O
)  O
,  O
xerostomia  B-TOXI
(  O
20  O
%  O
)  O
,  O
and  O
dermatitis  B-TOXI
(  O
20  O
%  O
)  O
;  O
53  O
%  O
of  O
patients  O
experienced  O
grade  O
3  O
leukopenia  B-TOXI
,  O
while  O
grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
developed  O
in  O
20  O
%  O
/  O
13  O
%  O
.  O

No  O
grade  O
4  O
/  O
5  O
nonhematologic  B-TOXI
toxicities  I-TOXI
were  O
encountered  O
.  O

Forty  O
percent  O
of  O
patients  O
completed  O
RT  O
without  O
unscheduled  O
treatment  O
breaks  O
secondary  O
to  O
treatment-related  B-TOXI
toxicity  I-TOXI
.  O

Median  O
treatment-break  O
time  O
was  O
5  O
days  O
(  O
range  O
,  O
0  O
to  O
20  O
days  O
)  O
.  O

Clinical  O
complete  O
response  O
at  O
both  O
the  O
primary  O
site  O
of  O
disease  O
and  O
neck  O
was  O
achieved  O
in  O
75  O
%  O
of  O
patients  O
2  O
months  O
following  O
completion  O
of  O
RT.  O
Weekly  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
administered  O
concurrently  O
with  O
definitive  O
RT  O
and  O
daily  O
amifostine  O
is  O
well  O
tolerated  O
,  O
with  O
over  O
85  O
%  O
of  O
patients  O
completing  O
therapy  O
with  O
acceptable  O
toxicity  O
.  O

The  O
addition  O
of  O
amifostine  B-DRUG
appears  O
to  O
decrease  O
treatment-related  B-TOXI
toxicity  I-TOXI
without  O
impacting  O
efficacy  O
.  O

Initial  O
experience  O
from  O
a  O
combination  O
of  O
systemic  O
and  O
regional  O
chemotherapy  O
in  O
the  O
treatment  O
of  O
patients  O
with  O
nonresectable  O
cholangiocellular  B-CANCER
carcinoma  I-CANCER
in  I-CANCER
the  I-CANCER
liver  I-CANCER
.  O


In  O
nonresectable  O
cholangiocellular  B-CANCER
carcinoma  I-CANCER
(  O
CCC  B-CANCER
)  O
therapeutic  O
options  O
are  O
limited  O
.  O

Recently  O
,  O
systemic  O
chemotherapy  O
has  O
shown  O
response  O
rates  O
of  O
up  O
to  O
30  O
%  O
.  O

Additional  O
regional  O
therapy  O
of  O
the  O
arterially  B-CANCER
hyper  I-CANCER
vascularized  I-CANCER
hepatic  I-CANCER
tumors  I-CANCER
might  O
represent  O
a  O
rational  O
approach  O
in  O
an  O
attempt  O
to  O
further  O
improve  O
response  O
and  O
palliation  O
.  O

Hence  O
,  O
a  O
protocol  O
combining  O
transarterial  O
chemoembolization  O
and  O
systemic  O
chemotherapy  O
was  O
applied  O
in  O
patients  O
with  O
CCC  B-CANCER
limited  I-CANCER
to  I-CANCER
the  I-CANCER
liver  I-CANCER
.  O

Eight  O
patients  O
(  O
6  O
women  O
,  O
2  O
men  O
,  O
mean  O
age  O
62  O
years  O
)  O
with  O
nonresectable  O
CCC  B-CANCER
received  O
systemic  O
chemotherapy  O
(  O
gemcitabine  B-DRUG
1  O
000  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
and  O
additional  O
transarterial  O
chemoembolization  O
procedures  O
(  O
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
cisplatin  B-DRUG
,  O
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
doxorubicin  B-DRUG
,  O
up  O
to  O
600  O
mg  O
degradable  O
starch  O
microspheres  O
)  O
.  O

Clinical  O
follow-up  O
of  O
patients  O
,  O
tumor  O
markers  O
,  O
CT  O
and  O
ultrasound  O
were  O
performed  O
to  O
evaluate  O
maximum  O
response  O
and  O
toxicity  O
.  O

Both  O
systemic  O
and  O
regional  O
therapies  O
were  O
tolerated  O
well  O
;  O
no  O
severe  O
toxicity  O
(  O
WHO  O
III  O
/  O
IV  O
)  O
was  O
encountered  O
.  O

Nausea  B-TOXI
and  O
fever  B-TOXI
were  O
the  O
most  O
commonly  O
observed  O
side  O
effects  O
.  O

A  O
progressive  O
rarefication  O
of  O
the  O
intrahepatic  O
arteries  O
limited  O
the  O
maximum  O
number  O
of  O
chemoembolization  O
procedures  O
in  O
4  O
patients  O
.  O

A  O
median  O
of  O
2  O
chemoembolization  O
cycles  O
(  O
range  O
,  O
1-3  O
)  O
and  O
a  O
median  O
of  O
6.5  O
gemcitabine  B-DRUG
cycles  O
(  O
range  O
,  O
4-11  O
)  O
were  O
administered  O
.  O

Complete  O
responses  O
were  O
not  O
achieved  O
.  O

As  O
maximum  O
response  O
,  O
partial  O
responses  O
were  O
achieved  O
in  O
3  O
cases  O
,  O
stable  O
diseases  O
in  O
5  O
cases  O
.  O

Two  O
patients  O
died  B-TOXI
from  I-TOXI
progressive  I-TOXI
disease  I-TOXI
after  O
9  O
and  O
10  O
mo.  O
Six  O
patients  O
are  O
still  O
alive  O
.  O

The  O
current  O
median  O
survival  O
is  O
12  O
mo  O
(  O
range  O
,  O
9-18  O
)  O
;  O
the  O
median  O
time  O
to  O
tumor  O
progression  O
is  O
7  O
mo  O
(  O
range  O
,  O
3-18  O
)  O
.  O

Seven  O
patients  O
suffered  O
from  O
tumor-related  O
symptoms  O
prior  O
to  O
therapy  O
,  O
3  O
of  O
these  O
experienced  O
a  O
treatment-related  O
clinical  O
relief  O
.  O

In  O
one  O
patient  O
the  O
tumor  O
became  O
resectable  O
under  O
therapy  O
and  O
was  O
successfully  O
removed  O
after  O
10  O
mo.  O
The  O
present  O
results  O
indicate  O
that  O
a  O
combination  O
of  O
systemic  O
gemcitabine  B-DRUG
therapy  O
and  O
repeated  O
regional  O
chemoembolizations  O
is  O
well  O
tolerated  O
and  O
may  O
enhance  O
the  O
effect  O
of  O
palliation  O
in  O
a  O
selected  O
group  O
of  O
patients  O
with  O
intrahepatic  O
nonresectable  O
CCC  B-CANCER
.  O

Australian  O
experience  O
of  O
a  O
modified  O
schedule  O
of  O
FOLFOX  B-DRUG
with  O
high  O
activity  O
and  O
tolerability  O
and  O
improved  O
convenience  O
in  O
untreated  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
patients  O
.  O


This  O
study  O
determined  O
the  O
efficacy  O
and  O
safety  O
of  O
a  O
modified  O
FOLFOX  B-DRUG
regimen  O
that  O
improved  O
patient  O
convenience  O
without  O
compromising  O
oxaliplatin  B-DRUG
dose  O
intensity  O
.  O

A  O
total  O
of  O
62  O
patients  O
with  O
previously  O
untreated  O
metastatic  B-DRUG
colorectal  I-DRUG
cancer  I-DRUG
were  O
enrolled  O
to  O
receive  O
,  O
entirely  O
as  O
outpatients  O
,  O
2-weekly  O
cycles  O
of  O
oxaliplatin  B-DRUG
100  O
mg  O
m  O
(  O
-2  O
)  O
i.v.  O
over  O
2  O
h  O
,  O
together  O
with  O
leucovorin  B-DRUG
400  O
mg  O
m  O
(  O
-2  O
)  O
over  O
2  O
h  O
,  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
400  O
mg  O
m  O
(  O
-2  O
)  O
,  O
bolus  O
,  O
followed  O
by  O
a  O
46-h  O
infusion  O
of  O
5-FU  B-DRUG
at  O
2.4  O
g  O
m  O
(  O
-2  O
)  O
.  O

Treatment  O
was  O
given  O
until  O
progression  B-TOXI
or  I-TOXI
unmanageable  I-TOXI
toxicity  I-TOXI
.  O

In  O
all  O
,  O
61  O
patients  O
received  O
&  O
gt  O
;  O
or  O
=one  O
oxaliplatin  B-DRUG
dose  O
and  O
a  O
median  O
of  O
11  O
treatment  O
cycles  O
(  O
range  O
1-20  O
cycles  O
)  O
;  O
22  O
(  O
36  O
%  O
)  O
reported  O
grade  O
3  O
/  O
4  O
neutropenia  B-TOXI
and  O
13  O
patients  O
(  O
21  O
%  O
)  O
experienced  O
grade  O
3  O
neurotoxicity  B-TOXI
;  O
16  O
patients  O
(  O
26  O
%  O
)  O
discontinued  O
treatment  O
due  O
to  O
disease  B-TOXI
progression  I-TOXI
or  O
death  B-TOXI
,  O
15  O
(  O
25  O
%  O
)  O
due  O
to  O
neurotoxicity  B-TOXI
and  O
six  O
(  O
10  O
%  O
)  O
due  O
to  O
haematological  B-TOXI
toxicity  I-TOXI
.  O

Of  O
the  O
56  O
eligible  O
patients  O
,  O
complete  O
or  O
partial  O
responses  O
were  O
observed  O
in  O
29  O
or  O
52  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
38-65  O
%  O
)  O
.  O

Median  O
progression-free  O
survival  O
was  O
8.2  O
months  O
(  O
7.1-9.9  O
)  O
and  O
median  O
overall  O
survival  O
was  O
18.7  O
months  O
(  O
14.0-23.4  O
)  O
.  O

In  O
our  O
experience  O
,  O
a  O
modified  O
schedule  O
of  O
FOLFOX  B-DRUG
improves  O
convenience  O
without  O
compromising  O
efficacy  O
or  O
toxicity  O
.  O

Chemoimmunotherapy  O
with  O
fludarabine  B-DRUG
,  O
cyclophosphamide  B-DRUG
,  O
and  O
rituximab  B-DRUG
for  O
relapsed  O
and  O
refractory  O
chronic  B-CANCER
lymphocytic  I-CANCER
leukemia  I-CANCER
.  O


The  O
efficacy  O
,  O
toxicity  O
,  O
and  O
tolerability  O
of  O
chemoimmunotherapy  O
with  O
the  O
combination  O
of  O
fludarabine  B-DRUG
,  O
cyclophosphamide  B-DRUG
,  O
and  O
rituximab  B-DRUG
(  O
FCR  B-DRUG
)  O
were  O
evaluated  O
in  O
previously  O
treated  O
patients  O
with  O
chronic  B-CANCER
lymphocytic  I-CANCER
leukemia  I-CANCER
(  O
CLL  B-CANCER
)  O
.  O

The  O
purpose  O
of  O
this  O
study  O
was  O
to  O
improve  O
the  O
complete  O
remission  O
(  O
CR  O
)  O
rate  O
for  O
previously  O
treated  O
patients  O
and  O
evaluate  O
the  O
quality  O
of  O
bone  O
marrow  O
response  O
.  O

One  O
hundred  O
seventy-seven  O
previously  O
treated  O
patients  O
with  O
CLL  B-CANCER
were  O
evaluated  O
.  O

Treatment  O
consisted  O
of  O
rituximab  B-DRUG
375  O
mg  O
/  O
m  O
(  O
2  O
)  O
day  O
1  O
of  O
course  O
1  O
and  O
500  O
mg  O
/  O
m  O
(  O
2  O
)  O
day  O
1  O
of  O
courses  O
2  O
to  O
6  O
;  O
fludarabine  B-DRUG
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
days  O
2  O
to  O
4  O
of  O
course  O
1  O
and  O
days  O
1  O
to  O
3  O
of  O
courses  O
2  O
to  O
6  O
;  O
and  O
cyclophosphamide  B-DRUG
250  O
mg  O
/  O
m  O
(  O
2  O
)  O
/  O
d  O
days  O
2  O
to  O
4  O
of  O
course  O
1  O
and  O
days  O
1  O
to  O
3  O
of  O
courses  O
2  O
to  O
6.  O
Courses  O
were  O
repeated  O
every  O
4  O
weeks  O
.  O

CR  O
was  O
achieved  O
in  O
25  O
%  O
of  O
177  O
patients  O
,  O
and  O
nodular  O
partial  O
remission  O
and  O
partial  O
remission  O
were  O
achieved  O
in  O
16  O
%  O
and  O
32  O
%  O
of  O
patients  O
,  O
respectively  O
;  O
the  O
overall  O
response  O
rate  O
was  O
73  O
%  O
.  O

Twelve  O
(  O
32  O
%  O
)  O
of  O
37  O
complete  O
responders  O
tested  O
achieved  O
molecular  O
remission  O
in  O
bone  O
marrow  O
.  O

Univariate  O
and  O
multivariate  O
analyses  O
were  O
used  O
to  O
identify  O
pretreatment  O
patient  O
characteristics  O
associated  O
with  O
CR  O
and  O
overall  O
remission  O
,  O
longer  O
time  O
to  O
progression  O
,  O
and  O
overall  O
survival  O
.  O

The  O
FCR  B-DRUG
regimen  O
was  O
an  O
active  O
and  O
well-tolerated  O
treatment  O
for  O
previously  O
treated  O
patients  O
with  O
CLL  B-CANCER
.  O

Myelosuppression  B-TOXI
was  O
the  O
most  O
common  O
toxicity  O
.  O

FCR  B-DRUG
induced  O
the  O
highest  O
CR  O
rate  O
reported  O
in  O
a  O
clinical  O
trial  O
of  O
previously  O
treated  O
patients  O
with  O
CLL  B-CANCER
.  O

Furthermore  O
,  O
molecular  O
remissions  O
were  O
achieved  O
in  O
a  O
third  O
of  O
patients  O
achieving  O
CR  O
.  O

Mitomycin-C  B-DRUG
and  O
capecitabine  B-DRUG
as  O
third-line  O
chemotherapy  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
II  O
study  O
.  O


The  O
aim  O
of  O
this  O
study  O
was  O
to  O
investigate  O
the  O
therapeutic  O
value  O
and  O
safety  O
of  O
third-line  O
treatment  O
with  O
mitomycin-C  B-DRUG
(  O
MMC  B-DRUG
)  O
and  O
capecitabine  B-DRUG
(  O
Xeloda  B-DRUG
)  O
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
pretreated  O
with  O
combination  O
regimens  O
including  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
,  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
and  O
irinotecan  B-DRUG
(  O
CPT-11  B-DRUG
)  O
or  O
5-FU  B-DRUG
,  O
FA  B-DRUG
and  O
oxaliplatin  B-DRUG
(  O
L-OHP  B-DRUG
)  O
.  O

A  O
total  O
of  O
21  O
patients  O
(  O
M  O
/  O
F  O
16  O
/  O
5  O
,  O
median  O
age  O
60.0  O
years  O
)  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
,  O
all  O
of  O
whom  O
had  O
developed  O
progressive  B-TOXI
disease  I-TOXI
while  O
receiving  O
or  O
within  O
6  O
months  O
of  O
discontinuing  O
two  O
sequential  O
chemotherapy  O
lines  O
with  O
5-FU  B-DRUG
,  O
FA  B-DRUG
and  O
CPT-11  B-DRUG
or  O
5-FU  B-DRUG
,  O
FA  B-DRUG
and  O
L-OHP  B-DRUG
,  O
were  O
accrued  O
to  O
this  O
study  O
.  O

At  O
the  O
time  O
of  O
their  O
relapse  O
or  O
progression  O
,  O
cytotoxic  O
chemotherapy  O
,  O
consisting  O
of  O
intravenous  O
MMC  B-DRUG
7  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
therapeutic  O
day  O
1  O
plus  O
oral  O
capecitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
twice  O
daily  O
on  O
days  O
1-14  O
,  O
was  O
initiated  O
.  O

After  O
rest  O
for  O
7  O
days  O
,  O
capecitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
twice  O
daily  O
was  O
administered  O
on  O
days  O
22-35  O
followed  O
by  O
7  O
days  O
rest  O
.  O

Treatment  O
courses  O
were  O
repeated  O
every  O
6  O
weeks  O
unless  O
there  O
was  O
evidence  O
of  O
progressive  B-TOXI
disease  I-TOXI
,  O
unacceptable  O
toxicity  O
or  O
patient  O
refusal  O
of  O
treatment  O
.  O

All  O
the  O
patients  O
were  O
assessable  O
for  O
toxicity  O
and  O
19  O
for  O
response  O
.  O

The  O
median  O
number  O
cycles  O
of  O
chemotherapy  O
was  O
two  O
(  O
range  O
one  O
to  O
four  O
)  O
.  O

Only  O
1  O
patient  O
(  O
4.8  O
%  O
)  O
had  O
a  O
partial  O
response  O
,  O
4  O
patients  O
(  O
19.0  O
%  O
)  O
had  O
stable  O
disease  O
,  O
and  O
14  O
patients  O
(  O
66.7  O
%  O
)  O
progressed  O
.  O

The  O
median  O
follow-up  O
period  O
was  O
7.3  O
months  O
and  O
median  O
time  O
to  O
progression  O
was  O
2.6  O
months  O
.  O

The  O
median  O
overall  O
survival  O
was  O
6.8  O
months  O
.  O

No  O
toxic  B-TOXI
deaths  I-TOXI
occurred  O
.  O

Toxicities  O
of  O
third-line  O
treatment  O
were  O
mild  O
and  O
manageable  O
.  O

As  O
NCI  O
/  O
NIH  O
common  O
toxicity  O
criteria  O
,  O
grade  O
3  O
/  O
4  O
anemia  B-TOXI
,  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
occurred  O
in  O
two  O
,  O
one  O
and  O
one  O
patients  O
,  O
respectively  O
.  O

Our  O
findings  O
suggest  O
that  O
the  O
combination  O
of  O
MMC  B-DRUG
and  O
capecitabine  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
pretreated  O
with  O
combination  O
regimens  O
including  O
5-FU  B-DRUG
,  O
FA  B-DRUG
and  O
CPT-11  B-DRUG
or  O
5-FU  B-DRUG
,  O
FA  B-DRUG
and  O
L-OHP  B-DRUG
is  O
safe  O
.  O

However  O
,  O
this  O
regimen  O
had  O
a  O
poor  O
response  O
rate  O
and  O
no  O
definitive  O
contribution  O
to  O
increasing  O
patients  O
'  O
overall  O
survival  O
time  O
.  O

Further  O
evaluation  O
of  O
other  O
salvage  O
regimens  O
seems  O
to  O
be  O
warranted  O
.  O

Effects  O
of  O
Onyx-015  B-DRUG
among  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
patients  O
that  O
have  O
failed  O
prior  O
treatment  O
with  O
5-FU  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
.  O


Despite  O
recent  O
improvements  O
in  O
the  O
treatment  O
of  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
,  O
few  O
patients  O
are  O
cured  O
and  O
the  O
response  O
rates  O
to  O
second-line  O
treatments  O
are  O
poor  O
.  O

Onyx-015  B-DRUG
,  O
an  O
oncolytic  O
virus  O
,  O
was  O
administered  O
to  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
by  O
hepatic  O
artery  O
infusion  O
.  O

No  O
dose-limiting  O
toxicities  O
were  O
observed  O
in  O
the  O
phase  O
I  O
/  O
II  O
studies  O
.  O

Onyx-015  B-DRUG
can  O
kill  O
tumor  O
cells  O
by  O
mechanisms  O
that  O
are  O
distinct  O
from  O
chemotherapeutic  O
agents  O
and  O
may  O
therefore  O
have  O
activity  O
among  O
patients  O
who  O
have  O
failed  O
first-line  O
chemotherapy  O
.  O

The  O
24  O
patients  O
included  O
in  O
this  O
analysis  O
had  O
failed  O
first-line  O
therapy  O
with  O
5-FU  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
,  O
79  O
%  O
of  O
the  O
patients  O
failed  O
two  O
or  O
more  O
regimens  O
and  O
58  O
%  O
had  O
failed  O
treatment  O
with  O
Irinotecan  B-DRUG
.  O

Despite  O
the  O
extensive  O
prior  O
therapy  O
,  O
the  O
median  O
survival  O
of  O
these  O
patients  O
was  O
10.7  O
months  O
,  O
46  O
%  O
were  O
alive  O
at  O
1  O
year  O
and  O
two  O
patients  O
(  O
8  O
%  O
)  O
had  O
partial  O
responses  O
.  O

In  O
all  O
,  O
11  O
patients  O
(  O
46  O
%  O
)  O
had  O
stable  O
disease  O
at  O
the  O
completion  O
of  O
the  O
four  O
planned  O
viral  O
treatments  O
(  O
3  O
months  O
)  O
.  O

The  O
median  O
survival  O
of  O
this  O
group  O
of  O
patients  O
was  O
19  O
months  O
,  O
suggesting  O
that  O
stable  O
disease  O
may  O
be  O
an  O
important  O
predictor  O
of  O
benefit  O
with  O
oncolytic  O
viruses  O
.  O

Eight  O
of  O
the  O
11  O
patients  O
with  O
stable  O
disease  O
at  O
3  O
months  O
demonstrated  O
a  O
unique  O
radiographic  O
pattern  O
of  O
transient  O
enlargement  O
of  O
tumor  O
masses  O
(  O
10-48  O
%  O
)  O
after  O
the  O
initial  O
infusions  O
of  O
Onyx-015  B-DRUG
,  O
followed  O
by  O
radiographic  O
evidence  O
of  O
extensive  O
tumor  O
necrosis  O
and  O
regression  O
.  O

The  O
initial  O
enlargement  O
and  O
subsequent  O
tumor  O
necrosis  O
resulted  O
in  O
a  O
prolonged  O
time  O
to  O
achieve  O
objective  O
tumor  O
regression  O
.  O

In  O
addition  O
,  O
the  O
transient  O
enlargement  O
of  O
the  O
tumor  O
masses  O
may  O
have  O
resulted  O
in  O
premature  O
removal  O
of  O
responding  O
patients  O
.  O

Treatment  O
of  O
eight  O
patients  O
was  O
stopped  O
prior  O
to  O
completion  O
of  O
the  O
planned  O
four  O
treatments  O
due  O
to  O
presumed  O
progression  O
as  O
defined  O
by  O
standard  O
radiographic  O
criteria  O
(  O
&  O
gt  O
;  O
25  O
%  O
increase  O
in  O
tumor  O
size  O
)  O
.  O

Functional  O
imaging  O
,  O
such  O
as  O
positron  O
emission  O
tomography  O
(  O
PET  O
)  O
scans  O
,  O
may  O
help  O
distinguish  O
clinical  O
responses  O
from  O
progressive  B-TOXI
disease  I-TOXI
following  O
treatment  O
with  O
oncolytic  O
viruses  O
.  O

Onyx-015  B-DRUG
may  O
benefit  O
patients  O
with  O
refractory  O
colorectal  O
cancer  O
and  O
additional  O
studies  O
that  O
include  O
PET  O
scans  O
to  O
assess  O
clinical  O
response  O
are  O
warranted  O
.  O

Phase  O
I  O
and  O
initial  O
phase  O
II  O
results  O
from  O
a  O
trial  O
investigating  O
weekly  O
docetaxel  B-DRUG
and  O
carboplatin  B-DRUG
given  O
neoadjuvantly  O
and  O
then  O
concurrently  O
with  O
concomitant  O
boost  O
radiotherapy  O
for  O
locally  O
advanced  B-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
.  O


The  O
current  O
Phase  O
I  O
/  O
II  O
study  O
assessed  O
induction  O
docetaxel  B-DRUG
/  I-DRUG
carboplatin  I-DRUG
given  O
weekly  O
for  O
4  O
weeks  O
,  O
followed  O
by  O
weekly  O
docetaxel  B-DRUG
/  I-DRUG
carboplatin  I-DRUG
and  O
concomitant  O
boost  O
radiotherapy  O
(  O
CB-XRT  O
)  O
for  O
locally  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
squamous  I-CANCER
cell  I-CANCER
carcinoma  I-CANCER
.  O

Twenty  O
patients  O
with  O
Stage  O
III  O
or  O
IV  O
(  O
M0  O
)  O
disease  B-CANCER
of  I-CANCER
the  I-CANCER
oropharynx  I-CANCER
,  O
supraglottic  B-CANCER
larynx  I-CANCER
,  O
or  O
hypopharynx  B-CANCER
were  O
enrolled  O
.  O

Patients  O
initially  O
received  O
docetaxel  B-DRUG
20  O
mg  O
/  O
m2  O
and  O
carboplatin  B-DRUG
area  O
under  O
the  O
curve  O
(  O
AUC  O
)  O
2  O
weekly  O
x  O
4.  O
Patients  O
with  O
stable  O
(  O
SD  O
)  O
or  O
responding  O
disease  O
subsequently  O
received  O
dose-escalated  O
docetaxel  B-DRUG
(  O
10-20  O
mg  O
/  O
m2  O
in  O
sequential  O
patient  O
cohorts  O
)  O
and  O
carboplatin  B-DRUG
AUC  O
1  O
weekly  O
x  O
5  O
with  O
CB-XRT  O
(  O
1.8  O
gray  O
[  O
Gy  O
]  O
every  O
day  O
x  O
15  O
days  O
,  O
followed  O
by  O
1.8  O
/  O
1.5  O
Gy  O
twice  O
per  O
day  O
x  O
13  O
days  O
)  O
.  O

All  O
patients  O
were  O
evaluable  O
,  O
and  O
15  O
patients  O
(  O
5  O
patients  O
with  O
Stage  O
III  O
disease  O
,  O
10  O
patients  O
with  O
Stage  O
IV  O
disease  O
)  O
completed  O
all  O
planned  O
therapy  O
.  O

The  O
target  O
docetaxel  B-DRUG
dose  O
level  O
of  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
weekly  O
with  O
radiotherapy  O
was  O
achieved  O
with  O
no  O
dose-limiting  O
toxicities  O
.  O

The  O
most  O
frequent  O
maximum  O
toxicities  O
during  O
chemoradiotherapy  O
were  O
Grade  O
3  O
mucositis  B-TOXI
,  O
dysphagia  B-TOXI
,  O
and  O
/  O
or  O
pain  B-TOXI
.  O

Primary  O
site  O
responses  O
after  O
induction  O
included  O
4  O
patients  O
with  O
partial  O
responses  O
,  O
11  O
patients  O
with  O
SD  O
,  O
and  O
5  O
patients  O
with  O
disease  B-TOXI
progression  I-TOXI
.  O

Fifteen  O
patients  O
(  O
75  O
%  O
)  O
continued  O
to  O
receive  O
chemoradiotherapy  O
,  O
with  O
14  O
patients  O
attaining  O
a  O
complete  O
response  O
(  O
CR  O
)  O
.  O

Overall  O
,  O
a  O
clinicopathologic  O
neck  O
CR  O
after  O
chemoradiotherapy  O
was  O
achieved  O
in  O
9  O
of  O
10  O
patients  O
.  O

One  O
patient  O
had  O
persistent  B-TOXI
primary  I-TOXI
disease  I-TOXI
and  O
underwent  B-TOXI
salvage  I-TOXI
surgery  I-TOXI
,  O
whereas  O
another  O
died  B-TOXI
of  O
unrelated  O
causes  O
before  O
neck  O
assessment  O
.  O

Thirteen  O
patients  O
remain  O
free  O
of  O
any  O
disease  O
event  O
,  O
with  O
a  O
median  O
follow-up  O
of  O
15  O
months  O
(  O
range  O
,  O
3-29  O
months  O
)  O
.  O

This  O
regimen  O
was  O
feasible  O
,  O
safe  O
,  O
and  O
particularly  O
well  O
tolerated  O
.  O

Early  O
Phase  O
II  O
outcomes  O
revealed  O
promising  O
activity  O
in  O
patients  O
completing  O
all  O
treatment  O
.  O

Initial  O
induction  O
response  O
results  O
suggested  O
that  O
further  O
investigation  O
of  O
this  O
regimen  O
with  O
more  O
aggressive  O
induction  O
therapy  O
is  O
warranted  O
.  O

Salvage  O
chemotherapy  O
with  O
irinotecan  B-DRUG
,  O
5-fluorouracil  B-DRUG
and  O
leucovorin  B-DRUG
for  O
taxane-  B-DRUG
and  O
cisplatin-refractory  B-DRUG
,  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


We  O
performed  O
a  O
phase  O
II  O
study  O
of  O
combination  O
chemotherapy  O
with  O
irinotecan  B-DRUG
,  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
and  O
leucovorin  B-DRUG
in  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
patients  O
who  O
were  O
previously  O
treated  O
with  O
taxane  B-DRUG
and  O
cisplatin  B-DRUG
,  O
to  O
evaluate  O
the  O
antitumour  O
activity  O
and  O
toxicity  O
of  O
the  O
combination  O
chemotherapy  O
.  O

The  O
metastatic  B-CANCER
gastric  I-CANCER
adenocarcinoma  I-CANCER
patients  O
who  O
were  O
previously  O
treated  O
with  O
taxane  B-DRUG
and  O
cisplatin  B-DRUG
combination  O
as  O
first  O
line  O
,  O
and  O
had  O
at  O
least  O
one  O
measurable  O
lesion  O
,  O
0-2  O
ECOG  O
performance  O
status  O
and  O
adequate  O
organ  O
functions  O
,  O
were  O
considered  O
eligible  O
.  O

They  O
received  O
irinotecan  B-DRUG
(  O
150  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
1  O
)  O
and  O
leucovorin  B-DRUG
(  O
100  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
1  O
)  O
,  O
followed  O
by  O
continuous  O
infusion  O
of  O
5-FU  B-DRUG
(  O
1000  O
mg  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
,  O
days  O
1  O
and  O
2  O
)  O
every  O
2  O
weeks  O
.  O

Treatment  O
was  O
continued  O
until  O
progression  B-TOXI
of  I-TOXI
disease  I-TOXI
was  O
observed  O
.  O

In  O
all  O
,  O
64  O
patients  O
were  O
treated  O
with  O
this  O
combination  O
chemotherapy  O
.  O

The  O
median  O
age  O
of  O
the  O
patients  O
was  O
55  O
years  O
(  O
range  O
,  O
33-74  O
years  O
)  O
,  O
and  O
the  O
median  O
ECOG  O
performance  O
status  O
was  O
1  O
(  O
0-1  O
,  O
61  O
(  O
95  O
%  O
)  O
)  O
.  O

Out  O
of  O
64  O
patients  O
,  O
57  O
were  O
assessable  O
for  O
response  O
.  O

Among  O
57  O
assessable  O
patients  O
,  O
no  O
complete  O
response  O
and  O
12  O
partial  O
responses  O
were  O
observed  O
(  O
overall  O
response  O
rate  O
,  O
21  O
%  O
;  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
,  O
10-32  O
%  O
)  O
.  O

Stable  O
disease  O
was  O
observed  O
in  O
14  O
patients  O
(  O
25  O
%  O
)  O
and  O
progressive  B-TOXI
disease  I-TOXI
in  O
31  O
patients  O
(  O
54  O
%  O
)  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
2.5  O
months  O
(  O
95  O
%  O
CI  O
,  O
1.6-3.4  O
)  O
and  O
the  O
median  O
overall  O
survival  O
since  O
the  O
start  O
of  O
the  O
second-line  O
modified  O
FOLFIRI  B-DRUG
was  O
7.6  O
months  O
(  O
95  O
%  O
CI  O
,  O
6.5-8.7  O
)  O
.  O

Grade  O
3-4  O
haematologic  B-TOXI
toxicities  I-TOXI
included  O
neutropenia  B-TOXI
in  O
seven  O
patients  O
(  O
11  O
%  O
)  O
and  O
thrombocytopenia  B-TOXI
in  O
five  O
patients  O
(  O
8  O
%  O
)  O
.  O

Grade  O
3-4  O
nonhaematologic  B-TOXI
toxicities  I-TOXI
included  O
diarrhoea  B-TOXI
in  O
two  O
patients  O
(  O
3  O
%  O
)  O
and  O
vomiting  B-TOXI
in  O
two  O
patients  O
(  O
3  O
%  O
)  O
.  O

There  O
were  O
no  O
treatment-related  B-TOXI
deaths  I-TOXI
.  O

The  O
combination  O
of  O
irinotecan  B-DRUG
,  O
5-FU  B-DRUG
and  O
leucovorin  B-DRUG
showed  O
moderate  O
activity  O
and  O
favourable  O
toxicity  O
profile  O
as  O
a  O
second-line  O
treatment  O
in  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
patients  O
,  O
who  O
were  O
previously  O
treated  O
with  O
taxane  B-DRUG
and  O
cisplatin  B-DRUG
.  O

A  O
phase  O
II  O
trial  O
of  O
gefitinib  B-DRUG
with  O
5-fluorouracil  B-DRUG
,  O
leucovorin  B-DRUG
,  O
and  O
irinotecan  B-DRUG
in  O
patients  O
with  O
colorectal  B-CANCER
cancer  I-CANCER
.  O


Inhibition  O
of  O
epidermal  B-DRUG
growth  I-DRUG
factor  I-DRUG
receptor  I-DRUG
(  O
EGFR  B-DRUG
)  O
signalling  O
contributes  O
to  O
the  O
therapy  O
of  O
colorectal  B-CANCER
cancer  I-CANCER
.  O

Gefitinib  B-DRUG
,  O
an  O
oral  O
EGFR  B-DRUG
tyrosine  O
kinase  O
inhibitor  O
,  O
shows  O
supra-additive  O
growth  O
inhibition  O
with  O
irinotecan  B-DRUG
and  O
fluoropyrimidines  B-DRUG
in  O
xenograft  O
models  O
.  O

We  O
designed  O
a  O
study  O
to  O
determine  O
the  O
tolerability  O
and  O
efficacy  O
of  O
gefitinib  B-DRUG
in  O
combination  O
with  O
irinotecan  B-DRUG
,  O
infusional  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
and  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
,  O
on  O
a  O
2-week  O
schedule  O
.  O

Among  O
13  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
,  O
10  O
required  O
dose  O
reductions  O
of  O
irinotecan  B-DRUG
and  O
5-FU  B-DRUG
because  O
of  O
dehydration  B-TOXI
,  O
diarrhoea  B-TOXI
,  O
and  O
neutropenia  B-TOXI
,  O
seven  O
of  O
whom  O
required  O
hospitalisation  O
,  O
three  O
with  O
neutropenic  B-TOXI
fever  I-TOXI
.  O

One  O
patient  O
achieved  O
partial  O
response  O
and  O
seven  O
had  O
disease  O
stabilisation  O
.  O

The  O
combination  O
of  O
this  O
standard  O
chemotherapy  O
regimen  O
with  O
gefitinib  B-DRUG
is  O
associated  O
with  O
excessive  O
toxicity  O
,  O
suggesting  O
an  O
interaction  O
at  O
a  O
pharmacokinetic  O
or  O
pharmacodynamic  O
level  O
.  O

Bevacizumab  B-DRUG
in  O
combination  O
with  O
fluorouracil  B-DRUG
and  O
leucovorin  B-DRUG
:  O
an  O
active  O
regimen  O
for  O
first-line  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
.  O


In  O
a  O
phase  O
III  O
trial  O
,  O
combining  O
bevacizumab  B-DRUG
(  O
BV  B-DRUG
)  O
--  O
a  O
recombinant  O
,  O
humanized  O
,  O
monoclonal  O
antibody  O
targeting  O
vascular  O
endothelial  O
growth  O
factor  O
--  O
with  O
irinotecan  B-DRUG
,  O
bolus  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
,  O
and  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
;  O
IFL  B-DRUG
)  O
increased  O
survival  O
compared  O
with  O
IFL  B-DRUG
alone  O
in  O
first-line  O
treatment  O
of  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
(  O
CRC  B-CANCER
)  O
.  O

Results  O
for  O
the  O
parent  O
study  O
of  O
IFL  B-DRUG
/  I-DRUG
BV  I-DRUG
versus  O
IFL  B-DRUG
/  I-DRUG
placebo  I-DRUG
are  O
reported  O
elsewhere  O
.  O

Here  O
,  O
we  O
describe  O
efficacy  O
and  O
safety  O
results  O
for  O
the  O
third  O
patient  O
cohort  O
in  O
this  O
trial  O
,  O
who  O
received  O
BV  B-DRUG
combined  O
with  O
FU  B-DRUG
/  I-DRUG
LV  I-DRUG
,  O
and  O
compare  O
them  O
with  O
results  O
for  O
concurrently  O
enrolled  O
patients  O
who  O
received  O
IFL  B-DRUG
.  O

Patients  O
(  O
N  O
=  O
923  O
)  O
were  O
randomly  O
assigned  O
to  O
receive  O
IFL  B-DRUG
/  I-DRUG
placebo  I-DRUG
(  O
control  O
)  O
,  O
IFL  B-DRUG
/  I-DRUG
BV  I-DRUG
,  O
or  O
FU  B-DRUG
/  I-DRUG
LV  I-DRUG
/  I-DRUG
BV  I-DRUG
.  O

Bevacizumab  B-DRUG
(  O
Avastin  O
;  O
Genentech  O
Inc  O
,  O
South  O
San  O
Francisco  O
,  O
CA  O
)  O
5  O
mg  O
/  O
kg  O
was  O
administered  O
intravenously  O
every  O
2  O
weeks  O
.  O

Before  O
an  O
interim  O
analysis  O
confirmed  O
acceptable  O
safety  O
for  O
IFL  B-DRUG
/  I-DRUG
BV  I-DRUG
,  O
313  O
patients  O
were  O
concurrently  O
randomly  O
assigned  O
to  O
these  O
three  O
arms  O
;  O
after  O
this  O
analysis  O
,  O
the  O
FU  B-DRUG
/  I-DRUG
LV  I-DRUG
/  I-DRUG
BV  I-DRUG
arm  O
was  O
discontinued  O
.  O

Median  O
overall  O
survivals  O
were  O
18.3  O
and  O
15.1  O
months  O
with  O
FU  B-DRUG
/  I-DRUG
LV  I-DRUG
/  I-DRUG
BV  I-DRUG
(  O
n  O
=  O
110  O
)  O
and  O
IFL  B-DRUG
/  I-DRUG
placebo  I-DRUG
(  O
n  O
=  O
100  O
)  O
,  O
respectively  O
.  O

Median  O
progression-free  O
survivals  O
were  O
8.8  O
and  O
6.8  O
months  O
,  O
respectively  O
.  O

Overall  O
response  O
rates  O
were  O
40.0  O
%  O
and  O
37.0  O
%  O
,  O
and  O
median  O
response  O
durations  O
were  O
8.5  O
and  O
7.2  O
months  O
,  O
respectively  O
.  O

Adverse  O
events  O
consistent  O
with  O
those  O
expected  O
from  O
FU  B-DRUG
/  I-DRUG
leucovorin-  I-DRUG
or  O
IFL-based  B-DRUG
regimens  O
were  O
seen  O
,  O
as  O
were  O
modest  O
increases  O
in  O
hypertension  B-TOXI
and  O
bleeding  B-TOXI
in  O
the  O
bevacizumab  B-DRUG
arm  O
,  O
which  O
were  O
generally  O
easily  O
managed  O
.  O

The  O
FU  O
/  B-DRUG
LV  I-DRUG
/  I-DRUG
BV  I-DRUG
regimen  O
seems  O
as  O
effective  O
as  O
IFL  B-DRUG
and  O
has  O
an  O
acceptable  O
safety  O
profile  O
.  O

FU  B-DRUG
/  I-DRUG
LV  I-DRUG
/  I-DRUG
BV  I-DRUG
is  O
an  O
active  O
alternative  O
treatment  O
regimen  O
for  O
patients  O
with  O
previously  O
untreated  O
metastatic  B-CANCER
CRC  I-CANCER
.  O

Randomized  O
phase  O
III  O
trial  O
of  O
cisplatin  B-DRUG
with  O
or  O
without  O
topotecan  B-DRUG
in  O
carcinoma  B-CANCER
of  I-CANCER
the  I-CANCER
uterine  I-CANCER
cervix  I-CANCER
:  O
a  O
Gynecologic  O
Oncology  O
Group  O
Study  O
.  O


On  O
the  O
basis  O
of  O
reported  O
activity  O
of  O
methotrexate  B-DRUG
,  O
vinblastine  B-DRUG
,  O
doxorubicin  B-DRUG
,  O
and  O
cisplatin  B-DRUG
(  O
MVAC  B-DRUG
)  O
or  O
topotecan  B-DRUG
plus  O
cisplatin  B-DRUG
in  O
advanced  B-CANCER
cervix  I-CANCER
cancer  I-CANCER
,  O
we  O
undertook  O
a  O
randomized  O
trial  O
comparing  O
these  O
combinations  O
versus  O
cisplatin  B-DRUG
alone  O
,  O
to  O
determine  O
whether  O
survival  O
is  O
improved  O
with  O
either  O
combination  O
compared  O
with  O
cisplatin  B-DRUG
alone  O
,  O
and  O
to  O
compare  O
toxicities  O
and  O
quality  O
of  O
life  O
(  O
QOL  O
)  O
among  O
the  O
regimens  O
.  O

Eligible  O
patients  O
were  O
randomly  O
allocated  O
to  O
receive  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
every  O
3  O
weeks  O
(  O
CPT  O
)  O
;  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
day  O
1  O
plus  O
topotecan  B-DRUG
0.75  O
mg  O
/  O
m  O
(  O
2  O
)  O
days  O
1  O
to  O
3  O
every  O
3  O
weeks  O
(  O
CT  O
)  O
;  O
or  O
methotrexate  B-DRUG
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
days  O
1  O
,  O
15  O
,  O
and  O
22  O
,  O
vinblastine  B-DRUG
3  O
mg  O
/  O
m  O
(  O
2  O
)  O
days  O
2  O
,  O
15  O
,  O
and  O
22  O
,  O
doxorubicin  B-DRUG
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
day  O
2  O
,  O
and  O
cisplatin  B-DRUG
70  O
mg  O
/  O
m  O
(  O
2  O
)  O
day  O
2  O
every  O
4  O
weeks  O
(  O
MVAC  O
)  O
.  O

Survival  O
was  O
the  O
primary  O
end  O
point  O
;  O
response  O
rate  O
and  O
progression-free  O
survival  O
(  O
PFS  O
)  O
were  O
secondary  O
end  O
points  O
.  O

QOL  O
data  O
are  O
reported  O
separately  O
.  O

The  O
MVAC  B-DRUG
arm  O
was  O
closed  O
by  O
the  O
Data  O
Safety  O
Monitoring  O
Board  O
after  O
four  O
treatment-related  B-TOXI
deaths  I-TOXI
occurred  O
among  O
63  O
patients  O
,  O
and  O
is  O
not  O
included  O
in  O
this  O
analysis  O
.  O

Two  O
hundred  O
ninety-four  O
patients  O
enrolled  O
onto  O
the  O
remaining  O
regimens  O
:  O
146  O
to  O
CPT  B-DRUG
and  O
147  O
to  O
CT.  B-DRUG
Grade  O
3  O
to  O
4  O
hematologic  B-TOXI
toxicity  I-TOXI
was  O
more  O
common  O
with  O
CT.  B-DRUG
Patients  O
receiving  O
CT  B-DRUG
had  O
statistically  O
superior  O
outcomes  O
to  O
those  O
receiving  O
CPT  B-DRUG
,  O
with  O
median  O
overall  O
survival  O
of  O
9.4  O
and  O
6.5  O
months  O
(  O
P  O
=  O
.017  O
)  O
,  O
median  O
PFS  O
of  O
4.6  O
and  O
2.9  O
months  O
(  O
P  O
=  O
.014  O
)  O
,  O
and  O
response  O
rates  O
of  O
27  O
%  O
and  O
13  O
%  O
,  O
respectively  O
.  O

This  O
is  O
the  O
first  O
randomized  O
phase  O
III  O
trial  O
to  O
demonstrate  O
a  O
survival  O
advantage  O
for  O
combination  O
chemotherapy  O
over  O
cisplatin  B-DRUG
alone  O
in  O
advanced  B-CANCER
cervix  I-CANCER
cancer  I-CANCER
.  O

Paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
combination  O
in  O
a  O
biweekly  O
schedule  O
in  O
patients  O
with  O
advanced  B-CANCER
non  I-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
I  O
study  O
.  O


This  O
phase  O
I  O
study  O
was  O
designed  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
dose  O
limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
the  O
paclitaxel-gemcitabine  B-DRUG
combination  O
in  O
a  O
biweekly  O
schedule  O
in  O
chemotherapy-naive  O
patients  O
with  O
advanced  B-CANCER
non  I-CANCER
small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

Treatment  O
was  O
administered  O
on  O
an  O
outpatient  O
basis  O
every  O
2  O
weeks  O
:  O
paclitaxel  B-DRUG
over  O
a  O
1-h  O
IV  O
infusion  O
and  O
gemcitabine  B-DRUG
as  O
a  O
30-min  O
IV  O
infusion  O
immediately  O
following  O
paclitaxel  B-DRUG
.  O

Twenty-nine  O
patients  O
were  O
treated  O
at  O
six  O
different  O
dose  O
levels  O
,  O
ranging  O
from  O
paclitaxel  B-DRUG
135-175  O
mg  O
/  O
m2  O
and  O
gemcitabine  B-DRUG
1,500-3,000  O
mg  O
/  O
m2  O
.  O

A  O
total  O
of  O
198  O
cycles  O
were  O
administered  O
(  O
median  O
7  O
,  O
range  O
1-13  O
)  O
.  O

DLTs  O
in  O
the  O
first  O
two  O
cycles  O
were  O
grade  O
4  O
neutropenia  B-TOXI
and  O
myocardial  B-TOXI
ischemia  I-TOXI
at  O
the  O
dose  O
level  O
paclitaxel  B-DRUG
/  I-DRUG
gemcitabine  I-DRUG
150  O
/  O
2,000  O
mg  O
/  O
m2  O
,  O
febrile  B-TOXI
neutropenia  I-TOXI
and  O
grade  O
4  O
neutropenia  B-TOXI
at  O
the  O
dose  O
level  O
paclitaxel  B-DRUG
/  I-DRUG
gemcitabine  I-DRUG
175  O
/  O
2,500  O
mg  O
/  O
m2  O
,  O
fatal  B-TOXI
pneumonitis  I-TOXI
,  O
sudden  B-TOXI
death  I-TOXI
and  O
grade  O
3  O
neutropenia  B-TOXI
at  O
the  O
dose  O
level  O
paclitaxel  B-DRUG
/  I-DRUG
gemcitabine  I-DRUG
175  O
/  O
3,000  O
mg  O
/  O
m2  O
.  O

The  O
MTD  O
was  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m2  O
and  O
gemcitabine  B-DRUG
2,500  O
mg  O
/  O
m2  O
.  O

The  O
average  O
dose  O
intensity  O
at  O
this  O
dose  O
level  O
was  O
98  O
%  O
.  O

The  O
overall  O
intent-to-treat  O
response  O
rate  O
was  O
35.7  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
[  O
CI  O
]  O
17.97  O
%  O
-53.47  O
%  O
)  O
.  O

Overall  O
median  O
survival  O
was  O
36  O
weeks  O
(  O
95  O
%  O
CI  O
,  O
24-48  O
)  O
.  O

Paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
can  O
be  O
safely  O
administered  O
at  O
a  O
high  O
dose  O
intensity  O
on  O
an  O
every-other-week  O
schedule  O
.  O

The  O
recommended  O
phase  O
II  O
dose  O
is  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m2  O
and  O
gemcitabine  B-DRUG
2,500  O
mg  O
/  O
m2  O
.  O

Study  O
of  O
paclitaxel  B-DRUG
,  O
etoposide  B-DRUG
,  O
and  O
cisplatin  B-DRUG
chemotherapy  O
combined  O
with  O
twice-daily  O
thoracic  O
radiotherapy  O
for  O
patients  O
with  O
limited-stage  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
a  O
Radiation  O
Therapy  O
Oncology  O
Group  O
9609  O
phase  O
II  O
study  O
.  O


To  O
determine  O
the  O
response  O
rate  O
,  O
progression-free  O
survival  O
and  O
overall  O
survival  O
,  O
and  O
toxicity  O
of  O
paclitaxel  B-DRUG
,  O
etoposide  B-DRUG
,  O
and  O
cisplatin  B-DRUG
combined  O
with  O
accelerated  O
hyperfractionated  O
thoracic  O
radiotherapy  O
in  O
patients  O
with  O
limited-disease  O
(  O
LD  O
)  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
SCLC  B-CANCER
)  O
.  O

LD-SCLC  B-CANCER
patients  O
with  O
measurable  O
disease  O
,  O
Karnofsky  O
performance  O
score  O
of  O
&  O
gt  O
;  O
or  O
=  O
70  O
,  O
and  O
adequate  O
organ  O
function  O
who  O
were  O
previously  O
untreated  O
were  O
eligible  O
for  O
the  O
study  O
.  O

Treatment  O
was  O
as  O
follows  O
.  O

In  O
cycle  O
1  O
of  O
chemotherapy  O
,  O
concurrent  O
thoracic  O
radiation  O
therapy  O
was  O
administered  O
.  O

In  O
cycles  O
2  O
to  O
4  O
,  O
chemotherapy  O
was  O
administered  O
alone  O
.  O

In  O
cycle  O
1  O
,  O
chemotherapy  O
consisted  O
of  O
paclitaxel  B-DRUG
135  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenous  O
over  O
3  O
hours  O
on  O
day  O
1  O
,  O
etoposide  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenous  O
on  O
day  O
1  O
and  O
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
orally  O
on  O
days  O
2  O
and  O
3  O
,  O
and  O
cisplatin  B-DRUG
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenous  O
on  O
day  O
1.  O
In  O
cycles  O
2  O
to  O
4  O
,  O
the  O
paclitaxel  B-DRUG
dose  O
was  O
increased  O
to  O
175  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
with  O
the  O
etoposide  B-DRUG
and  O
cisplatin  B-DRUG
doses  O
remaining  O
the  O
same  O
as  O
in  O
cycle  O
1.  O
The  O
thoracic  O
radiation  O
therapy  O
consisted  O
of  O
1.5  O
Gy  O
in  O
30  O
fractions  O
(  O
total  O
dose  O
,  O
45  O
Gy  O
)  O
administered  O
5  O
days  O
a  O
week  O
for  O
3  O
weeks  O
.  O

Fifty-five  O
patients  O
were  O
enrolled  O
onto  O
the  O
study  O
,  O
and  O
53  O
were  O
assessable  O
.  O

The  O
major  O
toxicities  O
included  O
grade  O
3  O
and  O
4  O
acute  B-TOXI
neutropenia  I-TOXI
(  O
32  O
%  O
and  O
43  O
%  O
,  O
respectively  O
)  O
and  O
grade  O
3  O
and  O
4  O
esophagitis  B-TOXI
(  O
32  O
%  O
and  O
4  O
%  O
,  O
respectively  O
)  O
.  O

Two  O
patients  O
died  O
as  O
a  O
result  O
of  O
therapy  O
(  O
one  O
died  B-TOXI
of  I-TOXI
acute  I-TOXI
respiratory  I-TOXI
distress  I-TOXI
syndrome  I-TOXI
,  O
and  O
one  O
died  B-TOXI
of  I-TOXI
sepsis  I-TOXI
)  O
.  O

There  O
was  O
one  O
late  B-TOXI
fatal  I-TOXI
pulmonary  I-TOXI
toxicity  I-TOXI
.  O

The  O
median  O
survival  O
time  O
was  O
24.7  O
months  O
.  O

The  O
2-year  O
survival  O
rate  O
was  O
54.7  O
%  O
.  O

The  O
median  O
progression-free  O
survival  O
time  O
was  O
13  O
months  O
,  O
with  O
a  O
2-year  O
progression-free  O
survival  O
rate  O
of  O
26.4  O
%  O
.  O

Although  O
this  O
therapeutic  O
regimen  O
is  O
effective  O
in  O
the  O
treatment  O
of  O
patients  O
with  O
LD-SCLC  B-CANCER
,  O
it  O
is  O
unlikely  O
that  O
the  O
three-drug  O
combination  O
with  O
thoracic  O
radiation  O
therapy  O
will  O
improve  O
the  O
survival  O
times  O
compared  O
with  O
the  O
etoposide  B-DRUG
plus  O
cisplatin  B-DRUG
chemotherapy  O
regimen  O
with  O
thoracic  O
radiation  O
therapy  O
in  O
LD-SCLC  B-CANCER
patients  O
.  O

Randomised  O
phase  O
II  O
evaluation  O
of  O
irinotecan  B-DRUG
plus  O
high-dose  O
5-fluorouracil  B-DRUG
and  O
leucovorin  B-DRUG
(  O
ILF  B-DRUG
)  O
vs  O
5-fluorouracil  B-DRUG
,  O
leucovorin  B-DRUG
,  O
and  O
etoposide  B-DRUG
(  O
ELF  B-DRUG
)  O
in  O
untreated  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


An  O
open-label  O
randomised  O
comparison  O
of  O
efficacy  O
and  O
tolerability  O
of  O
irinotecan  B-DRUG
plus  O
high-dose  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
and  O
leucovorin  B-DRUG
(  O
LV  B-DRUG
)  O
(  O
ILF  B-DRUG
)  O
with  O
etoposide  B-DRUG
plus  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
(  O
ELF  B-DRUG
)  O
in  O
patients  O
with  O
untreated  O
metastatic  O
or  O
locally  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

One  O
cycle  O
of  O
ILF  B-DRUG
comprised  O
six  O
once-weekly  O
infusions  O
of  O
irinotecan  B-DRUG
80  O
mg  O
m  O
(  O
-2  O
)  O
,  O
LV  O
500  O
mg  O
m  O
(  O
-2  O
)  O
,  O
24-h  O
5-FU  B-DRUG
2000  O
mg  O
m  O
(  O
-2  O
)  O
,  O
and  O
ELF  B-DRUG
comprised  O
three  O
once-daily  O
doses  O
of  O
etoposide  B-DRUG
120  O
mg  O
m  O
(  O
-2  O
)  O
,  O
LV  O
300  O
mg  O
m  O
(  O
-2  O
)  O
,  O
5-FU  B-DRUG
500  O
mg  O
m  O
(  O
-2  O
)  O
.  O

In  O
all  O
,  O
56  O
patients  O
received  O
ILF  B-DRUG
and  O
58  O
ELF  B-DRUG
.  O

Median  O
age  O
was  O
62  O
years  O
,  O
Karnofsky  O
performance  O
90  O
%  O
,  O
and  O
disease  O
status  O
was  O
comparable  O
for  O
both  O
arms  O
.  O

The  O
objective  O
clinical  O
response  O
rates  O
after  O
14  O
weeks  O
treatment  O
(  O
primary  O
end  O
point  O
)  O
were  O
30  O
%  O
for  O
ILF  B-DRUG
and  O
17  O
%  O
for  O
ELF  B-DRUG
(  O
risk  O
ratio  O
(  O
RR  O
)  O
0.57  O
,  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
0.29-1.13  O
,  O
P  O
=  O
0.0766  O
)  O
.  O

Overall  O
response  O
rates  O
over  O
the  O
entire  O
treatment  O
period  O
for  O
ILF  B-DRUG
and  O
ELF  B-DRUG
were  O
43  O
and  O
24  O
%  O
,  O
respectively  O
(  O
RR  O
0.56  O
,  O
95  O
%  O
CI  O
0.33-0.97  O
;  O
P  O
=  O
0.0467  O
)  O
.  O

For  O
ILF  B-DRUG
and  O
ELF  B-DRUG
,  O
respectively  O
,  O
median  O
progression-free  O
survival  O
was  O
4.5  O
vs  O
2.3  O
months  O
,  O
time  O
to  O
treatment  O
failure  O
was  O
3.6  O
vs  O
2.2  O
months  O
(  O
P  O
=  O
0.4542  O
)  O
,  O
and  O
overall  O
survival  O
was  O
10.8  O
vs  O
8.3  O
months  O
(  O
P  O
=  O
0.2818  O
)  O
.  O

Both  O
regimens  O
were  O
well  O
tolerated  O
,  O
the  O
main  O
grade  O
3  O
/  O
4  O
toxicities  O
being  O
diarrhoea  B-TOXI
(  O
18  O
%  O
,  O
ILF  B-DRUG
)  O
and  O
neutropenia  B-TOXI
(  O
57  O
%  O
,  O
ELF  B-DRUG
)  O
.  O

The  O
data  O
from  O
this  O
randomised  O
phase  O
II  O
study  O
indicate  O
that  O
ILF  B-DRUG
provides  O
a  O
better  O
response  O
rate  O
than  O
ELF  B-DRUG
,  O
and  O
that  O
ILF  B-DRUG
should  O
be  O
investigated  O
further  O
for  O
the  O
treatment  O
of  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

Phase  O
I  O
trial  O
of  O
oral  O
S-1  B-DRUG
combined  O
with  O
gemcitabine  B-DRUG
in  O
metastatic  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
.  O


The  O
objective  O
of  O
this  O
study  O
was  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
S-1  O
,  O
an  O
oral  O
fluorouracil  B-DRUG
derivative  I-DRUG
,  O
combined  O
with  O
gemcitabine  B-DRUG
,  O
the  O
current  O
standard  O
treatment  O
for  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
(  O
APC  B-CANCER
)  O
.  O

The  O
subjects  O
were  O
histopathologically  O
proven  O
APC  B-CANCER
patients  O
with  O
distant  B-CANCER
metastasis  I-CANCER
.  O

S-1  B-DRUG
was  O
administered  O
orally  O
twice  O
daily  O
each  O
day  O
for  O
14  O
days  O
and  O
gemcitabine  B-DRUG
on  O
days  O
8  O
and  O
15  O
of  O
each  O
cycle  O
,  O
and  O
this  O
was  O
repeated  O
every  O
21  O
days  O
.  O

Doses  O
of  O
each  O
drug  O
were  O
planned  O
as  O
follows  O
:  O
level  O
1  O
:  O
800  O
/  O
60  O
,  O
level  O
2a  O
:  O
800  O
/  O
80  O
,  O
level  O
2b  O
:  O
1000  O
/  O
60  O
,  O
level  O
3  O
:  O
1000  O
/  O
80  O
(  O
gemcitabine  B-DRUG
(  O
mg  O
m  O
(  O
-2  O
)  O
)  O
/  O
S-1  O
(  O
mg  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
)  O
)  O
.  O

In  O
all  O
,  O
21  O
patients  O
with  O
APC  B-CANCER
were  O
enrolled  O
.  O

The  O
main  O
grade  O
3-4  O
toxicities  O
observed  O
during  O
first  O
cycle  O
were  O
neutropenia  B-TOXI
(  O
33  O
%  O
)  O
,  O
anaemia  B-TOXI
(  O
10  O
%  O
)  O
,  O
thrombocytopenia  B-TOXI
(  O
14  O
%  O
)  O
and  O
anorexia  B-TOXI
(  O
10  O
%  O
)  O
.  O

There  O
were  O
no  O
DLT  O
observed  O
in  O
level  O
1.  O
Three  O
of  O
six  O
patients  O
in  O
level  O
2a  O
had  O
DLT  O
and  O
this  O
level  O
was  O
considered  O
the  O
MTD  O
.  O

In  O
all  O
,  O
12  O
patients  O
in  O
level  O
2b  O
had  O
no  O
DLT  O
and  O
this  O
level  O
was  O
selected  O
as  O
the  O
recommended  O
dose  O
.  O

Applicable  O
responses  O
were  O
one  O
complete  O
response  O
and  O
nine  O
partial  O
responses  O
(  O
48  O
%  O
)  O
.  O

As  O
toxicities  O
were  O
well  O
tolerated  O
and  O
antitumour  O
activities  O
seem  O
to  O
be  O
promising  O
,  O
this  O
combination  O
can  O
be  O
recommended  O
for  O
further  O
phase  O
II  O
studies  O
with  O
APC  B-CANCER
.  O

Capecitabine  B-DRUG
plus  O
oxaliplatin  B-DRUG
for  O
the  O
first-line  O
treatment  O
of  O
elderly  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
:  O
final  O
results  O
of  O
the  O
Southern  O
Italy  O
Cooperative  O
Oncology  O
Group  O
Trial  O
0108  O
.  O


In  O
patients  O
with  O
metastatic  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
(  O
MCC  B-CANCER
)  O
,  O
capecitabine  O
has  O
demonstrated  O
a  O
superior  O
response  O
rate  O
(  O
RR  O
)  O
,  O
equivalent  O
disease  O
progression-free  O
(  O
PFS  O
)  O
and  O
overall  O
survival  O
(  O
OS  O
)  O
,  O
and  O
an  O
improved  O
overall  O
tolerability  O
profile  O
compared  O
with  O
bolus  O
5-fluorouracil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
(  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
)  O
.  O

The  O
FOLFOX4  B-DRUG
regimen  O
,  O
combining  O
oxaliplatin  O
with  O
LV  B-DRUG
and  O
bolus  O
plus  O
infusional  O
5-FU  B-DRUG
(  O
LV5FU2  B-DRUG
)  O
,  O
has  O
been  O
shown  O
to  O
improve  O
RR  O
and  O
PFS  O
versus  O
LV5FU2  B-DRUG
,  O
and  O
it  O
was  O
more  O
effective  O
and  O
less  O
toxic  O
than  O
irinotecan  B-DRUG
plus  O
bolus  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
.  O

Capecitabine  B-DRUG
(  O
an  O
oral  O
fluoropyrimidine  B-DRUG
)  O
may  O
be  O
an  O
effective  O
,  O
well  O
tolerated  O
,  O
and  O
more  O
convenient  O
alternative  O
to  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
in  O
combination  O
with  O
oxaliplatin  B-DRUG
,  O
especially  O
in  O
older  O
patients  O
.  O

Elderly  O
(  O
&  O
gt  O
;  O
or  O
=  O
70  O
years  O
)  O
patients  O
with  O
MCC  B-CANCER
were  O
treated  O
with  O
a  O
3-weekly  O
regimen  O
of  O
oxaliplatin  B-DRUG
at  O
an  O
initial  O
dose  O
of  O
85  O
mg  O
/  O
m  O
(  O
2  O
)  O
intravenously  O
on  O
Day  O
1  O
plus  O
capecitabine  B-DRUG
1000  O
mg  O
/  O
m  O
(  O
2  O
)  O
orally  O
twice  O
daily  O
from  O
Days  O
2  O
to  O
15  O
(  O
XELOX  O
regimen  O
)  O
.  O

In  O
the  O
absence  O
of  O
Grade  O
&  O
gt  O
;  O
or  O
=  O
2  O
hematologic  B-TOXI
toxicity  I-TOXI
,  O
oxaliplatin  B-DRUG
was  O
increased  O
to  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
the  O
second  O
cycle  O
,  O
and  O
in  O
the  O
absence  O
of  O
Grade  O
&  O
gt  O
;  O
or  O
=  O
2  O
nonhematologic  B-TOXI
adverse  I-TOXI
events  I-TOXI
during  O
Cycle  O
2  O
,  O
capecitabine  B-DRUG
was  O
increased  O
to  O
1250  O
mg  O
/  O
m  O
(  O
2  O
)  O
twice  O
daily  O
in  O
the  O
third  O
and  O
subsequent  O
cycles  O
.  O

After  O
the  O
first  O
35  O
patients  O
(  O
first  O
series  O
)  O
,  O
the  O
treatment  O
protocol  O
was  O
amended  O
so  O
that  O
only  O
an  O
oxaliplatin  B-DRUG
increase  O
to  O
110  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
130  O
mg  O
/  O
m  O
(  O
2  O
)  O
during  O
Cycles  O
2  O
and  O
3  O
,  O
respectively  O
,  O
was  O
planned  O
in  O
the  O
remaining  O
41  O
patients  O
(  O
second  O
series  O
)  O
.  O

Seventy-six  O
patients  O
with  O
a  O
median  O
age  O
of  O
75  O
years  O
(  O
range  O
,  O
70-82  O
years  O
)  O
entered  O
the  O
current  O
study  O
.  O

In  O
the  O
first  O
series  O
,  O
the  O
oxaliplatin  B-DRUG
dose  O
was  O
increased  O
in  O
18  O
(  O
51  O
%  O
)  O
patients  O
,  O
and  O
the  O
capecitabine  B-DRUG
dose  O
was  O
increased  O
in  O
4  O
(  O
11  O
%  O
)  O
patients  O
.  O

In  O
the  O
second  O
series  O
,  O
the  O
oxaliplatin  B-DRUG
dose  O
was  O
increased  O
to  O
110  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
26  O
(  O
63  O
%  O
)  O
patients  O
,  O
and  O
to  O
130  O
mg  O
/  O
m  O
(  O
2  O
)  O
in  O
19  O
(  O
46  O
%  O
)  O
patients  O
.  O

In  O
all  O
,  O
2  O
complete  O
and  O
29  O
partial  O
responses  O
were  O
observed  O
,  O
for  O
an  O
overall  O
RR  O
of  O
41  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
[  O
CI  O
]  O
,  O
30-53  O
%  O
)  O
.  O

The  O
median  O
PFS  O
was  O
8.5  O
months  O
(  O
95  O
%  O
CI  O
,  O
6.7-10.3  O
months  O
)  O
,  O
and  O
the  O
median  O
OS  O
was  O
14.4  O
months  O
(  O
95  O
%  O
CI  O
,  O
11.9-16.9  O
months  O
)  O
.  O

In  O
a  O
multivariate  O
analysis  O
,  O
the  O
presence  O
of  O
disease  O
symptoms  O
affected  O
both  O
PFS  O
and  O
OS  O
,  O
whereas  O
OS  O
also  O
was  O
independently  O
affected  O
by  O
male  O
gender  O
and  O
disease  O
spread  O
.  O

Age  O
had  O
no  O
independent  O
effect  O
on  O
PFS  O
or  O
OS  O
.  O

Five  O
percent  O
of  O
patients  O
developed  O
Grade  O
&  O
gt  O
;  O
or  O
=  O
3  O
hematologic  B-TOXI
toxicity  I-TOXI
during  O
treatment  O
,  O
Grade  O
3  O
peripheral  B-TOXI
neuropathy  I-TOXI
occurred  O
in  O
8  O
%  O
of  O
patients  O
,  O
and  O
severe  B-TOXI
hand-foot  I-TOXI
syndrome  I-TOXI
in  O
13  O
%  O
of  O
patients  O
.  O

Fit  O
elderly  O
patients  O
with  O
MCC  B-CANCER
showed  O
a  O
good  O
RR  O
to  O
XELOX  O
with  O
only  O
mild  O
toxicity  O
observed  O
in  O
most  O
patients  O
.  O

XELOX  O
,  O
should  O
,  O
therefore  O
be  O
considered  O
as  O
an  O
important  O
therapeutic  O
option  O
for  O
elderly  O
patients  O
with  O
MCC  B-CANCER
.  O

Pharmacokinetically  O
guided  O
phase  O
I  O
trial  O
of  O
topotecan  B-DRUG
and  O
etoposide  B-DRUG
phosphate  I-DRUG
in  O
recurrent  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O


A  O
pharmacokinetically  O
guided  O
phase  O
I  O
study  O
of  O
topotecan  B-DRUG
and  O
etoposide  B-DRUG
phosphate  I-DRUG
was  O
conducted  O
in  O
recurrent  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

The  O
scheduling  O
of  O
the  O
topoisomerase  B-DRUG
I  O
and  O
II  O
inhibitors  O
was  O
determined  O
using  O
in  O
vitro  O
activity  O
data  O
.  O

All  O
patients  O
had  O
recurrent  O
disease  O
following  O
prior  O
platinum-containing  B-DRUG
chemotherapy  O
.  O

Patients  O
had  O
a  O
World  O
Health  O
Organisation  O
performance  O
status  O
of  O
0-2  O
and  O
adequate  O
bone  O
marrow  O
,  O
renal  O
and  O
hepatic  O
function  O
.  O

Treatment  O
was  O
with  O
topotecan  B-DRUG
intravenously  O
for  O
5  O
days  O
followed  O
immediately  O
by  O
a  O
5-day  O
intravenous  O
infusion  O
of  O
etoposide  B-DRUG
phosphate  I-DRUG
(  O
EP  B-DRUG
)  O
,  O
with  O
pharmacokinetically  O
guided  O
dose  O
adjustment  O
.  O

Plasma  B-DRUG
etoposide  I-DRUG
levels  O
were  O
measured  O
on  O
days  O
2  O
and  O
4  O
of  O
the  O
infusion  O
.  O

A  O
total  O
of  O
21  O
patients  O
entered  O
the  O
study  O
.  O

In  O
all  O
,  O
48  O
%  O
were  O
platinum  B-DRUG
resistant  O
and  O
71  O
%  O
had  O
received  O
prior  O
paclitaxel  B-DRUG
.  O

The  O
main  O
toxicities  O
were  O
haematological  O
,  O
short  O
lived  O
and  O
reversible  O
.  O

A  O
total  O
of  O
29  O
%  O
of  O
patients  O
experienced  O
grade  O
4  O
thrombocytopenia  B-TOXI
and  O
66  O
%  O
grade  O
4  O
neutropenia  B-TOXI
after  O
the  O
first  O
cycle  O
.  O

Neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
was  O
dose  O
limiting  O
.  O

The  O
maximum-tolerated  O
dose  O
was  O
topotecan  B-DRUG
0.85  O
mg  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
days  O
1-5  O
followed  O
immediately  O
by  O
a  O
5-day  O
infusion  O
of  O
EP  B-DRUG
at  O
a  O
plasma  O
concentration  O
of  O
1  O
mug  O
ml  O
(  O
-1  O
)  O
.  O

The  O
response  O
rate  O
(  O
RR  O
)  O
was  O
28  O
%  O
in  O
18  O
evaluable  O
patients  O
.  O

There  O
was  O
marked  O
interpatient  O
variability  O
in  O
topoisomerase  B-DRUG
IIalpha  O
levels  O
measured  O
from  O
peripheral  O
lymphocytes  O
,  O
with  O
no  O
observed  O
increase  O
following  O
topotecan  B-DRUG
.  O

This  O
regimen  O
of  O
topotecan  B-DRUG
followed  O
by  O
EP  B-DRUG
demonstrated  O
good  O
activity  O
in  O
recurrent  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
and  O
was  O
noncrossresistant  O
with  O
paclitaxel  B-DRUG
.  O

Both  O
the  O
toxicity  O
and  O
RR  O
was  O
higher  O
than  O
would  O
be  O
expected  O
from  O
the  O
single  O
agent  O
data  O
,  O
in  O
keeping  O
with  O
synergy  O
of  O
action  O
.  O

Phase  O
I  O
study  O
of  O
etoposide  B-DRUG
,  O
cisplatin  B-DRUG
and  O
irinotecan  B-DRUG
triplet  O
in  O
patients  O
with  O
advanced-stage  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


The  O
irinotecan-cisplatin  B-DRUG
combination  O
has  O
emerged  O
as  O
a  O
new  O
standard  O
for  O
the  O
treatment  O
of  O
advanced-stage  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
AS-SCLC  B-CANCER
)  O
.  O

To  O
move  O
forward  O
we  O
developed  O
a  O
3-day  O
regimen  O
of  O
cisplatin  B-DRUG
,  O
etoposide  B-DRUG
and  O
irinotecan  B-DRUG
.  O

Successive  O
cohorts  O
of  O
AS-SCLC  B-CANCER
patients  O
were  O
treated  O
with  O
irinotecan  B-DRUG
administered  O
as  O
a  O
single  O
1-h  O
infusion  O
in  O
combination  O
with  O
fixed  O
doses  O
of  O
cisplatin  B-DRUG
(  O
20  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
and  O
etoposide  B-DRUG
(  O
75  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
,  O
both  O
given  O
for  O
three  O
consecutive  O
days  O
(  O
ECI  B-DRUG
regimen  O
)  O
.  O

Irinotecan  B-DRUG
dose  O
was  O
escalated  O
from  O
60  O
mg  O
/  O
m  O
(  O
2  O
)  O
by  O
40-mg  O
/  O
m  O
(  O
2  O
)  O
increments  O
.  O

At  O
mid-step  O
between  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
the  O
previous  O
dose  O
level  O
,  O
patients  O
were  O
randomized  O
for  O
the  O
day  O
of  O
administration  O
of  O
irinotecan  B-DRUG
(  O
day  O
1  O
vs  O
day  O
3  O
)  O
.  O

A  O
total  O
of  O
36  O
AS-SCLC  B-CANCER
patients  O
received  O
166  O
courses  O
of  O
treatment  O
at  O
four  O
dose  O
levels  O
.  O

The  O
MTD  O
of  O
irinotecan  B-DRUG
was  O
140  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
three  O
dose-limiting  O
toxicities  O
,  O
DLTs  O
)  O
,  O
and  O
the  O
recommended  O
optimal  O
dose  O
(  O
ROD  O
)  O
120  O
mg  O
/  O
m  O
(  O
2  O
)  O
(  O
two  O
DLTs  O
)  O
.  O

DLTs  O
were  O
febrile  B-TOXI
neutropenia  I-TOXI
and  O
grade  O
3  O
diarrhea  B-TOXI
.  O

Other  O
toxicities  O
were  O
mild  O
.  O

No  O
difference  O
in  O
toxicity  O
was  O
seen  O
between  O
the  O
two  O
time  O
schedules  O
.  O

A  O
77  O
%  O
(  O
95  O
%  O
CI  O
63.25-90.75  O
%  O
)  O
response  O
rate  O
was  O
recorded  O
among  O
31  O
evaluable  O
patients  O
and  O
the  O
median  O
survival  O
was  O
12  O
months  O
.  O

The  O
ECI  B-DRUG
regimen  O
was  O
well  O
tolerated  O
and  O
showed  O
considerable  O
activity  O
in  O
patients  O
with  O
AS-SCLC  B-CANCER
.  O

Phase  O
II  O
/  O
III  O
evaluation  O
is  O
ongoing  O
.  O

Carboplatin  B-DRUG
plus  O
paclitaxel  B-DRUG
in  O
the  O
treatment  O
of  O
advanced  O
or  O
recurrent  O
endometrial  B-CANCER
carcinoma  I-CANCER
.  O


To  O
evaluate  O
the  O
efficacy  O
and  O
safety  O
of  O
the  O
combination  O
of  O
carboplatin  B-DRUG
plus  O
paclitaxel  B-DRUG
in  O
patients  O
with  O
advanced  O
,  O
metastatic  O
and  O
recurrent  O
endometrial  B-CANCER
cancer  I-CANCER
.  O

Medical  O
records  O
were  O
retrospectively  O
reviewed  O
to  O
identify  O
endometrial  B-CANCER
cancer  I-CANCER
patients  O
treated  O
in  O
the  O
Gynecologic  O
Cancer  O
Program  O
of  O
the  O
Cleveland  O
Clinic  O
with  O
carboplatin  B-DRUG
/  I-DRUG
paclitaxel  I-DRUG
who  O
had  O
both  O
a  O
histologic  O
diagnosis  O
of  O
endometrial  B-CANCER
adenocarcinoma  I-CANCER
and  O
either  O
measurable  O
(  O
CT  O
scan  O
,  O
physical  O
examination  O
)  O
or  O
evaluable  O
(  O
CA-125  O
criteria  O
)  O
disease  O
.  O

From  O
1994  O
to  O
2003  O
,  O
22  O
individuals  O
(  O
median  O
age  O
65  O
years  O
)  O
meeting  O
the  O
above  O
noted  O
criteria  O
received  O
a  O
total  O
of  O
23  O
courses  O
of  O
carboplatin  B-DRUG
(  O
AUC  O
4-6  O
)  O
/  O
paclitaxel  B-DRUG
(  O
135-175  O
mg  O
/  O
m2  O
)  O
administered  O
on  O
a  O
21-day  O
schedule  O
(  O
median  O
six  O
cycles  O
/  O
patient  O
)  O
.  O

The  O
overall  O
response  O
rate  O
was  O
87  O
%  O
(  O
20  O
/  O
23  O
)  O
.  O

The  O
most  O
common  O
toxicity  O
was  O
hematologic  O
.  O

Five  O
patients  O
required  O
dose  O
reductions  O
due  O
to  O
excessive  O
toxicity  O
(  O
three  O
hematologic  O
,  O
one  O
gastrointestinal  O
,  O
one  O
fatigue  B-TOXI
)  O
.  O

There  O
were  O
no  O
treatment  B-TOXI
related  I-TOXI
deaths  I-TOXI
.  O

With  O
a  O
median  O
follow-up  O
of  O
42  O
months  O
,  O
13  O
patients  O
have  O
died  B-TOXI
of  I-TOXI
progressive  I-TOXI
cancer  I-TOXI
,  O
while  O
four  O
currently  O
have  O
no  O
evidence  O
of  O
disease  O
at  O
the  O
time  O
of  O
last  O
follow-up  O
.  O

The  O
combination  O
of  O
carboplatin  B-DRUG
plus  O
paclitaxel  B-DRUG
demonstrates  O
substantial  O
biological  O
activity  O
in  O
endometrial  B-CANCER
adenocarcinoma  I-CANCER
.  O

The  O
safety  O
and  O
efficacy  O
of  O
this  O
regimen  O
makes  O
it  O
an  O
attractive  O
option  O
for  O
first-line  O
chemotherapy  O
in  O
patients  O
with  O
advanced  O
or  O
recurrent  O
endometrial  B-CANCER
carcinoma  I-CANCER
.  O

Gemcitabine  B-DRUG
with  O
or  O
without  O
continuous  O
infusion  O
5-FU  B-DRUG
in  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
:  O
a  O
randomised  O
phase  O
II  O
trial  O
of  O
the  O
Italian  O
oncology  O
group  O
for  O
clinical  O
research  O
(  O
GOIRC  O
)  O
.  O


This  O
study  O
was  O
performed  O
to  O
determine  O
the  O
activity  O
of  O
adding  O
continuous  O
infusion  O
(  O
CI  O
)  O
of  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
to  O
gemcitabine  B-DRUG
(  O
GEM  B-DRUG
)  O
vs  O
GEM  B-DRUG
alone  O
in  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
(  O
APC  B-CANCER
)  O
.  O

In  O
all  O
,  O
94  O
chemo-na√Øve  O
patients  O
with  O
APC  B-CANCER
were  O
randomised  O
to  O
receive  O
GEM  B-DRUG
alone  O
(  O
arm  O
A  O
:  O
1000  O
mg  O
m  O
(  O
-2  O
)  O
per  O
week  O
for  O
7  O
weeks  O
followed  O
by  O
a  O
2  O
week  O
rest  O
period  O
,  O
then  O
weekly  O
for  O
3  O
consecutive  O
weeks  O
out  O
of  O
every  O
4  O
weeks  O
)  O
or  O
in  O
combination  O
with  O
CI  O
5-FU  B-DRUG
(  O
arm  O
B  O
:  O
CI  O
5-FU  B-DRUG
200  O
mg  O
m  O
(  O
-2  O
)  O
day  O
(  O
-1  O
)  O
for  O
6  O
weeks  O
followed  O
by  O
a  O
2  O
week  O
rest  O
period  O
,  O
then  O
for  O
3  O
weeks  O
every  O
4  O
weeks  O
)  O
.  O

Overall  O
response  O
rate  O
(  O
RR  O
)  O
was  O
the  O
primary  O
end  O
point  O
and  O
criteria  O
for  O
decision  O
were  O
planned  O
according  O
to  O
the  O
Simon  O
's  O
optimal  O
two-stage  O
design  O
.  O

The  O
overall  O
RR  O
was  O
8  O
%  O
(  O
arm  O
A  O
)  O
and  O
11  O
%  O
(  O
arm  O
B  O
)  O
(  O
95  O
%  O
confidence  O
interval  O
:  O
0.5-16  O
%  O
and  O
2-22  O
%  O
)  O
,  O
respectively  O
,  O
and  O
stable  O
disease  O
was  O
29  O
and  O
28  O
%  O
.  O

The  O
median  O
duration  O
of  O
RR  O
was  O
34  O
weeks  O
(  O
range  O
25-101  O
weeks  O
)  O
for  O
GEM  B-DRUG
and  O
26  O
weeks  O
(  O
range  O
16-46  O
weeks  O
)  O
for  O
the  O
combination  O
.  O

The  O
median  O
progression-free  O
survival  O
(  O
PFS  O
)  O
was  O
14  O
weeks  O
(  O
range  O
2-65  O
weeks  O
)  O
and  O
18  O
weeks  O
(  O
range  O
4-51  O
weeks  O
)  O
,  O
respectively  O
.  O

The  O
median  O
overall  O
survival  O
(  O
OS  O
)  O
was  O
31  O
weeks  O
(  O
range  O
1-101  O
weeks  O
)  O
and  O
30  O
weeks  O
(  O
1-101  O
weeks  O
)  O
.  O

Toxicity  O
was  O
mild  O
in  O
both  O
arms  O
.  O

This  O
study  O
does  O
not  O
show  O
promising  O
activity  O
in  O
terms  O
of  O
RR  O
,  O
PFS  O
and  O
OS  O
for  O
the  O
double  O
combination  O
arm  O
in  O
APC  B-CANCER
.  O

Hepatic  O
arterial  O
oxaliplatin  B-DRUG
infusion  O
plus  O
intravenous  O
chemotherapy  O
in  O
colorectal  B-CANCER
cancer  I-CANCER
with  O
inoperable  O
hepatic  O
metastases  O
:  O
a  O
trial  O
of  O
the  O
gastrointestinal  O
group  O
of  O
the  O
Federation  O
Nationale  O
des  O
Centres  O
de  O
Lutte  O
Contre  O
le  O
Cancer  O
.  O


Isolated  O
hepatic  O
metastases  O
of  O
colorectal  B-CANCER
cancer  I-CANCER
constitute  O
a  O
frequent  O
and  O
serious  O
therapeutic  O
problem  O
that  O
has  O
led  O
to  O
the  O
evaluation  O
of  O
hepatic  O
arterial  O
infusion  O
(  O
HAI  O
)  O
of  O
different  O
drugs  O
.  O

Oxaliplatin  B-DRUG
combined  O
with  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
)  O
and  O
leucovorin  B-DRUG
is  O
effective  O
in  O
the  O
treatment  O
of  O
colorectal  B-CANCER
cancer  I-CANCER
.  O

In  O
this  O
context  O
,  O
a  O
phase  O
II  O
study  O
was  O
conducted  O
to  O
evaluate  O
concomitant  O
administration  O
of  O
oxaliplatin  B-DRUG
by  O
HAI  O
and  O
intravenous  O
(  O
IV  O
)  O
FU  B-DRUG
plus  O
leucovorin  B-DRUG
according  O
to  O
the  O
LV5FU2  B-DRUG
protocol  O
(  O
leucovorin  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
FU  B-DRUG
400  O
mg  O
/  O
m  O
(  O
2  O
)  O
IV  O
bolus  O
,  O
FU  B-DRUG
600  O
mg  O
/  O
m  O
(  O
2  O
)  O
22-hour  O
continuous  O
infusion  O
on  O
days  O
1  O
and  O
2  O
every  O
2  O
weeks  O
)  O
.  O

Patients  O
had  O
metastatic  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
that  O
was  O
restricted  O
to  O
the  O
liver  O
and  O
inoperable  O
.  O

The  O
patients  O
were  O
not  O
to  O
have  O
previously  O
received  O
oxaliplatin  B-DRUG
.  O

After  O
surgical  O
insertion  O
of  O
a  O
catheter  O
in  O
the  O
hepatic  O
artery  O
,  O
patients  O
were  O
treated  O
with  O
oxaliplatin  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
HAI  O
combined  O
with  O
FU  B-DRUG
+  O
leucovorin  B-DRUG
IV  O
according  O
to  O
the  O
LV5FU2  B-DRUG
protocol  O
.  O

Treatment  O
was  O
continued  O
until  O
disease  B-TOXI
progression  I-TOXI
or  O
toxicity  O
.  O

Response  O
was  O
evaluated  O
every  O
2  O
months  O
.  O

Twenty-eight  O
patients  O
were  O
included  O
,  O
and  O
26  O
patients  O
were  O
treated  O
.  O

Two  O
hundred  O
courses  O
of  O
therapy  O
were  O
administered  O
,  O
and  O
the  O
median  O
number  O
of  O
courses  O
received  O
was  O
eight  O
courses  O
(  O
range  O
,  O
zero  O
to  O
20  O
courses  O
)  O
.  O

The  O
most  O
frequent  O
toxicity  O
consisted  O
of  O
neutropenia  B-TOXI
.  O

The  O
main  O
toxicity  O
related  O
to  O
HAI  O
was  O
pain  B-TOXI
.  O

The  O
intent-to-treat  O
objective  O
response  O
rate  O
was  O
64  O
%  O
(  O
95  O
%  O
CI  O
,  O
44  O
%  O
to  O
81  O
%  O
;  O
18  O
of  O
28  O
patients  O
)  O
.  O

With  O
a  O
median  O
follow-up  O
of  O
23  O
months  O
,  O
the  O
median  O
overall  O
and  O
disease-free  O
survival  O
times  O
were  O
27  O
and  O
27  O
months  O
,  O
respectively  O
.  O

The  O
combination  O
of  O
oxaliplatin  B-DRUG
HAI  O
and  O
FU  B-DRUG
+  O
leucovorin  B-DRUG
according  O
to  O
the  O
LV5FU2  B-DRUG
protocol  O
is  O
feasible  O
and  O
effective  O
in  O
patients  O
presenting  O
with  O
isolated  O
hepatic  O
metastases  O
of  O
colorectal  B-CANCER
cancer  I-CANCER
.  O

Phase  O
II  O
study  O
of  O
weekly  O
oxaliplatin  B-DRUG
plus  O
infusional  O
fluorouracil  B-DRUG
and  O
folinic  B-DRUG
acid  I-DRUG
(  O
FUFOX  B-DRUG
regimen  O
)  O
as  O
first-line  O
treatment  O
in  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


Oxaliplatin  B-DRUG
plus  O
fluorouracil  B-DRUG
/  I-DRUG
folinic  I-DRUG
acid  I-DRUG
(  O
5-FU  B-DRUG
/  I-DRUG
FA  I-DRUG
)  O
every  O
2  O
weeks  O
has  O
shown  O
promising  O
activity  O
in  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

This  O
study  O
assessed  O
the  O
efficacy  O
and  O
safety  O
of  O
weekly  O
oxaliplatin  B-DRUG
plus  O
5-FU  B-DRUG
/  I-DRUG
FA  I-DRUG
(  O
FUFOX  B-DRUG
regimen  O
)  O
in  O
the  O
metastatic  O
setting  O
.  O

Patients  O
with  O
previously  O
untreated  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
received  O
oxaliplatin  B-DRUG
(  O
50  O
mg  O
m  O
(  O
-2  O
)  O
)  O
plus  O
FA  B-DRUG
(  O
500  O
mg  O
m  O
(  O
-2  O
)  O
,  O
2-h  O
infusion  O
)  O
followed  O
by  O
5-FU  B-DRUG
(  O
2000  O
mg  O
m  O
(  O
-2  O
)  O
,  O
24-h  O
infusion  O
)  O
given  O
on  O
days  O
1  O
,  O
8  O
,  O
15  O
and  O
22  O
of  O
a  O
5-week  O
cycle  O
.  O

The  O
primary  O
end  O
point  O
of  O
this  O
multicentre  O
phase  O
II  O
study  O
was  O
the  O
response  O
rate  O
according  O
to  O
RECIST  O
criteria  O
.  O

A  O
total  O
of  O
48  O
patients  O
were  O
enrolled  O
.  O

Median  O
age  O
was  O
62  O
years  O
and  O
all  O
patients  O
had  O
metastatic  O
disease  O
,  O
with  O
a  O
median  O
number  O
of  O
three  O
involved  O
organs  O
.  O

The  O
most  O
common  O
treatment-related  O
grade  O
3  O
/  O
4  O
adverse  O
events  O
were  O
diarrhoea  B-TOXI
(  O
17  O
%  O
)  O
,  O
deep  B-TOXI
vein  I-TOXI
thrombosis  I-TOXI
(  O
15  O
%  O
)  O
,  O
neutropenia  B-TOXI
(  O
8  O
%  O
)  O
,  O
nausea  B-TOXI
(  O
6  O
%  O
)  O
,  O
febrile  B-TOXI
neutropenia  I-TOXI
(  O
4  O
%  O
)  O
,  O
fatigue  B-TOXI
(  O
4  O
%  O
)  O
,  O
anaemia  B-TOXI
(  O
4  O
%  O
)  O
,  O
tumour  B-TOXI
bleeding  I-TOXI
(  O
4  O
%  O
)  O
,  O
emesis  B-TOXI
(  O
2  O
%  O
)  O
,  O
cardiac  B-TOXI
ischaemia  I-TOXI
(  O
2  O
%  O
)  O
and  O
pneumonia  B-TOXI
(  O
2  O
%  O
)  O
.  O

Grade  O
1  O
/  O
2  O
sensory  B-TOXI
neuropathy  I-TOXI
occurred  O
in  O
67  O
%  O
of  O
patients  O
but  O
there  O
were  O
no  O
episodes  O
of  O
grade  O
3  O
neuropathy  B-TOXI
.  O

Intent-to-treat  O
analysis  O
showed  O
a  O
response  O
rate  O
of  O
54  O
%  O
(  O
95  O
%  O
CI  O
,  O
39-69  O
%  O
)  O
,  O
including  O
two  O
complete  O
responses  O
.  O

At  O
a  O
median  O
follow-up  O
of  O
18.1  O
months  O
(  O
range  O
11.2-26.2  O
months  O
)  O
,  O
median  O
survival  O
is  O
11.4  O
months  O
(  O
95  O
%  O
CI  O
,  O
8.0-14.9  O
months  O
)  O
and  O
the  O
median  O
time  O
to  O
progression  O
is  O
6.5  O
months  O
(  O
95  O
%  O
CI  O
,  O
3.9-9.2  O
months  O
)  O
.  O

The  O
weekly  O
FUFOX  B-DRUG
regimen  O
is  O
well  O
tolerated  O
and  O
shows  O
notable  O
activity  O
as  O
first-line  O
treatment  O
in  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

Gemcitabine  B-DRUG
(  O
GEM  B-DRUG
)  O
plus  O
oxaliplatin  B-DRUG
,  O
folinic  B-DRUG
acid  I-DRUG
,  O
and  O
5-fluorouracil  B-DRUG
(  O
FOLFOX-4  B-DRUG
)  O
in  O
patients  O
with  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O


oxaliplatin  B-DRUG
in  O
combination  O
with  O
folinic  B-DRUG
acid  I-DRUG
(  O
FA  B-DRUG
)  O
and  O
infusional  O
5-fluorouracil  B-DRUG
(  O
5-FU  B-DRUG
)  O
has  O
shown  O
significant  O
anti-tumor  O
activity  O
in  O
gastric  B-CANCER
cancer  I-CANCER
patients  I-CANCER
(  O
FOLFOX  B-DRUG
)  O
.  O

Previous  O
studies  O
have  O
shown  O
that  O
gemcitabine  B-DRUG
(  O
GEM  B-DRUG
)  O
,  O
a  O
new  O
fluorinated  O
anti-metabolite  O
,  O
enhances  O
the  O
individual  O
anti-tumor  O
activity  O
of  O
either  O
5-FU  B-DRUG
or  O
oxaliplatin  B-DRUG
.  O

We  O
have  O
therefore  O
designed  O
a  O
multi-center  O
phase  O
II  O
trial  O
in  O
order  O
to  O
test  O
a  O
novel  O
GEM+FOLFOX-4  B-DRUG
regimen  O
in  O
patients  O
with  O
metastatic  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

we  O
enrolled  O
36  O
patients  O
,  O
28  O
males  O
and  O
8  O
females  O
,  O
with  O
an  O
average  O
age  O
of  O
64.4  O
years  O
(  O
range  O
37-78  O
)  O
,  O
who  O
received  O
bi-weekly  O
treatment  O
with  O
GEM  B-DRUG
(  O
1,000  O
mg  O
/  O
m2  O
on  O
day  O
1  O
)  O
,  O
levo-FA  B-DRUG
(  O
100  O
mg  O
/  O
m2  O
on  O
days  O
1  O
and  O
2  O
)  O
,  O
a  O
5-FU  B-DRUG
(  O
400  O
mg  O
/  O
m2  O
)  O
bolus  O
injection  O
followed  O
by  O
22-h  O
continuous  O
infusion  O
(  O
800  O
mg  O
/  O
m2  O
)  O
on  O
days  O
1  O
and  O
2  O
,  O
and  O
oxaliplatin  B-DRUG
85  O
mg  O
/  O
m2  O
in  O
a  O
4-6  O
h  O
intravenous  O
(  O
i.v.  O
)  O
infusion  O
before  O
the  O
second  O
FUFA  B-DRUG
administration  O
on  O
day  O
2.  O
the  O
most  O
frequent  O
side  O
effect  O
was  O
grade  O
1-2  O
hematological  B-TOXI
toxicity  I-TOXI
and  O
late  O
sensorial  B-TOXI
neurotoxicity  I-TOXI
.  O

Two  O
patients  O
developed  O
hypersensitivity  B-TOXI
to  O
oxaliplatin  B-DRUG
while  O
another  O
developed  O
an  O
aseptic  B-TOXI
eosinophilic  I-TOXI
pneumonitis  I-TOXI
.  O

Two  O
patients  O
refused  O
to  O
continue  O
the  O
treatment  O
after  O
two  O
cycles  O
of  O
chemotherapy  O
and  O
were  O
lost  O
at  O
the  O
follow-up  O
.  O

Among  O
the  O
remaining  O
34  O
patients  O
four  O
achieved  O
a  O
complete  O
response  O
,  O
15  O
a  O
partial  O
response  O
,  O
12  O
had  O
a  O
stable  O
disease  O
and  O
three  O
progressed  O
.  O

these  O
results  O
may  O
grant  O
the  O
rationale  O
to  O
evaluate  O
this  O
multi-drug  O
combination  O
in  O
randomized  O
phase  O
III  O
trials  O
in  O
advanced  B-CANCER
gastric  I-CANCER
cancer  I-CANCER
.  O

A  O
phase  O
I  O
study  O
to  O
determine  O
the  O
effect  O
of  O
tamoxifen  B-DRUG
on  O
the  O
pharmacokinetics  O
of  O
a  O
single  O
250  O
mg  O
oral  O
dose  O
of  O
gefitinib  B-DRUG
(  O
IRESSA  O
)  O
in  O
healthy  O
male  O
volunteers  O
.  O


To  O
determine  O
the  O
effect  O
of  O
tamoxifen  B-DRUG
on  O
the  O
pharmacokinetics  O
of  O
a  O
single  O
250  O
mg  O
oral  O
dose  O
of  O
gefitinib  B-DRUG
(  O
IRESSA  O
)  O
in  O
healthy  O
volunteers  O
.  O

An  O
open-label  O
,  O
single-center  O
,  O
phase  O
I  O
study  O
in  O
healthy  O
male  O
volunteers  O
.  O

Each  O
volunteer  O
received  O
a  O
single  O
250  O
mg  O
oral  O
dose  O
of  O
gefitinib  B-DRUG
on  O
day  O
1.  O
On  O
days  O
11-14  O
,  O
oral  O
loading  O
doses  O
of  O
60  O
mg  O
tamoxifen  B-DRUG
were  O
administered  O
,  O
followed  O
by  O
20  O
mg  O
tamoxifen  B-DRUG
for  O
a  O
further  O
16  O
days  O
to  O
maintain  O
steady-state  O
exposure  O
.  O

On  O
day  O
24  O
,  O
volunteers  O
received  O
a  O
second  O
single  O
250  O
mg  O
oral  O
dose  O
of  O
gefitinib  B-DRUG
.  O

The  O
last  O
dose  O
of  O
tamoxifen  B-DRUG
was  O
given  O
on  O
day  O
30  O
.  O

Pharmacokinetic  O
and  O
safety  O
assessments  O
were  O
conducted  O
throughout  O
the  O
trial  O
.  O

A  O
total  O
of  O
18  O
volunteers  O
were  O
recruited  O
.  O

The  O
presence  O
of  O
tamoxifen  B-DRUG
did  O
not  O
have  O
a  O
clinically  O
significant  O
effect  O
on  O
the  O
primary  O
variables  O
AUC  O
and  O
Cmax  O
of  O
gefitinib  B-DRUG
,  O
nor  O
on  O
the  O
secondary  O
variables  O
AUC  O
(  O
0-t  O
)  O
,  O
tmax  O
,  O
t1  O
/  O
2  O
,  O
and  O
lambdaz  O
.  O

The  O
geometric  O
least  O
square  O
mean  O
values  O
for  O
AUC  O
were  O
3,407.6  O
versus  O
3,397.9  O
ng.h  O
/  O
ml  O
in  O
the  O
absence  O
and  O
presence  O
of  O
tamoxifen  B-DRUG
,  O
respectively  O
(  O
90  O
%  O
CL  O
0.894  O
,  O
1.112  O
)  O
and  O
for  O
Cmax  O
were  O
110.8  O
versus  O
103.6  O
ng  O
/  O
ml  O
,  O
respectively  O
(  O
90  O
%  O
CL  O
0.786  O
,  O
1.111  O
)  O
.  O

The  O
combination  O
of  O
gefitinib  B-DRUG
with  O
tamoxifen  B-DRUG
was  O
generally  O
well  O
tolerated  O
by  O
the  O
volunteers  O
.  O

There  O
were  O
no  O
serious  O
adverse  O
events  O
and  O
no  O
volunteer  O
discontinued  O
the  O
study  O
due  O
to  O
an  O
adverse  O
event  O
.  O

NCI-CTC  O
grade  O
1  O
/  O
2  O
drug-related  O
adverse  O
events  O
were  O
observed  O
in  O
seven  O
volunteers  O
,  O
including  O
loose  B-TOXI
stools  I-TOXI
and  O
skin  B-TOXI
events  I-TOXI
associated  O
with  O
gefitinib  B-DRUG
,  O
and  O
lethargy  B-TOXI
and  O
headache  B-TOXI
,  O
flushing  B-TOXI
,  O
and  O
dizziness  B-TOXI
associated  O
with  O
tamoxifen  B-DRUG
.  O

This  O
study  O
suggests  O
that  O
tamoxifen  B-DRUG
has  O
no  O
significant  O
effect  O
on  O
the  O
pharmacokinetics  O
,  O
tolerability  O
,  O
or  O
safety  O
of  O
a  O
single  O
250  O
mg  O
oral  O
dose  O
of  O
gefitinib  B-DRUG
.  O

Therefore  O
,  O
in  O
clinical  O
investigations  O
of  O
this  O
combination  O
,  O
no  O
dose  O
adjustment  O
of  O
gefitinib  B-DRUG
is  O
indicated  O
.  O

Fluoropyrimidine  B-DRUG
therapy  O
:  O
hyperbilirubinemia  B-TOXI
as  O
a  O
consequence  O
of  O
hemolysis  B-TOXI
.  O


Hemolytic  B-TOXI
anemia  I-TOXI
has  O
been  O
noted  O
during  O
treatment  O
with  O
a  O
variety  O
of  O
chemotherapeutic  O
agents  O
.  O

We  O
observed  O
mild  O
compensated  O
hemolytic  B-TOXI
anemia  I-TOXI
in  O
a  O
patient  O
receiving  O
capecitabine  B-DRUG
during  O
a  O
randomized  O
,  O
controlled  O
trial  O
of  O
adjuvant  O
therapy  O
.  O

In  O
order  O
to  O
investigate  O
the  O
hypothesis  O
that  O
hemolysis  B-TOXI
is  O
the  O
underlying  O
cause  O
of  O
the  O
hyperbilirubinemia  B-TOXI
sometimes  O
observed  O
during  O
capecitabine  B-DRUG
treatment  O
,  O
we  O
evaluated  O
factors  O
associated  O
with  O
hemolysis  B-TOXI
in  O
ten  O
patients  O
.  O

Factors  O
were  O
also  O
analyzed  O
in  O
ten  O
patients  O
receiving  O
5-fluorourocil  B-DRUG
/  I-DRUG
leucovorin  I-DRUG
(  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
)  O
.  O

Twenty  O
chemotherapy-na√Øve  O
patients  O
undergoing  O
surgery  O
for  O
Dukes  O
'  O
C  O
colon  B-CANCER
cancer  I-CANCER
were  O
included  O
in  O
the  O
phase  O
III  O
,  O
'X-ACT  O
'  O
trial  O
,  O
and  O
randomized  O
to  O
receive  O
24-week  O
adjuvant  O
treatment  O
with  O
either  O
oral  O
capecitabine  B-DRUG
(  O
eight  O
cycles  O
of  O
1,250  O
mg  O
/  O
m2  O
twice  O
daily  O
for  O
14  O
days  O
,  O
followed  O
by  O
a  O
7-day  O
rest  O
period  O
)  O
(  O
n=10  O
)  O
or  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
administered  O
according  O
to  O
the  O
Mayo  O
Clinic  O
regimen  O
(  O
six  O
cycles  O
of  O
LV  B-DRUG
20  O
mg  O
/  O
m2  O
followed  O
by  O
5-FU  B-DRUG
425  O
mg  O
/  O
m2  O
,  O
administered  O
as  O
an  O
i.v.  O
bolus  O
on  O
days  O
1-5  O
every  O
28  O
days  O
)  O
(  O
n=10  O
)  O
.  O

Ten  O
patients  O
randomized  O
in  O
each  O
treatment  O
arm  O
were  O
evaluated  O
.  O

Hemolytic  O
parameters  O
evaluated  O
included  O
bilirubin  O
,  O
lactate  O
dehydrogenase  O
,  O
haptoglobin  O
,  O
and  O
reticulocytes  O
.  O

Seven  O
patients  O
receiving  O
capecitabine  B-DRUG
and  O
three  O
patients  O
receiving  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
experienced  O
grade  O
1  O
/  O
2  O
elevations  O
of  O
bilirubin  B-TOXI
during  O
the  O
24-week  O
treatment  O
period  O
.  O

In  O
most  O
cases  O
,  O
hyperbilirubinemia  B-TOXI
was  O
associated  O
with  O
concomitant  O
alterations  O
in  O
other  O
hemolytic  O
parameters  O
.  O

Five  O
episodes  O
of  O
grade  O
1  O
compensated  O
hemolytic  B-TOXI
anemia  I-TOXI
were  O
reported  O
in  O
four  O
capecitabine-treated  B-DRUG
patients  O
,  O
all  O
of  O
which  O
were  O
associated  O
with  O
hyperbilirubinemia  B-TOXI
.  O

Adjuvant  O
treatment  O
with  O
capecitabine  B-DRUG
or  O
5-FU  B-DRUG
/  I-DRUG
LV  I-DRUG
in  O
a  O
small  O
sample  O
of  O
patients  O
with  O
Dukes  O
'  O
C  O
colon  B-CANCER
cancer  I-CANCER
was  O
associated  O
with  O
alterations  O
in  O
hemolytic  O
parameters  O
.  O

These  O
alterations  O
,  O
in  O
particular  O
hyperbilirubinemia  B-TOXI
,  O
were  O
associated  O
in  O
some  O
patients  O
with  O
low-grade  O
compensated  O
hemolytic  B-TOXI
anemia  I-TOXI
.  O

All  O
changes  O
were  O
clinically  O
insignificant  O
,  O
fully  O
reversible  O
,  O
and  O
may  O
represent  O
a  O
fluoropyrimidine  B-DRUG
class  O
effect  O
.  O

Further  O
studies  O
are  O
indicated  O
to  O
evaluate  O
the  O
incidence  O
and  O
implications  O
of  O
this  O
effect  O
.  O

Phase  O
II  O
study  O
with  O
a  O
combination  O
of  O
epirubicin  B-DRUG
,  O
cisplatin  B-DRUG
,  O
UFT  B-DRUG
,  O
and  O
leucovorin  B-DRUG
in  O
advanced  B-CANCER
hepatocellular  I-CANCER
carcinoma  I-CANCER
.  O


Hepatocellular  B-CANCER
carcinoma  I-CANCER
(  O
HCC  B-CANCER
)  O
is  O
one  O
of  O
the  O
most  O
common  O
malignancies  O
worldwide  O
.  O

Because  O
HCC  B-CANCER
usually  O
presents  O
as  O
an  O
advanced  O
disease  O
and  O
occurs  O
in  O
the  O
background  O
of  O
liver  O
cirrhosis  O
,  O
most  O
patients  O
are  O
not  O
suitable  O
for  O
treatment  O
with  O
curative  O
intent  O
,  O
thus  O
effective  O
systemic  O
chemotherapy  O
is  O
required  O
.  O

However  O
,  O
the  O
outcome  O
of  O
systemic  O
chemotherapy  O
has  O
been  O
disappointing  O
in  O
advanced  B-CANCER
HCC  I-CANCER
.  O

This  O
study  O
was  O
conducted  O
to  O
test  O
the  O
efficacy  O
and  O
toxicity  O
of  O
the  O
combined  O
regimen  O
of  O
epirubicin  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
UFT  B-DRUG
moderated  O
by  O
leucovorin  B-DRUG
in  O
advanced  O
or  O
recurrent  O
HCC  B-CANCER
.  O

All  O
53  O
patients  O
received  O
epirubicin  B-DRUG
(  O
50  O
mg  O
/  O
m2  O
i.v.  O
)  O
on  O
day  O
1  O
and  O
cisplatin  B-DRUG
(  O
60  O
mg  O
/  O
m2  O
i.v.  O
)  O
after  O
epirubicin  B-DRUG
administration  O
.  O

Oral  O
UFT  B-DRUG
400-600  O
mg  O
/  O
day  O
,  O
determined  O
by  O
body  O
surface  O
area  O
,  O
and  O
leucovorin  B-DRUG
75  O
mg  O
/  O
day  O
were  O
administered  O
for  O
21  O
consecutive  O
days  O
,  O
followed  O
by  O
a  O
7-day  O
drug  O
free  O
interval  O
.  O

Nine  O
had  O
a  O
partial  O
response  O
,  O
representing  O
16.9  O
%  O
of  O
response  O
rate  O
(  O
95  O
%  O
confidence  O
interval  O
rate  O
;  O
7.0-26.8  O
%  O
)  O
with  O
median  O
response  O
duration  O
of  O
17.1  O
weeks  O
(  O
95  O
%  O
CI  O
;  O
5.0-29.3  O
weeks  O
,  O
range  O
;  O
7.1-51.7  O
weeks  O
)  O
.  O

Fifteen  O
patients  O
had  O
stable  O
disease  O
and  O
the  O
disease  B-TOXI
progressed  I-TOXI
in  O
26  O
patients  O
.  O

The  O
median  O
overall  O
survival  O
for  O
the  O
patients  O
was  O
24.6  O
weeks  O
(  O
95  O
%  O
CI  O
;  O
17.3-31.9  O
weeks  O
,  O
range  O
;  O
3.0-131.3  O
weeks  O
)  O
.  O

The  O
main  O
toxicities  O
were  O
hematologic  B-TOXI
toxicities  I-TOXI
including  O
neutropenia  B-TOXI
,  O
which  O
reached  O
grade  O
3  O
/  O
4  O
in  O
17  O
patients  O
(  O
38.5  O
%  O
)  O
,  O
and  O
grade  O
3  O
or  O
4  O
thrombocytopenia  B-TOXI
in  O
five  O
patients  O
(  O
9.4  O
%  O
)  O
.  O

The  O
combination  O
of  O
epirubicin  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
UFT  B-DRUG
moderated  O
by  O
leucovorin  B-DRUG
showed  O
modest  O
anti-tumor  O
activity  O
with  O
relatively  O
tolerable  O
toxicities  O
.  O

However  O
,  O
a  O
randomized  O
phase  O
III  O
trial  O
based  O
on  O
this  O
regimen  O
is  O
warranted  O
to  O
clarify  O
its  O
survival  O
benefit  O
in  O
patients  O
with  O
advanced  B-CANCER
HCC  I-CANCER
.  O

Bi-weekly  O
chemotherapy  O
of  O
paclitaxel  B-DRUG
and  O
cisplatin  B-DRUG
in  O
patients  O
with  O
metastatic  O
or  O
recurrent  O
esophageal  B-CANCER
cancer  I-CANCER
.  O


Although  O
various  O
combinations  O
of  O
chemotherapy  O
regimens  O
have  O
been  O
tried  O
for  O
patients  O
with  O
esophageal  B-CANCER
cancer  I-CANCER
,  O
their  O
duration  O
of  O
survival  O
is  O
extremely  O
poor  O
.  O

In  O
this  O
study  O
,  O
we  O
investigated  O
the  O
safety  O
and  O
clinical  O
efficacy  O
of  O
paclitaxel  B-DRUG
and  O
cisplatin  B-DRUG
chemotherapy  O
in  O
metastatic  O
or  O
recurrent  O
esophageal  B-CANCER
cancer  I-CANCER
.  O

32  O
patients  O
enrolled  O
in  O
this  O
study  O
and  O
the  O
median  O
age  O
was  O
60  O
yr  O
.  O

Of  O
all  O
the  O
32  O
,  O
28  O
patients  O
(  O
88  O
%  O
)  O
had  O
been  O
treated  O
previously  O
,  O
22  O
of  O
them  O
with  O
chemotherapy  O
or  O
radiation  O
therapy  O
.  O

All  O
patients  O
in  O
the  O
study  O
received  O
biweekly  O
paclitaxel  B-DRUG
(  O
90  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
followed  O
by  O
cisplatin  B-DRUG
(  O
50  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
.  O

One  O
patient  O
(  O
3  O
%  O
)  O
responded  O
completely  O
,  O
and  O
12  O
patients  O
(  O
38  O
%  O
)  O
showed  O
a  O
partial  O
response  O
;  O
in  O
9  O
patients  O
(  O
28  O
%  O
)  O
the  O
disease  O
remained  O
stable  O
,  O
and  O
in  O
10  O
patients  O
(  O
31  O
%  O
)  O
it  O
progressed  O
.  O

The  O
objective  O
response  O
rate  O
was  O
41  O
%  O
.  O

The  O
median  O
duration  O
of  O
response  O
was  O
4.8  O
months  O
,  O
and  O
the  O
median  O
overall  O
survival  O
in  O
all  O
patients  O
was  O
7  O
months  O
.  O

The  O
1-yr  O
and  O
2-yr  O
survival  O
rates  O
were  O
28.1  O
%  O
and  O
7.1  O
%  O
,  O
respectively  O
.  O

Grade  O
3  O
or  O
4  O
of  O
neutropenia  B-TOXI
and  O
anemia  B-TOXI
were  O
observed  O
in  O
6  O
(  O
19  O
%  O
)  O
and  O
5  O
(  O
16  O
%  O
)  O
patients  O
,  O
respectively  O
.  O

The  O
major  O
non-hematologic  B-TOXI
toxicity  I-TOXI
was  O
fatigue  B-TOXI
,  O
but  O
most  O
of  O
them  O
could  O
manageable  O
.  O

In  O
conclusion  O
,  O
biweekly  O
paclitaxel  B-DRUG
and  O
cisplatin  B-DRUG
is  O
effective  O
in  O
patients  O
with  O
metastatic  O
or  O
recurrent  O
esophageal  B-CANCER
cancer  I-CANCER
.  O

Phase  O
II  O
trial  O
of  O
the  O
novel  O
retinoid  B-DRUG
,  O
bexarotene  B-DRUG
,  O
and  O
gemcitabine  B-DRUG
plus  O
carboplatin  B-DRUG
in  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Platinum-based  B-DRUG
chemotherapy  O
is  O
the  O
standard  O
treatment  O
for  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

Unfortunately  O
,  O
a  O
plateau  O
in  O
efficacy  O
with  O
currently  O
available  O
agents  O
has  O
been  O
reached  O
.  O

Previous  O
studies  O
of  O
the  O
retinoid  B-DRUG
,  O
bexarotene  B-DRUG
,  O
a  O
retinoid  O
X  O
receptor-specific  O
ligand  O
,  O
have  O
indicated  O
that  O
it  O
may  O
improve  O
outcome  O
in  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

Patients  O
with  O
previously  O
untreated  O
stage  O
IIIB  O
or  O
stage  O
IV  O
disease  O
,  O
a  O
performance  O
status  O
of  O
0  O
to  O
2  O
,  O
and  O
adequate  O
organ  O
status  O
were  O
entered  O
.  O

Treatment  O
consisted  O
of  O
up  O
to  O
six  O
cycles  O
of  O
carboplatin  B-DRUG
(  O
area  O
under  O
the  O
curve  O
=  O
5.0  O
on  O
day  O
1  O
)  O
and  O
gemcitabine  B-DRUG
(  O
1,000  O
mg  O
/  O
m2  O
on  O
days  O
1  O
and  O
8  O
)  O
administered  O
every  O
21  O
days  O
.  O

Bexarotene  B-DRUG
400  O
mg  O
/  O
m2  O
orally  O
was  O
to  O
be  O
administered  O
continuously  O
beginning  O
on  O
day  O
1  O
and  O
until  O
progression  B-TOXI
of  I-TOXI
disease  I-TOXI
.  O

All  O
patients  O
received  O
atorvastatin  B-DRUG
10  O
mg  O
orally  O
beginning  O
before  O
bexarotene  B-DRUG
.  O

The  O
objective  O
was  O
to  O
demonstrate  O
a  O
1-year  O
survival  O
rate  O
of  O
more  O
than  O
50  O
%  O
.  O

Forty-eight  O
patients  O
were  O
entered  O
;  O
all  O
were  O
assessable  O
for  O
survival  O
,  O
and  O
47  O
were  O
assessable  O
for  O
toxicity  O
and  O
response  O
.  O

The  O
therapeutic  O
regimen  O
was  O
well  O
tolerated  O
except  O
for  O
hypertriglyceridemia  B-TOXI
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
6.7  O
months  O
,  O
and  O
overall  O
median  O
survival  O
was  O
12.7  O
months  O
.  O

There  O
was  O
a  O
25  O
%  O
response  O
rate  O
and  O
a  O
1-year  O
survival  O
rate  O
of  O
53  O
%  O
.  O

These  O
results  O
were  O
compared  O
with  O
the  O
outcome  O
of  O
33  O
patients  O
treated  O
at  O
our  O
institution  O
with  O
two-drug  O
,  O
platinum-based  B-DRUG
chemotherapy  O
on  O
controlled  O
trials  O
with  O
similar  O
entry  O
criteria  O
in  O
the  O
previous  O
5  O
years  O
.  O

Bexarotene  B-DRUG
can  O
be  O
safely  O
added  O
to  O
platinum-based  B-DRUG
chemotherapy  O
provided  O
that  O
there  O
is  O
aggressive  O
prophylaxis  O
of  O
hypertriglyceridemia  B-TOXI
.  O

The  O
median  O
time  O
to  O
progression  O
and  O
overall  O
survival  O
are  O
promising  O
and  O
warrant  O
further  O
evaluation  O
of  O
bexarotene  B-DRUG
in  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

High  O
efficacy  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
patients  O
with  O
predominantly  O
anthracycline-  B-DRUG
and  O
taxane-pretreated  B-DRUG
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O


Effective  O
and  O
tolerable  O
regimens  O
are  O
sought  O
specifically  O
in  O
patients  O
who  O
have  O
been  O
pretreated  O
with  O
anthracyclines  B-DRUG
and  O
taxanes  B-DRUG
.  O

Gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
demonstrated  O
synergistic  O
activity  O
in  O
vitro  O
and  O
provides  O
a  O
new  O
mechanism  O
of  O
drug  O
interaction  O
.  O

Previously  O
treated  O
patients  O
with  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
(  O
MBC  B-CANCER
)  O
were  O
enrolled  O
in  O
a  O
multicentre  O
phase  O
II  O
study  O
.  O

Treatment  O
consisted  O
of  O
gemcitabine  B-DRUG
(  O
750  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
and  O
cisplatin  B-DRUG
(  O
30  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
given  O
on  O
day  O
1  O
and  O
8  O
every  O
3  O
weeks  O
.  O

Thirty-eight  O
patients  O
were  O
recruited  O
,  O
all  O
of  O
whom  O
had  O
previously  O
received  O
chemotherapy  O
(  O
35  O
pretreated  O
with  O
taxanes  B-DRUG
,  O
33  O
pretreated  O
with  O
anthracyclines  B-DRUG
)  O
.  O

A  O
median  O
of  O
5  O
cycles  O
of  O
the  O
study  O
treatment  O
was  O
delivered  O
.  O

There  O
were  O
2  O
complete  O
and  O
13  O
partial  O
responses  O
,  O
for  O
an  O
overall  O
response  O
rate  O
of  O
40  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
:  O
23-56  O
%  O
)  O
.  O

Thirteen  O
patients  O
(  O
35  O
%  O
)  O
had  O
stable  O
disease  O
.  O

Tumour  O
response  O
appeared  O
independent  O
of  O
previously  O
applied  O
chemotherapy  O
.  O

Median  O
time-to-progression  O
was  O
6  O
months  O
and  O
median  O
overall  O
survival  O
was  O
13.5  O
months  O
.  O

Main  O
toxicities  O
were  O
leucopenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
(  O
grade  O
3  O
/  O
4  O
in  O
26  O
and  O
16  O
%  O
of  O
cycles  O
,  O
respectively  O
)  O
.  O

Non-haematological  B-TOXI
toxicity  I-TOXI
was  O
rarely  O
severe  O
.  O

Combination  O
chemotherapy  O
with  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
given  O
on  O
2  O
out  O
of  O
3  O
weeks  O
is  O
well  O
tolerated  O
and  O
active  O
in  O
heavily  O
pretreated  O
patients  O
with  O
MBC  B-CANCER
,  O
even  O
after  O
prior  O
exposure  O
to  O
anthracyclines  B-DRUG
and  O
taxanes  B-DRUG
.  O

Second-line  O
treatment  O
with  O
irinotecan  B-DRUG
plus  O
cisplatin  B-DRUG
vs  O
cisplatin  B-DRUG
of  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
pretreated  O
with  O
taxanes  B-DRUG
and  O
gemcitabine  B-DRUG
:  O
a  O
multicenter  O
randomised  O
phase  O
II  O
study  O
.  O


The  O
aim  O
of  O
this  O
study  O
was  O
to  O
compare  O
the  O
irinotecan  B-DRUG
/  I-DRUG
cisplatin  I-DRUG
regimen  O
with  O
cisplatin  B-DRUG
as  O
second-line  O
chemotherapy  O
in  O
patients  O
with  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
pretreated  O
with  O
a  O
taxane  B-DRUG
/  I-DRUG
gemcitabine  I-DRUG
regimen  O
.  O

Patients  O
(  O
n  O
=  O
147  O
)  O
with  O
stage  O
IV  O
NSCLC  B-CANCER
pretreated  O
with  O
a  O
taxane  B-DRUG
/  I-DRUG
gemcitabine  I-DRUG
regimen  O
were  O
randomly  O
assigned  O
to  O
receive  O
either  O
irinotecan  B-DRUG
(  O
110  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
1  O
and  O
100  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
8  O
)  O
and  O
cisplatin  B-DRUG
(  O
80  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
8  O
)  O
(  O
IC  O
;  O
n  O
=  O
74  O
)  O
or  O
CDDP  B-DRUG
(  O
80  O
mg  O
m  O
(  O
-2  O
)  O
,  O
day  O
1  O
)  O
(  O
C  O
;  O
n  O
=  O
73  O
)  O
every  O
3  O
weeks  O
.  O

Patients  O
treated  O
with  O
IC  O
and  O
C  O
had  O
a  O
median  O
survival  O
of  O
7.8  O
and  O
8.8  O
months  O
,  O
respectively  O
(  O
P  O
=  O
0.933  O
)  O
.  O

The  O
1-year  O
survival  O
rate  O
was  O
34.3  O
%  O
for  O
IC-treated  O
patients  O
and  O
31.7  O
%  O
for  O
C-treated  O
patients  O
.  O

Cox  O
's  O
regression  O
analysis  O
revealed  O
that  O
response  O
to  O
treatment  O
(  O
hazard  O
ratio  O
(  O
HR  O
)  O
=  O
2.787  O
;  O
95  O
%  O
confidence  O
interval  O
(  O
CI  O
)  O
:  O
1.1578-4.922  O
)  O
and  O
performance  O
status  O
(  O
HR  O
=  O
1.865  O
;  O
95  O
%  O
CI  O
:  O
1.199-2.872  O
)  O
was  O
independent  O
prognostic  O
factors  O
for  O
survival  O
.  O

Overall  O
response  O
rate  O
was  O
22.5  O
%  O
(  O
95  O
%  O
CI  O
:  O
12.8-32.2  O
%  O
)  O
for  O
IC-treated  O
patients  O
and  O
7.0  O
%  O
(  O
95  O
%  O
CI  O
:  O
1.15-13.6  O
%  O
)  O
for  O
C-treated  O
patients  O
(  O
P  O
=  O
0.012  O
)  O
;  O
tumour  O
growth  O
control  O
(  O
partial  O
remission  O
(  O
PR  O
)  O
+  O
stable  O
disease  O
(  O
SD  O
)  O
)  O
was  O
observed  O
in  O
26  O
(  O
38  O
%  O
)  O
IC  O
and  O
25  O
(  O
36  O
%  O
)  O
C  O
patients  O
(  O
P  O
=  O
0.878  O
)  O
.  O

There  O
was  O
no  O
difference  O
in  O
terms  O
of  O
quality  O
of  O
life  O
between  O
the  O
two  O
chemotherapy  O
arms  O
.  O

The  O
incidence  O
of  O
febrile  B-TOXI
neutropenia  I-TOXI
,  O
grade  O
3  O
and  O
4  O
neutropenia  B-TOXI
and  O
grade  O
3  O
and  O
4  O
diarrhoea  B-TOXI
was  O
significantly  O
higher  O
in  O
the  O
IC-  O
than  O
the  O
C-treated  O
patients  O
.  O

Other  O
toxicities  O
were  O
mild  O
.  O

There  O
were  O
no  O
treatment-related  B-TOXI
deaths  I-TOXI
in  O
either  O
arm  O
.  O

The  O
IC  O
regimen  O
did  O
not  O
confer  O
a  O
survival  O
benefit  O
compared  O
with  O
C  O
as  O
second-line  O
treatment  O
of  O
patients  O
with  O
advanced  B-CANCER
NSCLC  I-CANCER
pretreated  O
with  O
a  O
taxane  B-DRUG
/  I-DRUG
gemcitabine  I-DRUG
regimen  O
,  O
despite  O
its  O
better  O
efficacy  O
in  O
terms  O
of  O
response  O
rate  O
.  O

Concurrent  O
hyperfractionated  O
radiotherapy  O
and  O
low-dose  O
daily  O
carboplatin  B-DRUG
/  I-DRUG
paclitaxel  I-DRUG
in  O
patients  O
with  O
early-stage  O
(  O
I  O
/  O
II  O
)  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
long-term  O
results  O
of  O
a  O
phase  O
II  O
study  O
.  O


Feasibility  O
and  O
activity  O
of  O
concurrent  O
hyperfractionated  O
radiotherapy  O
(  O
Hfx  O
RT  O
)  O
and  O
low-dose  O
,  O
daily  O
carboplatin  B-DRUG
and  O
paclitaxel  B-DRUG
were  O
investigated  O
in  O
patients  O
with  O
early-stage  O
(  O
I  O
/  O
II  O
)  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
in  O
a  O
phase  O
II  O
study  O
.  O

Fifty-six  O
patients  O
started  O
their  O
treatment  O
on  O
day  O
1  O
with  O
30  O
mg  O
/  O
m2  O
of  O
paclitaxel  B-DRUG
.  O

Hfx  O
RT  O
using  O
1.3  O
Gy  O
bid  O
to  O
a  O
total  O
dose  O
of  O
67.6  O
Gy  O
and  O
concurrent  O
low-dose  O
daily  O
carboplatin  B-DRUG
25  O
mg  O
/  O
m2  O
and  O
paclitaxel  B-DRUG
10  O
mg  O
/  O
m2  O
,  O
both  O
given  O
Mondays  O
through  O
Fridays  O
during  O
the  O
RT  O
course  O
,  O
started  O
from  O
the  O
second  O
day  O
.  O

There  O
were  O
29  O
complete  O
responses  O
(  O
52  O
%  O
)  O
and  O
15  O
partial  O
responses  O
(  O
27  O
%  O
)  O
,  O
and  O
12  O
patients  O
(  O
21  O
%  O
)  O
,  O
experienced  O
stable  O
disease  O
.  O

The  O
median  O
survival  O
time  O
was  O
35  O
months  O
,  O
and  O
3-  O
and  O
5-year  O
survival  O
rates  O
were  O
50  O
%  O
and  O
36  O
%  O
,  O
respectively  O
.  O

The  O
median  O
time  O
to  O
local  O
progression  O
has  O
not  O
been  O
achieved  O
,  O
but  O
3-  O
and  O
5-year  O
local  O
progression-free  O
survival  O
rates  O
were  O
56  O
%  O
and  O
54  O
%  O
,  O
respectively  O
.  O

The  O
median  O
time  O
to  O
distant  O
metastasis  O
has  O
not  O
been  O
achieved  O
,  O
but  O
3-  O
and  O
5-  O
year  O
distant  O
metastasis-free  O
survival  O
rates  O
were  O
61  O
%  O
and  O
61  O
%  O
,  O
respectively  O
.  O

The  O
median  O
and  O
5-year  O
cause-specific  O
survivals  O
were  O
39  O
months  O
and  O
43  O
%  O
,  O
respectively  O
.  O

Acute  O
high-grade  O
(  O
&  O
gt  O
;  O
3  O
)  O
toxicity  O
was  O
hematologic  O
(  O
22  O
%  O
)  O
,  O
esophageal  O
(  O
7  O
%  O
)  O
,  O
or  O
bronchopulmonary  O
(  O
7  O
%  O
)  O
.  O

No  O
grade  O
5  O
toxicity  O
was  O
observed  O
.  O

Late  O
high-grade  O
toxicity  O
was  O
rarely  O
observed  O
(  O
total  O
,  O
10  O
%  O
)  O
.  O

Hfx  O
RT  O
and  O
concurrent  O
low-dose  O
daily  O
carboplatin  B-DRUG
/  I-DRUG
paclitaxel  I-DRUG
was  O
feasible  O
with  O
low  O
toxicity  O
and  O
effective  O
in  O
patients  O
with  O
stage  O
I  O
/  O
II  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

It  O
should  O
continue  O
to  O
be  O
investigated  O
for  O
this  O
disease  O
.  O

Phase  O
II  O
trial  O
of  O
tamoxifen  B-DRUG
and  O
goserelin  B-DRUG
in  O
recurrent  O
epithelial  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O


Endocrine  O
therapy  O
is  O
a  O
recognised  O
option  O
in  O
the  O
treatment  O
of  O
chemo-resistant  O
ovarian  B-CANCER
cancer  I-CANCER
.  O

We  O
conducted  O
a  O
nonrandomised  O
phase  O
II  O
evaluation  O
of  O
combination  O
endocrine  O
therapy  O
with  O
tamoxifen  B-DRUG
and  O
goserelin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
that  O
had  O
recurred  O
following  O
chemotherapy  O
.  O

In  O
total  O
,  O
26  O
patients  O
entered  O
the  O
study  O
,  O
of  O
which  O
17  O
had  O
platinum-resistant  B-DRUG
disease  O
.  O

The  O
median  O
age  O
was  O
63  O
years  O
and  O
enrolled  O
patients  O
had  O
received  O
a  O
median  O
of  O
three  O
chemotherapy  O
regimens  O
prior  O
to  O
trial  O
entry  O
.  O

Patients  O
were  O
given  O
oral  O
tamoxifen  B-DRUG
20  O
mg  O
twice  O
daily  O
on  O
a  O
continuous  O
basis  O
and  O
subcutaneous  O
goserelin  B-DRUG
3.6  O
mg  O
once  O
a  O
month  O
until  O
disease  B-TOXI
progression  I-TOXI
.  O

Using  O
the  O
definition  O
of  O
endocrine  O
response  O
that  O
included  O
patients  O
with  O
stable  O
disease  O
(  O
SD  O
)  O
of  O
6  O
months  O
or  O
greater  O
,  O
the  O
overall  O
response  O
rate  O
(  O
clinical  O
benefit  O
rate  O
)  O
was  O
50  O
%  O
.  O

This  O
included  O
one  O
complete  O
response  O
(  O
CR  O
)  O
(  O
3.8  O
%  O
)  O
,  O
two  O
partial  O
responses  O
(  O
PR  O
)  O
(  O
7.7  O
%  O
)  O
and  O
10  O
patients  O
with  O
SD  O
(  O
38.5  O
%  O
)  O
.  O

The  O
median  O
progression-free  O
interval  O
(  O
PFI  O
)  O
was  O
4  O
months  O
(  O
95  O
%  O
CI  O
2.4-9.6  O
)  O
while  O
the  O
median  O
overall  O
survival  O
(  O
OS  O
)  O
was  O
13.6  O
months  O
(  O
95  O
%  O
CI  O
5.5-30.6  O
)  O
.  O

Four  O
patients  O
received  O
treatment  O
for  O
more  O
than  O
2  O
years  O
(  O
range  O
1-31  O
)  O
and  O
one  O
of  O
them  O
is  O
still  O
on  O
treatment  O
.  O

In  O
none  O
of  O
the  O
four  O
patients  O
was  O
there  O
any  O
evidence  O
of  O
recurrent  O
or  O
cumulative  O
treatment  O
related  O
toxicity  O
.  O

Treatment-limiting  O
toxicity  O
was  O
not  O
seen  O
in  O
any  O
of  O
the  O
study  O
population  O
.  O

Endocrine  O
data  O
demonstrated  O
a  O
marked  O
suppression  O
of  O
luteinising  O
hormone  O
(  O
LH  O
)  O
and  O
follicle-stimulating  O
hormone  O
(  O
FSH  O
)  O
to  O
less  O
than  O
4  O
%  O
of  O
baseline  O
values  O
.  O

No  O
consistent  O
correlation  O
could  O
be  O
established  O
between  O
LH  O
/  O
FSH  O
suppression  O
and  O
tumour  O
response  O
.  O

Likewise  O
no  O
relationship  O
was  O
observed  O
between  O
Inhibin  O
A  O
/  O
B  O
and  O
pro-alpha  O
C  O
levels  O
and  O
tumour  O
response  O
.  O

Inhibin  O
is  O
unlikely  O
to  O
be  O
a  O
useful  O
surrogate  O
marker  O
for  O
response  O
in  O
locally  O
advanced  B-CANCER
or  I-CANCER
metastatic  I-CANCER
ovarian  I-CANCER
cancer  I-CANCER
.  O

Combination  O
endocrine  B-DRUG
therapy  O
with  O
tamoxifen  B-DRUG
and  O
goserelin  B-DRUG
is  O
an  O
active  O
regimen  O
in  O
platinum-resistant  B-DRUG
ovarian  B-CANCER
cancer  I-CANCER
patients  O
.  O

Hormonal  O
therapy  O
is  O
advantageous  O
in  O
its  O
relative  O
lack  O
of  O
toxicity  O
,  O
ease  O
of  O
administration  O
and  O
tolerability  O
,  O
thus  O
making  O
it  O
suitable  O
for  O
patients  O
with  O
heavily  O
pretreated  O
disease  O
,  O
compromised  O
bone  O
marrow  O
function  O
and  O
other  O
comorbid  O
conditions  O
that  O
contraindicate  O
cytotoxic  O
therapy  O
as  O
well  O
as  O
in  O
patients  O
with  O
indolent  O
disease  O
.  O

Multicenter  O
phase  O
I  O
/  O
II  O
study  O
of  O
cetuximab  B-DRUG
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
in  O
untreated  O
patients  O
with  O
stage  O
IV  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Epidermal  B-DRUG
growth  I-DRUG
factor  I-DRUG
receptor  I-DRUG
(  O
EGFR  B-DRUG
)  O
tyrosine  O
kinase  O
inhibitors  O
have  O
demonstrated  O
antitumor  O
activity  O
in  O
patients  O
with  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

This  O
study  O
examined  O
the  O
safety  O
profile  O
of  O
the  O
monoclonal  O
antibody  O
EGFR  B-DRUG
inhibitor  O
,  O
cetuximab  B-DRUG
,  O
when  O
added  O
to  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
in  O
untreated  O
patients  O
with  O
stage  O
IV  O
NSCLC  B-CANCER
.  O

Secondary  O
objectives  O
included  O
efficacy  O
and  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
pharmacokinetics  O
during  O
cetuximab  B-DRUG
treatment  O
.  O

Patients  O
with  O
tumor  O
evidence  O
of  O
EGFR  B-DRUG
by  O
immunohistochemistry  O
,  O
performance  O
status  O
of  O
0  O
to  O
2  O
,  O
and  O
measurable  O
disease  O
received  O
paclitaxel  B-DRUG
225  O
mg  O
/  O
m2  O
with  O
carboplatin  B-DRUG
area  O
under  O
the  O
curve  O
=  O
6  O
on  O
day  O
1  O
every  O
3  O
weeks  O
.  O

Cetuximab  B-DRUG
was  O
administered  O
at  O
400  O
mg  O
/  O
m2  O
,  O
1  O
week  O
before  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
,  O
then  O
weekly  O
at  O
250  O
mg  O
/  O
m2  O
.  O

The  O
regimen  O
continued  O
until  O
disease  B-TOXI
progression  I-TOXI
or  O
intolerable  O
toxicity  O
.  O

Thirty-one  O
of  O
32  O
enrolled  O
patients  O
were  O
treated  O
.  O

The  O
most  O
common  O
cetuximab  B-TOXI
toxicity  I-TOXI
was  O
rash  O
in  O
84  O
%  O
of  O
patients  O
(  O
grade  O
3  O
in  O
13  O
%  O
)  O
.  O

Pharmacokinetic  O
sampling  O
did  O
not  O
reveal  O
an  O
interaction  O
between  O
carboplatin  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
cetuximab  B-DRUG
.  O

An  O
objective  O
response  O
was  O
observed  O
in  O
eight  O
patients  O
(  O
26  O
%  O
)  O
.  O

With  O
a  O
median  O
follow-up  O
of  O
19  O
months  O
,  O
the  O
median  O
time  O
to  O
progression  O
was  O
5  O
months  O
,  O
median  O
survival  O
was  O
11  O
months  O
,  O
and  O
the  O
1-  O
and  O
2-year  O
survival  O
rates  O
were  O
40  O
%  O
and  O
16  O
%  O
,  O
respectively  O
.  O

The  O
combination  O
of  O
cetuximab  B-DRUG
,  O
paclitaxel  B-DRUG
,  O
and  O
carboplatin  B-DRUG
was  O
safe  O
and  O
well  O
tolerated  O
in  O
this  O
population  O
of  O
stage  O
IV  O
patients  O
.  O

The  O
response  O
rate  O
,  O
time  O
to  O
progression  O
,  O
and  O
median  O
survival  O
were  O
slightly  O
superior  O
to  O
historical  O
controls  O
treated  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
alone  O
.  O

A  O
randomized  O
phase  O
II  O
trial  O
has  O
completed  O
accrual  O
.  O

Neoadjuvant  O
chemotherapy  O
with  O
high-dose  O
Ifosfamide  B-DRUG
,  O
high-dose  O
methotrexate  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
doxorubicin  B-DRUG
for  O
patients  O
with  O
localized  O
osteosarcoma  B-CANCER
of  I-CANCER
the  I-CANCER
extremity  I-CANCER
:  O
a  O
joint  O
study  O
by  O
the  O
Italian  O
and  O
Scandinavian  O
Sarcoma  O
Groups  O
.  O


To  O
explore  O
the  O
effect  O
of  O
high-dose  O
ifosfamide  B-DRUG
in  O
first-line  O
treatment  O
for  O
patients  O
&  O
lt  O
;  O
or  O
=  O
40  O
years  O
of  O
age  O
with  O
nonmetastatic  O
osteosarcoma  B-CANCER
of  I-CANCER
the  I-CANCER
extremity  I-CANCER
.  O

From  O
March  O
1997  O
to  O
September  O
2000  O
,  O
182  O
patients  O
were  O
evaluated  O
.  O

Primary  O
treatment  O
consisted  O
of  O
two  O
blocks  O
of  O
high-dose  O
ifosfamide  B-DRUG
(  O
15  O
g  O
/  O
m2  O
)  O
,  O
methotrexate  B-DRUG
(  O
12  O
g  O
/  O
m2  O
)  O
,  O
cisplatin  B-DRUG
(  O
120  O
mg  O
/  O
m2  O
)  O
,  O
and  O
doxorubicin  B-DRUG
(  O
75  O
mg  O
/  O
m2  O
)  O
.  O

Postoperatively  O
,  O
patients  O
received  O
two  O
cycles  O
of  O
doxorubicin  B-DRUG
(  O
90  O
mg  O
/  O
m2  O
)  O
,  O
and  O
three  O
cycles  O
each  O
of  O
high-dose  O
ifosfamide  B-DRUG
,  O
methotrexate  B-DRUG
,  O
and  O
cisplatin  B-DRUG
(  O
120  O
to  O
150  O
mg  O
/  O
m2  O
)  O
.  O

Granulocyte  B-DRUG
colony-stimulating  I-DRUG
factor  I-DRUG
support  O
was  O
mandatory  O
after  O
the  O
high-dose  O
ifosfamide  B-DRUG
/  I-DRUG
cisplatin  I-DRUG
/  I-DRUG
doxorubicin  I-DRUG
combination  O
.  O

No  O
disease  B-TOXI
progression  I-TOXI
was  O
recorded  O
during  O
primary  O
chemotherapy  O
,  O
164  O
patients  O
(  O
92  O
%  O
)  O
underwent  O
limb-salvage  B-TOXI
surgery  I-TOXI
,  O
four  O
patients  O
(  O
2  O
%  O
)  O
underwent  O
rotation  B-TOXI
plasty  I-TOXI
,  O
and  O
11  O
patients  O
(  O
6  O
%  O
)  O
had  O
limbs  B-TOXI
amputated  I-TOXI
.  O

Three  O
(  O
1.6  O
%  O
)  O
patients  O
died  B-TOXI
as  O
a  O
result  O
of  O
treatment-related  B-TOXI
toxicity  I-TOXI
,  O
and  O
one  O
died  B-TOXI
as  O
a  O
result  O
of  O
pulmonary  B-TOXI
embolism  I-TOXI
after  O
pathologic  B-TOXI
fracture  I-TOXI
.  O

Grade  O
4  O
neutropenia  B-TOXI
and  O
thrombocytopenia  B-TOXI
followed  O
52  O
%  O
and  O
31  O
%  O
of  O
all  O
courses  O
,  O
respectively  O
,  O
and  O
mild  O
to  O
severe  B-TOXI
nephrotoxicity  I-TOXI
was  O
recorded  O
in  O
19  O
patients  O
(  O
10  O
%  O
)  O
.  O

The  O
median  O
received  O
dose-intensity  O
compared  O
with  O
protocol  O
was  O
0.82  O
.  O

With  O
a  O
median  O
follow-up  O
of  O
55  O
months  O
,  O
the  O
5-year  O
probability  O
of  O
event-free  O
survival  O
was  O
64  O
%  O
(  O
95  O
%  O
CI  O
,  O
57  O
%  O
to  O
71  O
%  O
)  O
and  O
overall  O
survival  O
was  O
77  O
%  O
(  O
95  O
%  O
CI  O
,  O
67  O
%  O
to  O
81  O
%  O
)  O
,  O
whereas  O
seven  O
patients  O
(  O
4  O
%  O
)  O
experienced  O
local  O
recurrence  O
.  O

The  O
addition  O
of  O
high-dose  O
ifosfamide  B-DRUG
to  O
methotrexate  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
doxorubicin  B-DRUG
in  O
the  O
preoperative  O
phase  O
is  O
feasible  O
,  O
but  O
with  O
major  O
renal  O
and  O
hematologic  B-TOXI
toxicities  I-TOXI
,  O
and  O
survival  O
rates  O
similar  O
to  O
those  O
obtained  O
with  O
four-drug  O
regimens  O
using  O
standard-dose  O
ifosfamide  B-DRUG
.  O

Italian  O
Sarcoma  O
Group  O
/  O
Scandinavian  O
Sarcoma  O
Group  O
study  O
I  O
showed  O
that  O
in  O
a  O
multicenter  O
setting  O
,  O
more  O
than  O
90  O
%  O
of  O
patients  O
with  O
osteosarcoma  B-CANCER
of  I-CANCER
the  I-CANCER
extremity  I-CANCER
can  O
undergo  O
conservative  O
surgery  O
.  O

Phase  O
I  O
and  O
pharmacological  O
study  O
of  O
the  O
farnesyltransferase  O
inhibitor  O
tipifarnib  B-DRUG
(  O
Zarnestra  O
,  O
R115777  O
)  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumours  I-CANCER
.  O


This  O
phase  O
I  O
trial  O
was  O
designed  O
to  O
determine  O
the  O
safety  O
and  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
of  O
tipifarnib  B-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
tumours  I-CANCER
.  O

Furthermore  O
,  O
the  O
pharmacokinetics  O
of  O
each  O
of  O
these  O
agents  O
was  O
evaluated  O
.  O

Patients  O
were  O
treated  O
with  O
tipifarnib  B-DRUG
b.i.d.  O
on  O
days  O
1-7  O
of  O
each  O
21-day  O
cycle  O
.  O

In  O
addition  O
,  O
gemcitabine  B-DRUG
was  O
given  O
as  O
a  O
30-min  O
i.v.  O
infusion  O
on  O
days  O
1  O
and  O
8  O
and  O
cisplatin  B-DRUG
as  O
a  O
3-h  O
i.v.  O
infusion  O
on  O
day  O
1.  O
An  O
interpatient  O
dose-escalation  O
scheme  O
was  O
used  O
.  O

Pharmacokinetics  O
was  O
determined  O
in  O
plasma  O
and  O
white  O
blood  O
cells  O
.  O

In  O
total  O
,  O
31  O
patients  O
were  O
included  O
at  O
five  O
dose  O
levels  O
.  O

Dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
consisted  O
of  O
thrombocytopenia  B-TOXI
grade  O
4  O
,  O
neutropenia  B-TOXI
grade  O
4  O
,  O
febrile  B-TOXI
neutropenia  I-TOXI
grade  O
4  O
,  O
electrolyte  B-TOXI
imbalance  I-TOXI
grade  O
3  O
,  O
fatigue  B-TOXI
grade  O
3  O
and  O
decreased  B-TOXI
hearing  I-TOXI
grade  O
2.  O
The  O
MTD  O
was  O
tipifarnib  B-DRUG
200  O
mg  O
b.i.d.  O
,  O
gemcitabine  B-DRUG
1000  O
mg  O
m  O
(  O
-2  O
)  O
and  O
cisplatin  B-DRUG
75  O
mg  O
m  O
(  O
-2  O
)  O
.  O

Eight  O
patients  O
had  O
a  O
confirmed  O
partial  O
response  O
and  O
12  O
patients  O
stable  O
disease  O
.  O

No  O
clinically  O
relevant  O
pharmacokinetic  O
interactions  O
were  O
observed  O
.  O

Tipifarnib  B-DRUG
can  O
be  O
administered  O
safely  O
at  O
200  O
mg  O
b.i.d.  O
in  O
combination  O
with  O
gemcitabine  B-DRUG
1000  O
mg  O
m  O
(  O
-2  O
)  O
and  O
cisplatin  B-DRUG
75  O
mg  O
m  O
(  O
-2  O
)  O
.  O

This  O
combination  O
showed  O
evidence  O
of  O
antitumour  O
activity  O
and  O
warrants  O
further  O
evaluation  O
in  O
a  O
phase  O
II  O
setting  O
.  O

Phase  O
III  O
study  O
comparing  O
cisplatin  B-DRUG
plus  O
fluorouracil  B-DRUG
to  O
paclitaxel  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
fluorouracil  B-DRUG
induction  O
chemotherapy  O
followed  O
by  O
chemoradiotherapy  O
in  O
locally  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
.  O


To  O
compare  O
the  O
antitumor  O
activity  O
and  O
toxicity  O
of  O
the  O
two  O
induction  O
chemotherapy  O
treatments  O
of  O
paclitaxel  B-DRUG
,  O
cisplatin  B-DRUG
,  O
and  O
fluorouracil  B-DRUG
(  O
FU  B-DRUG
;  O
PCF  B-DRUG
)  O
versus  O
standard  O
cisplatin  B-DRUG
and  O
FU  B-DRUG
(  O
CF  B-DRUG
)  O
,  O
both  O
followed  O
by  O
chemoradiotherapy  O
(  O
CRT  O
)  O
,  O
in  O
locally  O
advanced  B-CANCER
head  I-CANCER
and  I-CANCER
neck  I-CANCER
cancer  I-CANCER
(  O
HNC  B-CANCER
)  O
.  O

Eligibility  O
criteria  O
included  O
biopsy-proven  O
,  O
previously  O
untreated  O
,  O
stage  O
III  O
or  O
IV  O
locally  O
advanced  B-CANCER
HNC  I-CANCER
.  O

Patients  O
received  O
either  O
CF  B-DRUG
(  O
cisplatin  B-DRUG
100  O
mg  O
/  O
m2  O
on  O
day  O
1  O
plus  O
FU  B-DRUG
1000  O
[  O
corrected  O
]  O
mg  O
/  O
m2  O
continuous  O
infusion  O
on  O
days  O
1  O
through  O
5  O
)  O
or  O
PCF  B-DRUG
(  O
paclitaxel  B-DRUG
175  O
mg  O
/  O
m2  O
on  O
day  O
1  O
,  O
cisplatin  B-DRUG
100  O
mg  O
/  O
m2  O
on  O
day  O
2  O
,  O
and  O
FU  B-DRUG
500  O
mg  O
/  O
m2  O
continuous  O
infusion  O
on  O
days  O
2  O
through  O
6  O
)  O
;  O
both  O
regimens  O
were  O
administered  O
for  O
three  O
cycles  O
every  O
21  O
days  O
.  O

Patients  O
with  O
complete  O
response  O
(  O
CR  O
)  O
or  O
partial  O
response  O
of  O
greater  O
than  O
80  O
%  O
in  O
primary  O
tumor  O
received  O
additional  O
CRT  O
(  O
cisplatin  B-DRUG
100  O
mg  O
/  O
m2  O
on  O
days  O
1  O
,  O
22  O
,  O
and  O
43  O
plus  O
70  O
Gy  O
)  O
.  O

A  O
total  O
of  O
382  O
eligible  O
patients  O
were  O
randomly  O
assigned  O
to  O
CF  B-DRUG
(  O
n  O
=  O
193  O
)  O
or  O
PCF  B-DRUG
(  O
n  O
=  O
189  O
)  O
.  O

The  O
CR  O
rate  O
was  O
14  O
%  O
in  O
the  O
CF  B-DRUG
arm  O
v  O
33  O
%  O
in  O
the  O
PCF  B-DRUG
arm  O
(  O
P  O
&  O
lt  O
;  O
.001  O
)  O
.  O

Median  O
time  O
to  O
treatment  O
failure  O
was  O
12  O
months  O
in  O
the  O
CF  B-DRUG
arm  O
compared  O
with  O
20  O
months  O
in  O
the  O
PCF  B-DRUG
arm  O
(  O
log-rank  O
test  O
,  O
P  O
=  O
.006  O
;  O
Tarone-Ware  O
,  O
P  O
=  O
.003  O
)  O
.  O

PCF  B-DRUG
patients  O
had  O
a  O
trend  O
to  O
longer  O
overall  O
survival  O
(  O
OS  O
;  O
37  O
months  O
in  O
CF  B-DRUG
arm  O
v  O
43  O
months  O
in  O
PCF  B-DRUG
arm  O
;  O
log-rank  O
test  O
,  O
P  O
=  O
.06  O
;  O
Tarone-Ware  O
,  O
P  O
=  O
.03  O
)  O
.  O

This  O
difference  O
was  O
more  O
evident  O
in  O
patients  O
with  O
unresectable  O
disease  O
(  O
OS  O
:  O
26  O
months  O
in  O
CF  B-DRUG
arm  O
v  O
36  O
months  O
in  O
PCF  B-DRUG
arm  O
;  O
log-rank  O
test  O
,  O
P  O
=  O
.04  O
;  O
Tarone-Ware  O
,  O
P  O
=  O
.03  O
)  O
.  O

CF  B-DRUG
patients  O
had  O
a  O
higher  O
occurrence  O
of  O
grade  O
2  O
to  O
4  O
mucositis  B-TOXI
than  O
PCF  B-DRUG
patients  O
(  O
53  O
%  O
v  O
16  O
%  O
,  O
respectively  O
;  O
P  O
&  O
lt  O
;  O
.001  O
)  O
.  O

Induction  O
chemotherapy  O
with  O
PCF  B-DRUG
was  O
better  O
tolerated  O
and  O
resulted  O
in  O
a  O
higher  O
CR  O
rate  O
than  O
CF  B-DRUG
.  O

However  O
,  O
new  O
trials  O
that  O
compare  O
induction  O
chemotherapy  O
plus  O
CRT  O
versus  O
CRT  O
alone  O
are  O
needed  O
to  O
better  O
define  O
the  O
role  O
of  O
neoadjuvant  O
treatment  O
.  O

Phase  O
II  O
study  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
locally  O
advanced  O
/  O
metastatic  O
oesophageal  B-CANCER
cancer  I-CANCER
.  O


Palliative  O
chemotherapy  O
for  O
inoperable  O
/  O
metastatic  O
oesophageal  B-CANCER
cancer  I-CANCER
has  O
limited  O
activity  O
.  O

This  O
study  O
assesses  O
the  O
feasibility  O
and  O
activity  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
this  O
group  O
of  O
patients  O
.  O

In  O
total  O
,  O
42  O
patients  O
with  O
locally  O
advanced  O
/  O
metastatic  O
squamous  O
or  O
adenocarcinoma  B-CANCER
of  I-CANCER
the  I-CANCER
oesophagus  I-CANCER
were  O
treated  O
with  O
gemcitabine  B-DRUG
1250  O
mg  O
m  O
(  O
-2  O
)  O
days  O
1  O
and  O
8  O
and  O
cisplatin  B-DRUG
75  O
mg  O
m  O
(  O
-2  O
)  O
day  O
1  O
in  O
a  O
21-day  O
cycle  O
.  O

Interim  O
safety  O
analysis  O
was  O
carried  O
out  O
after  O
the  O
first  O
19  O
patients  O
suggested  O
significant  O
toxicity  O
.  O

The  O
dose  O
of  O
gemcitabine  B-DRUG
was  O
subsequently  O
reduced  O
to  O
1000  O
mg  O
m  O
(  O
-2  O
)  O
.  O

Patients  O
were  O
assessed  O
for  O
toxicity  O
and  O
response  O
.  O

The  O
median  O
number  O
of  O
treatment  O
cycles  O
per  O
patient  O
was  O
4  O
(  O
range  O
1-6  O
)  O
.  O

Grade  O
3-4  O
neutropenia  B-TOXI
occurred  O
in  O
37  O
%  O
of  O
cycles  O
;  O
however  O
,  O
there  O
was  O
only  O
one  O
episode  O
of  O
neutropenic  B-TOXI
fever  I-TOXI
.  O

Nonhaematological  B-TOXI
toxicities  I-TOXI
included  O
fatigue  B-TOXI
,  O
nausea  B-TOXI
and  O
vomiting  B-TOXI
.  O

Among  O
32  O
patients  O
eligible  O
for  O
response  O
,  O
there  O
were  O
three  O
complete  O
responses  O
and  O
16  O
partial  O
responses  O
(  O
overall  O
response  O
rate  O
of  O
45  O
%  O
)  O
;  O
nine  O
patients  O
had  O
stable  O
disease  O
.  O

Median  O
survival  O
was  O
11  O
months  O
.  O

The  O
response  O
rate  O
appears  O
to  O
be  O
greatest  O
in  O
those  O
with  O
squamous  B-CANCER
carcinoma  I-CANCER
compared  O
to  O
adenocarcinoma  B-CANCER
(  O
71  O
vs  O
33  O
%  O
,  O
P=0.036  O
)  O
.  O

The  O
combination  O
of  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
in  O
this  O
schedule  O
has  O
manageable  O
toxicity  O
and  O
significant  O
activity  O
in  O
patients  O
with  O
locally  O
advanced  O
/  O
metastatic  O
oesophageal  B-CANCER
cancer  I-CANCER
and  O
is  O
worthy  O
of  O
further  O
study  O
.  O

Phase  O
I  O
trial  O
of  O
UCN-01  B-DRUG
in  O
combination  O
with  O
topotecan  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
solid  I-CANCER
cancers  I-CANCER
:  O
a  O
Princess  O
Margaret  O
Hospital  O
Phase  O
II  O
Consortium  O
study  O
.  O


7-Hydroxystaurosporine  B-DRUG
(  O
UCN-01  B-DRUG
)  O
inhibits  O
serine-threonine  O
kinases  O
including  O
the  O
Ca2+  O
and  O
phospholipid-dependent  O
protein  O
kinase  O
C  O
(  O
PKC  O
)  O
,  O
CDKs  O
2  O
,  O
4  O
,  O
6  O
,  O
Chk-1  O
and  O
PDK1  O
.  O

UCN-01  B-DRUG
mediates  O
distinct  O
effects  O
in  O
vitro  O
/  O
in  O
vivo  O
:  O
cell  O
cycle  O
arrest  O
in  O
G1  O
,  O
abrogation  O
of  O
G2  O
arrest  O
by  O
inhibiting  O
chk1  O
,  O
induction  O
of  O
apoptosis  O
and  O
potentiation  O
of  O
cytotoxicity  O
of  O
S-phase-active  O
chemotherapeutics  O
including  O
the  O
topoisomerase  O
1  O
inhibitor  O
topotecan  B-DRUG
(  O
T  O
)  O
.  O

This  O
phase  O
I  O
study  O
was  O
designed  O
to  O
determine  O
the  O
maximal  O
tolerated  O
dose  O
(  O
MTD  O
)  O
,  O
recommended  O
phase  O
2  O
dose  O
(  O
RPTD  O
)  O
,  O
toxicity  O
profile  O
,  O
pharmacokinetics  O
and  O
antitumor  O
activity  O
of  O
T  O
and  O
UCN-01  B-DRUG
in  O
patients  O
with  O
refractory  O
solid  B-CANCER
tumors  I-CANCER
.  O

Both  O
agents  O
were  O
administered  O
every  O
21  O
days  O
intravenously  O
through  O
central  O
venous  O
access  O
in  O
escalating  O
doses  O
to  O
eligible  O
patients  O
.  O

On  O
day  O
1  O
,  O
following  O
antiemetic  O
prophylaxis  O
with  O
dexamethasone  B-DRUG
and  O
a  O
serotonin  B-DRUG
type  O
3  O
(  O
A  O
)  O
receptor  O
(  O
5HT3  O
)  O
inhibitor  O
,  O
UCN-01  B-DRUG
was  O
infused  O
over  O
3  O
h  O
,  O
followed  O
by  O
T  O
infused  O
over  O
30  O
min  O
.  O

On  O
days  O
2-5  O
,  O
patients  O
received  O
T  O
only  O
.  O

UCN-01  B-DRUG
doses  O
were  O
reduced  O
by  O
50  O
%  O
in  O
cycles  O
2  O
and  O
beyond  O
because  O
of  O
its  O
prolonged  O
half-life  O
.  O

Thirty-three  O
patients  O
were  O
entered  O
in  O
three  O
cohorts  O
:  O
Dose  O
Level  O
(  O
DL  O
)  O
1  O
(  O
UCN-01  B-DRUG
70  O
mg  O
/  O
m2  O
,  O
T  O
0.75  O
mg  O
/  O
m2  O
)  O
,  O
three  O
patients  O
;  O
DL  O
2  O
(  O
UCN-01  O
70  O
mg  O
/  O
m2  O
,  O
T  O
1.0  O
mg  O
/  O
m2  O
)  O
,  O
24  O
patients  O
;  O
DL  O
3  O
(  O
UCN-01  B-DRUG
90  O
mg  O
/  O
m2  O
,  O
T  O
1.0  O
mg  O
/  O
m2  O
)  O
,  O
six  O
patients  O
.  O

All  O
but  O
three  O
patients  O
were  O
PS  O
0  O
or  O
1  O
,  O
median  O
age  O
was  O
54  O
years  O
(  O
range  O
,  O
29-72  O
)  O
,  O
91  O
%  O
were  O
female  O
.  O

Primary  O
tumor  O
types  O
:  O
ovary  O
/  O
peritoneal  O
(  O
23  O
patients  O
)  O
,  O
colon  O
(  O
three  O
patients  O
)  O
,  O
salivary  O
gland  O
(  O
two  O
patients  O
)  O
,  O
others  O
(  O
five  O
patients  O
)  O
.  O

All  O
patients  O
were  O
eligible  O
for  O
adverse  O
event  O
(  O
AE  O
)  O
analysis  O
and  O
22  O
patients  O
were  O
eligible  O
for  O
survival  O
and  O
tumor  O
response  O
analysis  O
.  O

Two  O
of  O
six  O
patients  O
had  O
dose  O
limiting  O
toxicity  O
(  O
DLT  O
)  O
at  O
DL  O
3  O
(  O
grade  O
3  O
N  O
/  O
V  O
;  O
grade  O
4  O
neutropenia  B-TOXI
with  I-TOXI
infection  I-TOXI
)  O
.  O

One  O
DLT  O
was  O
seen  O
in  O
one  O
patient  O
at  O
DL  O
2  O
,  O
consisting  O
of  O
grade  O
4  O
leukopenia  B-TOXI
.  O

This  O
cohort  O
was  O
expanded  O
and  O
no  O
further  O
DLTs  O
were  O
observed  O
.  O

Most  O
common  O
drug-related  O
AEs  O
were  O
mild  O
(  O
grade  O
1-2  O
)  O
.  O

Non-hematological  O
grade  O
3-4  O
AEs  O
consisted  O
of  O
transient  B-TOXI
hyperglycemia  I-TOXI
(  O
4  O
)  O
,  O
infection  B-TOXI
(  O
3  O
)  O
,  O
coagulation  B-TOXI
,  O
fatigue  B-TOXI
,  O
hypotension  B-TOXI
,  O
nausea  B-TOXI
(  O
2  O
)  O
,  O
hypomagnesemia  B-TOXI
,  O
vomiting  B-TOXI
,  O
headache  B-TOXI
(  O
1  O
)  O
.  O

Hematologic  B-TOXI
toxicities  I-TOXI
occurred  O
in  O
100  O
%  O
of  O
patients  O
.  O

Grade  O
3-4  O
hematologic  B-TOXI
abnormalities  I-TOXI
included  O
neutropenia  B-TOXI
(  O
16  O
,  O
including  O
three  O
with  O
infection  B-TOXI
)  O
,  O
leukopenia  B-TOXI
(  O
11  O
)  O
,  O
lymphopenia  B-TOXI
(  O
7  O
)  O
,  O
thrombocytopenia  B-TOXI
(  O
5  O
)  O
.  O

Best  O
response  O
for  O
22  O
evaluable  O
patients  O
was  O
PD  O
(  O
8  O
)  O
,  O
SD  O
for  O
at  O
least  O
six  O
cycles  O
(  O
12  O
)  O
,  O
PR  O
(  O
1  O
:  O
carcinoma  B-CANCER
of  I-CANCER
ovary  I-CANCER
,  O
dose  O
level  O
2  O
)  O
and  O
one  O
not  O
assessable  O
.  O

Pharmacokinetic  O
analysis  O
confirmed  O
the  O
prolonged  O
half-life  O
of  O
UCN-01  B-DRUG
of  O
approximately  O
15  O
days  O
.  O

DLT  O
was  O
observed  O
at  O
DL  O
3  O
and  O
RPTD  O
was  O
determined  O
to  O
be  O
DL  O
2.  O
To  O
date  O
,  O
this  O
combination  O
has  O
been  O
relatively  O
well  O
tolerated  O
with  O
some  O
preliminary  O
evidence  O
of  O
efficacy  O
.  O

A  O
phase  O
II  O
study  O
of  O
this  O
combination  O
in  O
patients  O
with  O
ovarian  B-CANCER
cancer  I-CANCER
is  O
underway  O
.  O

Phase  O
I  O
/  O
IIa  O
study  O
of  O
cetuximab  B-DRUG
with  O
gemcitabine  B-DRUG
plus  O
carboplatin  B-DRUG
in  O
patients  O
with  O
chemotherapy-naive  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


This  O
multicenter  O
,  O
open-label  O
,  O
phase  O
I  O
/  O
IIa  O
study  O
was  O
undertaken  O
to  O
establish  O
the  O
safety  O
/  O
toxicity  O
profile  O
of  O
cetuximab  B-DRUG
in  O
combination  O
with  O
gemcitabine  B-DRUG
and  O
carboplatin  B-DRUG
in  O
patients  O
with  O
chemotherapy-na√Øve  O
,  O
epidermal  B-DRUG
growth  I-DRUG
factor  I-DRUG
receptor-positive  I-DRUG
,  O
stage  O
IV  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

Secondary  O
objectives  O
were  O
to  O
gather  O
preliminary  O
evidence  O
of  O
efficacy  O
including  O
tumor  O
response  O
rate  O
,  O
time  O
to  O
progression  O
,  O
and  O
overall  O
survival  O
.  O

Thirty-five  O
patients  O
received  O
a  O
total  O
of  O
264  O
3-week  O
cycles  O
of  O
treatment  O
with  O
cetuximab  B-DRUG
,  O
carboplatin  B-DRUG
,  O
and  O
gemcitabine  B-DRUG
.  O

An  O
initial  O
dose  O
of  O
cetuximab  B-DRUG
400  O
mg  O
/  O
m2  O
intravenously  O
was  O
administered  O
the  O
first  O
week  O
,  O
followed  O
by  O
weekly  O
doses  O
of  O
250  O
mg  O
/  O
m2  O
.  O

Carboplatin  B-DRUG
(  O
area  O
under  O
the  O
curve  O
=  O
5  O
,  O
day  O
1  O
)  O
and  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m2  O
on  O
days  O
1  O
and  O
8  O
were  O
administered  O
every  O
3  O
weeks  O
.  O

Patients  O
were  O
evaluated  O
for  O
tumor  O
response  O
after  O
every  O
two  O
cycles  O
of  O
therapy  O
.  O

The  O
most  O
frequently  O
reported  O
adverse  O
events  O
related  O
to  O
cetuximab  B-DRUG
included  O
an  O
acne-like  B-TOXI
rash  I-TOXI
(  O
88.6  O
%  O
)  O
,  O
dry  B-TOXI
skin  I-TOXI
(  O
34.3  O
%  O
)  O
,  O
asthenia  B-TOXI
and  O
skin  B-TOXI
disorders  I-TOXI
(  O
31.4  O
%  O
)  O
,  O
mucositis  B-TOXI
/  O
stomatitis  B-TOXI
(  O
25.7  O
%  O
)  O
,  O
fever  B-TOXI
/  O
chills  B-TOXI
(  O
20  O
%  O
)  O
,  O
and  O
nausea  B-TOXI
/  I-TOXI
vomiting  I-TOXI
(  O
17.1  O
%  O
)  O
.  O

The  O
majority  O
of  O
these  O
toxicities  O
were  O
mild  O
to  O
moderate  O
.  O

One  O
patient  O
withdrew  O
from  O
the  O
study  O
because  O
of  O
a  O
grade  O
3  O
allergic  B-TOXI
reaction  I-TOXI
.  O

Myelosuppression  B-TOXI
was  O
the  O
most  O
frequently  O
observed  O
toxicity  O
related  O
to  O
chemotherapy  O
.  O

Responses  O
among  O
35  O
assessable  O
patients  O
included  O
10  O
partial  O
responses  O
(  O
28.6  O
%  O
)  O
.  O

Twenty-one  O
patients  O
had  O
stable  O
disease  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
165  O
days  O
,  O
and  O
the  O
median  O
overall  O
survival  O
was  O
310  O
days  O
.  O

The  O
combination  O
of  O
cetuximab  B-DRUG
,  O
carboplatin  B-DRUG
,  O
and  O
gemcitabine  B-DRUG
was  O
well  O
tolerated  O
with  O
an  O
acceptable  O
toxicity  O
profile  O
.  O

Most  O
grade  O
3  O
adverse  O
events  O
were  O
attributable  O
to  O
chemotherapy  O
.  O

The  O
response  O
rate  O
and  O
median  O
survival  O
are  O
encouraging  O
and  O
warrant  O
additional  O
investigation  O
.  O

Biweekly  O
regimen  O
of  O
cisplatin  B-DRUG
,  O
gemcitabine  B-DRUG
and  O
vinorelbine  B-DRUG
for  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


Improving  O
chemotherapeutic  O
efficacy  O
in  O
non-small  B-CANCER
cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
will  O
require  O
the  O
development  O
of  O
new  O
strategies  O
to  O
better  O
use  O
currently  O
available  O
agents  O
.  O

To  O
assess  O
the  O
efficacy  O
and  O
safety  O
of  O
a  O
biweekly  O
regimen  O
of  O
cisplatin  B-DRUG
,  O
gemcitabine  B-DRUG
and  O
vinorelbine  B-DRUG
for  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

Patients  O
with  O
selected  O
stage  O
IIIb  O
(  O
pleural  O
effusion  O
)  O
/  O
stage  O
IV  O
NSCLC  B-CANCER
,  O
performance  O
status  O
of  O
0-2  O
and  O
normal  O
organ  O
function  O
were  O
eligible  O
.  O

Treatment  O
consisted  O
of  O
cisplatin  B-DRUG
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
day  O
1  O
plus  O
gemcitabine  B-DRUG
,  O
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
vinorelbine  B-DRUG
25  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
15  O
every  O
28  O
days  O
.  O

Of  O
the  O
40  O
patients  O
enrolled  O
and  O
assessable  O
for  O
response  O
,  O
there  O
were  O
five  O
(  O
12.5  O
%  O
)  O
with  O
confirmed  O
complete  O
response  O
and  O
14  O
(  O
35  O
%  O
)  O
with  O
a  O
confirmed  O
partial  O
response  O
for  O
an  O
overall  O
response  O
rate  O
of  O
47.5  O
%  O
.  O

Nine  O
patients  O
had  O
stable  O
disease  O
while  O
12  O
(  O
30  O
%  O
)  O
progressed  O
.  O

Median  O
progression-free  O
survival  O
and  O
overall  O
survival  O
for  O
all  O
patients  O
were  O
6.3  O
and  O
11.1  O
months  O
,  O
respectively  O
.  O

Toxicity  O
was  O
principally  O
hematologic  O
,  O
with  O
grade  O
3-4  O
neutropenia  B-TOXI
in  O
30  O
%  O
,  O
and  O
grade  O
3-4  O
nausea  B-TOXI
/  I-TOXI
vomiting  I-TOXI
in  O
22.5  O
%  O
.  O

There  O
were  O
no  O
treatment-related  B-TOXI
deaths  I-TOXI
.  O

The  O
biweekly  O
regimen  O
of  O
cisplatin  B-DRUG
,  O
gemcitabine  B-DRUG
and  O
vinorelbine  B-DRUG
is  O
associated  O
with  O
a  O
high  O
rate  O
of  O
response  O
,  O
lesser  O
toxicity  O
than  O
other  O
three-drug  O
regimens  O
and  O
no  O
benefit  O
of  O
survival  O
.  O

Therefore  O
,  O
the  O
regimen  O
under  O
study  O
may  O
be  O
an  O
appealing  O
alternative  O
when  O
considering  O
other  O
treatment  O
modalities  O
for  O
advanced  B-CANCER
lung  I-CANCER
cancer  I-CANCER
,  O
such  O
as  O
neoadjuvant  O
therapy  O
.  O

First-line  O
therapy  O
with  O
gemcitabine  B-DRUG
and  O
paclitaxel  B-DRUG
in  O
locally  O
,  O
recurrent  O
or  O
metastatic  O
breast  B-CANCER
cancer  I-CANCER
:  O
a  O
phase  O
II  O
study  O
.  O


This  O
phase  O
II  O
study  O
evaluated  O
the  O
efficacy  O
and  O
safety  O
of  O
gemcitabine  B-DRUG
(  O
G  O
)  O
plus  O
paclitaxel  B-DRUG
(  O
T  O
)  O
as  O
first-line  O
therapy  O
in  O
recurrent  O
or  O
metastatic  O
breast  B-CANCER
cancer  I-CANCER
.  O

Patients  O
with  O
locally  O
,  O
recurrent  O
or  O
metastatic  O
breast  B-CANCER
cancer  I-CANCER
and  O
no  O
prior  O
chemotherapy  O
for  O
metastatic  O
disease  O
received  O
G  O
1200  O
mg  O
/  O
m2  O
on  O
days  O
1  O
and  O
8  O
,  O
and  O
T  O
175  O
mg  O
/  O
m2  O
on  O
day  O
1  O
(  O
before  O
G  O
)  O
every  O
21  O
days  O
for  O
a  O
maximum  O
of  O
10  O
cycles  O
.  O

Forty  O
patients  O
,  O
39  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
and  O
1  O
locally-advanced  O
disease  O
,  O
were  O
enrolled  O
.  O

Their  O
median  O
age  O
was  O
61.5  O
years  O
,  O
and  O
85  O
%  O
had  O
a  O
World  O
Health  O
Organization  O
performance  O
status  O
(  O
PS  O
)  O
of  O
0  O
or  O
1.  O
Poor  O
prognostic  O
factors  O
at  O
baseline  O
included  O
visceral  O
involvement  O
(  O
87.5  O
%  O
)  O
and  O
&  O
gt  O
;  O
or  O
=2  O
metastatic  O
sites  O
(  O
70  O
%  O
)  O
.  O

Also  O
,  O
27  O
(  O
67.5  O
%  O
)  O
patients  O
had  O
prior  O
adjuvant  O
chemotherapy  O
,  O
25  O
of  O
which  O
had  O
prior  O
anthracyclines  B-DRUG
.  O

A  O
total  O
of  O
220  O
cycles  O
(  O
median  O
6  O
;  O
range  O
,  O
1-10  O
)  O
were  O
administered  O
.  O

Of  O
the  O
40  O
enrolled  O
patients  O
,  O
2  O
had  O
complete  O
response  O
and  O
12  O
partial  O
response  O
,  O
for  O
an  O
overall  O
response  O
rate  O
of  O
35.0  O
%  O
for  O
intent-to-treat  O
population  O
.  O

Among  O
35  O
patients  O
evaluable  O
for  O
efficacy  O
the  O
response  O
rate  O
was  O
40  O
%  O
.  O

Additional  O
14  O
patients  O
had  O
stable  O
disease  O
,  O
and  O
7  O
had  O
progressive  B-TOXI
disease  I-TOXI
.  O

The  O
median  O
duration  O
of  O
response  O
was  O
12  O
months  O
;  O
median  O
time  O
to  O
progression  O
,  O
7.2  O
months  O
;  O
median  O
survival  O
,  O
25.7  O
months  O
.  O

Common  O
grade  O
3  O
/  O
4  O
toxicities  O
were  O
neutropenia  B-TOXI
in  O
17  O
(  O
42.5  O
%  O
)  O
patients  O
each  O
,  O
grade  O
3  O
leukopenia  B-TOXI
in  O
19  O
(  O
47.5  O
%  O
)  O
,  O
and  O
grade  O
3  O
alopecia  B-TOXI
in  O
30  O
(  O
75.0  O
%  O
)  O
patients  O
;  O
1  O
(  O
2.5  O
%  O
)  O
patient  O
had  O
grade  O
4  O
thrombocytopenia  B-TOXI
.  O

GT  O
exhibited  O
encouraging  O
activity  O
and  O
tolerable  O
toxicity  O
as  O
first-line  O
therapy  O
in  O
metastatic  B-CANCER
breast  I-CANCER
cancer  I-CANCER
.  O

Phase  O
III  O
trials  O
for  O
further  O
evaluation  O
are  O
ongoing  O
.  O

Second-line  O
chemotherapy  O
with  O
weekly  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
patients  O
with  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
pretreated  O
with  O
platinum  B-DRUG
and  O
etoposide  B-DRUG
:  O
a  O
single  O
institution  O
phase  O
II  O
trial  O
.  O


The  O
safety  O
and  O
efficacy  O
of  O
a  O
combined  O
regimen  O
of  O
weekly  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
was  O
tested  O
in  O
patients  O
with  O
refractory  O
and  O
sensitive  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
SCLC  B-CANCER
)  O
.  O

Treatment  O
consisted  O
of  O
paclitaxel  B-DRUG
80  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
,  O
8  O
,  O
15  O
and  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m  O
(  O
2  O
)  O
on  O
days  O
1  O
and  O
8  O
every  O
3  O
weeks  O
.  O

Of  O
the  O
31  O
patients  O
enrolled  O
,  O
10  O
had  O
refractory  O
and  O
21  O
had  O
sensitive  O
disease  O
.  O

Objective  O
responses  O
occurred  O
in  O
8  O
patients  O
(  O
26  O
%  O
)  O
,  O
including  O
2  O
out  O
of  O
10  O
patients  O
with  O
refractory-  O
and  O
6  O
out  O
of  O
21  O
patients  O
with  O
sensitive  O
SCLC  B-CANCER
.  O

Median  O
time  O
to  O
progression  O
and  O
median  O
survival  O
were  O
9.4  O
and  O
32  O
weeks  O
,  O
respectively  O
.  O

The  O
schedule  O
was  O
very  O
well  O
tolerated  O
,  O
with  O
grade  O
3-4  O
thrombocytopenia  B-TOXI
in  O
26  O
%  O
of  O
the  O
patients  O
,  O
grade  O
3  O
neutropenia  B-TOXI
in  O
26  O
%  O
,  O
grade  O
3-4  O
asthenia  B-TOXI
in  O
13  O
%  O
and  O
grade  O
1-2  O
sensory  B-TOXI
neuropathy  I-TOXI
in  O
32  O
%  O
.  O

To  O
conclude  O
,  O
this  O
weekly  O
schedule  O
of  O
paclitaxel  B-DRUG
and  O
gemcitabine  B-DRUG
was  O
found  O
to  O
have  O
moderate  O
activity  O
in  O
platinum-etoposide  B-DRUG
pretreated  O
SCLC  B-CANCER
patients  O
and  O
a  O
favorable  O
toxicity  O
profile  O
.  O

Phase  O
II  O
study  O
of  O
fixed  O
dose  O
rate  O
gemcitabine  B-DRUG
with  O
cisplatin  B-DRUG
for  O
metastatic  B-CANCER
adenocarcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
pancreas  I-CANCER
.  O


Although  O
gemcitabine  B-DRUG
remains  O
the  O
standard  O
of  O
care  O
for  O
patients  O
with  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
,  O
additional  O
improvements  O
may  O
be  O
realized  O
by  O
combining  O
therapeutic  O
agents  O
with  O
synergistic  O
activity  O
,  O
and  O
optimizing  O
drug  O
delivery  O
using  O
pharmacokinetic  O
principles  O
such  O
as  O
fixed  O
dose  O
rate  O
(  O
FDR  O
)  O
infusion  O
.  O

The  O
objectives  O
of  O
this  O
study  O
were  O
to  O
determine  O
safety  O
and  O
efficacy  O
in  O
patients  O
with  O
metastatic  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
treated  O
with  O
FDR  O
gemcitabine  B-DRUG
in  O
combination  O
with  O
low-dose  O
cisplatin  B-DRUG
.  O

Chemotherapy-naive  O
patients  O
with  O
metastatic  B-CANCER
pancreatic  I-CANCER
adenocarcinoma  I-CANCER
were  O
treated  O
with  O
a  O
combination  O
of  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m2  O
at  O
10  O
mg  O
/  O
m2  O
/  O
min  O
together  O
with  O
cisplatin  B-DRUG
20  O
mg  O
/  O
m2  O
on  O
days  O
1  O
and  O
8  O
of  O
a  O
21-day  O
cycle  O
.  O

Patient  O
follow-up  O
was  O
performed  O
using  O
computerized  O
tomographic  O
scans  O
and  O
serial  O
CA  O
19-9  O
measurements  O
.  O

A  O
total  O
of  O
51  O
patients  O
were  O
enrolled  O
onto  O
the  O
study  O
,  O
with  O
a  O
median  O
follow-up  O
time  O
of  O
215  O
days  O
.  O

Twenty-two  O
of  O
40  O
patients  O
(  O
55.0  O
%  O
)  O
with  O
a  O
baseline  O
serum  O
CA  O
19-9  O
level  O
&  O
gt  O
;  O
or  O
=  O
2x  O
the  O
upper  O
limit  O
of  O
normal  O
demonstrated  O
a  O
&  O
gt  O
;  O
or  O
=  O
50  O
%  O
biomarker  O
decline  O
during  O
treatment  O
.  O

Nine  O
of  O
47  O
patients  O
(  O
19.1  O
%  O
)  O
with  O
measurable  O
disease  O
achieved  O
a  O
partial  O
response  O
,  O
and  O
28  O
patients  O
(  O
59.6  O
%  O
)  O
had  O
disease  O
stabilization  O
for  O
at  O
least  O
two  O
treatment  O
cycles  O
.  O

Median  O
time  O
to  O
progression  O
was  O
3.9  O
months  O
and  O
median  O
survival  O
was  O
7.1  O
months  O
,  O
with  O
an  O
estimated  O
1-year  O
survival  O
rate  O
of  O
29  O
%  O
.  O

The  O
most  O
frequently  O
reported  O
grade  O
3  O
or  O
4  O
adverse  O
events  O
were  O
neutropenia  B-TOXI
(  O
52.9  O
%  O
)  O
and  O
thrombocytopenia  B-TOXI
(  O
15.7  O
%  O
)  O
.  O

Most  O
patients  O
were  O
switched  O
to  O
an  O
every-other-week  O
dosing  O
schedule  O
.  O

The  O
combination  O
of  O
FDR  O
gemcitabine  B-DRUG
and  O
cisplatin  B-DRUG
is  O
well  O
tolerated  O
and  O
appears  O
to  O
be  O
an  O
acceptable  O
,  O
albeit  O
not  O
clearly  O
superior  O
,  O
alternative  O
to  O
other  O
gemcitabine  B-DRUG
/  I-DRUG
platinum  I-DRUG
regimens  O
for  O
the  O
treatment  O
of  O
metastatic  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
.  O

Clindamycin-paclitaxel  B-DRUG
pharmacokinetic  O
interaction  O
in  O
ovarian  B-CANCER
cancer  I-CANCER
patients  O
.  O


Plasma  O
protein  O
binding  O
is  O
an  O
important  O
factor  O
for  O
many  O
drugs  O
that  O
can  O
influence  O
the  O
tissue  O
distribution  O
and  O
pharmacokinetics  O
.  O

alpha  B-DRUG
(  I-DRUG
1  I-DRUG
)  I-DRUG
-acid  I-DRUG
glycoprotein  I-DRUG
(  O
AGP  B-DRUG
)  O
is  O
an  O
acute-phase  O
protein  O
that  O
can  O
increase  O
in  O
plasma  O
of  O
patients  O
with  O
several  O
pathological  O
conditions  O
including  O
cancer  O
.  O

Studies  O
performed  O
in  O
cultured  O
cells  O
indicate  O
that  O
paclitaxel  B-DRUG
cytotoxicity  O
is  O
reduced  O
by  O
adding  O
AGP  B-DRUG
and  O
the  O
sensitivity  O
to  O
paclitaxel  B-DRUG
is  O
restored  O
by  O
displacing  O
its  O
binding  O
to  O
AGP  B-DRUG
with  O
clindamycin  B-DRUG
,  O
resulting  O
in  O
an  O
increased  O
paclitaxel  B-DRUG
cell  O
uptake  O
.  O

The  O
purpose  O
of  O
this  O
study  O
was  O
to  O
evaluate  O
whether  O
clindamycin  B-DRUG
modifies  O
paclitaxel  B-DRUG
pharmacokinetics  O
also  O
in  O
cancer  O
patients  O
.  O

Sixteen  O
patients  O
with  O
advanced  B-CANCER
ovarian  I-CANCER
cancer  I-CANCER
,  O
previously  O
treated  O
with  O
surgery  O
and  O
chemotherapy  O
were  O
enrolled  O
in  O
this  O
study  O
.  O

A  O
pharmacokinetic  O
study  O
of  O
paclitaxel  B-DRUG
was  O
performed  O
in  O
the  O
first  O
three  O
cycles  O
of  O
the  O
consolidation  O
therapy  O
(  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
)  O
in  O
each  O
patient  O
.  O

In  O
these  O
cycles  O
paclitaxel  B-DRUG
was  O
administered  O
alone  O
and  O
with  O
two  O
different  O
doses  O
(  O
600  O
and  O
1,200  O
mg  O
)  O
of  O
concurrent  O
clindamycin  B-DRUG
.  O

The  O
sequence  O
of  O
the  O
three  O
treatments  O
was  O
randomly  O
assigned  O
in  O
each  O
patient  O
in  O
order  O
to  O
avoid  O
the  O
same  O
order  O
of  O
treatments  O
.  O

Paclitaxel  B-DRUG
pharmacokinetics  O
were  O
partly  O
modified  O
by  O
the  O
concurrent  O
administration  O
of  O
clindamycin  B-DRUG
.  O

C  O
(  O
max  O
)  O
and  O
AUC  O
(  O
0-last  O
)  O
of  O
paclitaxel  B-DRUG
were  O
significantly  O
higher  O
when  O
the  O
drug  O
was  O
given  O
alone  O
than  O
when  O
it  O
was  O
coadministered  O
with  O
1,200  O
mg  O
clindamycin  B-DRUG
.  O

Moreover  O
,  O
AGP  B-DRUG
concentrations  O
seem  O
to  O
have  O
a  O
small  O
but  O
statistically  O
significant  O
influence  O
on  O
paclitaxel  B-DRUG
pharmacokinetic  O
,  O
since  O
AUC  O
(  O
0-last  O
)  O
showed  O
a  O
positive  O
significant  O
correlation  O
with  O
AGP  B-DRUG
plasma  O
concentration  O
when  O
paclitaxel  B-DRUG
was  O
given  O
alone  O
.  O

The  O
linear  O
relation  O
was  O
lost  O
when  O
paclitaxel  B-DRUG
was  O
coadministered  O
with  O
1,200  O
mg  O
clindamycin  B-DRUG
.  O

Toxicity  O
was  O
not  O
influenced  O
by  O
the  O
coadministration  O
of  O
clindamycin  B-DRUG
.  O

The  O
hypothesis  O
that  O
clindamycin  B-DRUG
could  O
affect  O
paclitaxel  B-DRUG
pharmacokinetics  O
seems  O
to  O
be  O
verified  O
with  O
this  O
study  O
.  O

Nevertheless  O
,  O
changes  O
induced  O
by  O
giving  O
the  O
combination  O
of  O
the  O
two  O
drugs  O
are  O
minimal  O
and  O
thus  O
of  O
questionable  O
clinical  O
relevance  O
.  O

A  O
dose  O
escalation  O
study  O
of  O
pegylated  B-DRUG
liposomal  I-DRUG
Doxorubicin  I-DRUG
(  O
caelyx  O
)  O
in  O
combination  O
with  O
capecitabine  B-DRUG
(  O
xeloda  O
)  O
in  O
patients  O
with  O
refractory  O
solid  B-CANCER
tumors  I-CANCER
.  O


Pegylated  B-DRUG
liposomal  I-DRUG
doxorubicin  I-DRUG
(  O
PLD  B-DRUG
)  O
and  O
capecitabine  B-DRUG
(  O
CAP  B-DRUG
)  O
have  O
separately  O
shown  O
significant  O
antitumor  O
activity  O
in  O
a  O
wide  O
range  O
of  O
solid  B-CANCER
tumors  I-CANCER
.  O

A  O
phase  O
I  O
study  O
was  O
conducted  O
in  O
order  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
their  O
combination  O
in  O
patients  O
with  O
refractory  O
solid  B-CANCER
tumors  I-CANCER
.  O

Fifteen  O
patients  O
with  O
histologically  O
confirmed  O
inoperable  O
solid  B-CANCER
neoplasms  I-CANCER
were  O
enrolled  O
.  O

The  O
patients  O
'  O
median  O
age  O
was  O
65  O
years  O
,  O
10  O
were  O
male  O
,  O
and  O
12  O
had  O
a  O
performance  O
status  O
score  O
(  O
WHO  O
)  O
of  O
0-1  O
.  O

PLD  B-DRUG
was  O
administered  O
on  O
day  O
1  O
as  O
a  O
1-hour  O
intravenous  O
infusion  O
at  O
escalated  O
doses  O
ranging  O
from  O
35  O
to  O
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

CAP  B-DRUG
was  O
administered  O
on  O
days  O
1-14  O
per  O
os  O
,  O
at  O
escalated  O
doses  O
ranging  O
from  O
1,600  O
to  O
1,800  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
given  O
as  O
two  O
daily  O
divided  O
doses  O
.  O

Treatment  O
was  O
repeated  O
every  O
3  O
weeks  O
.  O

At  O
the  O
dose  O
of  O
PLD  B-DRUG
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
CAP  B-DRUG
1,800  O
mg  O
/  O
m  O
(  O
2  O
)  O
,  O
all  O
3  O
enrolled  O
patients  O
presented  O
DLTs  O
[  O
2  O
patients  O
grade  O
3  O
palmar-plantar  B-TOXI
erythrodysesthesia  I-TOXI
(  O
PPE  B-TOXI
)  O
and  O
1  O
patient  O
grade  O
3  O
asthenia  B-TOXI
]  O
and  O
thus  O
,  O
the  O
recommended  O
MTD  O
for  O
future  O
phase  O
II  O
studies  O
is  O
PLD  B-DRUG
40  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
CAP  B-DRUG
1,700  O
mg  O
/  O
m  O
(  O
2  O
)  O
.  O

A  O
total  O
of  O
57  O
treatment  O
cycles  O
were  O
administered  O
.  O

Grade  O
2  O
/  O
3  O
neutropenia  B-TOXI
complicated  O
9  O
(  O
17  O
%  O
)  O
cycles  O
and  O
1  O
patient  O
was  O
hospitalized  O
for  O
febrile  B-TOXI
neutropenia  I-TOXI
.  O

There  O
was  O
no  O
septic  B-TOXI
death  I-TOXI
.  O

The  O
main  O
nonhematologic  B-TOXI
toxicity  I-TOXI
was  O
PPE  O
grade  O
2  O
in  O
3  O
(  O
19  O
%  O
)  O
patients  O
and  O
grade  O
3  O
in  O
4  O
(  O
27  O
%  O
)  O
.  O

PPE  B-TOXI
was  O
the  O
reason  O
of  O
treatment  O
interruption  O
for  O
3  O
patients  O
.  O

Other  O
toxicities  O
were  O
mild  O
and  O
easily  O
manageable  O
.  O

Two  O
patients  O
(  O
16  O
%  O
)  O
with  O
partial  O
response  O
suffering  O
from  O
gastric  B-CANCER
cancer  I-CANCER
and  O
5  O
patients  O
with  O
(  O
42  O
%  O
)  O
stable  O
disease  O
were  O
observed  O
among  O
12  O
evaluable  O
patients  O
.  O

The  O
results  O
of  O
this  O
phase  O
I  O
study  O
demonstrate  O
that  O
PLD  B-DRUG
and  O
CAP  B-DRUG
can  O
be  O
combined  O
at  O
clinically  O
effective  O
and  O
relevant  O
doses  O
.  O

However  O
,  O
PPE  B-TOXI
is  O
a  O
common  O
side  O
effect  O
and  O
further  O
investigation  O
is  O
warranted  O
to  O
define  O
its  O
precise  O
role  O
in  O
the  O
treatment  O
of  O
solid  B-CANCER
malignancies  I-CANCER
.  O

Phase  O
I  O
trial  O
of  O
sorafenib  B-DRUG
and  O
gemcitabine  B-DRUG
in  O
advanced  B-CANCER
solid  I-CANCER
tumors  I-CANCER
with  O
an  O
expanded  O
cohort  O
in  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
.  O


With  O
its  O
potent  O
inhibitory  O
effects  O
against  O
Raf-1  O
kinase  O
and  O
vascular  O
endothelial  O
growth  O
factor  O
receptor-2  O
,  O
sorafenib  B-DRUG
is  O
a  O
novel  O
oral  O
anticancer  O
agent  O
targeting  O
signal  O
transduction  O
and  O
angiogenic  O
pathways  O
.  O

This  O
study  O
is  O
designed  O
to  O
combine  O
sorafenib  B-DRUG
and  O
gemcitabine  B-DRUG
due  O
to  O
their  O
compatibility  O
in  O
preclinical  O
models  O
and  O
nonoverlapping  O
clinical  O
toxicities  O
.  O

An  O
initial  O
dose-escalation  O
part  O
of  O
the  O
study  O
enrolled  O
patients  O
with  O
advanced  B-TOXI
solid  I-TOXI
tumors  I-TOXI
,  O
followed  O
by  O
an  O
expanded  O
cohort  O
at  O
the  O
recommended  O
dose  O
for  O
patients  O
with  O
advanced  O
unresectable  O
or  O
metastatic  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
.  O

Sorafenib  B-DRUG
is  O
administered  O
continuously  O
,  O
whereas  O
gemcitabine  B-DRUG
is  O
given  O
at  O
1,000  O
mg  O
/  O
m2  O
weekly  O
x  O
7  O
followed  O
by  O
1  O
rest  O
week  O
,  O
then  O
weekly  O
x  O
3  O
every  O
4  O
weeks  O
.  O

Forty-two  O
patients  O
have  O
been  O
enrolled  O
overall  O
,  O
including  O
19  O
in  O
the  O
dose-escalation  O
part  O
and  O
23  O
in  O
the  O
extended  O
pancreatic  B-CANCER
cancer  I-CANCER
cohort  O
.  O

Demographics  O
were  O
as  O
follows  O
:  O
male-to-female  O
ratio  O
=  O
26:16  O
;  O
median  O
age  O
=  O
61  O
years  O
(  O
range  O
39-83  O
years  O
)  O
;  O
Eastern  O
Cooperative  O
Oncology  O
Group  O
performance  O
status  O
0:1:2  O
ratio  O
=  O
16:21:5.  O
The  O
recommended  O
dose  O
of  O
this  O
combination  O
is  O
sorafenib  B-DRUG
400  O
mg  O
twice  O
daily  O
and  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m2  O
.  O

The  O
most  O
frequent  O
grade  O
3  O
or  O
4  O
adverse  O
events  O
of  O
all  O
causalities  O
were  O
thrombocytopenia  B-TOXI
(  O
28.6  O
%  O
)  O
,  O
lymphopenia  B-TOXI
(  O
21.4  O
%  O
)  O
,  O
lipase  B-TOXI
elevation  I-TOXI
(  O
19  O
%  O
)  O
,  O
neutropenia  B-TOXI
(  O
16.7  O
%  O
)  O
,  O
and  O
fatigue  B-TOXI
(  O
14.3  O
%  O
)  O
.  O

Antitumor  O
activity  O
was  O
observed  O
in  O
both  O
groups  O
,  O
with  O
2  O
(  O
10.5  O
%  O
)  O
confirmed  O
partial  O
responses  O
in  O
ovarian  B-CANCER
cancer  I-CANCER
and  O
12  O
patients  O
(  O
63.2  O
%  O
)  O
with  O
disease  O
stabilization  O
in  O
the  O
dose-escalation  O
part  O
;  O
13  O
patients  O
(  O
56.5  O
%  O
)  O
achieved  O
disease  O
stabilization  O
in  O
the  O
pancreatic  O
cohort  O
.  O

There  O
was  O
no  O
consistent  O
pharmacokinetic  O
drug-to-drug  O
interaction  O
between  O
sorafenib  B-DRUG
and  O
gemcitabine  B-DRUG
.  O

Sorafenib  B-DRUG
and  O
gemcitabine  B-DRUG
are  O
well  O
tolerated  O
in  O
combination  O
;  O
further  O
evaluations  O
in  O
pancreatic  O
and  O
ovarian  B-CANCER
cancers  I-CANCER
are  O
warranted  O
.  O

Fixed  O
dose-rate  O
infusion  O
of  O
gemcitabine  B-DRUG
in  O
combination  O
with  O
cisplatin  B-DRUG
and  O
UFT  B-DRUG
in  O
advanced  B-CANCER
carcinoma  I-CANCER
of  I-CANCER
the  I-CANCER
pancreas  I-CANCER
.  O


Gemcitabine  B-DRUG
is  O
currently  O
considered  O
the  O
standard  O
treatment  O
for  O
advanced  B-CANCER
pancreatic  I-CANCER
cancer  I-CANCER
(  O
APC  B-CANCER
)  O
.  O

Cisplatin  B-DRUG
and  O
a  O
fluoropyrimidine  B-DRUG
have  O
some  O
activity  O
in  O
the  O
treatment  O
of  O
this  O
cancer  O
.  O

The  O
aim  O
of  O
this  O
trial  O
is  O
to  O
evaluate  O
the  O
efficacy  O
and  O
toxicity  O
of  O
a  O
fixed  O
dose-rate  O
infusion  O
of  O
gemcitabine  O
associated  O
with  O
cisplatin  B-DRUG
and  O
UFT  B-DRUG
in  O
patients  O
with  O
APC  B-CANCER
.  O

Forty-six  O
chemotherapy-na√Øve  O
patients  O
with  O
APC  B-CANCER
that  O
was  O
either  O
unresectable  O
or  O
metastatic  O
were  O
included  O
in  O
this  O
phase  O
II  O
study  O
.  O

All  O
of  O
them  O
had  O
Karnofsky  O
performance  O
status  O
&  O
gt  O
;  O
or  O
=50  O
and  O
unidimensionally  O
measurable  O
disease  O
.  O

Treatment  O
consisted  O
of  O
gemcitabine  B-DRUG
1,200  O
mg  O
/  O
m2  O
given  O
as  O
a  O
120-min  O
infusion  O
weekly  O
for  O
three  O
consecutive  O
weeks  O
,  O
cisplatin  B-DRUG
50  O
mg  O
/  O
m2  O
on  O
day  O
1  O
and  O
oral  O
UFT  B-DRUG
400  O
mg  O
/  O
m2  O
/  O
day  O
(  O
in  O
two  O
to  O
three  O
daily  O
doses  O
)  O
on  O
days  O
1  O
to  O
21  O
;  O
cycles  O
of  O
treatment  O
were  O
given  O
every  O
28  O
days  O
.  O

A  O
total  O
of  O
208  O
cycles  O
of  O
chemotherapy  O
were  O
given  O
with  O
a  O
median  O
of  O
4  O
per  O
patient  O
.  O

Fourteen  O
patients  O
(  O
30  O
%  O
)  O
achieved  O
partial  O
responses  O
(  O
95  O
%  O
CI  O
19-48  O
%  O
)  O
and  O
17  O
(  O
37  O
%  O
)  O
had  O
stable  O
disease  O
.  O

The  O
median  O
time  O
to  O
progression  O
was  O
5  O
months  O
,  O
and  O
the  O
median  O
overall  O
survival  O
9  O
months  O
.  O

Nineteen  O
patients  O
(  O
49  O
%  O
;  O
95  O
%  O
CI  O
32-64  O
%  O
)  O
had  O
a  O
clinical  O
benefit  O
response  O
.  O

Grade  O
3-4  O
WHO  O
toxicities  O
were  O
as  O
follows  O
:  O
neutropaenia  B-TOXI
in  O
26  O
patients  O
(  O
57  O
%  O
)  O
,  O
with  O
5  O
cases  O
of  O
febrile  B-TOXI
neutropaenia  I-TOXI
(  O
11  O
%  O
)  O
,  O
thrombocytopaenia  B-TOXI
in  O
15  O
(  O
33  O
%  O
)  O
,  O
anaemia  B-TOXI
in  O
six  O
(  O
13  O
%  O
)  O
,  O
diarrhoea  B-TOXI
in  O
5  O
(  O
11  O
%  O
)  O
,  O
asthenia  B-TOXI
in  O
2  O
(  O
4  O
%  O
)  O
and  O
mucositis  B-TOXI
in  O
1  O
(  O
2  O
%  O
)  O
.  O

Seven  O
patients  O
required  O
hospitalisation  O
for  O
treatment-related  B-TOXI
complications  I-TOXI
.  O

A  O
fixed  O
dose-rate  O
infusion  O
of  O
gemcitabine  B-DRUG
associated  O
with  O
cisplatin  B-DRUG
and  O
UFT  B-DRUG
is  O
active  O
in  O
patients  O
with  O
APC  B-CANCER
,  O
though  O
at  O
the  O
cost  O
of  O
considerable  O
toxicity  O
.  O

Phase  O
I  O
dose  O
escalation  O
of  O
iodine-131-metaiodobenzylguanidine  B-DRUG
with  O
myeloablative  O
chemotherapy  O
and  O
autologous  O
stem-cell  O
transplantation  O
in  O
refractory  O
neuroblastoma  B-CANCER
:  O
a  O
new  O
approaches  O
to  O
Neuroblastoma  B-CANCER
Therapy  O
Consortium  O
Study  O
.  O


To  O
determine  O
the  O
maximum-tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
toxicity  O
of  O
iodine-131-metaiodobenzylguanidine  B-DRUG
(  B-DRUG
(  I-DRUG
131  I-DRUG
)  I-DRUG
I-MIBG  I-DRUG
)  O
with  O
carboplatin  B-DRUG
,  O
etoposide  B-DRUG
,  O
melphalan  B-DRUG
(  O
CEM  B-DRUG
)  O
and  O
autologous  O
stem-cell  O
transplantation  O
(  O
ASCT  O
)  O
in  O
refractory  O
neuroblastoma  B-CANCER
.  O

Twenty-four  O
children  O
with  O
primary  O
refractory  O
neuroblastoma  B-CANCER
and  O
no  O
prior  O
ASCT  O
were  O
entered  O
;  O
22  O
were  O
assessable  O
for  O
toxicity  O
and  O
response  O
.  O

(  B-DRUG
131  I-DRUG
)  I-DRUG
I-MIBG  I-DRUG
was  O
administered  O
on  O
day  O
-21  O
,  O
CEM  B-DRUG
was  O
administered  O
on  O
days  O
-7  O
to  O
-4  O
,  O
and  O
ASCT  O
was  O
performed  O
on  O
day  O
0  O
,  O
followed  O
by  O
13-cis-retinoic  B-DRUG
acid  I-DRUG
.  O

(  B-DRUG
131  I-DRUG
)  I-DRUG
I-MIBG  I-DRUG
was  O
escalated  O
in  O
groups  O
of  O
three  O
to  O
six  O
patients  O
,  O
stratified  O
by  O
corrected  O
glomerular  O
filtration  O
rate  O
(  O
GFR  O
)  O
.  O

The  O
MTD  O
for  O
patients  O
with  O
normal  O
GFR  O
(  O
&  O
gt  O
;  O
or  O
=  O
100  O
mL  O
/  O
min  O
/  O
1.73  O
m2  O
)  O
was  O
131I-MIBG  B-DRUG
12  O
mCi  O
/  O
kg  O
,  O
carboplatin  B-DRUG
1,500  O
mg  O
/  O
m2  O
,  O
etoposide  B-DRUG
1,200  O
mg  O
/  O
m2  O
,  O
and  O
melphalan  B-DRUG
210  O
mg  O
/  O
m2  O
.  O

In  O
the  O
low-GFR  O
cohort  O
,  O
at  O
the  O
initial  O
dose  O
level  O
using  O
12  O
mCi  O
/  O
kg  O
of  O
131I-MIBG  B-DRUG
and  O
reduced  O
chemotherapy  O
,  O
one  O
in  O
six  O
patients  O
had  O
dose  O
limiting  O
toxicity  O
(  O
DLT  O
)  O
,  O
including  O
veno-occlusive  B-TOXI
disease  I-TOXI
(  O
VOD  B-TOXI
)  O
.  O

Three  O
more  O
patients  O
in  O
this  O
group  O
had  O
grade  O
3  O
or  O
4  O
hepatotoxicity  B-TOXI
,  O
and  O
two  O
had  O
VOD  B-TOXI
,  O
without  O
meeting  O
DLT  O
criteria  O
.  O

There  O
was  O
only  O
one  O
death  B-TOXI
as  O
a  O
result  O
of  O
toxicity  O
among  O
all  O
24  O
patients  O
.  O

All  O
assessable  O
patients  O
engrafted  O
,  O
with  O
median  O
time  O
for  O
neutrophils  O
&  O
gt  O
;  O
or  O
=  O
500  O
/  O
microL  O
of  O
10  O
days  O
and  O
median  O
time  O
for  O
platelets  O
&  O
gt  O
;  O
or  O
=  O
20,000  O
/  O
microL  O
of  O
26  O
days  O
.  O

Six  O
of  O
22  O
assessable  O
patients  O
had  O
complete  O
or  O
partial  O
response  O
,  O
and  O
15  O
patients  O
had  O
mixed  O
response  O
or  O
stable  O
disease  O
.  O

The  O
estimated  O
probability  O
of  O
event-free  O
survival  O
and  O
survival  O
from  O
the  O
day  O
of  O
MIBG  B-DRUG
infusion  O
for  O
all  O
patients  O
at  O
3  O
years  O
was  O
0.31  O
+  O
/  O
-  O
0.10  O
and  O
0.58  O
+  O
/  O
-  O
0.10  O
,  O
respectively  O
.  O

131I-MIBG  B-DRUG
with  O
myeloablative  O
chemotherapy  O
is  O
feasible  O
and  O
effective  O
for  O
patients  O
with  O
neuroblastoma  B-CANCER
exhibiting  O
de  O
novo  O
resistance  O
to  O
chemotherapy  O
.  O

Adding  O
gemcitabine  B-DRUG
to  O
paclitaxel  B-DRUG
/  I-DRUG
carboplatin  I-DRUG
combination  O
increases  O
survival  O
in  O
advanced  B-CANCER
non-small-cell  I-CANCER
lung  I-CANCER
cancer  I-CANCER
:  O
results  O
of  O
a  O
phase  O
II-III  O
study  O
.  O


Paclitaxel  B-DRUG
/  I-DRUG
carboplatin  I-DRUG
(  O
PC  B-DRUG
)  O
is  O
one  O
of  O
the  O
reference  O
combinations  O
in  O
the  O
treatment  O
of  O
non-small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
NSCLC  B-CANCER
)  O
.  O

No  O
triplet  O
novel  O
agent  O
combination  O
has  O
until  O
now  O
shown  O
superiority  O
over  O
a  O
two-drug  O
combination  O
for  O
advanced  B-CANCER
NSCLC  I-CANCER
.  O

We  O
therefore  O
conducted  O
a  O
clinical  O
trial  O
to  O
test  O
if  O
paclitaxel  B-DRUG
/  I-DRUG
carboplatin  I-DRUG
/  I-DRUG
gemcitabine  I-DRUG
(  O
PCG  B-DRUG
)  O
increases  O
overall  O
survival  O
(  O
OS  O
)  O
and  O
response  O
rate  O
(  O
RR  O
)  O
over  O
PC  B-DRUG
.  O

Stage  O
IIIB  O
patients  O
not  O
suitable  O
for  O
radical  O
radiation  O
treatment  O
and  O
stage  O
IV  O
chemotherapy-naive  O
patients  O
with  O
measurable  O
disease  O
and  O
performance  O
status  O
of  O
0  O
to  O
2  O
were  O
randomly  O
assigned  O
to  O
PC  B-DRUG
arm  O
(  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m2  O
and  O
carboplatin  B-DRUG
area  O
under  O
the  O
concentration-time  O
curve  O
6  O
day  O
1  O
/  O
q21  O
days  O
)  O
or  O
the  O
PCG  B-DRUG
arm  O
(  O
paclitaxel  B-DRUG
200  O
mg  O
/  O
m  O
(  O
2  O
)  O
and  O
carboplatin  B-DRUG
area  O
under  O
the  O
concentration-time  O
curve  O
6  O
day  O
1  O
,  O
and  O
gemcitabine  B-DRUG
1,000  O
mg  O
/  O
m2  O
days  O
1  O
and  O
8  O
every  O
21  O
days  O
)  O
.  O

A  O
total  O
of  O
324  O
patients  O
were  O
randomly  O
assigned  O
to  O
the  O
two  O
arms  O
.  O

The  O
RR  O
for  O
PC  B-DRUG
arm  O
and  O
PCG  B-DRUG
arm  O
were  O
20.2  O
%  O
and  O
43.6  O
%  O
[  O
corrected  O
]  O
(  O
P  O
&  O
lt  O
;  O
.0001  O
)  O
.  O

The  O
median  O
time  O
to  O
the  O
progression  O
was  O
5.1  O
months  O
in  O
the  O
PC  B-DRUG
group  O
and  O
7.6  O
months  O
in  O
the  O
PCG  B-DRUG
group  O
(  O
P  O
=  O
.012  O
;  O
hazard  O
ratio  O
[  O
HR  O
]  O
1.34  O
;  O
95  O
%  O
CI  O
:  O
1.06  O
to  O
1.72  O
)  O
.  O

Median  O
OS  O
was  O
8.3  O
months  O
and  O
10.8  O
months  O
(  O
P  O
=  O
.032  O
;  O
HR  O
1.309  O
;  O
95  O
%  O
CI  O
:  O
1.03  O
to  O
1.67  O
)  O
in  O
favor  O
of  O
the  O
PCG  B-DRUG
arm  O
.  O

One-year  O
survival  O
was  O
34  O
%  O
(  O
PC  B-DRUG
arm  O
)  O
and  O
45  O
%  O
(  O
PCG  B-DRUG
arm  O
;  O
P  O
=  O
.032  O
)  O
.  O

Only  O
hematologic  B-TOXI
toxicity  I-TOXI
(  O
neutropenia  B-TOXI
,  O
thrombocytopenia  B-TOXI
,  O
and  O
anemia  B-TOXI
)  O
was  O
significantly  O
increased  O
in  O
the  O
PCG  B-DRUG
arm  O
and  O
the  O
experimental  O
arm  O
required  O
more  O
platelet  O
and  O
red  O
blood  O
cell  O
transfusions  O
,  O
and  O
more  O
granulocyte  O
colony-stimulating  O
factor  O
usage  O
.  O

No  O
toxic  O
/  O
early  O
deaths  B-TOXI
were  O
observed  O
.  O

The  O
PCG  B-DRUG
regimen  O
offers  O
a  O
significant  O
survival  O
advantage  O
over  O
PC  B-DRUG
in  O
advanced  B-CANCER
NSCLC  I-CANCER
,  O
making  O
PCG  B-DRUG
a  O
treatment  O
option  O
for  O
advanced  B-CANCER
NSCLC  I-CANCER
patients  O
.  O

Pilot  O
phase  O
II  O
study  O
of  O
weekly  O
chemotherapy  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
for  O
refractory  O
or  O
relapsed  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O


The  O
safety  O
and  O
efficacy  O
of  O
weekly  O
chemotherapy  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
for  O
the  O
treatment  O
of  O
patients  O
with  O
refractory  O
or  O
relapsed  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
(  O
SCLC  B-CANCER
)  O
were  O
evaluated  O
.  O

Paclitaxel  B-DRUG
(  O
100  O
mg  O
/  O
m  O
(  O
2  O
)  O
)  O
and  O
carboplatin  B-DRUG
(  O
with  O
a  O
target  O
area  O
under  O
the  O
concentration  O
versus  O
time  O
curve  O
of  O
2  O
mg  O
min  O
/  O
ml  O
using  O
the  O
Calvert  O
formula  O
)  O
were  O
administered  O
to  O
patients  O
with  O
previously-  O
treated  O
SCLC  B-CANCER
on  O
days  O
1  O
and  O
8  O
at  O
every  O
3-4  O
weeks  O
.  O

A  O
total  O
of  O
29  O
patients  O
(  O
pts  O
)  O
[  O
male  O
/  O
female  O
,  O
26  O
/  O
3  O
pts  O
;  O
median  O
age  O
62.7  O
years  O
(  O
43-74  O
)  O
;  O
performance  O
status  O
0  O
/  O
1  O
/  O
2  O
,  O
9  O
/  O
10  O
/  O
10  O
pts  O
]  O
were  O
enrolled  O
between  O
March  O
2000  O
and  O
June  O
2002  O
.  O

The  O
mean  O
number  O
of  O
cycles  O
administered  O
per  O
pt  O
was  O
3  O
(  O
1-7  O
)  O
.  O

The  O
overall  O
response  O
rate  O
was  O
69  O
%  O
(  O
95  O
%  O
confidence  O
interval  O
52-86  O
%  O
)  O
,  O
and  O
83  O
%  O
(  O
15  O
/  O
18  O
)  O
in  O
sensitive  O
pts  O
and  O
45  O
%  O
(  O
5  O
/  O
11  O
)  O
in  O
refractory  O
pts  O
(  O
P  O
&  O
lt  O
;  O
0.01  O
)  O
.  O

The  O
overall  O
median  O
survival  O
time  O
was  O
29.6  O
weeks  O
with  O
a  O
1-year  O
survival  O
rate  O
of  O
37  O
%  O
[  O
34.1  O
weeks  O
in  O
sensitive  O
pts  O
and  O
23.1  O
weeks  O
in  O
refractory  O
pts  O
(  O
P=0.085  O
)  O
,  O
46.9  O
weeks  O
in  O
PS  O
0-1  O
and  O
16.3  O
weeks  O
in  O
PS  O
2  O
(  O
P  O
&  O
lt  O
;  O
0.001  O
)  O
]  O
.  O

The  O
median  O
time  O
to  O
progressive  B-TOXI
disease  I-TOXI
was  O
16.4  O
weeks  O
[  O
21.7  O
weeks  O
in  O
sensitive  O
pts  O
and  O
15.3  O
weeks  O
in  O
refractory  O
pts  O
(  O
P=0.32  O
)  O
]  O
.  O

Hematologic  B-TOXI
toxicities  I-TOXI
observed  O
included  O
grade  O
&  O
gt  O
;  O
or=3  O
neutropenia  B-TOXI
in  O
55  O
%  O
,  O
grade  O
&  O
gt  O
;  O
or=3  O
anemia  B-TOXI
in  O
36  O
%  O
,  O
and  O
grade  O
&  O
gt  O
;  O
or=3  O
thrombocytopenia  B-TOXI
in  O
3  O
%  O
.  O

Non-hematologic  B-TOXI
toxicities  I-TOXI
were  O
mild  O
except  O
for  O
grade  O
3  O
diarrhea  B-TOXI
in  O
three  O
pts  O
and  O
grade  O
3  O
pneumonitis  B-TOXI
in  O
one  O
pt  O
.  O

Weekly  O
chemotherapy  O
with  O
paclitaxel  B-DRUG
and  O
carboplatin  B-DRUG
was  O
well-  O
tolerated  O
and  O
gave  O
a  O
high-response  O
rate  O
in  O
pts  O
with  O
refractory  O
or  O
relapsed  O
small-cell  B-CANCER
lung  I-CANCER
cancer  I-CANCER
.  O

A  O
Phase  O
I  O
study  O
of  O
escalating  O
doses  O
of  O
the  O
tyrosine  O
kinase  O
inhibitor  O
semaxanib  B-DRUG
(  O
SU5416  B-DRUG
)  O
in  O
combination  O
with  O
irinotecan  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
carcinoma  I-CANCER
.  O


One  O
of  O
the  O
most  O
studied  O
pro-angiogenic  O
factors  O
involved  O
in  O
the  O
development  O
of  O
colorectal  B-CANCER
cancer  I-CANCER
is  O
the  O
vascular  B-DRUG
endothelial  I-DRUG
growth  I-DRUG
factor  I-DRUG
(  O
VEGF  B-DRUG
)  O
.  O

The  O
small  O
molecule  O
tyrosine  O
kinase  O
inhibitor  O
semaxanib  B-DRUG
(  O
SU5416  B-DRUG
)  O
is  O
one  O
of  O
the  O
several  O
agents  O
targeting  O
the  O
VEGF  B-DRUG
signaling  O
pathway  O
,  O
and  O
its  O
development  O
centered  O
mostly  O
in  O
the  O
treatment  O
of  O
colorectal  B-CANCER
cancer  I-CANCER
.  O

We  O
designed  O
and  O
conducted  O
an  O
NCI-sponsored  O
trial  O
to  O
determine  O
the  O
maximum  O
tolerated  O
dose  O
(  O
MTD  O
)  O
and  O
dose-limiting  O
toxicities  O
(  O
DLTs  O
)  O
of  O
semaxanib  B-DRUG
given  O
twice  O
weekly  O
in  O
combination  O
with  O
weekly  O
irinotecan  B-DRUG
in  O
patients  O
with  O
advanced  B-CANCER
colorectal  I-CANCER
cancer  I-CANCER
who  O
had  O
failed  O
at  O
least  O
one  O
prior  O
treatment  O
.  O

